<SEC-DOCUMENT>0000950123-17-011380.txt : 20180216
<SEC-HEADER>0000950123-17-011380.hdr.sgml : 20180216
<ACCEPTANCE-DATETIME>20171215145041
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-17-011380
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		25
FILED AS OF DATE:		20171215
<PUBLIC-REL-DATE>20180216
DATE AS OF CHANGE:		20180112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcus Biosciences, Inc.
		CENTRAL INDEX KEY:			0001724521
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473898435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-01833
		FILM NUMBER:		171258730

	BUSINESS ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		650-489-9000

	MAIL ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Confidential draft registration statement submitted to the Securities and Exchange
Commission on December 15, 2017. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information contained herein remains strictly confidential. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Under </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Arcus Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">47-3898435</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or Other Jurisdiction of<BR>Incorporation or Organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial<BR>Classification Code Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification Number)</B></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Arcus Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3928 Point Eden Way </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Hayward, CA 94545 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Terry Rosen, Ph.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Arcus Biosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3928 Point Eden Way </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Hayward, CA 94545 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name,
address, including zip code and telephone number, including area code, of agent for service) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to:
</I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Marcia A. Hatch</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Heidi E. Mayon</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Richard C.
Blake</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Gunderson Dettmer Stough Villeneuve</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Franklin&nbsp;&amp; Hachigian, LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1200 Seaport Blvd.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Redwood
City, CA 94063</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">321-2400</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jennifer Jarrett</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief Business and Financial Officer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Arcus Biosciences, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3928 Point Eden Way</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Hayward, CA 94545</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(510)
694-6261</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Kenneth L. Guernsey</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jonie I. Kondracki</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Charles
S. Kim</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>101 California Street, 5<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Francisco, CA 94111</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(415) 693-2000</B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933,
check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the
Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT>
filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. (Check one): </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF
REGISTRATION FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>securities to be registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed<BR>maximum<BR>aggregate<BR>offering&nbsp;price(1)(2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>registration fee</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, $0.0001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Estimated pursuant to Rule 457(o) under the Securities Act of 1933, as amended. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Includes the aggregate offering price of additional shares that the underwriters have the option to purchase. </TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>The Registrant hereby amends
this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in
accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to such Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#eb0029"><B>The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction
where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#eb0029"><B>SUBJECT TO COMPLETION, DATED&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g89w98.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Arcus Biosciences, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is the initial public
offering of our common stock. We are selling&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering. Prior to this offering, there has been no public market for our common
stock. We currently expect the initial public offering price to be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. We intend to apply to list our common stock on the
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; under the symbol &#147;RCUS.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined under the federal securities laws and, as such, have elected to comply with certain reduced public
company reporting requirements. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. See &#147;<A HREF="#rom317356_2">Risk Factors</A>&#148; beginning on page 12 to read about
factors you should consider before buying shares of our common stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; for a description of the compensation payable to the underwriters. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
granted the underwriters an option for a period of 30 days to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares from us at the public offering price, less the underwriting discounts and
commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the shares to purchasers on or
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>Citigroup</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Leerink&nbsp;Partners</B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2018 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the applicable provisions of the Fixing America&#146;s Surface Transportation Act, we are omitting our financial statements for the period from
April&nbsp;30, 2015 (inception) to December&nbsp;31, 2015 and the nine months ended September&nbsp;30, 2017 because they relate to historical periods that we believe will not be required to be included in the prospectus at the time of the
contemplated offering. We intend to amend the registration statement to include all financial information required by Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> at the date of such amendment before distributing a preliminary prospectus
to investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>Page<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_3">Information Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_4">Market, Industry and Other Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_9">Selected Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_10">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_13">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_14">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_15">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_16">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_18">Material U.S. Federal Income Tax Considerations For <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_18a">Underwriting </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_19">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_20">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_21">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom317356_22">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have authorized anyone to provide any information or to make any
representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to
the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this
prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have
changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through and including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 (25 days after the date of this prospectus), all dealers that effect transactions in these securities, whether or not
participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus or any free writing
prospectus we may provide to you in connection with this offering in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to
this offering and the distribution of this prospectus and any such free writing prospectus outside of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information contained elsewhere in this prospectus. This summary is not complete and does not contain all of the
information you should consider in making your investment decision. You should read the entire prospectus carefully before making an investment in our common stock. You should carefully consider, among other things, our financial statements and the
related notes and the sections titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included elsewhere in this prospectus. Except as otherwise indicated herein or
as the context otherwise requires, references in this prospectus to &#147;Arcus,&#148; &#147;the company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to Arcus Biosciences, Inc. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Arcus Biosciences, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company
Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited
biological opportunities. Specifically, we target well-characterized biological pathways with significant scientific data supporting their importance in regulating the immune response against cancer and for which either there are no molecules in
development or those that exist have suboptimal profiles. To exploit these pathways, we have built a robust and highly efficient discovery capability to create and optimize highly differentiated small-molecule immuno-oncology product candidates that
we believe will be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> and/or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class.</FONT></FONT> Since our inception in 2015, we
have built a broad portfolio of small-molecule and antibody product candidates that we plan to develop together as intra-portfolio combinations. We have initiated clinical trials for our two most advanced product candidates, both of which are
expected to generate data in 2018, and we expect initial efficacy data from our first intra-portfolio combination in early 2019. We plan to advance two additional product candidates into clinical trials by the end of 2018. Members of the Arcus team
have worked together for more than 10 years discovering innovative small-molecule product candidates while at companies such as Tularik Inc., Amgen, Inc. and Flexus Biosciences, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our initial focus is on the <FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> pathway, a key driver of immunosuppression in the tumor microenvironment.
Decades of scientific research have demonstrated that extracellular adenosine, generated by the CD73 enzyme, acts as a powerful inhibitor of immune cell activity. The compelling therapeutic rationale for inhibition of the <FONT
STYLE="white-space:nowrap">ATP-adenosine</FONT> pathway has led several companies to repurpose for oncology existing adenosine A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R receptor antagonists that were originally designed for the
treatment of central nervous system indications. We believe our lead product candidate, AB928, which we designed using our small-molecule discovery capability, is the first adenosine receptor antagonist that effectively blocks the adenosine receptor
in the tumor microenvironment and potently inhibits both the adenosine 2a receptor (A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R) and the adenosine 2b receptor (A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R). Our <I>in
vitro</I> studies have demonstrated that AB928 reverses adenosine-induced immunosuppression and inhibits the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R and A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors more
potently and effectively than the other adenosine receptor antagonists in clinical development. In addition to AB928, we have created a potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT>
small-molecule inhibitor of CD73, AB680, which could represent another powerful approach to inhibiting the <FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> pathway, and have generated additional potential product candidates against <FONT
STYLE="white-space:nowrap">ATP-adenosine</FONT> and other important immuno-oncology pathways using our internal discovery capability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the
immuno-oncology market evolves toward the use of combination therapies, a key element of our strategy is to build a broad portfolio of product candidates that target a wide range of immune mechanisms, which will enable us to pursue multiple
intra-portfolio combinations. Consistent with this strategy, we are developing antibody drug candidates that are currently considered backbone therapy or that have the potential to be future backbone therapies, such as our <FONT
STYLE="white-space:nowrap">in-licensed</FONT> antibodies targeting the immune checkpoint receptors <FONT STYLE="white-space:nowrap">PD-1</FONT> and TIGIT. By combining these antibodies with our differentiated, internally discovered small-molecule
product candidates, we intend to create <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> and/or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> combination
products. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Portfolio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following chart summarizes our product pipeline and our upcoming milestones. We currently hold world-wide rights to all of our product candidates other
than the rights to AB122 in China and five other countries that are outside of the United States, Europe and Japan. In addition, Taiho Pharmaceutical Co., Ltd. (Taiho) has an option to exclusively license the development and commercialization rights
to each of our programs for Japan and certain other territories in Asia (excluding China). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g61c05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are rapidly advancing our two lead, internally discovered small-molecule product candidates, the profiles of which are
summarized below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>AB928.</I></B> Our lead adenosine receptor antagonist, AB928, is an orally bioavailable, highly potent, reversible inhibitor of the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R and A<SUB
STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors. We believe AB928 is the first adenosine receptor antagonist in clinical development to be designed specifically for the biology of the tumor microenvironment and has multiple
advantages over other adenosine receptor antagonists in clinical development, including: (i)&nbsp;significantly greater potency under conditions that closely resemble the tumor microenvironment, for example, high concentrations of adenosine and
albumin, (ii)&nbsp;inhibition of both the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R and A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors, (iii)&nbsp;low penetration through the blood-brain barrier,
(iv)&nbsp;high penetration of tumor tissue and (v)&nbsp;attractive pharmacokinetics, with high oral bioavailability and a human half-life that enables once-daily dosing. AB928 is currently in a Phase 1 trial in healthy volunteers. This trial will
provide us with significant insights into the safety and pharmacokinetic and pharmacodynamic profiles of AB928, which could allow us to initiate the dose-escalation portion of our planned Phase 1/2 combination trials in cancer patients at a higher
dose than would otherwise be possible. We expect to report safety, pharmacokinetic and pharmacodynamic data from our Phase 1 trial and to initiate dose-escalation trials in cancer patients of AB928 in combination with AB122, our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody, and in combination with chemotherapy, in the second quarter of 2018. We are also focused on the identification of additional molecules that block adenosine
2 receptor signaling and have identified a second dual A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R/A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R antagonist as well as a selective A<SUB
STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonist. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>AB680.</I></B> Our lead CD73 inhibitor, AB680, is a highly potent, reversible and selective inhibitor of
the CD73 enzyme and is expected to be the first small-molecule inhibitor of CD73 to enter clinical development. As CD73 plays a critical role in the extracellular generation of adenosine, AB680 may provide a highly effective approach to preventing
adenosine-mediated immune suppression. We expect to advance AB680 for intravenous dosing into a Phase 1 trial in the second half of 2018. Based upon its </P></TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
projected pharmacokinetic profile, AB680 has the potential to be administered on the same dosing schedule as our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody, AB122, and various chemotherapeutic agents, which would be attractive from a patient compliance and commercial perspective. We are also evaluating
oral formulations of other internally discovered small-molecule CD73 inhibitors and expect to select an oral development candidate in 2018. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have <FONT STYLE="white-space:nowrap">in-licensed</FONT> two antibody drug candidates that represent current or potential backbone therapies, the profiles
of which are summarized below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>AB122.</I></B> Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody, AB122, is a fully human antibody with similar binding affinity and other characteristics to
the marketed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies, pembrolizumab and nivolumab. AB122 is currently in a Phase 1 dose-escalation trial in cancer patients in Australia. We expect to
initiate a Phase 1/2 trial of AB122 in combination with AB928 in cancer patients during the second quarter of 2018 and to report safety, pharmacokinetic and pharmacodynamic data from our ongoing Phase 1 trial of AB122 in cancer patients in the third
quarter of 2018. We also plan to develop AB122 in combination with our other small-molecule and antibody product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>AB154.</I></B> Our anti-TIGIT antibody, AB154,<B> </B>is a humanized antibody that inhibits a unique immune checkpoint target involved in a pathway that plays both inhibitory and stimulatory roles in the immune
system.<B> </B>We plan to file an investigational new drug application (IND) for AB154 in <FONT STYLE="white-space:nowrap">mid-2018</FONT> and to develop AB154 in combination with our other product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have initiated several other programs against promising immuno-oncology targets such as arginase, and we expect to select a development candidate in 2018
and file an IND or foreign regulatory application for the first development candidate from one of these programs by early 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background on the
Immuno-Oncology Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For decades, it has been understood that the immune system can be harnessed to eradicate and prevent the proliferation of
cancer cells. Unfortunately, multiple early clinical trial failures discouraged the biopharmaceutical industry from making a significant investment in immuno-oncology. However, when the immune checkpoint inhibitor ipilimumab, which blocks the
function of a receptor called <FONT STYLE="white-space:nowrap">CTLA-4,</FONT> generated positive Phase 3 data in melanoma in 2010, demonstrating durable responses in patients with very advanced disease, the biopharmaceutical industry&#146;s view of
the importance of immuno-oncology changed significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the ipilimumab data, biopharmaceutical companies focused their development efforts on
another class of immune checkpoint inhibitors that includes <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies, which block the <FONT STYLE="white-space:nowrap">PD-1</FONT> receptor found on
T&nbsp;cells, B cells and myeloid cells, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> antibodies, which block the <FONT STYLE="white-space:nowrap">PD-L1</FONT> ligand on cancer cells. Collectively, <FONT
STYLE="white-space:nowrap">anti-CTLA-4,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> antibodies
represent the first generation of immune checkpoint inhibitors. According to EvaluatePharma, a life sciences market intelligence firm, by 2022, these antibody products are expected to generate revenues of approximately $30&nbsp;billion globally.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the success of the first generation of immune checkpoint inhibitors, patient response rates for single-agent therapy are relatively low. For
example, the two approved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies, when administered as single agents, have only demonstrated response rates of approximately 30% in melanoma patients, and
the majority of these patients see their disease ultimately progress. The response rates in other tumor types are even lower. In addition, these therapies have not demonstrated meaningful single-agent activity in many of the most prevalent types of
cancer, such as breast, prostate, pancreatic, ovarian and colorectal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To address the limitations of single-agent immuno-oncology therapy, a significant
academic and industry effort is now underway to evaluate combinations of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies with other agents in order to
achieve </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
more frequent and durable responses. The challenge remains to identify and develop combinations that will ultimately succeed in important clinical settings. We believe that we are uniquely
positioned to address this opportunity by pursuing mechanisms and combinations supported by strong biological rationale derived from existing and evolving scientific data sets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Focus on Scientifically Validated Immuno-Oncology Pathways </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To exploit the significant opportunity in the immuno-oncology market in the most efficient manner and to maximize the addressable patient population for our
portfolio, we focus on the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Scientifically Validated Pathways.</I></B><I> </I>Academia has spent decades elucidating the biology behind the immune system&#146;s role in cancer, generating a large amount of information on pathways and
potential therapeutic targets. However, much of this information has yet to be translated into the discovery of high-quality product candidates. We are focusing on biological pathways for which we can leverage this body of existing scientific
knowledge to rapidly generate highly differentiated, small-molecule drug candidates and to identify promising combination therapies and clinical settings in which to pursue them. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Broad Range of Mechanisms.</I></B><B> </B>Currently approved immuno-oncology therapeutics target a relatively narrow spectrum of the immune system. We are focused on developing product candidates that act against
a broad range of mechanisms that enable tumors to evade eradication by the immune system. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Ubiquitously Important Targets. </I></B>We focus on targets that are ubiquitous, meaning that they are believed to play an important role in a broad range of human cancer types and settings. For example, CD73, the
key enzyme responsible for the generation of extracellular adenosine, has been found to be over-expressed in many tumor types, implying that the generation of extracellular adenosine is a relatively common occurrence in human cancer. As such, we
expect to pursue the development of AB928, AB680, and our other product candidates in multiple tumor types, utilizing an adaptive trial design that will allow us to explore several combination settings in parallel, starting with relatively small
patient cohorts. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Approach to Building a Broad and Differentiated Portfolio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To exploit the potential of these scientifically well understood immuno-oncology pathways and targets, we are focusing our internal discovery effort on novel
small-molecule product candidates. While all immuno-oncology agents approved to date are large molecules, we believe that both small and large molecule modalities will be critical in addressing the many different immune-mediated pathways that may be
dysregulated in a patient&#146;s tumor. As many immuno-oncology pathways are not amenable to intervention by antibodies or protein therapeutics, we expect that small-molecule approaches will allow us to access a significantly greater number of
potential targets. In addition, in some cases, small molecules may prove superior to large-molecule approaches against the same target. For example, we have shown in <I>in vitro</I> studies that our small-molecule CD73 inhibitors can achieve a
greater degree of CD73 inhibition than certain antibodies against this target that are in clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our internal discovery effort is designed
to create and advance small-molecule product candidates with the ideal pharmacological properties for the tumor micro-environment and the target of interest. Small-molecule drugs against the same biological target can be highly differentiated from
each other based on their respective pharmacokinetic, pharmacodynamic and biophysical properties. For example, many small-molecule drugs are potent when tested in buffer solution but lose a significant amount of this potency in physiologically
relevant media such as blood or tumor tissue. We rigorously test our molecules in whole blood or other physiologically relevant systems and only advance molecules that retain a high degree of activity when tested under such &#147;real world&#148;
conditions. We also design our molecules to have the ideal pharmacological properties for the targeted pathway and the desired clinical effect. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To support our intra-portfolio combinations, we are also developing antibody product candidates that target
what we believe are some of the most important immune checkpoint receptors, including <FONT STYLE="white-space:nowrap">PD-1</FONT> and TIGIT, and that we expect to be critical components of our future intra-portfolio combinations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Internal Discovery Capability and Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our discovery
capability and organization have enabled the rapid and efficient generation of potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> small-molecule immuno-oncology drug candidates. In the case of
our A<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>R antagonist program, we identified the first compounds in February 2016, synthesized AB928 in December 2016, and initiated our first clinical trial of AB928 in November 2017, essentially
progressing from program initiation to first subject dosed within 21 months. We believe our discovery capability and our expertise and efficiency will allow us to replicate the rapid timeline that we achieved with AB928. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assembled a management team with highly relevant experience in immuno-oncology, small-molecule drug discovery and clinical development. Members of our
scientific and senior management team, including our founders, Dr.&nbsp;Terry Rosen and Dr.&nbsp;Juan Jaen, have demonstrated their ability to rapidly discover product candidates, most recently at Flexus Biosciences, Inc., which was acquired by
Bristol-Myers Squibb in 2015 for up to $1.25&nbsp;billion in total payments for its preclinical-stage <FONT STYLE="white-space:nowrap">IDO-1</FONT> enzyme inhibitor, now called <FONT STYLE="white-space:nowrap">BMS-986205,</FONT> approximately 18
months after the company&#146;s formation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception in 2015, we have raised approximately $227&nbsp;million in equity capital from investors
that have significant life sciences experience and that share our vision to create a leading company in the immuno-oncology field, including: GV (formerly Google Ventures), The Column Group, Foresite Capital, Wellington Management Company LLP, EcoR1
Capital, BVF Partners L.P., Decheng Capital, Invus Opportunities, Hillhouse, Aisling Capital, Novartis Institute for BioMedical Research, Inc., Celgene Corporation, Stanford University, Taiho Ventures and DROIA Oncology Ventures. This equity capital
includes approximately $22&nbsp;million in investments made by our founders and management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our objective is to transform the treatment of cancer by creating a broad portfolio of innovative immuno-oncology therapeutics and developing combinations that
offer significant improvement over current treatment options. To achieve this objective, we are pursuing the following strategies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Rapidly advance our lead product candidates and combinations through clinical development in multiple tumor types.</I></B> We plan to pursue development strategies, such as initiating clinical trials in healthy
volunteers for certain of our product candidates and utilizing adaptive trial designs, that will potentially allow us to expedite the development of our product candidates and to rapidly generate meaningful clinical data. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Pursue combinations and tumor types based on strong biological rationale.</I></B><I> </I>We are pursuing therapeutic combinations driven by strong biological rationale that suggests synergy between the agents. We
are also selecting tumor types that we believe will be most sensitive to our product candidates&#146; mechanisms of action, such as those that have high CD73 expression and T cell infiltration in the case of AB928 and AB680. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Control, or otherwise secure access to, all the components of our desired therapeutic combinations.</I></B><I> </I>We plan to secure access to product candidates that will be critical components of our
intra-portfolio combinations, as we did with our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and anti-TIGIT antibodies. By having these assets in our portfolio, we can better control the combinations we
pursue, as well as capture a greater share of the commercial value of the combination products. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Continue to expand our pipeline of novel small-molecule product candidates</I></B><B>.</B><B><I> </I></B>More than 80% of our workforce is dedicated to research and development, and we plan to continue to invest
in our discovery capability and to expand our pipeline. By the end of 2018, we expect to have filed at least four regulatory applications to initiate clinical trials in the United States or other countries, including two for product candidates that
we discovered and developed <FONT STYLE="white-space:nowrap">in-house.</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Retain significant economic and commercial rights to our programs in key geographic areas.</I></B> We plan to retain significant economic and commercial rights to our portfolio in the United States and certain
other regions. We have pursued and will continue to evaluate opportunities to <FONT STYLE="white-space:nowrap">out-license</FONT> rights to our product candidates in regions in which we are unlikely to pursue development and commercialization on our
own, as was the case with our option and license agreement with Taiho for Japan and certain other territories in Asia (excluding China). </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to
implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully in the section entitled &#147;Risk Factors&#148; immediately following this
prospectus summary. These risks include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are an early-stage immuno-oncology company with a very limited operating history. We have incurred net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable
future. We have never generated any revenue from product sales and may never be profitable. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Even if this offering is successful, we will need to obtain substantial additional funding to complete the development and any commercialization of our product candidates. If we are unable to raise this capital when
needed, we may be forced to delay, reduce or eliminate our product development programs or other operations. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our product candidates are in the early stages of development. We only recently began clinical trials to test some of our product candidates in humans and, as a company, we have limited experience in this area.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Clinical drug development is a lengthy, expensive and uncertain process. The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance
into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their product candidates are shown to be safer
or more effective than ours, or if we are not able to differentiate our small molecules from other products which are approved or in development, then our commercial opportunity will be reduced or eliminated. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Serious adverse events, undesirable side effects or other unexpected properties of our product candidates, or reports of any such occurrences or lack of efficacy by third parties that are developing the same product
candidates in other territories, may be identified during development or after approval, which could adversely affect our clinical development programs or otherwise limit the commercial potential of our product candidates. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We rely on third parties to conduct our clinical trials, manufacture our product candidates and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their
contractual duties or fail to meet expected deadlines, our development programs, including our clinical trials, may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are currently party to several <FONT STYLE="white-space:nowrap">in-license</FONT> agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our product candidates. If we
breach our obligations under these agreements, we may be required to pay damages, lose our rights to these product candidates or both, which would adversely affect our business and prospects. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we are unable to obtain and maintain patent protection for our current or any future product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete
effectively in our markets. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We expect to expand our development, regulatory and operational capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). An emerging growth company may take advantage of relief from certain reporting requirements and other burdens that are
otherwise applicable generally to public companies. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced obligations with respect to financial data, including presenting only two years of audited financial statements in addition to any required unaudited interim financial statements and only two years of selected
financial data; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an exemption from compliance with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes Oxley Act of 2002 (the Sarbanes Oxley Act); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing
additional information about the audit and the financial statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations about our executive compensation arrangements in our periodic reports, proxy statements and registration statements; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive compensation or golden parachute arrangements. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions for up to five years or such earlier time that we no longer qualify as an emerging growth company. We may choose to
take advantage of some but not all of these reduced reporting burdens. We would cease to be an emerging growth company if we have more than $1.07&nbsp;billion in annual gross revenues, have more than $700&nbsp;million in market value of our capital
stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> or issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to
private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards. Accordingly, we will be subject to the same new or revised accounting standards as other public companies that are not
emerging growth companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
were incorporated in Delaware on April&nbsp;30, 2015. Our principal executive offices are located at 3928 Point Eden Way, Hayward, CA 94545, and our telephone number is (510) <FONT STYLE="white-space:nowrap">694-6200.</FONT> Our website address is
www.arcusbio.com. The information on, or that can be accessed through, our website is not part of this prospectus. We have included our website address as an inactive textual reference only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arcus Biosciences and the Arcus Biosciences logo are the property of Arcus. Trade names, trademarks and service marks of other companies appearing in this
prospectus are the property of their respective holders. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuer </P></TD>
<TD>Arcus Biosciences, Inc. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock we are offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock to be outstanding after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their option to
purchase additional shares in full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Underwriters&#146; option to purchase additional shares </P></TD>
<TD>We have granted the underwriters the option, exercisable for 30 days following the date of this prospectus, to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to
purchase additional shares in full, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus. The principal purposes of this offering are to increase our financial flexibility and create a public market for our common stock. We intend to
use the net proceeds from this offering as follows: (i)&nbsp;approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the clinical development of AB928 (our dual A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R/A<SUB
STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R antagonist) and AB122 (our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody) and (ii)&nbsp;the remaining proceeds to fund the development of
other product candidates in our pipeline, including AB680 (our CD73 inhibitor) and AB154 (our anti-TIGIT antibody), our drug discovery and optimization programs, and other general corporate purposes, which may include the hiring of additional
personnel, capital expenditures and the costs of operating as a public company. See &#147;Use of Proceeds&#148; on page 64. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See &#147;Risk Factors&#148; beginning on page 12 and the other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symbol </P></TD>
<TD>&#147;RCUS&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock to be outstanding after this offering is based
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding as of December&nbsp;31, 2017, and excludes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the exercise of options outstanding as of December&nbsp;31, 2017 with a
weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the exercise of options granted after December&nbsp;31, 2017 with a
weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; and </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under our equity compensation plans, consisting
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that were reserved for issuance under our 2015 Stock Plan as of December&nbsp;31,
2017,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for issuance under our 2018 Equity Incentive Plan, which will become effective in connection with the
completion of this offering and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for issuance under our 2018 Employee Stock Purchase Plan, which will become
effective in connection with the completion of this offering. We expect that the number of shares reserved for issuance under each of our 2018 Equity Incentive Plan and 2018 Employee Stock Purchase Plan will be increased automatically on the first
business day of each of our fiscal years, by a number equal to the smallest of (i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, (ii)&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of common stock outstanding on the
last business day of the prior fiscal year or (iii)&nbsp;the number of shares determined by our board of directors. On the date immediately prior to the date of this prospectus, we expect that any remaining shares available for issuance under our
2015 Stock Plan will be added to the shares reserved under our 2018 Equity Incentive Plan in effect following the completion of this offering and we will cease granting awards under our 2015 Stock Plan. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information in this prospectus assumes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the automatic conversion of all outstanding shares of our preferred stock into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock immediately prior to and in connection with the completion of this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of the underwriters&#146; option to purchase additional shares; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise or cancellation of outstanding options or acceleration of vesting of any restricted stock subsequent to December&nbsp;31, 2017; however, any such awards issued under our 2015 Stock Plan that expire,
terminate or are forfeited will become available for issuance under our 2018 Equity Incentive Plan. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables set forth a summary of our historical financial data as of, and for the periods ended on, the dates indicated. The statement of
operations data for the fiscal year ended December&nbsp;31, 2016, and the balance sheet data as of December&nbsp;31, 2016, are derived from our audited financial statements and related notes included elsewhere in this prospectus. You should read
these data together with our financial statements and related notes appearing elsewhere in this prospectus and the information in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical
results are not necessarily indicative of the results to be expected in the future. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used to compute basic and diluted net loss per common
share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,421,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per common share, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used to compute pro forma basic and diluted net loss per
common share (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See Note &nbsp;&nbsp;&nbsp;&nbsp; to our audited financial statements for an explanation of the calculation of our historical and pro forma basic and diluted net loss per common share. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="10" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The pro forma column in the balance sheet data above gives effect to: (i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock; and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation, each of which will occur
immediately prior to the completion of this offering. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted column gives effect to the adjustments described in footnote (1)&nbsp;above and the sale by us of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">A $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the estimated price range set forth on the cover page of this
prospectus, would increase (decrease) each of pro forma as adjusted cash, cash equivalents and short-term investments, working capital, total assets and stockholders&#146; (deficit) equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million,
assuming the number of shares we are offering, as set forth on the cover page of this prospectus, remains the same, after deducting estimated underwriting discounts and commissions. We may also increase or decrease the number of shares we are
offering. An increase (decrease) of 1,000,000 in the number of shares we are offering would increase (decrease) each of pro forma as adjusted cash, cash equivalents and short-term investments, working capital, total assets and total
stockholders&#146; (deficit) equity by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the initial public offering price per share remains the same. The pro forma as adjusted information is illustrative only, and we
will adjust this information based on the actual initial public offering price, number of shares offered and other terms of this offering determined at pricing. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. See our audited financial statements for further details regarding our current assets and current liabilities. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock is speculative and involves a high degree of risk. Before investing in our common stock, you should consider carefully the
risks described below, together with the other information contained in this prospectus, including our financial statements and the related notes appearing at the end of this prospectus. If any of the following risks occur, our business, financial
condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose all or part of your investment. This prospectus
also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described
below. See &#147;Information Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Limited Operating History, Financial Position and
Capital Requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an early-stage immuno-oncology company with a very limited operating history. We have incurred net losses since our
inception and anticipate that we will continue to incur significant losses for the foreseeable future. We have never generated any revenue from product sales and may never be profitable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an early-stage immuno-oncology company with a very limited operating history that may make it difficult to evaluate the success of our business to date
and to assess our future viability. Our operations have been limited to organizing and staffing our company, business planning, raising capital, identifying potential product candidates, establishing licensing arrangements and/or acquiring any
necessary technology, and undertaking research and preclinical studies and clinical trials of our product candidates. All of our product candidates are in early development, and none have been approved for commercial sale. We have never generated
any revenue from product sales and have incurred net losses each year since we commenced operations. For the years ended December&nbsp;31, 2016 and December&nbsp;31, 2017, our net losses were $18.0 million and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, respectively. As of December&nbsp;31, 2017, we had an accumulated deficit of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. We expect that it will be several years, if ever, before
we have a product candidate ready for commercialization. We expect to incur increasing levels of operating losses over the next several years and for the foreseeable future as we advance our product candidates. Our prior losses, combined with
expected future losses, have had and will continue to have an adverse effect on our stockholders&#146; deficit and working capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To become and remain
profitable, we must develop and eventually commercialize a product with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our
product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in
these activities and, even if we succeed in commercializing one or more of our product candidates, we may never generate revenues that are significant or large enough to achieve profitability. In addition, as a young business, we may encounter
unforeseen expenses, difficulties, complications, delays and other known and unknown challenges. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur
substantial research and development and other expenditures to develop and market additional product candidates. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital,
maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if this offering is successful, we will need to obtain substantial additional funding to complete the development and any commercialization of our
product candidates. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially during the next few
years. The development of biopharmaceutical product candidates is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital intensive. As our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our clinical, regulatory,
quality and manufacturing capabilities. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to marketing, sales, manufacturing and distribution.
Furthermore, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
of&nbsp;December&nbsp;31, 2017, we had $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million in cash, cash equivalents and short-term investments. Based on our current operating plan, we believe that our existing cash, cash equivalents and
short-term investments, together with the net proceeds from this offering, will be sufficient to fund our anticipated level of operations through at least the next 12 months. We have based this estimate on assumptions that may prove to be incorrect
or require adjustment as a result of business decisions, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, rate of progress and costs of our drug discovery, preclinical development activities, laboratory testing and clinical trials for our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and scope of clinical programs we decide to pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope and costs of manufacturing development and commercial manufacturing activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and amount of milestone payments, if any, we receive from Taiho Pharmaceuticals Co., Ltd. (Taiho) under our option and license agreement (the Taiho Agreement); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost, timing and outcome of regulatory review of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of establishing sales and marketing capabilities, if any of our product candidates receive marketing approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain collaborations on favorable terms, if at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with being a public company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost associated with commercializing our product candidates, if they receive marketing approval. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Identifying potential product candidates and conducting preclinical studies and clinical trials is a time consuming, expensive and uncertain process that
takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval. In addition, our product candidates, if approved, may not achieve product sales or commercial success. We do not expect to have
any products commercially available for sale for many years, if at all. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive
terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The amount of
our future losses is uncertain and our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and
may be difficult to predict, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our
competitors or partners; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully recruit and retain subjects for clinical trials, and any delays caused by difficulties in such efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain marketing approval for our product candidates, and the timing and scope of any such approvals we may receive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may change from time to time; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of our agreements with manufacturers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to attract, hire and retain qualified personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenditures that we will or may incur to develop additional product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of demand for our product candidates should they receive approval, which may vary significantly; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future therapeutics that compete with our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the changing and volatile U.S. and global economic environments; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">future accounting pronouncements or changes in our accounting policies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cumulative effects of these
factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial
analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the
expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or
require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product
revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or
convertible debt securities, your ownership interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve
agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to
delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Discovery and Development of our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates are in the early stages of development. We only recently began clinical trials to test some of our product candidates in humans
and, as a company, we have limited experience in this area. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are early in our development efforts and most of our operations to date have been
limited to drug discovery and preclinical studies. Our two lead product candidates entered Phase 1 clinical trials in November 2017 and we plan to advance two additional product candidates into Phase 1 clinical trials in 2018. As a result, we will
need to expand our clinical operations, quality and regulatory capabilities to support these activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have not had any interactions with
the FDA regarding our product candidates or an investigational new drug application (IND) to authorize us to conduct clinical trials in the United States. Our ongoing Phase 1 clinical trials are being conducted outside the United States. Because of
our lack of interaction with the FDA, we may not learn of certain information or data that the FDA may request until after we begin such interactions or, without such interaction, submit our IND in the future, which may necessitate conducting
additional preclinical studies or generating such information at significant time and expense, including under a clinical hold imposed on the IND. Even if we conducted the additional studies or generated the additional information requested, the FDA
could disagree that we have satisfied their requirements, all of which will cause significant delays to our programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In part because of our limited
infrastructure, experience conducting clinical trials as a company and regulatory interactions, we cannot be certain that our clinical trials will be completed on time, that our planned clinical trials will be initiated on time, if at all, that our
planned development programs would be acceptable to the FDA or other comparable foreign regulatory authorities, or that, if approval is obtained, such product candidates can be successfully commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on our ability to successfully
complete the above activities and any other activities required for the successful development and eventual commercialization of one or more of our product candidates. The success of our product candidates will further depend on factors such as:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful completion of preclinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval of IND or other regulatory applications for our planned clinical trials or future clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful enrollment in, and completion of, clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of marketing approvals from applicable regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing manufacturing capabilities or arrangements with third party manufacturers for clinical supply and, if and when approved, for commercial supply; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in combination with others; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively competing with other therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing and implementing marketing and reimbursement strategies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining and maintaining third party coverage and adequate reimbursement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability to obtain clearance or approval of companion diagnostic tests, if required, on a timely basis, or at all; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining a continued acceptable safety profile of any product following approval. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not achieve one or more of these factors in a timely manner, we could experience significant delays
or an inability to successfully commercialize our product candidates, which would materially harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical drug development is a
lengthy, expensive and uncertain process. The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate that we advance into clinical trials may not achieve favorable results in later
clinical trials, if any, or receive marketing approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The research and development of drugs and biological products is an extremely risky
industry. Only a small percentage of product candidates that enter the development process ever receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete
preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, can take many years to complete and its outcome is uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results of preclinical and early clinical trials of our product candidates and other products with the same mechanism of action may not be predictive of
the results of later-stage clinical trials. Clinical trial failure may result from a multitude of factors including flaws in study design, dose selection, placebo effect, patient enrollment criteria and failure to demonstrate favorable safety or
efficacy traits. As such, failure in clinical trials can occur at any stage of testing. A number of companies in the biopharmaceutical industry have suffered setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety
profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from
clinical trials are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may further delay, limit or prevent marketing approval. Furthermore, as more product candidates within a particular
class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have two product candidates in clinical development and their risk of failure is high. We are unable to predict if these product candidates or
any of our future product candidates that advance into clinical trials will prove safe or effective in humans or will obtain marketing approval. If we are unable to complete preclinical or clinical trials of current or future product candidates, due
to safety concerns, or if the results of these trials are not satisfactory to convince regulatory authorities of their safety or efficacy, we will not be able to obtain marketing approval for commercialization. Even if we are able to obtain
marketing approvals for any of our product candidates, those approvals may be for indications that are not as broad as desired or may contain other limitations that would adversely affect our ability to generate revenue from sales of those products.
Moreover, if we are not able to differentiate our product against other approved products within the same class of drugs, or if any of the other circumstances described above occur, our business would be materially harmed and our ability to generate
revenue from that class of drugs would be severely impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A key element of our strategy is the development of intra-portfolio combinations. If
we are not successful in discovering, developing and commercializing product candidates that take advantage of different mechanisms of action to achieve superior outcomes relative to the use of single agents or other combination therapies, our
ability to achieve our strategic objectives would be impaired. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A key element of our strategy is to build a broad portfolio of product candidates
that will allow for the development of intra-portfolio combinations. We believe that by developing or licensing these product candidates, we can control the combinations we pursue and, if and when approved, maximize the commercial potential of these
combinations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, these combinations have not been tested before and may fail to demonstrate synergistic activity against immunological targets, may
fail to achieve superior outcomes relative to the use of single agents or other combination therapies, may exacerbate adverse events associated with one of the product candidates when used </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as monotherapy, or may fail to demonstrate sufficient safety or efficacy traits in clinical trials to enable us to complete those clinical trials or obtain marketing approval for the combination
therapy. We expect that AB122 will form the backbone of many of our intra-portfolio combinations. In the event that AB122, which is currently in a Phase 1 trial, were to fail to demonstrate sufficient safety and efficacy, we would need to identify
alternatives for accessing an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody. In the event we are unable to do so, or are unable to do so on commercially reasonable terms, our business and
prospects would be materially harmed. All of our product candidates are targeting mechanisms that other companies are pursuing as either monotherapy or combination products. Please see &#147;Business&#151;Competition&#148; for a discussion of our
competitors. As such, even if we are successful in developing combination therapies, competition from other product candidates in the same class which are either already approved or further along in development than ours may prevent us from
realizing the commercial potential of our combination therapies and prevent us from achieving our strategic objectives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our intra-portfolio
combination strategy relies on discovering, developing and commercializing highly differentiated small molecules. If we are not able to differentiate our small molecules from other products which are approved or in development, our business
prospects would be materially adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our combination therapy strategy relies on discovering and developing differentiated small
molecules with optimal pharmacologic properties for the targeted pathway to complement our antibody product candidates, which we believe will form the backbone of our combination therapies. We conduct in our laboratories those activities that we
consider to be critical for creating a development candidate with optimal properties. These activities include medicinal chemistry, assay development, assessment of compound potency and selectivity, <I>in vitro</I> and <I>in vivo</I> pharmacokinetic
profile evaluation, <I>in vivo</I> pharmacology and exploratory safety evaluation, among others. As such, we have invested heavily in these internal capabilities and over 80% of our current workforce is dedicated to research and development. If the
small molecules that we discover and design do not have optimal pharmacologic properties, or are not differentiated from other product candidates in development, either through their efficacy or toxicity profile, our product development activities,
business and prospects would be materially harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Serious adverse events, undesirable side effects or other unexpected properties of our product
candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following
marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have only tested AB928 in healthy volunteers and AB122 in a limited number of oncology subjects. As we continue our development of these product
candidates and initiate clinical trials of our additional product candidates, serious adverse events, undesirable side effects or unexpected characteristics may emerge causing us to abandon these product candidates or limit their development to more
narrow uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if our product candidates initially show promise in these early clinical trials, the side effects of drugs are frequently only detectable after they are
tested in large, Phase 3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. Sometimes, it can be difficult to determine if the serious adverse or unexpected side effects were caused by
the product candidate or another factor, especially in oncology subjects who may suffer from other medical conditions and be taking other medications. If serious adverse or unexpected side effects are identified during development and are determined
to be attributed to our product candidate, we may be required to develop a Risk Evaluation and Mitigation Strategy (REMS) to mitigate those serious safety risks, which could impose significant distribution and use restrictions on our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drug-related side effects could also affect subject recruitment or the ability of enrolled subjects to complete the trial or result in potential product
liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if one or more of our product candidates receives marketing approval, and we or others later
identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw approvals of such product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require additional warnings on the label; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for harm caused to patients; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market
acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lack
of efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third parties investigating the same product candidates as us in different territories, which could adversely affect our development program.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lack of efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third parties investigating the same
product candidates as us in different territories. For example, we and Harbin Gloria Pharmaceuticals Co. Ltd. (Gloria Pharmaceuticals) each licensed our rights to the same
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody (which we refer to as AB122) from WuXi Biologics (Cayman) Inc. (WuXi Biologics). Gloria Pharmaceuticals refers to this antibody as <FONT
STYLE="white-space:nowrap">GLS-010</FONT> and is conducting clinical trials with <FONT STYLE="white-space:nowrap">GLS-010</FONT> in China. We have no control over their clinical trials or development program, and lack of efficacy, adverse events or
undesirable side effects experienced by subjects in their clinical trials could adversely affect our development of AB122 or even the viability of AB122 as a product candidate. We may be required to report Gloria Pharmaceuticals&#146; adverse events
or unexpected side effects to the FDA or comparable foreign regulatory authorities, which could, among other things, order us to cease further development of AB122. We may face similar risks if Taiho exercises its option to license development
rights to any of our programs under the Taiho Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Enrollment and retention of subjects in clinical trials is expensive and time consuming,
can be made more difficult or rendered impossible by competing treatments or clinical trials of competing product candidates in the same or other indications, and could result in significant delays and additional costs in our product development
activities, or in the failure of such activities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may encounter delays in enrolling, or be unable to enroll and maintain, a sufficient number
of subjects to complete any of our clinical trials. Patient enrollment and retention in clinical studies is a significant factor in the timing of clinical studies and depends on many factors, including the size of the patient population required for
analysis of the trial&#146;s primary endpoints, the nature of the trial protocol, our ability to recruit clinical trial investigators with the appropriate competencies and experience, the existing body of safety and efficacy data with respect to the
product candidate, the number and nature of competing products or product candidates and ongoing clinical trials of competing product candidates for the same indication, the proximity of subjects to clinical trial sites, the eligibility criteria for
the clinical trial and our ability to obtain and maintain subject consents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, enrollment of oncology subjects in our AB122 clinical trial may
be hampered by nivolumab from Bristol-Myers Squibb and pembrolizumab from Merck, both of which are approved and on the market. Subjects may opt to be treated with an approved product with substantially more safety and efficacy data as is currently
available for our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody product candidate. Bristol-Myers Squibb and Merck may also be conducting clinical trials of these products in additional
indications, and some of those clinical sites may also participate in our clinical trials, which could reduce the number of subjects available for our clinical trials at those sites. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, any negative results that we may report in clinical trials of our product candidates may make
it difficult or impossible to recruit and retain subjects in other clinical trials of that same product candidate. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which
could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. Failures in planned subject enrollment or retention may result in increased costs or program delays and could render
further development impossible. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our product candidates may require companion diagnostics in certain indications. Failure to successfully
develop, validate and obtain regulatory clearance or approval for such tests could harm our product development strategy or prevent us from realizing the full commercial potential of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our product candidates may require companion diagnostics to identify appropriate patients for those product candidates in certain indications.
Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as a medical device and may require separate regulatory authorization prior to commercialization. We may rely on third parties for the design,
development, testing and manufacturing of these companion diagnostics, the application for and receipt of any required regulatory authorization, and the commercial supply of these companion diagnostics. If these parties are unable to successfully
develop companion diagnostics for these product candidates, or experience delays in doing so, the development of our product candidates may be adversely affected and we may not be able to obtain marketing authorization for these product candidates.
Furthermore, our ability to market and sell, as well as the commercial success, of any of our product candidates that require a companion diagnostic will be tied to, and dependent upon, the receipt of required regulatory authorization and the
continued ability of such third parties to make the companion diagnostic commercially available on reasonable terms in the relevant geographies. Any failure to develop, validate, obtain and maintain marketing authorization for a companion diagnostic
and supply such companion diagnostic will harm our business, results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The design or our execution of our
ongoing and future clinical trials may not support marketing approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The design or execution of a clinical trial can determine whether its
results will support marketing approval, and flaws in the design or execution of a clinical trial may not become apparent until the clinical trial is well advanced. In some instances, there can be significant variability in safety or efficacy
results between different trials with the same product candidate due to numerous factors, including differences in trial protocols, size and type of the patient populations, variable adherence to the dosing regimen or other protocol requirements and
the rate of dropout among clinical trial participants. We do not know whether any clinical trials we conduct will demonstrate consistent or adequate efficacy and safety to obtain marketing approval to market our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and in determining when or whether
marketing approval will be obtained for any of our product candidates. Our product candidates may not be approved even if they achieve their primary endpoints in future Phase 3 clinical trials or registrational trials. The FDA or comparable foreign
regulatory authorities may disagree with our trial designs and our interpretation of data from preclinical studies or clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate
even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 clinical trial that has the potential to result in FDA or other comparable foreign regulatory authorities&#146; approval. In addition, any of these regulatory
authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or comparable foreign regulatory authorities
may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates, if approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Both of our current clinical trials are being conducted outside the United States, and the FDA may not
accept data from trials conducted in foreign locations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both of our current clinical trials are being conducted outside the United States.
Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and
performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the
FDA deems clinically meaningful. In general, the patient population for any clinical trials conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. In addition,
while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. We cannot assure you that the FDA
will accept data from trials conducted outside of the United States. If the FDA does not accept the data from such clinical trials, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or
permanently halt our development of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular product candidate or
indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we must prioritize our research programs and will need to focus our product candidates on the
potential treatment of certain indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions
may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially
viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty
arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any termination or suspension of, or delays in the commencement or completion of, our planned clinical trials could result in increased costs to us,
delay or limit our ability to generate revenue and adversely affect our commercial prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before we can initiate clinical trials in the United
States for our product candidates, we must submit the results of preclinical testing to the FDA along with other information, including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial
protocol, as part of an IND. We do not know whether our planned trials will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA placing the clinical trial on hold; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subjects failing to enroll or remain in our trial at the rate we expect; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subjects choosing an alternative treatment or other product candidates, or participating in competing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of adequate funding to continue the clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subjects experiencing severe or unexpected drug-related adverse effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any interruptions or delays in the supply of our product candidates for our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a facility manufacturing any of our product candidates or any of their components being ordered by the FDA or
comparable foreign regulatory authorities to temporarily or permanently shut down due to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
violations of good manufacturing practice (cGMP) regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any changes to our manufacturing process that may be necessary or desired; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any failure or delay in reaching an agreement with contract research organizations (CROs) and clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol,
good clinical practices (GCP) or regulatory requirements or other third parties not performing data collection or analysis in a timely or accurate manner; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other comparable foreign regulatory authorities for violations of applicable regulatory requirements, in which case we may need
to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">one or more Institutional Review Boards (IRBs) refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing its approval of the trial;
or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in regulatory requirements and policies, which may require us to amend clinical trial protocols to comply with these changes and resubmit our clinical trial protocols to IRBs for reexamination.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and
jeopardize the commercial prospects of our product candidates and our ability to commence product sales and generate revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, many of the
factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. For example, if we make
manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Further, if one or more clinical trials are delayed, our competitors may be able
to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly. Any termination of any
clinical trial of our product candidates will harm our commercial prospects and our ability to generate revenues. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our
efforts to identify or discover additional product candidates in the future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research programs may initially show promise in identifying
potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to design such product candidates with the pharmacological properties that we desire or attractive pharmacokinetics; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be medicines that will receive marketing approval and achieve
market acceptance. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research programs to identify new product candidates require substantial technical, financial and human resources. If we
are unable to identify suitable compounds for preclinical and clinical development, we will not be able to obtain product revenues in future periods, which likely would result in significant harm to our financial position and adversely impact our
stock price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not achieve our product development goals in the time frames we announce and expect, the
commercialization of our product candidates may be delayed and as a result our share price may decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drug development is inherently risky and
uncertain. We cannot be certain that we will be able to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complete <FONT STYLE="white-space:nowrap">IND-enabling</FONT> preclinical studies in time to initiate clinical trials in the timeframes we announce; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain sufficient clinical supply of our product candidates to support our ongoing or planned clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiate our clinical trials within the timeframes we announce; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enroll and maintain a sufficient number of subjects to complete any of our clinical trials; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">analyze the data collected from any completed clinical trials in the timeframes we announce. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The actual
timing of our development milestones can vary significantly compared to our estimates, in some cases for reasons beyond our control. If we are unable to achieve our goals within the timeframes we announce, the commercialization of our product
candidates may be delayed and, as a result, the stock price of our common stock could fall and you may lose all of your investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if any of
our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, healthcare payors and others in the medical community necessary for commercial
success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by
physicians, patients, healthcare payors and others in the medical community. For example, current cancer treatments like chemotherapy and radiation therapy are well established in the medical community, and physicians may continue to rely on these
treatments. Most of our product candidates currently target mechanisms for which there are no currently approved products. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and
we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">efficacy and potential advantages compared to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to offer our medicines for sale at competitive prices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">convenience and ease of administration compared to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the strength of marketing and distribution support; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sufficient third-party coverage or reimbursement; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Manufacturing, Commercialization and
Reliance on Third Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our clinical trials, manufacture our product candidates and perform some of our
research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an
adverse effect on our business and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have the ability to conduct all aspects of our preclinical testing or clinical trials
ourselves. As a result, we are and expect to remain dependent on third parties to conduct our ongoing Phase 1 clinical trials and any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
future clinical trials of our product candidates. The timing of the initiation and completion of these trials will therefore be partially controlled by such third parties and may result in delays
to our development programs. Specifically, we expect CROs, clinical investigators, and consultants to play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, we will not be able to control
all aspects of their activities. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other
third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the
European Economic Area, Australian Therapeutic Goods Administration and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic
inspections of trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites fail to comply with applicable GCP requirements, the data generated in our clinical trials may be deemed
unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under
cGMP regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have any manufacturing facilities. We produce in our laboratory relatively small quantities of compounds for evaluation in our research programs. We
rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates are approved. We currently have limited
manufacturing arrangements and expect that each of our product candidates will only be covered by single source suppliers for the foreseeable future. This reliance increases the risk that we will not have sufficient quantities of our product
candidates or products, if approved, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. Furthermore, all entities involved in the preparation of therapeutics for
clinical trials or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical trials
must be manufactured in accordance with cGMP requirements. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of
investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable
in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a New Drug Application (NDA) or Biologics Licensing Application (BLA) on a timely basis and must adhere to the FDA&#146;s Good
Laboratory Practice regulations and cGMP regulations enforced by the FDA through its facilities inspection program. Comparable foreign regulatory authorities may require compliance with similar requirements. The facilities and quality systems of our
third-party contractor manufacturers must pass a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection for compliance with the applicable regulations as a condition of marketing approval of our product candidates. We do not control the
manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMP regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no
guarantee that any such CROs, clinical trial investigators, contract manufacturers or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. If any of these
third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise performs in a substandard manner, or terminates its engagement with us, the timelines for our development programs may be
extended or delayed or our development activities may be suspended or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of <FONT STYLE="white-space:nowrap">follow-up</FONT> information on subjects
enrolled in such clinical trials unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. In addition, clinical trial investigators for our clinical trials may serve as scientific
advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or comparable foreign regulatory authorities concludes that the financial relationship
may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or
rejection of any marketing application we submit by the FDA or any comparable foreign regulatory authority. Any such delay or rejection could prevent us from commercializing our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not
successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing
approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because
we rely on third-party manufacturing organizations and suppliers, our supply of product candidates for use in clinical trials and raw materials for use in development may become limited or interrupted or may not be of satisfactory quality and
quantity. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on third-party contract manufacturers to manufacture our preclinical and clinical trial supplies of product candidates. We do
not own manufacturing facilities for producing such supplies. We cannot assure you that our preclinical and clinical development product supplies will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable
prices. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacturing process for a product candidate is subject to FDA and comparable foreign regulatory authority review. Suppliers and manufacturers must meet
applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory requirements, such as cGMP. In the event that any of our manufacturers fails to
comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the
materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on commerically reasonable terms, if at all. In some cases, the technical
skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not
exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for
any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new
manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue to rely on
third-party manufacturers if we receive marketing approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their
obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to maintain third-party manufacturing for our product candidates on commercially
reasonable terms, we may not be able to develop and commercialize our future product candidates successfully. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our or a third party&#146;s failure to
execute on our manufacturing requirements, to do so on commercially reasonable terms and comply with cGMP could adversely affect our business in a number of ways, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an inability to initiate or continue clinical trials of our product candidates under development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of the cooperation of an existing or future collaborator, including option exercises by Taiho under the Taiho Agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requirements to cease development or to recall batches of our product candidates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product or any other future product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We, or our third-party manufacturers, may be unable to successfully <FONT STYLE="white-space:nowrap">scale-up</FONT> manufacturing of our product
candidates in sufficient quality and quantity, which would delay or prevent us from conducting clinical trials and developing our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to conduct clinical trials of our product candidates, we will need to manufacture them in large quantities. We, or our manufacturing partners, may be
unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during <FONT STYLE="white-space:nowrap">scale-up</FONT> activities.
If we or our manufacturing partners are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or become
infeasible, and marketing approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As product candidates progress through preclinical to late stage clinical trials to marketing approval and commercialization, it is common that various aspects
of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield, manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk
that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered
materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our
ability to commercialize our product candidates and generate revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of biologics is complex and our third-party manufacturers may
encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or
prevented. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies to handle
living cells. Each lot of an approved biologic must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing biologics requires facilities specifically designed for and validated for this purpose, and sophisticated
quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures,
product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such
changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical
trials and adversely harm our business. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial
scale including, among others, cost overruns, potential problems with process <FONT STYLE="white-space:nowrap">scale-up,</FONT> process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely
availability of raw materials. Even if we obtain marketing approval for any of our product candidates, there is no assurance that our manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other
comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential commercial launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient
quantities for clinical trials or for commercialization, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Affordable Care Act includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which created an abbreviated approval
pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the
FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until twelve years from the date on which the reference product
was first licensed. During this twelve-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#146;s own preclinical
data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact,
implementation and meaning are subject to uncertainty. While the processes to implement the BPCIA have not yet been fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our
biological products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AB122 and AB154 are biological products and we may develop additional biological products in the future. We believe that any of our
current and future product candidates approved as a biological product under a BLA should qualify for the twelve-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise,
or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the
BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our reference products in a way that is similar to traditional generic
substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products will depend on a number of marketplace and regulatory factors that are still developing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive marketing approval, we may not be able to successfully commercialize our product candidates due to unfavorable pricing regulations or
third-party coverage and reimbursement policies, which could make it difficult for us to sell our product candidates profitably. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining
coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our
products to the payor. There may be significant delays in obtaining such coverage and reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or comparable foreign
regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a product will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale
and distribution expenses. Interim reimbursement levels for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical
setting in which it is used, may be based on reimbursement levels already set for lower cost products and may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors, by
any future laws limiting drug prices and by any future relaxation of laws that presently restrict imports of product from countries where they may be sold at lower prices than in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Third-party payors often rely upon Medicare
coverage policy and payment limitations in setting reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination that use of a
product is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a covered benefit under its health plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safe, effective and medically necessary; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appropriate for the specific patient; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effective; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">neither experimental nor investigational. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be sure that reimbursement will be available for any
product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement will be. Obtaining reimbursement for our products may be particularly difficult because of the higher prices often associated with
branded therapeutics and therapeutics administered under the supervision of a physician. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we
develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reimbursement may impact the demand for, and the price of, any product for which we obtain marketing approval. Assuming we obtain coverage for a given product
by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Patients who are prescribed medications for the treatment
of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with those medications. Patients are unlikely to use our products unless coverage is provided and
reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards
that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect
to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward
pressure on healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the successful
commercialization of new products. Further, the adoption and implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the price that we may receive for any approved
product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside of the United States, many countries require approval of the sale price of a product before it can be marketed and the pricing review
period only begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some of these countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product
candidate to other available therapies. In some foreign </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a
product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues, if any, we are able to generate from the sale
of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if such product candidates obtain marketing approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the market opportunities for any product that we or our strategic partners develop are smaller than we believe they are, our revenue may be adversely
affected and our business may suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are focused on the development of treatments for cancer. Our projections of addressable patient
populations that have the potential to benefit from treatment with our product candidates are based on estimates. If any of our estimates are inaccurate, the market opportunities for any of our product candidates could be significantly diminished
and have an adverse material impact on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, clinical trial investigators, CROs, consultants, vendors and any potential
commercial partners may engage in misconduct or other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud or other misconduct by our employees, clinical trial investigators, CROs, consultants, vendors and any potential commercial
partners. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i)&nbsp;FDA laws and regulations or those of comparable foreign regulatory authorities,
including those laws that require the reporting of true, complete and accurate information, (ii)&nbsp;manufacturing standards, (iii)&nbsp;federal and state health and data privacy, security, fraud and abuse, government price reporting, transparency
reporting requirements, and other healthcare laws and regulations in the United States and abroad, or (iv)&nbsp;laws that require the true, complete and accurate reporting of financial information or data. Such misconduct could also involve the
improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We intend to adopt a code of conduct applicable to all of our employees upon the completion
of this offering, as well as a disclosure program and other applicable policies and procedures, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted
against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our
trade secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we rely on third parties to research and develop and to manufacture our product
candidates, we must share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements
with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential
information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our
competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and
trade secrets, a competitor&#146;s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, employees, third-party
contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with will likely expect to
be granted rights to publish data arising out of such collaboration and any joint research and development programs may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to
protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#146;s
discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any of our product candidates
are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize
our product candidates if and when they are approved. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no sales, marketing or distribution capabilities or experience. To achieve
commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization, which would be expensive and time consuming, or outsource these functions to other third
parties. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these
services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities
is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing
personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize our medicines on our own include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future medicines; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of complementary medicines to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we
enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product revenues to us are likely to be lower than if we were to market and sell any medicines that
we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. In entering into third-party
marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or devote the necessary
resources and attention to sell and market our medicines effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our
product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or
commercialize such products outside of the United States, which would limit our ability to realize their full market potential. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to market
any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory
authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation
and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time
consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and
subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for
sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain
required approvals, our ability to realize the full market potential of our products will be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our <FONT
STYLE="white-space:nowrap">In-Licenses</FONT> and Other Strategic Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are currently party to several
<FONT STYLE="white-space:nowrap">in-license</FONT> agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our product candidates. If we breach our obligations under these agreements, we may be required
to pay damages, lose our rights to these product candidates or both, which would adversely affect our business and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely, in part, on
license and other strategic agreements, which subject us to various obligations, including diligence obligations with respect to development and commercialization activities, payment obligations for achievement of certain milestones and royalties on
product sales, negative covenants and other material obligations. If we fail to comply with the obligations under our license agreements or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and
our licensors may have the right to terminate the license. If our license agreements are terminated, we may not be able to develop, manufacture, market or sell the products covered by our agreements and those being tested or approved in combination
with such products. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement and any other product candidates being developed or tested in combination. For example, we intend to
test many of our small-molecule product candidates with AB122, which we <FONT STYLE="white-space:nowrap">in-licensed</FONT> from WuXi Biologics. In the event we breach our license agreement with WuXi Biologics, and WuXi Biologics terminates our
license agreement, we would be unable to test those combinations, or we would have to negotiate a new or reinstated agreement, which may not be available to us on equally favorable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which we license intellectual property or technology to or from third parties are complex, and certain provisions in such
agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or
increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes
over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual
property rights we have, we may have to abandon development of the relevant research program or product candidate and our business, financial condition, results of operations and prospects could suffer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not realize the benefits of any acquisitions,
<FONT STYLE="white-space:nowrap">in-license</FONT> or other collaborations or strategic alliances that we enter into. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into <FONT
STYLE="white-space:nowrap">in-license</FONT> agreements with multiple licensors and an option agreement to out-license certain of our product candidates in select markets and in the future may seek and form strategic alliances, create joint ventures
or collaborations, or enter into acquisitions or additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future
product candidates that we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These transactions can entail numerous operational and financial risks, including exposure to unknown
liabilities, disruption of our business and diversion of our management&#146;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive
issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and
cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership
and the inability to retain key employees of any acquired business. As a result, if we enter into collaboration agreements, strategic partnerships or license our products, we may not be able to realize the benefit of such transactions if we are
unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such
transaction or such other benefits that led us to enter into the arrangement. For example, the Taiho Agreement provides us with <FONT STYLE="white-space:nowrap">non-dilutive</FONT> capital to fund our operations and a strategic development and
commercialization partner for our product candidates in Japan and certain other Asian territories. If Taiho does not exercise any of its options to our development programs, our capital requirements relating to our development programs will
significantly increase and we may need to seek a new partner in order to develop and commercialize our product candidates in the territories optioned by Taiho. Failure to realize the benefits of any collaborations or strategic alliances may further
cause us to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any planned sales or marketing
activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we will need to obtain additional
expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization
activities, we may not be able to further develop our product candidates or bring them to market and generate product sales revenue, which would harm our business prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may wish to acquire rights to future assets through <FONT STYLE="white-space:nowrap">in-licensing</FONT> or may attempt to form collaborations in the
future with respect to our product candidates, but may not be able to do so, which may cause us to alter or delay our development and commercialization plans. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and potential commercialization of our product candidates will require substantial additional capital to fund expenses. We have entered into an
option and license agreement with Taiho for the potential development and commercialization of our product candidates in Japan and certain other Asian territories. We may, in the future, decide to collaborate with other biopharmaceutical companies
for the development and potential commercialization of those product candidates in other countries or territories of the world. We will face significant competition in seeking appropriate collaborators. We may not be successful in our efforts to
establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third party for development and commercialization of a product
candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our
assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the design or results of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of approval by the FDA or comparable foreign regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential market for the product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs and complexities of manufacturing and delivering such product candidate to patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential of competing products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the existence of uncertainty with respect to our ownership of technology or other rights, which can exist if there is a challenge to such ownership without regard to the merits of the challenge; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">industry and market conditions generally. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collaborator may also consider alternative product candidates
or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under any license agreements from
entering into agreements on certain terms or at all with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large
pharmaceutical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable
terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned
sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development,
manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product
candidates or bring them to market and generate product revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Managing our obligations under our
<FONT STYLE="white-space:nowrap">in-license</FONT> agreements and our option agreement may divert management time and attention, causing delays or disruptions to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into and may in the future enter into <FONT STYLE="white-space:nowrap">in-license</FONT> agreements with multiple licensors and a strategic
option agreement, which subject us to various obligations, including diligence obligations, reporting and notification obligations, payment obligations for achievement of certain milestone as well as other material obligations. We may need to devote
substantial time and attention to ensuring that we successfully integrate these transactions into our existing operations and are compliant with our obligations under these agreements, which may divert management&#146;s time and attention away from
our research and development programs or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
<FONT STYLE="white-space:nowrap">in-license</FONT> and strategic agreements are also complex and certain provisions in those agreements may be susceptible to multiple interpretations. In the event of any disagreement about the interpretation of
these provisions, our management may need to devote a disproportionate amount of its attention to resolving these disagreements. Such disruptions may cause delays in our research and development programs and other business objectives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operating activities may be restricted by certain covenants in our license and other strategic
agreements, which could limit our development and commercial opportunities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with certain of our acquisitions, <FONT
STYLE="white-space:nowrap">in-license</FONT> or other collaborations or strategic alliances, we may agree to and be bound by negative covenants which may limit our development and commercial opportunities. For example, pursuant to our <FONT
STYLE="white-space:nowrap">in-license</FONT> of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies from WuXi Biologics, we made certain covenants to not commercialize any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody licensed or obtained by us after the date of the license agreement with WuXi Biologics other than <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies licensed from WuXi Biologics, subject to certain exceptions as set forth in our license agreement with WuXi Biologics. Furthermore, we agreed in our license agreement that WuXi Biologics
would be our exclusive manufacturer of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies licensed thereunder until a certain number of years has elapsed following commercialization of such an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody and that we would utilize WuXi Biologics as our exclusive provider of CMC development services for our biologic product candidates for three years from the
date of our license agreement, subject to certain exceptions in each case. These exclusivity provisions may inhibit our development efforts, prevent us from forming strategic collaborations to develop and potentially commercialize any other <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody product candidates and may materially harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are
unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar
or identical to ours, and our ability to successfully commercialize our products may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends in large part on
our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and research programs. We seek to protect our proprietary position by filing patent applications in the United
States and abroad related to our novel discoveries and technologies that are important to our business. Our pending and future patent applications may not result in patents being issued which protect our product candidates or their intended uses or
which effectively prevent others from commercializing competitive technologies, products or product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining and enforcing patents is
expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain and/or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely
manner. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to obtain patent protection. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and
confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract
manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been
the subject of much litigation, resulting in court decisions, including Supreme Court decisions, that have increased uncertainties as to the ability to enforce patent rights in the future. In addition, the laws of foreign countries may not protect
our rights to the same extent as the laws of the United States, or vice versa. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, we may not be aware of all third-party intellectual property
rights potentially relating to our product candidates or their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of
such third-party intellectual property upon our freedom to operate, is highly uncertain. Patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all.
Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent
rights are highly uncertain. Our patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third party
<FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the U.S. Patent and Trademark Office, or become involved in post-grant review procedures, oppositions, derivations, reexaminations, or inter partes review proceedings,
in the United States or elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held
unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition,
given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third party patent which might
adversely affect our ability to develop and market our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot guarantee that any of our patent searches or analyses, including the
identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third party patent and pending application in the United
States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The scope of a patent claim
is determined by an interpretation of the law, the written disclosure in a patent and the patent&#146;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively
impact our ability to market our products. We may incorrectly determine that our products are not covered by a third party patent or may incorrectly predict whether a third party&#146;s pending application will issue with claims of relevant scope.
Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and
correctly interpret relevant patents may negatively impact our ability to develop and market our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In the future, we may need to obtain
additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not
anticipated. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time we may be required to license technology from additional third parties to further develop or commercialize our
product candidates. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our product candidates, such licenses may not be available to us on commercially reasonable
terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on
our patent applications will not be challenged and rendered invalid and/or unenforceable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have pending U.S. and foreign patent applications in
our portfolio, however, we cannot predict: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if and when patents may issue based on our patent applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of protection of any patent issuing based on our patent applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the claims of any patent issuing based on our patent applications will provide protection against competitors, </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether or not third parties will find ways to invalidate or circumvent our patent rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose; and/or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in
other foreign countries. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be certain that the claims in our pending patent applications directed to our product candidates and/or
technologies will be considered patentable by the U.S. Patent and Trademark Office (USPTO) or by patent offices in foreign countries. One aspect of the determination of patentability of our inventions depends on the scope and content of the
&#147;prior art,&#148; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of
our patent claims or, if issued, affect the validity or enforceability of a patent claim. Even if the patents do issue based on our patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in
such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around
our claims. If the breadth or strength of our intellectual property position with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize our
product candidates. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not
adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">it is possible that our pending patent applications will not lead to issued patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our
major commercial markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not develop additional proprietary technologies that are patentable; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the patents of others may have an adverse effect on our business. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they
could significantly harm our business, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are sued for infringing intellectual property rights of third parties, such litigation could be
costly and time consuming and could prevent or delay us from developing or commercializing our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends,
in part, on our ability to develop, manufacture, market and sell our product candidates without infringing the intellectual property and other proprietary rights of third parties. Third parties may allege that we have infringed or misappropriated
their intellectual property. Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and, even if resolved in our favor, is likely to divert
significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim
proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially
increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or
proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios.
Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or
threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our products candidates. Third parties may assert infringement claims against us based on existing or future intellectual property
rights. For example, we are aware of certain patents owned or exclusively licensed by Bristol-Myers Squibb (BMS) having claims directed broadly to treating cancer with anti-PD-1 antibodies (the BMS Patents), which expire in 2023 and 2024. The BMS
Patents are currently the subject of litigation between BMS and several other parties. If the validity of the BMS Patents is upheld following all such challenges, and if we receive regulatory approval for AB122 prior to expiration of the BMS
Patents, then we may need to delay our commercialization of AB122 or we may need to obtain a license from BMS, which license may not be available on commercially reasonable terms, or at all. The pharmaceutical and biotechnology industries have
produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and
the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent
claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a showing of clear and convincing evidence to overcome the
presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings,
which could have a material adverse effect on our business and operations. In addition, we may not have sufficient resources to bring these actions to a successful conclusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are found to infringe a third party&#146;s intellectual property rights, we could be forced, including by court order, to cease developing,
manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing
the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A
finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or
trade secrets of third parties could have a similar negative impact on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents or other intellectual property,
which could be expensive, time consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents, trademarks, copyrights or other intellectual
property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert
against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent
infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a
risk that, even if the validity of such patents is upheld, the court will construe the patent&#146;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent
claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude
third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement
claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be
forced to cease use of such trademarks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may decide not to grant an injunction against further infringing
activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive
these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims,
which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we
receive as a result of the proceedings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because of the expense and uncertainty of litigation, we may not be in a position to enforce our
intellectual property rights against third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the expense and uncertainty of litigation, we may conclude that even if a third
party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too
high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other
<FONT STYLE="white-space:nowrap">non-litigious</FONT> action or solution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants or
independent contractors have wrongfully used or disclosed confidential information of third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could in the future be subject to claims
that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the
intellectual property, proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or her <FONT
STYLE="white-space:nowrap">non-competition</FONT> or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other
proprietary information of a former employer or competitor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we may litigate to defend ourselves against these claims, even if we are successful, litigation could
result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our
product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our
reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations and
financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents are of national or regional effect, and filing, prosecuting and defending patents on all of our product candidates throughout the world would be
prohibitively expensive. As such, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or
other jurisdictions. Further, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals or
biologics, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. In addition, certain developing countries, including China and India, have
compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a
license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to
obtain a significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent law in the United States and
other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the
case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is
therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs. Recent patent reform legislation in the United States
and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act), signed into law on September&nbsp;16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more
efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent
by USPTO administered post-grant proceedings, including post-grant review, <I>inter partes </I>review, and derivation proceedings. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in
which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. However,
the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on
our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. Supreme Court has ruled on several patent cases in recent years, either
narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant <FONT
STYLE="white-space:nowrap">law-making</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and
patents that we might obtain in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural, document
submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the
USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment
and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance
can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in
abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly
legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may rely on trade secret and proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> which can be difficult to trace and enforce and, if we are
unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to seeking patents
for some of our technology and product candidates, we may also rely on trade secrets, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position. Elements
of our product candidate, including processes for their preparation and manufacture, may involve proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology that is not covered by patents, and thus for these aspects we
may consider trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> to be our primary intellectual property. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our
facilities or third party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary
information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade
secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. We require our employees to enter into written employment agreements containing provisions of confidentiality and obligations to assign to us any inventions
generated in the course of their employment. We and any third parties with whom we share facilities enter into written agreements that include confidentiality and intellectual property obligations to protect each party&#146;s property, potential
trade secrets, proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> and information. We further seek to protect our potential trade secrets, proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> and information in part, by entering
into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, contract research organizations, contract
manufacturers, consultants, advisors and other third parties. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. Despite these efforts, any of these parties
may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade
secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be
lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an
inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views
regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in
developing our product candidates or as a result of questions regarding <FONT STYLE="white-space:nowrap">co-ownership</FONT> of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or
ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims,
litigation could result in substantial costs and be a distraction to management and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our
competitive position on our product candidates for an adequate amount of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent rights are of limited duration. Given the amount of time
required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product
candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. A patent term extension based on regulatory delay may be available in the United States. However, only a
single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not extend to the full scope of the
claim, but instead only to the scope of the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family.
Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term
extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products
following our patent expiration, and our revenue could be reduced, possibly materially. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Business Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are highly dependent on the services of our founders, Terry Rosen, Ph.D., who serves as our Chief Executive Officer, and Juan Jaen, Ph.D., who serves
as our President. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are highly dependent on the services of our founders, Terry Rosen, Ph.D., who serves as our Chief Executive Officer, and Juan
Jaen, Ph.D., who serves as our President. Although we have entered into employment agreements with them, they are not for a specific term and each of them may terminate their employment with us at any time, though we are not aware of any present
intention of either of these individuals to leave us. We maintain &#147;key person&#148; insurance on each of them, but not for any of our other executives or employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drs. Rosen and Jaen have significant experience identifying and developing biopharmaceuticals. Drs. Rosen and Jaen were previously the founders of Flexus
Biosciences, Inc., which was acquired by Bristol-Myers Squibb </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approximately 18&nbsp;months after it was founded to access its IDO-1 enzyme inhibitor. Previously, Dr.&nbsp;Rosen was Vice President of Therapeutic Discovery at Amgen, overseeing large and
small-molecule drug discovery efforts, and Dr.&nbsp;Jaen was Senior Vice President, Drug Discovery and Chief Scientific Officer at ChemoCentryx, having built a track record of efficiently moving quality product candidates from discovery into
clinical development across a wide range of therapeutic areas, including oncology. We believe that their drug discovery and development experience, and overall biopharmaceutical company management experience, would be difficult to replace. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drs. Rosen and Jaen have certain other business and personal commitments outside of serving as the Chief Executive Officer and President of Arcus, including
serving on the boards of other companies and foundations. Drs. Rosen and Jaen are defendants in an ongoing litigation with Incyte Corporation related to their previous company, Flexus Biosciences, Inc., alleging misappropriation of trade secrets,
which litigation our founders believe has no merit. While such litigation involves no claims against our company, our founders may be required to focus time on the defense of such litigation, and any adverse developments in the litigation could
affect our company&#146;s reputation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our development, regulatory and operational capabilities and, as a result, we may
encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;1, 2017, we had 78 full-time employees. As
we advance our research and development programs, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, quality, regulatory affairs and, if any
of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify, recruit integrate, maintain and motivate additional qualified personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manage our development efforts effectively, including the initiation and conduct of clinical trials for our product candidates, both as monotherapy and in combination with other intra-portfolio product candidates; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">improve our operational, financial and management controls, reporting systems and procedures. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future
financial performance and our ability to develop, manufacture and commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert financial and other
resources, and a disproportionate amount of its attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities in order to devote a substantial amount of time, to managing these growth
activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain third party contract organizations,
advisors and consultants to provide certain services, including assuming substantial responsibilities for the conduct of our clinical trials and the manufacture of our product candidates. We cannot assure you that the services of such third party
contract organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the
quality or accuracy of the services provided by our vendors or consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of our product candidates or
otherwise advance our business. We cannot assure you that we will be able to properly manage our existing vendors or consultants or find other competent outside vendors and consultants on economically reasonable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able
to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key employees, consultants and advisors and to
attract, retain and motivate qualified personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our industry has experienced a high rate of turnover in recent years. Our ability to compete in
the highly competitive biopharmaceuticals industry depends upon our ability to attract, retain and motivate highly skilled and experienced personnel with scientific, medical, regulatory, manufacturing and management skills and experience. We conduct
our operations in the San Francisco Bay Area, a region that is home to many other biopharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel. We may not be able to attract
or retain qualified personnel in the future due to the intense competition for a limited number of qualified personnel among biopharmaceutical companies. Many of the other biopharmaceutical companies against which we compete have greater financial
and other resources, different risk profiles and a longer history in the industry than we do. Our competitors may provide higher compensation, more diverse opportunities and/or better opportunities for career advancement. Any or all of these
competing factors may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize our product candidates and to grow our business and operations as
currently contemplated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to
additional regulatory burdens and other risks and uncertainties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future profitability may depend, in part, on our ability to commercialize our
product candidates in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our product candidates before we receive marketing approval from the applicable regulatory authority in
that foreign market, and we may never receive such marketing approval for any of our product candidates. To obtain marketing approval in many foreign countries, we must comply with numerous and varying regulatory requirements of such countries
regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our product
candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to additional risks and uncertainties, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our customers&#146; ability to obtain reimbursement for our product candidates in foreign markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to directly control commercial activities because we are relying on third parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">import or export licensing requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">longer accounts receivable collection times; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">longer lead times for shipping; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">language barriers for technical training; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced protection of intellectual property rights in some foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the existence of additional potentially relevant third-party intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">foreign currency exchange rate fluctuations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign sales of our product candidates could also be adversely affected by the imposition of governmental controls, political and economic instability, trade
restrictions and changes in tariffs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face substantial competition, which may result in others discovering, developing or commercializing
products more quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The development and commercialization of new products is highly competitive. We compete in the segments of the pharmaceutical, biotechnology and other related
markets that develop immunotherapies for the treatment of cancer. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects,
are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> Our competitors also may obtain marketing
approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other products in the same class as some of our product candidates have already been approved or are further along in development. With respect to our dual
adenosine receptor antagonist, AB928, we are aware of several other companies that are developing selective adenosine receptor antagonists including AstraZeneca/MedImmune, Corvus, iTEOS, Merck and Novartis. For our small-molecule CD73 inhibitor,
AB680, we are aware of several pharmaceutical companies developing antibodies against this target including AstraZeneca/MedImmune, Bristol-Myers Squibb, Corvus, Innate Pharma, Merck and Surface Oncology. Regarding our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody, AB122, multiple large pharmaceutical companies have already received regulatory approvals for their <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies including AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer in partnership with Merck Kgaa and Roche/Genentech and there are also many other
anti-PD-1 and anti-PD-L1 antibodies in clinical development. With respect to our anti-TIGIT antibody, AB154, we are aware of several pharmaceutical companies developing antibodies against this target including Bristol-Myers Squibb, Merck, OncoMed
and Genentech. As more product candidates within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or
change. Consequently, the results of our clinical trials for product candidates in those class will likely need to show a risk benefit profile that is competitive with or more favorable than those products and product candidates in order to obtain
marketing approval or, if approved, a product label that is favorable for commercialization. If the risk benefit profile is not competitive with those products or product candidates, we may have developed a product that is not commercially viable,
that we are not able to sell profitably or that is unable to achieve favorable pricing or reimbursement. In such circumstances, our future product revenues and financial condition would be materially and adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our competitors, such as large pharmaceutical and biotechnology companies like AstraZeneca/MedImmune, Bristol-Myers Squibb, Merck, Novartis and
Roche/Genentech, have longer operating histories and significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals and marketing
approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may
also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel,
establishing clinical trial sites and subject enrollment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of all of our programs are likely to be their efficacy, safety, convenience, and availability of
reimbursement. If we are not successful in developing, commercializing and achieving higher levels of reimbursement than our competitors, we will not be able to compete against them and our business would be materially harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The development and commercialization of AB122 may face strong competition from other <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies that have already received marketing approval by larger companies with substantial resources and more experience developing, manufacturing and
commercializing biologic compounds. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed above, some companies, such as AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer in partnership
with Merck Kgaa and Roche/Genentech, have <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT> antibodies that are approved and on the market, and other companies are developing <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT> antibodies for various oncology indications that are further along in development than AB122. This competitive environment could limit our development
opportunities for AB122 or compromise our ability to successfully enroll our ongoing and future clinical trials with AB122 by limiting the availability of clinical trial investigators, sites and/or subjects which could slow, delay or limit the
progress of AB122&#146;s development. As a result of these or other problems and risks, we may never receive marketing approval for AB122, may not realize the full commercial potential of AB122 as monotherapy or in combination with our other product
candidates, may never recoup our financial investment or may never generate significant value or revenues from this asset. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal information
technology systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our product
candidates&#146; development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we
collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and
integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third party contractors who have access to our confidential information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, given their size and complexity and the increasing amounts of confidential information that they maintain,
our internal information technology systems and those of our third-party CROs and other contractors and consultants are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural
disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from
cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, social engineering and other means to
affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure or lead to data leakage. Certain data breaches must be reported to affected individuals and the
government, and in some cases to the media, under provisions of the Health Insurance Portability and Accountability Act (HIPAA), other U.S. federal and state law, and financial penalties may also apply. To the extent that any disruption or security
breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and reputational damage and the further development and commercialization of
our drug candidates could be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we have not experienced any such system failure, accident or security breach to date, we cannot assure you
that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems or other cyber incidents that could have a material adverse effect upon our reputation,
business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be
delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of
our internal information technology systems or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets
or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or
disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law
equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure
and reputational damages that could potentially have an adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We or the third parties upon whom we depend may be
adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our headquarters and main research facility are located in the San Francisco Bay Area, which in the past has experienced severe earthquakes and fires. If these
earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevented us from using all or a significant portion of our headquarters or research facility, it may be difficult or, in certain cases,
impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or
third party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. Furthermore, integral parties in our
supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our
ability to conduct our clinical trials, our development plans and business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unfavorable global economic conditions could adversely affect our
business, financial condition or results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our results of operations could be adversely affected by general conditions in the global
economy and in the global financial markets. We currently conduct both of our clinical trials outside of the United States and unfavorable economic conditions resulting in the weakening of the U.S. dollar would make those clinical trials more costly
to operate. Furthermore, the most recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including a
reduced ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot
anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We conduct
clinical development operations through our Australian wholly owned subsidiary. If we lose our ability to operate in Australia, our business and results of operations may suffer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2017, we formed a whollyowned Australian subsidiary, Arcus Biosciences Australia Pty Ltd, to develop our product candidates in Australia. Due to
the geographical distance and lack of employees currently in Australia, as well as our lack of experience operating in Australia, we may not be able to efficiently or successfully monitor any clinical trials we conduct in Australia nor the
development of our product candidates in Australia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss carryforwards and certain other tax attributes may be
limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never
achieve profitability. To the extent that we continue to generate taxable losses, unused losses </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will carry forward to offset future taxable income, if any, until such unused losses expire. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation
undergoes an &#147;ownership change,&#148; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#146;s ability to use its <FONT
STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards (NOLs) and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited.
As a result, if we earn net taxable income, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs to offset such taxable income may be subject to limitations. Similar provisions of state tax law may also apply to limit our
use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, even if we
attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Industry </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability
lawsuits against us could cause us to incur substantial liabilities and could limit our commercialization of any product candidates that we may develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater
risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual
outcome, product liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or termination of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for any product candidates or products that we may develop; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injury to our reputation and significant negative media attention; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial subjects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiation of investigations by regulators; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant costs to defend the related litigation and diversion of management&#146;s time and our resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to study subjects or patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product recalls, withdrawals or labeling, marketing or promotional restrictions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenue; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize any products that we may develop. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we maintain product liability
insurance coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as our product candidates advance through clinical trials and if we successfully commercialize
any products. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our industry is highly regulated by the FDA and comparable foreign regulatory agencies. We must comply with extensive, strictly enforced regulatory
requirements to develop, obtain, and maintain marketing approval for any of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securing FDA or comparable foreign regulatory
approval requires the submission of extensive preclinical and clinical data and supporting information for each therapeutic indication to establish the product candidate&#146;s safety and efficacy for its intended use. It takes years to complete the
testing of a new drug or biologic and development delays and/or failure can occur at any stage of testing. Any of our present and future clinical trials may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delayed, halted, not authorized, or approval of any of our products may be delayed or may not be obtained due to any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any preclinical test or clinical trial may fail to produce safety and efficacy results satisfactory to the FDA or comparable foreign regulatory authorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preclinical and clinical data can be interpreted in different ways, which could delay, limit or prevent marketing approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative or inconclusive results from a preclinical test or clinical trial or adverse events during a clinical trial could cause a preclinical study or clinical trial to be repeated or a development program to be
terminated, even if other studies relating to the development program are ongoing or have been completed and were successful; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or comparable foreign regulatory authorities can place a clinical hold on a trial if, among other reasons, it finds that subjects enrolled in the trial are or would be exposed to an unreasonable and significant
risk of illness or injury; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the facilities that we utilize, or the processes or facilities of third party vendors, including without limitation the contract manufacturers who will be manufacturing drug substance and drug product for us or any
potential collaborators, may not satisfactorily complete inspections by the FDA or comparable foreign regulatory authorities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may encounter delays or rejections based on changes in FDA policies or the policies of comparable foreign regulatory authorities during the period in which we develop a product candidate or the period required for
review of any final marketing approval before we are able to market any product candidate. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, information generated during the
clinical trial process is susceptible to varying interpretations that could delay, limit, or prevent marketing approval at any stage of the approval process. Moreover, early positive preclinical or clinical trial results may not be replicated in
later clinical trials. As more product candidates within a particular class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may
increase or change. Failure to demonstrate adequately the quality, safety and efficacy of any of our product candidates would delay or prevent marketing approval of the applicable product candidate. We cannot assure you that if clinical trials are
completed, either we or our potential collaborators will submit applications for required authorizations to manufacture or market potential products or that any such application will be reviewed and approved by appropriate regulatory authorities in
a timely manner, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive marketing approval for a product candidate, we will be subject to ongoing regulatory obligations and
continued regulatory review, which may result in significant additional expense and subject us to restrictions, withdrawal from the market, or penalties if we fail to comply with applicable regulatory requirements or if we experience unanticipated
problems with our product candidates, when and if approved. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once marketing approval has been granted by the FDA and comparable foreign regulatory
authorities, the approved product and those entities within the product&#146;s supply chain are subject to continual review by the applicable regulatory authorities. Any marketing approval that we receive for our product candidates may be subject to
limitations on the indicated uses for which the product may be marketed or contain requirements for potentially costly post-marketing <FONT STYLE="white-space:nowrap">follow-up</FONT> trials or surveillance to monitor the safety and efficacy of the
product. In addition, if the FDA and comparable foreign regulatory authorities approve any of our product candidates, we will be subject to extensive and ongoing regulatory requirements with regard to labeling, packaging, adverse event reporting,
storage, distribution, advertising, promotion, recordkeeping and submission of safety and other post-market information. Manufacturers of our products and manufacturers&#146; facilities are required to comply with cGMP regulations, which include
requirements related to quality control and quality assurance as well as the corresponding maintenance of records and documentation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, regulatory authorities must approve these manufacturing facilities before they can be used to
manufacture our products, and these facilities are subject to continual review and periodic inspections by the FDA and other comparable foreign regulatory authorities for compliance with cGMP regulations. Accordingly, we and others with whom we work
must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. We will also be required to report certain adverse reactions and production problems, if any, to the FDA
and other comparable regulatory authorities and to comply with requirements concerning advertising and promotion for our products. If we, any future collaboration partner or a regulatory authority discovers previously unknown problems with a
product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory authority may impose restrictions on that product, the collaboration partner, the manufacturer or
us, including requiring withdrawal of the product from the market or suspension of manufacturing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA as well as other comparable regulatory
authorities closely regulate the post-approval marketing and promotion of therapeutic products to ensure they are marketed only for the approved indications and in accordance with the provisions of the approved labeling and regulatory requirements.
The FDA and other comparable regulatory authorities also impose stringent restrictions on communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> use and if we do not restrict the marketing of our products only to their approved
indications, we may be subject to enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing. If we, our product candidates or the manufacturing facilities for our product candidates are not found to be in compliance with
regulatory requirements of the FDA and comparable foreign regulatory authorities, we could be subject to administrative or judicially imposed sanctions, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning letters or untitled letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">mandated modifications to promotional materials or the required provision of corrective information to healthcare practitioners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions imposed on the product or its manufacturers or manufacturing processes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions imposed on the labeling or marketing of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions imposed on product distribution or use; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requirements for post-marketing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension of any ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension of or withdrawal of marketing approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voluntary or mandatory product recalls and publicity requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to approve pending applications for marketing approval of new products or supplements to approved applications filed by us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on operations, including costly new manufacturing requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seizure or detention of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to permit the import or export of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">required entry into a consent decree, which can include imposition of various fines (including restitution or disgorgement of profits or revenue), reimbursements for inspection costs, required due dates for specific
actions and penalties for noncompliance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">civil or criminal penalties; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Widely publicized events concerning the safety risk of certain products have resulted in their
withdrawal from the market, revisions to product labeling that further limit use of the products and the imposition by the FDA of REMS to ensure that the benefits of the product outweigh its risks. In addition, because of the serious public health
risks of high profile adverse safety events with certain products, the FDA may require, as a condition of approval, costly REMS programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulatory requirements and policies may change and additional government regulations may be enacted for
which we may also be required to comply. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or in other countries. If we or any
future collaboration partner are not able to maintain regulatory compliance, we or such collaboration partner, as applicable, will not be permitted to market our future products and our business will suffer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the European Union, various penalties and sanctions exist in different EU Member States for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with the
EU marketing authorization procedure. The European Commission may also impose financial penalties on the holders of marketing authorizations if they fail to comply with certain obligations in connection with the authorizations. If we or our
potential collaborators fail to comply with applicable EU, or other foreign jurisdictions, regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of
products, operating restrictions and criminal prosecution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to comply with health and data protection laws and regulations could lead to
government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and any potential collaborators may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address
privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state
consumer protection laws (e.g., Section&nbsp;5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In
addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under federal Health Insurance Portability and
Accountability Act of 1996 (HIPAA) as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH). Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain,
use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">International data protection laws, including Directive 95/46/EC (EU Data Protection Directive) and EU Member State implementing legislation, may also apply
to health-related and other personal information obtained outside of the United States. The EU Data Protection Directive and the national implementing legislation of the individual EU Member States impose strict obligations on the ability to process
health-related and other personal information of EU data subjects, including in relation to collection, analysis and transfer. These include several requirements relating to the consent of the individuals to whom the personal data relates, the
information provided to the individuals, notification of data processing obligations to the competent national data protection authorities and the security and confidentiality of the personal data. The EU Data Protection Directive prohibits the
transfer of personal data to countries outside of the European Economic Area (EEA) such as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar
restrictions. Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland to the United States, uncertainty about compliance with EU data protection laws remains and data protection authorities from
the different EU Member States may interpret the EU Data Protection Directive and national laws differently, and guidance on implementation and compliance practices are often updated or otherwise revised, which adds to the complexity of processing
personal data in the European Union. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulation 2016/679 (EU Data Protection Regulation) will replace the EU Data Protection Directive in May 2018. The
EU Data Protection Regulation will introduce new data protection requirements in the European Union, as well as substantial fines for breaches of the data protection rules. The EU Data Protection Regulation will increase our responsibility and
liability in relation to personal data that we process, and we may be required to put in place additional mechanisms to ensure compliance with the new EU data protection rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to comply with U.S. and international data protection laws and regulations could result in
government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our
potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#146; privacy rights, failed
to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot
currently predict, and may have a significant adverse effect on our business and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and some foreign
jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate
post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Among policy makers and payors in the United States and elsewhere, including in the European Union, there is
significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these
efforts and has been significantly affected by major legislative initiatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act, as amended by the Health
Care and Education Reconciliation Act of 2010, or collectively the Affordable Care Act, substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The
Affordable Care Act, among other things: (i)&nbsp;introduced a new average manufacturer price definition for drugs and biologics that are inhaled, infused, instilled, implanted or injected and not generally dispensed through retail community
pharmacies; (ii)&nbsp;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and expanded rebate liability from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-service</FONT></FONT> Medicaid utilization to include the utilization of Medicaid managed care organizations as well; (iii)&nbsp;established a branded prescription drug fee
that pharmaceutical manufacturers of branded prescription drugs must pay to the federal government; (iv)&nbsp;expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to the program;
(v)&nbsp;established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of
applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; (vi)&nbsp;extended manufacturers&#146; Medicaid rebate liability to
covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; (vii)&nbsp;expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional
individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; (viii)&nbsp;created a licensure
framework for follow on biologic products; and (ix)&nbsp;established a Center for Medicare Innovation at the Centers for Medicare and Medicaid Services (CMS) to test innovative payment and service delivery models to lower Medicare and Medicaid
spending, potentially including prescription drug spending that began on January&nbsp;1, 2011. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial and
Congressional challenges to certain aspects of the Affordable Care Act, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the Affordable Care Act. Since January 2017, President Trump has signed two
Executive Orders designed to delay the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the Affordable Care Act. The Trump administration has also
announced that it will discontinue the payment of cost-sharing reduction (CSR) payments to insurance companies until Congress approves the appropriation of funds for the CSR payments. The loss of the CSR payments is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expected to increase premiums on certain policies issued by qualified health plans under the Affordable Care Act. A bipartisan bill to appropriate funds for CSR payments has been introduced in
the Senate, but the future of that bill is uncertain. In addition, CMS has recently proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the
effect of relaxing the essential health benefits required under the Affordable Care Act for plans sold through such marketplaces.&nbsp;Furthermore, each chamber of Congress has put forth multiple bills this year designed to repeal or repeal and
replace portions of the Affordable Care Act. Although none of these measures have been enacted by Congress to date, Congress may consider other legislation to repeal and replace elements of the Affordable Care Act. We continue to evaluate the effect
that the Affordable Care Act and its possible repeal and replacement has on our business. It is uncertain the extent to which any such changes may impact our business or financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes include aggregate reductions to Medicare
payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011 and subsequent laws, which began in 2013 and will remain in effect through 2025 unless additional Congressional action is taken. New laws may result in
additional reductions in Medicare and other healthcare funding, which may materially adversely affect customer demand and affordability for our products and, accordingly, the results of our financial operations. Additional changes that may affect
our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) which will first affect physician payment in 2019. At this
time, it is unclear how the introduction of the Medicare quality payment program will impact overall physician reimbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, there has been
heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which have resulted in several Congressional inquiries and proposed bills, as well as state efforts, designed to, among
other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Individual states in the United States
have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain
product access and marketing cost disclosure and transparency measures. For example, in September 2017, the California State Assembly approved SB17 which requires pharmaceutical companies to notify health insurers and government health plans at
least 60 days before any scheduled increases in the prices of their products if they exceed 16% over a <FONT STYLE="white-space:nowrap">two-year</FONT> period, and further requiring pharmaceutical companies to explain the reasons for such increase.
Effective in 2016, Vermont passed a law requiring certain manufacturer identified by the state to justify their price increases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that these and
other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. Any reduction in
reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability or commercialize our drugs, once marketing approval is obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the European Union, coverage and reimbursement status
of any product candidates for which we obtain regulatory approval are provided for by the national laws of EU Member States. The requirements may differ across the EU Member States. Also at national level, actions have been taken to enact
transparency laws regarding payments between pharmaceutical companies and health care professionals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will be subject to applicable fraud and abuse, transparency, government price reporting, and other
healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any future product candidates we may
develop and any product candidates for which we obtain marketing approval. Our arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may affect the
business or financial arrangements and relationships through which we would market, sell and distribute our products. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other
third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#146; rights are and will be applicable to our business. The laws that may affect our ability to operate include, but are not limited
to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or
covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare
and Medicaid programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and
prescribers, purchasers, and formulary managers on the other the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">federal civil and criminal false claims laws and civil monetary penalty laws, such as the False Claims Act (FCA) which imposes significant penalties and can be enforced by private citizens through civil qui tam actions,
prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of federal funds, and knowingly making, using or causing to be made or used a false
record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the FCA in connection with their alleged
<FONT STYLE="white-space:nowrap">off-label</FONT> promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to
customers with the expectation that the customers would bill federal health care programs for the product. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or
fraudulent claim for purposes of the FCA. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. In addition,
manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. Criminal prosecution is also possible for making
or presenting a false, fictitious or fraudulent claim to the federal government. Government enforcement agencies and private whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA for a variety of alleged
promotional and marketing activities, such as providing free product to customers with the expectation that the customers would bill federal programs for the product, providing consulting fees and other benefits to physicians to induce them to
prescribe products, engaging in promotion for <FONT STYLE="white-space:nowrap">&#147;off-label&#148;</FONT> uses, and submitting inflated best price information to the Medicaid Rebate Program; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud
any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal
criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in
connection with the delivery of or payment for healthcare benefits, items or services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by HITECH and its implementing regulations, which imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the
law, such as health plans, healthcare clearinghouses and healthcare providers and their respective business associates that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil
monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the
federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal transparency requirements under the Physician Payments Sunshine Act, created under the Affordable Care Act, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical
supplies reimbursed under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to report to the Department of Health and Human Services information related to payments and other transfers of value provided to physicians and teaching
hospitals and physician ownership and investment interests, including such ownership and investment interests interests held by a physician&#146;s immediate family members; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed
by any <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">state and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other health care providers, and other federal, state and foreign laws that govern the privacy and security of health
information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other
personal information, many of which differ from each other in significant ways and often are not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by HIPAA, thus requiring additional compliance efforts. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into consulting and scientific advisory board arrangements with physicians and other healthcare providers, including some who could influence
the use of our product candidates, if approved. Because of the complex and <FONT STYLE="white-space:nowrap">far-reaching</FONT> nature of these laws, regulatory agencies may view these transactions as prohibited arrangements that must be
restructured, or discontinued, or for which we could be subject to other significant penalties. We could be adversely affected if regulatory agencies interpret our financial relationships with providers who may influence the ordering of and use our
product candidates, if approved, to be in violation of applicable laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The scope and enforcement of each of these laws is uncertain and subject to rapid
change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies
and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be <FONT STYLE="white-space:nowrap">time-and</FONT> resource-consuming and
can divert management&#146;s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ensuring that our business arrangements with third parties comply with applicable healthcare laws and
regulations will likely be costly. If our operations are found to be in violation of any of these laws or any other current or future governmental laws and regulations that may apply to us, we may be subject to significant civil, criminal and
administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings,
additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or
restructuring of our operations, any of which could substantially disrupt our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws,
they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject
to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, &#147;Trade Laws&#148;)
prohibit, among other things, companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving
directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of
trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated
hospitals, universities, and other organizations. We also expect our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> activities to increase over time. We expect to rely on third parties for research, preclinical studies, and clinical trials and/or
to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior
knowledge of such activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or
penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, and the third parties with whom we share
our facilities, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Each of our
operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Each of our operations also produce hazardous waste products. We generally contract with third parties for the disposal of
these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. We could be held liable for any resulting damages in the event of contamination or injury resulting from the use of hazardous materials by us
or the third parties with whom we share our facilities, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the
use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage
or disposal of biological, hazardous or radioactive materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future
environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research and development. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other
sanctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Common Stock and this Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There has been no prior public market for our common stock, the stock price of our common stock may be volatile or may decline regardless of our
operating performance and you may not be able to resell your shares at or above the initial public offering price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There has been no public market
for our common stock prior to this offering. The initial public offering price for our common stock will be determined through negotiations between the underwriters and us and may vary from the market price of our common stock following this
offering. If you purchase shares of our common stock in this offering, you may not be able to resell those shares at or above the initial public offering price. An active or liquid market in our common stock may not develop upon the completion of
this offering or, if it does develop, it may not be sustainable. The market price of our common stock may fluctuate significantly in response to numerous factors, many of which are beyond our control, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overall performance of the equity markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our operating performance and the performance of other similar companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results from our ongoing clinical trials and future clinical trials with our current and future product candidates or of our competitors; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by securities analysts that elect to follow our common stock;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory or legal developments in the United States and other countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of expenses related to future product candidates or clinical development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our failure to achieve product development goals in the timeframe we announce; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of acquisitions, strategic alliances or significant agreements by us or by our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recruitment or departure of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the economy as a whole and market conditions in our industry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trading activity by a limited number of stockholders who together beneficially own a majority of our outstanding common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expiration of market standoff or contractual <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size of our market float; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other factors discussed in this prospectus. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the stock markets have experienced extreme price
and volume fluctuations that have affected and continue to affect the market prices of equity securities of many immuno-oncology companies. Stock prices of many immuno-oncology companies have fluctuated in a manner unrelated or disproportionate to
the operating performance of those companies. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial
costs, divert resources and the attention of management from our business and adversely affect our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Substantial amounts of our outstanding
shares may be sold into the market when <FONT STYLE="white-space:nowrap">lock-up</FONT> or market standoff periods end. If there are substantial sales of shares of our common stock, the price of our common stock could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our directors, executive officers and
significant stockholders, or if there is a large number of shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our common stock available for sale and the market perceives that sales will occur. After this offering, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
outstanding shares of our common stock, based on the number of shares outstanding as of December&nbsp;31, 2017. All of the shares of common stock sold in this offering will be available for sale in the public market. Substantially all of our
outstanding shares of common stock are currently restricted from resale as a result of market standoff and <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, as more fully described in &#147;Shares Eligible for Future
Sale.&#148; These shares will become available to be sold 181 days after the date of this prospectus. Shares held by directors, executive officers and other affiliates will be subject to volume limitations under Rule 144 under the Securities Act of
1933, as amended (the Securities Act), and various vesting agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After our initial public offering, certain of our stockholders will have rights,
subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our stockholders, subject to market standoff and lockup
agreements. We also intend to register shares of common stock that we have issued and may issue under our employee equity incentive plans. Once we register these shares, they will be able to be sold freely in the public market upon issuance, subject
to existing market standoff or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc., Goldman Sachs&nbsp;&amp; Co.
LLC and Leerink Partners LLC may, in their discretion, permit our stockholders to sell shares prior to the expiration of the restrictive provisions contained in those <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of the shares of our common stock could decline as a result of the sale of a substantial number of our shares of common stock in the public
market or the perception in the market that the holders of a large number of shares intend to sell their shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of our
common stock in this offering, you will experience substantial and immediate dilution. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you purchase shares of our common stock in this
offering, you will experience substantial and immediate dilution in the pro forma net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share as of December&nbsp;31, 2017, based on an assumed initial public
offering price of our common stock of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range on the cover page of this prospectus, because the price that you pay will be substantially greater than the pro forma
net tangible book value per share of the common stock that you acquire. This dilution is due in large part to the fact that our earlier investors paid substantially less than the initial public offering price when they purchased their shares of our
capital stock. You will experience additional dilution upon exercise of options to purchase common stock under our equity incentive plans, upon vesting of options to purchase common stock under our equity incentive plans, if we issue restricted
stock to our employees under our equity incentive plans or if we otherwise issue additional shares of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad
discretion in the use of the net proceeds of this offering and may not use them effectively or in ways that increase the value of our share price. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot specify with any certainty the particular uses of the net proceeds that we will receive from this offering, but we currently expect such uses will
include advancing our clinical product candidates into later-stage clinical trials and combination trials, advancing our research product candidates into clinical development, supporting our ongoing drug discovery efforts and supporting our growing
infrastructure and needs in operating as a public company. We will have broad discretion in the application of the net proceeds, including working capital and other general corporate purposes, and you and other stockholders may disagree with how we
spend or invest these proceeds. The failure by our management to apply these funds effectively could adversely affect our business and financial condition. Pending their use, we may invest the net proceeds from our initial public offering in a
manner that does not produce income or that loses value. These investments may not yield a favorable return to our investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable
research about our business, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will depend in part on the
research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no or only very few securities analysts commence
coverage of us, or if industry analysts cease coverage of us, the trading price for our common stock would be negatively affected. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research
about our business, our common stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our common stock price
and trading volume to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Requirements associated with being a public company will increase our costs significantly, as well as divert
significant company resources and management attention. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the completion of this offering, we will be subject to the reporting requirements of
the Securities Exchange Act of 1934, as amended (Securities Exchange Act) or the other rules and regulations of the Securities and Exchange Commission (SEC) or any securities exchange relating to public companies. Compliance with the various
reporting and other requirements applicable to public companies requires considerable time and attention of management. We cannot assure you that we will satisfy our obligations as a public company on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as a public company, it may be more difficult or more costly for us to obtain certain types of insurance, including directors&#146; and
officers&#146; liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to
attract and retain qualified personnel to serve on our board of directors, our board committees or as executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to maintain
proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could result in sanctions or other penalties that would harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the completion of this offering, we will be subject to the reporting requirements of the Securities Exchange Act, the Sarbanes-Oxley Act and the rules
and regulations of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal controls over financial
reporting. Commencing with our fiscal year ending the year after this offering is completed, we must perform system and process design evaluation and testing of the effectiveness of our internal controls over financial reporting to allow management
to report on the effectiveness of our internal controls over financial reporting in our Form <FONT STYLE="white-space:nowrap">10-K</FONT> filing for that year, as required by Section&nbsp;404 of the Sarbanes-Oxley Act. This will require that we
incur substantial additional professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. Prior to this offering, we have never been required to test our internal controls
within a specified period and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may discover
weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and
all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#146;s objectives will be met. Because of the inherent limitations in all control systems, no
evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are not able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper
and effective internal controls over financial reporting, we may not be able </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to produce timely and accurate financial statements. If that were to happen, our investors could lose confidence in our reported financial information, the market price of our stock could decline
and we could be subject to sanctions or investigations by the SEC or other regulatory authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our disclosure controls and procedures may not
prevent or detect all errors or acts of fraud. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, we will become subject to the periodic reporting requirements
of the Securities Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and
recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These inherent limitations include the realities
that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to
fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the
inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth
company,&#148; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the JOBS Act) and we intend to take
advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis
of Financial Condition and Results of Operations&#148; disclosure; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing
additional information about the audit and the financial statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to hold a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on executive compensation or obtain stockholder approval of any golden parachute payments not previously approved.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find
our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth
company. We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the completion of this offering, (b)&nbsp;in which we have total annual gross revenue of at
least $1.07&nbsp;billion or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the
prior June 30th and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not intend to pay dividends for the foreseeable future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared nor paid cash dividends on our capital stock. We currently intend to retain any future earnings to finance the operation and expansion
of our business, and we do not expect to declare or pay any dividends in the foreseeable future. Consequently, stockholders must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any
future gains on their investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The concentration of our stock ownership will likely limit your ability to influence corporate matters, including
the ability to influence the outcome of director elections and other matters requiring stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon shares outstanding as of
December&nbsp;1, 2017, prior to this offering, our executive officers, directors and the holders of more than 5% of our outstanding common stock, in the aggregate, beneficially owned approximately 59% of our common stock, and upon the completion of
this offering, that same group, in the aggregate, will beneficially own approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our common stock, assuming no exercise by the underwriters of their option to purchase additional shares, no exercise of
outstanding options or warrants and after giving effect to the issuance of shares in this offering. As a result, these stockholders, acting together, will have significant influence over all matters that require approval by our stockholders,
including the election of directors and approval of significant corporate transactions. Corporate actions might be taken even if other stockholders, including those who purchase shares in this offering, oppose them. This concentration of ownership
might also have the effect of delaying or preventing a change of control of our company that other stockholders may view as beneficial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware
law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect at the completion of this offering could make a merger, tender offer or proxy contest difficult, thereby depressing
the trading price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, our status as a Delaware corporation and the anti-takeover
provisions of the Delaware General Corporation Law may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an
interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect at the completion of this
offering will contain provisions that may make the acquisition of our company more difficult, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of our board of directors; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of our board of directors to issue shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be
used to significantly dilute the ownership of a hostile acquiror; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from
being able to fill vacancies on our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the requirement that a special meeting of stockholders may be called only by a majority vote of our entire board of directors, the chairman of our board of directors or our chief executive officer, which could delay the
ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement for the affirmative vote of holders of at least&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the voting
power of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend the provisions </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
of our amended and restated certificate of incorporation relating to the management of our business or our amended and restated bylaws, which may inhibit the ability of an acquiror to effect such
amendments to facilitate an unsolicited takeover attempt; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#146; meeting, which may discourage or deter a
potential acquiror from conducting a solicitation of proxies to elect the acquiror&#146;s own slate of directors or otherwise attempting to obtain control of us. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as a Delaware corporation, we are subject to Section&nbsp;203 of the Delaware General Corporation Law. These provisions may prohibit large
stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original
certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult
for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company.
The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For information regarding these and other provisions, see &#147;Description of Capital Stock.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for
substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will provide that the Court of Chancery of the State of Delaware is the exclusive forum for any
derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws
or any action asserting a claim against us that is governed by the internal affairs doctrine. This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or
our directors, officers or other employees and may discourage these types of lawsuits. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or
unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_3"></A>INFORMATION REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus includes forward-looking statements. All statements other than statements of historical facts contained in this prospectus are forward-looking
statements, including statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the uses of the net proceeds from this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the timing and achievement of our product candidate development activities and ongoing and planned clinical studies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations for reporting data from clinical studies in certain timeframes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop intra-portfolio combinations and highly-differentiated small-molecule candidates that are <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> and/or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> including our ability to create small-molecule product candidates with ideal pharmacological properties and desired clinical effects; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the efficiency and speed with which we can create and advance small-molecule product candidates and develop our product candidates and combination therapies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reliance on third parties to conduct our ongoing and future clinical studies and third-party manufacturers to manufacture and supply our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the nature of the immuno-oncology pathways we are targeting, the size of the potential patient population and the potential market size; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain control of our combination products and maximize the commercial potential of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain regulatory approvals of our product candidates, the potential market opportunities for commercializing our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to retain and recruit key personnel, estimates of our expenses, future revenue, capital requirements and our needs for additional financing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop, acquire and advance product candidates into, and successfully complete, clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our initiation, timing, progress and results of future research and development programs, preclinical studies and clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain intellectual property rights covering our product candidates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the composition of our board of directors, developments and projections relating to our competitors and our industry, and our expectations regarding the time during which we will be an
emerging growth company under the JOBS Act. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148;
&#147;continue,&#148; &#147;anticipate,&#148; &#147;design,&#148; &#147;intend,&#148; &#147;expect,&#148; &#147;could,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;would&#148; or the
negative version of these words and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe
may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives and financial needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These
forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#147;Risk Factors.&#148; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from
time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from
those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially
and adversely from those anticipated or implied in the forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should not rely upon forward-looking statements as predictions of future events. Although we believe
that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, advancements, discoveries, levels of activity, performance or events and circumstances reflected in the forward-looking
statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any
forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission as exhibits
to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_4"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains estimates, projections and other information concerning our industry, our business and the markets for certain cancers, including
data regarding the estimated size of those markets and the incidence and prevalence of certain medical conditions. Information based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to
uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports,
research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional shares in full, after deducting estimated underwriting discounts and commissions and estimated offering
expenses payable by us, assuming an initial offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus. Each
$1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus,
would increase (decrease) the net proceeds to us from this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus,
remains the same and after deducting estimated underwriting discounts and commissions. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) our
net proceeds from this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and
commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal purposes of this offering are to increase our financial flexibility and create a public market for our common stock. We intend
to use the net proceeds from this offering as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund the clinical development of AB928 (our dual A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R/A<SUB
STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R antagonist) and AB122 (our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody); and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the remaining proceeds to fund the development of other product candidates in our pipeline, including AB680 (our CD73 inhibitor) and AB154 (our anti-TIGIT antibody), our drug discovery and optimization programs, and
other general corporate purposes, which may include the hiring of additional personnel, capital expenditures and the costs of operating as a public company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. As of the date of
this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of
our actual expenditures and the extent of our preclinical, clinical and future development activities may vary significantly depending on numerous factors, including the progress of our development efforts, the status of and results from our ongoing
and planned clinical trials, our ability to take advantage of expedited programs or to obtain regulatory approval for product candidates, the timing and costs associated with the manufacture and supply of product candidates for clinical development
or commercialization and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expected net proceeds of this offering will not be sufficient for us to fund any of our product candidates through regulatory approval, and we will need
to raise substantial additional capital to complete the development and commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds
from this offering, we plan to invest the net proceeds in a variety of capital preservation investments, including short-term interest-bearing investment-grade securities, certificates of deposit or government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock and we do not currently intend to pay any cash dividends on our capital stock for the
foreseeable future. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. Any future determination to pay dividends will be made at the discretion
of our board of directors subject to applicable laws and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions and capital requirements. Our future ability to pay cash dividends on our
capital stock may also be limited by the terms of any future debt or preferred securities or future credit facility. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash, cash equivalents and short-term investments and capitalization as of December&nbsp;31, 2017: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an actual basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma basis to reflect: (i)&nbsp;the automatic conversion of all outstanding shares of our preferred stock into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock; and (ii)&nbsp;the filing and effectiveness of our amended restated certificate of incorporation, each of which will
occur immediately prior to the completion of this offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma as adjusted basis to give effect to (i)&nbsp;the pro forma adjustments set forth above and (ii)&nbsp;the sale and issuance
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock by us in this offering, based upon the receipt by us of the estimated net proceeds from this offering at the
assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts
and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this information together with our consolidated financial
statements and related notes appearing elsewhere in this prospectus and the information set forth in &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.0001 par value per share: 120,958,867 shares
authorized,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, actual; no shares authorized, issued, and outstanding, pro forma and pro forma as adjusted</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value, no shares authorized, issued or outstanding, actual or pro
forma;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, no shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 153,993,327 shares
authorized,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding,
actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, shares issued and outstanding, pro
forma;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase (decrease) in the assumed initial offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the estimated price range set forth on the cover page of this
prospectus, would increase (decrease) each of cash, cash equivalents and short-term investments, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; (deficit) equity and total capitalization by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions. We may
also increase or decrease the number of shares we are offering. Each increase (decrease) of 1,000,000 shares in the number of shares offered by us would increase (decrease) each of cash, cash equivalents and short-term investments, additional <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital,</FONT></FONT> total stockholders&#146; (deficit) equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the
initial public offering price to the public remains the same, and after deducting the estimated underwriting discounts and commissions. The pro forma as adjusted information discussed above is illustrative only and will adjust based on the actual
initial price to the public and other terms of this offering determined at pricing. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of common stock to be outstanding after this offering is based
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding as of December&nbsp;31, 2017, and excludes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the exercise of options outstanding as of December&nbsp;31, 2017 with a
weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the exercise of options granted after December&nbsp;31, 2017 with a
weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under our equity compensation plans, consisting
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that were reserved for issuance under our 2015 Stock Plan as of December&nbsp;31,
2017,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for issuance under our 2018 Equity Incentive Plan, which will become effective in connection with the
completion of this offering, and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for issuance under our 2018 Employee Stock Purchase Plan, which will become
effective in connection with the completion of this offering. We expect that the number of shares reserved for issuance under each of our 2018 Equity Incentive Plan and 2018 Employee Stock Purchase Plan will be increased automatically on the first
business day of each of our fiscal years by a number equal to the smallest of (i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, (ii)&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of common
stock outstanding on the last business day of the prior fiscal year or (iii)&nbsp;the number of shares determined by our board of directors. On the date immediately prior to the date of this prospectus, we expect that any remaining shares available
for issuance under our 2015 Stock Plan will be added to the shares reserved under our 2018 Equity Incentive Plan in effect following the completion of this offering and we will cease granting awards under our 2015 Stock Plan. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the assumed
initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share represents our total tangible assets less our liabilities and preferred stock that is not included in
equity divided by the total number of shares outstanding. As of December&nbsp;31, 2017, our historical net tangible book value (deficit) was approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. Our pro forma net tangible book value as of December&nbsp;31, 2017, was approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, after giving effect to the automatic conversion of all outstanding shares of our preferred stock into an aggregate
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock immediately prior to the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving further effect to receipt of the net proceeds of our sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock at an assumed initial offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of
the estimated price range set forth on the cover page of this prospectus and after deducting estimated underwriting discounts and commissions and estimated offering expenses, our pro forma as adjusted net tangible book value as of December&nbsp;31,
2017 would have been approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This represents an immediate increase in pro forma as adjusted net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to our existing stockholders and an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to investors purchasing common stock in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution to new investors on a per share basis: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to new investors in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share immediately after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the underwriters&#146; option to purchase additional shares in this offering is exercised in full, the pro forma as
adjusted net tangible book value would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the increase in the pro forma net tangible book value per share for existing stockholders would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and the dilution to new investors participating in this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the
estimated price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value, by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and the dilution per share to new
investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also increase or decrease the number of shares we are offering. An increase (decrease)
of 1,000,000 shares in the number of shares we are offering would increase (decrease) our pro forma as adjusted net tangible book value by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and the pro forma dilution per share to investors in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming that the assumed initial public offering price
remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. The pro forma information discussed above is illustrative only and will change based on the actual initial public
offering price, number of shares and other terms of this offering determined at pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below summarizes, as of December&nbsp;31, 2017, on the
pro forma basis described above, the number of shares of our common stock, the total consideration, and the average price per share (i)&nbsp;paid to us by our existing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders and (ii)&nbsp;to be paid by new investors participating in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share,
the midpoint of the estimated price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total Consideration</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Price</B><br><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if the underwriters&#146; option to purchase additional shares is exercised in full, the number of shares held by
existing stockholders will be reduced to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of common stock to be outstanding upon completion of this offering, and the number of shares of
common stock held by new investors participating in this offering will be further increased to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of common stock to be outstanding upon
completion of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease) total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and increase (decrease) the percent of total consideration paid by new
investors by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%, assuming the number of shares we are offering, as set forth on the cover page of this prospectus, remains the same, after deducting estimated underwriting discounts and commissions. We may also increase
or decrease the number of shares we are offering. An increase (decrease) of 1,000,000 in the number of shares offered by us would increase (decrease) total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
assuming that the assumed initial price to the public remains the same, and after deducting the estimated underwriting discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
number of shares of common stock to be outstanding after this offering is based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding as of December&nbsp;31,
2017, and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the exercise of options outstanding as of December&nbsp;31, 2017 with a
weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the exercise of options granted after December&nbsp;31, 2017 with a
weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future issuance under our equity compensation plans, consisting
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that were reserved for issuance under our 2015 Stock Plan as of December&nbsp;31,
2017,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for issuance under our 2018 Equity Incentive Plan, which will become effective in connection with the
completion of this offering, and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for issuance under our 2018 Employee Stock Purchase Plan, which will become
effective in connection with the completion of this offering. We expect that the number of shares reserved for issuance under each of our 2018 Equity Incentive Plan and 2018 Employee Stock Purchase Plan will be increased automatically on the first
business day of each of our fiscal years by a number equal to the smallest of (i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, (ii)&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of common
stock outstanding on the last business day of the prior fiscal year or (iii)&nbsp;the number of shares determined by our board of directors. On the date immediately prior to the date of this prospectus, we expect that any remaining shares available
for issuance under our 2015 Stock Plan will be added to the shares reserved under our 2018 Equity Incentive Plan in effect following the completion of this offering and we will cease granting awards under our 2015 Stock Plan. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any outstanding options are exercised or new awards are granted under our equity compensation plans, new investors will experience further
dilution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_9"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following selected financial data should be read in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; and the financial statements and related notes included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The statement of operations data for the year
ended December&nbsp;31, 2016, and the balance sheet data as of December&nbsp;31, 2016, are derived from our audited financial statements and related notes included elsewhere in this prospectus. Our historical results are not necessarily indicative
of the results to be expected in the future. The selected financial data in this section are not intended to replace our financial statements and the related notes, and are qualified in their entirety by the financial statements and related notes
included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used to compute basic and diluted net loss per common
share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,421,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per common share, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used to compute pro forma basic and diluted net loss per
common share (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See Note&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to our audited financial statements for an explanation of the calculation of our historical and pro forma basic and diluted net loss per common share. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. See our audited financial statements for further details regarding our current assets and current liabilities. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations
together with the section of this prospectus entitled &#147;Selected Financial Data&#148; and our financial statements and related notes included elsewhere in this prospectus. This discussion and other parts of this prospectus contain
forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations, and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors
that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this prospectus entitled &#147;Risk Factors.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical
company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Specifically, we target well-characterized biological pathways with significant scientific data supporting their importance in
regulating the immune response against cancer and for which either there are no molecules in development or those that exist have suboptimal profiles. To exploit these pathways, we have built a robust and highly efficient discovery capability to
create and optimize highly differentiated small-molecule immuno-oncology product candidates that we believe will be best-in-class and/or first-in-class. Since our inception in 2015, we have built a broad portfolio of small-molecule and antibody
product candidates that we plan to develop together as intra-portfolio combinations. We have initiated clinical trials for our two most advanced product candidates, both of which are expected to generate data in 2018, and we expect initial efficacy
data from our first intra-portfolio combination in early 2019. We plan to advance two additional product candidates into clinical trials by the end of 2018. Members of the Arcus team have worked together for more than 10 years discovering innovative
small-molecule product candidates while at companies, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">such as Tularik Inc., Amgen, Inc. and Flexus Biosciences, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since commencing operations in 2015,
we have devoted substantially all of our efforts and financial resources to building our research and development capabilities and establishing our corporate infrastructure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not generated any revenue from product sales and, as a result, we have never been profitable and have incurred net losses since commencement of our
operations. As of December&nbsp;31, 2016, we had an accumulated deficit of $20.2&nbsp;million, primarily as a result of research and development and general and administrative expenses. We incurred net losses of $18.0&nbsp;million in the year ended
December&nbsp;31, 2016. We do not expect to generate product revenue unless and until we obtain marketing approval for and commercialize a product candidate, and we cannot assure you that we will ever generate significant revenue or profits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have financed our operations primarily through private placements of convertible preferred stock and through proceeds from an option and licensing
agreement. From inception through December&nbsp;31, 2016, we received net proceeds of $119.5&nbsp;million through private placements of convertible preferred stock. As of December&nbsp;31, 2016, we had cash, cash equivalents, and short-term
investments of $98.9&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2017, we received an upfront payment from Taiho Pharmaceutical Co., Ltd. (Taiho) under the terms of an
option and license agreement (the Taiho Agreement) that we entered into with Taiho in September 2017. Pursuant to the Taiho Agreement, Taiho is obligated to provide a total of $35.0&nbsp;million of
<FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> cash payments, inclusive of the upfront payment, to us during the first three years of the agreement in exchange for an exclusive option,
over a five-year period, to <FONT STYLE="white-space:nowrap">in-license</FONT> the development and commercialization rights to clinical-stage product candidates from our portfolio for Japan and certain other territories in Asia (excluding China).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2017, we received net proceeds of $106.7&nbsp;million from the sale and issuance of shares of
our Series C convertible preferred stock. As of December&nbsp;31, 2017, our cash, cash equivalents, and short-term investments totaled approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. We believe that our existing cash, cash
equivalents, and short-term investments will be sufficient to fund our planned operations for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital
resources sooner than we expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to incur substantial expenditures in the foreseeable future as we expand our pipeline and advance our product
candidates through clinical development, the regulatory approval process and, if approved, commercial launch activities. Specifically, in the near term we expect to incur substantial expenses relating to our ongoing Phase 1 and planned Phase 1/2
clinical trials, the development and validation of our manufacturing processes, and other development activities. Furthermore, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company,
including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will need substantial
additional funding to support our continuing operations and pursue our development strategy. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our operations through the sale
of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or
enter into such agreements as, and when, needed, we may have to significantly delay, scale back, or discontinue the development and commercialization of our product candidates or delay our efforts to expand our product pipeline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Operating Results </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
research and development expenses consist of expenses incurred in connection with the research and development of our research programs. In 2016, these expenses included payroll and personnel expenses including stock-based compensation for our
research and product development employees, laboratory supplies, product licenses, consulting costs, contract research, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> expenses, and depreciation. We expense research and development costs as
they are incurred. <FONT STYLE="white-space:nowrap">Non-refundable</FONT> advance payments for services that will be used or rendered for future research and development activities are recorded as prepaid expenses and recognized as an expense as the
related services are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase substantially during the next few years as we seek to
complete existing and initiate additional clinical trials, pursue regulatory approval of AB928 and AB122, and advance other programs including AB154 and AB680 into the clinic. Specifically, in 2017, we expect our preclinical, clinical, and contract
manufacturing expenses to increase relative to 2016, as our first clinical trials on AB928 and AB122 started in 2017. In addition, under a license agreement with WuXi Biologics (Cayman) Inc. (WuXi Biologics) entered into in August 2017, in which we
acquired an exclusive license to develop, use, manufacture, and commercialize products that include an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody, we made upfront and milestone payments of
$18.5&nbsp;million and we may be required to pay additional clinical and regulatory milestone payments based on the development progress of AB122. Predicting the timing or the final cost to complete our clinical program or validation of our
manufacturing and supply processes is difficult and delays may occur because of many factors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist principally of personnel-related costs including payroll and stock-based compensation for personnel in executive,
finance, human resources, business and corporate development, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and other administrative functions, professional fees for legal, consulting, and accounting services, rent and other facilities costs, depreciation, and other general operating expenses not
otherwise classified as research and development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses will increase substantially during
the next few years as a result of staff expansion and additional occupancy costs, as well as costs associated with being a public company, including higher legal and accounting fees, investor relations costs, higher insurance premiums and other
compliance costs associated with being a public company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest and Other Income, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest and other income, net consists primarily of interest earned on our short-term investments in corporate notes and government agency notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years
Ended December&nbsp;31, 2016 and 2017 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the periods indicated (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B><br><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have financed our operations primarily through private placements of convertible preferred stock and proceeds from an option and licensing
agreement. We received net proceeds of $49.6&nbsp;million from the sale and issuance of shares of our Series A convertible preferred stock in 2015 and net proceeds of $69.8&nbsp;million from the sale and issuance of shares of our Series B
convertible preferred stock in 2016. In December 2016, we entered into a license agreement with Abmuno Therapeutics LLC (Abmuno) for an exclusive license to anti-TIGIT antibodies, for which we made upfront and milestone payments in 2017 of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. In October 2017, we received an upfront, <FONT STYLE="white-space:nowrap">non-refundable</FONT> payment from Taiho under the Taiho Agreement. Through December&nbsp;31, 2017, we made upfront
and milestone payments of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million under our license agreement with WuXi Biologics. In November 2017, we received net proceeds of $106.7&nbsp;million from the sale and issuance of shares of our Series
C convertible preferred stock. Our cash, cash investments, and short-term investments are held in money market funds, and investments in corporate securities and government agency obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our existing business plan, we believe that our existing cash, cash investments, and short-term investments provide sufficient funds to sustain
operations through at least the next twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will continue to require additional capital to develop our product candidates and fund operations
for the foreseeable future. We may seek to raise capital through private or public equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing. Adequate additional funding
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our
business strategies. We anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, rate of progress and costs of our drug discovery, preclinical development activities, laboratory testing and clinical trials for our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and scope of clinical programs we decide to pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope and costs of manufacturing development and commercial manufacturing activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and amount of milestone payments, if any, we receive under the Taiho Agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost, timing and outcome of regulatory review of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of establishing sales and marketing capabilities, if any of our product candidates receive marketing approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain collaborations on favorable terms, if at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with being a public company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost associated with commercializing our product candidates, if they receive marketing approval. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we
raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability
to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms
that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell
or license to others rights to our product candidates in certain territories or indications that we would prefer to develop and commercialize ourselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;Risk Factors&#148; for additional risks associated with our substantial capital requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary Statement of Cash Flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,861</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Used in Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $12.9&nbsp;million for the year ended December&nbsp;31, 2016. Cash used in operating activities in 2016 was primarily
due to the use of funds in our operations and the resulting net loss of $18.0&nbsp;million, an increase in prepaid expenses, other current assets and long-term assets that totaled $0.8&nbsp;million, partially offset by
<FONT STYLE="white-space:nowrap">non-cash</FONT> depreciation and amortization expense of $1.3&nbsp;million, and an increase in accounts payable and accrued liabilities of $4.4&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Used in Investing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in investing
activities for the year ended December&nbsp;31, 2016 primarily represented the purchase of investments of $33.8&nbsp;million, purchases of property and equipment of $4.1&nbsp;million, and our $1.0&nbsp;million equity investment in PACT Pharma, Inc.
(PACT Pharma), a related party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Provided by Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities was $70.1&nbsp;million for the year ended December&nbsp;31, 2016 which consisted primarily of net proceeds from the
issuance and sale of shares of our Series B convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations as of December&nbsp;31, 2016 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments due by period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2&nbsp;to&nbsp;3<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>4&nbsp;to&nbsp;5<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After&nbsp;5<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, we have lease obligations consisting of an operating lease for our operating facility for
approximately 40,100 square feet. The original term of the lease commenced in 2016 and expires in 2024. This term was extended to 2025 when we executed an amendment to the operating lease in October 2017 to include approximately 30,000 square feet
in an adjacent building. Under the terms of the lease amendment, we will have additional lease obligations consisting of $5.9&nbsp;million in payments through 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2016, we entered into a license agreement (the Abmuno Agreement) with Abmuno for an exclusive license to develop, use, manufacture, and
commercialize products including AB154. Under the Abmuno Agreement, we made upfront and milestone payments in 2017 of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and we may be required to make additional clinical, regulatory and
commercialization milestone payments up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. However, because the achievement of these milestones is not fixed and determinable, such commitments have not been included on our balance sheet or
in the Contractual Obligations and Commitments table above. For additional information regarding future payments to third parties, including milestone payments to Abmuno, please see &#147;Business&#151;License Agreements.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2017, we entered into a license agreement (the WuXi Agreement) with WuXi Biologics for an exclusive license to develop, use, manufacture, and
commercialize products including AB122. Under the WuXi Agreement, we have made upfront and milestone payments of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million as of December&nbsp;31, 2017 and we may be required to make additional clinical
and regulatory milestone payments, commercialization milestone payments up to $375.0&nbsp;million, and royalty payments that range from high single-digits to low double-digits of net sales. However, because the achievement of these milestones is not
fixed and determinable, such commitments have not been included on our balance sheet or in the Contractual Obligations and Commitments table above. For additional information regarding future payments to third parties, including milestone and
royalty payments to WuXi Biologics, please see &#147;Business&#151;License Agreements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business with third party contract organizations for
clinical trials, <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and testing, manufacturing, and other services and products for operating purposes. These contracts generally provide for termination following a certain period after
notice, and therefore we believe that our <FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations under these agreements are not material. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies, Significant Judgments and Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these financial
statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses
incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical
to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#146;s judgments and estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in the notes to our financial statements, we believe that the following critical accounting policies
are most important to understanding and evaluating our reported financial results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development expenses consist primarily of personnel costs for our research and product
development employees. Also included are <FONT STYLE="white-space:nowrap">non-personnel</FONT> costs such as professional fees payable to third parties for preclinical studies and research services, laboratory supplies, product licenses, equipment
maintenance, and other consulting costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate preclinical study and research expenses based on the services performed, pursuant to contracts with
research institutions that conduct and manage preclinical studies and research services on our behalf. We estimate these expenses based on discussions with internal management personnel and external service providers as to the progress or stage of
completion of services and the contracted fees to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments associated
with licensing arrangements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternative commercial use are expensed as incurred. Payments made to
third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We account for
stock-based compensation arrangements with employees in accordance with Accounting Standards Codification (ASC)&nbsp;718, Stock Compensation. Stock-based awards granted include stock options with time-based vesting. ASC 718 requires the recognition
of compensation expense, using a fair value-based method, for costs related to all stock-based payments. Our determination of the fair value of stock options with time-based vesting on the date of grant utilizes the Black-Scholes option-pricing
model, and is impacted by our common stock price as well as other variables including, but not limited to, expected term that options will remain outstanding, expected common stock price volatility over the term of the option awards, risk-free
interest rates and expected dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of a stock-based award is recognized over the period during which an optionee is required to
provide services in exchange for the option award, known as the requisite service period (usually the vesting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period) on a straight-line basis. Stock-based compensation expense is recognized based on the fair value determined on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equity instruments issued to <FONT STYLE="white-space:nowrap">non-employees</FONT> are accounted for in accordance with ASC
<FONT STYLE="white-space:nowrap">505-50</FONT> Equity Based Payments to <FONT STYLE="white-space:nowrap">Non-Employees</FONT> and are recorded at their fair value on the measurement date and are subject to periodic adjustments as the underlying
equity instruments vest. The fair value of options granted to consultants is expensed when vested. <FONT STYLE="white-space:nowrap">Non-employee</FONT> stock-based compensation expense was not material for all periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimating the fair value of equity-settled awards as of the grant date using valuation models, such as the Black-Scholes option pricing model, is affected by
assumptions regarding a number of complex variables. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require
significant analysis and judgment to develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected Term</I>&#151;We have opted to use the &#147;simplified method&#148; for estimating the
expected term of options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected Volatility</I>&#151;Due to our limited operating history and a lack of company specific historical and implied volatility data, we have based our
estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#146; shares during the
equivalent period of the calculated expected term of the stock-based awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Risk-Free Interest Rate</I>&#151;The risk-free rate assumption is based
on the U.S. Treasury instruments with maturities similar to the expected term of our stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected Dividend</I>&#151;We have not issued any
dividends in our history and do not expect to issue dividends over the life of the options and therefore have estimated the dividend yield to be zero. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following assumptions were used to calculate the fair value of awards granted to employees, <FONT STYLE="white-space:nowrap">non-employees</FONT> and
directors during the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2016</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1.2%&nbsp;-&nbsp;2.45%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">6.25&nbsp;-&nbsp;9.84</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">67.0%&nbsp;-&nbsp;77.8%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will continue to use judgment in evaluating the expected volatility, expected terms, and interest rates utilized for our
stock-based compensation expense calculations on a prospective basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense, net of estimated forfeitures, is reflected in the
statement of operations and comprehensive loss as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, total unamortized stock-based compensation was $0.4&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The intrinsic value of all outstanding stock options as of December&nbsp;31, 2017 was approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
based on a hypothetical common stock fair value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the estimated price range set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Common Stock Valuations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated fair value of the
common stock underlying our stock options was determined at each grant date by our board of directors, with input from management. All options to purchase shares of our common stock are intended to be exercisable at a price per share not less than
the <FONT STYLE="white-space:nowrap">per-share</FONT> fair value of our common stock underlying those options on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the absence of a
public trading market for our common stock, on each grant date, we develop an estimate of the fair value of our common stock based on the information known to us on the date of grant, upon a review of any recent events and their potential impact on
the estimated fair value per share of the common stock, and in part on input from an independent third-party valuation. As is provided for in Section&nbsp;409A of the U.S. Internal Revenue Code (the Code) we generally rely on our valuations for up
to twelve months unless we have experienced a material event that would have affected the estimated fair value per common share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our valuations of our
common stock were determined in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I> (the Practice Aid).
The methodology to determine the fair value of our common stock included estimating the fair value of the enterprise using a market approach, which estimates the fair value of the company by including an estimation of the value of the business based
on guideline public companies under a number of different scenarios. The assumptions used to determine the estimated fair value of our common stock are based on numerous objective and subjective factors, combined with management judgment, including
external market conditions affecting the pharmaceutical and biotechnology industry and trends within the industry; our stage of development; the rights, preferences and privileges of our convertible preferred stock relative to those of our common
stock; the prices at which we sold shares of our convertible preferred stock; our financial condition and operating results, including our levels of available capital resources; the progress of our research and development efforts, our stage of
development and business strategy; equity market conditions affecting comparable public companies; general U.S. market conditions and the lack of marketability of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated
fair value of common stock at each valuation date. In accordance with the Practice Aid, we considered the following methods: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Option Pricing Method.</I> Under the option pricing method (OPM), shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity
class. The estimated fair values of the preferred and common stock are inferred by analyzing these options. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Probability-Weighted Expected Return Method.</I> The probability-weighted expected return method (PWERM) is a scenario-based analysis that estimates value per share based on the probability-weighted present value of
expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our early stage of development and other relevant factors, we determined that an OPM was the most appropriate method for allocating our enterprise
value to determine the estimated fair value of our common stock for valuations performed during May 2015, May and August 2016, and May 2017. For the valuation that we performed in November 2017, we began using a hybrid approach of the OPM and the
PWERM methods to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determine the estimated fair value of our common stock. In determining the estimated fair value of our common stock, our board of directors also considered the fact that our stockholders could
not freely trade our common stock in the public markets. Accordingly, we applied discounts to reflect the lack of marketability of our common stock based on the weighted-average expected time to liquidity. The estimated fair value of our common
stock at each grant date reflected a <FONT STYLE="white-space:nowrap">non-marketability</FONT> discount partially based on the anticipated likelihood and timing of a future liquidity event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, our board of directors intends to determine the fair value of our common stock based on the closing price of our
common stock on the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; on the date of grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We provide for income taxes under the asset and liability method. Current income tax expense or benefit represents the amount of income taxes expected to be
payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating loss and credit
carryforwards, and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more
likely than not that some or all of the tax benefits will not be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We account for uncertain tax positions in accordance with ASC <FONT
STYLE="white-space:nowrap">740-10,</FONT> <I>Accounting for Uncertainty in Income Taxes</I>. We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to
assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#146;s sustainability and is measured at the largest amount of benefit that is greater than fifty
percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether (i)&nbsp;the factors underlying the sustainability assertion have changed
and (ii)&nbsp;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new
information becomes available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, our total deferred tax assets were $8.4&nbsp;million. Due to our lack of earnings history
and uncertainties surrounding our ability to generate future taxable income, the net deferred tax assets have been fully offset by a valuation allowance. The deferred tax assets were primarily comprised of federal and state tax net operating losses
(NOLs). Utilization of NOLs may be limited by the &#147;ownership change&#148; rules, as defined in Section&nbsp;382 of the Code. Similar rules may apply under state tax laws. Our ability to use our remaining NOLs may be further limited if we
experience an ownership change in connection with this offering, future offerings or as a result of future changes in our stock ownership. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we have not engaged in any
<FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission (SEC). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with PACT Pharma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2016, we
purchased approximately 3.6&nbsp;million shares of common stock of PACT Pharma, a privately funded, early-stage biopharmaceutical company focused on adoptive cell therapy.&nbsp;We determined the fair value of such investment to be insignificant
given the <FONT STYLE="white-space:nowrap">start-up</FONT> nature of PACT Pharma&#146;s operations, and it was recorded at a nominal amount. In December 2016, we and PACT Pharma entered into a Master Services Agreement (the PACT Agreement) under
which we provide PACT Pharma with general administrative support, including finance, human resources, legal, and other operational support.&nbsp;We also received certain warrants to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase PACT Pharma common stock exercisable upon PACT Pharma&#146;s achievement of certain valuation thresholds pursuant to the PACT Agreement. The PACT Agreement will terminate no later than
December&nbsp;31, 2018. Also in December 2016, we purchased 1.0&nbsp;million shares of Series A preferred stock of PACT Pharma for $1.0&nbsp;million. Our investment in PACT Pharma is accounted for as an equity method investment, and as a result we
record our share of PACT Pharma&#146;s operating results in our statement of operations and comprehensive loss. For the year ended December 31, 2016, our share of PACT Pharma&#146;s operating results was not significant. We monitor the investment
for events or circumstances indicative of potential other-than-temporary impairment, and make appropriate reductions in carrying values if we determine that an impairment charge is required. As of December&nbsp;31, 2016, no impairment charge had
been recorded. See Note 5 to our financial statements included elsewhere in this prospectus for further discussion of our equity investment in PACT Pharma. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As permitted under Delaware law and in
accordance with our bylaws, we indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. We are also party to indemnification agreements with our officers and directors.
We believe the fair value of the indemnification rights and agreements is minimal. Accordingly, we have not recorded any liabilities for these indemnification rights and agreements as of December&nbsp;31, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Accounting Election </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Jumpstart Our Business
Startups Act of 2012 (the JOBS Act), permits an &#147;emerging growth company&#148; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are choosing to
opt out of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted. This decision to opt out of the extended transition period under the JOBS Act is irrevocable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earliest of (1)&nbsp;the last day of our first fiscal year (a)&nbsp;following the fifth anniversary of the
completion of this offering, (b)&nbsp;in which we have total annual gross revenues of at least $1.07&nbsp;billion, or (ii)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million of the prior June 30th and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities
during the prior three-year period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies and adopted by
us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our financial statements upon adoption. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Standards Updates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
November 2015, the FASB issued Accounting Standards Update (ASU) <I>No.</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;2015-17</FONT> (Topic 740), Balance Sheet Classification of Deferred Taxes.</I> ASU
<FONT STYLE="white-space:nowrap">2015-17</FONT> requires deferred tax liabilities and assets to be classified as noncurrent in the balance sheet. For public entities, the standard will be effective for financial statements issued for annual periods
beginning after December&nbsp;15, 2016, and interim periods within those annual periods. Early adoption is permitted for financial statements that have not been previously issued. The ASU may be applied either prospectively to all deferred tax
liabilities and assets or retrospectively to all periods presented. We early adopted this ASU during 2016 on a retrospective basis and the adoption had no material impact on our financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2015, the FASB issued ASU
<I>No.</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;2015-02</FONT></I> <I>(Topic 810), Consolidation, Amendments to the Consolidations Analysis, </I>which amends the consolidation requirements in ASC 810. The ASU modifies the evaluation of
whether limited partnerships and similar legal entities are variable interest entities or voting interest entities and significantly amends the consolidation analysis of reporting entities that are involved with variable interest entities,
particularly those that have fee arrangements and related party relationships. For public business entities, the guidance was effective for annual periods and interim periods beginning after December&nbsp;15, 2015 with early adoption permitted. We
adopted this ASU in 2016 and the adoption had no material impact on our financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2014-15,</FONT> <I>Disclosure of Uncertainties About an Entity&#146;s Ability to Continue as a Going Concern.</I> The new standard provides guidance around management&#146;s responsibility to evaluate whether
there is substantial doubt about an entity&#146;s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for all entities for annual periods ending after December&nbsp;15, 2016, and interim
periods with annual periods beginning after December&nbsp;15, 2016. Our adoption of this standard in 2016 did not have a material impact on our financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Standards or Updates Not Yet Effective </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2016, the FASB issued ASU <I>No.</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;2016-18</FONT> (Topic 230), Restricted Cash, Statement of Cash
Flows</I>. ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> requires that a statement of cash flows explain the change during the period in the total of cash and cash equivalents, and amounts generally described as restricted cash or restricted
cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">beginning-of-period</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-period</FONT></FONT> total amounts shown on the statement of cash flows.
ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> is effective for public business entities for fiscal years beginning after December&nbsp;15, 2017, and interim periods within those fiscal years, with early adoption permitted. The amendments in
this ASU should be applied using a retrospective transition method to each period presented. The adoption of this standard is not expected to have a material impact on our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU <I>No.</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;2016-09,</FONT> Compensation&#151;Stock Compensation (Topic
718)</I>, which simplifies the accounting for employee share-based transactions. The amendments in this update cover such areas as the recognition of excess tax benefits and deficiencies, the classification of those excess tax benefits on the
statement of cash flows, an accounting policy election for forfeitures, the amount an employer can withhold to cover income taxes and still qualify for equity classification, and the classification of those taxes paid on the statement of cash flows.
For public entities, ASU <FONT STYLE="white-space:nowrap">2016-09</FONT> is effective for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2016, with early adoption permitted. We will adopt ASU <FONT
STYLE="white-space:nowrap">2016-09</FONT> as of January&nbsp;1, 2017 and the adoption is not expected to have a material impact on our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <I>No.</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;2016-02</FONT> (Topic 842), Leases. </I>ASU <FONT
STYLE="white-space:nowrap">2016-02</FONT> requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors
and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. For public entities, ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> is effective for fiscal years beginning after
December&nbsp;15, 2018, with early adoption permitted. We have not determined the potential effects of this ASU on our financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest
rates or exchange rates. As of December&nbsp;31, 2016, we had cash, cash equivalents, and short-term investments of $98.9&nbsp;million, consisting of interest-bearing money market accounts and investments in corporate notes and government agency
securities, for which the fair market value would be affected by changes in the general level of United States interest rates. However, due to the short-term maturities and the <FONT STYLE="white-space:nowrap">low-risk</FONT> profile of our
investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash and investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not believe that inflation, interest rate changes, or exchange rate fluctuations had a significant impact on our results of operations for any periods
presented herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Specifically, we target well-characterized biological pathways with significant scientific data supporting their
importance in regulating the immune response against cancer and for which either there are no molecules in development or those that exist have suboptimal profiles. To exploit these pathways, we have built a robust and highly efficient discovery
capability to create and optimize highly differentiated small-molecule immuno-oncology product candidates that we believe will be <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> and/or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class.</FONT></FONT> Since our inception in 2015, we have built a broad portfolio of small-molecule and antibody product candidates that we plan to develop together as
intra-portfolio combinations. We have initiated clinical trials for our two most advanced product candidates, both of which are expected to generate data in 2018, and we expect initial efficacy data from our first intra-portfolio combination in
early 2019. We plan to advance two additional product candidates into clinical trials by the end of 2018. Members of the Arcus team have worked together for more than 10 years discovering innovative small-molecule product candidates while at
companies such as Tularik Inc., Amgen, Inc. and Flexus Biosciences, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our initial focus is on the
<FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> pathway, a key driver of immunosuppression in the tumor microenvironment. Decades of scientific research have demonstrated that extracellular adenosine, generated by the CD73 enzyme, acts as a
powerful inhibitor of immune cell activity. The compelling therapeutic rationale for inhibition of the <FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> pathway has led several companies to repurpose for oncology existing adenosine A<SUB
STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R receptor antagonists that were originally designed for the treatment of central nervous system (CNS) indications. We believe our lead product candidate, AB928, which we designed using our
small-molecule discovery capability, is the first adenosine receptor antagonist that effectively blocks the adenosine receptor in the tumor microenvironment and potently inhibits both the adenosine 2a receptor (A<SUB
STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R) and the adenosine 2b receptor (A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R). Our <I>in vitro</I> studies have demonstrated that AB928 reverses adenosine-induced
immunosuppression and inhibits the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R and A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors more potently and effectively than the other adenosine receptor antagonists in
clinical development. In addition to AB928, we have created a potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> small-molecule inhibitor of CD73, AB680, which could represent another powerful
approach to inhibiting the <FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> pathway, and have generated additional potential product candidates against <FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> and other important immuno-oncology
pathways using our internal discovery capability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the immuno-oncology market evolves toward the use of combination therapies, a key element of our
strategy is to build a broad portfolio of product candidates that target a wide range of immune mechanisms, which will enable us to pursue multiple intra-portfolio combinations. Consistent with this strategy, we are developing antibody drug
candidates that are currently considered backbone therapy or that have the potential to be future backbone therapies, such as our <FONT STYLE="white-space:nowrap">in-licensed</FONT> antibodies targeting the immune checkpoint receptors <FONT
STYLE="white-space:nowrap">PD-1</FONT> and TIGIT. By combining these antibodies with our differentiated, internally discovered small-molecule product candidates, we intend to create
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> and/or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> combination products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Product Portfolio </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following chart summarizes our product pipeline and our upcoming milestones. We currently hold world-wide rights to all of our product candidates other
than the rights to AB122 in China and five other countries that are outside of the United States, Europe and Japan. In addition, Taiho Pharmaceutical Co., Ltd. (Taiho) has an option to exclusively license the development and commercialization rights
to each of our programs for Japan and certain other territories in Asia (excluding China). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g61c05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are rapidly advancing our two lead, internally discovered small-molecule product candidates, the profiles of which are
summarized below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>AB928.</I></B> Our lead adenosine receptor antagonist, AB928, is an orally bioavailable, highly potent, reversible inhibitor of the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R and A<SUB
STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors. We believe AB928 is the first adenosine receptor antagonist in clinical development to be designed specifically for the biology of the tumor microenvironment and has multiple
advantages over other adenosine receptor antagonists in clinical development, including: (i)&nbsp;significantly greater potency under conditions that closely resemble the tumor microenvironment, for example, high concentrations of adenosine and
albumin, (ii)&nbsp;inhibition of both the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R and A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors, (iii)&nbsp;low penetration through the blood-brain barrier,
(iv)&nbsp;high penetration of tumor tissue and (v)&nbsp;attractive pharmacokinetics, with high oral bioavailability and a human half-life that enables once-daily dosing. AB928 is currently in a Phase 1 trial in healthy volunteers. This trial will
provide us with significant insights into the safety and pharmacokinetic and pharmacodynamic profiles of AB928, which could allow us to initiate the dose-escalation portion of our planned Phase 1/2 combination trials in cancer patients at a higher
dose than would otherwise be possible. We expect to report safety, pharmacokinetic and pharmacodynamic data from our Phase 1 trial and to initiate dose-escalation trials in cancer patients of AB928 in combination with AB122, our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody, and in combination with chemotherapy, in the second quarter of 2018. We are also focused on the identification of additional molecules that block adenosine
2 receptor signaling and have identified a second dual A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R/A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R antagonist as well as a selective A<SUB
STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonist. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>AB680.</I></B> Our lead CD73 inhibitor, AB680, is a highly potent, reversible and selective inhibitor of
the CD73 enzyme and is expected to be the first small-molecule inhibitor of CD73 to enter clinical development. As CD73 plays a critical role in the extracellular generation of adenosine, AB680 may provide a highly effective approach to preventing
adenosine-mediated immune suppression. We expect to advance AB680 for intravenous dosing into a Phase 1 trial in the second half of 2018. Based upon its projected pharmacokinetic profile, AB680 has the potential to be administered on the same dosing
schedule as our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody, AB122, and various chemotherapeutic agents, which would be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
attractive from a patient compliance and commercial perspective. We are also evaluating oral formulations of other internally discovered small-molecule CD73 inhibitors and expect to select an
oral development candidate in 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have <FONT STYLE="white-space:nowrap">in-licensed</FONT> two antibody drug candidates that
represent current or potential backbone therapies, the profiles of which are summarized below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>AB122</I></B>. Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody, AB122, is a fully human antibody with similar binding affinity and other characteristics to
the marketed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies, pembrolizumab and nivolumab. AB122 is currently in a Phase 1 dose-escalation trial in cancer patients in Australia. We expect to
initiate a Phase 1/2 trial of AB122 in combination with AB928 in cancer patients, during the second quarter of 2018 and to report safety, pharmacokinetic and pharmacodynamic data from our ongoing Phase&nbsp;1 trial of AB122 in cancer patients in the
third quarter of 2018. We also plan to develop AB122 in combination with our other small-molecule and antibody product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>AB154</I></B>. Our anti-TIGIT antibody, AB154,<B> </B>is a humanized antibody that inhibits a unique immune checkpoint target involved in a pathway that plays both inhibitory and stimulatory roles in the immune
system.<B> </B>We plan to file an investigational new drug application (IND) for AB154 in <FONT STYLE="white-space:nowrap">mid-2018</FONT> and to develop AB154 in combination with our other product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have initiated several other programs against promising immuno-oncology targets such as arginase, and we expect to select a development candidate in 2018
and file an IND or foreign regulatory application for the first development candidate from one of these programs by early 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we plan to retain
significant economic and commercial rights to our portfolio, we may <FONT STYLE="white-space:nowrap">out-license</FONT> the rights to our product candidates in certain regions where we are unlikely to pursue commercialization on our own. In
September 2017, we entered into an option and license agreement with Taiho for the potential development and commercialization of our product candidates in Japan and certain other territories in Asia (excluding China). Under the terms of the
agreement, we will receive a <FONT STYLE="white-space:nowrap">non-refundable</FONT> and <FONT STYLE="white-space:nowrap">non-creditable</FONT> upfront payment and research payments totaling $35&nbsp;million during the first three years of the
agreement. For any program for which Taiho exercises its option for an exclusive license, we will receive an option payment and will be eligible to receive up to $275&nbsp;million in development, regulatory, and commercial milestone payments arising
from such program, as well as royalties, ranging from high single digits to <FONT STYLE="white-space:nowrap">mid-double</FONT> digits, on net sales in Taiho&#146;s territories. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Internal Discovery Capability and Team </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
discovery capability and organization have enabled the rapid and efficient generation of potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> small-molecule immuno-oncology drug candidates. In the
case of our A<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>R antagonist program, we identified the first compounds in February 2016, synthesized AB928 for the first time in December 2016, and initiated our first clinical trial of AB928 in
November 2017, essentially progressing from program initiation to first subject dosed within 21 months. We believe that our discovery capability and our expertise and efficiency will allow us to replicate the rapid timeline that we achieved with
AB928. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assembled a management team with highly relevant experience in immuno-oncology, small-molecule drug discovery and clinical development.
Members of our scientific and senior management team, including our founders, Dr.&nbsp;Terry Rosen and Dr.&nbsp;Juan Jaen, have demonstrated their ability to rapidly discover product candidates, most recently at Flexus Biosciences, Inc., which was
acquired by Bristol-Myers Squibb in 2015 for up to $1.25&nbsp;billion in total payments for its preclinical-stage <FONT STYLE="white-space:nowrap">IDO-1</FONT> enzyme inhibitor, now called <FONT STYLE="white-space:nowrap">BMS-986205,</FONT>
approximately 18 months after the company&#146;s formation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Scientific Advisory Board includes several thought leaders in the immuno-oncology field,
including Jeffrey A. Bluestone, Ph.D., the CEO of the Parker Institute for Cancer Immunotherapy and the A.W. and Mary Margaret Clausen Distinguished Professor Director, Hormone Research Institute University of California, San
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Francisco; Antoni Ribas, M.D. Ph.D., Professor of Medicine of Hematology / Oncology and the Director of JCCC Tumor Immunology at UCLA; David Lacey, M.D. Ph.D., former Senior Vice President of
Discovery Research at Amgen; Jonathan Yingling, Ph.D., Senior Vice President of Early Development at Idera Pharmaceuticals and former Vice President, Oncology Discovery and Translational Research at Bristol-Myers Squibb; Ramy Ibrahim, M.D., Vice
President, Clinical Development at the Parker Institute for Cancer Immunotherapy and previously Clinical Vice President, Immuno-Oncology at AstraZeneca; and Chris Garcia, Ph.D., Professor of Molecular&nbsp;&amp; Cellular Physiology and Structural
Biology at Stanford University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;1, 2017, we have 78 employees, including 63 in R&amp;D, of which 43 hold Ph.D. or M.D. degrees, and
have established internal expertise in chemistry, immunology, biochemistry, pharmacology, structural biology, translational medicine, and preclinical and clinical development. An important element of our strategy is to build and maintain significant
internal capabilities in the areas, such as medicinal chemistry, that we believe are critical for the discovery of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> small-molecule compounds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception in 2015, we have raised approximately $227&nbsp;million in equity capital from investors that have significant life sciences experience
and that share our vision to create a leading company in the immuno-oncology field, including: GV (formerly Google Ventures), The Column Group, Foresite Capital, Wellington Management Company LLP, EcoR1 Capital, BVF Partners L.P., Decheng Capital,
Invus Opportunities, Hillhouse, Aisling Capital, Novartis Institute for BioMedical Research, Inc., Celgene Corporation, Stanford University, Taiho Ventures and DROIA Oncology Ventures. This equity capital includes approximately $22&nbsp;million in
investments made by our founders and management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background on the Immuno-Oncology Market </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For decades, it has been understood that the immune system can be harnessed to eradicate and prevent the proliferation of cancer cells. Unfortunately, multiple
early clinical trial failures discouraged the biopharmaceutical industry from making a significant investment in immuno-oncology. However, when the immune checkpoint inhibitor ipilimumab generated positive Phase 3 data in melanoma in 2010,
demonstrating durable responses in patients with very advanced disease, the biopharmaceutical industry&#146;s view of the importance of immuno-oncology changed significantly. Ipilimumab acts by blocking the function of a receptor called <FONT
STYLE="white-space:nowrap">CTLA-4,</FONT> which is found primarily on T cells. While ipilimumab has yet to demonstrate meaningful activity in other tumor types as a single agent, the melanoma data catalyzed a massive increase in investment in the
immuno-oncology field at biopharmaceutical companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the ipilimumab data, biopharmaceutical companies focused their development efforts on
another class of immune checkpoint inhibitors that includes <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies, which block the <FONT STYLE="white-space:nowrap">PD-1</FONT> receptor found on
T&nbsp;cells, B cells and myeloid cells, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> antibodies, which block the <FONT STYLE="white-space:nowrap">PD-L1</FONT> ligand on cancer cells. Collectively, <FONT
STYLE="white-space:nowrap">anti-CTLA-4,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> antibodies
represent the first generation of immune checkpoint inhibitors. These drugs all act to release the &#147;brakes&#148; on the immune system by activating T&nbsp;cells and enabling them to recognize and eradicate cancer cells. Compared to ipilimumab, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies have demonstrated higher clinical response rates, more frequent durable responses, activity in a broader
range of tumors and a better safety profile. Currently, this class of molecules is approved in at least six tumor types, including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung carcinoma, melanoma, squamous cell head and neck cancer,
bladder cancer, renal cell carcinoma and Hodgkin&#146;s Lymphoma. According to EvaluatePharma, a life sciences market intelligence firm, by 2022, these antibody products are expected to generate revenues of approximately $30&nbsp;billion globally.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opportunities for Combination Therapies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the success of the first generation of immune checkpoint inhibitors, patient response rates for single-agent therapy are relatively low. For example,
the two approved <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies, when administered as single agents, have only demonstrated response rates of approximately 30% in melanoma patients, and the
majority of these patients see their disease ultimately progress. The response rates in other tumor types are even </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lower. In addition, these therapies have not demonstrated meaningful single-agent activity in many of the most prevalent types of cancer, such as breast, prostate, pancreatic, ovarian and
colorectal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To address the limitations of single-agent immuno-oncology therapy, efforts are now focused on combining <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies with other types of drugs. These combination efforts are designed to address the multiple mechanisms that likely prevent effective anti-tumor
immunity and are based on the understanding that several immune processes may need to be modulated concurrently to overcome the adaptations that tumors use to escape immunity. For example, in addition to T cells, there are several other types of
immune cells that are critical to an effective anti-tumor immune response, which can be dysregulated in cancer. In addition, tumors can affect their microenvironment in ways that suppress effective immune function, thereby creating favorable
conditions for tumor growth and proliferation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The first combination of immuno-oncology agents to be approved by the FDA was the combination of two
immune checkpoint inhibitors, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody nivolumab and the <FONT STYLE="white-space:nowrap">anti-CTLA-4</FONT> antibody ipilimumab, for the treatment of
advanced metastatic melanoma. While this combination improved survival rates relative to either agent alone, it also resulted in increased toxicities. Regardless, this therapy demonstrates the opportunity for combinations of drugs that target
multiple immune mechanisms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A significant academic and industry effort is now underway to evaluate combinations of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies with other agents in order to achieve more frequent and durable responses. Despite recent clinical successes with combination therapy, such
as the growing body of data supporting combining inhibitors of an enzyme known as <FONT STYLE="white-space:nowrap">IDO-1</FONT> with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies in a number of
tumor types, the challenge remains to identify and develop combinations that will ultimately succeed in important clinical settings. We believe that we are uniquely positioned to address this opportunity by pursuing mechanisms and combinations
supported by strong biological rationale derived from existing and evolving scientific data sets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Unique Approach to Immuno-Oncology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Focus on Scientifically Validated Immuno-Oncology Pathways </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To exploit the significant opportunity in the immuno-oncology market in the most efficient manner and to maximize the addressable patient population for our
portfolio, we focus on the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Scientifically Validated Pathways. </I></B>Academia has spent decades elucidating the biology behind the immune system&#146;s role in cancer, generating a large amount of information on pathways and potential
therapeutic targets. However, much of this information has yet to be translated into the discovery of high-quality product candidates. We are focusing on biological pathways for which we can leverage this body of existing scientific knowledge to
rapidly generate highly differentiated, small-molecule drug candidates and to identify promising combination therapies and clinical settings in which to pursue them. We believe that this approach mitigates our risk and allows us to create and
develop high-quality drug candidates targeting critical immune pathways more quickly and efficiently than would otherwise be possible. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Broad Range of Mechanisms.</I></B> We are focused on developing product candidates that act against a broad range of mechanisms that enable tumors to evade eradication by the immune system. The following graphic
illustrates the diverse set of opportunities for therapeutic intervention, as well as the pathways in which we are currently conducting research. In the first row of the graphic, <I>Eliminate Immune Suppression</I> refers to opportunities to reverse
mechanisms that actively suppress the immune response against cancer cells.<I>&nbsp;Enhance APC Function</I> refers to the stimulation of dendritic cells to effectively present tumor antigens for recognition by T cells. <I>Enhance Effector
Activity</I> refers to the opportunity to enhance the activity of certain immune cells that are critical to generating a successful immune response against tumors. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">As shown below, the approved checkpoint inhibitors only relieve T cell suppression and do not directly impact other immune cells nor directly
enhance immune system function. Collectively, the Arcus small </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
molecules and antibodies in the box below illustrate the breadth of the mechanisms that we are currently pursuing with our portfolio and where they fall in the spectrum of anti-tumor immune
mechanisms. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g85h82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:8pt; font-family:Times New Roman">APC: antigen-presenting cells; NK cells: natural killer cells; T<SUB
STYLE="font-size:85%; vertical-align:bottom">reg</SUB>: regulatory T cells; MDSC: myeloid-derived suppressor cells; M2: anti-inflammatory macrophages; DC: dendritic cells; Effector Activity: the ability of immune cells to attack target cells by
various mechanisms, depending on the cell type. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Ubiquitously Important Targets.</I></B><I> </I>We focus on targets that are ubiquitous, meaning that they are believed to play an important role in a broad range of human cancer types and settings. For example,
CD73, the key enzyme responsible for the generation of extracellular adenosine, has been found to be over-expressed in many tumor types, including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, colorectal cancer,
gastroesophageal cancer, breast cancer (particularly triple-negative breast cancer), ovarian cancer, and others, suggesting that it plays a broad immuno-protective role in tumor survival. In fact, high levels of CD73 expression have been shown to
correlate with reduced survival rates in cancer patients. Given the broad applicability of our targets, we expect to pursue the development of AB928, AB680, and our other product candidates in multiple tumor types, utilizing an adaptive trial design
that will allow us to explore several combination settings in parallel, starting with relatively small patient cohorts. We expect that our focus on targets and pathways that are ubiquitously involved in cancer will enable our product candidates to
address broad patient populations and significant market opportunities. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Approach to Building a Broad and Differentiated Portfolio
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To exploit the potential of these scientifically well understood immuno-oncology pathways and targets, we are focusing our internal discovery
effort on novel small-molecule product candidates. While all immuno-oncology agents approved to date are large molecules, such as the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> and <FONT STYLE="white-space:nowrap">anti-CTLA-4</FONT> antibodies, we believe that both small and large molecule modalities will be critical in addressing the many
different immune-mediated pathways that may be dysregulated in a patient&#146;s tumor. As many immuno-oncology pathways are not amenable to intervention by antibodies or protein therapeutics, we expect that small-molecule approaches will allow us to
access a significantly greater number of potential targets, including intracellular and extracellular enzymes, <FONT STYLE="white-space:nowrap">G-protein</FONT> coupled receptors (GPCRs), and kinases. In addition, in some cases, small molecules may
prove superior to large-molecule approaches against the same target. For example, we have shown in <I>in vitro</I> studies that our small-molecule CD73 inhibitors can achieve a greater degree of CD73 inhibition than certain antibodies against this
target that are in clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our internal discovery effort is designed to create and advance small-molecule product candidates with the ideal
pharmacological properties for the tumor micro-environment and the target of interest. Small-molecule drugs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
against the same biological target can be highly differentiated from each other based on their respective pharmacokinetic, pharmacodynamic and biophysical properties. For example, many
small-molecule drugs are potent when tested in buffer solution but lose a significant amount of this potency in physiologically relevant media such as blood or tumor tissue, due to a phenomenon known as &#147;plasma protein binding&#148; in which
compounds bind <FONT STYLE="white-space:nowrap">non-specifically</FONT> to albumin and other abundant proteins found in such tissues. We rigorously test our molecules in whole blood or other physiologically relevant systems and only advance
molecules that retain a high degree of activity when tested under such &#147;real world&#148; conditions. We also design our molecules to have the ideal pharmacological properties for the targeted pathway and the desired clinical effect. For
example, we specifically designed our A<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>R antagonist AB928 to have a greatly reduced ability to cross the blood brain barrier, as we believe that this attribute will allow us to dose the
compound at higher levels before the appearance of any potential adverse events associated with inhibition of the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R receptor in the brain. We also designed our A<SUB
STYLE="font-size:85%; vertical-align:bottom">2</SUB>R antagonist AB928 to inhibit both the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R and A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors, as we believe a
&#147;dual A<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>R antagonist&#148; will have broader immunological and anti-tumor activity than a &#147;selective A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonist.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To support our strategy of pursuing multiple intra-portfolio combinations, we are building a diverse portfolio of product candidates that target
different immune mechanisms. In addition to small molecules, we are also developing antibody product candidates that target what we believe are some of the most important immune checkpoint receptors, including
<FONT STYLE="white-space:nowrap">PD-1</FONT> and TIGIT, and that we expect to be critical components of our future intra-portfolio combinations. We believe that these antibody candidates will enable us to develop products that are <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> and/or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> by combining them with our highly differentiated
small-molecule candidates. We also plan to fully explore potential synergies between our molecules and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> treatments, such as chemotherapy, when there is a
strong biological rationale, such as the case of combining our <FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> pathway inhibitors AB928 and AB680 with certain chemotherapeutic agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given that the treatment of cancer continues to evolve towards the use of agents that are specific for particular tumor profiles, we intend to explore
biomarkers that may predict a patient&#146;s response to treatment. Patients&#146; tumors being considered for immune-based therapies are already routinely tested for certain markers, such as <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression
or the absence of mutation-repair mechanisms, to determine whether they are appropriate candidates for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> or <FONT STYLE="white-space:nowrap">PD-L1</FONT>
therapy. In certain settings, we may incorporate biomarker screening into our clinical trials to increase the likelihood of success by focusing on patients that are most likely to respond to our product candidates. For example, we will measure CD73
levels in patients during our early clinical trials with our <FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> pathway inhibitors AB928 and AB680 in order to determine the value of incorporating screening for CD73 expression into our future
clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Small-Molecule Discovery Capability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We leverage existing chemical and structural knowledge about the pathway or target to identify chemical starting points for our drug discovery programs. We
then conduct extensive optimization of the biological and pharmacological properties of those leads guided by structure-activity relationship (SAR) knowledge generated under the direction of our experienced drug discovery scientists. In some cases,
we utilize structural biology <FONT STYLE="white-space:nowrap">(x-ray</FONT> crystallography) to improve the way in which our compounds bind to their target. For example, we have a collaboration with Professor Norbert Stratter at the University of
Leipzig in Germany for the elucidation, using <FONT STYLE="white-space:nowrap">x-ray</FONT> crystallography, of the structures of more than 15 of our internally discovered CD73 inhibitors bound to human CD73; this effort contributed in a meaningful
way to the identification of our lead development candidate AB680. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We determine upfront the properties that we believe are critical to effectively
modulate the target pathway of interest. These properties include high potency under physiologically relevant conditions, e.g., blood; selectivity against the target; lack of drug-drug interactions; high penetration of tumor tissue; optimal
pharmacokinetic properties; and good safety profile. We conduct in our laboratories those activities that we consider to be critical for creating a molecule with optimal properties. These activities include medicinal chemistry, assay development,
assessment of compound potency and selectivity, <I>in vitro</I> and <I>in vivo</I> pharmacokinetic profile evaluation, <I>in vivo</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pharmacology, and exploratory safety evaluation, among others. Having these capabilities and expertise <FONT STYLE="white-space:nowrap">in-house</FONT> allows us to iterate on the design of our
product candidates, until we achieve the predefined optimal properties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have utilized our drug discovery capability to create several potentially <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> product candidates, including our dual adenosine receptor antagonist AB928 and our small-molecule CD73 inhibitor AB680. The robustness and integrated nature of
our drug discovery capability has also enabled rapid advancement of our programs. For example, in our A<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>R receptor program, we progressed from lead identification to first synthesis of AB928 in
10 months, and to the start of our first clinical trial in another 11 months. We believe that we can consistently take molecules from lead identification to IND or foreign regulatory application in about 18&nbsp;months. Our plan is to advance into
clinical development at least one new product candidate generated by our internal discovery effort each year for the next several years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Approach
to Clinical Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our approach to clinical development is to pursue strategies that allow us to generate meaningful data on our product
candidates in the most efficient manner possible, which should allow us to rapidly advance our product candidates through clinical trials. Some of the key elements of our approach include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Focus our development efforts on combination products, particularly those that are intra-portfolio.</I></B> To maximize the potential of our small-molecule product candidates, we will focus our development efforts
on combining them with other agents which we expect to be synergistic with our small molecules. We have <FONT STYLE="white-space:nowrap">in-licensed</FONT> two antibody product candidates, both of which we expect to be synergistic with our small
molecule product candidates, which will allow us to pursue multiple intra-portfolio combinations incorporating our internally discovered small-molecule product candidates. While we initially plan to focus on the development of doublet therapies,
such as the combination of AB928 and AB122, we also plan to pursue triplet therapies, which would incorporate two or three of our product candidates. The table below summarizes some of the combination studies we could pursue with our existing
portfolio. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>&nbsp;&nbsp;Arcus&nbsp;Product</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:54.00pt; font-size:8pt; font-family:Times New Roman"><B>&nbsp;&nbsp;Candidate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Potential&nbsp;Doublet&nbsp;Partner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Potential Triplet Partners</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;AB928&nbsp;(A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R/A<SUB
STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+ AB122 (anti-PD-1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+ AB122 <FONT STYLE="white-space:nowrap">(anti-PD-1)</FONT> + AB154 (anti-TIGIT)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+ Chemotherapy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+ AB122 (anti-PD-1) + Chemotherapy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">+&nbsp;AB154&nbsp;(anti-TIGIT)</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+ AB122 (anti-PD-1) + Radiation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;AB680&nbsp;(CD73)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+ AB122 (anti-PD-1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+ AB122 (anti-PD-1) + AB154 (anti-TIGIT)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+ Chemotherapy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+ AB122 (anti-PD-1) + Chemotherapy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+ AB154 (anti-TIGIT)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;AB154&nbsp;(anti-TIGIT)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+ AB122 (anti-PD-1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">See above</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Design our clinical trials to advance our compounds as quickly and efficiently as possible</I></B>. Following the identification of our recommended dose from our dose escalation trials, we plan to initiate the
enrollment of expansion cohorts in multiple tumor types using an adaptive trial design. The adaptive trial design allows us to enroll patients with multiple tumor types, where we believe our product candidate has the potential for clinical activity,
into a single trial and to allocate patients to the appropriate cohort based on their tumor type. Given the ubiquitous nature of the targets upon which we are focused, we believe that this design provides us with an efficient mechanism for studying
our product candidates in multiple tumor types. Adaptive trial designs give us the ability to quickly close or increase the size of our expansion cohorts based on initial tumor response data generated in that cohort. Each cohort will enroll <FONT
STYLE="white-space:nowrap">15-30</FONT> patients, which we believe is sufficient in size to allow us to determine whether the response rate would likely be clinically meaningful and differentiated from the current standard of care. We could increase
the size of any expansion cohort for which we observe a promising initial response rate, in order to generate a sufficient amount of information to support the advancement of the product candidate or combination product into a potentially
registrational trial. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">For some of our small-molecule product candidates, we may choose to initiate clinical
testing in healthy volunteers, as we have done with AB928. Because AB928 has been shown to have a fairly benign safety profile in our animal toxicology studies, particularly relative to other oncology agents, we were able to start clinical testing
of AB928 in healthy volunteers. A healthy volunteer trial allows us to evaluate our product candidates in a relatively large number of subjects over a relatively short time period, and to study the behavior of our product candidates in a more
controlled setting than is possible in a clinical trial with cancer patients. These trials should allow us to generate significant data on the safety and pharmacodynamic and pharmacokinetic profile of our product candidates, providing meaningful
information on receptor coverage, half-life, optimal dosing regimen and consistency of the drug&#146;s activity across human subjects. This should allow us to initiate dosing in cancer patients at a higher dose and therefore accelerate the time
required for our dose-escalation studies. We will only pursue this approach when we believe that it could accelerate our overall clinical development timelines and meaningfully <FONT STYLE="white-space:nowrap">de-risk</FONT> our future trials. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">We may also initiate clinical trials for our product candidates in certain regions outside the United States, which may allow us to accelerate
our enrollment times. For example, we initiated our first clinical trial for AB122 in Australia, which we believe allowed us to accelerate the time from regulatory submission to the initiation of dosing in patients relative to what would have been
possible in the United States. We also believe that we can enroll patients into this trial faster in Australia than in the United States. We currently plan to also initiate clinical testing of our first intra-portfolio combination, AB928 + AB122, in
Australia. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Select tumor types and settings based on biological and commercial rationale. </I></B>In selecting tumor types to pursue, we will focus on those types that are most dependent on the pathways targeted by our
agents, such as tumors with high levels of CD73 expression for <FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> inhibitors. We will also focus on patient populations and settings where we believe there is still considerable unmet need. As an
example, for our AB122 combinations, we will focus on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> relapsed/refractory patients in indications like <FONT STYLE="white-space:nowrap">non-small</FONT> cell
lung cancer where <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy is currently considered the standard of care. In the case of our chemotherapy combinations, we will focus on tumor types in which
that particular chemotherapy is already considered the standard of care, such as the case of oxaliplatin-containing regimens in the treatment of colorectal cancer. In addition, we are pursuing settings where significant clinical data already exist
for the agent that will be evaluated in combination with our product candidates. We believe that this will allow us to determine whether the data we generate in our expansion cohorts are clinically meaningful and differentiated from the current
standard of care. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
objective is to transform the treatment of cancer by creating a broad portfolio of innovative immuno-oncology therapeutics and developing combinations that offer significant improvement over current treatment options. To achieve this objective, we
are pursuing the following strategies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Rapidly advance our lead product candidates and combinations through clinical development in multiple tumor
types.</I></B> We have initiated Phase 1 trials for our two lead product candidates, AB928 and AB122. Leveraging the benign safety profile of AB928 observed in extensive preclinical toxicology studies, we are conducting our initial trial of this
product candidate in healthy human volunteers. Data from this trial should support selection of a higher starting dose and more rapid dose escalation in our first AB928 clinical trial in cancer patients, which will be a Phase 1/2 combination trial
with AB122. For this trial, we will utilize an adaptive trial design where our goal is to generate sufficiently robust data in certain tumor types to allow us to advance the AB928+AB122 combination into a large, randomized trial that could
potentially support regulatory approval. Concurrently with the AB928+AB122 combination, we intend to evaluate the clinical activity of AB928 in combination with certain forms of chemotherapy, which will implement a similar adaptive trial design as
the AB928+AB122 trial. We plan to pursue similar adaptive trial designs for our other product candidates, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
including AB680 and AB154. The objective of our adaptive trial designs is to rapidly generate meaningful clinical data that potentially supports the initiation of a registrational trial.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Pursue combinations and tumor types based on strong biological rationale.</I></B><I> </I>We are pursuing therapeutic combinations driven by strong biological rationale that suggests synergy between the agents. For
example, activation of A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R receptors on T cells has been shown to impair the ability of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies to
enhance activation of those T cells, providing a strong rationale for combining <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy with our agents that target the
<FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> pathway. We are also selecting tumor types that we believe will be most sensitive to our product candidates&#146; mechanisms of action, such as those that have high CD73 expression and T cell
infiltration in the cases of AB928 and AB680. In our later-stage trials, we will likely screen for patients with certain tumor profiles, such as high CD73 expression, which should enhance the likelihood of success of these product candidates. In
combination trials that involve AB122, we will determine whether expression level of <FONT STYLE="white-space:nowrap">PD-L1</FONT> influences the response rate in a particular tumor type. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Control, or otherwise secure access to, all the components of our desired therapeutic combinations.</I></B><I> </I>As <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies are currently considered the backbone therapy of immuno-oncology treatment, we believed that it was critical to ensure access to this type of molecule to pursue and control
the development of multiple intra-portfolio combinations. In September 2017, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> an <FONT STYLE="white-space:nowrap">IND-ready</FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody from WuXi Biologics. We have also <FONT STYLE="white-space:nowrap">in-licensed</FONT> a preclinical-stage anti-TIGIT antibody that we believe has the
potential to become a backbone therapy in the future, and we will continue to evaluate and pursue other molecules that we believe will be critical elements of our combination strategy. By having these antibody product candidates in our portfolio, we
can better control the clinical trial design and timelines and retain much of the economics of any resulting products that receive regulatory approval. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Continue to expand our pipeline of novel small-molecule product candidates</I></B><B>.</B> More than 80% of our workforce is dedicated to research and development, and we plan to continue to invest in our
discovery capability and to expand our pipeline. By the end of 2018, we expect to have filed at least four regulatory applications to initiate clinical trials in the United States or other countries, including two for product candidates that we
discovered and developed <FONT STYLE="white-space:nowrap">in-house.</FONT> We have initiated several other drug discovery programs that target promising immuno-oncology pathways, such as arginase, and expect to file our first IND or foreign
regulatory application from one of these programs by early 2019. A key element of our portfolio strategy is to create second-generation molecules for our small-molecule programs; these compounds may possess differentiated pharmacological profiles
and are generally derived from chemical scaffolds distinct from the one from which the first generation product candidate was selected. We have active second-generation programs in place for AB928 and AB680. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Retain significant economic and commercial rights to our programs in key geographic areas.</I></B> We plan to retain significant economic and commercial rights to our portfolio in the United States and certain
other regions. We have pursued and will continue to evaluate opportunities to <FONT STYLE="white-space:nowrap">out-license</FONT> rights to our product candidates in regions in which we are unlikely to pursue development and commercialization on our
own, as was the case with our option and license agreement with Taiho for Japan and certain other territories in Asia (excluding China). In the future, we may enter into strategic collaborations with pharmaceutical companies in the United States or
Europe if we believe the partnership enables us to accelerate the development and commercialization of our programs while allowing us to retain meaningful rights to our product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our <FONT STYLE="white-space:nowrap">ATP-Adenosine</FONT> Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The <FONT STYLE="white-space:nowrap">ATP-Adenosine</FONT> Pathway and Its Relevance in Cancer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our initial focus is on the <FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> pathway, which, when activated, has potent immuno-suppressive effects in the
tumor microenvironment, thereby preventing the immune system from recognizing and destroying </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cancer cells. The activation of this pathway begins with the release from cells of adenosine triphosphate (ATP), a nucleotide that is the primary source of cellular energy. Under normal
conditions, ATP is found primarily intracellularly; however, under conditions of cellular damage or cell death, large amounts of ATP are released extracellularly. On its own, ATP acts as a &#147;danger signal&#148; to alert and activate the innate
immune system. However, an enzyme known as CD39 converts the extracellular ATP into adenosine monophosphate (AMP), and another enzyme known as CD73 subsequently converts AMP into adenosine, which has profound immunosuppressive properties. This
process, which results in the generation of large amounts of extracellular adenosine, evolved to protect human tissue from excessive inflammation by counteracting the <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> effects of ATP. However,
cancer cells have hijacked this mechanism to prevent the immune system from efficiently recognizing and eradicating them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once generated, adenosine can
bind to and activate four different <FONT STYLE="white-space:nowrap">G-protein</FONT> coupled receptors: A<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>R, A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R, A<SUB
STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R and A<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>R. Of these, only the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R and A<SUB
STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors are believed to play a role in intra-tumoral immune suppression as described below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R.</I></B> The binding of adenosine to the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R receptor, which is expressed on T cells, natural
killer (NK) cells and myeloid cells such as dendritic cells, leads to increased intracellular levels of cyclic AMP (cAMP) and the impairment of maturation and/or activation of T cells, NK cells and dendritic cells. This process significantly impairs
the activation of the immune system against cancer cells. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In addition, the relationship between A<SUB
STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R, <FONT STYLE="white-space:nowrap">PD-1,</FONT> and T cell receptor (TCR) activation on T cells is becoming increasingly elucidated. Increased cAMP levels induce specific biochemical and
transcriptional changes in T cells that interfere with TCR activation, decrease the levels of certain proteins (such as CD28) necessary for optimal T cell activation and elevate the levels of certain proteins (such as
<FONT STYLE="white-space:nowrap">PD-1)</FONT> that inhibit T cell activation. As a result, A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R receptor signaling may play a role in development of resistance to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R.</I></B> The binding of adenosine to the A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptor, which is primarily expressed on myeloid
cells, further contributes to the impaired maturation/activation of dendritic cells, a process that is critical for the generation of an adaptive immune response against tumor antigens. Activation of the A<SUB
STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptor by adenosine also enhances the tumor-protective effects of myeloid-derived suppressor cells (MDSC) and anti-inflammatory macrophages (M2). Therefore adenosine binding to A<SUB
STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R results in further impairment of the maturation/activation of these myeloid cells and activates a distinct process that protects tumor cells from the immune system. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One of the significant consequences of A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R and
A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R activation on tumor-infiltrating immune cells is a decrease in effector T cell (T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB>) numbers and activity, as well as simultaneous
increases in regulatory T cell (T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB>) numbers and activity and decreases in inflammatory cytokine production. T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> and T<SUB
STYLE="font-size:85%; vertical-align:bottom">reg</SUB> play opposite roles in their attack and protection, respectively, of cancer cells. Their numbers and, more importantly, their ratio is frequently indicative of a cancer patient&#146;s likely
prognosis; specifically, a higher T<SUB STYLE="font-size:85%; vertical-align:bottom">eff</SUB> to T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB> ratio is generally correlated with a better prognosis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The enzymes CD39 and CD73 are upregulated in response to various stimuli, such as the hypoxic tumor microenvironment and certain growth factors and cytokines.
In addition, the commonly prescribed chemotherapeutic agents oxaliplatin and doxorubicin also induce elevated CD39 and CD73 levels, which may result in an immunosuppressive response that counteracts some of the potentially beneficial effects of
these chemotherapies. Consistent with the relationship between hypoxia and elevated CD73 expression, several studies and public databases have shown that CD73 is overexpressed in multiple tumor types and that high CD73 expression is correlated with
a poor prognosis in many types of cancer. These include <FONT STYLE="white-space:nowrap">non-small-cell</FONT> lung carcinoma, colorectal cancer, head and neck squamous cell carcinoma, ovarian cancer, triple-negative breast cancer, renal cell
carcinoma, prostate cancer and gastroesophageal cancer. These studies demonstrate the broad potential of CD73 inhibition in many oncology settings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Product Candidates Targeting the <FONT STYLE="white-space:nowrap">ATP-Adenosine</FONT> Pathway
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are pursuing what we consider to be the two most critical targets within the <FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> pathway: the
A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R/A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors and the enzyme CD73. Due to the significant and growing amount of scientific literature supporting the critical role
of the <FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> pathway in cancer, several companies have recently repurposed for oncology A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R receptor-selective antagonists that were originally
developed for Parkinson&#146;s disease and other CNS disorders. These repurposed molecules were originally developed to inhibit the effects of adenosine in the brain, where adenosine is present in much smaller quantities than in the tumor
microenvironment. These molecules were also specifically designed to cross the blood brain barrier, which could limit the use of higher doses in other settings, like oncology, because of the potential for
<FONT STYLE="white-space:nowrap">CNS-mediated</FONT> adverse events. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Dual Adenosine Receptor Antagonist, AB928 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most advanced small molecule targeting the <FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> pathway, AB928, is an orally bioavailable, highly potent,
reversible antagonist of the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R and A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors. AB928 is currently in a Phase 1 trial in healthy volunteers. We will initiate
clinical testing of AB928 in cancer patients in the second quarter of 2018. We plan to develop AB928 in combination with AB122, our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody, and other agents
for which a strong biological rationale exists supporting their synergy with A<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>R antagonism. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
believe that AB928 is the first A<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>R antagonist in clinical development that inhibits both the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R and A<SUB
STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors and which was designed specifically for the oncology setting. As a result, AB928 has several attributes that differentiate it from the other A<SUB
STYLE="font-size:85%; vertical-align:bottom">2</SUB>R antagonists in clinical development, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><B><I>High potency and low plasma protein binding</I></B><I>.</I> We have shown that AB928 is more potent against A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R in buffer than the A<SUB
STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonists currently in clinical development. More importantly, AB928 is significantly more potent than these A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonists when we
evaluated them under conditions that more closely resemble the tumor microenvironment. In these studies, we evaluated AB928 in an assay using whole blood, instead of buffer, and in the presence of high levels of NECA (a synthetic analogue of
adenosine). Blood, like tumors, contains much higher concentrations of albumin than the brain. As albumin <FONT STYLE="white-space:nowrap">non-specifically</FONT> binds to many small-molecule drugs, resulting in a dramatic loss of effective potency,
blood represents a more representative biological medium for the evaluation of the potency of small-molecule drugs. The high levels of NECA used in this experiment are representative of the high concentrations of adenosine that have been measured in
many solid tumors; these levels can be as much as 100 times higher than those found in the brain. Because the other A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonists in clinical development were developed with a focus on
activity in the brain, they were not necessarily designed to work in the presence of the much higher levels of adenosine that are found in tumors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">When we evaluated AB928 under these conditions, AB928 was significantly more potent at
inhibiting A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R activation, as measured by phosphorylation CREB (pRCEB), than the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonists in clinical development, as shown in
the graph below. CREB is a transcription factor that becomes phosphorylated when A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R is activated; thus, the level of pCREB inhibition is a measure of an A<SUB
STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonist&#146;s ability to inhibit A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R. The table below on the right shows the calculated IC<SUB
STYLE="font-size:85%; vertical-align:bottom">50</SUB> values for the various compounds in this experiment. The IC<SUB STYLE="font-size:85%; vertical-align:bottom">50 </SUB>values indicate the concentration of each compound necessary to achieve 50%
inhibition of pCREB formation. Therefore, lower values reflect greater compound potency. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ROWSPAN="5"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g317356g31k47.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:38.25pt; font-size:8pt; font-family:Times New Roman"><B>Compound</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"><B><SUB STYLE="font-size:85%; vertical-align:bottom"></SUB><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB>&nbsp;(nM)<SUP STYLE="font-size:85%; vertical-align:top">a</SUP></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUB STYLE="font-size:85%; vertical-align:bottom"></SUB><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">AB928</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CPI-444</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">~10,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">AZD 4635</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,6000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">PBF-509<SUP STYLE="font-size:85%; vertical-align:top">b</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">~10,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">a</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Arcus data generated with compound samples synthesized by Arcus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">b</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Molecule synthesized by Arcus, believed to be <FONT STYLE="white-space:nowrap">PBF-509</FONT> based on published patent documents. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Dual antagonism of the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R and A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors.</I></B> Unlike the repurposed A<SUB
STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R receptor-selective molecules that were initially developed for CNS indications, we designed our A<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>R antagonist to optimize its properties
for use in immuno-oncology. As such, we designed AB928 to inhibit both the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R and A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors, since the binding of adenosine to A<SUB
STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors on myeloid cells contributes to adenosine-mediated immune suppression. Therefore, we expect that AB928 could have broader immunological activity than the selective A<SUB
STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonists. The scientific literature also supports the role of A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors in different types of cancer, such as triple-negative
breast and ovarian cancers. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes data we have generated in our cell-based assays conducted in
buffer evaluating the potency of AB928 against A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R and A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R, relative to the selective
A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonists. As shown below, AB928 is the most potent inhibitor of A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R receptors and is the only compound that meaningfully
inhibits A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R receptors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:53.50pt; font-size:8pt; font-family:Times New Roman"><B>A<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>R
Antagonist</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R&nbsp;(K<SUB STYLE="font-size:85%; vertical-align:bottom">B</SUB><SUP
STYLE="font-size:85%; vertical-align:top">&nbsp;</SUP>,&nbsp;nM)<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;c</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R&nbsp;(K<SUB STYLE="font-size:85%; vertical-align:bottom">B</SUB><SUP
STYLE="font-size:85%; vertical-align:top">&nbsp;</SUP>,&nbsp;nM)&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">c</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AB928 (Dual A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R/A<SUB
STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R Antagonist)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2.4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">CPI-444</FONT>
<SUP STYLE="font-size:85%; vertical-align:top">a</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AZD 4635 <SUP STYLE="font-size:85%; vertical-align:top">a</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">PBF-509</FONT> <SUP STYLE="font-size:85%; vertical-align:top">a,
b</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">a</SUP></TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Arcus data generated with compound samples synthesized by Arcus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">b</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Molecule synthesized by Arcus, believed to be <FONT STYLE="white-space:nowrap">PBF-509</FONT> based on published patent documents. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">c</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">K<SUB STYLE="font-size:85%; vertical-align:bottom">B</SUB> is a measure of a compound&#146;s thermodynamic ability to bind/block its target receptor; lower K<SUB STYLE="font-size:85%; vertical-align:bottom">B</SUB>
values reflect greater potency for a given receptor. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><B><I>Low penetration across the blood brain barrier.</I></B><I> </I>Unlike the other A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonists that were specifically designed to penetrate and act
in the brain, we have designed AB928 to minimize penetration of the blood-brain barrier. We have shown in animal studies the concentration of AB928 measured in brain corresponds to approximately 1% of the concentration found in blood<B><I>.
</I></B>We believe that this characteristic could allow us to dose at levels necessary to achieve high receptor coverage of AB928 in the tumor microenvironment while avoiding the potential for <FONT STYLE="white-space:nowrap">CNS-related</FONT>
toxicities. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><B><I>High tumor / plasma ratio.</I></B><I> </I>Another rationale for selecting AB928 as our lead
A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R/A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R antagonist development candidate is that a relatively high level of the compound penetrates the tumor. The blood vessels that
provide nutrients to tumors are poorly organized and may represent an obstacle against deep penetration of the tumor tissue by drugs arriving from the blood. The graph below shows the concentration of AB928 in the tumor and plasma over time in
tumor-bearing mice and demonstrates that AB928 achieves significant tumor penetration. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tissue distribution in
tumor-bearing mice after a single </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>30 mg/kg subcutaneous dose of AB928 to CT26-tumor bearing mice </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g57w17.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:38.25pt; font-size:8pt; font-family:Times New Roman"><B>Compound</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Tumor/Plasma</B><br><B>Ratio</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Brain/Plasma</B><br><B>Ratio</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AB928</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><B><I>Attractive pharmacokinetics</I></B><I>.</I> We designed AB928 to have high oral bioavailability and a human half-life to support once-daily dosing. Other
A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonists in clinical development are being dosed to patients twice per day, presumably reflecting their relatively low oral bioavailability and/or short half-life in humans. Molecules
with good oral bioavailability and long half-lives that can be dosed only once per day generally have lower <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;peak-to-trough&#148;</FONT></FONT> changes in plasma levels between
doses. This is important in cases in which the dose-limiting toxicities of the drugs are associated with high peak plasma levels; in these cases, higher overall drug exposures are possible when those drugs have longer half-lives, such as is the case
with AB928. Preliminary data from our ongoing Phase 1 trial in healthy volunteers shows an excellent half-life of about 21 hours, which allows for once-daily dosing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the important differentiated characteristics summarized above, we believe that AB928 could prove to have more robust anti-tumor effects and activity
in a broader range of tumor types than the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonists in clinical development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>In Vitro and In Vivo Data Supporting the Selection of AB928 as our Development Candidate </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The objective of our <I>in vitro</I> and <I>in vivo</I> studies is to characterize the effect of our molecules on immune function in systems that we believe
are representative of human and cancer biology. Our highly comprehensive <I>in vitro </I>and <I>in vivo</I> work has helped to elucidate the immune biology behind the pathways we pursue, demonstrate the differentiation of our product candidates
relative to other agents in their classes, identify a likely effective dose for human studies and determine potential combinations to explore in clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since AB928 was first synthesized at Arcus in December 2016, we have conducted multiple <I>in vitro</I> studies to assess the ability of AB928 to reverse the
immuno-suppressive activity of adenosine. In these studies, we measure readouts such as secretion of IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and <FONT STYLE="white-space:nowrap">IL-2,</FONT> which are cytokines released upon T cell
activation and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that have potent effects on anti-tumor immunity. For our assays, we typically use primary immune cells isolated from human blood, including
CD4<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells (also known as T helper cells because they activate other immune cells), CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells (also known as cytotoxic T cells for their
ability to directly kill cancer cells), dendritic cells and natural killer (NK) cells. The table below summarizes some of the key <I>in vitro </I>studies that we have conducted to date and shows that AB928 consistently reversed adenosine-mediated
immune suppression in multiple cell types and under various experimental conditions. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:24.40pt; font-size:8pt; font-family:Times New Roman"><B>System</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Key Findings</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Human CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp; AB928 inhibited
A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R receptor-mediated cAMP accumulation, in a dose-dependent manner, demonstrating that AB928 effectively blocks the activation of
A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp; Measured AB928 potency: K<SUB STYLE="font-size:85%; vertical-align:bottom">B</SUB> = 540 pM;
IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> = 940 pM</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Human CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp; AB928 blocked the adenosine-dependent inhibition of IFN-<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and granzyme B production, in a dose-dependent manner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Human CD4<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp; AB928 blocked the adenosine-dependent inhibition of proliferation and of <FONT
STYLE="white-space:nowrap">IL-2</FONT> production, in a dose-dependent manner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mixed lymphocyte reaction (MLR) between human dendritic cells and T cells</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp; AB928 blocked the adenosine-dependent inhibition of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1-induced</FONT></FONT></FONT> IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> production, in a dose-dependent manner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mouse NK cells</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp; AB928 blocked the adenosine-dependent inhibition of NK cell cytotoxicity,
in a dose dependent manner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Maturation/Activation of monocyte-derived dendritic cells</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp; AB928 inhibited the suppressive effects of adenosine on the maturation
and activation of dendritic cells, as measured by the impaired performance of these dendritic cells in an MLR assay. These results are consistent with the hypothesis that a dual A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R/A<SUB
STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R antagonist may have a broader immune-activation profile than selective A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonists</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An example of one of many studies that we have performed <FONT STYLE="white-space:nowrap">in-house</FONT> to demonstrate the
ability of AB928 to block adenosine-mediated impairment of T cell activation is illustrated in the figure below. In this study, activation of human CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells leads to a profound release of IFN-<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>. This assay recapitulates certain elements of the process by which T cells recognize their target. Introduction of adenosine (6 &micro;M) into this assay induced a profound inhibition of IFN-<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> production, as demonstrated by the second bar. When we also introduced increasing concentrations of AB928, in addition to adenosine, we demonstrated that AB928, at concentrations as low as 5 nM, was able to
completely block the inhibitory effects of adenosine on IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> production. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g42x54.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In another study aimed at understanding the role of the
A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R receptor on NK cell activation, we isolated NK cells from mouse spleen and cultured them together with labeled LLC cells (a common test system to measure the cell-killing activity of NK
cells). In this experiment, we used various concentrations of the synthetic adenosine receptor agonist NECA to inhibit the cytotoxic activity of the NK cells. As shown in the figure below, AB928 was very effective at blocking the inhibitory effects
of NECA in this assay system, restoring the NK cells&#146; killing activity in a dose-dependent manner. In this figure, the Y axis (% Cell Killing) reflects the % of the target cells that were killed as a result of being <FONT
STYLE="white-space:nowrap">co-cultured</FONT> with the NK cells. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g87a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also conducted several <I>in vivo</I> studies of AB928 in mouse tumor models to assess the compound&#146;s
pharmacokinetics, anti-tumor activity and the degree of target inhibition necessary for anti-tumor activity and effects on tumor-infiltrating lymphocytes (TIL), a generic term for the immune cells that can be retrieved from tumor tissue. We are
particularly interested in the latter assessment and the way in which AB928 alters the size and composition of the TIL, such as the ratio between CD8<SUP STYLE="font-size:85%; vertical-align:top">+ </SUP>T cells and T<SUB
STYLE="font-size:85%; vertical-align:bottom">reg</SUB> cells, towards a more favorable anti-tumor profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <I>in vivo</I> experiments have evaluated
AB928 in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies as well as with certain chemotherapies, both of which are believed to be
synergistic with A<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>R antagonism. In the case of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibody
combinations, previous studies conducted by others have demonstrated that higher CD73 expression limits the efficacy of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies and, therefore, A<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>R inhibition (which prevents
the downstream effects of CD73 expression and activity) could increase the effectiveness of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies. In
addition, certain chemotherapies, specifically anthracyclines and platinum-based agents, are known to induce immunogenic cell death (ICD), which results in the extracellular release of significant amounts of ATP, which is converted into adenosine by
the sequential actions of CD39 and CD73. As a result, we expect that A<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>R antagonists, like AB928, will be synergistic with <FONT STYLE="white-space:nowrap">ICD-inducing</FONT> chemotherapies.
This synergy has been demonstrated in animal models in several academic labs and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In one experiment in the MC38 mouse colon adenocarcinoma tumor model, we evaluated the combination of AB928
and an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> antibody. Despite the fact that the tumors in this highly variable mouse model do not express CD73, and therefore would not be expected to respond to
adenosine inhibition, and only the TIL do, we observed a reduction in tumor volumes, as well as an improvement in survival, for the AB928 and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> antibody
combination compared to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> antibody alone, as summarized in the graph below. It should be noted that human tumors are very different from mouse tumors in
that, in the former, cancer cells are often found to express significant levels of CD73; based on this difference, we believe that human tumors may be more dependent than mouse tumors on adenosine for their protection against the immune system. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g47j95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In another study, in the <FONT STYLE="white-space:nowrap">AT-3</FONT> OVA mouse breast tumor model, we evaluated the
combination of AB928 with <FONT STYLE="white-space:nowrap">ICD-inducing</FONT> chemotherapies such as doxorubicin and oxaliplatin. Again, despite the fact that tumors in this mouse model do not express CD73 and only the TIL do, we observed a
significant reduction in tumor volume with the AB928 + oxaliplatin combination, compared to either agent alone, as shown in the figure below. We observed similar results when evaluating AB928 in combination with doxorubicin in this same mouse model.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g92p14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:8pt; font-family:Arial Narrow">**** Statistically significant (p&lt;0.0001) </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Clinical Development Strategy for AB928 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our initial development efforts for AB928 will focus on combination studies evaluating AB928 with our PD-1 antibody, AB122, and with certain chemotherapeutics.
The rationale for selecting these two combination partners for AB928 are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Anti-PD-1 Therapy</I></B><B><I>,</I></B><B><I> such as AB-122. </I></B>A<SUB
STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R activation by adenosine induces biochemical and transcriptional changes in T cells that interfere with TCR activation, decreases the levels of certain
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
proteins (such as CD28) necessary for optimal T cell activation and elevates levels of certain proteins (such as PD-1) that inhibit T cell activation. As a result, A<SUB
STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R receptor signaling may play a role in the development of resistance to anti-PD-1 therapy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Certain Chemotherapy.</I></B> Certain chemotherapies, such as oxaliplatin and doxorubicin, induce <I>immunogenic cell death </I>(ICD) in cancer cells, a process that is characterized by, among other features,
endoplasmic reticulum stress and enhanced release of ATP into the extracellular environment. In tumors that express high levels of CD73, this ATP is readily converted into adenosine, resulting in profound immune suppression which can counteract the
potential anti-tumor effects of chemotherapy. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our clinical development strategy for AB928 is designed to achieve rapid <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in one or more tumor types and to advance AB928 into a registrational trial as quickly as possible. As we expect that the anti-tumor activity of AB928 will
result primarily from combination with other agents, we will focus our development efforts on combination trials of AB928 with other mechanisms that are expected to be synergistic with inhibition of the
<FONT STYLE="white-space:nowrap">ATP-adenosine</FONT> pathway, such as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies and <FONT STYLE="white-space:nowrap">ICD-inducing</FONT> chemotherapies. In
our combination trials, we will focus on tumor types for which there is substantial evidence that they may rely on the immune-suppressive effects of adenosine. These tumor types share the following characteristics: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Infiltration with T cells (as T cells need to be present in the tumor for an adenosine receptor antagonist to have an effect). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Tumors characterized by high CD73 expression, as evidence that the tumor has the ability to produce adenosine (examples, based on published literature, include <FONT STYLE="white-space:nowrap">non-small-cell</FONT> lung
carcinoma, colorectal cancer, head and neck squamous cell carcinoma, ovarian cancer, triple-negative breast cancer, renal cell carcinoma, prostate cancer and gastroesophageal cancer). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies or <FONT STYLE="white-space:nowrap">ICD-inducing</FONT> chemotherapy are
currently considered standard of care or, in the case of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies, the likely response rate in certain tumor
settings has been clearly established in earlier clinical trials. Examples include the use of oxaliplatin-containing chemotherapy in colorectal cancer and esophageal cancer; cisplatin and carboplatin in the treatment of <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer and ovarian cancer; or the use of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies in <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer and renal cell carcinoma. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We initiated a Phase 1 trial of AB928 in healthy
volunteers in November 2017. This trial will enroll up to about 80 subjects at a single site in the Netherlands and will include parallel single-ascending-dose and multiple-ascending-dose escalation cohorts. Study subjects will be randomized 3:1 to
either AB928 or placebo. We have developed a proprietary pCREB assay to study the pharmacodynamics of AB928, or the degree to which AB928 inhibits pCREB formation (a marker for A<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>R inhibition)
in blood samples from the subjects. This trial will also provide us with significant insights into the safety, pharmacokinetic and pharmacodynamic profiles of AB928, which could allow us to start the dose-escalation portion of our planned Phase 1/2
combination trials in cancer patients at a higher dose than would otherwise be possible. Complete results from this healthy volunteer trial will be available in the second quarter of 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to submit a regulatory filing in Australia for a Phase 1/2 dose-escalation trial of AB928 + AB122 in cancer patients during the second quarter of
2018. Conducting this trial in Australia will enable us to accelerate the clinical development timeline for this combination. The goal of this dose-escalation trial will be to assess the safety profile of increasing dose levels of AB928 when
combined with a fixed dose of AB122 and to identify the recommended dose of AB928 + AB122 for future trials. We also expect to file an IND for AB978 in the second quarter of 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once we have determined the recommended dose of AB928 + AB122, we will initiate several expansion cohorts to evaluate that combination in multiple cancer
types and settings. We expect to initiate up to 6 expansion cohorts with this combination. Tumor selection will be based on the criteria expressed earlier in this section, namely, tumor types that are known to be responsive to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> therapy, are associated with high </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expression of CD73, and are generally known to be accessible to T cell infiltration. For tumor types in which patients are likely to have already been treated with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies, we will recruit patients that are either refractory or relapsed after initial response to this type
of therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each cohort will include approximately <FONT STYLE="white-space:nowrap">15-30</FONT> patients, a number that we believe will be sufficient to
establish evidence of anti-tumor activity. We plan to utilize an adaptive trial design that will allow us to review data from initial patients and expand only those cohorts in which signs of clinical benefit are detected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In parallel with our AB928 + AB122 combination Phase 1/2 trial, we plan to initiate another Phase 1/2 trial to evaluate AB928 in combination with three
different types of <FONT STYLE="white-space:nowrap">ICD-inducing</FONT> chemotherapies (generally referred to here as chemotherapy), specifically platinum-based therapy and anthracycline-based therapy. We plan to file an IND for this trial in the
second quarter of 2018. Following IND clearance, we will initiate enrollment for the three dose-escalation cohorts of AB928 and chemotherapy. Once the recommended dose is determined for each AB928 and chemotherapy combination, we will advance these
combinations into selected expansion cohorts. We have selected tumor types in which to evaluate these combinations based on considerations consistent with those outlined above, namely, tumor types that are associated with high expression of CD73,
that are generally known to be accessible to T cell infiltration, and for which one of the chemotherapies of interest are already considered standard of care. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the graphic below, the shaded boxes represent the combinations and tumor types that we plan to explore for AB928 in our expansion cohorts. For these
cohorts, there already exists significant historical response data for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy or <FONT STYLE="white-space:nowrap">ICD-inducing</FONT> chemotherapy alone. This
will enable us to better quantify the potential clinical benefits of our combination therapies in comparison to these standards of care. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g08r74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An important component of our development program will be the incorporation of a biomarker strategy to identify patients
most likely to benefit from AB928. In our Phase 1/2 trial of AB928, we will test patients&#146; tumors for CD73 expression and expect to use CD73 expression as a tool to select patients in future trials. We will also evaluate other tumor and blood
markers designed to establish the extent of <I>in vivo</I> inhibition of the adenosine system, assess the effects of AB928 on the anti-tumor immune response, and identify additional biomarkers that are potentially predictive of response to AB928 and
that could be used to screen patients in our future clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Second-Generation A<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>R
Antagonist Strategy </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have an active discovery program focused on the identification of additional molecules that block adenosine 2 receptor
signaling. We have identified a second dual A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R/A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R antagonist as well as a selective
A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonist, both of which are derived from a chemical scaffold different from that of AB928. In the design of these candidates, our focus has been on retaining or improving on the potency
of AB928 for the A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R receptor, while potentially increasing the selectivity of the compounds. We expect to take at least one of these development candidates through <FONT
STYLE="white-space:nowrap">non-GLP</FONT> toxicology studies in the near-term, so that it could be advanced into clinical development within <FONT STYLE="white-space:nowrap">6-9</FONT> months of making such decision. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our CD73 Inhibitor Program </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our next most advanced
program in the adenosine pathway targets the CD73 enzyme, which plays a critical role in the last step of the process of extracellular ATP conversion into adenosine. CD73 inhibition should therefore be a highly effective approach to inhibiting the
activation of adenosine-mediated immune suppression, as it could significantly suppress adenosine generation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently pursuing two structurally
distinct chemical series of small-molecule CD73 inhibitors. Optimization of our first series was facilitated through a collaboration with Professor Norbert Stratter (University of Leipzig), a structural biologist who has solved the structure of
multiple complexes of CD73 bound to our compounds. We have utilized this information in a structure-based drug design effort to create small-molecule inhibitors of CD73 with extraordinary potency in the picomolar range. This series includes
compounds with extremely long half-lives, such as our lead development candidate, AB680, which we believe could be dosed intravenously or subcutaneously in the clinic every two or three weeks at the same time that a patient receives <FONT
STYLE="white-space:nowrap">anti-PD1</FONT> therapy or chemotherapy. This series also includes compounds that could be dosed orally. We have also identified a second chemical series, and we are evaluating compounds from this series that could be
orally administered. We expect to nominate an oral development candidate from one of our two series in 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that AB680 will be the first small-molecule CD73 inhibitor to enter clinical development, and we
are not aware of any other small-molecule CD73 inhibitors in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development. While there are several anti-CD73 antibodies in development, we believe that a small-molecule approach to CD73 inhibition
could offer several advantages, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>More complete inhibition of CD73 enzymatic activity. </I>As illustrated in the graph below, we have shown in our assays that our small-molecule CD73 inhibitor, AB680, inhibits CD73 more potently and effectively than
one of the CD73 antibodies in clinical development, MEDI9447. One explanation for this difference in potency is that our small-molecule CD73 inhibitors bind in the active site of the CD73 enzyme and they do so with an affinity about ten million
times greater than the affinity of its substrate, AMP for CD73. In contrast, many CD73 antibodies were not designed to inhibit the enzymatic activity of CD73 but to instead induce internalization of CD73 from the cell surface and therefore are not
expected to inhibit soluble forms of CD73. There are significant levels of CD73 which are shed from the cell surface. Our small-molecule inhibitors display comparable potency and effectiveness against soluble as well as membrane-bound forms of CD73,
while at least some of the CD73 antibodies in development are unable to completely inhibit the enzymatic action of soluble CD73. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g84s24.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Deeper tumor penetration. </I>As small molecules, we expect that our CD73 inhibitors should be able to achieve better penetration of tumor tissue relative to the CD73 antibodies which are much larger molecules. We
have shown, in tumor-bearing mice, that the concentrations of our inhibitors in the tumor tissue are approximately 15-20% of those in the blood, demonstrating their ability to permeate well beyond the tumor micro-vasculature. It is well accepted
that monoclonal antibodies, because of their molecular size and properties, cannot diffuse further than a few microns from the blood vessel that delivers them to the tumor. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Potential for both intravenous and oral delivery. </I>We are developing both oral and injectable formulations of our CD73 inhibitors, which could provide flexibility on dosing regimens. We expect that AB680 dosed
once every two or three weeks, on the same schedule as an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody or a chemotherapeutic agent, would be very convenient for patients and also be very
attractive commercially. An orally formulated CD73 inhibitor would be highly convenient for patients not undergoing regular infusions. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>In Vitro and In Vivo Data Supporting the Reversal of Immune Suppression by AB680 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to our work with AB928, our <I>in vitro</I> and <I>in vivo</I> work with AB680 and our other small-molecule CD73 inhibitors has focused on
characterizing the effects of these compounds on human immune cells, in assays that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we believe are relevant to the biology of human tumors. The table below summarizes some of the key studies that we have performed with AB680 and demonstrates that our CD73 inhibitors effectively
and consistently reverse CD73-adenosine mediated immune suppression.<I> </I>We have used variations of the assay systems described earlier for our AB928 program, with the main difference being that we suppress immune cell activation by introducing
AMP (which is converted to adenosine by CD73) into the assay instead of introducing adenosine or a synthetic adenosine analogue for this purpose. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Assay</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Key Findings</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Human CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp; AB680 reversed the
<FONT STYLE="white-space:nowrap">AMP-dependent</FONT> inhibition of T cell activation, proliferation&nbsp;and IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and granzyme B production, in a dose-dependent manner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Human CD4<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> T cells</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp; AB680 reversed the
<FONT STYLE="white-space:nowrap">AMP-dependent</FONT> inhibition of T cell activation, proliferation, IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and <FONT STYLE="white-space:nowrap">IL-2</FONT> production, in a dose-dependent
manner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mixed lymphocyte reaction (MLR) between allogeneic peripheral blood mononuclear cells from two different donors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp; AB680 blocked the
<FONT STYLE="white-space:nowrap">AMP-dependent</FONT> inhibition of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1-enhanced</FONT></FONT></FONT>
IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> production, in a dose-dependent manner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">MLR between human dendritic cells and T cells from two different donors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp; AB680 blocked the
<FONT STYLE="white-space:nowrap">AMP-dependent</FONT> inhibition of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1-enhanced</FONT></FONT></FONT>
IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and <FONT STYLE="white-space:nowrap">IL-2</FONT> production, in a dose-dependent manner</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The last experiment summarized in the table above is illustrated in the figure below and demonstrates the ability of AB680 to
block the <FONT STYLE="white-space:nowrap">AMP-dependent</FONT> inhibition of IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> production by CD4+ T cells in a mixed lymphocyte reaction (MLR) assay with allogeneic dendritic cells. In this study,
the activity of the T cells was boosted by the introduction of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody (AB122). Despite the high level of T cell stimulation induced by the combination of
allogeneic reaction and <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibition, introduction of a high concentration of AMP (100 &micro;M) almost completely inhibited IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> production; this effect was
potently reversed by AB680, in a dose-dependent fashion. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g50c90.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have evaluated our CD73 inhibitors in mouse tumor models, such as the B16F10 melanoma model. The graphs below show data
from an experiment we conducted with A000830, a representative molecule from the same series as AB680 that we have used extensively to characterize the <I>in vivo </I>activity of CD73 inhibitors. When dosed in combination with an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody, the CD73 inhibitor significantly reduced tumor volume in established tumors when dosing was initiated after the tumors were palpable. An analysis of the
tumor-infiltrating-lymphocyte (TIL) population in these tumors at the end of the study demonstrated that CD73 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inhibition resulted in increased TIL infiltration (as measured by the CD45+ to CD45- cell ratio), as well as increased ratios of cytotoxic T cells (CD8) relative to immunosuppressive TIL
(regulatory T cells (T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB>) and myeloid-derived suppressor cells (MDSC)). The changes of these ratios are indicative of a more productive anti-tumor immune response. We are currently evaluating
our other CD73 inhibitors, including AB680, in this and other tumor models. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g75x91.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g02z15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">** statistically significant (p&#060;0.01) </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Clinical Development Strategy for AB680 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to submit a regulatory filing for AB680 in the second half of 2018 to enable us to initiate clinical trials. We currently plan to model the early
development program for AB680 after our development strategy for AB928 and expect that we could initiate dose-escalation trials of AB680 in combination with AB122 and with chemotherapy by the first half of 2019. The selection of tumor types in which
to evaluate the clinical effects of AB680 will be influenced by any emerging efficacy data from the AB928 clinical trial. It is possible that response rates and/or duration of response of a particular tumor type might be different for AB928 versus
AB680 treatment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Second-Generation CD73 Strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the chemical series from which AB680 was derived, we are evaluating another chemical series of CD73 inhibitors. We have an active effort to
identify a CD73 inhibitor to be developed as an orally administered agent from one of these chemical series. We anticipate selecting a preclinical development candidate from one of these chemical series in 2018. In addition to our efforts to advance
a CD73 inhibitor that can be administered orally, we are also identifying other potential <FONT STYLE="white-space:nowrap">back-up</FONT> compounds to AB680. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Antibody Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to our small-molecule
programs, we are developing antibody drug candidates that are currently considered to be backbone therapy in immuno-oncology or that have the potential to be backbone therapies in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
future, such as our <FONT STYLE="white-space:nowrap">in-licensed</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and anti-TIGIT antibodies. By
combining these antibodies with our differentiated, internally discovered small-molecule product candidates, we intend to create <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> and/or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> combination products. In addition, by having these antibodies in our portfolio, we can better control the combinations that we pursue, as well as potentially
capture a greater share of the value of the combination products. As a result, we have established capabilities at Arcus that allow us to evaluate and develop antibody drug candidates and will continue to explore opportunities to create or <FONT
STYLE="white-space:nowrap">in-license</FONT> antibodies that we believe will be critical to our intra-portfolio combination development strategy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-1</FONT></FONT> Antibody, AB122 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2017, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody, which we refer to as AB122, from WuXi Biologics. AB122 is a fully human IgG4 antibody that was generated by WuXi Biologics using the transgenic rat
platform from Open Monoclonal Technology. The biochemical, biological and preclinical properties of AB122 have been shown by WuXi Biologics and Arcus to be comparable to those of the marketed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies nivolumab and pembrolizumab. We are currently evaluating AB122 in cancer patients in a Phase 1 dose-escalation trial being conducted in Australia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>In Vivo and In Vitro Data Supporting AB122 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arcus and WuXi Biologics have completed multiple <I>in vitro</I> and <I>in vivo</I> studies to assess the binding, ligand-blocking <FONT
STYLE="white-space:nowrap">(PD-L1</FONT> and <FONT STYLE="white-space:nowrap">PD-L2),</FONT> immune cell activation and <I>in vivo</I> properties of AB122. In these studies, we and WuXi Biologics have demonstrated that AB122 has very similar binding
properties and similar in vivo efficacy to those of nivolumab. Among the most important of these properties is that AB122 binds to human <FONT STYLE="white-space:nowrap">PD-1</FONT> (equilibrium binding constant, K<SUB
STYLE="font-size:85%; vertical-align:bottom">D</SUB>, of 1.75x10<SUP STYLE="font-size:85%; vertical-align:top">-10</SUP> M), with greater affinity than that of nivolumab (K<SUB STYLE="font-size:85%; vertical-align:bottom">D</SUB> = 1.16x10<SUP
STYLE="font-size:85%; vertical-align:top">-9</SUP> M), as determined by surface plasmon resonance. The K<SUB STYLE="font-size:85%; vertical-align:bottom">D</SUB> reflects the ratio between the <I>on rate</I> (rate at which the antibody binds to its
target) and the <I>off rate</I> (rate at which the antibody becomes detached from its target); a lower K<SUB STYLE="font-size:85%; vertical-align:bottom">D</SUB> value reflects greater binding affinity for its target. As shown in the table below,
the lower K<SUB STYLE="font-size:85%; vertical-align:bottom">D</SUB> value of AB122 relative to that of nivolumab reflects a greater <I>on rate</I> (k<SUB STYLE="font-size:85%; vertical-align:bottom">a</SUB>) and a slower <I>off rate </I>(K<SUB
STYLE="font-size:85%; vertical-align:bottom">d</SUB>). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:24.45pt; font-size:8pt; font-family:Times New Roman"><B>Ligand</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>k<SUB STYLE="font-size:85%; vertical-align:bottom">a</SUB>&nbsp;(1/Ms)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>K<SUB STYLE="font-size:85%; vertical-align:bottom">d</SUB> (1/s)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>K<SUB STYLE="font-size:85%; vertical-align:bottom">D</SUB> (M)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AB122</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.12<SUP STYLE="font-size:85%; vertical-align:top">+06</SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.96<SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="white-space:nowrap">-04</FONT></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.75<SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="white-space:nowrap">-10</FONT></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nivolumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.76<SUP STYLE="font-size:85%; vertical-align:top">+05</SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.97<SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="white-space:nowrap">-04</FONT></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.16<SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="white-space:nowrap">-09</FONT></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An important feature for any antibody is the ability to block the interaction between its target <FONT
STYLE="white-space:nowrap">(PD-1,</FONT> in this case) and the target&#146;s ligands <FONT STYLE="white-space:nowrap">(PD-L1</FONT> and <FONT STYLE="white-space:nowrap">PD-L2,</FONT> in this case). As shown in the figure below, AB122 is able to
potently and completely block the interaction between <FONT STYLE="white-space:nowrap">PD-1</FONT> and <FONT STYLE="white-space:nowrap">PD-L1.</FONT> Similar results were obtained for the blockade of binding of
<FONT STYLE="white-space:nowrap">PD-1</FONT> to <FONT STYLE="white-space:nowrap">PD-L2.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g45t81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Another important objective of our <I>in vitro</I> studies was to assess the ability of AB122 to potently and effectively
relieve the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-mediated</FONT></FONT> inhibition of <FONT STYLE="white-space:nowrap">T-cell</FONT> receptor (TCR) activation on T cells. As illustrated in the figure below, AB122,
pembrolizumab and nivolumab were assayed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">side-by-side</FONT></FONT> in an assay in which the extent of TCR </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
activation was determined in a reporter gene assay. AB122 demonstrated very similar potency to those of both nivolumab and pembrolizumab in this measure of functional inhibition. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g20p40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AB122 was also evaluated in tumor models performed with human <FONT STYLE="white-space:nowrap">PD-1</FONT> transgenic mice.
AB122 was shown to possess similar and maximal <I>in vivo</I> anti-tumor activity to that of pembrolizumab. The graph below shows the effect on tumor size of two different dose levels of AB122 administered every three weeks compared to that of
pembrolizumab administered 20 mg/kg every three weeks. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g92e49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our Clinical Development Strategy for AB122 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2017, we initiated dosing in Australia in our Phase 1 trial of AB122 in cancer patients. We decided to start our clinical testing of AB122 in
Australia, because we were able to proceed from regulatory filing to dosing of the first patient much more quickly than would have been the case in the United States We also believe that we may be able to enroll patients more quickly in Australia
than in the United States, because we are more likely to identify patients that have not received <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy. The first portion of this dose-escalation trial will
evaluate fixed doses of 80 mg, 240 mg and 720 mg of AB122 as monotherapy administered every two weeks. Once we identify our recommended dose for future trials of AB122, we will initiate the second portion of this dose-escalation trial, which will
evaluate AB122 in combination with our A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R/A<SUB STYLE="font-size:85%; vertical-align:bottom">2b</SUB>R antagonist, AB928. As discussed above under the section titled &#147;Business&#151;Our
Clinical Development Strategy for AB928&#148;, this will be followed by various dose-expansion cohorts that will evaluate the combination in carefully chosen tumor types. We expect to file an IND for AB122 in the United States in the second quarter
of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are evaluating various strategies to demonstrate the clinical benefit of AB122 monotherapy, given its role as a cornerstone of our
combination strategy. Following the identification of the recommended monotherapy dose and regimen, we will recruit <FONT STYLE="white-space:nowrap">30-40</FONT> cancer patients into a Phase 2 trial in a tumor type known to be responsive to <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> therapy, such as <FONT STYLE="white-space:nowrap">non-small-cell</FONT> lung cancer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Anti-TIGIT Antibody, AB154 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our second antibody program targets TIGIT <FONT STYLE="white-space:nowrap">(T-cell</FONT> immunoreceptor with Ig and ITIM domains), a unique immune checkpoint
target, because its primary ligand, CD155, plays both inhibitory and stimulatory roles in regulating the activity of effector immune cells such as T and NK cells. TIGIT is an inhibitory receptor highly expressed on T cells displaying an exhausted
phenotype, tumor-infiltrating T<SUB STYLE="font-size:85%; vertical-align:bottom">reg</SUB>, and NK cells. The ligands for TIGIT are expressed on a large number of cancer cells and on other immune cells such as dendritic cells, and their binding to
TIGIT results in inhibition of immune cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to TIGIT, CD155 binds, with lower affinity, to <FONT STYLE="white-space:nowrap">DNAM-1</FONT>
(also known as CD226), a stimulatory receptor also expressed on T cells and NK cells. As a result, when anti-TIGIT antibodies bind to TIGIT, thereby blocking the TIGIT:CD155 interaction, they not only block an inhibitory signal on T cells and NK
cells but also free up CD155 to bind to and activate <FONT STYLE="white-space:nowrap">DNAM-1,</FONT> leading to increased activation of T cells and NK cells. The graphic below further illustrates the TIGIT:CD155 interaction and consequences of
inhibiting TIGIT. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g52w03.jpg" ALT="LOGO">
 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">TIGIT binds to CD155 (high affinity) and CD112 (low affinity) </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">DNAM-1 competes, with lower affinity than TIGIT, for binding to CD155 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">TIGIT binding to CD155 results in reduced function of effector immune cells </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">CD155 binding to DNAM-1 results in activation of immune cells </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">When an anti-TIGIT antibody binds to TIGIT, it frees up CD155 to bind to DNAM-1, resulting in activation of effector immune cells </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent blockade of TIGIT and <FONT STYLE="white-space:nowrap">PD-1</FONT> has been shown to be more effective than
<FONT STYLE="white-space:nowrap">PD-1</FONT> blockade alone in both <I>in vitro</I> and <I>in vivo</I> models. Importantly, high TIGIT expression at initial cancer diagnosis is associated with CD8+ T cell exhaustion and poor clinical outcomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AB154 is our humanized anti-TIGIT IgG1 monoclonal antibody engineered to lack Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R binding and effector function
(that is, it will not trigger antibody-dependent cellular cytotoxicity&#151;ADCC&#151;or complement-dependent cytotoxicity&#151;CDC). We <FONT STYLE="white-space:nowrap">in-licensed</FONT> AB154 in December 2016. Since that time, we have initiated
cell line development and other CMC activities and preclinical safety assessment studies and expect to initiate clinical trials for AB154 in cancer subjects in 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Data Supporting the Benefits of TIGIT Blockade and AB154 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have demonstrated that AB154 binds with high affinity and selectively to human (IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> = 0.3 nM) and
cynomolgus monkey TIGIT. This affinity for TIGIT allows AB154 to block TIGIT:CD155 binding with great potency (IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB>&nbsp;=&nbsp;0.4 nM). We have demonstrated that blocking TIGIT <I>in vitro</I>
enhances the activation and function of human T cells and NK cells and also synergizes with <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibition <I>in vitro</I>. The table below provides a summary of the key preclinical immune function data
generated for this molecule. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Assay</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Key Findings</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jurkat T cell stably expressing TIGIT (reporter gene assay)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp; AB154 reversed TIGIT-mediated inhibition of T cell receptor
activation, in a dose-dependent manner</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="65%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Assay</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Key Findings</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Polyclonal activation of human T cells by staphylococcal enterotoxin B (SEB)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp; AB154 produced robust enhancement of effector cytokines production
by human T cells; effects similar to those obtained with an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Antigen-specific T cell activation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp; AB154 induced robust <FONT STYLE="white-space:nowrap">IL-2</FONT>
secretion<B> </B>and proliferation by T cells in response to Tetanus Toxin recall antigen; effects similar to those obtained with an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Antigen-dependent T cell cytotoxicity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp; AB154 enhanced CD8+ T cell killing of target cells in an
antigen-dependent manner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Natural killer (NK) cell natural cytotoxicity</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp; AB154 enhanced NK cell-mediated natural cytotoxicity of target K562
cells</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mixed lymphocyte reaction (MLR) between human dendritic cells and T cells</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp; AB154 enhanced the production of effector cytokines (e.g., IFN-<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>) by CD4+ T cells <FONT STYLE="white-space:nowrap">co-cultured</FONT> with allogeneic dendritic cells. AB154 was able to enhance the effects of an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody in this assay.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The figure below illustrates the ability of AB154 to enhance the production of
IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> in a mixed lymphocyte reaction assay (allogeneic <FONT STYLE="white-space:nowrap">co-culture</FONT> of dendritic cells and CD4+ T cells) in combination with AB122. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g94e89.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Development Status of AB154 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To support our clinical development activities, GLP toxicology studies are ongoing and we plan to file an IND in mid-2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following regulatory submission, our plan is to initiate a dose-escalation Phase&nbsp;1 trial investigating both AB154 as monotherapy and in combination with
AB122 in cancer patients. We estimate that safety and initial efficacy data will be available from this dose-escalation trial in 2019; once the recommended Phase 2 dosing regimen (as monotherapy and in the combination) has been established, we will
evaluate these therapies in selected tumor types, which will be based on results from our work to identify those tumor types with the highest expression levels of CD155 and TIGIT. Leading clinical settings at this time include the following types of
cancer: colorectal, head and neck, triple-negative breast and lung (both <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer and small cell lung cancer). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Early-Stage Drug Discovery Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Arginase Program </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have an active research effort
directed at the discovery of novel inhibitors of <FONT STYLE="white-space:nowrap">arginase-1</FONT> <FONT STYLE="white-space:nowrap">(ARG-1),</FONT> another immuno-suppressive enzyme. <FONT STYLE="white-space:nowrap">ARG-1</FONT> is highly expressed
by various elements in the tumor microenvironment, including cancer cells and myeloid-derived immune cells. <FONT STYLE="white-space:nowrap">ARG-1</FONT> depletes arginine from the tumor microenvironment, which creates a shortage of a key building
block for the efficient activation and proliferation of both T cells and NK cells. Addition of recombinant <FONT STYLE="white-space:nowrap">ARG-1</FONT> or extracts of myeloid cells to <I>in vitro</I> T cell cultures results in reduced proliferation
and cytokine secretion. This effect is blocked by inhibition of <FONT STYLE="white-space:nowrap">ARG-1</FONT> activity. Arginase levels in blood are elevated in multiple tumor types, including gastric, renal and lung, and this elevation is
correspondingly associated with reduced arginine levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently optimizing small-molecule inhibitors of
<FONT STYLE="white-space:nowrap">ARG-1</FONT> with the goal of creating a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> arginase inhibitor. As of today, we are only aware of one <FONT
STYLE="white-space:nowrap">ARG-1</FONT> inhibitor in clinical development. We plan to select a lead candidate in 2018 and to initiate a Phase 1 clinical trial for this compound in 2019. Preclinical studies by third parties suggest that <FONT
STYLE="white-space:nowrap">ARG-1</FONT> inhibitors could work synergistically with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies. Additionally, <FONT STYLE="white-space:nowrap">ARG-1</FONT>
inhibitors may work well in combination with our adenosine pathway inhibitors, allowing us to reverse inhibition by two immunosuppressive pathways in the tumor microenvironment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rationale for the Development of Triplet Combinations Involving our Development Candidates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to evaluating multiple doublet combinations with our product candidates, we plan to explore triplet combinations and have already demonstrated the
potential of at least one novel triplet combination involving three of our product candidates. For example, there is a strong rationale for developing a doublet combination of AB154 (our anti-TIGIT antibody) and AB122 (our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody) in certain settings. However, we have shown in cell-based studies that the profound T cell activation that results from the combination of anti-TIGIT and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies can be almost completely blocked by the introduction of adenosine monophosphate (AMP), which is converted by CD73 into adenosine, as illustrated in the
figure below. This experiment demonstrates how powerfully adenosine suppresses T cell function, even in the presence of two highly potent immune checkpoint inhibitors. However, when we introduced our CD73 inhibitor AB680 to the assay, it completely
reversed the AMP-induced immune suppression as shown in the last bar. This experiment demonstrates how triplet combination therapy has the potential to overcome adenosine-induced immune suppression. Hence, it is likely that there be value in
exploring a triplet combination involving either AB928 or AB680 together with AB154 and AB122. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g77v65.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The experiment referenced above was conducted in a mixed lymphocyte reaction (MLR) assay, in which human
CD4+ T cells are stimulated to produce IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> by <FONT STYLE="white-space:nowrap">co-culturing</FONT> them with allogeneic dendritic cells. The first two bars in this figure are controls that reflect the
amount of IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> production in the absence of any immune checkpoint blockade. The third bar illustrates the pronounced enhancement of IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> production as a
result of <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibition. The fourth bar illustrates the additional increase in IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> production that results from combining
<FONT STYLE="white-space:nowrap">PD-1</FONT> inhibition with TIGIT inhibition. Importantly, as seen in the fifth column, introduction of AMP into the experiment resulted in very pronounced reduction in the extent of stimulation obtained from
combined <FONT STYLE="white-space:nowrap">PD-1</FONT> and TIGIT inhibition. We believe that AMP is converted into adenosine by the CD73 expressed on the immune cells used for the assay. In the last column, on the right side of the figure, we show
that the profound immunosuppression produced by AMP was reversed by our CD73 inhibitor, AB680. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to retain significant development and commercial rights to our product candidates and, if marketing approval is obtained, to commercialize our
product candidates on our own, or potentially with a partner, in the United States and other regions. We currently have no sales, marketing or commercial product distribution capabilities and have no experience as a company commercializing products.
We intend to build the necessary infrastructure and capabilities over time for the United States, and potentially other regions, following further advancement of our product candidates. Clinical data, the size of the addressable patient population,
the size of the commercial infrastructure and manufacturing needs may all influence or alter our commercialization plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Abmuno Therapeutics LLC License Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
December 2016, we entered into a license agreement (the Abmuno Agreement) with Abmuno Therapeutics LLC (Abmuno) for a worldwide exclusive license to develop, use, manufacture, and commercialize products that include an anti-TIGIT antibody. We
license AB154 under the Abmuno Agreement. Under the Abmuno Agreement, we have made upfront and milestone payments of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million as of December&nbsp;31, 2017 and we may be required to make additional
clinical, regulatory and commercialization milestone payments up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Abmuno Agreement
terminates on the latest of (i)&nbsp;the expiry of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Abmuno licensed patent that covers a product that contains an anti-TIGIT antibody, (ii)&nbsp;the
date on which there is no longer an Abmuno licensed patent application that is still pending and has been pending for a certain period of time that covers a product that contains an anti-TIGIT antibody and (iii)&nbsp;a certain period of time from
the date of first commercial sale. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>WuXi Biologics (Cayman) Inc. License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2017, we entered into a license agreement (the WuXi Agreement) with WuXi Biologics (Cayman) Inc. (WuXi Biologics) for an exclusive license to
develop, use, manufacture, and commercialize products that include an anti-PD-1 antibody throughout the world except for China and five other countries outside of the United States, Europe and Japan. We license AB122 under the WuXi Agreement. Under
the WuXi Agreement, we have made upfront and milestone payments of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million as of December&nbsp;31, 2017 and we may be required to make additional clinical and regulatory milestone payments,
commercialization milestone payments up to $375.0&nbsp;million, and royalty payments that range from high single-digits to low double-digits of net sales. We are also required to pay WuXi Biologics a percentage in the low double digits of certain
sublicense income that we receive from our sublicensees in direct connection with our sublicensees&#146; rights to use WuXi Biologics&#146;s patents, patent applications and <FONT STYLE="white-space:nowrap">know-how.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are obligated to appoint WuXi Biologics as our exclusive manufacturer of such licensed products for a certain period of time subject to certain exceptions.
Our sublicensees, however, may manufacture, at any time, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain portions of their requirements for such product subject to certain conditions. We made certain covenants not to commercialize any anti-PD-1 antibody licensed or obtained by us after the
date of the license agreement with WuXi Biologics other than anti-PD-1 antibodies licensed from WuXi Biologics, subject to certain exceptions as set forth in the WuXi agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This agreement terminates, on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, on expiration of the royalty term for such licensed product for the applicable country. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taiho Pharmaceutical Co., Ltd. Option and License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2017, we entered into an option and license agreement (the Taiho Agreement) with Taiho Pharmaceutical Co., Ltd. (Taiho) pursuant to which Taiho
will provide $35.0&nbsp;million of <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> cash payments to us during the first three years of the agreement in exchange for an exclusive option,
over a five-year period, to <FONT STYLE="white-space:nowrap">in-license</FONT> the development and commercialization rights to clinical stage product candidates from our portfolio for Japan and certain other territories in Asia (excluding China). If
Taiho elects to exercise any such options, the license described above will be granted under terms and conditions set forth in the agreement. Under such terms, Taiho is obligated to pay an option exercise payment for each option exercise depending
upon when in the development process of the applicable program Taiho decides to exercise the option. In addition, Taiho is obligated to pay to us clinical, regulatory and commercialization milestones up to $275&nbsp;million with respect to each
program for which Taiho exercises the option and been granted the applicable license, as well as royalties ranging from high single digits to mid-double digits, on net sales in Taiho&#146;s territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This agreement will remain in effect until (i)&nbsp;expiration of the last option exercise period if Taiho has not exercised any of its options or
(ii)&nbsp;if Taiho has exercised any of its options, expiry of all royalty terms for the licensed products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing and Supply </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for
the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates obtain marketing approval. We also rely, and expect to continue to rely, on third parties to
package, label, store and distribute our investigational product candidates, as well as for our commercial products if marketing approval is obtained. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating
the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have obtained active pharmaceutical ingredients (API) and drug product for our product candidates from single-source third party contract
manufacturers. We are in the process of developing our supply chain for each of our product candidates and intend to put in place framework agreements under which third-party contract manufacturers will generally provide us with necessary quantities
of API and drug product on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">project-by-project</FONT></FONT> basis based on our development needs. With respect to AB122, we agreed, as part of our license agreement with WuXi
Biologics, that WuXi Biologics would be our exclusive manufacturer of AB122 with respect to clinical and commercial supplies until a certain number of years after marketing approval for AB122, subject to certain exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we advance our product candidates through development, we will consider our lack of redundant supply for the API and drug product for each of our product
candidates to protect against any potential supply disruptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We generally expect to rely on third parties for the manufacture of any companion
diagnostics we may develop. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary
products. While we believe that our technology, development experience and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including large pharmaceutical and biotechnology
companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for the research, development, manufacturing and
commercialization of cancer immunotherapies. Any product candidates that we successfully develop and commercialize will compete with new immunotherapies that may become available in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immuno-oncology treatments. There are many other
companies that have commercialized and/or are developing immuno-oncology treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca/MedImmune, Bristol-Myers Squibb, Merck, Novartis, Pfizer and
Roche/Genentech. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For our dual adenosine receptor antagonist, AB928, we are aware of several other companies that are developing selective adenosine A<SUB
STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonists, including AstraZeneca/MedImmune, Corvus, iTEOS, Merck and Novartis. To our knowledge, there are no adenosine receptor antagonists approved for the treatment of cancer and the most
advanced such selective A<SUB STYLE="font-size:85%; vertical-align:bottom">2a</SUB>R antagonists are in Phase 1/2 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For our small molecule
CD73 inhibitor, AB680, we are aware of several pharmaceutical companies developing antibodies against this target, including AstraZeneca/MedImmune, Bristol-Myers Squibb, Corvus, Innate Pharma, Merck and Surface Oncology. To our knowledge, only
AstraZeneca and Bristol-Myers Squibb have advanced their CD73 antibodies into clinical development. We believe that AB680 will be the first small molecule CD73 inhibitor to enter clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody, AB122, multiple large pharmaceutical companies
have already received regulatory approvals for their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies, including AstraZeneca, Bristol-Myers Squibb,
Merck, Pfizer in partnership with Merck Kgaa, and Roche/Genentech. There are also many other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> antibodies in clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For our anti-TIGIT antibody, AB154, we are aware of several
pharmaceutical companies developing antibodies against this target including Bristol-Myers Squibb, Merck, OncoMed and Genentech. To our knowledge, there are no approved anti-TIGIT antibodies and the most advanced antibodies are in Phase 1 clinical
trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources
and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and
diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with
large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and enrolling subjects for our clinical trials, as well as in
acquiring technologies complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could see a reduction or elimination of our commercial opportunity if our
competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may
obtain FDA or foreign regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market.
The key competitive factors affecting the success of all of our product candidates, if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of companion diagnostics (if required), the level of biosimilar or generic competition and the
availability of reimbursement from government and other third-party payors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries for our product
candidates, to operate without infringing valid and enforceable patents and proprietary rights of others, and to prevent others from infringing on our proprietary or intellectual property rights. We seek to protect our proprietary position by
filing, in the United States and other foreign jurisdictions, patent applications intended to cover the composition of matter of our product candidates, their methods of use, and related discoveries, technologies, inventions and improvements that
may be commercially important to our business. We may also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. We also intend to take advantage of
regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions where available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not yet own or license any
issued patents relating to our product candidates. As of December&nbsp;1, 2017, we own or have <FONT STYLE="white-space:nowrap">in-licensed</FONT> 8 pending U.S. patent applications, 7 pending PCT patent applications, and 6 pending foreign patent
applications. As of December&nbsp;1, 2017, with respect to our adenosine receptor antagonist program, we own 4 U.S. provisional patent applications that cover compositions of matter and methods of use. As of December&nbsp;1, 2017, with respect to
our CD73 inhibitor program, we own 1 U.S. patent application, 3 PCT patent applications and 3 foreign patent applications that cover compositions of matter and methods of use. As of December&nbsp;1, 2017, with respect to our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody program, we <FONT STYLE="white-space:nowrap">in-license</FONT> 2 PCT applications and we own 1 U.S. provisional application that cover compositions of
matter and methods of use. As of December&nbsp;1, 2017, with respect to our anti-TIGIT antibody program, we <FONT STYLE="white-space:nowrap">in-license</FONT> 1 U.S. patent application, 1 PCT patent application and 3 foreign patent applications that
cover compositions of matter and methods of use. The term of any patents that may issue will vary in accordance with the laws of each jurisdiction, but is typically 20 years from the earliest effective filing date. Any patents that may issue from
our company-owned or licensed pending applications are projected to expire between 2035 and 2038, absent any patent term adjustments or extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
patent positions for biotechnology and pharmaceutical companies like us are generally uncertain and can involve complex legal, scientific and factual issues. Changes in either the patent laws or their interpretation in the United States and other
countries may diminish our ability to protect our product candidates and enforce the patent rights that we own or license, and could affect the value of such intellectual property. With respect to both company-owned and licensed intellectual
property, we cannot guarantee that the patent applications we are currently pursuing or may file in the future will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary
protection from competitors. Our competitors may independently develop similar product candidates or technologies that are outside the scope of the rights granted under any issued patents that we own or exclusively
<FONT STYLE="white-space:nowrap">in-license.</FONT> We cannot be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products or their methods of use or manufacture. Moreover, even issued
patents do not guarantee us the right to commercialize our products. For example, third parties may have blocking patents that could be used to prevent us from commercializing or manufacturing our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the extensive time required for development, testing and regulatory review of a product candidate, it is possible that, before a product can be
commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides. In the United States, the term of a patent
covering an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product may, in certain cases, be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process.
The period of extension may be up to five years, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent among those eligible for an extension and only those claims covering the approved product, a method for using it, or a method for manufacturing it may be extended. Similar provisions are
available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved product. While we intend to seek patent term extensions in any jurisdictions where they are available, there is no guarantee that the
applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Regulation and
Product Approval </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions,
including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing,
post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with
applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA
Approval Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, the Food and Drug Administration (FDA) regulates drugs and biological products under the Federal Food,
Drug, and Cosmetic Act (FDCA), the Public Health Service Act (PHSA), and implementing regulations. These laws and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage,
recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of therapeutic products. The process of obtaining regulatory approvals and the subsequent compliance
with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative
or judicial sanctions, such as clinical hold, FDA refusal to approve pending regulatory applications, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines,
civil penalties, and criminal prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a drug or biological product may be marketed in the United States
generally includes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices (GLP) or other applicable regulations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Submission to the FDA of an investigational new drug application (IND), which must become effective before human clinical trials may begin in the United States; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Performance of adequate and well-controlled human clinical trials according to Good Clinical Practices (GCP), to establish the safety and efficacy of the product candidate for its intended use; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Submission to the FDA of a New Drug Application (NDA) or Biological Licensing Application (BLA) for a new product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Satisfactory completion of an FDA inspection of the facility or facilities where the product candidate is manufactured to assess compliance with the FDA&#146;s current good manufacturing practices (cGMP), to assure that
the facilities, methods and controls are adequate to preserve the therapeutic product candidate&#146;s identity, strength, quality, purity, and potency; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Potential FDA audit of the preclinical and clinical trial sites that generated the data in support of the NDA/BLA; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FDA review and approval of the NDA/BLA. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Satisfaction of FDA <FONT STYLE="white-space:nowrap">pre-market</FONT> approval requirements typically takes
many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product candidate or disease. A clinical hold may occur at any time during the life of an IND and may affect one or more specific
trials or all trials conducted under the IND. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preclinical tests include laboratory evaluation of product candidate&#146;s chemistry, formulation, and
toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements, including GLP. The results of
preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product candidate&#146;s chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long term preclinical
tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. A <FONT STYLE="white-space:nowrap">30-day</FONT> waiting period after the submission of each IND is required prior to the commencement
of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this <FONT STYLE="white-space:nowrap">30-day</FONT> period, the clinical trial proposed in the IND may begin. Clinical trials involve the administration
of the investigational product to healthy volunteers or subjects under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with GCP, an
international standard meant to protect the rights and health of subjects and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&nbsp;under protocols detailing the objectives of the trial, the parameters
to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. subjects and subsequent protocol amendments must be submitted to the FDA as part of the IND. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions if it believes that the clinical trial
either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial subjects. The trial protocol and informed consent information for subjects in clinical trials must also be submitted to an
institutional review board (IRB) for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#146;s requirements, or may impose other conditions. The study
sponsor may also suspend a clinical trial at any time on various grounds, including a determination that the subjects are being exposed to an unacceptable health risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials to support NDAs/BLAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase 1, the
initial introduction of the product candidate usually into healthy human subjects, the product candidate is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible,
early evidence on effectiveness. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the product candidate for a particular indication, dosage tolerance, and optimal dosage, and to identify common
adverse effects and safety risks. If a product candidate demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain additional information about clinical efficacy and
safety in a larger number of subjects, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit risk relationship of the product candidate and to provide adequate information for the labeling of
the product candidate. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the product candidate. A single Phase 3 trial may be sufficient in certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A therapeutic product candidate being studied in clinical trials may be made available for treatment of individual patients, in certain circumstances.
Pursuant to the 21st Century Cures Act (Cures Act) which was signed into law in December 2016, the manufacturer of an investigational product for a serious disease or condition is required to make available, such as by posting on its website, its
policy on evaluating and responding to requests for individual patient access to such investigational product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the development of a new product
candidate, sponsors are given opportunities to meet with the FDA at certain points; specifically, prior to the submission of an IND, at the end of Phase 2 and before an NDA/BLA is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide
advice on the next phase of development. Sponsors typically use the meeting at the end of Phase 2 to discuss their Phase 2 clinical results and present their plans for the pivotal Phase 3 clinical trials that they believe will support the approval
of the new product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, sponsors usually complete additional animal safety studies and also develop additional
information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing commercial quantities of the product candidate in accordance with cGMP requirements. The manufacturing process must be
capable of consistently producing quality batches of the product candidate and the manufacturer must develop methods for testing the quality, purity and potency of the product candidate. Additionally, appropriate packaging must be selected and
tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its proposed shelf-life. After completion of the required clinical testing, an NDA, for a drug product
candidate, or a BLA, for a biological product candidate, is prepared and submitted to the FDA. FDA approval of the NDA or BLA is required before marketing of the product may begin in the United States. The NDA or BLA must include the results of all
preclinical, clinical, and other testing and a compilation of data relating to the product candidate&#146;s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an NDA or BLA is substantial. The submission of most
NDAs and BLAs is additionally subject to a substantial application user fee, and the applicant under an approved NDA or BLA is also subject to annual product and establishment user fees. These fees are typically increased annually. On August&nbsp;3,
2017, Congress passed the FDA Reauthorization Act of 2017 (FDARA) which reauthorizes the various user fees to facilitate the FDA&#146;s product review and oversight. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has 60 days from its receipt of an NDA or BLA to determine whether the application will be accepted for filing based on the agency&#146;s threshold
determination that it is sufficiently complete to permit substantive review. Combination products are typically marketed under an application type associated with the constituent part that provides the primary mode of action (PMOA) for the
combination product (i.e., an NDA or abbreviated new drug application (ANDA) if it has a drug PMOA, a BLA if it has a biological product PMOA. A single marketing application is generally sufficient for a combination product. In some cases, however,
a sponsor may wish to submit separate marketing applications for different constituent parts of a combination product, and the FDA may consider this permissible. The FDA may refuse to file any NDA or BLA that it deems incomplete or not properly
reviewable at the time of submission, and may request additional information. In this event, the NDA or BLA must be resubmitted with the additional information and the resubmitted application also is subject to review before the FDA accepts it for
filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review. The FDA has agreed to certain performance goals in the review of NDAs and BLAs. Most such applications for standard review
product candidates are reviewed within ten months of the date the FDA files the NDA or BLA; most applications for priority review product candidates are reviewed within six months of the date the FDA files the NDA or BLA. Priority review can be
applied to a product candidate that the FDA determines has the potential to treat a serious or life-threatening condition and, if approved, would be a significant improvement in safety or effectiveness compared to available therapies. The review
process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among other things, the FDA reviews an NDA to determine whether the product is safe and effective for its intended use, a BLA to determine whether the product
is safe, pure, and potent, and in each case, whether the product candidate is being manufactured in accordance with cGMP. The FDA may also refer applications for novel product candidates, or product candidates that present difficult questions of
safety or efficacy, to an advisory committee&#151;typically a panel that includes clinicians and other experts&#151;for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the
recommendation of an advisory committee, but it generally follows such recommendations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure
compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the product candidate is manufactured. The FDA will not approve the product candidate unless it determines that the manufacturing processes and
facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. To assure GCP and cGMP compliance, an applicant must incur significant expenditures of time, money and
effort in the areas of training, record keeping, production and quality control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the submission of relevant data and information, the FDA
may ultimately decide that the NDA or BLA does not satisfy the criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive. The FDA may disagree with our trial design or interpret data from preclinical
studies and clinical trials differently than we interpret the same data. If the agency decides not to approve the NDA or BLA in its present form, the FDA will issue a complete response letter that describes all of the specific deficiencies in the
application identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. If a complete response letter is issued, the applicant may either
resubmit the NDA or BLA, addressing the deficiencies identified in the letter, or withdraw the application. If, or when, those deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the NDA or BLA, the FDA will issue an
approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. An approval letter authorizes commercial marketing of the drug or biological product in the United States with
specific prescribing information for specific indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if a product candidate receives regulatory approval, the approval may be significantly
limited to specific indications and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be
included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk evaluation and mitigation strategy (REMS), or otherwise limit the scope of any approval. REMS
can include medication guides, communication plans for healthcare professionals, and elements to assure safe use (ETASU). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only
under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the product. In addition, the FDA may require post marketing clinical
trials, sometimes referred to as &#147;Phase 4&#148; clinical trials, designed to further assess a product&#146;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been
commercialized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Clinical Studies to Support an IND, NDA, or BLA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA will accept as support for an IND, NDA, or BLA a well-designed, well-conducted, <FONT STYLE="white-space:nowrap">non-IND</FONT> foreign clinical trial
if it was conducted in accordance with GCP and the FDA is able to validate the data from the trial through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection, if necessary. A sponsor or applicant who wishes to rely on a <FONT
STYLE="white-space:nowrap">non-IND</FONT> foreign clinical trial to support an IND must submit the following supporting information to the FDA to demonstrate that the trial conformed to GCP: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the investigator&#146;s qualifications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of the research facilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a detailed summary of the protocol and trial results and, if requested, case records or additional background data; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of the drug substance and drug product, including the components, formulation, specifications, and, if available, the bioavailability of the product candidate; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information showing that the trial is adequate and well controlled; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name and address of the independent ethics committee that reviewed the trial and a statement that the independent ethics committee meets the required definition; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a summary of the independent ethics committee&#146;s decision to approve or modify and approve the trial, or to provide a favorable opinion; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of how informed consent was obtained; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of what incentives, if any, were provided to subjects to participate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of how the sponsor monitored the trial and ensured that the trial was consistent with the protocol; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of how investigators were trained to comply with GCP and to conduct the trial in accordance with the trial protocol; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a statement on whether written commitments by investigators to comply with GCP and the protocol were obtained. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory applications based solely on foreign clinical data meeting these criteria may be approved if the foreign data are applicable to the U.S. population
and U.S. medical practice, the trials have been performed by clinical investigators of recognized competence, and the data may be considered valid without the need for an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection by FDA or, if FDA
considers such an inspection to be necessary, FDA is able to validate the data through an <FONT STYLE="white-space:nowrap">on-site</FONT> inspection or other appropriate means. Failure of an application to meet any of these criteria may result in
the application not being approvable based on the foreign data alone. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure of Clinical Trial Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sponsors of clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products are required to register and disclose certain clinical trial
information. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to
disclose the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly
available information to gain knowledge regarding the progress of development programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has various programs, including Fast Track, priority review, accelerated approval and breakthrough therapy, which are intended to expedite or simplify
the process for reviewing product candidates, or provide for the approval of a product candidate on the basis of a surrogate endpoint. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product
candidate no longer meets the conditions for qualification or that the time period for FDA review or approval will be lengthened. Generally, product candidates that are eligible for these programs are those for serious or life-threatening
conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. For example, Fast Track is a process designed to facilitate the development and expedite the review of product
candidates to treat serious or life-threatening diseases or conditions and fill unmet medical needs. Priority review is designed to give a product candidate that treats a serious condition and, if approved, would provide a significant improvement in
safety or effectiveness, an initial review within eight months as compared to a standard review time of twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Fast Track and priority
review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track designated product candidate and expedite review of the application for a product candidate designated for
priority review. Accelerated approval provides for an earlier approval for a new product candidate that meets the following criteria: is intended to treat a serious </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or life-threatening disease or condition, generally provides a meaningful advantage over available therapies and demonstrates an effect on a surrogate endpoint that is reasonably likely to
predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM) that is reasonably likely to predict an effect on IMM or other clinical benefit. A surrogate endpoint is a laboratory
measurement or physical sign used as an indirect or substitute measurement representing a clinically meaningful outcome. As a condition of approval, the FDA may require that a sponsor of a product candidate receiving accelerated approval perform
post-marketing clinical trials to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the product may be subject to accelerated withdrawal procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Food and Drug Administration Safety and Innovation Act (FDASIA) which was signed into law in July 2012, the U.S. Congress encouraged the FDA to utilize
innovative and flexible approaches to the assessment of product candidates under accelerated approval. The law required the FDA to issue related guidance and also promulgate confirming regulatory changes. In May 2014, the FDA published a final
Guidance for Industry titled &#147;Expedited Programs for Serious Conditions&#151;Drugs and Biologics,&#148; which provides guidance on FDA programs that are intended to facilitate and expedite development and review of new product candidates as
well as threshold criteria generally applicable to concluding that a product candidate is a candidate for these expedited development and review programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the Fast Track, accelerated approval and priority review programs discussed above, the FDA also provided guidance on a new program for
Breakthrough Therapy designation, established by FDASIA to subject a new category of product candidates to accelerated approval. A sponsor may seek FDA designation of a product candidate as a &#147;breakthrough therapy&#148; if the product candidate
is intended, alone or in combination with one or more other therapeutics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. A request for Breakthrough Therapy designation should be submitted concurrently with, or as an
amendment to, an IND, but ideally no later than the end of Phase 2 meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term Restoration and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After approval, owners of relevant drug or biological product patents may apply for up to a five year patent extension under the Drug Price Competition and
Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The allowable patent term extension is calculated as half of the product&#146;s testing phase&#151;the time between IND and NDA or BLA submission&#151;and all of the review
phase&#151;the time between NDA or BLA submission and approval, up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension
may not exceed 14 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim
patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the U.S. Patent and Trademark Office
must determine that approval of the product candidate covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a product candidate for which an NDA or BLA has not been submitted.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period
of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity. A product candidate is a new chemical entity if the FDA has not previously
approved any other new product candidate containing the same active moiety, which is the molecule or ion responsible for the action of the product candidate substance. During the exclusivity period, the FDA may not accept for review an abbreviated
new drug application (ANDA) or a 505(b)(2) NDA submitted by another company for another version of such product candidate where the applicant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent
invalidity or <FONT STYLE="white-space:nowrap">non-infringement.</FONT> The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an approved NDA if new clinical investigations, other than bioavailability
studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing product candidate. This three-year exclusivity
covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for product candidates containing the original active agent. Five-year and three-year exclusivity will not delay the
submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate
safety and effectiveness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated approval pathway for biological product candidates shown to be highly similar to or interchangeable with an FDA licensed reference biological product.
Biosimilarity sufficient to reference a prior <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful
differences between the biological product candidate and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical trials, animal trials, and a clinical trial or trials, unless the Secretary of
Health and Human Services waives a required element. A biosimilar product candidate may be deemed interchangeable with a prior approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical
results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy
relative to exclusive use of the reference biologic. To date, a handful of biosimilar products and no interchangeable products have been approved under the BPCIA. Complexities associated with the larger, and often more complex, structures of
biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation, which is still being evaluated by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reference biologic is granted 12 years of exclusivity from the time of first licensure of the reference product, and no application for a biosimilar can be
submitted for four years from the date of licensure of the reference product. The first biologic product candidate submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity
against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i)&nbsp;one year after first commercial marketing of the first interchangeable biosimilar, (ii) 18 months after the first interchangeable
biosimilar is approved if there is no patent challenge, (iii) 18 months after resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv) 42 months after the first
interchangeable biosimilar&#146;s application has been approved if a patent lawsuit is ongoing within the <FONT STYLE="white-space:nowrap">42-month</FONT> period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-approval Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once an approval is
granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in
restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject
to further FDA review and approval. In addition, the FDA may under some circumstances require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA under some circumstances has the
power to prevent or limit further marketing of a product based on the results of these post-marketing programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product manufactured or distributed by us or our collaborators pursuant to FDA approvals are subject to
continuing regulation by the FDA, including, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">record-keeping requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reporting of adverse experiences associated with the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">providing the FDA with updated safety and efficacy information; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">therapeutic sampling and distribution requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">notifying the FDA and gaining its approval of specified manufacturing or labeling changes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">registration and listing requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complying with FDA promotion and advertising requirements, which include, among other things, standards for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising,
restrictions on promoting products for uses or in patient populations that are not described in the product&#146;s approved labeling, limitations on industry-sponsored scientific and educational activities and requirements for promotional activities
involving the internet. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturers, their subcontractors, and other entities involved in the manufacture and distribution of approved
drug and biological products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMP, including data
integrity requirements, and other laws. The FDA periodically inspects manufacturing facilities to assess compliance with ongoing regulatory requirements, including cGMP, which impose extensive procedural, substantive and record-keeping requirements
upon us and third-party manufacturers engaged by us if our products are approved. In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being
implemented. FDA regulations would also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and our third-party manufacturers. Accordingly, manufacturers must continue to
expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to
possible legal or regulatory actions, such as warning letters, suspension of manufacturing, seizures of products, injunctive actions or other civil penalties. We cannot be certain we or our present or future third-party manufacturers or suppliers
will be able to comply with the cGMP regulations and other ongoing FDA regulatory requirements. If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA may halt our clinical
trials or require us to recall a product from distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, therapeutic manufacturers in the United States must comply with applicable
provisions of the Drug Supply Chain Security Act and provide and receive product tracing information, maintain appropriate licenses, ensure they only work with other properly licensed entities, and have procedures in place to identify and properly
handle suspect and illegitimate product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Controls for Biological Products </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose
attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical
public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a BLA is approved, the biological product may also be subject to official lot release as a condition of approval. As part of the manufacturing process,
the manufacturer is required to perform certain tests on each lot </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a
release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral
vaccines, before releasing the lots for distribution by the manufacturer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the FDA conducts laboratory research related to the regulatory
standards on the safety, purity, potency, and effectiveness of biological products. As with drugs, after approval of biological products, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and
are subject to periodic inspection after approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Regulation of Companion Diagnostics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If use of an<I> in vitro</I> diagnostic is essential to safe and effective use of a drug or biologic product, then the FDA generally will require approval or
clearance of the diagnostic, known as a companion diagnostic and regulated by FDA as a medical device, at the same time that the FDA approves the product candidate. The review of an<I> in vitro</I> companion diagnostic in conjunction with the review
of a product candidate involves coordination of review between internal organizations within FDA. Most companion diagnostics require approval of a premarket approval application (PMA). The PMA process, including the gathering of clinical and
preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#146;s safety
and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMAs are subject to an application fee, which exceeds $250,000 for most devices. In addition, PMAs for
certain devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In
particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. As part of the PMA review, the FDA will
typically inspect the manufacturer&#146;s facilities for compliance with the Quality System Regulation (QSR) which imposes elaborate testing, control, documentation and other quality assurance requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the
application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA&#146;s evaluation of the PMA application is favorable, the FDA typically
issues an approvable letter requiring the applicant&#146;s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the
FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA
believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a device is placed on the market following appropriate approval or clearance from the FDA, it remains subject to significant regulatory requirements.
Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#146;s manufacturing
processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and
shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New Legislation and Regulations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing,
approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products.
It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations will be changed or what the effect of such changes, if any, may be. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. Healthcare Laws and Compliance Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including
but not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (such as the Office of Inspector General and the Health Resources and Service Administration), the U.S.
Department of Justice (DOJ) and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, sales, marketing and scientific/educational grant programs may have to comply with the anti-fraud and abuse provisions of
the Social Security Act, the false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act (HIPAA) and similar state laws, each as amended, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving
any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable, in whole or in part, under
Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between therapeutic product
manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors
are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of
the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a
statutory exception or regulatory safe harbor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Patient Protection
and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (ACA) , to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in
order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal
False Claims Act (FCA) (discussed below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal false claims and civil monetary penalty laws, including the FCA, which imposes significant
penalties and can be enforced by private citizens through civil qui tam actions, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by,
the federal healthcare programs, including Medicare and Medicaid, or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#147;any
request or demand&#148; for money or property presented to the U.S. government. For instance, historically, pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with
the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#146; marketing of the product for unapproved, <FONT
STYLE="white-space:nowrap">off-label,</FONT> and thus generally <FONT STYLE="white-space:nowrap">non-reimbursable,</FONT> uses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HIPAA created additional federal criminal statutes that prohibit, among other things, knowingly and
willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit
program, including private third-party payors, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any
materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, the ACA amended the intent standard for certain healthcare fraud statutes
under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, many states have similar, and typically more prohibitive, fraud and abuse statutes or regulations that apply to items and services reimbursed under
Medicaid and other state programs, or, in several states, apply regardless of the payor. Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended
by the Health Information Technology for Economic and Clinical Health Act (HITECH) and its implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. Among other
things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to business associates, independent contractors, or agents of covered entities that receive or obtain protected health information in connection with providing a
service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to
file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health
information in specified circumstances, many of which differ from each other in significant ways, are often not pre-empted by HIPAA, and may have a more prohibitive effect than HIPAA, thus complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our products, once approved, may be administered by a physician. Under currently applicable U.S. law, certain products not usually
self-administered (including injectable drugs) may be eligible for coverage under Medicare through Medicare Part B. Medicare Part B is part of original Medicare, the federal health care program that provides health care benefits to the aged and
disabled, and covers outpatient services and supplies, including certain pharmaceutical products, that are medically necessary to treat a beneficiary&#146;s health condition. As a condition of receiving Medicare Part B reimbursement for a
manufacturer&#146;s eligible drugs or biologicals, the manufacturer is required to participate in other government healthcare programs, including the Medicaid Drug Rebate Program and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program
requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the
manufacturer&#146;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities eligible to participate in the program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price (ASP)
and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private
payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. It is difficult to predict how Medicare coverage and reimbursement policies will be
applied to our products in the future and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the federal Physician Payments Sunshine Act (Sunshine Act) within the ACA, and its
implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) report
annually to CMS information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching
hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members. Failure to report accurately could report in penalties. In addition, many states also govern the reporting of payments
or other transfers of value, many of which differ from each other in significant ways, are often not <FONT STYLE="white-space:nowrap">pre-empted,</FONT> and may have a more prohibitive effect than the Sunshine Act, thus further complicating
compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and
wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state.
Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and
tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic
public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to
pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition
laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ensuring business arrangements with third parties comply with applicable healthcare laws and regulations is a costly endeavor. If our operations
are found to be in violation of any of the federal and state healthcare laws described above or any other current or future governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal
and/or administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#147;qui tam&#148; actions brought by individual
whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting obligations and
oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of our operations, any of
which could adversely affect our ability to operate our business and our results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage, Pricing and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may obtain regulatory approval. In the United
States and in foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such
products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. Adequate coverage and reimbursement from governmental healthcare programs,
such as Medicare and Medicaid in the United States, and commercial payors are critical to new product acceptance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to commercialize any
products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other
organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which therapeutics they will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pay for and establish reimbursement levels. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination that use of
a therapeutic is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a covered benefit under its health plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safe, effective and medically necessary; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appropriate for the specific patient; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effective; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">neither experimental nor investigational. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be sure that reimbursement will be available for any
product that we commercialize and, if coverage and reimbursement are available, what the level of reimbursement will be. Coverage may also be more limited than the purposes for which the product is approved by the FDA or comparable foreign
regulatory authorities. Reimbursement may impact the demand for, or the price of, any product for which we obtain regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third-party payors
are increasingly challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. Obtaining reimbursement for our products
may be particularly difficult because of the higher prices often associated with branded drugs and drugs administered under the supervision of a physician. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical
necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. Obtaining coverage and reimbursement approval of a
product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our product on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate reimbursement will be obtained. A payor&#146;s decision to provide coverage for a product does not imply
that an adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not
be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully
commercialize any product candidate that we successfully develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Different pricing and reimbursement schemes exist in other countries. In the European
Union, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate
positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare
the cost effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs
has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from <FONT STYLE="white-space:nowrap">low-priced</FONT> markets exert a commercial
pressure on pricing within a country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer
if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care, the increasing influence of health maintenance organizations, and additional legislative changes in the United
States has increased, and we expect will continue to increase, the pressure on healthcare pricing. The downward pressure on the rise in healthcare costs in general, particularly prescription medicines, medical devices and surgical procedures and
other treatments, has become very intense. Coverage </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory
approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is
obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In
the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, the ACA has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the ACA provisions of
importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above, are the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some
government healthcare programs that began in 2011; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January&nbsp;1, 2010, to 23.1% and 13% of the average manufacturer price for most branded and
generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price (AMP); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated
prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#146; outpatient drugs to be covered under Medicare Part D; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals beginning in 2014 and by adding new mandatory eligibility categories
for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the 340B Drug Discount Program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of healthcare fraud and abuse laws, including the FCA and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requirements to report certain financial arrangements with physicians and teaching hospitals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on
January&nbsp;1, 2011; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a licensure framework for follow on biologic products. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the provisions of the ACA have yet to be
implemented, and there have been legal and political challenges to certain aspects of the ACA. Since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements
mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress not has passed any such legislation, the future of the ACA remains uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that the ACA, if substantially maintained in its current form, will continue to result in additional downward pressure on coverage and the price
that we receive for any approved product, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost
containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenues from product candidates that
we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have
been proposed and adopted since the ACA was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to
Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation&#146;s automatic
reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April&nbsp;1, 2013 and will stay in effect through 2025 unless additional
Congressional action is taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to
specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription
drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Individual states in the United States have also become increasingly aggressive in
passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Foreign Corrupt Practices Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Foreign Corrupt Practices Act (FCPA), prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of
value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA
also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international
subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health
Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes
generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with
applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Regulations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to numerous
federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs
to comply with such laws and regulations now or in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Union / Rest of World Government Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical
trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval to conduct clinical trials or market a product, we must obtain the requisite approvals from regulatory authorities in foreign jurisdictions prior
to the commencement of clinical trials or marketing of the product in those countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain countries outside of the United States have a similar
process that requires the submission of a clinical trial application, much like the IND, prior to the commencement of human clinical trials. In the European Union , for example, before starting a clinical trial, a valid request for authorization
must be submitted by the sponsor to the competent authority of the EU Member State(s) in which the sponsor plans to conduct the clinical trial, as well as to an independent national Ethics Committee. A clinical trial may commence only once the
relevant Ethics Committee(s) has (have) issued a favorable opinion and the competent authority of the EU Member State(s) concerned has (have) not informed the sponsor of any grounds for <FONT STYLE="white-space:nowrap">non-acceptance.</FONT> Failure
to comply with the EU requirements may subject a company to the rejection of the request and the prohibition to start a clinical trial. Clinical trials conducted in the European Union (or used for marketing authorization application in the European
Union) must be conducted in accordance with applicable GCP and GMP rules, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines and be consistent with ethical
principles. EU Member State inspections are regularly conducted to verify the sponsor&#146;s compliance with applicable rules. The sponsor is required to record and report to the relevant national competent authorities (and to the Ethics Committee)
information about suspected serious unexpected adverse reactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The authorization of a clinical trial may be suspended or revoked by EU Member States
in their territory if the conditions in the request for an authorization are no longer met, or if an EU Member State has information raising doubts about the safety or scientific validity of the clinical trial. Various penalties exist in EU Member
States for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with the clinical trial rules and related requirements, for example with respect to data protection and privacy. If we or our potential collaborators fail to comply with applicable EU
regulatory requirements, we may also be subject to damage compensation and civil and criminal liability. The way clinical trials are conducted in the European Union will undergo a major change when the new EU Clinical Trial Regulation (Regulation
536/2014) comes into application in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As in the United States, no medicinal product may be placed on the EU market unless a marketing authorization
has been issued. Biological products, including immunological medicinal products, must be authorized through </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the centralized procedure, i.e., at EU level. Products submitted for approval via the centralized procedure are assessed by the Committee for Medicinal Products for Human Use (CHMP), a committee
within the European Medicine Agency (EMA). The CHMP assesses, <I>inter alia</I>, whether a medicine meets the necessary quality, safety and efficacy requirements and whether it has a positive risk-benefit balance. The requirements for an application
dossier for a biological product contain different aspects than that of a chemical medicinal product. Suspected unexpected&nbsp;serious adverse reactions related to authorized medicinal products must be recorded and reported to the national
competent authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Various penalties and sanctions exist in different EU Member States for <FONT STYLE="white-space:nowrap">non-compliance</FONT>
with the EU marketing authorization procedure. The European Commission may also impose financial penalties on the holders of marketing authorizations if they fail to comply with certain obligations in connection with the authorizations. If we or our
potential collaborators fail to comply with applicable EU &#150; or other <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> &#150; regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory
approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Coverage and reimbursement status of any product
candidates for which we obtain regulatory approval are provided for by the national laws of EU Member States. The requirements may differ across the EU Member States. Also at national level, actions have been taken<B> </B>to enact transparency laws
regarding payments between pharmaceutical companies and health care professionals (HCPs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EU Data Protection Directive<B> </B>and Member State
implementing legislation may also apply to health-related and other personal information obtained outside of the United States. The Directive will be replaced by the EU General Data Protection Regulation in May 2018. The Regulation will increase our
responsibility and liability in relation to personal data that we process, and we may be required to put in place additional mechanisms to ensure compliance with the new EU data protection rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For other countries outside of the European Union , such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. The requirements and
process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Australia </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conducting clinical trials for therapeutic drug candidates in Australia is subject to regulation by Australian regulatory bodies. The Therapeutic Goods
Administration (TGA) and the National Health and Medical Research Council set the codes of Good Clinical Practice (GCP) for clinical research in Australia, and compliance with these codes is mandatory. Australia has also adopted international codes,
such as those promulgated by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (the ICH). The ICH guidelines must be complied with across all fields of clinical research,
including those related to pharmaceutical quality, nonclinical and clinical data requirements and trial designs. The basic requirements for preclinical data to support a <FONT STYLE="white-space:nowrap">first-in-human</FONT> trial under ICH
guidelines are applicable in Australia. Requirements related to adverse event reporting in Australia are similar to those required in other major jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials conducted using &#147;unapproved therapeutic goods&#148; in Australia, being those which have not yet been evaluated by the TGA for quality,
safety and efficacy must occur pursuant to either the Clinical Trial Notification Scheme (CTN Scheme), or the Clinical Trial Exemption Scheme (CTX Scheme). In each case, the trial is supervised by a Human Research Ethics Committee (HREC) an
independent review committee set up under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
guidelines of the Australian National Health and Medical Research Council that ensures the protection of rights, safety and well-being of human subjects involved in a clinical trial. A HREC does
this by reviewing, approving and providing continuing examination of trial protocols and amendments, and of the methods and material to be used in obtaining and documenting informed consent of the trial subjects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The CTN Scheme broadly involves: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completion of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> laboratory and animal testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to a HREC, of all material relating to the proposed clinical trial, including the trial protocol; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the institution or organisation at which the trial will be conducted, referred to as the &#147;Approving Authority&#148;, giving final approval for the conduct of the trial at the site, having regard to the advice from
the HREC; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the investigator submitting a &#145;Notification of Intent to Conduct a Clinical Trial&#146; form (the CTN Form) to the TGA. The CTN form must be signed by the sponsor, the principal investigator, the chairman of the
HREC and a person responsible from the Approving Authority. The TGA does not review any data relating to the clinical trial however CTN trials cannot commence until the trial has been notified to the TGA. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the CTX Scheme: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a sponsor submits an application to conduct a clinical trial to the TGA for evaluation and comment; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a sponsor must forward any comments made by the TGA Delegate to the HREC(s) at the sites where the trial will be conducted. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A sponsor cannot commence a trial under the CTX Scheme until written advice has been received from the TGA regarding the application and approval for the
conduct of the trial has been obtained from an ethics committee and the institution at which the trial will be conducted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approval for inclusion in the
Australian Register of Therapeutic Goods (ARTG) is required before a pharmaceutical product may be marketed (or imported, exported or manufactured) in Australia. In order to obtain registration of the product on the ARTG, it is required that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adequate and well-controlled clinical trials demonstrate the quality, safety and efficacy of the therapeutic product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evidence is compiled which demonstrates that the manufacture of the therapeutic product complies with the principles of cGMP; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing and clinical data is derived to submit to the Advisory Committee on Prescription Medicines, which makes recommendations to the TGA as to whether or not to grant approval to include the therapeutic product
in the ARTG; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an ultimate decision is made by the TGA whether to include the therapeutic product in the ARTG. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;1, 2017, we had 78&nbsp;full-time&nbsp;employees, 43 of whom hold Ph.D. or M.D. degrees. Of these employees, 63 were engaged in
research and development activities and 15 were engaged in general and administrative activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees
to be good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently lease 70,100
square feet of office and laboratory space in Hayward, California under a lease that expires on October&nbsp;31, 2025. We believe that this space is sufficient to meet our needs for the foreseeable future and that any additional space we may require
will be available on commercially reasonable terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course
of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding our executive officers, key employees and directors, as of December&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="64%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:35.90pt; font-size:8pt; font-family:Times New Roman"><B>Position(s)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terry Rosen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Juan Carlos Jaen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Jarrett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Business Officer and Chief Financial Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Key Employees</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Chan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President, Finance, Corporate Controller and Principal Accounting Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joyson&nbsp;Joseph&nbsp;Karakunnel,&nbsp;MD, MSc,&nbsp;FACP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President, Clinical Development</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Pennell, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President, Preclinical Development</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jay P. Powers, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President, Drug Discovery</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ulrike Schindler, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President, Biology</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tim Sullivan, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President, Business Development</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nigel Walker, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President, Protein Science</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steve Young, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President, Technology</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathryn Falberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yasunori Kaneko, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Member of the audit committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Member of the compensation committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Member of the nominating and corporate governance committee. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Terry Rosen, Ph.D.</I> is our <FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as our Chief Executive Officer and as a member of our board
of directors since April 2015. He also served as the Chief Executive Officer of PACT Pharma, Inc. (PACT&nbsp;Pharma), a biopharmaceutical company, from November 2016 to December 2017. Immediately prior to the founding of our company, Dr.&nbsp;Rosen
served briefly in April 2015 as the Chief Executive Officer of FLX Bio, Inc., (FLX Bio), a biopharmaceutical company that was spun-off by Flexus Biosciences, Inc. (Flexus), a biopharmaceutical company. Previously, Dr.&nbsp;Rosen <FONT
STYLE="white-space:nowrap">co-founded</FONT> (with Dr.&nbsp;Jaen) and served as the Chief Executive Officer of Flexus from October 2013 to April 2015, when it was acquired by Bristol-Myers Squibb. Prior to that, Dr.&nbsp;Rosen was at Amgen, Inc.
(Amgen), a biopharmaceutical company, from August 2004 to January 2013 where he most recently served as Vice President of Therapeutic Discovery from November 2011 to January 2013. He also worked at Tularik Inc. (Tularik), a biopharmaceutical
company, from October 1993 to August 2004 when it was acquired by Amgen, Pfizer Central Research, a biopharmaceutical company, from December 1987 to September 1993, and Abbott Laboratories, a health care company, from July 1985 to December 1987.
Dr.&nbsp;Rosen serves on the board of trustees of the Salk Institute as well as on the board of trustees of the California Life Sciences Association. He also serves on the boards of Ideaya Biosciences, Inc., PACT Pharma and TUSK Therapeutics Ltd.
Dr.&nbsp;Rosen holds a B.S. in Chemistry from the University of Michigan and a Ph.D. in Chemistry from the University of California, Berkeley. We believe that Dr.&nbsp;Rosen should serve as a director based on his position as one of our founders and
as our Chief Executive Officer, his extensive experience in general management and business development and his experience in the field of biosciences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Juan Carlos Jaen, Ph.D.</I> is our <FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as our President and as a member of our board of
directors since April 2015. He has also served as the President of PACT Pharma since November 2016. Immediately prior to the founding of our company, Dr.&nbsp;Jaen served briefly in April 2015 as the President of FLX
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Bio. Previously, Dr.&nbsp;Jaen <FONT STYLE="white-space:nowrap">co-founded</FONT> (with Dr.&nbsp;Rosen) and served as the President and head of research and development at Flexus from October
2013 to April 2015, when it was acquired by Bristol-Myers Squibb. Prior to that, Dr.&nbsp;Jaen served as Senior Vice President of Drug Discovery and as the Chief Scientific Officer of ChemoCentryx, Inc. (ChemoCentryx), a biopharmaceutical company,
from 2007 to September 2013. From August 2004 to December 2006, Dr.&nbsp;Jaen was Vice President of Chemistry at Amgen and from 1996 to 2004, Dr.&nbsp;Jaen held positions as Director of Medicinal Chemistry and Vice President of Chemistry at Tularik.
Prior to that, Dr.&nbsp;Jaen held several positions in drug discovery and program management, from 1983 to 1996, at the Parke-Davis Pharmaceutical Research division of Warner-Lambert Company, a pharmaceutical company. Dr.&nbsp;Jaen also serves on
the board of directors of R2M Pharma, Inc., PACT Pharma, LakePharma, Inc. and the Bella Charitable Foundation. Dr.&nbsp;Jaen holds a B.S. in Chemistry from the Universidad Complutense de Madrid and a Ph.D. in Organic Chemistry from the University of
Michigan. We believe that Dr.&nbsp;Jaen should serve as a director based on his position as one of our founders and as our President, his extensive experience in general management and business development and his experience in the field of
biomedical research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jennifer Jarrett </I>has served as our Chief Business Officer and Chief Financial Officer since March 2017. From April 2016 to
September 2016, Ms.&nbsp;Jarrett was the Chief Financial Officer of Medivation, Inc., a biopharmaceutical company, which was acquired by Pfizer Inc. (Pfizer). Prior to that, Ms.&nbsp;Jarrett spent 20 years in investment banking, most recently as
Managing Director at Citigroup from July 2010 to April 2016, where she was responsible for managing their west coast life sciences investment banking practice. Before that, Ms.&nbsp;Jarrett was a Director and Managing Director at Credit Suisse from
2000 to 2010, and an associate at Donaldson, Lufkin&nbsp;&amp; Jenrette from 1998 to 2000. During her tenure as an investment banker, Ms.&nbsp;Jarrett covered biotechnology and pharmaceutical companies, primarily in the San Francisco Bay Area. She
currently serves on the board of directors of Audentes Therapeutics, Inc. and Arena Pharmaceuticals, Inc. Ms.&nbsp;Jarrett holds a B.A. in Economics, <I>cum laude</I>, from Dartmouth College and an M.B.A. from Stanford Graduate School of Business.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Steven Chan </I>has served as our
Vice President, Finance&nbsp;and Corporate Controller since March 2017 and our Principal Accounting Officer since December 2017. Before that, from November 2014 to March 2017, he served as the Vice President of Finance and Corporate Controller at
MyoKardia, Inc., a biopharmaceutical company, where he helped lead the company to an initial public offering in 2015. He previously worked as the Vice President of Finance and Corporate Controller at Solta Medical, Inc., a medical device company,
from 2010 to November 2014 and as the Vice President of Finance at Moody&#146;s Analytics from 2007 to 2010. He started his career at KPMG. Mr.&nbsp;Chan received a B.A. in Business Administration from the University of California at Berkeley, Haas
School of Business and is a Certified Public Accountant in California (inactive status). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Joyson Joseph Karakunnel, M.D., M.Sc., FACP </I>has served as
our Vice President, Clinical Development since April 2017. Dr.&nbsp;Karakunnel has also served as a Medical Director and Advisor of the Parker Institute for Cancer Immunotherapy since April 2017. Previously, Dr.&nbsp;Karakunnel served as a Director
at MedImmune, LLC, a pharmaceutical company, from June 2013 to April 2017. Dr.&nbsp;Karakunnel has been an Associate Professor of Medicine at the Uniformed Services University of the Health Sciences from 2011 to April 2017. He previously worked as a
hospitalist within the Johns Hopkins Health System from 2010 to February 2014, as a hematologic group team leader and attending physician in hematology and oncology within the Walter Reed National Military Medical Center from February 2010 to May
2013, and as an attending physician and investigator within the National Cancer Institute from 2008 to June 2013. He also worked for the Food and Drug Administration as a medical reviewer from 2007 to 2008. Dr.&nbsp;Karakunnel received a B.S. in
Microbiology from the University of Miami. He received a medical degree from Annamalai University and completed his internal medicine residency at Overlook Hospital/University of Medicine and Dentistry of New Jersey, where he was subsequently the
chief resident. He has completed fellowships in Hematology, Oncology, and Pain and Palliative Care at the NCI and has also received his M.S. in Molecular Medicine from the University of Maryland. He was elected to be a fellow in the American College
of Physicians. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Andrew Pennell, Ph.D.</I> has served as our Vice President, Preclinical Development since November 2016.
From 2002 to November 2016, Dr.&nbsp;Pennell worked at ChemoCentryx, as the Director of Medicinal Chemistry from 2002 to 2007, as the Executive Director of Preclinical Drug Evaluation from 2007 to 2010, as the Senior Director of Preclinical
Development from 2010 to July 2015 and, finally, as Executive Director of Preclinical Development from July 2015 to November 2016. Between 1993 and 2002, Dr.&nbsp;Pennell held various scientific management positions, including those of Medicinal
Chemistry Group Leader at GlaxoWellcome Inc., a biopharmaceutical company, from 1994 to 2000, and Director of Medicinal Chemistry at Genesoft Inc., a biotechnology company, from 2000 to 2002. Dr.&nbsp;Pennell received a B.Sc. (Hons) in Chemistry and
a Ph.D. in Organic Chemistry from Imperial College London. He also worked as a postdoctoral scientist at Columbia University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Jay P. Powers, Ph.D.</I>
has served as our Vice President, Drug Discovery since January 2016. Before that, he served as the Vice President of Drug Discovery at FLX Bio, from April 2015 to November 2015. Previously, Dr.&nbsp;Powers served as the Vice President of Drug
Discovery of Flexus, from November 2013 to April 2015, when it was acquired by Bristol-Myers Squibb. From May 2007 to November 2013, Dr.&nbsp;Powers worked at ChemoCentryx, as Director of Medicinal Chemistry from 2007 to 2010, Senior Director of
Chemistry from 2010 to January 2013 and, lastly, as Vice President of Drug Discovery from January 2013 to November 2013. Dr.&nbsp;Powers also worked as a Scientific Director at Amgen from 2004 to 2007, Senior Research Investigator at Tularik, from
1998 to 2004, and as a Research Chemist at Abbott Laboratories from 1996 to 1998. Dr.&nbsp;Powers received a B.S. in Biochemistry and a Ph.D. in Chemistry from the University of Minnesota and completed postdoctoral studies in the laboratories of
Professor Gilbert Stork at Columbia University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ulrike Schindler, Ph.D. </I>has served as our Vice President, Biology since January 2016. Since
January 2014, she consulted for <FONT STYLE="white-space:nowrap">non-profit</FONT> research organizations such as the <FONT STYLE="white-space:nowrap">Max-Planck</FONT> Institute and the Fraunhofer Society. Dr.&nbsp;Schindler was employed by Amgen
from January 2001 to August 2013, with a wide range of responsibilities, including Head of Biologics as Executive Director, Executive Director of Amgen Research GmbH and Regional Director of Operations. From July 2007 to August 2013, Dr. Schindler
was the Chief Executive Officer of Alantos Pharmaceuticals AG, a subsidiary of Amgen. Dr.&nbsp;Schindler began her career in February 1993 at Tularik, where she worked as a postdoctoral fellow, a Scientist, and a Principal Investigator before moving
to Tularik GmbH as a Regional Director of Operations. Dr.&nbsp;Schindler received her B.S. in Biochemistry and her Ph.D. in Physical Chemistry, Genetics and Cell Biology from the University of Freiburg. She performed all practical work for her Ph.D.
at the University of Pennsylvania, where she was employed as Visiting Scientist from 1987 to 1992. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tim Sullivan, Ph.D.</I> has served as our Vice
President, Business Development since January 2017. Previously, Dr.&nbsp;Sullivan worked as a Senior Director of External Research&nbsp;&amp; Development Innovation at Pfizer from June 2015 to January 2017. Before that, Dr.&nbsp;Sullivan worked as a
Director of New Frontier Science at Takeda Pharmaceutical Company Ltd, a pharmaceutical company, from December 2012 to June 2015. Dr.&nbsp;Sullivan previously worked at ChemoCentryx, as a Principal Scientist from December 2007 to March 2010 and as
the Director of Immunology from March 2010 to December 2012. He also worked at Amgen as a Senior Scientist, from August 2004 to March 2007, and as a Principal Scientist from March 2007 to November 2007. He previously worked as a Scientist at
Tularik, from 2001 to 2004. Dr.&nbsp;Sullivan received a B.A. in Psychology from the University of Notre Dame and a Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nigel Walker, Ph.D.</I> has served as our Vice President, Protein Science since May 2016. Since November 2014, Dr.&nbsp;Walker has also served as the
founder and principal of Molecular Consulting, LLC, a consulting company. Before his time with our company, Dr.&nbsp;Walker worked at Amgen as a Director of Research from 2004 to 2006, as a Scientific Executive Director from 2006 to March 2013, and
finally as the Executive Director, Research from April 2013 to October 2014. Dr.&nbsp;Walker also worked as a Research Scientist at BASF AG from 1985 to 1998 and as the Director of Structural Biology at Tularik from 1998 to 2004. Dr.&nbsp;Walker
received a B.Sc. (Hons) and a Ph.D. in Biochemistry from the University of Bristol. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stephen Young, Ph.D.</I> has served as our Vice President, Technology since March 2016. Prior to that,
Dr.&nbsp;Young was the Vice President of Technology at FLX Bio from April 2015 to November 2015. Previously, Dr.&nbsp;Young was the Vice President of Technology of Flexus from November 2013 to April 2015, when it was acquired by Bristol-Myers
Squibb. Dr.&nbsp;Young previously was the Executive Director of Lead Discovery and then of Discovery Technologies at Amgen from 2004 to July 2013. Before that, he was Director of Lead Discovery at Tularik from 2001 to 2004. Dr.&nbsp;Young also
worked as the Head of High Throughput Screening at Roche U.K. from 1999 to 2001 and as a Senior Biologist from 1994 to 1999 at Glaxo Wellcome Plc (now known as GlaxoSmithKline Plc). He currently serves on the board of directors of the Society for
Laboratory Automation and Screening. Dr.&nbsp;Young received a B.Sc. and a Ph.D. in Biochemistry from the University of Bristol and a diploma in Business Administration from Open University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Kathryn Falberg</I> has served as a member of our board of directors since September 2017. She served as the Executive Vice President and Chief Financial
Officer of Jazz Pharmaceuticals plc, a biopharmaceutical company, from March 2012 to March 2014, after serving as its Senior Vice President and Chief Financial Officer since December 2009. From 2001 through 2009, Ms.&nbsp;Falberg worked with a
number of smaller companies while serving as a corporate director and audit committee chair for several companies. From 1995 to 2001, Ms.&nbsp;Falberg was with Amgen, where she served as Senior Vice President, Finance and Strategy, and Chief
Financial Officer and prior to that as Vice President, Chief Accounting Officer, and Vice President, Treasurer. Ms.&nbsp;Falberg holds an M.B.A. in Finance and B.A. in Economics from the University of California, Los Angeles and is an inactive
certified public accountant. Ms.&nbsp;Falberg also serves as a member of the boards of directors of biopharmaceutical companies Aimmune Therapeutics, Inc., Axovant Sciences Ltd. and Urogen Pharma Ltd., and a technology company, The Trade Desk, Inc.
Ms.&nbsp;Falberg previously served on the boards of directors of BioMarin Pharmaceutical Inc., Medivation Inc., Halozyme Therapeutics, Inc., aTyr Pharma, Inc., and multiple other companies. We believe Ms.&nbsp;Falberg is able to make valuable
contributions to our board of directors due to her extensive business experience as an executive in the pharmaceutical industry and her service as a director and audit committee member of various other companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Yasunori Kaneko, M.D.</I> has served as a member of our board of directors since May 2015. Dr.&nbsp;Kaneko has been a Managing Director at Skyline Venture
Partners, L.P., a venture capital firm, since January 1999. Previously, Dr.&nbsp;Kaneko served on the board of LeukoSite Inc., a biopharmaceutical company, until its merger with Millennium Pharmaceuticals, Inc. in 1999. Dr.&nbsp;Kaneko also served
as Chief Financial Officer and Vice President, Business Development at Tularik, a biopharmaceutical company, from 1992 until 1999. Dr.&nbsp;Kaneko served as a Senior Vice President and Chief Financial Officer of Ionis Pharmaceuticals, Inc., a
pharmaceutical company, which went public in May 1991 during his tenure from 1991 to 1992. Dr.&nbsp;Kaneko began his career at Genentech, Inc., a biotechnology company, where he served in a business development role, from 1981 to 1987 and as head of
corporate finance in the investment banking division of Paribas Capital Markets LTD, from 1987 to 1991. Dr.&nbsp;Kaneko received an undergraduate degree and a medical degree from Keio University in Tokyo, and an M.B.A. from Stanford Graduate School
of Business. We believe Dr.&nbsp;Kaneko is able to make valuable contributions to our board of directors due to his educational background in medicine and sciences, as well as his experience in the life science, pharmaceutical and related financial
industries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no
family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to apply to have our common stock listed on the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Our board of directors has
determined that none of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these
directors is &#147;independent&#148; as that term is defined under the rules of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Audit committee members must also satisfy the independence rules in Securities and Exchange Commission (SEC)
Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> adopted under the Securities Exchange Act of 1934, as amended (the Exchange Act). In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> a member
of an audit committee of a public company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: accept, directly or indirectly, any consulting, advisory or other
compensatory fee from the listed company or any of its subsidiaries, or be an affiliated person of the listed company or any of its subsidiaries. Each of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; qualify as an
independent director pursuant to Rule <FONT STYLE="white-space:nowrap">10A-3.</FONT> We also intend to satisfy the audit committee independence requirement of the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors currently
consists of four members, who were elected pursuant to the amended and restated voting agreement that we entered into with certain holders of our common stock and certain holders of our preferred stock and the related provisions of our amended and
restated certificate of incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of this voting agreement will terminate upon the completion of this offering, after which there
will be no further contractual obligations regarding the election of our directors. Our directors hold office until their successors have been elected and qualified or appointed, or the earlier of their death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately after the completion of this offering, our board of directors will be divided into three classes with staggered three-year terms. At each annual
meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors will be divided among the three
classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class&nbsp;I directors will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at the annual meeting of stockholders to be held in 2019; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class&nbsp;II directors will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at the annual meeting of stockholders to be held in 2020; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class&nbsp;III directors will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will expire at the annual meeting of stockholders to be held in 2021.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Directors in a particular class will be elected for three-year terms at the annual meeting of stockholders in the year in which their terms
expire. As a result, only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Each director&#146;s term continues until the
election and qualification of his or her successor, or the earlier of his or her death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of
incorporation and amended and restated bylaws that will be in effect upon the completion of this offering provide that only our board of directors can fill vacant directorships, including newly-created seats. Any additional directorships resulting
from an increase in the authorized number of directors would be distributed pro rata among the three classes so that, as nearly as possible, each class would consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the authorized number of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The classification of our board of directors may have the effect of delaying or preventing changes in our control or management. See
&#147;Description of Capital Stock&#151;Anti-Takeover Provisions&#151;Certificate of Incorporation and Bylaw Provisions.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Oversight of Risk
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One of the key functions of our board of directors is informed oversight of our risk management process. In particular, our board of directors is
responsible for monitoring and assessing strategic risk exposure. Our executive officers are responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of the material risks we face. Our
board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors administers its oversight function directly as a whole. Our board of directors will also administer its oversight through various standing committees, which will be constituted prior to
the completion of this offering, that address risks inherent in their respective areas of oversight. For example, our audit committee will be responsible for overseeing the management of risks associated with our financial reporting, accounting and
auditing matters; our compensation committee will oversee the management of risks associated with our compensation policies and programs; and our nominating and corporate governance committee will oversee the management of risks associated with
director independence, conflicts of interest, composition and organization of our board of directors and director succession planning. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board
Committees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors will establish an audit committee, a compensation committee and a nominating and corporate governance committee
prior to the completion of this offering. Our board of directors may establish other committees to facilitate the management of our business. Our board of directors and its committees will set schedules for meeting throughout the year and can also
hold special meetings and act by written consent from time to time, as appropriate. Our board of directors expects to delegate various responsibilities and authority to committees as generally described below. The committees will regularly report on
their activities and actions to the full board of directors. Each member of each committee of our board of directors will qualify as an independent director in accordance with the listing standards
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . Each committee of our board of directors will have a written charter approved by our board of directors. Upon the completion of this offering, copies of each charter will
be posted on our website at www.arcusbio.com under the Investor Relations section. The inclusion of our website address in this prospectus does not include or incorporate by reference the information on our website into this prospectus. Members will
serve on these committees until their resignation or until otherwise determined by our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of our audit committee are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, each of whom can read and understand
fundamental financial statements. Each member of our audit committee is independent under the rules and regulations of the SEC and the listing standards of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; applicable to audit
committee members.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is the chair of the audit committee. Our board of directors has determined that each
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;qualify as an audit committee financial expert within the meaning of SEC
regulations and meet the financial sophistication requirements of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit
committee will assist our board of directors with its oversight of the integrity of our financial statements; our compliance with legal and regulatory requirements; the qualifications, independence and performance of the independent registered
public accounting firm; the design and implementation of our risk assessment and risk management. Among other things, our audit committee is responsible for reviewing and discussing with our management the adequacy and effectiveness of our
disclosure controls and procedures. The audit committee also will discuss with our management and independent registered public accounting firm the annual audit plan and scope of audit activities, scope and timing of the annual audit of our
financial statements, and the results of the audit, quarterly reviews of our financial statements and, as appropriate, initiates inquiries into certain aspects of our financial affairs. Our audit committee is responsible for establishing and
overseeing procedures for the receipt, retention and treatment of any complaints regarding accounting, internal accounting controls or auditing matters, as well as for the confidential and anonymous submissions by our employees of concerns regarding
questionable accounting or auditing matters. In addition, our audit committee has direct responsibility for the appointment, compensation, retention and oversight of the work of our independent registered public accounting firm. Our audit committee
has sole authority to approve the hiring and discharging of our independent registered public accounting firm, all audit engagement terms and fees and all permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> engagements with the independent
auditor. Our audit committee will review and oversee all related person transactions in accordance with our policies and procedures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of our compensation committee are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
..&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is the chair of the compensation committee. Each member of our compensation committee is independent under the rules and regulations of the SEC and the listing standards of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; applicable to compensation committee members. Our compensation committee will assist our board of directors with its oversight of the forms and amount of compensation for our
executive officers (including officers reporting under Section&nbsp;16 of the Securities Exchange Act of 1934, as amended), the administration of our equity and <FONT STYLE="white-space:nowrap">non-equity</FONT> incentive plans for employees and
other service providers and certain other matters related to our compensation programs. Our compensation committee, among other responsibilities, evaluates the performance of our chief executive officer and, in consultation with him, evaluates the
performance of our other executive officers (including officers reporting under Section&nbsp;16 of the Securities Exchange Act of 1934, as amended). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
members of our nominating and corporate governance committee are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Each member of our nominating and governance committee is independent under the rules and regulations of the
SEC and the listing standards of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;applicable to nominating and governance committee members.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is the chair of the nominating and corporate governance committee. Our nominating and corporate governance committee will assist our board of directors with its oversight of and
identification of individuals qualified to become members of our board of directors, consistent with criteria approved by our board of directors, and selects, or recommends that our board of directors selects, director nominees; develops and
recommends to our board of directors a set of corporate governance guidelines and oversees the evaluation of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Conduct
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors will adopt a Code of Conduct (the Code) prior to the completion of this offering. The Code will apply to all of our employees,
officers, directors, contractors, consultants, suppliers and agents. Upon the completion of this offering, the full text of the Code will be posted on our website at www.arcusbio.com under the Investor Relations section. We intend to disclose future
amendments to, or waivers of, the Code, as and to the extent required by SEC regulations, at the same location on our website identified above or in public filings. Information contained on our website is not incorporated by reference into this
prospectus, and you should not consider information contained on our website to be part of this prospectus or in deciding whether to purchase shares of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal year ended December&nbsp;31, 2016, our board of directors did not have a compensation committee or a separate committee performing equivalent
functions. All members of our board of directors, including our Chief Executive Officer, Terry Rosen, Ph.D., and our President, Juan Carlos Jaen, Ph.D., participated in deliberations of our board of directors concerning executive officer
compensation. During the fiscal year ended December&nbsp;31, 2016, Dr.&nbsp;Rosen and Dr.&nbsp;Jaen served as executive officers and directors of both our company and PACT Pharma. Outside of the relationships set forth in the prior sentence, none of
our executive officers serves, or served during the fiscal year ended December&nbsp;31, 2016, as a member of the board of directors or compensation committee of any other entity that has or has had one or more executive officers serving as a member
of our board of directors. Each of Dr.&nbsp;Rosen, Dr.&nbsp;Jaen, Dr.&nbsp;Kaneko, and Ms.&nbsp;Falberg may be deemed to have an interest in certain transactions requiring disclosure under Item 404 of Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act of 1933, as amended, or the Securities Act, that are disclosed in &#147;Certain Relationships and Related Party Transactions,&#148; which disclosure is hereby incorporated by
reference in this section. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing on April&nbsp;1, 2017, with respect to Dr.&nbsp;Kaneko, and on October&nbsp;1, 2017, with respect to Ms.&nbsp;Falberg, and pursuant to letter
agreements with each of them, we paid our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors an annual retainer of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$50,000 for their service, payable quarterly in arrears. A <FONT STYLE="white-space:nowrap">non-employee</FONT> director is a director who is not employed by us and who does not receive
compensation from us or have a business relationship with us that would require disclosure under certain SEC rules. We also have a policy of reimbursing all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their reasonable
out of pocket expenses in connection with attending board of directors and committee meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;31, 2015, Dr.&nbsp;Kaneko was granted an
option to purchase 50,000 shares of our common stock at an exercise price of $0.10 per share. Dr.&nbsp;Kaneko subsequently exercised such option, with the unvested shares remaining subject to our right of repurchase upon termination of his service.
Such repurchase right lapses in 48 substantially equal monthly installments following the completion by Dr.&nbsp;Kaneko of each month of continuous service following May&nbsp;21, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;15, 2017, Dr.&nbsp;Kaneko was granted an option to purchase 75,000 shares of our common stock at an exercise price of $0.31 per share.
Dr.&nbsp;Kaneko subsequently exercised such option, with the unvested shares remaining subject to our right of repurchase upon termination of his service. Such repurchase right lapses in 48 substantially equal monthly installments following the
completion by Dr.&nbsp;Kaneko of each month of continuous service following March&nbsp;14, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;19, 2017, Dr.&nbsp;Kaneko was granted
an option to purchase 25,000 shares of our common stock, and Ms.&nbsp;Falberg was granted an option to purchase 100,000 shares of our common stock, in each case at an exercise price of $0.65 per share. Each director subsequently exercised such
option, with the unvested shares remaining subject to our right of repurchase upon termination of service. Such repurchase right lapses in 48 substantially equal monthly installments following the completion by the director of each month of
continuous service following September&nbsp;14, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our repurchase right with respect to the shares held by our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors lapses in full if we are subject to certain mergers or consolidations with or into another entity or our dissolution, liquidation or winding up, in each case prior to the termination of
such director&#146;s service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information about the compensation of the
<FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors who served as a director during the year ended December&nbsp;31, 2017. During our 2017 fiscal year, we did not pay any cash fees, make any equity or <FONT
STYLE="white-space:nowrap">non-equity</FONT> awards, or pay any other compensation to Drs. Rosen and Jaen other than in their capacities as our Chief Executive Officer and President, respectively, and thus they are not included in the table below.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned&nbsp;or</B><br><B>Paid in<BR>Cash<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathryn Falberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yasunori Kaneko, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts shown in this column represent the aggregate amounts of all fees earned or paid in cash for services as a director in 2017 as discussed above. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The amounts in this column represent the aggregate grant date fair value of option awards granted to the director in fiscal year 2017 computed in accordance with FASB ASC Topic 718. See Note
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to our consolidated financial statements included elsewhere in this prospectus for a discussion of the assumptions made by us in determining the grant date fair value of our
equity awards. Amount consists of: (i) $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with respect to the option granted to Ms.&nbsp;Falberg on September&nbsp;19, 2017; and (ii)
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with respect to the option granted to Dr.&nbsp;Kaneko on March&nbsp;15, 2017, and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with respect to the
option granted to Dr.&nbsp;Kaneko on September&nbsp;19, 2017. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both of Ms.&nbsp;Falberg and Dr.&nbsp;Kaneko have fully exercised their
options and now hold shares of our common stock. Such shares are subject to our right of repurchase, which right lapses in accordance with the vesting schedules described above. As a result, Ms.&nbsp;Falberg holds 93,750 restricted shares of our
common stock subject to the right of repurchase, and Dr.&nbsp;Kaneko holds an aggregate of 105,209 restricted shares of our common stock subject to the right of repurchase. As of December&nbsp;31, 2017, none of our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors held options to purchase shares of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_13"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table shows information regarding the compensation of our named executive officers for services performed in our fiscal year ended December&nbsp;31, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:97.00pt; font-size:8pt; font-family:Times New Roman"><B>Name and principal position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-equity</FONT><BR>Incentive&nbsp;
Plan<BR>Compensation<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terry Rosen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer and Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Juan Carlos Jaen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Director</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Jarrett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Business Officer and Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Represents the aggregate grant date fair value of option awards granted to the officer in the applicable fiscal year, computed in accordance with FASB ASC Topic 718. See Note
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to our consolidated financial statements included elsewhere in this prospectus for a discussion of the assumptions made by us in determining the grant date fair value of our
equity awards. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Represents payments made pursuant to our letter agreement with Ms.&nbsp;Jarrett. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Benefits and
Perquisites </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our named executive officers are eligible to participate in our health and welfare plans to the same extent as are all full-time
employees generally. We generally do not provide our named executive officers with perquisites or other personal benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Retirement Benefits
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have established a 401(k) <FONT STYLE="white-space:nowrap">tax-deferred</FONT> savings plan, which permits participants, including our named
executive officers, to make contributions by salary deduction pursuant to Section&nbsp;401(k) of the Internal Revenue Code of 1986, as amended. We are responsible for administrative costs of the 401(k) plan. We may, at our discretion, make matching
or profit sharing contributions to the 401(k) plan. No employer contributions have been made to date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We offer stock options and restricted shares to our named executive officers as the long-term incentive component of our compensation program. We typically
grant equity awards to new hires upon their commencing employment with us. Stock options allow employees to purchase shares of our common stock at a price per share at least equal to the fair market value of our common stock on the date of grant and
may or may not be intended to qualify as &#147;incentive stock options&#148; for U.S. federal income tax purposes. In the past, our board of directors has determined the fair market value of our common stock based upon inputs including valuation
reports prepared by third-party valuation firms. Generally, our equity awards vest over four years, subject to the employee&#146;s continued employment with us on each vesting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in the footnotes to the &#147;Outstanding Equity Awards at 2017 Fiscal <FONT STYLE="white-space:nowrap">Year-End&#148;</FONT> table and under
&#147;Severance and Change in Control Benefits&#148; below, equity awards granted to our named executive officers are subject to accelerated vesting in the event such officer is subject to an involuntary termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2017 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information regarding each unexercised option and all unvested stock held by each of our named executive officers as of
December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The vesting schedule applicable to each outstanding award is described in the footnotes to the table below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options granted to our named executive officers are immediately exercisable with respect to all of the option shares, subject to our repurchase right in the
event that the executive&#146;s service terminates before vesting in such shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Vested</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unvested</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares Or<BR>Units of<BR>Stock&nbsp;That<BR>Have Not<BR>Vested<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Value<BR>of Shares Or<BR>Units of<BR>Stock That<BR>Have Not<BR>Vested(*)<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terry Rosen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Juan Carlos Jean, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Jarrett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Market value is based on the fair market value of our common stock on December&nbsp;31, 2017. As there was no public market for our common stock on December&nbsp;31, 2017, we have assumed that the fair market value on
such date was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which represents the midpoint of the range set forth on the cover page of this prospectus. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Severance and Change in Control Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to
letter agreements entered into with each of Drs. Rosen and Jaen in June 2015, and with Ms.&nbsp;Jarrett in February 2017, if we terminate the respective officer&#146;s employment for reasons other than cause, or if the officer voluntarily resigns
for certain good reasons (which we refer to collectively as an involuntary termination), then the officer will be eligible to receive, contingent on returning all of our property in the officer&#146;s possession, executing and not revoking a general
release of claims against us and certain related parties, and resigning as a member of our board of directors, continued payment of base salary for a <FONT STYLE="white-space:nowrap">six-month</FONT> period, at the rate in effect at the time of
termination (but without giving effect to any reduction triggering a resignation for good reason). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cause means the officer&#146;s: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">willful failure to substantially perform his or her material duties and responsibilities after having received written notice and at least 30 days to remedy such failure; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conviction of, or plea of no contest to, a felony; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">commission of any act of fraud, misappropriation or embezzlement against us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">material breach of any confidentiality, invention assignment or proprietary information agreement with us; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">willful failure to comply in any material respect with our lawful written policies of general applicability that have been communicated to the officer. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Good reason means a resignation of employment within two years after one of the following conditions has come into existence without the officer&#146;s
consent, which remains uncured more than 30 days after delivery of notice to us of such condition within 30 days following the initial existence of such condition: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a material adverse change in the officer&#146;s position causing such position to be of materially reduced stature or responsibility; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a reduction in base salary compensation or other benefits; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a required relocation of the officer&#146;s work facility or location by more than 25 miles. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drs. Rosen and
Jaen and Ms.&nbsp;Jarrett are also eligible to receive full vesting of all existing and future equity compensation awards in the event of an involuntary termination in connection with or following our change in control, subject to the conditions
described above with respect to severance benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Change in control means certain mergers or consolidations of us with or into another entity; a sale,
conveyance or other disposition of all or substantially all of our assets, property or business; or the acquisition by any person or persons acting as a group of beneficial ownership (or a right to acquire beneficial ownership) of shares
representing a majority of the voting power of the then-outstanding shares of our capital stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General</I>.<I>
</I>Our board of directors adopted the 2018 Equity Incentive Plan (2018 Plan) in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018 and we expect it to be approved by our stockholders prior to the
completion of this offering. The 2018 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights and performance cash awards. Awards may be granted under
the 2018 Plan beginning on the effective date of the registration statement to which this prospectus is a part. The 2018 Plan will replace our 2015 Stock Plan (2015 Plan); however, awards outstanding under the 2015 Plan will continue to be governed
by their existing terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share Reserve</I>.<I> </I>The number of shares of our common stock reserved for issuance under the 2018 Plan is equal
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares plus up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares remaining available for issuance under our 2015 Plan on
the effective date of the registration statement to which this prospectus is a part or subject to awards outstanding under our 2015 Plan on such date that subsequently expire, lapse unexercised or are forfeited. The number of shares reserved for
issuance under our 2018 Plan will automatically increase on the first business day of each of our fiscal years beginning in 2019 and ending in 2028, by a number equal to the smallest of
(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of common stock outstanding on the last business day of the prior fiscal
year or (iii)&nbsp;the number of shares determined by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, if awards granted under the 2018 Plan are forfeited, cancelled,
repurchased or expire, if an award is settled in cash or if shares subject to an award are applied to the exercise price or tax withholding obligations related to the award, the corresponding shares will be available for future issuance under our
2018 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration</I>.<I> </I>The 2018 Plan will be administered by our board of directors or one or more committees to which our board of
directors delegates such administration (as applicable, the administrator). Subject to the terms of the 2018 Plan, the administrator has the complete discretion to determine the eligible individuals who are to receive awards under the plan, to
determine the terms and conditions of awards granted under the 2018 Plan and to make all decisions related to the 2018 Plan and awards granted thereunder. Our board of directors has delegated full authority to administer the 2018 Plan to its
compensation committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>.&nbsp;Employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants are eligible
to participate in the 2018 Plan. However, only employees are eligible to receive incentive stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options and Stock Appreciation
Rights</I>.&nbsp;The exercise price of stock options and stock appreciation rights (SARs) granted under the 2018 Plan may not be less than 100% of the fair market value of our common stock on the date of grant. Subject to limited exceptions, options
and SARs may have a maximum term of up to 10 years and will generally expire sooner if the optionee&#146;s service terminates. The vesting schedule of each option and SAR is determined by the administrator, however, in general, we grant options that
vest over four years.&nbsp;An </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
optionee may pay the exercise price of an option in cash, or, with the administrator&#146;s consent, with shares of common stock the optionee already owns, with proceeds from an immediate sale of
the option shares through a broker approved by us, through a net exercise procedure or by any other method permitted by applicable law. The administrator has full authority to reprice (reduce the exercise price of) options and stock appreciation
rights or to approve programs in which options and stock appreciation rights are exchanged for cash or other equity awards on terms the administrator determines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock and Restricted Stock Units</I>.<I> </I>Restricted stock may be awarded under the 2018 Plan for such consideration as the administrator
determines, including cash or services provided to us. Typically no payment is required in connection with the grant of restricted stock units. Each award of restricted stock or restricted stock units may or may not be subject to vesting and
vesting, if any, shall occur upon the satisfaction of the conditions specified by the administrator. Settlement of vested restricted stock units may be made in the form of cash, common stock or a combination of both. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Cash Awards</I>.&nbsp;Performance cash awards may be granted under the 2018 Plan that qualify as performance-based compensation that is not
subject to the income tax deductibility limitations imposed by Section&nbsp;162(m) of the Internal Revenue Code, if the award is approved by our compensation committee and the grant or vesting of the award is tied solely to the attainment of
performance goals during a designated performance period. Performance goals for the grant or vesting of performance awards under the 2018 Plan may be based on any one, or combination, of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Earnings (before or after taxes); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sales or revenue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Earnings per share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Expense or cost reduction; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Earnings before interest, taxes and depreciation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Working capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Earnings before interest, taxes, depreciation and amortization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Economic value added (or an equivalent metric); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Total stockholder return; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Market share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Return on equity or average stockholders&#146; equity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cash flow or cash balance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Return on assets, investment or capital employed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Operating cash flow; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Operating income; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cash flow per share; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Gross margin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Share price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Operating margin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Debt reduction; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Net operating income; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Customer satisfaction; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Net operating income after tax; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stockholders&#146; equity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Return on operating revenue; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Contract awards or backlog. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent a performance award is not intended to comply with
Section&nbsp;162(m) of the Internal Revenue Code, the compensation committee may select other measures of performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain Limitations</I>. No
more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares may be issued under the 2018 Plan upon exercise of incentive stock options.&nbsp;The 2018 Plan also limits the grant date fair value of equity awards
we may grant to a <FONT STYLE="white-space:nowrap">non-employee</FONT> director in any fiscal year to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. No participant may be granted stock options or stock appreciation rights under our 2018 Plan
covering more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares in any fiscal year, except that a new employee may receive stock options or stock appreciation rights covering up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares in the fiscal year in which employment commences. No participant may be granted restricted share awards or stock units with performance-based vesting
covering more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares during any fiscal year, except that a new employee may receive restricted shares or stock units covering up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares in the fiscal year in which employment commences. No participant may be paid more than $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in cash in any
calendar year pursuant to a performance cash award granted under the 2018 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transferability of Awards. </I>Unless the administrator determines
otherwise, an award generally will not be transferable other than by beneficiary designation, a will or the laws of descent and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>.<I> </I>If we are party to a merger or certain change in control transactions, each outstanding award will be treated as
described in the definitive transaction agreement or as the administrator determines, which may include the continuation, assumption or substitution of an outstanding equity award, the cancellation of an outstanding equity award after an opportunity
to exercise or the cancellation of an outstanding equity award in exchange for a payment equal to the value of the shares subject to such award less any applicable exercise price.&nbsp;In general, if an equity award held by a participant who remains
in service at the effective time of a change in control transaction is not continued, assumed or substituted, then the award will vest in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes in Capitalization</I>.<I> </I>In the event of certain changes in our capitalization, including a stock split, reverse stock split or stock
dividend, proportionate adjustments will be made in the number and kind of shares available for issuance under the 2018 Plan and the number and kind of shares subject to each outstanding award and/or the exercise price of outstanding award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment or Termination</I>.<I> </I>The administrator may amend or terminate the 2018 Plan at any time. Any such amendment or termination will not affect
outstanding awards. If not sooner terminated, the 2018 Plan will terminate automatically in 2028. Shareholder approval is not required for any amendment of the 2018 Plan, unless required by applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated 2015 Stock Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General</I>. Our board of directors adopted our Amended and Restated 2015 Stock Plan (our 2015 Plan) in May 2015, and it was approved by our stockholders.
The most recent amendment of our 2015 Plan was adopted by our board of directors in November 2017 and was subsequently approved by our stockholders. No further awards will be made under the 2015 Plan after this offering; however, awards outstanding
under the 2015 Plan will continue to be governed by their existing terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share Reserve</I>. As of December&nbsp;31, 2017, we have
reserved&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock for issuance under the 2015 Plan, all of which may be issued as incentive stock options. As of December&nbsp;31, 2017, options to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, at exercise prices ranging from
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, or a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share were outstanding under the 2015 Plan,
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock remained available for future issuance. Unissued shares subject to awards that expire or are cancelled, shares reacquired by us and shares
withheld in payment of the purchase price or exercise price of an award or in satisfaction of withholding taxes will again become available for issuance under the 2015 Plan or, following consummation of this offering, under our 2018 Equity Incentive
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. Our board of directors has administered the 2015 Plan since its adoption; however, following this offering, the compensation
committee of our board of directors will generally administer the 2015 Plan. The administrator has complete discretion to make all decisions relating to the 2015 Plan and outstanding awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. Employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors and consultants are eligible to
participate in the 2015 Plan. However, only employees are eligible to receive incentive stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Types of Awards</I>. The 2015 Plan provides for
the grant of options to purchase shares of our common stock and the direct grant or sale of shares of our common stock. The 2015 Plan allows for the grant of both incentive and nonstatutory stock options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Options</I>. The exercise price of options granted under the 2015 Plan may not be less than 100% of the fair market value of our common stock on the grant
date. Optionees may pay the exercise price in cash or cash equivalents or by one, or any combination of, the following forms of payment, as permitted by the administrator in its sole discretion: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">By delivery of a full-recourse promissory note, with the option shares pledged as security against the principal and accrued interest on the note; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">By surrender of shares of common stock that the optionee already owns; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">By an immediate sale through a company-approved broker of the option shares, if shares of our common stock are publicly traded; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">By surrendering a number of vested shares subject to the option having an aggregate fair market value no greater than the aggregate exercise price, or the sum of such exercise price plus all or a portion of the minimum
amount required to be withheld under applicable law; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">By other methods permitted by applicable law. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options vest as determined by the administrator. In general, we
have granted options that vest over a four-year period. Options expire at the time determined by the administrator, but in no event more than ten years after they are granted, and generally expire earlier if the optionee&#146;s service terminates.
We typically have granted options that are immediately exercisable, subject to our right to repurchase unvested shares upon termination of an optionee&#146;s service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Shares</I>. Restricted shares may be awarded or sold under the 2015 Plan in return for cash or cash equivalents or, as permitted by the
administrator in its sole discretion, in exchange for services rendered to us, by delivery of a full-recourse promissory note or through any other means permitted by applicable law. Restricted shares vest as determined by the administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. In the event that we are a party to a merger or consolidation or in the event of a sale of all or substantially all of our
stock or assets, all shares acquired under the 2015 Plan and all options and other plan awards outstanding on the effective date of the transaction will be subject to the agreement governing such transaction or, in the absence of such agreement, in
the manner determined by the administrator. Such treatment may include, without limitation, one or more of the following with respect to outstanding awards: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The continuation, assumption or substitution of an award by the surviving entity or its parent; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cancellation of the vested portion of the award in exchange for a <FONT STYLE="white-space:nowrap">per-share</FONT> payment equal to the excess, if any, of the value of the property received by a holder of a share of
our common stock as a result of the transaction over any exercise price per share applicable to the award; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cancellation of the award without payment of any consideration. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The administrator is not obligated to treat
all awards in the same manner. The administrator has the discretion, at any time, to provide that an award granted under the 2015 Plan will vest on an accelerated basis if we are subject to a change of control or if the participant is subject to an
involuntary termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes in Capitalization</I>. In the event of certain specified changes in the capital structure of our common stock, such
as a stock split, reverse stock split, stock dividend, reclassification or any other increase or decrease in the number of issued shares of stock effective without receipt of consideration by us, proportionate adjustments will automatically be made
in (i)&nbsp;each of the number and kind of shares available for future grants under the 2015 Plan, (ii)&nbsp;the number and kind of shares covered by each outstanding award, (iii)&nbsp;the exercise or purchase price per share subject to each
outstanding award and (iv)&nbsp;any repurchase price applicable to shares acquired under the 2015 Plan. In the event of an extraordinary cash dividend that has a material effect on the fair market value of our common stock, a recapitalization, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> or other similar occurrence, the administrator at its sole discretion may make appropriate adjustments to one or more of the items described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendments or Termination</I>. The administrator may at any time amend, suspend or terminate the 2015 Plan, subject to stockholder approval in the case of
an amendment if the amendment increases the number of shares available for issuance or materially changes the class of persons eligible to receive incentive stock options. The 2015 Plan will terminate automatically 10 years after the later of the
date when our board of directors adopted the 2015 Plan or approved the latest share increase that was also approved by our stockholders and in any event, it will terminate upon completion of this offering, but as noted above, awards outstanding
under the 2015 Plan will remain outstanding and will continue to be governed by their existing terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Employee Stock Purchase Plan
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General</I>.<I> </I>Our board of directors adopted the 2018 Employee Stock Purchase Plan (ESPP)
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018, and expect our stockholders to approve it prior to completion of this offering. The ESPP allows eligible employees to
purchase shares of our common stock through payroll deductions and is intended to qualify under Section&nbsp;423 of the Internal Revenue Code. It will become effective as of the effective date of the registration statement of which this prospectus
is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share Reserve</I>.<I> </I>We have reserved&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock for issuance under the ESPP. The number of shares reserved for issuance under the ESPP will automatically increase on the first day of each fiscal year during the term of the ESPP, commencing in 2019, by a number of shares equal to the
least of (i)&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding shares of common stock on the last business day of the prior fiscal year, (ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares or (iii)&nbsp;a number of
shares determined by our board of directors. The number and class of shares reserved under the ESPP will be adjusted automatically in the event of a stock split, stock dividend or other changes in our capitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration</I>.&nbsp;Our board of directors or its compensation committee will administer the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>.<I> </I>All of our employees or of any participating subsidiary are eligible to participate in the ESPP if they satisfy the eligibility
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Offering Periods</I>.<I> </I>Each offering period will last a number of months determined by the administrator, up to a maximum of 27
months. A new offering period will begin periodically, as determined by the compensation committee. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Offering periods may overlap or may be consecutive. Unless otherwise
determined by the compensation committee,&nbsp;offering periods of six months&#146; duration will begin in each year on May&nbsp;1 and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
November 1. However, if so determined by the compensation committee, the first offering period may start on the effective date of the registration statement related to this offering and will end
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with the first purchase date occurring on or about such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amount
of Contributions</I>.<I> </I>Participants may purchase our common stock through payroll deductions, up to a maximum of 15% of their eligible compensation. Each participant may purchase up to the number of shares determined by our administrator on
any purchase date, not to exceed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. The value of the shares purchased in any calendar year may not exceed $25,000. Participants may withdraw from the ESPP and
receive a refund of their accumulated payroll contributions at any time prior to a purchase date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase Price</I>.<I> </I>Unless changed by the
administrator, the purchase price for each share of our common stock purchased under the ESPP will be 85% of the lower of the fair market value per share on the first day of the applicable offering period (or, in the case of the initial offering
period, the price at which one share of common stock is offered to the public in this offering) or the fair market value per share on the applicable purchase date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>.<I> </I>In the event of certain corporate transactions, any offering periods then in progress may be continued, assumed or
substituted for by the acquiring corporation. If the acquiring corporation refuses to do so, a new purchase date will be set for each offering period prior to the effective time of the transaction and such offering periods will terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment or Termination</I>.<I> </I>The administrator may amend, suspend or terminate the ESPP at any time. If not sooner terminated, the ESPP will
automatically terminate in 2038. With the exception of increasing the number of shares reserved for issuance, shareholder approval is generally not required for any amendment of the ESPP unless required by applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_14"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of transactions since our incorporation on April&nbsp;30, 2015 to which we have been a party in which the amount involved
exceeded $120,000 and in which any of our executive officers, directors or beneficial holders of more than 5% of our capital stock had or will have a direct or indirect material interest, other than compensation arrangements which are described in
&#147;Management&#151;Director Compensation&#148; and &#147;Executive Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale of Series A Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;29, 2015, we entered into a Series A preferred stock purchase agreement pursuant to which we issued, in a series of closings in May 2015, August
2015 and September 2015, an aggregate of 49,725,000 shares of our Series A preferred stock at a cash purchase price of $1.00 per share to accredited investors for an aggregate purchase price of $49,725,000. Each share of our Series A preferred stock
will convert automatically into one share of our common stock immediately prior to the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes
purchases of shares of our Series A preferred stock by our executive officers, directors and holders of more than 5% of our capital stock: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;A</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:35.10pt; font-size:8pt; font-family:Times New Roman"><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Gross&nbsp;Cash<BR>Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with Terry Rosen, Ph.D.<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with Juan Carlos Jaen, Ph.D.<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foresite Capital Fund III, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with The Column Group II, L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with Yasunori Kaneko<SUP
STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 9,000,000 shares of Series A preferred stock purchased by The Rosen 1996 Family Trust Dated June&nbsp;28, 1996. Dr.&nbsp;Terry Rosen, our chief executive officer and a member of our board of directors, is
the trustee, beneficiary and/or otherwise affiliated with the foregoing stockholder. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 8,000,000 shares of Series A preferred stock purchased by Juan Carlos Jaen and Anita Galeana, Trustees of the Juan Carlos Jaen and Anita Galeana 2000 Trust. Dr.&nbsp;Juan Carlos Jaen, our president and a
member of our board of directors, is the trustee, beneficiary and/or otherwise affiliated with the foregoing stockholder. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Foresite Capital Fund III, L.P. holds more than 5% of our capital stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Entities and individuals affiliated with The Column Group II, L.P. holds more than 5% of our capital stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 3,000,000 shares of Series A preferred stock purchased by Yasunori Kaneko and Yumi Kaneko, Trustees of the Kaneko Family Trust U/D/T dated January&nbsp;20, 1992. Dr.&nbsp;Yasunori Kaneko, a member of our
board of directors, is affiliated with the foregoing stockholder. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale of Series B Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;15, 2016, we entered into a Series B preferred stock purchase agreement pursuant to which we issued, in a series of closings in August 2016, an
aggregate of 34,653,462 shares of our Series B preferred stock at a cash purchase price of $2.02 per share to accredited investors for an aggregate purchase price of approximately $69,999,993. Each share of our Series B preferred stock will convert
automatically into one share of our common stock immediately prior to the completion of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes purchases of shares of our Series B preferred stock by our executive
officers, directors and holders of more than 5% of our capital stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;B</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:35.10pt; font-size:8pt; font-family:Times New Roman"><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Gross&nbsp;Cash<BR>Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with Terry Rosen, Ph.D.<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">495,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with Juan Carlos Jaen, Ph.D.<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">495,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foresite Capital Fund III, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,950,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with The Column Group II, L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,465,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with Yasunori Kaneko<SUP
STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">249,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliates with GV 2016,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,376,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,905,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 495,050 shares of Series B preferred stock purchased by The Rosen 1996 Family Trust Dated June&nbsp;28, 1996. Dr.&nbsp;Terry Rosen, our chief executive officer and a member of our board of directors, is the
trustee, beneficiary and/or otherwise affiliated with the foregoing stockholder. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 495,050 shares of Series B preferred stock purchased by Juan Carlos Jaen and Anita Galeana, as trustees of the Juan Carlos Jaen and Anita Galeana 2000 Trust. Dr.&nbsp;Juan Carlos Jaen, our president and a
member of our board of directors, is the trustee, beneficiary and/or otherwise affiliated with the foregoing stockholder. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Foresite Capital Fund III, L.P. holds more than 5% of our capital stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Entities and individuals affiliated with The Column Group II, LP holds more than 5% of our capital stock. Consists of 3,465,347&nbsp;shares of Series&nbsp;B preferred stock purchased by The Column Group II, L.P.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 123,762 shares of Series B preferred stock purchased by Yasunori Kaneko and Yumi Kaneko, Trustees of the Kaneko Family Trust U/D/T dated January&nbsp;20, 1992. Dr.&nbsp;Yasunori Kaneko, a member of our board
of directors, is the trustee, beneficiary and/or otherwise affiliated with the foregoing stockholder. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Entities and individuals affiliates with GV 2016, L.P. GV 2016, L.P. holds more than 5% of our capital stock. Consists of 12,376,238&nbsp;shares of Series&nbsp;B preferred stock purchased by GV 2016, L.P.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale of Series C Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
November&nbsp;3, 2017, we entered into a Series C preferred stock purchase agreement pursuant to which we issued, in a series of closings in November 2017 an aggregate of 36,241,698 shares of our Series C preferred stock at a cash purchase price of
$2.9524 per share to accredited investors for an aggregate purchase price of approximately $106,999,989. Each share of our Series C preferred stock will convert automatically into one share of our common stock immediately prior to the completion of
this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes purchases of shares of our Series C preferred stock by our executive officers, directors and holders of
more than 5% of our capital stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;C</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:35.10pt; font-size:8pt; font-family:Times New Roman"><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Gross&nbsp;Cash<BR>Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with Terry Rosen, Ph.D.<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">969,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with Juan Carlos Jaen, Ph.D.<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">350,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foresite Capital Fund III, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,693,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,999,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with The Column Group II, L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,556,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with Yasunori Kaneko<SUP
STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with GV 2016,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,620,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,500,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with Kathryn Falberg<SUP
STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,395,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,549,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 328,546 shares of Series C preferred stock held by The Rosen 1996 Family Trust Dated June&nbsp;28, 1996. Dr.&nbsp;Terry Rosen, our chief executive officer and a member of our board of directors, is the
trustee, beneficiary and/or otherwise affiliated with the foregoing stockholder. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 118,548 shares of Series C preferred stock held by Juan Carlos Jaen and Anita Galeana, as trustees of the Juan Carlos Jaen and Anita Galeana 2000 Trust. Dr.&nbsp;Juan Carlos Jaen, our president and a member
of our board of directors, is the trustee, beneficiary and/or otherwise affiliated with the foregoing stockholder. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Foresite Capital Fund III, L.P. holds more than 5% of our capital stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Entities and individuals affiliated with The Column Group II, L.P. holds more than 5% of our capital stock. Consists of 1,693,537 shares of Series C preferred stock held by The Column Group II, L.P. and
1,862,892&nbsp;shares of Series C preferred stock held by Ponoi Capital, L.P. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 10,161 shares of Series C preferred stock purchased by Yasunori Kaneko and Yumi Kaneko, Trustees of the Kaneko Family Trust U/D/T dated January&nbsp;20, 1992. Dr.&nbsp;Yasunori Kaneko, a member of our board
of directors, is the trustee, beneficiary and/or otherwise affiliated with the foregoing stockholder. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Entities and individuals affiliated with GV 2016, L.P. holds more than 5% of our capital stock. Consists of 7,620,919 shares of Series C preferred stock held by GV 2017, L.P. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 67,741 shares of Series C preferred stock held by Kathryn E. Falberg, trustee of the Falberg-Redovich Family Trust dtd 6-11-12. Ms. Falberg, a member of our board of directors, is the trustee, beneficiary
and/or otherwise affiliated with the foregoing stockholder. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with PACT Pharma, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2016, we purchased approximately 3.6&nbsp;million shares of common stock of PACT Pharma, Inc. (PACT Pharma), a privately funded, early-stage
biopharmaceutical company focused on adoptive cell therapy, for a nominal amount. In December 2016, we and PACT Pharma entered into a Master Services Agreement (the PACT Agreement) under which we provide PACT Pharma with general and administrative
support, including finance, human resources, legal, and other operational support. We also received certain warrants to purchase PACT Pharma common stock exercisable upon PACT Pharma&#146;s achievement of certain valuation thresholds pursuant to the
PACT Agreement. Also in December 2016, we purchased 1.0&nbsp;million shares of Series A preferred stock of PACT Pharma for $1.0&nbsp;million. After this investment, we owned an aggregate of approximately 12% of the total equity of PACT Pharma on an
as-converted basis. As part of our support under the PACT Agreement, Dr.&nbsp;Terry Rosen, our Chief Executive Officer and a member of our board of directors, previously served as Chief Executive Officer of PACT Pharma on an interim basis.
Dr.&nbsp;Juan Carlos Jaen, our President and a member of our board of directors, previously served as President of PACT Pharma on an interim basis. Dr.&nbsp;Rosen and Dr.&nbsp;Jaen are also minority stockholders and members of the board of directors
of PACT Pharma. The PACT Agreement will terminate no later than December&nbsp;31, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amended and Restated Voting Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;3, 2017, we entered into an amended and restated voting agreement with certain holders of our common stock and the holders of our preferred
stock, including entities with which our chief executive officer, president and certain of our directors are affiliated, with respect to the election of our directors and certain other matters. All of our current directors were elected pursuant to
the terms of this agreement. The amended and restated voting agreement will terminate upon the completion of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amended and Restated First
Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;3, 2017, we entered into an amended and restated first refusal
and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement with holders of our common stock and holders of our preferred stock, including entities with which our chief executive officer, president and certain of our directors are affiliated. This
agreement provides the holders of preferred stock a right of purchase and of <FONT STYLE="white-space:nowrap">co-sale</FONT> in respect of sales of securities by certain holders of our common stock. The rights of purchase and <FONT
STYLE="white-space:nowrap">co-sale</FONT> will terminate upon the completion of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amended and Restated Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;3, 2017, we entered into an amended and restated investors&#146; rights agreement with holders of our preferred stock, including entities with
which our chief executive officer, president and certain of our directors are affiliated. These stockholders are entitled to rights with respect to the registration of their shares following this offering under the Securities Act. For a description
of these registration rights, see &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management Rights Letters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our sale of our preferred stock, we entered into management rights letters with certain purchasers of our preferred stock, including holders
of more than 5% of our capital stock and entities with which certain of our directors are affiliated, pursuant to which such entities were granted certain management rights, including the right to consult with and advise our management on
significant business issues, review our operating plans, examine our books and records and inspect our facilities. These management rights will terminate upon completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated
certificate of incorporation, which will be effective upon the completion of this offering, will contain provisions limiting the liability of directors, and our amended and restated bylaws, which will be effective upon the completion of this
offering, will provide that we will indemnify each of our directors to the fullest extent permitted under Delaware law. Our amended and restated certificate of incorporation and amended and restated bylaws will also provide our board of directors
with discretion to indemnify our officers and employees when determined appropriate by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to enter into indemnification
agreements with each of our directors and executive officers and certain other key employees. The indemnification agreements will provide that we will indemnify each of our directors, executive officers and such other key employees against any and
all expenses incurred by that director, executive officer or other key employee because of his or her status as one of our directors, executive officers or other key employees, to the fullest extent permitted by Delaware law, our amended and
restated certificate of incorporation and our amended and restated bylaws. In addition, the indemnification agreements will provide that, to the fullest extent permitted by Delaware law, we will advance all expenses incurred by our directors,
executive officers and other key employees in connection with a legal proceeding involving his or her status as a director, executive officer or key employee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audit committee has the primary responsibility for the review, approval and oversight of any &#147;related party transaction,&#148; which is any
transaction, arrangement or relationship (or series of similar transactions, arrangements, or relationships) in which we are, were or will be a participant and the amount involved exceeds $120,000, and in which the related person has, had or will
have a direct or indirect material interest. We intend to adopt a written related party transaction policy to be effective upon the completion of this offering. Under our related party transaction policy, our management will be required to submit
any related person transaction not previously approved or ratified by our audit committee to our audit committee. In approving or rejecting the proposed transactions, our audit committee will take into account all of the relevant facts and
circumstances available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of our common stock as of December&nbsp;1, 2017, and as adjusted
to reflect the sale of common stock offered by us in this offering, for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our named executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our executive officers and directors as a group; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each stockholder known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the Securities and Exchange Commission. Except as indicated in the footnotes below, we
believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of common stock that they beneficially own, subject to applicable community
property laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applicable percentage ownership is based on 136,808,355 shares of common stock outstanding at December&nbsp;1, 2017, after giving effect
to the conversion of all outstanding shares of preferred stock as of that date into an aggregate of 120,620,160 shares of our common stock. For purposes of computing percentage ownership after this offering, we have assumed that
(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock will be issued by us in this offering; and (ii)&nbsp;that the underwriters will not exercise their option to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares in full. In computing the number of shares of common stock beneficially owned by a person or entity and the percentage ownership of that
person or entity, we deemed to be outstanding all shares of common stock subject to options held by that person or entity that are currently exercisable or that will become exercisable within 60 days of December&nbsp;1, 2017. We did not deem these
shares outstanding, however, such shares were included for the purpose of computing the percentage ownership of any other person or entity. Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Arcus
Biosciences, Inc., 3928 Point Eden Way, Hayward, CA 94545. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number Of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent Of Shares<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:89.90pt; font-size:8pt; font-family:Times New Roman"><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before&nbsp;The<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After&nbsp;The<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terry Rosen, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,403,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Juan Carlos Jaen, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,138,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Jarrett<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,040,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yasunori Kaneko, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,283,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kathryn Falberg<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Executive Officers and Directors as a Group (five persons)<SUP
STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,033,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with GV 2016,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,997,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities and individuals affiliated with The Column Group II, L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,021,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foresite Capital Fund III, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,644,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 250,000 shares of common stock held by Terry Rosen, (ii) 9,803,596 shares of common stock upon the deemed conversion of our preferred stock held by The Rosen 1996 Family Trust Dated June&nbsp;28, 1996
and (iii) 5,350,000 shares of common stock held by The Rosen 1996 Family Trust Dated June&nbsp;28, 1996. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 250,000 shares of common stock held by Juan Jaen, (ii) 8,613,598&nbsp;shares of common stock upon the deemed conversion of our preferred stock held by Juan Carlos Jaen and Anita Galeana, as trustees of
the Juan Carlos Jaen and Anita Galeana 2000 Trust and (iii) 4,275,000 shares of common stock held by Juan Carlos Jaen and Anita Galeana, as trustees of the Juan Carlos Jaen and Anita Galeana 2000 Trust. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,040,000 shares of common stock underlying options held by Jennifer Jarrett that are exercisable as of December&nbsp;1, 2017 or will become exercisable within 60 days after such date. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 100,000 shares of common stock held by Kaneko Family Trust dated January&nbsp;20, 1992, (ii) 50,000 shares of common stock held by Yasunori Kaneko&nbsp;&amp; Yumi Kaneko, Trustees of The Kaneko Family
Trust dated January&nbsp;20, 1992, (iii) 2,000,000 shares of common stock upon the deemed conversion of our preferred stock held by Kaneko Capital, LLC, (iv) 1,000,000 shares of common stock upon the deemed conversion of our preferred stock held by
Kaneko Investments, LLC, (v) 133,923 shares of common stock upon the deemed conversion of our preferred stock held by Yasunori Kaneko and Yumi Kaneko, Trustees of the Kaneko Family Trust U/D/T dated January&nbsp;20, 1992. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 100,000 shares of common stock held by Kathryn Falberg and (ii) 67,741 shares of common stock upon the deemed conversion of our preferred stock held by Kathryn E. Falberg, trustee of the
Falberg-Predovich Family Trust dtd <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">6-11-12.</FONT></FONT> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Includes 1,040,000 shares of common stock underlying options that are exercisable as of December&nbsp;1, 2017 or will become exercisable within 60 days after such date. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 12,376,238 shares of Series B Preferred Stock held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC,
the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. The
principal business address of GV 2016, L.P., GV 2016 GP, L.P., GV 2016 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc. is 1600 Amphitheatre Parkway, Mountain View, CA 94043. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 7,620,919 shares of Series C Preferred Stock held by GV 2017, L.P. GV 2017 GP, L.P., the general partner of GV 2017, L.P. GV 2017 GP, L.L.C., the general partner of GV 2017 GP, L.P., Alphabet Holdings LLC,
the sole member of GV 2017 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., GV 2017 GP, L.P., GV 2017 GP, L.L.C. may each be deemed to have sole power to
vote or dispose of these shares. The principal business address of GV 2017, L.P., GV 2017 GP, L.P., GV 2017 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and Alphabet Inc. is 1600 Amphitheatre Parkway, Mountain View, CA 94043.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 14,021,776 shares of common stock upon the deemed conversion of our preferred stock held by The Column Group II, LP and Ponoi Capital, LP. The Column Group II GP, LP is the general partner of The Column
Group II, LP. Ponoi Management, LLC is the general partner of Ponoi Capital, LP. The managing partners of The Column Group II GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group, LLC and Ponoi Management, LLC are
David Goeddel, Peter Svennilson, and Tim Kutzley. The managing partners of The Column Group II GP, LP and Ponoi Management, LLC may be deemed to have voting and investment power with respect to such shares. The address of The Column Group II, LP and
Ponoi Capital, LP is 1700 Owens Street, Suite 500, San Francisco, California 94158. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 13,644,032 shares of common stock upon the deemed conversion of our preferred stock held by Foresite Capital Fund III, L.P. (FCF III). Foresite Capital Management III, LLC (FCM III) is the general partner of
FCF III. The managing director of FCM III, James Tananbaum, may be deemed to have voting and investment power with respect to such shares. The address of FCF III is c/o Foresite Capital Management, LLC, 101 California Street, Suite 4100, San
Francisco, California 94111. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A description of our capital stock and the material terms and provisions of our amended and restated certificate of incorporation and amended and restated
bylaws that will be in effect upon the completion of this offering and affecting the rights of holders of our capital stock is set forth below. The forms of our amended and restated certificate of incorporation and our amended and restated bylaws to
be adopted in connection with this offering are filed as exhibits to the registration statement relating to this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this
offering, our amended and restated certificate of incorporation will authorize shares of undesignated preferred stock, the rights, preferences and privileges of which may be designated from time to time by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our authorized capital stock will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, all with a par value of $0.0001 per share, of which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares are designated common stock; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares are designated preferred stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;1, 2017, after giving effect to the conversion of all outstanding shares of preferred stock into an aggregate of 120,620,160 shares of our
common stock, there were outstanding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">136,808,355 shares of our common stock held of record by 197 stockholders, including 7,443,414 shares of restricted common stock that are subject to our right of repurchase; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,071,741 shares of our common stock issuable upon exercise of outstanding stock options. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to preferences
that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to
issue dividends and only then at the times and in the amounts that our board of directors may determine. See &#147;Dividend Policy&#148; for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of our common stock are
entitled to one vote per share. Stockholders do not have the ability to cumulate votes for the election of directors. Our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect upon the completion of
this offering will provide for a classified board of directors consisting of three classes of approximately equal size, each serving staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders,
with the other classes continuing for the remainder of their respective three-year terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Preemptive or Similar Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is not entitled to preemptive rights and is not subject to conversion, redemption or sinking fund provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right to Receive Liquidation Distributions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon
our dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the assets legally available for distribution to our stockholders are distributable ratably among the holders of our common stock, subject to prior satisfaction of
all outstanding debt and liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding shares of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, no shares of preferred stock will be outstanding, but we will be authorized, subject to limitations prescribed by
Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any
associated qualifications, limitations or restrictions. Our board of directors also can increase or decrease the number of shares of any series, but not below the number of shares of that series then outstanding, without any further vote or action
by our stockholders. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred
stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and may adversely affect the
market price of our common stock and the voting and other rights of the holders of common stock. We have no current plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;1, 2017, there were options
to purchase 2,071,741 shares of our common stock outstanding under our 2015 Stock Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, the holders of 120,620,160 shares of our common stock issued upon the conversion of our preferred stock will be
entitled to contractual rights to require us to register those shares under the Securities Act. These registration rights are provided under the terms of our amended and restated investors&#146; rights agreement between us and the holders of these
shares, which was entered into on November&nbsp;3, 2017. Pursuant to this agreement, trusts associated with our Chief Executive Officer and director, Dr.&nbsp;Rosen, and our President and director, Dr.&nbsp;Jaen, are entitled to the piggyback
registration rights described below with respect to their shares of outstanding common stock not issued upon the conversion of our preferred stock, but are not entitled to either the demand or Form <FONT STYLE="white-space:nowrap">S-3</FONT>
registration rights described below with respect to such shares of common stock. These trusts collectively held 9,625,000 shares of such outstanding common stock as of December&nbsp;1, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay all expenses relating to any demand, piggyback or Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration described below, other than
underwriting discounts and commissions. The registration rights terminate upon the earliest to occur of: (i)&nbsp;the fourth anniversary of the completion of this offering; (ii)&nbsp;a liquidation event; or (iii)&nbsp;with respect to the
registration rights of an individual holder, such earlier time after this offering at which the holder (a)&nbsp;can sell all of its shares in compliance with Rule 144(b)(1)(i) or (b)&nbsp;holds one percent or less of our outstanding common stock and
all shares held by the holder can be sold in any three-month period without registration in compliance with Rule 144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the registrable securities will be entitled to certain demand registration rights. At any time beginning on the earlier of
November&nbsp;3, 2022 or six months following the effectiveness of this offering, the holders of 50% or more of the registrable securities then outstanding may make a written request that we register some or all of their registrable securities,
subject to certain specified conditions and exceptions. We are required to use commercially reasonable efforts to effect the registration and will pay all registration expenses, other than underwriting discounts and commissions, related to any
demand registration. Such request for registration must cover securities with an aggregate offering price of at least $20,000,000. We are not obligated to effect more than two of these registrations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this offering, holders of our registrable securities were entitled to, and the necessary percentage of holders waived, their rights to
notice of this offering and to include their registrable securities in this offering. If we propose to register any of our securities under the Securities Act either for our own account or for the account of other stockholders in another offering,
the holders of shares having registration rights will, subject to certain exceptions, be entitled to include their shares in our registration statement, provided that the underwriters of any such offering have the right to limit the number of shares
included in the registration. These registration rights are subject to specified other conditions and limitations as set forth in our amended and restated investors&#146; rights agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At any time after we are qualified to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> and subject to limitations and
conditions specified in the amended and restated investors&#146; rights agreement, the holders of 30% or more of the registrable securities then outstanding may make a written request that we prepare and file a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the Securities Act covering their shares, so long as the aggregate price to the public is at least $10,000,000. We are not obligated to effect more than two of these Form
<FONT STYLE="white-space:nowrap">S-3</FONT> registrations in any <FONT STYLE="white-space:nowrap">12-month</FONT> period or more than a total of three of these Form <FONT STYLE="white-space:nowrap">S-3</FONT> registrations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, we will be governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law regulating corporate
takeovers. This section prevents some Delaware corporations from engaging, under some circumstances, in a business combination, which includes a merger or sale of at least 10% of the corporation&#146;s assets with any interested stockholder, meaning
a stockholder who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of the corporation&#146;s outstanding voting stock, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the transaction is approved by the board of directors prior to the time that the interested stockholder became an interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon closing of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction began, excluding for purposes of determining the voting stock outstanding those shares owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans in which employee participants do not have the right
to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subsequent to such time that the stockholder became an interested stockholder the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders by at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Delaware
corporation may &#147;opt out&#148; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or amended and restated bylaws resulting from a
stockholders&#146; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certificate of Incorporation and Bylaw Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our amended and restated certificate of incorporation and our amended and restated bylaws will include a number of
provisions that may have the effect of deterring hostile takeovers or delaying or preventing changes in control of our management team, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Board of Directors Vacancies.</I> Our amended and restated certificate of incorporation and amended and restated bylaws will authorize our board of directors to fill vacant directorships, including newly-created
seats. In addition, the number of directors constituting our board of directors will be set only by resolution adopted by a majority vote of our entire board of directors. These provisions will prevent a stockholder from increasing the size of our
board of directors and gaining control of our board of directors by filling the resulting vacancies with its own nominees. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Classified Board.</I> Our amended and restated certificate of incorporation and amended and restated bylaws will provide that our board of directors will be classified into three classes of directors, each of which
will hold office for a three-year term. In addition, directors may only be removed from the board of directors for cause and only by the approval of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our then-outstanding shares of our common stock. A third party may
be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Stockholder Action; Special Meeting of Stockholders.</I> Our amended and restated certificate of incorporation will provide that stockholders will not be able to take action by written consent, and will only be able
to take action at annual or special meetings of our stockholders. Stockholders will not be permitted to cumulate their votes for the election of directors. Our amended and restated bylaws will further provide that special meetings of our
stockholders may be called only by a majority vote of our entire board of directors, the chairman of our board of directors or our chief executive officer. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Advance Notice Requirements for Stockholder Proposals and Director Nominations.</I> Our amended and restated bylaws will provide advance notice procedures for stockholders seeking to bring business before our annual
meeting of stockholders, or to nominate candidates for election as directors at any meeting of stockholders. Our amended and restated bylaws will also specify certain requirements regarding the form and content of a stockholder&#146;s notice. These
provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our meetings of stockholders. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Issuance of Undesignated Preferred Stock.</I> Our board of directors will have the authority, without further action by the holders of common stock, to issue up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by the board of directors. The existence
of authorized but unissued shares of preferred stock will enable our board of directors to render more difficult or discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering,
our amended and restated certificate of incorporation will provide that the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of
fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim against us
that is governed by the internal affairs doctrine. The enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find
these types of provisions in our certificate of incorporation to be inapplicable or unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, the transfer agent and registrar for our common stock will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . The transfer agent&#146;s address is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and its telephone number is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to apply to list our common stock on the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; under the symbol &#147;RCUS.&#148;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before this offering, there has not been a public market for shares of our common stock. Future sales of substantial amounts of shares of our common stock,
including shares issued upon the exercise of outstanding options, in the public market following this offering or the possibility of these sales occurring, could cause the prevailing market price for our common stock to fall or impair our ability to
raise equity capital in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following this offering, we will have
outstanding&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, based on the number of shares outstanding as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . This
includes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that we are selling in this offering, which shares may be resold in the public market immediately unless purchased by our affiliates,
and assumes no additional exercise of outstanding options other than as described elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
remaining&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that are not sold in this offering will be &#147;restricted securities,&#148; as that term is defined in Rule 144 under the
Securities Act of 1933, as amended. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule 144 or Rule 701 under the Securities
Act, which are summarized below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we, our executive officers and directors, and substantially all of our security holders have entered into
market standoff agreements with us or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters under which they have agreed, subject to specific exceptions, not to sell any of our capital stock until at least 181&nbsp;days
after the date of this prospectus, as described below. As a result of these agreements and the provisions of our investors&#146; rights agreement disclosed in &#147;Description of Capital Stock&#151;Registration Rights,&#148; subject to the
provisions of Rule&nbsp;144 or Rule&nbsp;701, based on an assumed offering date of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2018,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be available for sale in the public market as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">beginning on the date of this prospectus, the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares sold in this offering will be immediately available for sale in the public market,
unless purchased by our affiliates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">beginning 181&nbsp;days after the date of this prospectus,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares will become eligible for sale in the public market, of
which&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be held by affiliates and subject to the volume and other restrictions of Rule&nbsp;144, as described below; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the remainder of the shares will be eligible for sale in the public market from time to time thereafter, subject in some cases to the volume and other restrictions of Rule&nbsp;144, as described below.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, under Rule 144
as currently in effect, a person who has beneficially owned shares of our restricted common stock for at least six months would be entitled to sell their securities provided that such person is not deemed to have been one of our affiliates at the
time of, or at any time during the 90 days preceding, a sale, and we are subject to the periodic reporting requirements of the Exchange Act, for at least 90 days before the sale. In addition, under Rule 144, any person who is not an affiliate of
ours and has held their shares for at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited number of shares immediately upon the completion of this offering without
regard to whether current public information about us is available. Persons who have beneficially owned shares of our restricted common stock for at least six months but who are our affiliates at the time of, or any time during the 90 days
preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of common shares then outstanding, which will equal approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares immediately after this
offering assuming no exercise of the underwriters&#146; option to purchase additional shares, based on the number of common shares outstanding as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume of our common shares during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, in each case, that we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales both by
affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and notice provisions of Rule 144. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of our service providers who purchased
shares under a written compensatory plan or contract prior to this offering may be entitled to rely on the resale provisions of Rule 701. Rule 701, as currently in effect, permits resales of shares, including by affiliates, in reliance upon Rule 144
but without compliance with certain restrictions, including the holding period requirement, of Rule 144. Rule 701 further provides that <FONT STYLE="white-space:nowrap">non-affiliates</FONT> may sell such shares in reliance on Rule 144 without
having to comply with the public information, volume limitation or notice provisions of Rule 144. All holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling such shares if such resale is
pursuant to Rule 701. All Rule 701 shares are, however, subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and will only become eligible for sale upon the expiration of these <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this offering, we and all directors and officers and the holders of substantially all of our outstanding stock and stock options have agreed
with the underwriters, subject to certain exceptions, not to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise
transfer or dispose of, directly or indirectly, shares of our common stock or any securities convertible into or exchangeable for shares of our common stock or enter into any swap or other arrangement that transfers to another any of the economic
consequences of ownership of our common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of the Company or the underwriters. These
agreements are subject to certain exceptions, as set forth in &#147;Underwriting.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of our employees, including our executive officers, and
directors may enter into written trading plans that are intended to comply with Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act. Sales under these trading plans would not be permitted until the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements relating to our initial public offering described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, the holders of 120,620,160 shares of our common stock will be entitled to rights with respect to the registration of the sale
of such shares of common stock under the Securities Act. An additional 9,625,000 shares of our common stock will be entitled to piggyback but not demand or <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights. See &#147;Description of
Capital Stock&#151;Registration Rights.&#148; All such shares are covered by <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. Following the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, registration of these
shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to file a registration statement
on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act covering all of the shares of our common stock subject to options outstanding or reserved for issuance under our equity plans. We expect to file this registration statement
as soon as practicable after the completion of this offering. This registration statement will become effective immediately upon filing, and shares covered by this registration statement will thereupon be eligible for sale in the public markets,
subject to vesting restrictions, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above and Rule 144 limitations applicable to affiliates. For a more complete discussion of our stock plans, see &#147;Executive
Compensation&#151;Equity Plans.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a general discussion of the material U.S. federal income tax considerations applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering. For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial
owner of our common stock (other than an entity or arrangement that is treated as a partnership for U.S. federal income tax purposes) that is not, for U.S. federal income tax purposes, any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized in the United States or under the laws of the United States, any state thereof or the District of
Columbia; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate, the income of which is includable in gross income for U.S. federal income tax purposes regardless of its source; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust if (i)&nbsp;a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of
the trust or (ii)&nbsp;such trust has made a valid election to be treated as a U.S. person for U.S. federal income tax purposes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
discussion is based on current provisions of the U.S. Internal Revenue Code of 1986 (the Code) existing and proposed U.S. Treasury Regulations promulgated thereunder, judicial opinions, published positions of the Internal Revenue Service (IRS) and
other applicable authorities, all of which are subject to change or to differing interpretation, possibly with retroactive effect. This discussion assumes that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds shares of our common
stock as a capital asset (generally, property held for investment) for U.S. federal income tax purposes. This discussion does not address the tax considerations arising under the laws of any <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> state or
local jurisdiction, or, except to the limited extent provided below, under U.S. federal estate and gift tax laws. This discussion also does not consider any specific facts or circumstances that may apply to a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">banks, insurance companies or other financial institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">corporations that accumulate earnings to avoid U.S. federal income tax; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons subject to the alternative minimum tax or the Medicare contribution tax; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities (including private foundations) or <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">controlled foreign corporations or passive foreign investment companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who acquired our common stock as compensation for services; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">dealers in securities or currencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">traders in securities that elect to use a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for their securities holdings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that own, or are deemed to own, more than five percent of our capital stock (except to the extent specifically set forth below); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain former citizens or long term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who hold our common stock as a position in a hedging transaction, &#147;straddle,&#148; &#147;conversion transaction,&#148; or other risk reduction transaction; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our common stock under the constructive sale provisions of the Code. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, this discussion does not address the tax treatment of partnerships or other entities that are
pass-through entities for U.S. federal income tax purposes or persons who hold our common stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should
consult his, her or its own tax advisor regarding the tax consequences of the ownership and disposition of our common stock through a partnership or other pass-through entity, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTORS CONSIDERING THE PURCHASE OF OUR COMMON STOCK SHOULD CONSULT THEIR OWN TAX ADVISORS REGARDING THE APPLICATION OF THE U.S. FEDERAL
INCOME AND ESTATE TAX LAWS TO THEIR PARTICULAR SITUATIONS AND THE CONSEQUENCES OF <FONT STYLE="white-space:nowrap">NON-U.S.,</FONT> STATE, OR LOCAL LAWS AND TAX TREATIES. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect to declare or make any
distributions on our common stock in the foreseeable future. If we do pay dividends on shares of our common stock, however, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or
accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that is applied against and reduces, but not
below zero, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s adjusted tax basis in shares of our common stock. Any such gain will be subject to the treatment described below under &#147;&#151;Gain on Sale or Other Disposition of
Common Stock.&#148; Any such distributions will also be subject to the discussion below under &#147;&#151;Backup Withholding and Information Reporting&#148; and &#147;&#151;Foreign Account Tax Compliance Act.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any dividend paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder on our common stock that is not effectively connected with a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a trade or business in the United States will generally be subject to U.S. withholding tax at a 30% rate. The withholding tax might apply at a reduced rate, however, under the terms
of an applicable income tax treaty between the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence. You should consult your own tax advisors regarding your entitlement to benefits under a
relevant income tax treaty. Generally, in order for us or our paying agent to withhold tax at a lower treaty rate, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must certify its entitlement to treaty benefits. A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder generally can meet this certification requirement by providing an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap">W-8BENE</FONT> or other appropriate form
(or any successor or substitute form thereof) to us or our paying agent. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds the stock through a financial institution or other agent acting on the holder&#146;s behalf, the holder
will be required to provide appropriate documentation to the holder&#146;s agent. The holder&#146;s agent will then be required to provide certification to us or our paying agent, either directly or through other intermediaries. If you are eligible
for a reduced rate of U.S. federal withholding tax under an income tax treaty, you may obtain a refund or credit of any excess amounts withheld by filing an appropriate claim for a refund with the IRS in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that are effectively connected with a U.S. trade or business conducted by the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder, and if required by an applicable income tax treaty between the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence, are attributable to a
permanent establishment maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, are not subject to U.S. withholding tax. To obtain this exemption, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must
provide us or our paying agent with an IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> properly certifying such exemption. Such effectively connected dividends, although not subject to withholding tax, are taxed at the same graduated rates
applicable to U.S. persons, net of certain deductions and credits. In addition to being taxed at graduated tax rates, dividends received by a corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that are effectively connected with a
U.S. trade or business of the corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable tax treaty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Sale or Other Disposition of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#147;&#151;Backup Withholding and Information Reporting&#148; and &#147;&#151;Foreign Account Tax Compliance Act,&#148; <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders will generally not be subject to U.S. federal income tax on any gains realized on the sale, exchange or other disposition of our common stock unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the gain (i)&nbsp;is effectively connected with the conduct by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of a U.S. trade or business and (ii)&nbsp;if required by an applicable income tax treaty between
the United States and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence, is attributable to a permanent establishment maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United
States (in which case the special rules described below apply); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is an individual who is present in the United States for 183 days or more in the taxable year of the sale, exchange or other disposition of our common stock,
and certain other requirements are met (in which case the gain would be subject to a flat 30% tax, or such reduced rate as may be specified by an applicable income tax treaty, which may be offset by U.S. source capital losses, even though the
individual is not considered a resident of the United States); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rules of the Foreign Investment in Real Property Tax Act (FIRPTA) treat the gain as effectively connected with a U.S. trade or business. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FIRPTA rules may apply to a sale, exchange or other disposition of our common stock if we are, or were within the shorter of the five-year period
preceding the disposition and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, a &#147;U.S. real property holding corporation,&#148; or USRPHC. In general, we would be a USRPHC if interests in U.S. real estate
comprised at least half of the value of our business assets. We do not believe that we are a USRPHC and we do not anticipate becoming one in the future. Even if we become a USRPHC, as long as our common stock is regularly traded on an established
securities market, such common stock will be treated as U.S. real property interests only if beneficially owned by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that actually or constructively owned more than 5% of our outstanding common
stock at some time within the five-year period preceding the disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any gain from the sale, exchange or other disposition of our common stock,
(i)&nbsp;is effectively connected with a U.S. trade or business conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and (ii)&nbsp;if required by an applicable income tax treaty between the United States and the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s country of residence, is attributable to a permanent establishment maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, then the gain generally will
be subject to U.S. federal income tax at the same graduated rates applicable to U.S. persons, net of certain deductions and credits. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a corporation, under certain circumstances, that
portion of its earnings and profits that is effectively connected with its U.S. trade or business, subject to certain adjustments, generally would be subject also to a &#147;branch profits tax&#148; at a rate of 30% or such lower rate as may be
specified by an applicable income tax treaty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Estate Tax </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estates of nonresident alien individuals generally are subject to U.S. federal estate tax on property with a U.S. situs. Because we are a U.S. corporation,
our common stock will be U.S. situs property and therefore will be included in the taxable estate of a nonresident alien decedent, unless an applicable estate tax treaty between the United States and the decedent&#146;s country of residence provides
otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Code and the U.S. Treasury Regulations require those who make specified payments to report the payments to the IRS. Among the specified payments are
dividends and proceeds paid by brokers to their customers. The required information returns enable the IRS to determine whether the recipient properly included the payments in income. This reporting regime is reinforced by &#147;backup
withholding&#148; rules. These rules require the payors to withhold tax from payments subject to information reporting if the recipient fails to cooperate with the reporting regime by failing to provide his taxpayer identification number to the
payor, furnishing an incorrect identification </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number, or failing to report interest or dividends on his returns. The backup withholding tax rate is currently 28%. The backup withholding rules do not apply to payments to foreign corporations,
provided they establish such exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of dividends on common stock generally will
not be subject to backup withholding, and payments of proceeds made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders by a broker upon a sale of common stock will not be subject to information reporting or backup withholding, in each case
so long as the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder certifies its nonresident status (and we or the applicable paying agent do not have actual knowledge or reason to know the holder is a U.S. person or that the conditions of any
other exemption are not, in fact, satisfied) or otherwise establishes an exemption. The certification procedures to claim treaty benefits described under &#147;&#151;Dividends&#148; above will generally satisfy the certification requirements
necessary to avoid the backup withholding tax. We must report annually to the IRS any dividends paid to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and the tax withheld, if any, with respect to these dividends. Copies of these
reports may be made available to tax authorities in the country where the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the U.S. Treasury Regulations, the payment of proceeds from the disposition of shares of our common stock by a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder made to or through a U.S. office of a broker generally will be subject to information reporting and backup withholding unless the beneficial owner certifies, under penalties of perjury, among other
things, its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder (and the broker does not have actual knowledge or reason to know the holder is a U.S. person) or otherwise establishes an exemption. The payment of proceeds from the
disposition of shares of our common stock by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder made to or through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker generally will not be subject to backup withholding and
information reporting. Information reporting, but not backup withholding, however, will apply to a payment of proceeds, even if that payment is made outside of the United States, if you sell our common stock through a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker that is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a U.S. person (including a foreign branch or office of such person); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;controlled foreign corporation&#148; for U.S. federal income tax purposes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a foreign person 50% or more of whose gross income from certain periods is effectively connected with a U.S. trade or business; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a foreign partnership if at any time during its tax year (a)&nbsp;one or more of its partners are U.S. persons who, in the aggregate, hold more than 50% of the income or capital interests of the partnership or
(b)&nbsp;the foreign partnership is engaged in a U.S. trade or business; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">unless the broker has documentary evidence that the beneficial
owner is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and certain other conditions are satisfied, or the beneficial owner otherwise establishes an exemption (and the broker has no actual knowledge or reason to know to the contrary).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld from a payment to a holder of common stock under the backup withholding rules can be
credited against any U.S. federal income tax liability of the holder, if any, and may entitle the holder to a refund, provided that the required information is furnished to the IRS in a timely manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Account Tax Compliance Act </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Foreign Account
Tax Compliance Act (FATCA) generally imposes a U.S. federal withholding tax at a rate of 30% on payments of dividends on, or gross proceeds from the sale or other disposition of, our common stock paid to a foreign entity unless (i)&nbsp;if the
foreign entity is a &#147;foreign financial institution,&#148; such foreign entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial
institution,&#148; such foreign entity identifies certain of its U.S. investors, if any, or (iii)&nbsp;the foreign entity is otherwise exempt under FATCA. Under applicable U.S. Treasury Regulations, withholding under FATCA currently applies to
payments of dividends on our common stock, but will only apply to payments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of gross proceeds from a sale or other disposition of our common stock made after December&nbsp;31, 2018. Under certain circumstances,
<FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;holder</FONT> may be eligible for refunds or credits of this withholding tax. An intergovernmental agreement between the United States and an applicable foreign country may modify the
requirements described in this <FONT STYLE="white-space:nowrap">paragraph.&nbsp;Non-U.S.&nbsp;holders</FONT> should consult their own tax advisors regarding the possible implications of this legislation on their investment in our common stock and
the entities through which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTIVE INVESTORS SHOULD CONSULT THEIR OWN TAX ADVISORS REGARDING THE POTENTIAL APPLICATION OF WITHHOLDING UNDER FATCA TO THEIR INVESTMENT IN OUR
COMMON STOCK. THE PRECEDING DISCUSSION OF U.S. FEDERAL TAX CONSIDERATIONS IS FOR GENERAL INFORMATION PURPOSES ONLY. IT IS NOT TAX ADVICE. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE PARTICULAR U.S. FEDERAL, GIFT,
ESTATE, STATE, LOCAL, AND <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAX CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_18a"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc., Goldman Sachs&nbsp;&amp; Co. LLC and Leerink Partners LLC are acting as joint book-running managers of this offering and as
representatives of the underwriters named below. Subject to the terms and conditions stated in the underwriting agreement dated the date of this prospectus, each underwriter named below has severally agreed to purchase, and we have agreed to sell to
that underwriter, the number of shares of common stock set forth opposite the underwriter&#146;s name in the following table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:46.20pt; font-size:8pt; font-family:Times New Roman"><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the obligations of the underwriters to purchase the shares included in this offering
are subject to approval of legal matters by counsel and to other conditions. The underwriters are obligated to purchase all the shares (other than those covered by the underwriters&#146; option to purchase additional shares described below) if they
purchase any of the shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the
cover of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount from the initial public offering price not to exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. If
all the shares are not sold at the initial offering price, the underwriters may change the offering price and the other selling terms. The representatives have advised us that the underwriters do not intend to make sales to discretionary accounts.
The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#146; right to reject any order in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the underwriters sell more shares than the total number set forth in the table above, we have granted to the underwriters an option, exercisable for 30
days from the date of this prospectus, to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares at the public offering price less the underwriting discount. To the extent the option is exercised,
each underwriter must purchase a number of additional shares approximately proportionate to that underwriter&#146;s initial purchase commitment. Any shares issued or sold under the option will be issued and sold on the same terms and conditions as
the other shares that are the subject of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, our officers, directors and substantially all of our securityholders have agreed that,
subject to specified limited exceptions, for a period of 180 days from the date of this prospectus, we and they will not, without the prior written consent of Citigroup Global Markets Inc., Goldman Sachs&nbsp;&amp; Co. LLC and Leerink Partners LLC,
dispose of or hedge any shares or any securities convertible into or exchangeable for shares of our common stock. Citigroup Global Markets Inc., Goldman Sachs&nbsp;&amp; Co. LLC and Leerink Partners LLC, in their sole discretion, may release any of
the securities subject to these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time, which, in the case of officers and directors, shall be with notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our shares. Consequently, the initial public offering price for the shares will be determined by
negotiations between us and the representatives. Among the factors considered in determining the initial public offering price will be our results of operations, our current financial condition, our future prospects, our markets, the economic
conditions in and future prospects for the industry in which we compete, our management and currently prevailing general conditions in the equity securities markets, including current market valuations of publicly traded companies considered
comparable to our company. We cannot ensure however, that the price at which the shares will sell in the public market after this offering will not be lower than the initial public offering price or that an active trading market in our shares will
develop and continue after this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to apply to have our shares listed
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;under the symbol &#147;RCUS.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the
underwriting discounts and commissions that we are to pay to the underwriters in connection with this offering. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Paid by Arcus Biosciences, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;No&nbsp;Exercise&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;Full&nbsp;Exercise&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that our portion of the total expenses of this offering will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have also agreed to reimburse the underwriters for certain Financial Industry Regulatory Authority-related and other expenses incurred by them in connection with this
offering in an amount up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters
may purchase and sell shares in the open market. Purchases and sales in the open market may include short sales, purchases to cover short positions, which may include purchases pursuant to the underwriters&#146; option to purchase additional shares,
and stabilizing purchases. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Short sales involve secondary market sales by the underwriters of a greater number of shares than they are required to purchase in the offering. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;Covered&#148; short sales are sales of shares in an amount up to the number of shares represented by the underwriters&#146; option to purchase additional shares. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;Naked&#148; short sales are sales of shares in an amount in excess of the number of shares represented by the underwriters&#146; option to purchase additional shares. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Covering transactions involve purchases of shares either pursuant to the underwriters&#146; option to purchase additional shares or in the open market in order to cover short positions. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To close a naked short position, the underwriters must purchase shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the
price of the shares in the open market after pricing that could adversely affect investors who purchase in the offering. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To close a covered short position, the underwriters must purchase shares in the open market or must exercise the option to purchase additional shares. In determining the source of shares to close the covered short
position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option to purchase additional shares.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stabilizing transactions involve bids to purchase shares so long as the stabilizing bids do not exceed a specified maximum. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount
received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchases to cover short positions and stabilizing purchases, as well as other purchases by the underwriters for their own accounts, may have the effect of
preventing or retarding a decline in the market price of the shares. They may also cause the price of the shares to be higher than the price that would otherwise exist in the open market in the absence of these transactions. The underwriters may
conduct these transactions on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. If the underwriters commence any of these transactions, they may discontinue them at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment
banking, financial advisory, investment management, principal investment, hedging, financing and brokerage activities. The underwriters and their respective affiliates have in the past performed commercial banking, investment banking and advisory
services for us from time to time for which they have received customary fees and reimbursement of expenses and may, from time to time, engage in transactions with and perform services for us in the ordinary course of their business for which they
may receive customary fees and reimbursement of expenses. In the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity
securities (or related derivative securities) and financial instruments (which may include bank loans and credit default swaps) for their own account and for the accounts of their customers and may at any time hold long and short positions in such
securities and instruments. Such investments and securities activities may involve securities and instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and publish or express
independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and short positions in such securities and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Affiliates of Leerink Partners LLC purchased shares of our Series C preferred stock in our November 2017 private placement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments
the underwriters may be required to make because of any of those liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the European Economic Area </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to each member state of the European Economic Area, no offer of shares which are the subject of the offering has been, or will be made to the
public in that Member State, other than under the following exemptions under the Prospectus Directive: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the representatives for any such offer; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such
offer of shares referred to in (a)&nbsp;to (c) above shall result in a requirement for the company or any representative to publish a prospectus pursuant to Article 3 of the Prospectus Directive, or supplement a prospectus pursuant to Article 16 of
the Prospectus Directive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each person located in a Member State to whom any offer of shares is made or who receives any communication in respect of an
offer of shares, or who initially acquires any shares will be deemed to have represented, warranted, acknowledged and agreed to and with each representative and the company that (1)&nbsp;it is a &#147;qualified investor&#148; within the meaning of
the law in that Member State implementing Article 2(1)(e) of the Prospectus Directive; and (2)&nbsp;in the case of any shares acquired by it as a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive, the shares
acquired by it in the offer have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Member State other than qualified investors, as that term is defined in the Prospectus Directive, or
in circumstances in which the prior consent of the representatives has been given to the offer or resale; or where shares have been acquired by it on behalf of persons in any Member State other than qualified investors, the offer of those shares to
it is not treated under the Prospectus Directive as having been made to such persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company, the representatives and their respective affiliates will rely upon the truth and accuracy of
the foregoing representations, acknowledgments and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus has been prepared on the basis that any offer of shares in any Member
State will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an offer in that Member State of shares which are the
subject of the offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for the company or any of the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation
to such offer. Neither the company nor the representatives have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the company or the representatives to publish a prospectus for
such offer. For the purposes of this provision, the expression an &#147;offer of shares to the public&#148; in relation to any shares in any Member State means the communication in any form and by any means of sufficient information on the terms of
the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the
expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended) and includes any relevant implementing measure in each Member State. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above selling restriction is in addition to any other selling restrictions set out below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares may
be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions </I>or subsection 73.3(1) of the
<I>Securities Act </I>(Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration</I> <I>Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the
shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or
territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a <FONT STYLE="white-space:nowrap">non-Canadian</FONT>
jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts </I>(NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure
requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice
to Prospective Investors in the United Kingdom </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is only being distributed to, and is only directed at, persons in the United Kingdom
that are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive that are also (i)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order
2005, as amended (the Order) and/or (ii)&nbsp;high net worth entities falling within Article 49(2)(a) to (d)&nbsp;of the Order and other persons to whom it may lawfully be communicated (each such person being referred to as a &#147;relevant
person&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or
disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in France </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither this prospectus nor any other offering material relating to the shares described in this prospectus has been submitted to the clearance procedures of
the <I>Autorit&eacute; des March&eacute;s Financiers</I> or of the competent authority of another member state of the European Economic Area and notified to the <I>Autorit&eacute; des March&eacute;s Financiers.</I> The shares have not been offered
or sold and will not be offered or sold, directly or indirectly, to the public in France. Neither this prospectus nor any other offering material relating to the shares has been or will be: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">released, issued, distributed or caused to be released, issued or distributed to the public in France; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">used in connection with any offer for subscription or sale of the shares to the public in France. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such offers, sales and distributions will be made in France only: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to qualified investors (<I>investisseurs qualifi&eacute;s</I>) or to a restricted circle of investors (<I>cercle restreint d&#146;investisseurs</I>), in each case investing for their own account, all as defined in, and
in accordance with articles <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.411-1,</FONT> <FONT STYLE="white-space:nowrap">D.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.734-1,</FONT> <FONT
STYLE="white-space:nowrap">D.744-1,</FONT> <FONT STYLE="white-space:nowrap">D.754-1</FONT> and <FONT STYLE="white-space:nowrap">D.764-1</FONT> of the French <I>Code mon&eacute;taire et financier</I>; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to investment services providers authorized to engage in portfolio management on behalf of third parties; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in a transaction that, in accordance with article <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">L.411-2-II-1&deg;-or-2&deg;-or</FONT></FONT></FONT></FONT></FONT></FONT> 3&deg; of the French <I>Code mon&eacute;taire et financier</I> and article <FONT STYLE="white-space:nowrap">211-2</FONT> of the General Regulations
(<I>R&egrave;glement G&eacute;n&eacute;ral</I>) of the <I>Autorit&eacute; des March&eacute;s Financiers</I>, does not constitute a public offer (<I>appel public &agrave; l&#146;&eacute;pargne</I>). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may be resold directly or indirectly, only in compliance with articles <FONT STYLE="white-space:nowrap">L.411-1,</FONT> <FONT
STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">L.412-1</FONT> and <FONT STYLE="white-space:nowrap">L.621-8</FONT> through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.621-8-3</FONT></FONT> of the
French <I>Code mon&eacute;taire et financier</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary
business is to buy or sell shares or debentures, whether as principal or agent; or to professional investors, as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong (SFO) and any rules made under that Ordinance; or in other
circumstances which do not result in the document being a prospectus, as defined in the Companies Ordinance (Cap. 32) of Hong Kong (CO) or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO. No
document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the
contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside
Hong Kong or only to professional investors, as defined in the SFO and any rules made under that Ordinance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered with
the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the
securities will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and that he is not
acquiring, and has not been offered any securities in circumstances that contravene any such restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering has not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as
amended) (FIEL) and the initial purchaser will not offer or sell any securities, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity
organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan, except pursuant to an exemption from the
registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and ministerial guidelines of Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
prospectus has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for
subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other
than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the SFA), (ii) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and
in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities (as defined in
Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant
to an offer made under Section&nbsp;275 of the SFA except: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
prospectus is not a disclosure document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia (Corporations Act) has not been lodged with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to the
categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You confirm and warrant that you are either: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you have provided an accountant&#146;s certificate to the Company which complies with the requirements of section
708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a person associated with the Company under Section&nbsp;708(12) of the Corporations Act; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the
Corporations Act any offer made to you under this prospectus is void and incapable of acceptance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You warrant and agree that you will not offer any of
the securities issued to you pursuant to this prospectus for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the
Corporations Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_19"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Gunderson Dettmer Stough Villeneuve Franklin&nbsp;&amp;
Hachigian, LLP, Redwood City, California. Cooley LLP is representing the underwriters in this offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_20"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our financial statements at December&nbsp;31, 2016, and for the year
then ended, as set forth in their report. We have included our financial statements in this prospectus and elsewhere in the registration statement in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in
accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_21"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the Securities and Exchange Commission a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities
Act of 1933, as amended, with respect to the shares of common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement
or the exhibits and schedules to the registration statement. Please refer to the registration statement and exhibits for further information with respect to the common stock offered by this prospectus. Statements contained in this prospectus
regarding the contents of any contract or other document are only summaries. With respect to any contract or document that is filed as an exhibit to the registration statement, you should refer to the exhibit for a copy of the contract or document,
and each statement in this prospectus regarding that contract or document is qualified by reference to the exhibit. You may read and copy the registration statement and its exhibits and schedules at the SEC&#146;s public reference room, located at
100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may obtain information on the operation of the public reference room by calling the SEC at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330.</FONT></FONT></FONT> The SEC also maintains a website that contains reports, proxy and information statements and other information
regarding issuers, like us, that file documents electronically with the SEC. The address of that website is www.sec.gov. The information on the SEC&#146;s web site is not part of this prospectus, and any references to this web site or any other web
site are inactive textual references only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will become subject to the information and reporting requirements of the
Exchange Act, and, in accordance with this law, will be required to file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information will be available for inspection and
copying at the SEC&#146;s public reference facilities and the website of the SEC referred to above. We also maintain a website at www.arcusbio.com, at which you may access these materials free of charge as soon as reasonably practicable after they
are electronically filed with, or furnished to, the SEC. The information contained on, or that can be accessed through, our website is not a part of this prospectus. Investors should not rely on any such information in deciding whether to purchase
our common stock. We have included our website address in this prospectus solely as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom317356_22"></A>INDEX TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin317356_1">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audited Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin317356_2">Balance Sheet</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin317356_3">Statement of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin317356_4">Statement of Convertible Preferred Stock and Stockholders&#146;
Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin317356_5">Statement of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin317356_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin317356_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors and Stockholders </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arcus Biosciences, Inc.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheet of Arcus Biosciences, Inc., as of December&nbsp;31, 2016, and the related statements of operations and
comprehensive loss, changes in convertible preferred stock and stockholders&#146; deficit and cash flows for the year then ended. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an
opinion on these financial statements based on our audit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the standards of the Public Company Accounting
Oversight Board (United States) and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. We were not engaged to perform an audit of the Company&#146;s internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for
designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An
audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial
statement presentation. We believe that our audit provides a reasonable basis for our opinion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the financial statements referred to above
present fairly, in all material respects, the financial position of Arcus Biosciences, Inc. at December&nbsp;31, 2016 and the results of its operations and its cash flows for the year then ended in conformity with U.S. generally accepted accounting
principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst &amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redwood City,
California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;15, 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin317356_2"></A>Balance Sheet </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amounts owed by a related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity investment in related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.0001 par value, 84,875,000 shares authorized, 84,378,462 issued
and outstanding as of December&nbsp;31, 2016; aggregate liquidation preference of $119,725 as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock; $0.0001 par value; 109,000,000 shares authorized as of December&nbsp;31, 2016; and
13,894,041 shares issued and outstanding as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin317356_3"></A>Statement of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands except for share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used to compute basic and diluted net loss per common
share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,421,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin317356_4"></A>Statement of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands, except share and per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible Preferred</B><br><B>Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Other</B><br><B>Comprehensive</B><br><B>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,725,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,637</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,080,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,182</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series B convertible preferred stock for $2.02 per share, net of issuance costs of
$183</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,653,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,817</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of early exercised stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">543,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common stock upon exercise of stock options, net of amounts related to unvested
shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,378,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">119,454</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,812,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin317356_5"></A>Statement of Cash Flows </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flow from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in a related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,099</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,861</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flow from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series B preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> investing and financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment included in accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of early exercised options and restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See accompanying notes </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin317356_6"></A>Notes to the Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1. Organization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Description of Business
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arcus Biosciences, Inc. (Company or the Company) was&nbsp;incorporated&nbsp;in Delaware in April 2015 and is headquartered in Hayward, California.
The Company is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Specifically, the Company targets well-characterized biological pathways with
significant scientific data supporting their importance in regulating the immune response against cancer and for which either there are no molecules in development or those that exist have suboptimal profiles. To exploit these pathways, the Company
has built a robust and highly efficient discovery capability to create and optimize highly differentiated small-molecule immuno-oncology product candidates that it believes will be best-in-class and/or first-in-class. Since its inception in 2015,
the Company has built a broad portfolio of small-molecule and antibody product candidates that it plans to develop together as intra-portfolio combinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has incurred losses and negative cash flows from operations since inception and had an accumulated deficit of $20.2&nbsp;million as of
December&nbsp;31, 2016. The Company has funded operations primarily with the net proceeds of $119.5&nbsp;million from private placements of convertible preferred stock. The Company expects to incur additional operating losses in the near term. As of
December&nbsp;31, 2016, the Company had cash, cash equivalents and short-term investments of $98.9&nbsp;million, which it believes will be sufficient to fund its planned operations for a period of at least twelve months from the date of the issuance
of these financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements and
accompanying notes have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) and include all adjustments necessary for the fair presentation of the Company&#146;s financial position
for the periods presented. The Company has no subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#146;s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets, liabilities and expenses, as well as related disclosure of contingent assets and liabilities. Estimates are used for the fair value of common and preferred stock and stock-based awards and other issuances, contingent
liabilities, accruals for research and development costs, useful lives of long-lived assets, and uncertain tax positions. Actual results could differ materially from the Company&#146;s estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risk and Uncertainties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s future
results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#146;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of
results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#146;s potential drug candidates, uncertainty of market acceptance of the Company&#146;s product candidates, competition from substitute products
and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s product candidates require approvals from the U.S. Food and Drug Administration (FDA) and
comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed
or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects
to incur substantial operating losses for the next several years and will need to obtain additional financing in order to complete clinical trials and launch and commercialize any product candidates for which it receives regulatory approval. There
can be no assurance that such financing will be available or will be at terms acceptable to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing immunotherapies.
The Company&#146;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating and evaluating financial performance. All long-lived assets are maintained in the
United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Equivalents and Short-Term Investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash equivalents include marketable securities having an original maturity of three months or less at the time of purchase. Short-term investments are
investments in marketable securities with maturities of greater than three months at the time of purchase. Collectively, cash equivalents and short-term investments are considered
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> and are recorded at fair value. Unrealized gains and losses are recorded in accumulated other comprehensive loss in the statement of convertible
preferred stock and stockholders&#146; deficit. Realized gains and losses are included in Interest and other income, net in the statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash at
December&nbsp;31, 2016 comprises cash balances primarily held as security in connection with the Company&#146;s facility lease agreement and are included in long term assets on its balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Receivable From a Related Party </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Receivable from a
related party are recorded net of allowances. Estimates of the Company&#146;s allowance for doubtful accounts are determined based on existing contractual payment terms. As of December&nbsp;31, 2016, the outstanding amount is due from PACT Pharma,
Inc. (PACT Pharma) for equipment and expenses the Company paid for on its behalf. The Company is exposed to credit risk in the event of a default by PACT Pharma. To date, the Company has not experienced any losses related to these receivables (see
Note 5). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value
accounting is applied for all financial assets and liabilities, including short-term and long-term investments, and <FONT STYLE="white-space:nowrap">non-financial</FONT> assets and liabilities that are recognized or disclosed at fair value in the
financial statements on a recurring basis (at least annually). The carrying amount of the Company&#146;s financial instruments, including receivable from a related party, accounts payable and accrued expenses and other current liabilities
approximate fair value due to their short-term maturities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash equivalents and short-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. The Company
invests in money market funds, asset backed securities, commercial paper and corporate notes. The Company limits its credit risk associated with cash equivalents and short-term investments by placing them with banks and institutions it believes are
highly credit worthy and in highly rated investments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, ranging from one to
five years. Leasehold improvements are amortized over the shorter of their estimated useful lives or the related lease term. Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting
gain or loss is reflected in the statement of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of <FONT STYLE="white-space:nowrap">Long-Lived</FONT>
Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business
circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment charge would be recorded when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual
disposition are less than its carrying amount. Impairment, if any, is assessed using discounted cash flows or other appropriate measures of fair value. Through December&nbsp;31, 2016, there have been no such impairment charges. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development costs are expensed as incurred. Research and development costs consist primarily of personnel costs for the Company&#146;s research and product development employees. Also included are
<FONT STYLE="white-space:nowrap">non-personnel</FONT> costs such as professional fees payable to third parties for preclinical studies and research services, laboratory supplies, product licenses, equipment maintenance, and other consulting costs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates preclinical study and research expenses based on the services performed, pursuant to contracts with research institutions that
conduct and manage preclinical studies and research services on its behalf. The Company estimates these expenses based on discussions with internal management personnel and external service providers as to the progress or stage of completion of
services and the contracted fees to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments associated with
licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternative commercial use are expensed as incurred. Payments made to third
parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases and Rent&nbsp;Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records
rent expense on a straight-line basis over the life of the lease. In cases where there is a free rent period or future fixed rent escalations, the Company records a deferred rent liability. Additionally, the receipt of any lease incentives is
recorded as a deferred rent liability which is amortized over the lease term as a reduction of rent expense. Building improvements made with the lease incentives or tenant allowances are capitalized as leasehold improvements and included in Property
and equipment in the balance sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for stock-based compensation arrangements with employees in accordance with ASC 718, <I>Stock Compensation.</I> Stock-based awards granted
include stock options with time-based vesting. ASC 718 requires the recognition of compensation expense, using a fair value-based method, for costs related to all stock-based payments. The Company&#146;s determination of the fair value of stock
options with time-based vesting on the date of grant utilizes the Black-Scholes option-pricing model, and is impacted by its common stock price as well as other variables including, but not limited to, expected term that options will remain
outstanding, expected common stock price volatility over the term of the option awards, risk-free interest rates and expected dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value
of a stock-based award is recognized over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period (usually the vesting period) on a straight-line basis. Stock-based
compensation expense recognized at fair value includes the impact of estimated forfeitures. The Company estimates future forfeitures at the date of grant and revises the estimates, if necessary, in subsequent periods if actual forfeitures differ
from those estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equity instruments issued to <FONT STYLE="white-space:nowrap">non-employees</FONT> are accounted for in accordance with ASC <FONT
STYLE="white-space:nowrap">505-50</FONT> <I>Equity Based Payments to <FONT STYLE="white-space:nowrap">Non-Employees</FONT></I> and are recorded at their fair value on the measurement date and are subject to periodic adjustments as the underlying
equity instruments vest. The fair value of options granted to consultants is expensed when vested. <FONT STYLE="white-space:nowrap">Non-employee</FONT> stock-based compensation expense was not material for all periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimating the fair value of equity-settled awards as of the grant date using valuation models, such as the Black-Scholes option pricing model, is affected by
assumptions regarding a number of complex variables. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require
significant analysis and judgment to develop. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records all shares of convertible preferred stock at their respective fair values less issuance costs on the dates of issuance. The convertible
preferred stock is recorded outside of stockholders&#146; equity (deficit) because, in the event of certain deemed liquidation events considered not solely within the Company&#146;s control, such as a merger, acquisition and sale of all or
substantially all of the Company&#146;s assets, the convertible preferred stock will become redeemable at the option of the holders. In the event of a change of control of the Company, proceeds received from the sale of such shares will be
distributed in accordance with the liquidation preferences set forth in the Company&#146;s Amended and Restated Certificate of Incorporation unless the holders of convertible preferred stock have converted their shares of convertible preferred stock
into shares of common stock. The Company has elected not to adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because of the uncertainty of whether or when such an event would occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides for income
taxes under the asset and liability method. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on
differences between the financial statement reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards, and are measured using the enacted tax rates and laws that will be in effect when such items are expected
to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertain tax positions in accordance with ASC
<FONT STYLE="white-space:nowrap">740-10,</FONT> <I>Accounting for Uncertainty in Income Taxes.</I> The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are
still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#146;s sustainability and is measured at the largest amount of benefit that is greater
than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i)&nbsp;the factors underlying the sustainability
assertion have changed and (ii)&nbsp;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit
might change as new information becomes available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company includes any penalties and interest expense related to income taxes as a component of
interest and other income, net, as necessary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from
<FONT STYLE="white-space:nowrap">non-owner</FONT> sources. The Company had unrealized losses from its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities during the year ended
December&nbsp;31, 2016, which qualified as other comprehensive loss and, therefore, the Company reported comprehensive loss and net loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss
per Share of Common Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares
outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding
for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock, and common stock options are considered to be potentially dilutive securities. Because the Company has reported a net loss for the year ended
December&nbsp;31, 2016, diluted net loss per common share is the same as basic net loss per common share for the period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting
Pronouncements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard
setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company&#146;s financial statements
upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the JOBS Act), the Company meets the definition of an emerging growth company, and has irrevocably elected to opt out of the extended transition period for complying
with new or revised accounting standards pursuant to Section&nbsp;107(b) of the JOBS Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recently Adopted Accounting Standards Updates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2015, the FASB issued Accounting Standards Update (ASU) <I>No.</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;2015-17</FONT> (Topic 740),
Balance Sheet Classification of Deferred Taxes.</I> ASU <FONT STYLE="white-space:nowrap">2015-17</FONT> requires deferred tax liabilities and assets to be classified as noncurrent in the Balance Sheet. For public entities, the standard will be
effective for financial statements issued for annual periods beginning after December&nbsp;15, 2016, and interim periods within those annual periods. Early adoption is permitted for financial statements that have not been previously issued. The ASU
may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The Company early adopted this ASU during 2016 on a retrospective basis and
the adoption had no impact on the Company&#146;s financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2015, the FASB issued ASU <I>No.</I><I></I><I><FONT
STYLE="white-space:nowrap">&nbsp;2015-02</FONT></I> <I>(Topic 810), Consolidation, Amendments to the Consolidations Analysis, </I>which amends the consolidation requirements in ASC 810. The ASU modifies the evaluation of whether limited partnerships
and similar legal entities are variable interest entities or voting interest entities and significantly amends the consolidation analysis of reporting entities that are involved with variable interest entities, particularly those that have fee
arrangements and related party relationships. For public business entities, the guidance is effective for annual periods and interim periods beginning after December&nbsp;15, 2015 with early adoption permitted. The Company adopted this ASU in 2016
and the adoption did not have a material impact on its financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2014-15,</FONT> <I>Disclosure of Uncertainties About an Entity&#146;s Ability to Continue as a Going Concern.</I> The new standard provides guidance around management&#146;s responsibility to evaluate
whether there is substantial doubt about an entity&#146;s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for all entities for annual periods ending after December&nbsp;15, 2016, and
interim periods with annual periods beginning after December&nbsp;15, 2016. The adoption of this standard in 2016 did not have a material impact on the Company&#146;s financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recently Issued Accounting Standards or Updates Not Yet Effective </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2016, the FASB issued ASU <I>No.</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;2016-18</FONT> (Topic 230), Restricted Cash, Statement of Cash
Flows</I>. ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> requires that a statement of cash flows explain the change during the period in the total of cash and cash equivalents, and amounts generally described as restricted cash or restricted
cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">beginning-of-period</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-period</FONT></FONT> total amounts shown on the statement of cash flows.
ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> is effective for public business entities for fiscal years beginning after December&nbsp;15, 2017, and interim periods within those fiscal years, with early adoption permitted. The amendments in
this ASU should be applied using a retrospective transition method to each period presented. The adoption of this standard is not expected to have a material impact on the Company&#146;s financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU <I>No.</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;2016-09,</FONT> Compensation&#151;Stock Compensation (Topic
718)</I>, which simplifies the accounting for employee stock-based transactions. The amendments in this update cover such areas as the recognition of excess tax benefits and deficiencies, the classification of those excess tax benefits on the
statement of cash flows, an accounting policy election for forfeitures, the amount an employer can withhold to cover income taxes and still qualify for equity classification, and the classification of those taxes paid on the statement of cash flows.
For public entities, ASU <FONT STYLE="white-space:nowrap">2016-09</FONT> is effective for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2016, with early adoption permitted. The Company will adopt ASU <FONT
STYLE="white-space:nowrap">2016-09</FONT> as of January&nbsp;1, 2017 and there is not expected to be a material impact to the Company&#146;s financial statements as a result of the adoption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <I>No.</I><I></I><I><FONT STYLE="white-space:nowrap">&nbsp;2016-02</FONT> (Topic 842), Leases. </I>ASU <FONT
STYLE="white-space:nowrap">2016-02</FONT> requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. The ASU will also require new qualitative and quantitative disclosures to help investors
and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. For public entities, ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> is effective for fiscal years beginning after
December&nbsp;15, 2018, with early adoption permitted. The Company has not determined the potential effects of this ASU on its financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3. Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are recorded at fair value. The accounting guidance for fair value provides a framework for measuring fair value, clarifies
the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between
market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Inputs (other than quoted market prices included in Level&nbsp;1) are either directly or indirectly observable for the asset or
liability through correlation with market data at the measurement date and for the duration of the instrument&#146;s anticipated life. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Inputs reflect management&#146;s best estimate of what market participants would use in pricing the asset or liability at the
measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets and
liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#146;s assessment of the significance of a particular input to the fair value
measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the period presented,
the Company has not changed the manner in which it values assets and liabilities that are measured at fair value. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no
transfers within the hierarchy during the year ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the Company&#146;s financial instruments that
were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate securities and commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Classified as (with contractual maturities):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents (due within 90 days)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments (due within one year)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term investments (due between one and two years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The investments are classified as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities. At December&nbsp;31, 2016, the balance in the Company&#146;s accumulated other comprehensive loss was comprised solely of activity related
to the Company&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities. There were no realized gains or losses recognized on the sale or maturity of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities for the year ended December&nbsp;31, 2016 and as a result, the Company did not reclassify any amounts out of accumulated other comprehensive loss for the year. The Company has a
limited number of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities in insignificant loss positions as of December&nbsp;31, 2016, which the Company does not intend to sell and has concluded
it will not be required to sell before recovery of the amortized cost for the investment at maturity. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at December&nbsp;31, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Unrealized<BR>Gain</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Unrealized<BR>Loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government agency obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate securities and commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">98,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4: Balance Sheet Components </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net
consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scientific equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,366</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense was $1.3&nbsp;million for the year ended December&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued personnel expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5: Equity Investment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2016, the Company purchased approximately 3.6&nbsp;million shares of common stock of PACT Pharma, a privately funded, early-stage
biopharmaceutical company focused on adoptive cell therapy. The Company determined the fair value of such investment to be insignificant to the Company&#146;s 2016 financial statements given the <FONT STYLE="white-space:nowrap">start-up</FONT>
nature of operations of PACT Pharma, and it was recorded at a nominal amount. In December 2016, the Company and PACT Pharma entered into a Master Services Agreement (the PACT Agreement) under which the Company provides PACT Pharma with general
administrative support, including finance, human resources, legal, and other operational support. The Company also received certain warrants to purchase PACT Pharma common stock exercisable upon PACT Pharma&#146;s achievement of certain valuation
thresholds pursuant to the PACT Agreement. The PACT Agreement will terminate no later than December&nbsp;31, 2018. Also in December 2016, the Company purchased 1.0&nbsp;million shares of Series A preferred stock of PACT Pharma for $1.0&nbsp;million.
The Company determined PACT Pharma to be a variable interest entity. However, because the Company is not the primary beneficiary of PACT Pharma, it is not consolidating the results of operations of PACT Pharma in its financial statements. The
Company&#146;s investment in PACT Pharma is accounted for as an equity method investment, and as a result the Company records its share of PACT Pharma&#146;s operating results in its statement of operations and comprehensive loss. For the year ended
December&nbsp;31, 2016, the Company&#146;s share of PACT Pharma&#146;s operating results was not significant. The Company monitors the investment for events or circumstances indicative of potential other-than-temporary impairment, and makes
appropriate reductions in carrying values if determined that an impairment charge is required. As of December&nbsp;31, 2016, no impairment charge was recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also determined that the fair value of the warrants to be insignificant to the Company&#146;s 2016 financial statements. As of December&nbsp;31,
2016, the Company had a $0.4&nbsp;million receivable from PACT Pharma for equipment and expenses the Company paid for on its behalf, which PACT Pharma repaid in March 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6: Stockholders&#146; Equity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
Certificate of Incorporation, as amended and restated, authorizes the Company to issue 109,000,000 shares of $0.0001 par value common stock. Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive
dividends whenever funds are legally available and when and if declared by the board of directors, subject to the prior rights of holders of all classes of preferred stock outstanding. The Company has never declared any dividends on common stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the Company had reserved shares of common stock for issuance as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,378,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock options issued and outstanding under 2015 Stock Option Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remaining shares available for issuance under 2015 Stock Option Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,082,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,975,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7: Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue 84,875,000 shares of convertible preferred stock. As of December&nbsp;31, 2016, the outstanding convertible preferred stock
as was follows (in thousands, except share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Issued and</B><br><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,725,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,725,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,653,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,378,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">119,725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">119,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The significant rights and preferences of the outstanding convertible preferred stock are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends</I>&#151;The holders of the convertible preferred stock are entitled to receive dividends, out of assets legally available prior and in
preference to any declaration or payment of any other dividends, at the rates of $0.06 and $0.12 per share (as adjusted for stock splits, stock dividends, reclassifications, and the like) per annum on each outstanding share of Series A, and Series B
convertible preferred stock, respectively, when, as and if, declared by the board of directors. Such dividends are not cumulative. To date, no dividends have been declared. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation Preference</I>&#151;In the event of any liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, the holders of
Series A and Series B preferred stock shall be entitled to receive on a pari passu basis and in preference to any distribution to the common shareholders, the greater of their stated liquidation preference or the amount such holders would have
received had they converted their preferred stock into common stock immediately prior to such dissolution. For each series of convertible preferred stock, the stated liquidation preference per share is equal to $1.00 and $2.02 per share,
respectively, plus any declared but unpaid dividends. Any remaining assets shall be distributed among the holders of common stock pro rata, based on the number of shares of common stock held by each. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>&#151;Each share of convertible preferred stock is entitled to one vote for each share of common stock into which such share of
convertible preferred stock is convertible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conversion</I>&#151;Each share of convertible preferred stock is convertible, at the option of the holder,
into the number of shares of common stock that result from dividing the applicable original share price per share by the applicable conversion price per share at the time of conversion, as adjusted for stock splits, stock dividends,
reclassifications and the like. At December&nbsp;31, 2016, the conversion price equaled the original share price. Each share of convertible preferred stock shall automatically convert upon the earlier of (i)&nbsp;a vote by the majority of the
then-outstanding shares of preferred stock, (ii)&nbsp;a public offering of the Company&#146;s common stock which results in gross proceeds of at least $30.0&nbsp;million, or (iii)&nbsp;with respect to Series B preferred stock only, a public offering
of the Company&#146;s common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8: Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2015, the Company adopted the 2015 Stock Plan, which was amended in November 2015 as the 2015 Amended and Restated Stock Plan (the Plan). The Plan
provides for the granting of stock awards to employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, and consultants of the Company. Pursuant to the Plan, the Company may grant stock awards to purchase up to 8,460,590 shares of
common stock, of which 5,082,049 remain available for grant at December&nbsp;31, 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Plan permits the granting of incentive stock options, nonstatutory stock options, stock appreciation
rights, restricted stock or restricted stock units to employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, and service providers at exercise prices not less than the 100% of fair market value at the date of grant. The Board of
Directors, at its sole discretion, shall determine the exercise price. These options expire 10 years from the date of grant. Incentive stock options and nonstatutory options generally vest monthly and ratably over four years. Upon termination of
service, any shares issuable pursuant to unvested and unexercised options are automatically returned to Company. Shares issuable pursuant to vested options and not exercised within three months after an employee&#146;s, <FONT
STYLE="white-space:nowrap">non-employee</FONT> director&#146;s or consultant&#146;s termination of service to the Company are surrendered back to Company. Those shares are added back to the Plan and made available for future grants. Upon vesting of
restricted shares and exercise of options, the Company issues common stock from its authorized shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the Plan permit option holders to
exercise stock options before they are vested, subject to certain limitations. Such unvested shares are subject to repurchase by the Company at the original exercise price in the event the option holder&#146;s service to the Company is terminated
either voluntarily or involuntarily. As a result of early exercises under the Plan, approximately 2,081,340 shares had not vested and were subject to repurchase as of December&nbsp;31, 2016. The Company treats cash received from the exercise of
unvested options as a refundable deposit and classifies such amounts as a liability in its balance sheet. As of December&nbsp;31, 2016, the Company included cash received for the early exercise of unvested options of $0.2&nbsp;million in other
current and long-term liabilities. Amounts included in liabilities are transferred into common stock and additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital as the shares vest, which is generally over a period of 48 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of option activity under the Plan during 2016 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Available</B><br><B>for Grant</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Subject to</B><br><B>Outstanding</B><br><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Exercise</B><br><B>Price Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term</B><br><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options authorized</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,490,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,957,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,957,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,523,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,082,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options outstanding and exercisable as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options vested and expected to vest as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes employee and <FONT STYLE="white-space:nowrap">non-employee</FONT> stock-based
compensation expense for the year ended December&nbsp;31, 2016 and its allocation within the statement of operations and comprehensive loss: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates the fair value of its stock options utilizing the Black-Scholes option pricing model, which is dependent
upon several variables, such as expected term, volatility, risk-free interest rate, and expected dividends. Each of these inputs is subjective and generally requires significant judgment to determine. Stock-based compensation is measured at the
grant date based on the fair value of the award and is recognized as expense, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes compensation on a
straight-line basis over the requisite vesting period for each award. The following assumptions were used to calculate the fair value of its stock options as of December&nbsp;31, 2016: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2016</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1.2%&nbsp;-&nbsp;2.45%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.25&nbsp;-&nbsp;9.84</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">67.0%&nbsp;-&nbsp;77.8%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected Term</I>&#151;The Company has opted to use the &#147;simplified method&#148; for estimating the expected term of
options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected Volatility</I>&#151;Due to the Company&#146;s limited operating history and a lack of company specific historical and implied volatility data, the
Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#146;
shares during the equivalent period of the calculated expected term of the stock-based awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Risk-Free Interest Rate</I>&#151;The risk-free rate
assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the Company&#146;s stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected
Dividend</I>&#151;The Company has not issued any dividends in its history and does not expect to issue dividends over the life of the options and therefore has estimated the dividend yield to be zero. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair value of Common Stock</I>&#151;The fair value of the shares of common stock underlying the stock-based awards has historically been determined by the
board of directors, with input from management. Because there has been no public market for the Company&#146;s common stock, the board of directors has determined the fair value of the common stock on the grant-date of the stock-based award by
considering a number of objective and subjective factors, including enterprise valuations of the Company&#146;s common stock performed by an unrelated third-party specialist, valuations of comparable companies, sales of the Company&#146;s
convertible preferred stock to unrelated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third parties, operating and financial performance, the lack of liquidity of the Company&#146;s capital stock, and general and industry-specific economic outlook. The board of directors intended
all options granted to be exercisable at a price per share not less than the estimated per share fair value of common stock underlying those options on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, there was a total of $0.4&nbsp;million of unrecognized employee compensation costs net of estimated forfeitures related to <FONT
STYLE="white-space:nowrap">non-vested</FONT> stock option awards. During 2016, the intrinsic value of shares exercised was $1.2&nbsp;million and the fair value of shares vested during the year was $0.1&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, 147,792 vested stock options and 190,000 unvested stock options were held by
<FONT STYLE="white-space:nowrap">non-employees.</FONT> The Company remeasures the estimated fair value of the unvested portion of the award each period, until the award is fully vested. The Company believes that the fair value of the stock options
is more reliably measurable than the fair value of services received. The fair value of options granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> was estimated using the Black-Scholes method. The amount of stock-based compensation
expense related to <FONT STYLE="white-space:nowrap">non-employees</FONT> recognized in the financial statements for the year ended December&nbsp;31, 2016 was immaterial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Awards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2015, in conjunction
with the incorporation of the Company, the Company issued a total of 11,000,000 shares of common stock at $0.0001 per share to its two founders, the Chief Executive Officer and the President, under restricted stock agreements. At the date of grant,
the shares had an estimated fair value of $0.0001 per share. Under the terms of the restricted stock agreements, shares vest monthly over four years. Upon the termination of service of these individuals, unvested shares are subject to repurchase by
the Company at the original issue price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of the Company&#146;s <FONT STYLE="white-space:nowrap">non-vested</FONT> restricted stock for the
period presented is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average&nbsp;Grant<BR>Date Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Remaining&nbsp;Vesting<BR>(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,395,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.0001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.0001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance, December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,645,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.0001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9. Net Loss per Common Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per
share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,363,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: weighted-average common shares subject to repurchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,942,080</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares used to compute basic and diluted net loss per common
share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,421,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per
share attributable to common stockholders for the period presented because including them would have been antidilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,378,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock options issued and outstanding under 2015 Stock Option Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remaining shares available for issuance under 2015 Stock Option Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,082,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,645,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested early exercised common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,081,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,702,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10: Provision for Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.22</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33.78</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the components of the Company&#146;s deferred tax assets are as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal and state net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effects of (a)&nbsp;temporary differences between the carrying amounts of assets and
liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b)&nbsp;operating losses and tax credit carryforwards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of its net deferred tax assets.
The Company primarily considered such factors as its history of operating losses, the nature of the Company&#146;s deferred tax assets, and the timing, likelihood and amount, if any, of future taxable income during the periods in which those
temporary differences and carryforwards become deductible. At present, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance has been established and no
deferred tax asset is shown in the accompanying balance sheet. The valuation allowance increased by approximately $7.6&nbsp;million for the year ended 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2016, the Company has net operating loss carryforwards for federal income tax purposes of approximately $15.9&nbsp;million that begin to
expire in 2035, and federal research tax credits of approximately $0.5&nbsp;million that begin to expire in 2035. The Company also has state net operating loss carryforwards of approximately $15.9&nbsp;million that begin to expire in 2035, and state
research tax credits of approximately $0.5&nbsp;million that have no expiration date. Use of the net operating loss and credit carryforwards may be subject to a substantial annual limitation due to the ownership change provisions of U.S. tax law and
similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before use. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Uncertain Tax
Positions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has not been audited by the Internal Revenue Service or any state tax authority. It is subject to taxation in the United
States. Because of the net operating loss and research credit carryforwards, all of the Company&#146;s tax years, from 2015 to 2016, remain open to U.S. federal and California state tax examinations. There were no interest or penalties accrued at
December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows the provisions of FASB Accounting Standards Codification (ASC
<FONT STYLE="white-space:nowrap">740-10),</FONT> <I>Accounting for Uncertainty in Income Taxes</I>. ASC <FONT STYLE="white-space:nowrap">740-10</FONT> prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in
financial statements of uncertain tax positions that have been taken or expected to be taken on a tax return. No liability related to uncertain tax positions is recorded in the financial statements. The Company&#146;s reserve for unrecognized tax
benefits is approximately $0.2&nbsp;million at&nbsp;December 31, 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the full valuation allowance at December&nbsp;31, 2016, current adjustments to the unrecognized tax
benefit will have no impact on the Company&#146;s effective income tax rate; any adjustments made after the valuation allowance is released will have an impact on the tax rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases of unrecognized tax benefits related to current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not anticipate material changes to its uncertain tax positions through the next 12 months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11: Commitments and Contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purchase
Commitments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has contractual arrangements with research and development organizations and suppliers; however, these contracts are
generally cancelable on 30 days&#146; notice and the obligations under these contracts are largely based on services performed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases office space in Hayward, California under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating leases with various expiration
dates through 2024. Rent expense was $0.6&nbsp;million for the year ended December&nbsp;31, 2016. Future minimum lease payments under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating leases as of December&nbsp;31, 2016 are as follows
(in thousands): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2016, future minimum commitments under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating leases were
as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:91.30pt; font-size:8pt; font-family:Times New Roman"><B>Year ending December 31:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating</B><br><B>Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022 to 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has provided deposits for letters of credit totaling $0.2&nbsp;million to secure its obligations under its leases,
which have been classified as long-term assets on the Company&#146;s balance sheet as of December&nbsp;31, 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is not party to any legal proceedings and claims. In the Company&#146;s opinion, as of December&nbsp;31, 2016, there was not at
least a reasonable possibility that the Company had incurred a material loss, or a material loss in excess of a recorded accrual, with respect to any loss contingencies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As permitted under Delaware law
and in accordance with the Company&#146;s bylaws, the Company is required to indemnify its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to
indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as
of December&nbsp;31, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 12: Employee Benefit Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company sponsors a 401(k) defined contribution plan for its employees. This plan provides for <FONT STYLE="white-space:nowrap">tax-deferred</FONT> salary
deductions for all employees. Employee contributions are voluntary. Employees may contribute up to 100% of their annual compensation to this plan, as limited by an annual maximum amount as determined by the Internal Revenue Service. The Company may
match employee contributions in amounts to be determined at the Company&#146;s sole discretion. The Company made no contributions to the plan for the year ended December&nbsp;31, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 13: Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2017, the Company
entered into a license agreement (the WuXi Agreement) with WuXi Biologics (Cayman) Inc. (WuXi Biologics) for an exclusive license to develop, use, manufacture, and commercialize products including an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody in North America, Europe, Japan and certain other territories. The Company paid upfront and milestone payments of $18.5&nbsp;million. The WuXi Agreement also provides for clinical and
regulatory milestone payments, commercialization milestone payments of up to $375.0&nbsp;million, and tiered royalty payments to be made to WuXi Biologics that range from the high single-digits to low double-digits of net sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2017, the Company entered in an option and license agreement (Taiho Agreement) with Taiho Pharmaceutical Co., Ltd., (Taiho) in which Taiho will
provide $35.0&nbsp;million of <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable,</FONT> cash payments during the first three years of the agreement in exchange for an exclusive option, over a
five-year period, to <FONT STYLE="white-space:nowrap">in-license</FONT> the development and commercialization rights to clinical stage product candidates from the Company&#146;s portfolio for Japan and certain other territories in Asia (excluding
China). For each program for which Taiho exercises its option, the Company will receive an option payment and is eligible to receive up to $275.0&nbsp;million in clinical, regulatory, and commercial milestone payments, as well as royalties, ranging
from high single digits to <FONT STYLE="white-space:nowrap">mid-double</FONT> digits, on net sales in Taiho&#146;s territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2017, the
Company executed an operating lease (Lease Amendment) for an additional 30,000 square feet in an adjacent building to its headquarters in Hayward, California. Under the terms of the Lease Amendment on this new building, the Company has additional
lease obligations consisting of $5.9&nbsp;million in payments through 2025. This Lease Amendment also extended the terms of the operating lease on its existing facility by approximately eighteen months through 2025. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2017, the Company issued 36,241,698 shares of Series C convertible preferred stock to new and
existing stockholders in exchange for net proceeds of $106.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since December&nbsp;31, 2016, the Company has issued 4.1&nbsp;million common
stock option grants at a <FONT STYLE="white-space:nowrap">weighted-average</FONT> exercise price of $0.39 per share. These options vest monthly on a straight-line basis over 48&nbsp;months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has reviewed and evaluated material subsequent events from the balance sheet date of December&nbsp;31, 2016, through the date of the independent
auditors&#146; report. No subsequent events have been identified for disclosure, other than those matters noted above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g317356g91y73.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Arcus Biosciences, Inc. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PRELIMINARY
PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Citigroup </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Goldman
Sachs&nbsp;&amp; Co. LLC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Leerink</B><B><I> </I></B><B>Partners </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Through and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 (the 25th day after the
date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when
acting as an underwriter and with respect to an unsold allotment or subscription. </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Item 13. Other Expenses of Issuance and Distribution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the various expenses expected to be incurred and payable by us in connection with the sale and distribution of our common
stock, other than underwriting discounts and commissions. All amounts are estimates except for the Securities and Exchange Commission (SEC) registration fee, the Financial Industry Regulatory Authority (FINRA) filing fee and
the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; listing fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payable&nbsp;By<BR>Us</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue sky fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Registrar and transfer agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Item 14. Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law authorizes a court to award, or a corporation&#146;s board of directors to grant, indemnity to
directors and officers under certain circumstances and subject to certain limitations. The terms of Section&nbsp;145 of the Delaware General Corporation Law are sufficiently broad to permit indemnification under certain circumstances for
liabilities, including reimbursement of expenses incurred, arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As permitted by the Delaware General Corporation Law, our
amended and restated certificate of incorporation and amended and restated bylaws contain provisions relating to the limitation of liability and indemnification of directors and officers. The amended and restated certificate of incorporation
provides that our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for any breach of the director&#146;s duty of loyalty to us or our stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in respect of unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the Delaware General Corporation Law; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for any transaction from which the director derives any improper personal benefit. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated
certificate of incorporation also provides that if Delaware law is amended after the approval by our stockholders of the certificate of incorporation to authorize corporate action further eliminating or limiting the personal liability of directors,
then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws provide that we will indemnify our directors and officers to the fullest
extent permitted by Delaware law, as it now exists or may in the future be amended, against all expenses and liabilities reasonably incurred in connection with their service for or on our behalf. Our amended and restated bylaws provide that we shall
advance the expenses incurred by a director or officer in advance of the final disposition of an action or proceeding, and permit us to secure insurance on behalf of any director, officer, employee or other enterprise agent for any liability arising
out of his or her action in that capacity, whether or not Delaware law would otherwise permit indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to enter into indemnification
agreements with each of our directors and executive officers and certain other key employees, a form of which is attached as Exhibit 10.1. The form of agreement provides that we will indemnify each of our directors, executive officers and such other
key employees against any and all expenses incurred by that director, executive officer or other key employee because of his or her status as one of our directors, executive officers or other key employees, to the fullest extent permitted by
Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws. In addition, the form agreement provides that, to the fullest extent permitted by Delaware law, we will advance all expenses incurred by our
directors, executive officers and other key employees in connection with a legal proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the underwriting agreement contained in
Exhibit 1.1 to this registration statement, indemnifying our directors and officers against limited liabilities. In addition, Section&nbsp;1.10 of our amended and restated investors&#146; rights agreement (IRA) contained in Exhibit 4.2 to this
registration statement provides for indemnification of certain of our stockholders against liabilities described in our IRA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain insurance
policies that indemnify our directors and officers against various liabilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, that might be incurred by any director or officer in his or her
capacity as such. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Item 15. Recent Sales of Unregistered Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following sets forth information regarding all unregistered securities sold since April&nbsp;30, 2015, the date of our incorporation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have granted options to purchase 7,592,200 shares of our common stock to directors, officers and employees under our 2015 Stock Plan, with per share exercise prices ranging from $0.10 to $1.36. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have granted an option to purchase 30,000 shares of our common stock to an advisor outside of our 2015 Stock Plan, with a per share exercise price of $0.31. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have issued and sold an aggregate of 5,497,500 shares of our common stock upon exercise of options issued under our 2015 Stock Plan for aggregate consideration of $1,267,518, with per share exercise prices ranging
from $0.10 to $0.65. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In May 2015, August 2015, and September 2015, we issued and sold an aggregate of 49,725,000 shares of our Series A preferred stock at a purchase price of $1.00 per share to 56 accredited investors for an aggregate
purchase price of $49,725,000. In connection with the completion of this offering, all 49,725,000 shares of Series A preferred stock will automatically convert into an equivalent number of shares of common stock. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In August 2016, we issued and sold an aggregate of 34,653,462 shares of our Series B preferred stock at a purchase price of $2.02 per share to 44 accredited investors for an aggregate purchase price of approximately
$69,999,993. In connection with the completion of this offering, all 34,653,462 shares of Series B preferred stock will automatically convert into an equivalent number of shares of common stock. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In November 2017, we issued and sold an aggregate of 36,241,698 shares of our Series C preferred stock at a
purchase price of $2.9524 per share to 32 accredited investors for an aggregate purchase </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
price of approximately $106,999,989. In connection with the completion of this offering, all 36,241,698 shares of Series C preferred stock will automatically convert into an equivalent number of
shares of common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any
public offering. We believe that the offers, sales and issuances of the above securities were exempt from registration under the Securities Act by virtue of Section&nbsp;4(a)(2) of the Securities Act or Regulation D promulgated thereunder as
transactions by an issuer not involving any public offering, or in reliance on Rule 701 promulgated under Section&nbsp;3(b) of the Securities Act because the transactions were pursuant to compensatory benefit plans or contracts relating to
compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution
thereof, and appropriate legends were placed upon the stock certificates issued in these transactions. We believe all recipients had adequate information about us or had adequate access, through their relationships with us, to information about us.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Item 16. Exhibits and Financial Statement Schedules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Exhibits.</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>no.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Restated Certificate of Incorporation of Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation of Registrant, to be effective upon completion of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws of Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws of Registrant, to be effective upon completion of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Registrant&#146;s Common Stock Certificate.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Investors&#146; Rights Agreement, dated November&nbsp;3, 2017, between the Registrant and the parties thereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Gunderson Dettmer Stough Villeneuve Franklin&nbsp;&amp; Hachigian, LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Arcus Biosciences, Inc. 2015 Stock Plan and forms of agreements thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Arcus Biosciences, Inc. 2018 Equity Incentive Plan, to be in effect upon completion of the offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Arcus Biosciences, Inc. 2018 Employee Stock Purchase Plan, including form agreements, to be in effect upon the completion of the offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, between the Registrant and Terry Rosen, Ph.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, between the Registrant and Juan Carlos Jaen, Ph.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Offer Letter, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, between the Registrant and Jennifer Jarrett.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease, dated September&nbsp;30, 2015, between the Registrant and Hayward Point Eden I Limited Partnership, as amended on July&nbsp;22, 2016 and October&nbsp;12, 2017.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Compensation Program for <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement, dated December&nbsp;8, 2016, between the Registrant and Abmuno Therapeutics LLC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement, dated August&nbsp;16, 2017, between the Registrant and WuXi Biologics (Cayman) Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Option and License Agreement, dated September&nbsp;19, 2017, between the Registrant and Taiho Pharmaceutical Co., Ltd.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Independent Registered Public Accounting Firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Gunderson Dettmer Stough Villeneuve Franklin&nbsp;&amp; Hachigian, LLP (contained in Exhibit 5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (contained in the signature page to this registration statement).</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Registrant has requested confidential treatment for certain portions of this exhibit. This exhibit omits the information subject to this confidentiality request. Omitted portions have been filed separately with the
Securities and Exchange Commission. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Financial Statement Schedules.</I> All schedules have been omitted because the
information required to be presented in them is not applicable or is shown in the financial statements or related notes, which is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Item 17. Undertakings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreements certificates in such
denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for
liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the
securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby
undertakes that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of
prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)&nbsp;(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of
this registration statement as of the time it was declared effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(2) For the purpose of determining any liability under the
Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Signatures </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in Hayward, State of California, on the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; day of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-size:10pt"><B>ARCUS BIOSCIENCES, INC.</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">By:</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:8pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Terry Rosen, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Chief Executive Officer</I></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Power of Attorney </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Terry Rosen, Ph.D.
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and each of them, his or her true and lawful
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities,
to sign any and all amendments, including post-effective amendments, to this registration statement, and any registration statement relating to the offering covered by this registration statement and filed pursuant to Rule 462(b) under the
Securities Act of 1933, as amended, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <FONT STYLE="white-space:nowrap">attorneys-in</FONT> fact
and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming
all that each of said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons on behalf of the
registrant and in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Title</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Date</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Terry Rosen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer and Director<BR>(Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Juan Carlos Jaen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President and Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jennifer Jarrett</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Business Officer and Chief Financial Officer<BR>(Principal Financial Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Steven Chan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Principal Accounting Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yasunori Kaneko, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Kathryn Falberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>between </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS
BIOSCIENCES, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABMUNO THERAPEUTICS LLC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN
INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">DEFINITIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">LICENSE GRANTS, OWNERSHIP AND EXCLUSIVITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">License Grant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Sublicensing and Subcontracting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Promotion</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ownership of Improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No Implied Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Non-Competition</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section 365(n) of the Bankruptcy Code</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">2.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">JN Biosciences Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">DEVELOPMENT AND COMMERCIALIZATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Development and Commercialization Activities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Manufacturing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Assistance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Clarification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">REGULATORY MATTERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Recalls or Corrective Action</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">FINANCIAL PROVISIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Execution Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Milestone Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Payment Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">CONFIDENTIAL INFORMATION AND PROPRIETARY RIGHTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Definition</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Permitted Disclosure and Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Intentionally omitted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Survival</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">REPRESENTATIONS AND WARRANTIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">7.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Mutual Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">7.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Abmuno Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">7.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Disclaimer of Warranty</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">INDEMNIFICATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Indemnification by Abmuno</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Indemnification by Arcus</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table Of Contents </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(cont&#146;d) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Procedure for Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.4 </TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Set-Off Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Limitation of Damages</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">PATENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Prosecution and Maintenance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Infringement of Licensed Patents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Infringement Claims by Third Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">9.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Biosimilars</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">TERM AND TERMINATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Effects of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accrued Rights; Surviving Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">11.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">MISCELLANEOUS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Publications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Public Announcements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Relationship of the Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Registration of this Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Dispute Resolution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Assignment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Headings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Entire Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Modification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No Third Party Beneficiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ambiguities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This License Agreement (&#147;Agreement&#148;), effective as of December&nbsp;8, 2016 (&#147;Effective Date&#148;), is by and between Arcus
Biosciences, Inc. (&#147;Arcus&#148;), with offices at 3928 Point Eden Way, Hayward, CA 94545 and Abmuno Therapeutics LLC (&#147;Abmuno&#148;), with offices at 914 Channing Way, Berkeley, CA 94710. Arcus and Abmuno may be referred to in this
Agreement individually as a &#147;Party&#148; or together as the &#147;Parties.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BACKGROUND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Abmuno possesses certain patents, patent applications, proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT>
scientific and technical information relating to certain antibodies to TIGIT (as defined below); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Arcus wishes to obtain,
and Abmuno is willing to grant, an exclusive license to such intellectual property rights for the development, use, manufacture and commercialization of products for any use, including, without limitation, the treatment, prevention or control of any
human disease or condition; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, for good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Parties agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>DEFINITIONS</B><B>. </B>For purposes of this Agreement, the following capitalized terms, whether used in the singular or plural,
shall have the following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;&#147;Abmuno&#148; means Abmuno Therapeutics LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;&#147;Abmuno Indemnitees&#148; shall have the meaning assigned thereto in Section&nbsp;8.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.3&nbsp;&nbsp;&nbsp;&nbsp; &#147;Affiliate&#148; means any Person that, directly or indirectly, controls, is controlled by or is under common
control with a Party for so long as such control exists, where &#147;control&#148; means the decision-making authority as to such Person and, further, where such control shall be presumed to exist where a Person owns more than fifty percent (50%) of
the equity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) entitled to vote regarding composition of the board of directors or other body entitled to direct the affairs of
the entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.4&nbsp;&nbsp;&nbsp;&nbsp; &#147;Antibody&#148; means an anti-TIGIT antibody. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.5&nbsp;&nbsp;&nbsp;&nbsp; &#147;Applicable Law&#148; means any law, statute, rule or regulation issued by a Governmental Authority or
Regulatory Authority and any judicial, governmental, or administrative order, judgment, decree, or ruling, in each case as applicable to the subject matter of this Agreement and the Parties and having a binding effect on it and them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.6&nbsp;&nbsp;&nbsp;&nbsp;&#147;Arbitration Date&#148; shall have the meaning assigned
thereto in Section&nbsp;11.5 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.7&nbsp;&nbsp;&nbsp;&nbsp;&#147;Arcus&#148; means Arcus Biosciences, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.8&nbsp;&nbsp;&nbsp;&nbsp;&#147;Arcus Indemnitees&#148; shall have the meaning assigned thereto in Section&nbsp;8.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.9&nbsp;&nbsp;&nbsp;&nbsp;&#147;BLA&#148; means a Biologics License Application or any amendments thereto submitted to the FDA, or any
equivalent thereof submitted to a Regulatory Authority outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.10&nbsp;&nbsp;&nbsp;&nbsp; &#147;Claim&#148; means
any charge, complaint, action, suit, proceeding, hearing, investigation, claim or demand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.11&nbsp;&nbsp;&nbsp;&nbsp;&#147;Clinical
Trials&#148; means a clinical trial in human subjects designed to measure the safety and/or efficacy of a Licensed Product. Clinical Trials shall include Phase I Clinical Trials, Phase II Clinical Trials, Phase III Clinical Trials and any <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> or post-Regulatory Approval studies undertaken in relation to any Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.12&nbsp;&nbsp;&nbsp;&nbsp;&#147;Combination Product&#148; means a product that is a combination of a Licensed Product sold together with
another biologically active compound(s) or another biologically active ingredient(s) (such other compound or ingredient, the &#147;Other Product&#148;) for a single invoiced price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.13&nbsp;&nbsp;&nbsp;&nbsp;&#147;Commercialization&#148; or &#147;Commercialize&#148; means engaging in any and all activities directed to
marketing, promoting, conducting post-Regulatory Approval studies, distributing, offering for sale, selling, importing, exporting or exploiting a product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.14&nbsp;&nbsp;&nbsp;&nbsp;&#147;Commercially Reasonable Efforts&#148; means those efforts commensurate with those efforts commonly used in
the biopharmaceutical industry by a company of comparable size in connection with the development or commercialization of products that are of similar status, including market potential, profit potential and strategic value, as determined based on
conditions then prevailing, including safety, efficacy, competitive considerations within the marketplace, projected market size, intellectual property protection and duration, manufacturing costs and other relevant commercial and regulatory
considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.15&nbsp;&nbsp;&nbsp;&nbsp;&#147;Confidential Information&#148; shall have the meaning assigned thereto in
Section&nbsp;6.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.16&nbsp;&nbsp;&nbsp;&nbsp;&#147;Control&#148; or &#147;Controlled&#148; means with respect to any item of or right
under Licensed Patents or Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> the possession of (whether by ownership or license, other than pursuant to this Agreement) the ability of a Party to grant a license or sublicense of such items or
right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such license or sublicense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.17&nbsp;&nbsp;&nbsp;&nbsp;&#147;Cover&#148; or &#147;Covering&#148; means (i)&nbsp;with
respect to any Patent, that at least one Valid Claim of such Patent would be infringed by the manufacture, use or sale of a product, method or device, as applicable, and (ii)&nbsp;with respect to any other intellectual property right, that the
manufacture, use or sale of a product, method or device would infringe or misappropriate such rights, as applicable, unless in the case of either (i)&nbsp;or (ii), such manufacture, use or sale was in accordance with a granted license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.18&nbsp;&nbsp;&nbsp;&nbsp;&#147;Development&#148; or &#147;Develop&#148; means engaging in preclinical and clinical drug development
activities, including, but not limited to, discovery, test method development, stability testing, toxicology, formulation, process development, manufacturing <FONT STYLE="white-space:nowrap">scale-up,</FONT> development-stage manufacturing,
analytical method validation, manufacturing process validation, cleaning validation, post-approval changes, quality assurance/quality control, statistical analysis, report writing, preclinical studies, Clinical Trials, regulatory filing submission
and approval and regulatory affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.19&nbsp;&nbsp;&nbsp;&nbsp; &#147;Disclosing Party&#148; shall have the meaning assigned thereto in
Section&nbsp;6.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.20&nbsp;&nbsp;&nbsp;&nbsp;&#147;Effective Date&#148; shall have the meaning assigned thereto in the first paragraph
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.21&nbsp;&nbsp;&nbsp;&nbsp;&#147;FD&amp;C Act&#148; means the United States Federal Food, Drug&nbsp;&amp; Cosmetic
Act, as amended, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.22&nbsp;&nbsp;&nbsp;&nbsp;&#147;FDA&#148; means the United States Food and Drug Administration and any successor agency thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.23&nbsp;&nbsp;&nbsp;&nbsp;&#147;Field&#148; means all uses, including, without limitation, the diagnosis, treatment, prevention or control
of any human disease or condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.24&nbsp;&nbsp;&nbsp;&nbsp;&#147;First Commercial Sale&#148; means, with respect to any Licensed
Product and with respect to any country of the Territory, the first commercial transfer or disposition for value of a Licensed Product by Arcus, its Affiliates or their sublicensees to a Third Party following, if required by Applicable Law,
Regulatory Approval of such Licensed Product and, when Regulatory Approval is not required by Applicable Law for the Licensed Product, the first commercial sale in that country, in each case for use or consumption of such Licensed Product in such
country by the general public; provided that sales for clinical study purposes or compassionate, named patient (paid or unpaid) or similar use will not constitute a First Commercial Sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.25&nbsp;&nbsp;&nbsp;&nbsp;&#147;GLP Safety Study&#148; means toxicology studies that meet the requirements set forth in 21 CFR Part 58
pertaining to Good Laboratory Practices for use or intended for use in an investigational new drug application, but excluding toxicology studies performed in the course of evaluating compounds prior to selection of a development candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.26&nbsp;&nbsp;&nbsp;&nbsp;&#147;Good Manufacturing Practices&#148; or &#147;GMP&#148;
means, with respect to the United States, the minimum then-current good manufacturing practices for methods, facilities, and controls to be used for the manufacture, processing, packing, or holding of a drug to assure that it meets the requirements
of the FD&amp;C Act for safety and has the identity and strength and meets the quality and purity characteristics, specified in 21 C.F.R. Parts&nbsp;210 and 211, as may be amended, and, with respect to any other country or jurisdiction, the
equivalent regulations in such other country or jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.27&nbsp;&nbsp;&nbsp;&nbsp;&#147;Governmental Authority&#148; means an
applicable multi- or supra-national, federal, state, local, municipal or other government authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court
or other tribunal). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.28&nbsp;&nbsp;&nbsp;&nbsp; &#147;Improvements&#148; means any adaptation, change, redesign, modification,
invention, discovery, enhancement or development conceived, reduced to practice, developed or made after the Effective Date and (i)&nbsp;incorporated into any Licensed Product, (ii)&nbsp;made with respect to the specifications, the raw materials or
the method or process of manufacture or production of any Licensed Product, including any product which performs the same function as any Licensed Product, (iii)&nbsp;incorporating, utilizing, or developed utilizing, Licensed <FONT
STYLE="white-space:nowrap">Know-How,</FONT> or (iv)&nbsp;requiring the practice of an invention claimed in the Licensed Patents. Inventorship for Improvements shall be determined in accordance with the patent laws of the United States (Title 35,
United States Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.29&nbsp;&nbsp;&nbsp;&nbsp;&#147;IND&#148; means (i)&nbsp;in the United States, an Investigational New Drug
Application, as defined in the FD&amp;C Act, filed with the FDA that is required to be filed with the FDA before conducting a Clinical Trial (including all supplements and amendments that may be filed with respect to the foregoing); and
(ii)&nbsp;any foreign counterpart of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.30&nbsp;&nbsp;&nbsp;&nbsp;&#147;Intellectual Property Rights&#148; means any and
all patent rights, copyright rights, trade secret rights, <I>sui generis</I> database rights and all other intellectual and industrial property rights of any sort throughout the world (including any application therefor) whether now known or
hereafter existing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.31&nbsp;&nbsp;&nbsp;&nbsp;&#147;JAMS&#148; shall have the meaning assigned thereto in Section&nbsp;11.5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.32&nbsp;&nbsp;&nbsp;&nbsp;&#147;JN Biosciences&#148; means JN Biosciences LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.33&nbsp;&nbsp;&nbsp;&nbsp;&#147;JN Biosciences Agreement&#148; means the License Agreement between Abmuno and JN Biosciences LLC, dated
December&nbsp;8, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.34&nbsp;&nbsp;&nbsp;&nbsp; &#147;JN Biosciences Licensed Patents&#148; means any and all Patents licensed or
sublicensed to Abmuno pursuant to the JN Biosciences Agreement that are necessary and/or useful in Developing, using, manufacturing, Commercializing and/or otherwise exploiting Licensed Products in the Field within the Territory (solely as a result
of its containing an Antibody, or any portions or derivatives thereof or modifications to the sequence thereof, provided such derivatives or modifications do not incorporate or use any other technology of JN Biosciences covered by a Patent, and not
with respect to any other component or technology incorporated therein or used in connection therewith). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.35&nbsp;&nbsp;&nbsp;&nbsp;&#147;Joint Improvement&#148; means an Improvement with respect
to which employees and/or agents of both Arcus and Abmuno are joint inventors in the course of the activities hereunder, regardless of whether any Third Parties are also joint inventors, including, without limitation, all Intellectual Property
Rights therein. Inventorship for Joint Improvements shall be determined in accordance with the patent laws of the United States (Title 35, United States Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.36&nbsp;&nbsp;&nbsp;&nbsp;&#147;JSC&#148; shall have the meaning assigned thereto in Section&nbsp;3.3.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">1.37&nbsp;&nbsp;&nbsp;&nbsp;&#147;Know-How&#148;</FONT> means proprietary technical information, processes,
formulae, data, inventions, methods, knowledge, discoveries, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets and other information, whether or not patentable, but that is not generally known and is still Confidential Information,
including any tangible embodiments of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.38&nbsp;&nbsp;&nbsp;&nbsp;&#147;Licensed IP&#148; means the Licensed Patents and
Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and Abmuno&#146;s interest in the Joint Improvements collectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.39&nbsp;&nbsp;&nbsp;&nbsp;&#147;Licensed <FONT STYLE="white-space:nowrap">Know-How&#148;</FONT> means [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.40&nbsp;&nbsp;&nbsp;&nbsp;&#147;Licensed Patents&#148; means the Patents listed in Exhibit 1 hereto and (i)&nbsp;patent applications filed
either from the foregoing or from an application claiming priority to the foregoing, including all provisional patent applications, <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, substitutions, continuations, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisions, renewals and continued prosecution applications, and all patents granted thereon, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(ii)&nbsp;patents-of-addition,</FONT></FONT> revalidations, reissues, reexaminations and extensions, adjustments or restorations by existing or future extension or restoration mechanisms, including patent term adjustments,
patent term extensions, supplementary protection certificates or the equivalent thereof, (iii)&nbsp;inventor&#146;s certificates, utility models, innovation patents and design patents for any of the foregoing, (iv)&nbsp;other forms of
government-issued rights substantially similar to any of the foregoing, including <FONT STYLE="white-space:nowrap">so-called</FONT> pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or
patent of additions, to any of such foregoing, (v)&nbsp;United States and foreign counterparts of any of the foregoing, (vi)&nbsp;the JN Biosciences Licensed Patents and (vii)&nbsp;all other Patents that have at least one Valid Claim Covering, and
are necessary for, the Development, use, manufacture, Commercialization and/or other exploitation of a Licensed Product in the Field in the Territory, whether or not listed on Exhibit 1, in the case of (vii), to the extent any of such Patents are
owned or Controlled by Abmuno or any Affiliate of Abmuno as of the Effective Date or during the Term of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.41&nbsp;&nbsp;&nbsp;&nbsp;&#147;Licensed Products&#148; means any product that (i)&nbsp;contains an Antibody, and (ii)&nbsp;the Development,
manufacture, use, sale or importation of which incorporates or utilizes any Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> or, absent the licenses granted to Arcus under this Agreement, would infringe a Valid Claim of a Licensed Patent.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.42&nbsp;&nbsp;&nbsp;&nbsp;&#147;Losses&#148; means any and all damages (including, but not
limited to, all loss of profits, diminution in value, and incidental, indirect, consequential, special, reliance, exemplary, punitive, statutory and treble damages), awards, deficiencies, settlement amounts, defaults, assessments, fines, dues,
penalties, costs, fees, liabilities, obligations, taxes, liens, losses and expenses (including, but not limited to, court costs, interest and reasonable fees of attorneys, accountants and other experts) incurred by or awarded to Third Parties and
required to be paid to Third Parties with respect to a Claim by reason of any judgment, order, decree, stipulation or injunction, or any settlement entered into in accordance with the provisions of this Agreement, together with all documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses incurred in contesting any Third Party Claim or complying with any judgments, orders, decrees, stipulations and injunctions that arise from or
relate to a Third Party Claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.43&nbsp;&nbsp;&nbsp;&nbsp;&#147;Net Sales&#148; means, with respect to any Licensed Product, the gross
sales price of such Licensed Product invoiced by Arcus, its Affiliates or their sublicensee(s) (which sublicensees do not include distributors) (the &#147;Selling Party&#148;) to Third Parties (which Third Parties do not include distributors), less:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net Sales will be
determined from books and records maintained in accordance with GAAP, consistently applied throughout Arcus and across all products of Arcus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, a Licensed Product is sold in the form of a
Combination Product, the Net Sales for such Licensed Product in the Combination Product under this Agreement will be calculated by [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.44&nbsp;&nbsp;&nbsp;&nbsp;&#147;Other Product&#148; shall have the meaning assigned thereto in the definition of Combination Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.45&nbsp;&nbsp;&nbsp;&nbsp;&#147;Party&#148; or &#147;Parties&#148; shall have the meaning assigned thereto in the first paragraph of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.46&nbsp;&nbsp;&nbsp;&nbsp;&#147;Patent&#148; means any and all national, regional and international (i)&nbsp;issued patents
and pending patent applications (including provisional patent applications), (ii)&nbsp;patent applications filed either from the foregoing or from an application claiming priority to the foregoing, including all provisional applications, converted
provisionals, substitutions, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisions, renewals and continued prosecution applications, and all patents granted thereon, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(iii)&nbsp;patents-of-addition,</FONT></FONT> revalidations, reissues, reexaminations and extensions, adjustments or restorations by existing or future extension or restoration mechanisms,
including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (iv)&nbsp;inventor&#146;s certificates, utility models, innovation patents and design patents, (v)&nbsp;other forms of
government-issued rights substantially similar to any of the foregoing, including <FONT STYLE="white-space:nowrap">so-called</FONT> pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or
patent of additions to any of such foregoing and (vi)&nbsp;United States and foreign counterparts of any of the foregoing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.47&nbsp;&nbsp;&nbsp;&nbsp; &#147;Patented Products&#148; means any product, the
Development, manufacture, use, sale or importation of which, absent the licenses granted to Arcus under this Agreement, would infringe a Valid Claim of a Licensed Patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.48&nbsp;&nbsp;&nbsp;&nbsp;&#147;Person&#148; means any natural person, corporation, general partnership, limited partnership, limited
liability company, joint venture, proprietorship or other <I>de jure </I>entity organized under Applicable Laws of any jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.49&nbsp;&nbsp;&nbsp;&nbsp;&#147;Phase I Clinical Trial&#148; means a Clinical Trial that provides for the first introduction into humans of
a product with the primary purpose of determining safety, metabolism and pharmacokinetic properties and clinical pharmacology of such product, in a manner that is generally consistent with 21 CFR &#167; 312.21(a), as amended (or its successor
regulation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.50&nbsp;&nbsp;&nbsp;&nbsp;&#147;Phase II Clinical Trial&#148; means a Clinical Trial, the principal purpose of which is to
make a preliminary determination as to whether a product is safe for its intended use and to obtain sufficient information about such product&#146;s efficacy, in a manner that is generally consistent with 21 CFR &#167; 312.21(b), as amended (or its
successor regulation), to permit the design of further Clinical Trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.51&nbsp;&nbsp;&nbsp;&nbsp;&#147;Phase III Clinical Trials&#148;
means a pivotal Clinical Trial with a defined dose or a set of defined doses of a therapeutic product designed to ascertain efficacy and safety of such product, in a manner that is generally consistent with 21 CFR &#167; 312.21(c), as amended (or
its successor regulation), for the purpose of enabling the preparation and submission of a BLA or a foreign equivalent thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.52&nbsp;&nbsp;&nbsp;&nbsp; &#147;Pricing Approval&#148; means the later of (i)&nbsp;the approval, agreement, determination or governmental
decision establishing the price for a Licensed Product that can be legally charged to consumers, as required in a given jurisdiction or country in connection with Commercialization of such Licensed Product in such jurisdiction or country and
(ii)&nbsp;the approval, agreement, determination or governmental decision establishing, the level of reimbursement for such Licensed Product that will be reimbursed by Governmental Authorities, as required in a given jurisdiction or country in
connection with Commercialization of such Licensed Product in such jurisdiction or country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.53&nbsp;&nbsp;&nbsp;&nbsp;
&#147;Promotional Materials&#148; shall have the meaning set forth in Section&nbsp;2.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.54&nbsp;&nbsp;&nbsp;&nbsp; &#147;Receiving
Party&#148; shall have the meaning assigned thereto in Section&nbsp;6.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.55&nbsp;&nbsp;&nbsp;&nbsp; &#147;Regulatory Approval&#148;
means regulatory approval required to Commercialize a Licensed Product for a disease or condition in accordance with the Applicable Laws of a given country, including Pricing Approval if Pricing Approval is required under Applicable Law to
Commercialize such Licensed Product for such disease or condition in such country. In the United States, its territories and possessions, Regulatory Approval means approval of a BLA or an equivalent by the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.56&nbsp;&nbsp;&nbsp;&nbsp;&#147;Regulatory Authority&#148; means, with respect to a country
in the Territory, any national (e.g., the FDA), supra-national (e.g., the European Commission, the Council of the European Union, or the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council
or other Governmental Authority involved in the granting of a Regulatory Approval, for biopharmaceutical products in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.57&nbsp;&nbsp;&nbsp;&nbsp; &#147;Stage 1 Technology Transfer&#148; shall have the meaning assigned thereto in Section&nbsp;3.3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.58&nbsp;&nbsp;&nbsp;&nbsp;&#147;Stage 2 Technology Transfer&#148; shall have the meaning assigned thereto in Section&nbsp;3.3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.59&nbsp;&nbsp;&nbsp;&nbsp;&#147;Term&#148; shall have the meaning assigned thereto in Section&nbsp;10.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.60&nbsp;&nbsp;&nbsp;&nbsp;&#147;Territory&#148; means all the countries and territories of the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.61&nbsp;&nbsp;&nbsp;&nbsp;&#147;Third Party&#148; means a Person who is not a Party or an Affiliate of a Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.62&nbsp;&nbsp;&nbsp;&nbsp;&#147;Third Party Claim&#148; shall have the meaning assigned thereto in Section&nbsp;8.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.63&nbsp;&nbsp;&nbsp;&nbsp;&#147;TIGIT&#148; means T cell immunoreceptor with Ig and ITIM domains; also known as VSIG9, VSTM3 and WUCAM and
having the sequence and activity as described in UnitProt ID Q495A1, NCBI Reference Sequence: NP_776160.2, as well as splice variants and allotypic variants of the TIGIT protein with a sequence identity of at least [***]% of sequences referenced
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.64&nbsp;&nbsp;&nbsp;&nbsp;&#147;Trademarks&#148; shall have the meaning assigned thereto in Section&nbsp;2.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.65&nbsp;&nbsp;&nbsp;&nbsp;&#147;Transferred Technology&#148; shall have the meaning assigned thereto in Section&nbsp;3.3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.66&nbsp;&nbsp;&nbsp;&nbsp;&#147;United States&#148; means the United States of America and its territories and possessions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">1.67&nbsp;&nbsp;&nbsp;&nbsp;&#147;Valid Claim&#148; means with respect to a Patent in a country, any claim of an (i)&nbsp;issued Patent that
has not (a)&nbsp;expired, irretrievably lapsed or been abandoned, revoked, dedicated to the public or disclaimed or (b)&nbsp;been found to be unpatentable, invalid or unenforceable by an unreversed and unappealable decision of a Governmental
Authority in such country or (ii)&nbsp;application for a Patent that (a)&nbsp;has been pending for less than [***] years from the earliest claimed priority date and is being prosecuted in good faith and has not been abandoned or finally disallowed
without the possibility of appeal or <FONT STYLE="white-space:nowrap">re-filing</FONT> and (b)&nbsp;has not been admitted to be invalid or unenforceable through reissue, reexamination, or disclaimer, and which is not subject to an interference
claim. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;LICENSE GRANTS, OWNERSHIP AND EXCLUSIVITY</B>.<B></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>License Grant</U>. Subject to the terms and conditions of this Agreement, Abmuno grants to Arcus, and Arcus
accepts, an exclusive (even as to Abmuno and its Affiliates), <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except as set forth in Section&nbsp;11.7) license, with the right to sublicense (as provided in Section&nbsp;2.2) under the
Licensed IP, to make, have made, use, register, sell, offer to sell, have sold, import, export, exploit, research, improve, Develop and Commercialize Licensed Products in the Field in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Sublicensing and Subcontracting</U>. Arcus may sublicense at any time, without the prior written consent of
Abmuno, its rights to research, otherwise Develop, manufacture, sell, otherwise Commercialize or exploit Licensed Products, in whole or in part, to any (i)&nbsp;Affiliate or (ii)&nbsp;Third Parties; provided that, in the case of a sublicense to a
Third Party, such Third Party is a company that (a)&nbsp;engages in, and/or has one or more affiliates that engages in, research, development and/or commercialization of one or more biopharmaceuticals or biologics products and (b) [***]. In
addition, notwithstanding the foregoing, after Arcus has [***], Arcus may sublicense, without the prior written consent of Abmuno, its rights to research, otherwise Develop, manufacture, sell, otherwise Commercialize or exploit Licensed Products, in
whole or in part, to any Third Parties, provided only that such Third Party is a company that engages in, and/or has one or more affiliates that engages in, research, development and/or commercialization of one or more biopharmaceuticals or
biologics products. If Abmuno is unable to determine whether the information referenced in (b)&nbsp;above about the sublicensee is true based on publicly available information, then Arcus, within fifteen (15)&nbsp;days after a request from Abmuno,
at its option, shall either (A)&nbsp;provide information to Abmuno (subject to Section&nbsp;6 hereof) about the sublicensee sufficient to validate the criteria in (b)&nbsp;above or (B)&nbsp;have one of its officers certify in writing as to the truth
of the aforementioned criteria. If Abmuno&#146;s prior written consent is required for Arcus to sublicense its rights to research, otherwise Develop, manufacture, sell, otherwise Commercialize or exploit Licensed Products, in whole or in part, to a
Third Party, Abmuno may not unreasonably withhold, condition or delay any such consent, and if Abmuno fails to reject in writing any such proposed sublicense within ten (10)&nbsp;business days after delivery of written request by Arcus to Abmuno for
such sublicense, then Abmuno shall be deemed to have consented to such sublicense. Arcus shall secure all appropriate covenants, obligations and rights from any sublicensee to ensure that such sublicensee is subject to, and Arcus can comply with,
all of Arcus&#146;s applicable covenants and obligations to Abmuno under this Agreement. Arcus shall be responsible for any failure of its sublicensees to comply with the applicable provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If requested by Arcus, Abmuno will discuss, acting reasonably and in good faith, with Arcus any proposed modifications as may be requested by a potential
sublicensee with respect to the terms and conditions of this Agreement. Upon termination of this Agreement for any reason, any sublicensee shall have the right to seek a license from Abmuno to the Licensed IP, and Abmuno agrees to negotiate such
licenses in good faith under reasonable terms and conditions (e.g., under terms and conditions substantially similar to those herein); provided that such sublicensee was not the cause of such termination. At the request of Arcus, Abmuno agrees to
meet with any potential sublicensee or sublicensee to provide assurance of contingency terms for obtaining a license and sublicense from Abmuno in the event of termination of this Agreement prior to termination of the related sublicense agreement
with Arcus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the sake of clarity, contract manufacturers and distributors shall not be deemed sublicensees, but
instead, shall be deemed subcontractors for the purposes of this Section. Arcus may freely subcontract its rights to research, otherwise Develop, manufacture, sell, otherwise Commercialize or exploit Licensed Products, in whole or in part; provided
(A)&nbsp;Arcus shall secure all appropriate covenants, obligations and rights from any subcontractor to ensure that such subcontractor is subject to, and Arcus can comply with, all of Arcus&#146;s applicable covenants and obligations to Abmuno under
this Agreement and (B)&nbsp;Arcus shall be responsible for any failure of its subcontractors to comply with the applicable provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any Arcus sublicensee may further sublicense and subcontract its rights to research, otherwise Develop, manufacture, sell, otherwise Commercialize or exploit
Licensed Products, in whole or in part; provided that any such sublicense is granted, or such subcontract is entered into, in accordance with the terms of this Section above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Promotion</U>. Licensed Products shall be Commercialized solely under trademarks and trade dress selected by
Arcus (collectively, &#147;Trademarks&#148;) and solely in connection with packaging, inserts, digital content and similar information and materials selected by Arcus or its Affiliates or any of their sublicensees (collectively, &#147;Promotional
Materials&#148;). As between the Parties, Arcus shall exclusively own all Promotional Materials and all Trademarks for Licensed Products, and shall be responsible for the procurement, filing and maintenance of trademark registrations for such
Trademarks and all related costs and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Ownership of Improvements</U>. Arcus shall own all right,
title and interest in and to any Improvements invented solely by Arcus, including, without limitation, any Intellectual Property Rights therein. Each Party shall own a fifty percent (50%) undivided interest in all Joint Improvements. The Parties
hereby make any assignments necessary to accomplish the foregoing ownership provisions. Except as expressly provided in this Agreement and subject to any restrictions therein, each joint owner may make, sell, use, license, assign, mortgage or keep
Joint Improvements, and otherwise undertake all activities a sole owner might undertake with respect to such inventions, discoveries and <FONT STYLE="white-space:nowrap">know-how,</FONT> without the consent of and without accounting to the other
joint owner; provided that any assignment, license or other disposition or use (i)&nbsp;shall at all times be and remain subject to the grants of rights and accompanying conditions and obligations with respect thereto under this Agreement, and
(ii)&nbsp;allow the Parties to exercise their rights and perform their obligations under this Agreement, in particular to Develop and Commercialize Licensed Products in at least the same scope as prior to such assignment, license or other such
disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.5&nbsp;&nbsp;&nbsp;&nbsp;<U>No Implied Rights</U>. Nothing contained in this Agreement confers or will be construed to
confer any rights or licenses by implication, estoppel or otherwise, in, to or under any intellectual property rights, other than the rights and licenses expressly granted in this Agreement. All rights not expressly granted by a Party under this
Agreement are reserved to such Party. Without limitation, as between the Parties, Abmuno retains sole and exclusive ownership of all rights, title and interests in and to the Licensed IP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.6&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Competition</FONT></U>.
Abmuno shall not, and shall ensure that its Affiliates (if any) shall not, initiate, or be involved in, any new anti-TIGIT discovery, Development or Commercialization project for a period of [***] years following the Effective Date. In addition,
Abmuno shall cause each of [***], and shall use Commercially Reasonable Efforts to cause JN Biosciences, [***] to enter into an agreement with Arcus in such form as has been approved by Arcus, either concurrently with or prior to the Parties&#146;
execution of this Agreement, under which, in accordance with the terms of such agreements, [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Section
365(n) of the Bankruptcy Code</U>. All rights and licenses granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n) of the U.S. Bankruptcy Code, licenses of rights to
&#147;intellectual property&#148; as defined under Section&nbsp;101(35A) of the U.S. Bankruptcy Code to the extent permitted thereunder. The Parties shall retain and may fully exercise all of their respective rights and elections under the U.S.
Bankruptcy Code. Upon the bankruptcy of any Party, the <FONT STYLE="white-space:nowrap">non-bankrupt</FONT> Party shall further be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property, and such,
if not already in its possession, shall be promptly delivered to the <FONT STYLE="white-space:nowrap">non-bankrupt</FONT> Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.8&nbsp;&nbsp;&nbsp;&nbsp;<U>JN Biosciences Agreement</U>. Abmuno shall (i)&nbsp;faithfully and timely perform and discharge all of its
obligations under the JN Biosciences Agreement, (ii)&nbsp;to the extent within Abmuno&#146;s reasonable control, not take any action or allow any event to occur that would give JN Biosciences the right to terminate the JN Biosciences Agreement, and
(iii)&nbsp;not exercise any right to itself terminate the JN Biosciences Agreement. Abmuno shall not amend or modify the JN Biosciences Agreement to the extent that such amendment or modification would reasonably be expected to have a material
adverse effect on the Licensed Patents and/or Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> sublicensed to Arcus under this Agreement, or on Arcus&#146;s ability to exercise its rights under such sublicense, without the prior written
consent of Arcus, not to be unreasonably withheld, conditioned or delayed. Abmuno agrees, that if JN Biosciences seeks relief under any bankruptcy, reorganization, insolvency or similar laws, Abmuno shall act in good faith to take all reasonably
necessary action to preserve the sublicense rights granted to Arcus hereunder, including but not limited to, seeking to preserve Abmuno&#146;s and Arcus&#146;s rights under Section&nbsp;365(n) of the U.S. Bankruptcy Code, 11 U.S.C. section 101
through 1330 et seq. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>DEVELOPMENT AND COMMERCIALIZATION</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Development and Commercialization Activities</U>. Arcus shall use Commercially Reasonable Efforts to Develop and
Commercialize Patented Products in the Field. Notwithstanding the foregoing, Arcus is obligated to file an IND in the United States on a Patented Product no later than [***] months from the Effective Date; provided that Stage 2 Technology Transfer,
as defined in Section&nbsp;3.3.1 below, is completed no later than [***] days following the Effective Date. The deadline for Arcus to file an IND in the United States on a Patented Product shall be extended by one (1)&nbsp;day for each day that
Abmuno is late in completing Stage 2 Technology Transfer. Any delay or postponement in the filing of an IND in the United States on a Patented Product beyond the deadline for such filing will be subject to approval by Abmuno, which approval shall
not be unreasonably withheld, conditioned or delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Manufacturing</U>. Arcus shall use Commercially
Reasonable Efforts to manufacture or otherwise obtain supply of the requirements of formulated, packaged and labeled Patented Products in connection with its Development and Commercialization obligations hereunder, in accordance with all Applicable
Laws, GMP (as applicable) and this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Assistance</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3.1&nbsp;&nbsp;&nbsp;&nbsp;Abmuno shall use Commercially Reasonable Efforts to transfer or have transferred (i)&nbsp;the data, materials and
analytical methods described on the attached Exhibit 2A to Arcus within a period of [***] days following the Effective Date (unless otherwise expressly provided in Exhibit 2A), subject to the terms of any licenses covering such data, materials and
analytical methods that have been provided to Arcus in writing (&#147;Stage 1 Technology Transfer&#148;) and (ii)&nbsp;the reports and other materials described on the attached Exhibit 2B to Arcus within a period of [***] days following the
Effective Date (&#147;Stage 2 Technology Transfer&#148;). The data, materials and analytical methods described on the attached Exhibit 2A and the reports and other materials described on the attached Exhibit 2B shall be collectively referred to
herein as the &#147;Transferred Technology&#148;. For the avoidance of doubt, for the purposes of this Agreement, Transferred Technology shall be deemed to be included in Licensed <FONT STYLE="white-space:nowrap">Know-How.</FONT> Stage 1 Technology
Transfer and Stage 2 Technology Transfer will be performed by Abmuno at no charge to Arcus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3.2&nbsp;&nbsp;&nbsp;&nbsp;Within seven
(7)&nbsp;days after the Effective Date, Arcus and Abmuno will establish a Joint Steering Committee, composed of an equal number of representatives from the Parties, to oversee and assist in the transfer of the Transferred Technology (the
&#147;JSC&#148;). The JSC will meet monthly or as needed to review progress and to provide guidance, as required, to maximize the value of the Licensed Products. A representative from JN Biosciences may attend meetings of the JSC to advise the JSC
on scientific matters. The JSC will have solely an advisory role to aid Arcus in the most efficient advancement of the Licensed Products. Following the filing of the first IND for a Licensed Product in the United States by Arcus, the JSC will
continue to exist only and for as long the Parties mutually deem it to be helpful to the development of the Licensed Products. In addition, Abmuno shall use good faith, Commercially Reasonable Efforts to disclose to Arcus promptly, all other
information comprising the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> and any other information related to Licensed Patents as Arcus may reasonably request from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time.&nbsp;&nbsp;&nbsp;&nbsp;Abmuno</FONT></FONT> shall perform its obligations under this Section&nbsp;3.3.2 at no charge to Arcus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Clarification</U>. [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>REGULATORY MATTERS</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. Arcus shall be solely responsible for, and shall use Commercially Reasonable Efforts in connection
with seeking Regulatory Approval for the Patented Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Recalls or Corrective Action</U>. Arcus shall
have sole responsibility for and shall make all decisions with respect to any recall, market withdrawal or other corrective action related to the Licensed Products in the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>FINANCIAL PROVISIONS</B>. In consideration of the rights granted by Abmuno to Arcus hereunder, and of the
performance of technology transfer-related services under this Agreement, Arcus agrees to make the following payments: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution Payment</U>. Within thirty (30)&nbsp;days after (i)&nbsp;receipt of a written invoice, which shall be
provided on or as soon as practicable after the Effective Date, and (ii)&nbsp;delivery to Arcus of a copy of this Agreement duly executed by Abmuno, Arcus shall pay to Abmuno an upfront fee of [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Milestone Payments</U>. In the event Arcus (on its own or through an Affiliate or their sublicensees) achieves a
milestone specified below during the Term, Arcus shall promptly, but in no event more than thirty (30)&nbsp;days after the achievement of each such milestone, notify Abmuno in writing of the achievement of such milestone. Arcus shall pay to Abmuno
the milestone payments as specified below within thirty (30)&nbsp;days after receipt of a written invoice to be provided by Abmuno as soon as practicable following achievement of the particular milestone. Each milestone payment shall be payable only
once for the first Licensed Product to achieve such milestones, regardless of the total number of Licensed Products to achieve the applicable milestone or the number of times each such milestone is achieved for a given Licensed Product. If the first
Licensed Product to achieve an applicable milestone is not a Patented Product, then the payment specified in the table below earned with respect to such Licensed Product achieving such milestone shall be reduced by [***]. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:36.35pt; font-size:8pt; font-family:Times New Roman"><B>Milestones</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment Terms</U>. All sums due under this Agreement shall be payable in United States dollars by bank wire
transfer in immediately available funds from a bank account </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
domiciled in the United States and to such bank account(s) as the applicable payee shall designate. If any payment hereunder would be subject to withholding taxes under Applicable Law, Arcus
shall notify Abmuno of such legal requirement reasonably in advance of any such payment to permit Abmuno to try to qualify for any exemptions available under Applicable Law, including compliance with any applicable tax treaty, and Arcus shall
reasonably assist Abmuno in claiming exemption from or minimizing such withholding obligation, including by complying with any applicable tax treaty.&nbsp;If any such withholding tax is paid by Arcus, Arcus shall promptly furnish Abmuno with
evidence of such payment and provide such other reasonable assistance as may be reasonably required by Abmuno (and its shareholders) to claim a tax credit on United States tax returns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>CONFIDENTIAL INFORMATION</B><B> AND PROPRIETARY RIGHTS</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Definition</U>. &#147;Confidential Information&#148; means confidential or proprietary information, data or <FONT
STYLE="white-space:nowrap">know-how,</FONT> whether provided in written, oral, visual or other form, provided by one Party (the &#147;Disclosing Party&#148;) to the other Party (the &#147;Receiving Party&#148;) in connection with this Agreement,
including, but not limited to, the terms of this Agreement and information relating to the Disclosing Party&#146;s existing or proposed research, development efforts, patent applications, business or products. Confidential Information shall not
include any such information that: (i)&nbsp;is already known to the Receiving Party or its Affiliates (other than under an obligation of confidentiality) at the time of disclosure (as evidenced by written records of the Receiving Party); (ii) is or
becomes generally available to the public other than through any act or omission of the Receiving Party or its Affiliates that is in breach of this Agreement; (iii)&nbsp;is disclosed to the Receiving Party or its Affiliates by a Third Party who had
no separate nondisclosure obligation in respect of such information; or (iv)&nbsp;is independently discovered or developed by or on behalf of the Receiving Party or its Affiliates without the use of the Confidential Information of the Disclosing
Party (as evidenced by written records of the Receiving Party). The terms of this Agreement shall be deemed Confidential Information of each Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>. The Receiving Party shall keep in confidence all Confidential Information of the Disclosing
Party with the same degree of care it employs to maintain the confidentiality of its own Confidential Information, but no less than a reasonable degree of care. The Receiving Party shall not use such Confidential Information for any purpose other
than in performance of this Agreement, or in the case of Arcus as the Receiving Party, in accordance with the rights granted to Arcus under this Agreement, or disclose the same to any other Person other than to such of its own and its
Affiliates&#146; employees, agents, sublicensees and subcontractors who have a need to know such Confidential Information to implement the terms of this Agreement and who are bound by written obligations of confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> at least as restrictive as those set forth herein. A Receiving Party shall advise any employee, agent, sublicensee and subcontractor who receives Confidential Information of such obligations under this
Agreement. The Receiving Party will be liable for breach of this Section&nbsp;6 by any of its employees, agents, sublicensees and subcontractors. Notwithstanding anything to the contrary herein, Abmuno, as the Receiving Party, may disclose
Confidential Information of Arcus, as the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Disclosing Party, to JN Biosciences under terms of confidentiality at least as restrictive as those set forth herein and solely for purposes of JN Biosciences&#146; exercising rights and
enforcing obligations under the JN Biosciences Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Permitted Disclosure and Use</U>. The Receiving
Party shall have the right to disclose Confidential Information if, (i)&nbsp;in the reasonable opinion of the Receiving Party&#146;s legal counsel, such disclosure is required by any Applicable Laws (including the rules of any stock exchange);
provided that the Receiving Party gives adequate prior notice of such disclosure to the Disclosing Party and the Receiving Party uses Commercially Reasonable Efforts to seek confidential treatment of such Confidential Information; or (ii)&nbsp;a
court, tribunal, administrative agency or other Governmental Authority orders such disclosure, provided that the Receiving Party gives adequate prior notice of such disclosure to the Disclosing Party to permit the Disclosing Party to intervene and
to request protective orders or other confidential treatment. The Receiving Party will cooperate reasonably with any such efforts by the Disclosing Party. Furthermore, notwithstanding any other provision of this Agreement, Arcus may disclose
Confidential Information (a)&nbsp;as necessary in connection with any financing, merger, sublicensing or similar transaction, subject to enforceable obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> at least as
restrictive as those set forth herein, or as necessary to obtain legal or financial advice from its attorneys, accountants and legal or financial advisors and (b)&nbsp;as necessary in connection with prosecuting or defending litigation, Regulatory
Approvals, Pricing Approvals and other regulatory filings and communications, and filing, prosecuting and enforcing Patents in connection with Arcus&#146;s rights and obligations pursuant to this Agreement, in each case under this clause (b),
subject to reasonable efforts to limit public disclosure, including the seeking of protective orders. The Parties shall also be permitted to make disclosures consistent with, and pursuant to, Sections 11.1 and 11.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.4&nbsp;&nbsp;&nbsp;&nbsp;Intentionally omitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Attorney-Client Privilege</U>. Neither Party is waiving, nor will be deemed to have waived or diminished, any of
its attorney work product protections, attorney-client privileges or similar protections and privileges recognized under Applicable Law of any jurisdiction as a result of disclosing information pursuant to this Agreement, or any of its Confidential
Information (including Confidential Information related to pending or threatened litigation) to the Receiving Party, regardless of whether the Disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections. The
Parties may become joint defendants in proceedings to which the information covered by such protections and privileges relates and may determine that they share a common legal interest in disclosure between them that is subject to such privileges
and protections, and in such event, may enter into a joint defense agreement setting forth, among other things, the foregoing principles but are not obligated to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. This Section&nbsp;6 shall survive the expiration or termination of this Agreement for a period of
[***] years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>REPRESENTATIONS AND WARRANTIES</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Mutual Representations and Warranties</U>. Arcus and Abmuno each represents and warrants to the other as of the
Effective Date: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1.1&nbsp;&nbsp;&nbsp;&nbsp;Such Party (i)&nbsp;is a company duly organized, validly existing and in good standing
under the Applicable Laws of the jurisdiction of its organization; and (ii)&nbsp;has the requisite corporate power and authority and the legal right to enter into this Agreement and to carry out the provisions of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1.2&nbsp;&nbsp;&nbsp;&nbsp;The execution, delivery and performance of this Agreement by such Party, including, without limitation, in the
case of Abmuno, the delivery by Abmuno (or JN Biosciences on its behalf as described in Exhibit 2) of any Transferred Technology to Arcus for use as contemplated under this Agreement, (i)&nbsp;do not conflict with any provision of the organizational
documents of such Party; (ii)&nbsp;will not, to such Party&#146;s knowledge, violate any Applicable Laws or any order or decree of any court or Governmental Authority; and (iii)&nbsp;will not violate or conflict with any terms of any indenture,
mortgage, deed of trust, lease, agreement or other instrument to which such Party is a party, or by which such Party is bound or becomes bound during the Term; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1.3&nbsp;&nbsp;&nbsp;&nbsp;This Agreement has been duly executed and delivered by such Party and constitutes a legal, valid and binding
obligation of such Party, enforceable against such Party in accordance with its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Abmuno
Representations and Warranties</U>. Abmuno represents, warrants and covenants to Arcus as of the Effective Date: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2.1&nbsp;&nbsp;&nbsp;&nbsp;Abmuno (i)&nbsp;has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and
interest in the Licensed Patents, or any component of the Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> (ii)&nbsp;with respect to any agreements or other instruments pursuant to which Abmuno acquires its rights to the Licensed Patents
and Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> it will maintain, and use Commercially Reasonable Efforts to cause JN Biosciences to maintain, in full force and effect and commit no act or omission, and use Commercially Reasonable
Efforts to cause JN Biosciences to not commit any act or omission, that would give rise to any Third Party right to terminate such licenses or other instruments to the extent that termination of such license or other instrument would have a material
adverse effect on any right licensed to Arcus hereunder, and (iii)&nbsp;there are no Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> owned or controlled by Abmuno, other than the Licensed Patents and Licensed <FONT
STYLE="white-space:nowrap">Know-How,</FONT> that would prevent Arcus, its Affiliates or their sublicensees from Developing, manufacturing and/or Commercializing Licensed Products as set forth herein, and from exploiting the rights granted under
Section&nbsp;2.1. Abmuno has provided Arcus with a true and complete (other than redacted financial terms) copy of the Third Party agreements that are referenced in (ii)&nbsp;directly above, including, without limitation, any and all amendments and
side letters related thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2.2&nbsp;&nbsp;&nbsp;&nbsp;There are no claims, judgments or settlements against, pending with respect
to any Licensed IP, and to Abmuno&#146;s knowledge, no such claims, judgments or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
settlements are threatened. [***], except as otherwise set forth in Exhibit 4, Arcus&#146;s contemplated use of the Licensed IP by Arcus to make, use and sell a Licensed Product will not violate,
infringe, misappropriate or unlawfully use any intellectual property of any Person. To the knowledge of Abmuno, no Person has violated, infringed, misappropriated or unlawfully used any of the Licensed IP. Abmuno has not, and to Abmuno&#146;s
knowledge, JN Biosciences has not, commenced or threatened any proceeding, or asserted any allegation or claim, against any Person for infringement or misappropriation of any Licensed IP; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2.3&nbsp;&nbsp;&nbsp;&nbsp;The JN Biosciences Agreement is in full force and effect, and there are no defaults or threatened defaults
under, and no disputes between Abmuno and JN Biosciences with respect to, the JN Biosciences Agreement. Abmuno has provided Arcus with a true and complete (other than redacted financial terms) copy of the JN Biosciences Agreement, including, without
limitation, any and all amendments and side letters related thereto; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2.4&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise set forth in
Exhibit 5, neither Abmuno nor JN Biosciences is a party to any agreement that prohibits or restricts the full exploitation of any Licensed IP as contemplated under this Agreement. Abmuno has provided Arcus with a true and complete (other than
redacted financial terms) copy of the Third Party agreements that are set forth in Exhibit 5, including, without limitation, any and all amendments and side letters related thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2.5&nbsp;&nbsp;&nbsp;&nbsp;All functional data for HuTIG1 that is in the possession of Abmuno, JN Biosciences or any of its Affiliates,
including, without limitation, any such data arising or resulting from any failed experiments, will be delivered to Arcus in accordance with Section&nbsp;3.3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclaimer of Warranty</U>. Except for the express warranties set forth in this Agreement, nothing in this
Agreement shall be construed as a representation or warranty by either Party (i)&nbsp;that any Licensed Product made, used, sold or otherwise disposed of under this Agreement is or will be free from infringement of patents, copyrights, trademarks or
other intellectual property rights of any Third Party; (ii)&nbsp;regarding the effectiveness, value, safety, or <FONT STYLE="white-space:nowrap">non-toxicity</FONT> of any technology; or (iii)&nbsp;that any Licensed Product will obtain Regulatory
Approval or achieve any other milestone events specified in Section&nbsp;5.2. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES, AND EACH PARTY EXPRESSLY DISCLAIMS, WAIVES, RELEASES AND RENOUNCES, ANY OTHER WARRANTY,
EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY OF PATENT SUFFICIENCY AND ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT,</FONT> AND ALL WARRANTIES
ARISING FROM ANY COURSE OF DEALING OR PERFORMANCE OR USAGE OF TRADE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>INDEMNIFICATION</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification by </U><U>Abmuno</U>. Subject to Section&nbsp;8.3, Abmuno shall defend, indemnify and hold
harmless Arcus and its Affiliates and each of their officers, directors, shareholders, employees, independent contractors, successors and assigns (collectively, &#147;Arcus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Indemnitees&#148;) from and against all Third Party Claims, and pay all associated Losses, arising out of or relating to (i)&nbsp;any breaches by Abmuno of any of its representations or
warranties in this Agreement or (ii)&nbsp;the research, Development, manufacture, transfer, use, handling, storage, sale or other disposition of Licensed Products by or on behalf of Abmuno, JN Biosciences or any of its or their Affiliates, agents
and contractors prior to the Effective Date, including Third Party Claims based on product liability, bodily injury, risk of bodily injury, death or property damage or the failure to comply with Applicable Law, except in the case of (ii), to the
extent Arcus is obligated to defend, indemnify and hold harmless any Abmuno Indemnitees pursuant to Section&nbsp;8.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification by Arcus</U>. Subject to Section&nbsp;8.3, Arcus shall defend, indemnify and hold harmless
Abmuno and its Affiliates and JN Biosciences, and each of their officers, directors, shareholders, employees, independent contractors, successors and assigns (collectively, &#147;Abmuno Indemnitees&#148;) from and against all Third Party Claims, and
pay all associated Losses, arising out of or relating to (i)&nbsp;any breaches by Arcus of any of its representations or warranties in this Agreement or (ii)&nbsp;the research, Development, manufacture, transfer, use, handling, storage, sale or
other disposition of Licensed Products by or on behalf of Arcus or any of its Affiliates, agents and contractors after the Effective Date, including Third Party Claims based on product liability, bodily injury, risk of bodily injury, death or
property damage or the failure to comply with Applicable Law, except in the case of (ii), to the extent Abmuno is obligated to defend, indemnify and hold harmless any Arcus Indemnitees pursuant to Section&nbsp;8.1. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure for Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">8.3.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice</U>. The indemnified party will notify promptly the indemnifying party in writing if it becomes aware
of a Claim (actual or potential) by any Third Party or any proceeding (including any investigation by a Governmental Authority) (&#147;Third Party Claim&#148;) for which indemnification may be sought and will give such related information as the
indemnifying party shall reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">8.3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Defense of Claim</U>. The indemnifying party shall defend
or control the defense of Third Party Claims. The indemnifying party shall be responsible for satisfying and discharging any award made to or settlement reached with the Third Party pursuant to the terms of this Agreement. The indemnifying party
shall retain counsel reasonably acceptable to the indemnified party (such acceptance not to be unreasonably withheld, refused, conditioned or delayed) to represent the indemnified party and shall pay the reasonable fees and expenses of such counsel
related to such proceeding. In any such proceeding, the indemnified party, at its sole expense, shall have the right to retain its own counsel. The indemnified party shall cooperate in all reasonable respects in the defense of such Third Party
Claim, as requested by, and at the reasonable expense of, the indemnifying party. The indemnifying party shall not, without the written consent of the indemnified party (which consent shall not be unreasonably withheld, refused, conditioned or
delayed), effect any settlement of any such Third Party Claim, unless such settlement includes a full and unconditional release of the indemnified party from all liability on such Claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.4 <U><FONT STYLE="white-space:nowrap">Set-Off</FONT> Rights</U>. If it is determined under Section&nbsp;11.5 that Abmuno has failed to meet
or is in breach of any of its (i)&nbsp;indemnification obligations under Section&nbsp;8.1 or (ii)&nbsp;representations or warranties in Article 7, Arcus shall be entitled to, and may seek payment of, its damages by
<FONT STYLE="white-space:nowrap">set-off</FONT> against any milestone payment that has been earned but not yet paid pursuant to Section&nbsp;5.2, in each case, without limiting any of Arcus&#146; other rights under this Agreement or under Applicable
Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation of Damages</U>. IN NO EVENT SHALL EITHER PARTY BE
LIABLE HEREUNDER TO THE OTHER PARTY FOR ANY PUNITIVE, INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING LOST REVENUE, LOST PROFITS, OR LOST SAVINGS) HOWEVER CAUSED AND UNDER ANY THEORY, EVEN IF IT HAS NOTICE OF THE POSSIBILITY OF
SUCH DAMAGES. THE LIMITATIONS SET FORTH IN THIS SECTION SHALL NOT APPLY WITH RESPECT TO (I)&nbsp;ANY BREACH BY EITHER PARTY OF SECTION 6 (CONFIDENTIAL INFORMATION AND PROPRIETARY RIGHTS), (II)&nbsp;THE WILLFUL MISCONDUCT OR GROSS NEGLIGENCE OF A
PARTY OR (III)&nbsp;ANY BREACH BY ABMUNO OF THE FIRST SENTENCE OF SECTION 2.6 <FONT STYLE="white-space:nowrap">(NON-COMPETITION).</FONT> NOTHING IN THIS SECTION IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF A PARTY
UNDER SECTION&nbsp;8.1 OR SECTION 8.2. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>PATENT</B><B>S</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Prosecution and Maintenance</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.1.1&nbsp;&nbsp;&nbsp;&nbsp;Arcus shall have the first right to file, prosecute and maintain all Licensed Patents at Arcus&#146;s sole
expense using its own outside counsel reasonably acceptable to Abmuno. Arcus will use Commercially Reasonable Efforts to prepare, file, prosecute and maintain Licensed Patents; provided, however, that Arcus does not represent or warrant that any
patent will issue or be granted based on patent applications contained in the Licensed Patents. Arcus shall keep Abmuno reasonably informed of material decisions or actions concerning the prosecution and maintenance of such Licensed Patents,
including, without limitation, by providing copies of office actions and other material communications with patent offices, and providing a reasonable opportunity for Abmuno to deliver comments to Arcus regarding such prosecution materials, such
comments to be considered by Arcus in good faith. Abmuno shall reasonably cooperate with Arcus in its efforts to prepare, file, prosecute and maintain Licensed Patents, including, without limitation, in responding promptly to Arcus&#146;s requests
for data, affidavits, and other information and assistance to support filing, prosecution and maintenance of the Licensed Patents in a timely manner. Arcus shall not take any action during prosecution and maintenance of the Licensed Patents that
would materially adversely affect Abmuno, without Abmuno&#146;s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned. If Abmuno fails to provide in writing its consent or its reasons for not providing such
consent within [***] days after delivery of written request by Arcus to Abmuno for such consent, then Abmuno shall be deemed to have consented to such action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.1.2&nbsp;&nbsp;&nbsp;&nbsp;In the event that Arcus decides not to continue the prosecution
or maintenance of a Patent within the Licensed Patents in any country, Arcus shall provide Abmuno with express written notice of such decision at least [***] days prior to any pending lapse or abandonment thereof, or if a decision not to continue
prosecution or maintenance is responsive to an official communication from governmental agency that is received by Arcus less than [***] days prior to a deadline for taking action in response to such communication, then the deadline for giving such
notice to Abmuno shall be [***]% of the time remaining for response after such communication is received by Arcus. In such event, Arcus shall provide Abmuno with an opportunity to assume responsibility for prosecution and maintenance of such Patent.
In the event that Abmuno, at Abmuno&#146;s expense, assumes such responsibility, Arcus shall transfer the responsibility for prosecution and maintenance of such Patent to Abmuno, and in such case, Arcus, at Arcus&#146;s expense, shall provide Abmuno
an update of the filing, prosecution and maintenance status for each such Patent, including copies of any material official correspondence to or from patent offices. Arcus shall no longer have any right or license in, to or under such Patent under
this Agreement. For purposes of clarification, upon assuming responsibility for prosecution and maintenance of any Patent, Abmuno, at Abmuno&#146;s sole discretion, may or may not continue such prosecution and maintenance, and shall have a right, at
any time, to abandon such prosecution and/or maintenance or to transfer such prosecution and/or maintenance, or a share of such prosecution and maintenance, to JN Biosciences. In the event that Abmuno, solely or together with JN Biosciences,
prosecutes, or JN Biosciences solely prosecutes, such a Patent to issuance, Arcus may reinstate Arcus&#146;s rights and license under such Patent to the full extent of Abmuno&#146;s and JN Biosciences&#146; interests in such Patent by
(i)&nbsp;reimbursing Abmuno and JN Biosciences for their documented costs and expenses related to the prosecution and maintenance of such Patent and (ii)&nbsp;assuming, in writing, Abmuno&#146;s and JN Biosciences&#146; responsibility, to the full
extent of such responsibility, for the continued prosecution and maintenance of such Patent in accordance with this Section&nbsp;9. In the event a Patent issues with respect to any such Patent during the period that Abmuno, either solely or jointly
with JN Biosciences, or JN Biosciences by itself, is conducting the prosecution and maintenance of such Patent, Abmuno shall provide prompt written notice thereof to Arcus. If Arcus elects to reimburse Abmuno and JN Biosciences for their costs and
expenses related to the prosecution and maintenance of such Patent and to reassume Abmuno&#146;s and JN Biosciences&#146; responsibility for the continued prosecution and maintenance of such Patent, in order to reinstate its rights and license to
such Patent, then Arcus shall provide Abmuno with written notice of such election, and Abmuno shall provide to Arcus promptly its and JN Biosciences&#146; documented costs and expenses related to the prosecution and maintenance of such Patent, and
following receipt of Arcus&#146; reimbursement of such costs and expenses, shall transfer that portion of responsibility held by Abmuno, and shall use Commercially Reasonable Efforts to cause JN Biosciences to transfer that portion of responsibility
held by JN Biosciences, for prosecution and maintenance of such Patent to Arcus. In such case, Abmuno, at Abmuno&#146;s expense, shall provide Arcus an update of the filing, prosecution and maintenance status for each such Patent, including copies
of any material official correspondence to or from patent offices,that Abmuno is in possession of. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Infringement</U><U> of Licensed Patents</U>. Each Party will notify the other Party promptly in writing upon
becoming aware of any alleged or threatened infringement by a Third Party of any Licensed Patents. Arcus shall have the sole right to enforce any patent within the Licensed Patents against any infringement or alleged infringement thereof. Arcus may,
at its own expense, institute suit against any infringer or alleged infringer and control and defend such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
suit and recover any damages, awards or settlements resulting therefrom; provided that any such damages, awards or settlements shall be [***]. Arcus may retain one hundred percent (100%) of any
such damages, awards or settlements. Abmuno shall reasonably cooperate in any such litigation, including, without limitation, joining any such suit, at Arcus&#146;s request and expense. Arcus shall not enter into any settlement of any claim
described in this Section&nbsp;9.2 that would admit to the invalidity, narrowing of scope or unenforceability of the Licensed Patents, incur any financial liability on the part of Abmuno or require an admission of liability, wrongdoing or fault on
the part of Abmuno without Abmuno&#146;s prior written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Infringement Claims by Third Parties</U>.
If either (i)&nbsp;any Licensed Product Developed, made, Commercialized or otherwise exploited by or under authority of Arcus becomes the subject of a Third Party&#146;s claim or assertion of infringement of a patent relating to the manufacture,
use, sale, offer for sale or importation of such Licensed Product in the Field in the Territory, or (ii)&nbsp;if a declaratory judgment action is brought naming either Party as a defendant and alleging invalidity of any of the Licensed Patents, the
Party first having notice of the claim or assertion shall promptly notify the other Party, and the Parties shall promptly confer to consider the claim or assertion and the appropriate course of action. Unless the Parties otherwise agree in writing,
each Party shall have the right to defend itself against a suit that names it as a defendant (the &#147;Defending Party&#148;). If Abmuno is named in such legal action but not Arcus, then Arcus shall have the right to join, at its own expense, any
such legal action and to be represented in such action by its own counsel. None of the Parties shall enter into any settlement of any claim described in this Section that admits to the invalidity, narrowing of scope or unenforceability of the
Licensed Patents or this Agreement, incurs any financial liability on the part of the other Party or requires an admission of liability, wrongdoing or fault on the part of the other Party without such other Party&#146;s prior written consent. In any
event, the other Party shall reasonably assist the Defending Party and cooperate in any such litigation at the Defending Party&#146;s cost and the Defending Party shall reimburse the other Party&#146;s reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs associated therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Biosimilars</U>. Each
Party shall promptly, but in any event no later than ten (10)&nbsp;business days after receipt of notice of such application, notify the other Party if it becomes aware of any application for regulatory approval of a biosimilar anywhere in the
Territory where any Licensed Product is a reference product under such application. Arcus shall take the lead and be responsible for preparing and filing any responses with any Regulatory Authority and negotiating any patent resolution in connection
with any such application as set forth in paragraphs 2 through 6 of Section&nbsp;351(l) of the United States Public Health Service Act (42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">262(l)(2)-(6)),</FONT> or any foreign equivalent thereof.
Abmuno shall cooperate with Arcus&#146;s reasonable requests for assistance in connection therewith. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>TERM AND TERMINATION</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>. The term of this Agreement (the &#147;Term&#148;) shall commence on the Effective Date, and unless
terminated earlier as provided in this Section&nbsp;10, shall continue in full force and effect until the later of (i)&nbsp;the expiry of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Licensed
Patent which has at least one Valid Claim Covering a Licensed Product or (ii) [***] years from the date of First Commercial Sale of any Licensed Product in any country. Upon expiration of this Agreement,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the licenses granted to Arcus by Abmuno under this Agreement to make, have made, use, register, sell, offer to sell, have sold, import, export, exploit, research, improve, Develop and
Commercialize Licensed Products in the Field in the Territory shall be fully <FONT STYLE="white-space:nowrap">paid-up,</FONT> irrevocable and <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Convenience</U>. Arcus may terminate this Agreement, in its entirety, with or without cause at any time by
giving Abmuno at least [***] days prior written notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Material Breach</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;In the event a material breach of this Agreement, the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party
may deliver notice of such breach to the breaching Party, such notice containing full details of said breach. In such notice, the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party shall identify (acting reasonably and in good faith)
examples of the actions or conduct that such Party would consider to be an acceptable cure of such breach. The breaching Party shall have, subject to Section&nbsp;10.2.2(b), [***] days to cure such breach ([***] days in the case of a Party&#146;s
breach of its payment obligations). Subject to Section&nbsp;10.2.2(b), if the Party receiving notice of breach fails to cure such breach within the [***] day period or [***] day period (as applicable), the Party originally delivering the notice may
terminate this Agreement upon written notice to the other Party.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If a Party gives notice of termination under
Section&nbsp;10.2.2(a) and the other Party disputes in writing prior to the end of the applicable cure period whether such notice was proper, then the issues of whether a breach has occurred shall be resolved in accordance with Section&nbsp;11.5. If
as a result of such dispute resolution process it is determined that the notice of breach was proper, then such termination shall be deemed to have been effective if the breaching Party fails thereafter to cure such breach in accordance with the
determination made in the resolution process within the applicable cure period set forth in Section&nbsp;10.2.2(a) following such determination. If as a result of such dispute resolution process it is determined that the notice of breach was
improper, then no termination shall have occurred and this Agreement shall have remained in effect. All of the terms and conditions of this Agreement shall remain in full force and effect during the pendency of such dispute resolution process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.2.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Bankruptcy</U>. To the extent permitted under Applicable Law, either Party may terminate this Agreement in
its entirety immediately upon written notice, if the other Party makes an assignment for the benefit of creditors, or a receiver, trustee in bankruptcy or similar officer is appointed to take charge of all of the other Party&#146;s property, or the
other Party seeks protection under any bankruptcy, receivership, trust deed, creditors arrangement, composition or comparable proceeding or such a proceeding is instituted against the other Party and is not dismissed within [***] days, or the other
Party, without a successor, dissolves or liquidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.2.4&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Effects of Termination</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.3.1&nbsp;&nbsp;&nbsp;&nbsp;In the event that this Agreement is terminated pursuant to the terms of this Agreement, all rights and licenses
granted to Arcus and its Affiliates, as well as all sublicenses granted under this Agreement by Arcus and/or any of its Affiliates, shall immediately terminate; provided, however, Arcus and its Affiliates and any of their sublicensees shall be
entitled to sell, for a period of [***] months after the effective date of termination, any inventories of Licensed Products in the Field in the Territory that are <FONT STYLE="white-space:nowrap">on-hand</FONT> as of the effective date of
termination. In no event does this Section&nbsp;10.3.1 limit any rights of Arcus under the second paragraph of Section&nbsp;2.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.3.2&nbsp;&nbsp;&nbsp;&nbsp;In the event that this Agreement is terminated pursuant to Section&nbsp;10.2.1, or by Abmuno pursuant to
Section&nbsp;10.2.2, or by Abmuno pursuant to Section&nbsp;10.2.4: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions of
this Section&nbsp;10.3 and Section&nbsp;10.4, Arcus shall grant and hereby grants to Abmuno an exclusive license, with the right to grant sublicenses, under Arcus&#146;s rights to any Patents owned or Controlled by Arcus as of the effective date of
such termination claiming any invention conceived or reduced to practice by or on behalf of Arcus during the term of this Agreement, in each case, to the extent Covering any Improvement and any Joint Improvement and that, in each case, are necessary
to manufacture, Develop and Commercialize a Licensed Product, but only to manufacture, Develop and Commercialize Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Arcus shall provide to Abmuno the tangible embodiments of all material
<FONT STYLE="white-space:nowrap">Know-How</FONT> owned or Controlled by Arcus to the extent necessary for the Development and Commercialization of Licensed Products and in existence and in Arcus&#146; possession as of the date of such termination,
subject to Abmuno&#146;s reimbursement of Arcus&#146;s actual costs and expense incurred in transferring such items, and subject to the terms and conditions of this Section&nbsp;10.3 and Section&nbsp;10.4, Abmuno shall have an exclusive,
sublicensable right and license under such <FONT STYLE="white-space:nowrap">Know-How</FONT> solely for researching, manufacturing, Developing and Commercializing Licensed Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Arcus shall provide to Abmuno all data generated during the term of this Agreement in direct connection with the
Development and/or Commercialization of Licensed Products and assign to Abmuno all of Arcus&#146;s entire right, title and interest in and to all such data, subject to Abmuno&#146;s reimbursement of Arcus&#146;s actual costs incurred in transferring
such items, and preparing and making such items available in connection with such transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained
in this Section&nbsp;10.3.2 confers or will be construed to confer any rights or licenses by implication, estoppel or otherwise, in, to or under any intellectual property rights, other than the rights and licenses expressly granted in this
Section&nbsp;10.3.2. All rights not expressly granted by Arcus under this Section&nbsp;10.3.2 are reserved to Arcus, and Arcus may use and otherwise exploit Patents described in Section&nbsp;10.3.2(a) and
<FONT STYLE="white-space:nowrap">Know-How</FONT> described in Section&nbsp;10.3.2(b) to manufacture, Develop and Commercialize products other than Licensed Products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;Abmuno shall secure all appropriate covenants, obligations and
rights from any sublicensee of Abmuno to ensure that such sublicensees are subject to, and Abmuno can comply with, all of Abmuno&#146;s applicable covenants and obligations to Arcus under this Section&nbsp;10.3 and Section&nbsp;10.4. Abmuno shall be
responsible for any failure of its sublicensees to comply with the applicable provisions of this Section&nbsp;10.3 and Section&nbsp;10.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;The <FONT STYLE="white-space:nowrap">Know-How</FONT> described in Section&nbsp;10.3.2(b) is deemed to be the
Confidential Information of Arcus and shall be handled in accordance with Section&nbsp;6, except that (i)&nbsp;Abmuno may use such <FONT STYLE="white-space:nowrap">Know-How</FONT> in accordance with the rights granted to Abmuno under this
Section&nbsp;10.3.2 and (ii)&nbsp;Abmuno may disclose such <FONT STYLE="white-space:nowrap">Know-How</FONT> (A)&nbsp;as necessary in connection with any financing, merger, sublicensing or similar transaction, subject to confidentiality, or as
necessary to obtain legal or financial advice from its attorneys, accountants and legal or financial advisors and (B)&nbsp;in connection with prosecuting or defending litigation, Regulatory Approvals, Pricing Approvals and other regulatory filings
and communications in connection with Abmuno&#146;s rights under this Section&nbsp;10.3.2, in each case under this clause (B), subject to reasonable efforts to limit public disclosure, including the seeking of protective orders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Accrued Rights; Surviving Obligations</U>. Except as provided elsewhere, termination or expiration of this
Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration. Such termination or expiration shall not relieve any Party from obligations which are
expressly or by implication intended to survive termination or expiration of this Agreement, including, but not limited to, Sections 1, 6 and 11, and Sections 2.5, 7.3, 8.1, 8.2, 8.3, 8.5, 10.3 and 10.4, and shall not affect or prejudice any
provision of this Agreement which is expressly or by implication provided to come into effect on, or continue in effect after, such termination or expiration. Notwithstanding anything to the contrary in Section&nbsp;8.1(ii), following any
termination or expiration of this Agreement, Abmuno&#146;s obligation to defend, indemnify and hold harmless Arcus Indemnitees from and against certain Third Party Claims and Losses under Section&nbsp;8.1(ii) shall include those Third Party Claims
and associated Losses arising out of or relating to the research, Development, manufacture, transfer, use, handling, storage, sale or other disposition of Licensed Products by or on behalf of Abmuno, JN Biosciences or any of its or their Affiliates,
agents and contractors after the termination or expiration of this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>MISCELLANEOUS</B>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Publications</U>. As between the Parties, Arcus shall have the sole and exclusive right, but not the
obligation, to make any publication and other scientific disclosures in respect of the Licensed Products, including, without limitation, in respect of data and results arising out of Development of Licensed Products, and Abmuno shall make no such
publication or other scientific disclosure without the prior written consent of Arcus. Notwithstanding anything to the contrary in this Agreement, including, without limitation, Section&nbsp;6 (Confidential Information and Proprietary Rights), Arcus
may disclose, without the prior written consent of Abmuno (or JN Biosciences), any and all properties of the Licensed Products in connection with any publication and other scientific disclosures in respect of the Licensed Products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Public Announcements</U>. Except as may be expressly permitted
under this Section&nbsp;11.2 or mandated by Applicable Laws or the rules of any stock exchange, neither Party will make any public announcement of any information regarding this Agreement without the prior written consent of the other Party, such
consent not to be unreasonably withheld, conditioned or delayed. Once any statement is approved for disclosure by the Parties, either Party may make a subsequent public disclosure containing the same information disclosed in such prior public
announcement without further approval of the other Party. Notwithstanding the above, Arcus shall have the right to issue a press release and/or make a public announcement concerning the Development or Commercialization status of any Licensed
Product, including, but not limited to, achievement of any Development milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Relationship of the
Parties</U>. Each Party shall bear its own costs incurred in the performance of its obligations hereunder without charge or expense to the other except as expressly provided in this Agreement. Neither Party shall have any responsibility for the
hiring, termination or compensation of the other Party&#146;s employees or for any employee benefits of such employee. No employee or representative of a Party shall have any authority to bind or obligate the other Party to this Agreement in any
manner whatsoever, or to create or impose any contractual or other liability on the other Party without said Party&#146;s approval. For all purposes, the Parties&#146; legal relationship under this Agreement to each other shall be that of
independent contractor. This Agreement is not a partnership agreement and nothing in this Agreement shall be construed to establish a relationship of partners or joint venturers between the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration of this Agreement</U>. To the extent, if any, that either Party concludes in good faith and acting
reasonably that it or the other Party is required to file or register this Agreement or a notification thereof with any Governmental Authority, such Party shall inform the other Party thereof. If both Parties jointly agree that either Party is
required to submit or obtain any such filing, registration or notification, they shall cooperate in such filing, registration or notification and shall execute all documents reasonably required in connection therewith. In such filing, registration
or notification, the Parties shall request confidential treatment of sensitive provisions of this Agreement, to the extent permitted by Applicable Law. The Parties shall promptly inform each other as to the activities or inquiries of any such
Governmental Authority relating to this Agreement, and shall reasonably cooperate to respond to any request for further information therefrom on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Dispute Resolution</U>. Any dispute arising from or relating to the subject matter of this Agreement that
cannot be resolved within a period of thirty (30)&nbsp;days after notice of a dispute has been given by one Party hereunder to the other (the last day of such thirty (30)&nbsp;day period being herein referred to as the &#147;Arbitration Date&#148;),
shall be finally settled by arbitration in San Francisco, California, using the English language in accordance with the Arbitration Rules and Procedures of the Judicial Arbitration and Mediation Services, Inc. (&#147;JAMS&#148;) then in effect, by
one or more commercial arbitrator(s) with substantial experience in resolving complex commercial contract disputes, who may or may not be selected from the appropriate list of JAMS arbitrators. If the Parties cannot agree upon the number and
identity of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the arbitrators within fifteen (15)&nbsp;days following the Arbitration Date, then a single arbitrator shall be selected on an expedited basis in accordance with the Arbitration Rules and
Procedures of JAMS. Any arbitrator so selected shall have substantial experience in the biopharmaceutical industry. The arbitrator(s) shall have the authority to grant specific performance and to allocate between the Parties the costs of arbitration
(including service fees, arbitrator fees and all other fees related to the arbitration) in such equitable manner as the arbitrator(s) may determine. The prevailing Party in the arbitration shall be entitled to receive reimbursement of its reasonable
expenses (including reasonable attorneys&#146; fees, expert witness fees and all other expenses) incurred in connection therewith. Judgment upon the award so rendered may be entered in a court having jurisdiction or application may be made to such
court for judicial acceptance of any award and an order of enforcement, as the case may be. Notwithstanding the foregoing, each Party shall have the right to institute an action in a court of proper jurisdiction for preliminary injunctive relief
pending a final decision by the arbitrator(s); provided that a permanent injunction and damages shall only be awarded by the arbitrator(s). For all purposes of this Section, the parties consent to exclusive jurisdiction and venue in the United
States federal Courts located in the Northern District of California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This Agreement
shall be construed, and the respective rights of the Parties determined, according to the substantive law of California without regard to the provisions governing conflict of laws, except matters of intellectual property law, which shall be
determined in accordance with the intellectual property laws relevant to the intellectual property in question. The United Nations Convention on the International Sale of Goods shall not apply to this Agreement. Money damages may not be an adequate
remedy if certain provisions of this Agreement are breached by a Party and, therefore, the other Party may, in addition to any other legal or equitable remedies, seek an injunction or other equitable relief against such breach or threatened breach.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U>. This Agreement, and the rights and licenses granted hereunder, may not be assigned or
transferred by either Party, in whole or in part, without the prior written consent of the other Party; provided that, without consent of the other Party, either Party may assign this Agreement, in whole or in part, to any of its Affiliates if such
Party guarantees the performance of this Agreement by such Affiliate; and provided further that, without consent of the other Party, either Party may assign this Agreement to a successor to all or substantially all of the assets or business of such
Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or other similar transaction. Any assignment in violation of this provision is void and without effect. This Agreement shall be binding upon and inure to the
benefit of the Parties hereto, their permitted successors, legal representatives and assigns. In the event that Abmuno assigns or transfers any of the Licensed IP to a Third Party, Abmuno shall impose on such assignee or transferee such obligations
as are necessary so that Arcus retains and obtains all of the rights to which it is entitled with respect to such Licensed IP under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. All demands, notices, consents, approvals,
reports, requests and other communications hereunder must be in writing, in English, and will be deemed to have been duly given only if delivered personally, by mail (first class, postage prepaid, return receipt requested), or by overnight delivery
using a globally-recognized carrier, to the Parties at the following addresses: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Arcus:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Abmuno:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Arcus Biosciences, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Abmuno Therapeutics LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3928 Point Eden Way</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">914 Channing Way</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hayward, CA 94545</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Berkeley, CA 94710</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn: Juan Jaen, Ph.D., President</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Attn: Omar Duramad, Ph.D., President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>with a copy to:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>with a copy to:</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gunderson Dettmer Stough, Villeneuve,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Franklin
and Hachigian, LLP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shaheen Sheik-Sadhal, Esq.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Esse Law,
PC</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">201 South Main Street</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Suite 700</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5753 Santa Ana Canyon Rd.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Suite
G420</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ann Arbor, MI 48104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Anaheim Hills, CA 92807</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn: Marcia Hatch, Esq.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the addressee shall have last furnished in writing in accord with this provision. All notices
shall be deemed effective upon receipt by the addressee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. If any provision of this
Agreement is held to be invalid, illegal or unenforceable in any respect, that provision shall be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>. The headings used in this Agreement have been inserted for convenience of reference only and do
not define or limit the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>. No waiver of any term or condition of this
Agreement shall be effective unless set forth in a written instrument duly executed by or on behalf of the waiving Party. No waiver by any Party of any term or condition of this Agreement, in any one or more instances, shall be deemed to be or
construed as a waiver of the same or any other term or condition of this Agreement on any prior, concurrent or future occasion. Except as expressly set forth in this Agreement, all rights and remedies available to a Party, whether under this
Agreement or afforded by Applicable Law or otherwise, will be cumulative and not in the alternative to any other rights or remedies that may be available to such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement</U>. This Agreement (including any exhibits or schedules hereto) constitutes the entire
agreement between the Parties hereto with respect to the subject matter hereof and supersedes all previous agreements and understandings between the Parties, whether written or oral, including, but not limited, to all proposals, negotiations,
conversations, letters of intent, term sheets, memoranda of understanding or discussions, between the Parties relating to the subject matter of this Agreement and all past dealing or industry custom. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.13&nbsp;&nbsp;&nbsp;&nbsp;<U>Modification</U>. This Agreement may be altered, amended or
changed only by a writing making specific reference to this Agreement and the clause to be modified, which amendment is signed by duly authorized representatives of Arcus and Abmuno. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.14&nbsp;&nbsp;&nbsp;&nbsp;<U>No Third Party Beneficiaries</U>. None of the provisions of this Agreement shall be for the benefit of or
enforceable by any Third Party, including, but not limited to, any creditor of either Party hereto, except the Indemnification provision in Section&nbsp;8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.15&nbsp;&nbsp;&nbsp;&nbsp;<U>Ambiguities</U>. This Agreement shall be deemed to have been drafted jointly by both Parties; and ambiguities,
if any, shall not be construed against either Party, irrespective of which Party may have actually drafted the ambiguous provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.16&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be executed in counterparts, each of which, when executed, shall be
deemed to be an original and all of which together shall constitute one and the same document. Signatures received via facsimile, or other electronic means, including in a digitally produced format (e.g., .pdf), shall have the same force and effect
as execution of an original, and such signatures shall be deemed original and valid signatures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of Page Intentionally Left
Blank] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, Arcus and Abmuno, by their duly authorized officers, have executed
this Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARCUS BIOSCIENCES, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>ABMUNO THERAPEUTICS LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Juan C. Jaen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Omar Duramad</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Juan C. Jaen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Omar Duramad</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manager</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<B><I>Signature Page to Arcus-Abmuno License Agreement</I></B>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 1 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LICENSED
PATENTS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 2A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TRANSFERRED TECHNOLOGY IN STAGE 1 TECHNOLOGY TRANSFER </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 2B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>TRANSFERRED TECHNOLOGY IN STAGE 2 TECHNOLOGY TRANSFER </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Intentionally omitted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THIRD PARTY IP </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AGREEMENTS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>between </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCUS
BIOSCIENCES, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WUXI BIOLOGICS (CAYMAN) INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN
INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">DEFINITIONS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">LICENSE GRANTS, OWNERSHIP AND EXCLUSIVITY</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">License Grant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Sublicensing and Subcontracting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Required Provisions in Sublicenses and Subcontracts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Promotion</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ownership of Improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No Implied Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Section&nbsp;365(n) of the Bankruptcy Code</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">DEVELOPMENT AND COMMERCIALIZATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Development and Commercialization Activities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Manufacturing</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Biologic CMC Services</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Assistance; Technology and Material Transfer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-Competition</FONT> Related to Licensed IP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">REGULATORY MATTERS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Recalls or Corrective Action</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">FINANCIAL PROVISIONS/ROYALTIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Execution Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Delivery of Dose Escalation Batch</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Milestone Payments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Royalties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Royalty Adjustments</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Sublicensing Income</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Payment Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Taxes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">5.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Financial Audits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">6.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">CONFIDENTIAL INFORMATION AND PROPRIETARY RIGHTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Definition</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Confidentiality</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Permitted Disclosure and Use</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Remedies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">6.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Survival</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">7.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">REPRESENTATIONS AND WARRANTIES</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Mutual Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table Of Contents</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(cont&#146;d)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">WuXi Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Arcus Representations and Warranties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">7.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Disclaimer of Warranty</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">8.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">INDEMNIFICATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Indemnification by WuXi</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Indemnification by Arcus</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Procedure for Indemnification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Limitation of Liability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Insurance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">9.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">PATENTS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Prosecution and Maintenance</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Infringement of Licensed Patents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Infringement Claims by Third Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">9.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Biosimilars</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">10.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">TERM AND TERMINATION</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Term</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Effects of Termination</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accrued Rights; Surviving Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Certain Additional Matters Relating to Change of Control of Arcus</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">11.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">MISCELLANEOUS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Publications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Public Announcements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Relationship of the Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Dispute Resolution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Governing Law</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Assignment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Severability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Headings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Entire Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Modification</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">No Third Party Beneficiaries</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ambiguities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">11.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This License Agreement (&#147;<B><I>Agreement</I></B>&#148;), effective as of August&nbsp;16, 2017 (&#147;<B><I>Effective Date</I></B>&#148;),
is by and between Arcus Biosciences, Inc. (&#147;<B><I>Arcus</I></B>&#148;), with offices at 3928 Point Eden Way, Hayward, CA 94545, U.S.A., and WuXi Biologics (Cayman) Inc. (&#147;<B><I>WuXi</I></B>&#148;), with an address at Ugland House, Grand
Cayman, <FONT STYLE="white-space:nowrap">KY1-1104,</FONT> Cayman Islands. Arcus and WuXi may be referred to in this Agreement individually as a &#147;<B><I>Party</I></B>&#148; or together as the &#147;<B><I>Parties</I></B>.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BACKGROUND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, WuXi possesses certain patents, patent applications, proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> scientific
and technical information relating to certain Antibodies targeting <FONT STYLE="white-space:nowrap">PD-1</FONT> (as defined below); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Arcus wishes to obtain, and WuXi is willing to grant, an exclusive license to certain of such intellectual property rights in
the Territory (as defined below) for the development, use, manufacture and commercialization of products including the Antibody (as defined below) for any use, including, without limitation, the treatment, diagnosis, prevention or cure of any human
disease or condition; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B><B>, THEREFORE</B>, for good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Parties agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>DEFINITIONS</B>. For purposes of this Agreement, the following capitalized terms, whether used in the
singular or plural, shall have the following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Affiliate</I></B>&#148; means any Person that, directly or indirectly, controls, is
controlled by or is under common control with a Party for so long as such control exists, where &#147;control&#148; means the decision-making authority as to such Person and, further, where such control shall be presumed to exist where a Person owns
more than fifty percent (50%) of the equity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) entitled to vote regarding composition of the board of directors or other body
entitled to direct the affairs of the entity. For purposes of this Agreement, (i)&nbsp;WuXi AppTec (Cayman) Inc., SynTheAll Pharmaceutical Co., Ltd., and WuXi NextCode Genomics, Inc., and their respective subsidiaries, are expressly excluded from
being, and shall not be deemed, an Affiliate of WuXi and (ii)&nbsp;PACT Pharma, Inc. and its respective subsidiaries, are expressly excluded from being, and shall not be deemed, Affiliates of Arcus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Antibody</I></B>&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody owned or
Controlled by WuXi or any Affiliate of WuXi as of the Effective Date which is Covered by the Licensed Patents and/or Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> including without limitation, WuXi&#146;s proprietary <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> monoclonal antibody referred to as WBP3055. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Applicable</I></B> <B><I>Law</I></B>&#148; means any law, statute, rule or regulation issued by a Governmental Authority or Regulatory Authority
and any judicial, governmental, or administrative order, judgment, decree, or ruling, in each case as applicable to the subject matter of this Agreement and the Parties and having a binding effect on it and them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS
DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Arbitration</I></B> <B><I>Date</I></B>&#148; shall have the meaning assigned thereto in
Section&nbsp;11.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Arcus</I></B>&#148; means Arcus Biosciences, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Arcus</I></B> <B><I>Improvements</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;2.5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Arcus</I></B> <B><I>Indemnitees</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;8.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Biologics MSA</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;3.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Biosimilar</I></B> <B><I>Product</I></B>&#148; means, with respect to a particular Licensed Product and a particular country, any pharmaceutical
product of a third party (excluding any Arcus Affiliate, sublicensee, distributor or other subcontractor, or any other party deriving rights from Wuxi or Arcus related to this Agreement) that contains a substantially similar active ingredient as
such Licensed Product and that relies on such Licensed Product as a Reference Product under the Biologics Price Competition and Innovation Act, or any comparable regulatory regime in any other country in the Territory, and (i) for which
biosimilarity or interchangeability (as applicable) with such Licensed Product has been demonstrated and (ii) which has received Regulatory Approval in such country relying in whole or in part on any data generated in support of a Regulatory
Approval for such Licensed Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Biosimilar</I></B> <B><I>Product</I></B> <B><I>Presence</I></B>&#148; shall have the meaning assigned
thereto in Section&nbsp;5.5.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>BLA</I></B>&#148; means a Biologics License Application or any amendments thereto submitted to the FDA, or any
equivalent thereof submitted to a Regulatory Authority outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Change</I></B> <B><I>of</I></B> <B><I>Control</I></B>&#148;
shall have the meaning assigned thereto in Section&nbsp;10.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Claim</I></B>&#148; means any charge, complaint, action, suit, proceeding,
hearing, investigation, claim or demand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Clinical</I></B> <B><I>Trials</I></B>&#148; means a clinical trial in human subjects that has been
approved by a Regulatory Authority and an institutional review board or ethics committee, and is designed to measure the safety and/or efficacy of a Licensed Product. Clinical Trials shall include Phase I Clinical Trials, Phase II Clinical Trials,
Phase III Clinical Trials and any <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or post-Regulatory Approval studies undertaken in relation to any Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>CMO</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;3.2.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Combination</I></B> <B><I>Product</I></B>&#148; means (i)&nbsp;a finished dosage form of a Licensed Product containing the Antibody and one or
more pharmaceutically active ingredients other than such Antibody or (ii)&nbsp;a Licensed Product sold as one of a bundle of products without a separate price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commercialization</I></B>&#148; or &#147;<B><I>Commercialize</I></B>&#148; means engaging in any
and all activities directed to marketing, promoting, conducting post-Regulatory Approval studies, distributing, offering for sale, selling, having sold, making, having made, using, importing, exporting or exploiting, a Licensed Product (as defined
below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commercially</I></B> <B><I>Reasonable</I></B> <B><I>Efforts</I></B>&#148; means those efforts commensurate with those efforts
commonly used in the biopharmaceutical industry by a company of comparable size in connection with the development, manufacturing or commercialization of products that are of similar status, including market potential, profit potential and strategic
value, as determined based on conditions then prevailing, including safety, efficacy, competitive considerations within the marketplace, projected market size, intellectual property protection and duration, manufacturing costs, resource allocation,
pricing, <FONT STYLE="white-space:nowrap">re-importation</FONT> concerns, regulatory requirements needed to achieve Regulatory Approval, and other relevant commercial and regulatory considerations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Confidential</I></B> <B><I>Information</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;6.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Control</I></B>&#148; or &#147;<B><I>Controlled</I></B>&#148; means with respect to any item of or right under Licensed Patents or Licensed <FONT
STYLE="white-space:nowrap">Know-How,</FONT> the possession of (whether by ownership or license, other than pursuant to this Agreement) the ability of a Party to grant a license or sublicense of such items or right as provided for herein without
violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such license or sublicense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Cover</I></B>&#148; or &#147;<B><I>Covering</I></B>&#148; means (i)&nbsp;with respect to any Patent, that at least one Valid Claim of such Patent
would be infringed by the manufacture, use, import, offer for sale, or sale of a product, method or device, as applicable, and (ii)&nbsp;with respect to any other intellectual property right, that the manufacture, use, import, offer for sale, or
sale of a product, method or device would infringe or misappropriate such rights, as applicable, in each case in the absence of the licensed rights granted under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Defending</I></B> <B><I>Party</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;9.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Development</I></B>&#148; or &#147;<B><I>Develop</I></B>&#148; means engaging in preclinical and clinical drug development activities, including,
but not limited to, discovery, test method development, stability testing, toxicology, formulation, process development, manufacturing <FONT STYLE="white-space:nowrap">scale-up,</FONT> development-stage manufacturing, analytical method validation,
manufacturing process validation, cleaning validation, post-approval changes, quality assurance/quality control, statistical analysis, report writing, preclinical studies, Clinical Trials, regulatory filing submission and approval and regulatory
affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Disclosing</I></B> <B><I>Party</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;6.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Disclosure</I></B> <B><I>Obligations</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;6.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Dose</I></B> <B><I>Escalation</I></B> <B><I>Batch</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;3.4. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Dose</I></B> <B><I>Escalation</I></B> <B><I>Study</I></B>&#148; shall mean, with respect to a
Licensed Product, a Phase I Clinical Trial for such Licensed Product that includes the dosing of the number of patients defined in the protocol to (i)&nbsp;establish the maximum tolerated dose of such Licensed Product or, if no maximum tolerated
dose is established, evaluates dosing levels sufficient to establish recommended therapeutic dose for the Licensed Product provided for in the protocol for such Phase I Clinical Trial and (ii)&nbsp;establish the recommended dose of such Licensed
Product for use in any further Clinical Trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Effective</I></B> <B><I>Date</I></B>&#148; shall have the meaning assigned thereto in the
first paragraph of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Excluded</I></B> <B><I>Territory</I></B>&#148; means the countries of China (including Hong Kong, Taiwan,
and Macau), Thailand, Korea, Indonesia, Brazil and Russia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>FD&amp;C</I></B> Act&#148; means the United States Federal Food, Drug&nbsp;&amp;
Cosmetic Act, as amended, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>FDA</I></B>&#148; means the United States Food and Drug Administration and any successor agency thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Field</I></B>&#148; means any and all fields of use, including, without limitation, the diagnosis, treatment, prevention or control of any human
disease or condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>First</I></B> <B><I>Commercial</I></B> <B><I>Sale</I></B>&#148; means the date, following Regulatory Approval in a
given country, that the first Licensed Product is offered for sale or sold, whichever is earlier, to an arms&#146; length customer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>GAAP</I></B>&#148; means Generally Accepted Accounting Principles in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Good</I></B> <B><I>Manufacturing</I></B> <B><I>Practices</I></B>&#148; or &#147;<B><I>GMP</I></B>&#148; means, with respect to the United States,
the minimum then-current good manufacturing practices for methods, facilities, and controls to be used for the manufacture, processing, packing, or holding of a drug to assure that it meets the requirements of the FD&amp;C Act for safety and has the
identity and strength and meets the quality and purity characteristics, specified in 21 C.F.R. Parts&nbsp;210 and 211, as may be amended, and, with respect to any other country or jurisdiction, the equivalent regulations in such other country or
jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Governmental</I></B> <B><I>Authority</I></B>&#148; means an applicable multi- or supra-national, federal, state, local,
municipal or other government authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>IFRS</I></B>&#148; means International Financial Reporting Standards, as promulgated by the International Standards Accounting Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Improvements</I></B>&#148; means any adaptation, change, redesign, modification, invention,
discovery, enhancement or development conceived, reduced to practice, developed or made after the Effective Date and (i)&nbsp;incorporated into any Licensed Product, (ii)&nbsp;made with respect to the specifications, the raw materials or the method
or process of manufacture or production of any Licensed Product, including any product which performs the same function as any Licensed Product, (iii)&nbsp;incorporating, utilizing, or developed utilizing, Licensed
<FONT STYLE="white-space:nowrap">Know-How,</FONT> or (iv)&nbsp;requiring the practice of an invention claimed in the Licensed Patents. Inventorship for Improvements shall be determined in accordance with the patent laws of the United States (Title
35, United States Code). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Initiation</I></B>&#148; of a human Clinical Trial shall mean the first dosing, whether of the investigational
product, placebo or comparator, of the first subject so dosed in such trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Intellectual</I></B> <B><I>Property</I></B>
<B><I>Rights</I></B>&#148; means any and all patent rights, copyrights, trade secret rights, software rights, <I>sui generis</I> database rights, and all other intellectual and industrial property rights of any sort throughout the world (including
any application therefor) whether now known or hereafter existing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>JAMS</I></B>&#148; means Judicial Arbitration and Mediation Services, Inc.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Joint</I></B> <B><I>Improvement</I></B>&#148; means, if applicable, an Improvement with respect to which employees and/or agents of both
Arcus and WuXi are joint inventors in the course of the activities hereunder, regardless of whether any Third Parties are also joint inventors, including, without limitation, all Intellectual Property Rights therein. Inventorship for Joint
Improvements shall be determined in accordance with the patent laws of the United States (Title 35, United States Code). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Know</I></B>-<B><I>How</I></B>&#148; means proprietary technical information, processes, formulae, data, inventions, methods, knowledge,
discoveries, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets and other information, whether or not patentable and whether or not reduced to practice, but that is not known to the public and is still Confidential Information,
including any tangible embodiments of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Licensed</I></B> <B><I>IP</I></B>&#148; means the Licensed Patents, Licensed <FONT
STYLE="white-space:nowrap">Know-How</FONT> and WuXi&#146;s interest in the Improvements and Joint Improvements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Licensed <FONT
STYLE="white-space:nowrap">Know-How</FONT></I></B>&#148; means (i)&nbsp;the Licensed Technology and (ii)&nbsp;other <FONT STYLE="white-space:nowrap">Know-How</FONT> that is, in each case of (i)&nbsp;and (ii), (a)&nbsp;Controlled by WuXi or any
Affiliate of WuXi as of the Effective Date or at any time during the Term and (b)&nbsp;shared by WuXi with Arcus as required by this Agreement or as specifically requested by Arcus in direct connection with an Antibody, as can be demonstrated by
reasonable evidence. Notwithstanding the foregoing, Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> shall not include any materials or information that (1)&nbsp;exist in the public domain through no act or omission of Arcus, or its
Affiliates, sublicensees, or subcontractors, or (2)&nbsp;are in the possession of Arcus or otherwise known by Arcus before disclosure thereof to Arcus by or on behalf of WuXi, as can be demonstrated by reasonable written evidence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Licensed Patents</I></B>&#148; means the Patents listed in Exhibit 1 hereto and (i)&nbsp;patent
applications filed either from the foregoing or from an application claiming priority to the foregoing, including all provisionals, substitutions, continuations,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisions, renewals and continued prosecution applications, and all patents granted thereon, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(ii)&nbsp;patents-of-addition,</FONT></FONT> revalidations, reissues, reexaminations and extensions, adjustments or restorations by existing or future extension or restoration mechanisms, including patent term adjustments,
patent term extensions, supplementary protection certificates or the equivalent thereof, (iii)&nbsp;inventor&#146;s certificates, utility models, innovation patents and design patents for any of the foregoing, (iv)&nbsp;other forms of
government-issued rights substantially similar to any of the foregoing, including <FONT STYLE="white-space:nowrap">so-called</FONT> pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or
patent of additions, to any of such foregoing, (v)&nbsp;United States and foreign counterparts of any of the foregoing, and (vi)&nbsp;all other Patents that have at least one Valid Claim Covering the Development, manufacture, Commercialization
and/or other exploitation of a Licensed Product in the Field in the Territory, whether or not listed on Exhibit 1, in the case of (vi), to the extent any of such Patents are Controlled by WuXi or any Affiliate of WuXi as of the Effective Date or
during the Term of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Licensed Product</I></B>&#148; means any pharmaceutical product that contains an Antibody (as the same may
be modified or further developed) in all forms, presentations, formulations, administrations, dosages, dosage forms and packages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Licensed
Technology</I></B>&#148; means the data, reports, analytical methods, <FONT STYLE="white-space:nowrap">non-clinical</FONT> and safety information, regulatory filings and correspondences and/or other materials and information described in Exhibit 2,
attached hereto, and expressly excludes manufacturing information until and unless a Transfer Election occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Losses</I></B>&#148; means any
and all damages (including, but not limited to, all loss of profits, diminution in value, and incidental, indirect, consequential, special, reliance, exemplary, punitive, statutory and treble damages), awards, deficiencies, settlement amounts,
defaults, assessments, fines, dues, penalties, costs, fees, liabilities, obligations, taxes, liens, losses and expenses (including, but not limited to, court costs, interest and reasonable fees of attorneys, accountants and other experts) incurred
by or awarded to Third Parties and required to be paid to Third Parties with respect to a Claim by reason of any judgment, order, decree, stipulation or injunction, or any settlement entered into in accordance with the provisions of this Agreement,
together with all reasonable documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses incurred in contesting any Third Party Claim or complying with any judgments, orders, decrees,
stipulations and injunctions that arise from or relate to a Third Party Claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Manufacturing Agreements</I></B>&#148; shall have the meaning
assigned thereto in Section&nbsp;3.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Manufacturing Exclusivity Period</I></B>&#148; shall have the meaning assigned thereto in
Section&nbsp;3.2.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>NDA</I></B>&#148; means: (i)&nbsp;in the United States, a New Drug Application (as more fully defined in 21&nbsp;CFR
314.5, <I>et seq.</I>) filed with the FDA, or any successor application thereto; or (ii)&nbsp;in any other country or group of countries, the equivalent application or submission for approval to market a pharmaceutical product filed with the
governing Regulatory Authority in such country or group of countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Net Sales</I></B>&#148; means, with respect to any Licensed Product, the gross sales price of
such Licensed Product invoiced by or for Arcus, or its Affiliates or sublicensees (the &#147;Selling Party&#148;), to Third Parties negotiated at arms&#146; length (including without limitation any hospital or pharmacy), less any of the following
applicable deductions related to such sale and included in the invoiced amount: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net Sales will be determined from books and records maintained in accordance with GAAP or IFRS, consistently applied throughout Arcus, its Affiliates and
sublicensees, and across all Licensed Products of the foregoing. If there is overlap between any of deductions [***], each individual item shall only be deducted once in each Net Sales calculation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, a Licensed Product is sold in the form of a Combination Product, the Net Sales for such Licensed Product in the Combination Product under this Agreement will be calculated by [***].
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Other</I></B> <B><I>Product</I></B>&#148; means, with respect to a Combination Product, any active pharmaceutical ingredient other than a
particular Antibody within such Combination Product. It is understood that an Other Product may be another antibody. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Party</I></B>&#148; or
&#147;<B><I>Parties</I></B>&#148; shall have the meaning assigned thereto in the first paragraph of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Patent</I></B>&#148;
means any and all national, regional and international (i)&nbsp;issued patents and pending patent applications (including provisional patent applications), (ii)&nbsp;patent applications filed either from the foregoing or from an application claiming
priority to the foregoing, including all provisional applications, converted provisionals, substitutions, continuations, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisions, renewals and
continued prosecution applications, and all patents granted thereon, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(iii)&nbsp;patents-of-addition,</FONT></FONT> revalidations, reissues, reexaminations and extensions, adjustments
or restorations by existing or future extension or restoration mechanisms, including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (iv)&nbsp;inventor&#146;s certificates, utility
models, innovation patents and design patents, (v)&nbsp;other forms of government-issued rights substantially similar to any of the foregoing, including <FONT STYLE="white-space:nowrap">so-called</FONT> pipeline protection or any importation,
revalidation, confirmation or introduction patent or registration patent or patent of additions to any of such foregoing and (vi)&nbsp;United States and foreign counterparts of any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Patent Term Extensions</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;9.1.5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I><FONT STYLE="white-space:nowrap">PD-1</FONT></I></B>&#148; means the cell surface receptor protein commonly referred to as &#147;Programmed Cell
Death Protein 1&#148; or <FONT STYLE="white-space:nowrap">&#147;PD-1.&#148;</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Permitted Representatives</I></B>&#148; shall have the meaning assigned thereto in
Section&nbsp;6.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148; means any natural person, corporation, general partnership, limited partnership, limited liability
company, joint venture, proprietorship or other <I>de jure </I>entity organized under Applicable Laws of any jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Phase I Clinical
Trial</I></B>&#148; shall mean a Clinical Trial of a Licensed Product that would satisfy the requirements for a Phase I study as defined in 21 CFR &#167; 312.21(a) or a Phase I study as defined in ICH E8 Guideline, in each case, as amended (or its
successor regulation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Phase Ib Clinical Trial</I></B>&#148; shall mean the cohort expansion phase of a Phase I Clinical Trial of a Licensed
Product after the Dose Escalation Study portion of such Phase I Clinical Trial that includes the dosing of one or more cohorts of patients, the principal purpose of which cohort expansion phase is to evaluate safety, tolerability and indication of
efficacy of such Licensed Product in patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Phase II Clinical Trial</I></B>&#148; shall mean a proof of concept Clinical Trial, the
principal purpose of which is to make a preliminary determination as to whether a product is efficacious in one or more target populations and/or indications, including at the intended clinical dose or range of doses, to permit the design of further
Clinical Trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Phase III Clinical Trial</I></B>&#148; shall mean a pivotal Clinical Trial with a defined dose or a set of defined doses of
a therapeutic product designed to ascertain efficacy and safety of such product, in a manner that is generally consistent with and as defined in 21 CFR &#167; 312.21(c) as amended (or its successor regulation), for the purpose and design of
establishing with statistical significance that the Licensed Product is safe and effective with respect to a given indication sufficient to obtain Regulatory Approval for such Licensed Product. A Clinical Trial shall not be deemed a Phase III trial
unless it will fulfill the requirements of such a trial, or is described as such in the protocol for such trial filed with the applicable Regulatory Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Pricing Approval</I></B>&#148; means the later of (i)&nbsp;the approval, agreement, determination or governmental decision establishing the price
for a Licensed Product that can be legally charged to consumers, as required in a given jurisdiction or country in connection with Commercialization of such Licensed Product in such jurisdiction or country and (ii)&nbsp;the approval, agreement,
determination or governmental decision establishing, the level of reimbursement for such Licensed Product that will be reimbursed by Governmental Authorities, as required in a given jurisdiction or country in connection with Commercialization of
such Licensed Product in such jurisdiction or country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Promotional Materials</I></B>&#148; means packaging, inserts, digital content and
similar information and materials selected by Arcus or its Affiliates or any of its or their sublicensees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Receiving Party</I></B>&#148;
shall have the meaning assigned thereto in Section&nbsp;6.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Regulatory Approval</I></B>&#148; means final regulatory approval required to
Commercialize a Licensed Product for a disease or condition in accordance with the Applicable Laws of a given country, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including Pricing Approval if Pricing Approval is required to Commercialize such Licensed Product for such disease or condition in such country. In the United States, its territories and
possessions, Regulatory Approval means approval of a BLA or an equivalent by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Regulatory Authority</I></B>&#148; means, with respect
to a country in the Territory, any national (e.g., the FDA), supra-national (e.g., the European Commission, the Council of the European Union, or the European Medicines Agency), regional, state or local regulatory agency, department, bureau,
commission, council or other Governmental Authority involved in the granting of a Regulatory Approval, for biopharmaceutical products in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Royalty Term</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;5.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>SEC</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;6.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Sublicense Income</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;5.6.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Term</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;10.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Territory</I></B>&#148; means all the countries and territories of the world other than the Excluded Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Third</I></B> <B><I>Party</I></B>&#148; means a Person who is not a Party or an Affiliate of a Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Third</I></B> <B><I>Party</I></B> <B><I>Claim</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;8.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Third Party License</I></B>&#148; shall have the meaning set forth in Section&nbsp;5.5.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Third Party Royalties</I></B>&#148; shall have the meaning set forth in Section&nbsp;5.5.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trademarks</I></B>&#148; means trademarks and trade dress selected by Arcus or its Affiliates or any of its or their sublicensees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Transfer Election</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;3.2.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>United States</I></B>&#148; means the United States of America and its territories and possessions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>U.S.</I></B> <B><I>Bankruptcy</I></B> <B><I>Code</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;2.7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Valid Claim</I></B>&#148; means with respect to a Patent in a country, any claim of an (i)&nbsp;issued Patent that has not (a)&nbsp;expired,
irretrievably lapsed or been abandoned, revoked, dedicated to the public or disclaimed or (b)&nbsp;been found to be unpatentable, invalid or unenforceable by an unreversed and unappealable final decision of a Governmental Authority in such country
or (ii)&nbsp;application for a Patent that (a)&nbsp;has been pending for less than [***] years from the date of filing of that application, is being prosecuted in good faith, and has not been abandoned or finally disallowed without the possibility
of appeal or <FONT STYLE="white-space:nowrap">re-filing</FONT> and (b)&nbsp;has not been admitted to be invalid or unenforceable through reissue, reexamination, or disclaimer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>WuXi</I></B>&#148; means WuXi Biologics (Cayman) Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>WuXi Improvements</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;2.5. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B><I>WuXi Indemnitees</I></B>&#148; shall have the meaning assigned thereto in Section&nbsp;8.2. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;LICENSE GRANTS, OWNERSHIP AND EXCLUSIVITY</B>.<B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>License Grant</U>. Subject to the terms and conditions of this Agreement, WuXi shall grant and hereby grants to
Arcus, and Arcus accepts, (i)&nbsp;an exclusive (even as to WuXi and its Affiliates), <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except as set forth in Section&nbsp;11.6) license, with the right to sublicense (as provided in
Section&nbsp;2.2) under the Licensed IP, to make, have made, use, register, sell, offer to sell, have sold, import, export, exploit, research, improve, Develop and Commercialize Licensed Products in the Field in the Territory; and (ii)&nbsp;a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except as set forth in Section&nbsp;11.6) license, with the right to sublicense (as provided in Section&nbsp;2.2) under the Licensed IP to
Develop and manufacture Licensed Products anywhere in the world only for applications in the Field solely for the purpose of Developing, manufacturing and Commercializing Licensed Products for use in and for the Territory. All rights not expressly
granted to Arcus under this Agreement are reserved to WuXi. Exercise or attempted exercise of the licensed rights granted in Section&nbsp;2.1(i) by Arcus or its Affiliates in any Excluded Territory is a material breach of this Agreement. Arcus shall
prohibit its sublicensees and subcontractors from exercising such licensed rights in the Excluded Territory, and shall use Commercially Reasonable Efforts to enforce such prohibition. If Arcus or any of its Affiliates receives, or becomes aware of
the receipt by a sublicensee or subcontractor of any orders for any Licensed Product for use in the Excluded Territory, Arcus shall notify WuXi thereof and shall procure that such recipient refers such orders to WuXi or WuXi&#146;s designee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Sublicensing and Subcontracting</U>. Arcus may sublicense its rights under Section&nbsp;2.1(i) and/or 2.1(ii) to
the Licensed IP during the Term of this Agreement, provided that each such sublicense must be in writing and Arcus must provide a copy of each sublicense (and any <FONT STYLE="white-space:nowrap">sub-sublicense)</FONT> agreement to WuXi within [***]
days after execution of such sublicense, which copy may be redacted only to the extent not relevant to the determination of Arcus&#146; and any Affiliates&#146; or sublicensees&#146; compliance with its payment obligations under this Agreement.
Arcus shall secure all appropriate covenants, obligations and rights from any sublicensee to ensure that such sublicensee is subject to, and Arcus can comply with, all of Arcus&#146;s applicable representations, warranties, covenants and obligations
to WuXi under this Agreement including those required provisions in Section&nbsp;2.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Arcus agrees for itself that it shall be jointly
and severally responsible, along with its relevant sublicensee or Affiliate, for any failure of such sublicensee or Affiliate to comply with the applicable provisions of this Agreement; <I>provided that</I>, Arcus may, upon written notice to WuXi,
cause the relevant sublicensee to cure such failure within the cure period (if any) that would have been applicable to Arcus had the failure been attributable to the acts or omissions of Arcus. If Arcus does so, such failure by the sublicensee shall
not be deemed a breach of this Agreement so long as the failure has been cured. For the avoidance of doubt, in no event shall Arcus be deemed to have agreed to such joint and several responsibility on behalf of or for any of its sublicensees, and in
no event shall Arcus be deemed to have any obligation to obtain any such agreement or acknowledgement from any of its sublicensees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event any such sublicense is terminated by Arcus, Arcus shall notify WuXi of such
termination and provide WuXi with a summary of the reasons for such termination, to the extent they substantially relate to the rights granted to Arcus under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If requested by Arcus, WuXi will discuss, acting reasonably and in good faith, with Arcus any proposed modifications as may be requested by a
potential sublicensee with respect to the terms and conditions of this Agreement. Upon termination of this Agreement for any reason other than for an uncured material breach by Arcus pursuant to Section&nbsp;10.2.2(b) of this Agreement, any
sublicensee shall have the right to seek a license from WuXi to the Licensed IP, and WuXi agrees to negotiate such licenses in good faith under reasonable terms and conditions (<I>e.g.</I>, under terms and conditions substantially similar to those
herein; provided, however, that such sublicensee has previously met all obligations under this Agreement and its sublicense agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B></B>Contract manufacturers, wholesalers and distributors shall not be deemed sublicensees, but instead, shall be deemed
subcontractors.<B><I> </I></B>Subject to Section 3.1, Arcus may freely subcontract its rights, in whole or in part, to Develop, manufacture, Commercialize or otherwise exploit Licensed Products provided (i) any such agreements will be in writing;
(ii) Arcus shall secure all appropriate covenants, obligations and rights from any such subcontractor to ensure that such subcontractor is subject to, and Arcus can comply with, all of Arcus&#146;s applicable covenants and obligations to WuXi under
this Agreement; and (iii) Arcus shall be responsible for any failure of its subcontractors to comply with the applicable provisions of this Agreement; <I>provided that</I>, Arcus may, upon written notice to WuXi, cause the relevant subcontractors to
cure such failure within the cure period (if any) that would have been applicable to Arcus had the failure been attributable to the acts or omissions of Arcus. If Arcus does so, such failure by the subcontractor shall not be deemed a breach of this
Agreement so long as the failure has been cured. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Required Provisions in Sublicenses and Subcontracts</U>.
Any direct sublicensee of Arcus may further sublicense and subcontract its rights, in whole or in part, to Develop, manufacture, Commercialize or otherwise exploit Licensed Products, <I>provided that</I> any such sublicense is granted, or such
subcontract is entered into, in accordance with the terms of Section 2.2<I>. </I>Arcus shall use Commercially Reasonable Efforts to require its direct sublicensees to obtain Arcus&#146; written consent prior to granting any such further sublicenses.
If such requirement is included in the written sublicense agreement between Arcus and a direct sublicensee, Arcus agrees to seek WuXi&#146;s prior consent in the event of any sublicensing request by such Arcus direct sublicensee, which consent shall
not be unreasonably withheld, conditioned or delayed by WuXi. No further sublicensing or subcontracting is permitted beyond that expressly stated in this Section 2.3 without WuXi&#146;s written consent. Each such Arcus sublicense and further
sublicense by an Arcus sublicensee must be in writing and include language materially similar to the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Promotion</U>. Licensed Products shall be Commercialized solely
under Trademarks and solely in connection with Promotional Materials. Arcus and its Affiliates and its and their sublicensees shall exclusively own all Promotional Materials for the Licensed Products and all right, title and interest in and to, and
all goodwill from the use of, Trademarks for Licensed Products, and shall be responsible for the procurement, filing and maintenance of trademark registrations for such Trademarks and all related costs and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Ownership of Improvements</U>. WuXi shall own all right, title and interest in and to any Improvements invented
solely by WuXi including, without limitation, any Intellectual Property Rights therein, and all such Improvements will be included within the licensed rights granted in Section&nbsp;2.1. WuXi and Arcus (or if Arcus so designates in writing, its
Affiliates and its and their sublicensees) shall each have an undivided fifty percent (50%) ownership interest in all Joint Improvements, including without limitation, any Intellectual Property Rights therein. WuXi&#146;s interest in its own
Improvements and all Joint Improvements will be included within the licensed rights granted in Section&nbsp;2.1 provided they relate to the rights granted under this Agreement. WuXi shall obtain and maintain licenses for any and all improvements of
its other licensees and their direct and indirect sublicensees (collectively, with WuXi&#146;s own Improvements and its interest in the Joint Improvements, the &#147;<B><I>WuXi</I></B><B><I> Improvements</I></B>&#148;) so that it may include any and
all such WuXi Improvements within the licensed rights granted in Section&nbsp;2.1 provided they relate to the rights granted by WuXi under this Agreement, and any and all such WuXi Improvements shall automatically be included within the licensed
rights granted in Section&nbsp;2.1, provided they relate to the rights granted under this Agreement. WuXi will promptly disclose all such WuXi Improvements to Arcus during the Term of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Arcus shall own all right, title and interest in and to any Improvements invented solely by Arcus (the &#147;<B><I>Arcus
Improvements</I></B>&#148;) including, without limitation, any Intellectual Property Rights therein. Subject to the terms and conditions of this Agreement, Arcus shall grant and hereby grants to WuXi, and WuXi accepts, (i)&nbsp;an exclusive (even as
to Arcus and its Affiliates), <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except as set forth in Section&nbsp;11.6) license, with the right to sublicense (as provided in Section&nbsp;2.2<I>, mutatis mutandis</I>, as if Arcus was WuXi
and WuXi was Arcus) under Arcus&#146; interest in the Arcus Improvements to make, have made, use, register, sell, offer to sell, have sold, import, export, exploit, research, improve, Develop and Commercialize Licensed Products in the Field in the
Excluded Territory; and (ii)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except as set forth in Section&nbsp;11.6) license under Arcus&#146; interest in the Arcus
Improvements to manufacture Licensed Products anywhere in the world only for applications in the Field for the purpose of Developing, manufacturing and Commercializing Licensed Products solely for distribution and use in the Excluded Territory. As
between the Parties, subject to the foregoing license granted by Arcus to WuXi, Arcus retains sole and exclusive ownership of all rights, title and interests in and to the Arcus Improvements. All rights not expressly granted to WuXi under this
Agreement are reserved to Arcus. Exercise or attempted exercise of the licensed rights granted in part (i)&nbsp;of this paragraph in any part of the Territory is a material breach of this Agreement.<B><I> </I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except as expressly provided in this Agreement and subject to any restrictions therein, each
Party may make, have made, sell, have sold, use, license, assign, mortgage or keep Joint Improvements or <FONT STYLE="white-space:nowrap">co-owned</FONT> Improvements, and otherwise undertake all activities a sole owner might undertake with respect
to such <FONT STYLE="white-space:nowrap">co-owned</FONT> Improvements or Joint Improvements, without the consent of and without accounting to the other Party, provided that any assignment, license or other disposition or use (i)&nbsp;shall at all
times be and remain subject to the grants of rights and accompanying conditions and obligations with respect thereto under this Agreement, and (ii)&nbsp;allow the Parties to exercise their rights and perform their obligations under this Agreement,
in particular to Develop, manufacture and Commercialize Licensed Products in at least the same scope as prior to such assignment, license or other such disposition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.6&nbsp;&nbsp;&nbsp;&nbsp;<U>No Implied Rights</U>; <U>Express Reservation of Rights Not Licensed</U>. Nothing contained in this Agreement
confers or will be construed to confer any rights or licenses by implication, estoppel or otherwise, in, to or under any intellectual property rights, other than the rights and licenses expressly granted in this Agreement. All rights not expressly
granted by a Party under this Agreement are reserved to such Party. Without limitation, as between the Parties, subject to the licenses granted by WuXi to Arcus under this Agreement, WuXi retains sole and exclusive ownership of all rights, title and
interests in and to the Licensed IP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">2.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Section 365(n) of the Bankruptcy Code</U>. All rights and licenses
granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n) of title 11 of the United States Code (the &#147;<B><I>U.S. Bankruptcy Code</I></B>&#148;), licenses of rights
to &#147;intellectual property&#148; as defined under Section&nbsp;101(35A) of the U.S. Bankruptcy Code to the extent permitted thereunder. The Parties shall retain and may fully exercise all of their respective rights and elections under the U.S.
Bankruptcy Code. In the event of the bankruptcy of either Party, the <FONT STYLE="white-space:nowrap">non-bankrupt</FONT> Party shall further be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual
property, and such, if not already in its possession, shall be promptly made available to the <FONT STYLE="white-space:nowrap">non-bankrupt</FONT> Party for use solely in accordance with the terms of this Agreement and Section&nbsp;365(n) of the
U.S. Bankruptcy Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>DEVELOPMENT AND COMMERCIALIZATION</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Development and Commercialization Activities</U>. Arcus shall use Commercially Reasonable Efforts to Develop and
Commercialize Licensed Products. Arcus shall use Commercially Reasonable Efforts to manufacture or otherwise obtain supply of its requirements of packaged and labeled Licensed Products in connection with its Development and Commercialization
obligations hereunder, in accordance with all Applicable Laws, GMP (as applicable) and this Agreement. For so long as Arcus is conducting Development activities under this Agreement, Arcus shall provide to WuXi, no later than on June&nbsp;30 and
December&nbsp;31 of each calendar year, with written summaries of the Development activities it performed, or caused to be performed, in respect of Licensed Products since the preceding report (or, with respect to the first such report, since the
Effective Date), and the future Development activities it </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expects to initiate in respect of Licensed Products during the following six (6)-month period. Arcus agrees to consider any and all comments provided by WuXi in connection with such summaries in
good faith. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Manufacturing</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2.1&nbsp;&nbsp;&nbsp;&nbsp;The Parties shall negotiate in good faith the terms of, and shall seek to enter into, separate clinical and
commercial manufacturing agreements, and/or amendments to existing manufacturing agreements, under which WuXi<B><I> </I></B>would manufacture and supply Licensed Products for Arcus in the Territory (the &#147;<B><I>Manufacturing
Agreements</I></B>&#148;). The Parties intend to enter into such Manufacturing Agreements (i)&nbsp;no later than [***] prior to the Initiation of Phase I Clinical Studies for the first Licensed Product (for the clinical manufacturing agreement) and
(ii)&nbsp;no later than [***] prior to the anticipated date of Regulatory Approval of the first Licensed Product (for the commercial manufacturing agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2.2&nbsp;&nbsp;&nbsp;&nbsp;The Manufacturing Agreement(s) shall provide for Arcus&#146; appointment of WuXi as its exclusive manufacturer
of Licensed Products from and after the effective date of the Manufacturing Agreement(s) until Arcus makes a Transfer Election under Section&nbsp;3.2.3, where the Transfer Election is permitted only on or after [***] (the &#147;<B><I>Manufacturing
Exclusivity Period</I></B>&#148;), subject to (i)&nbsp;WuXi&#146;s ability to provide such Licensed Products in accordance with agreed-upon specifications, in the quantities, and on the timeframes reasonably requested by Arcus and according to the
prices set forth in Exhibit 4 hereto (subject to a maximum increase of [***] percent ([***]%) in any one calendar year prior to First Commercial Sale and [***] percent ([***]%) in any one calendar year beginning upon First Commercial Sale); (ii)
Arcus&#146;s right to engage a backup supplier to provide Licensed Products as further set forth in this Section&nbsp;3.2; and (iii)&nbsp;Arcus&#146; sublicensees rights to utilize their own manufacturing resources as further set forth in this
Section&nbsp;3.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Backup Supplier</U>. Upon request by Arcus at any time during the Term, WuXi shall
reasonably cooperate and promptly perform any technical transfer and validation activities reasonably necessary to enable Arcus&#146; designated backup supplier to supply Licensed Product. Prior to the expiration of the Manufacturing Exclusivity
Period, Arcus may procure supply from its designated backup supplier solely in the event WuXi is not able to supply Arcus with Licensed Products in accordance with the terms of the Manufacturing Agreement. From and after such time as WuXi resumes
its ability to provide accepted orders for Licensed Products in accordance with the terms of the Manufacturing Agreement, Arcus may continue to utilize the aforementioned backup supplier to provide up to [***] percent ([***]%) of Arcus&#146; needs
on an ongoing basis. The Manufacturing Agreement(s) will provide further terms and conditions regarding any such backup supplier. For the avoidance of doubt, Arcus&#146;s use of such backup supplier in accordance with this Section&nbsp;3.2 shall not
be deemed a Transfer Election nor be subject to the increased royalty rates set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Sublicensee
Manufacturing Rights</U>. The Manufacturing Agreements shall permit Arcus&#146; sublicensees to place orders for such Licensed Products on the same terms and conditions applicable to Arcus; <I>provided that</I> (i)&nbsp;prior to expiration of
Manufacturing Exclusivity Period, each Arcus sublicensee shall be free to manufacture up to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
[***] percent ([***]%) of their requirements for Licensed Products (or any components thereof) utilizing their own manufacturing resources, subject to an increase in the base royalty rate by
[***] percent ([***]%) and (ii)&nbsp;beginning on the earlier of (A)&nbsp;the [***] anniversary of the effective date of the respective sublicense agreement and (B)&nbsp;the expiration of the Manufacturing Exclusivity Period, Arcus&#146;
sublicensees shall be free to manufacture all or any portion of their requirements for Licensed Products using their own manufacturing resources (subject to an increase in the base royalty rate by [***] percent ([***]%)) or any Third Party
manufacturer (subject to an increase in the base royalty rate by [***] percent ([***]%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2.3&nbsp;&nbsp;&nbsp;&nbsp;For the avoidance
of doubt, nothing in this Agreement shall require Arcus to place orders for the clinical or commercial supply of any Licensed Products. Further, without limiting Arcus&#146; and its sublicensees&#146; rights under this Section&nbsp;3.2, Arcus would
have the option, upon expiration of the Manufacturing Exclusivity Period, to convert WuXi&#146;s manufacturing appointment from exclusive to <FONT STYLE="white-space:nowrap">non-exclusive</FONT> and either (i)&nbsp;grant an Affiliate, sublicensee,
subcontractor or any other Third Party (such subcontractor and Third Party, collectively, a &#147;<B><I>CMO</I></B>&#148;), the right to manufacture such Licensed Products for Arcus (and procure some or all of its requirements for such Licensed
Products from such Affiliate, sublicensee, or CMO) or (ii)&nbsp;manufacture such Licensed Products for itself, on its own behalf (either of such elections in (i)&nbsp;or (ii), a &#147;<B><I>Transfer Election</I></B>&#148;). WuXi shall reasonably
cooperate with Arcus in transferring technology to Arcus or Arcus&#146; designated Affiliate, sublicensee, or CMO promptly so that it may begin manufacturing Licensed Products. From and after the effective date of any Transfer Election, the
royalties payable to WuXi under Article 5 shall be increased by [***] percent ([***]%) for any transfer to a CMO, <I>provided that</I> if Arcus will itself manufacture or the transfer of manufacturing obligations is to an Affiliate or sublicensee of
Arcus, the royalties shall be increased by [***]-percent ([***]%), in each case above the base royalty already due under Section&nbsp;5.4. The preceding sentence shall not apply if the Transfer Election is due to WuXi&#146;s failure or inability to
supply the Licensed Products in accordance with the terms of the applicable Manufacturing Agreement. The increase by [***] percent or [***] percent in this Section [***]. For the avoidance of doubt, the maximum increase in the royalty rate under
this Section&nbsp;3.2 shall not exceed (x) [***] percent ([***]%) if Arcus, its Affiliates and all sublicensees each manufacture for itself or each other and (y) [***] percent ([***]%) irrespective of the number of CMOs used in the manufacturing of
the Licensed Products following expiration of the Manufacturing Exclusivity Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Biologic CMC
Services</U>. Subject to the terms of the Biologics Master Services Agreement by and between Arcus Biosciences, Inc. and WuXi Biologics (Hong Kong) Limited effective January&nbsp;24, 2017, as it may be amended from time to time (the
&#147;<B><I>Biologics MSA</I></B>&#148;), WuXi shall be Arcus&#146; exclusive provider of CMC services for biologic development candidates, including but not limited to cell line development, process development, analytical development,
manufacturing of toxicology materials, GMP manufacturing, QC testing and stability services for the period running three (3)&nbsp;years from the Effective Date, all to be carried out under such Biologics MSA. The Parties shall negotiate any
additional terms in good faith and acting reasonably, taking into account terms previously agreed upon by the Parties for such services for other projects. WuXi shall commit to annual pricing increase of no more than [***] percent ([***]%) in any
one calendar year prior to First Commercial Sale and [***] percent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
([***]%) in any one calendar year beginning upon First Commercial Sale for all services rendered under this Section&nbsp;3.3. Promptly after the Effective Date, the Parties shall negotiate in
good faith the terms of, and shall seek to enter into, an amendment to the Biologics MSA, which amendment shall provide for (i)&nbsp;WuXi&#146;s exclusive provision of CMC services as contemplated in this Section&nbsp;3.3 and (ii)&nbsp;Arcus&#146;
obligations to use WuXi as its exclusive provider of CMC services for biologic development candidates to cease upon any termination of the Biologics MSA due to a material breach thereof and/or upon Arcus&#146; termination of this Agreement pursuant
to Sections 10.2.2(a) or 10.2.3 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Assistance</U><U>; Technology and Material Transfer</U>. WuXi shall
use Commercially Reasonable Efforts to confidentially disclose the Licensed Technology to Arcus within a period of [***] ([***]) days from the Effective Date. In addition, WuXi shall deliver to Arcus or its designee [***] of GMP Licensed Product
that meets the specifications attached hereto as Exhibit 3 (&#147;<B><I>Dose Escalation Batch</I></B>&#148;) for the first Dose Escalation Study for a Licensed Product within thirty (30)&nbsp;days after Arcus&#146; written request for delivery (and
WuXi shall store, handle, and ship such Dose Escalation Batch in accordance with WuXi&#146;s standard operating procedures and all applicable and reasonable storage, handling and shipping instructions provided by Arcus prior to such delivery, with
all risk and title passing to Arcus when delivering such Dose Escalation Batch to a shipper in accordance with Arcus&#146; instructions). Furthermore, if reasonably requested by Arcus, WuXi shall provide to Arcus promptly any additional information
requested by Arcus that is under WuXi&#146;s Control, not otherwise already required to be provided by WuXi hereunder, and reasonably necessary for Arcus to Commercialize, manufacture and/or Develop Licensed Products in the Field in the Territory
and will issue an invoice with an appropriate fee based on the work requested and WuXi&#146;s then-current, customary labor rates for similar services. If requested by Arcus, WuXi shall use commercially reasonable efforts to introduce Arcus to one
or more of WuXi&#146;s other licensees of Licensed IP for the sole purpose of sharing clinical data and safety information regarding the Licensed Products in the Field in the Excluded Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3.5&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Competition</FONT> Related to Licensed IP</U>. As partial consideration for
the rights granted to it under Section&nbsp;2.1, Arcus hereby covenants, and will require each of its Affiliates and sublicensees to covenant, that, during the Term of this Agreement (or with respect to any Arcus sublicensees, during the term of the
respective sublicenses granted by Arcus to such sublicensees), each will not commercialize, in the Territory (or, with respect to Arcus&#146; sublicensees, the applicable countries of the Territory for which Arcus has granted them a sublicense under
the Licensed IP), any product for application in the Field, except a Licensed Product, if such product includes any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody that was licensed in or obtained
by Arcus, its Affiliates or the respective sublicensee (as the case may be) after being granted license rights to the Licensed IP. Notwithstanding the foregoing, in no event does the foregoing prohibit or restrict Arcus or any of its Affiliates or
sublicensees from (i)&nbsp;developing, manufacturing or commercializing any combination of a development compound of Arcus or any of its Affiliates or sublicensees with another party&#146;s <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody or (ii)&nbsp;developing, manufacturing or commercializing any product, other than Licensed Product, that includes any antibody against the target of
<FONT STYLE="white-space:nowrap">PD-1,</FONT> provided that such product is in an earlier stage of development than the first Licensed Product. In addition, notwithstanding the foregoing, the restriction in the first sentence
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of this Section shall not apply to any Third Party permitted assignee of this Agreement or any of such Third Party&#146;s affiliates. WuXi materially relies on this Section&nbsp;3.5 in the
formation of this Agreement, and would not have entered this Agreement but for the rights provided to WuXi by this Section&nbsp;3.5. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;REGULATORY MATTERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. Arcus shall be solely responsible for, and shall use Commercially Reasonable Efforts in connection
with seeking Regulatory Approval for Licensed Products in the Territory. Summaries of any substantive (but not merely procedural) communications or interactions with a Regulatory Authority in the United States, European Union and Japan, to the
extent material to Arcus&#146; performance of its obligations under this Agreement, will be included in the Development reports referred to in Section&nbsp;3.1. WuXi shall provide Arcus with all information, data and materials reasonably requested
by Arcus in support of its regulatory filings for Licensed Products, including (a)&nbsp;the Product/Manufacturing Information or Chemistry, Manufacturing and Controls section of an IND or NDA/BLA and any foreign equivalents thereof and (b)&nbsp;the
drug master file and/or letter of authorization permitting incorporation of such information in an IND or NDA/BLA and any foreign equivalents thereof.<B><I></I></B><B><I>&nbsp;</I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">4.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Recalls or Corrective Action</U>. As between the parties, Arcus shall have sole responsibility for and shall
make all decisions with respect to any recall, market withdrawal or other corrective action related to the Licensed Products in the Territory. Arcus shall use Commercially Reasonable Efforts to consult with WuXi before making any such recall, market
withdrawal, or taking other corrective action that relates to services performed by WuXi for Arcus, and shall in any event notify WuXi within [***] hours after initiating any recall or market withdrawal of the Licensed Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>FINANCIAL PROVISIONS/ROYALTIES</B>. In consideration of the rights granted by WuXi to Arcus hereunder, and
of the performance of technology transfer-related services under this Agreement, Arcus agrees to make the following payments: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution Payment</U>. Arcus shall pay to WuXi an upfront <FONT STYLE="white-space:nowrap">non-refundable</FONT>
fee of [***] in immediately available funds within [***] days of the Effective Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery of Dose
Escalation Batch</U>. Within [***] days after the later of (i)&nbsp;receipt of a written invoice for the Dose Escalation Batch or (ii)&nbsp;delivery to Arcus of the Dose Escalation Batch by WuXi, together with all batch records and a certificate of
compliance, and acceptance of the Dose Escalation Batch by Arcus, which shall not be unreasonably withheld by Arcus, Arcus shall pay to WuXi a <FONT STYLE="white-space:nowrap">non-refundable</FONT> amount of [***]. Arcus shall have [***] days from
the date of delivery to accept or reject the Dose Escalation Batch, and must state in writing the reasons each portion of the Dose Escalation Batch is rejected, if applicable. Upon expiration of the [***] day period, if Arcus has not rejected the
Dose Escalation Batch, in whole or in part, then Arcus is deemed to have accepted the Dose Escalation Batch, and payment shall be due in accordance with this paragraph. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Milestone Payments</U>. In the event Arcus (on its own or
through an Affiliate or their sublicensees) achieves a milestone specified below during the Term, Arcus shall promptly, but in no event more than [***] days after the achievement of each such milestone, notify WuXi in writing of the achievement of
such milestone and pay to WuXi the milestone payments as specified below. Each commercialization milestone payment shall be payable only once per Licensed Product, except as expressly noted below. All milestone payments are <FONT
STYLE="white-space:nowrap">non-refundable.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:83.20pt; font-size:8pt; font-family:Times New Roman"><B>Development Milestones</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>First&nbsp;Licensed&nbsp;Product<BR>to Achieve
Milestone</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Each&nbsp;Subsequent<BR>Licensed&nbsp;Product&nbsp;to<BR>Achieve Milestone</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:103.55pt; font-size:8pt; font-family:Times New Roman"><B>Commercialization Milestones</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When Licensed Products are sold for monies other than United States dollars, the Net Sales referenced in the table above and
elsewhere will first be determined in the foreign currency of the country in which such Licensed Products were sold and then converted into equivalent United States funds. The exchange rate will be the rate published by the <I>Wall Street
Journal</I> for purchase of United States dollars on the last business day of the applicable calendar quarter in which such Net Sales were made. For purposes of clarity, &#147;worldwide Net Sales&#148; means the sum total of all Net Sales of each
jurisdiction within the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Royalties</U>. On a Licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis, Arcus shall pay <FONT STYLE="white-space:nowrap">non-refundable</FONT> royalties to WuXi on Net Sales of Licensed Products in the Territory by Arcus, its Affiliates, and
sublicensees on an quarterly basis at the applicable rate(s) set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:108.05pt; font-size:8pt; font-family:Times New Roman"><B>Quarterly Net Sales Increments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty<BR>Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, if quarterly Net Sales of a Licensed Product
in the Territory is US$ 3,800,000,000, then the royalty payable by Arcus to WuXi would be calculated as [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalties under this Section&nbsp;5.4
shall be payable during the period of time commencing on the First Commercial Sale of a Licensed Product in a country and ending upon the later of: (i)&nbsp;[***] years from the date of First Commercial Sale of such Licensed Product in such country
[***]; and (ii)&nbsp;expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Licensed Patent which has at least one Valid Claim Covering a Licensed Product in such country (the &#147;Royalty
Term&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Royalty Adjustments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.5.1&nbsp;&nbsp;&nbsp;&nbsp; <U>Biosimilar Products</U>. If one or more Biosimilar Products with respect to a Licensed Product is sold
commercially by one Biosimilar (or Interchangeable) Applicant in a particular country in the Territory during a particular calendar quarter (&#147;<B><I>Biosimilar</I></B><B><I> Product Presence</I></B>&#148;), and during such calendar quarter the
Net Sales of such Licensed Product has decreased by [***] percent ([***]%) or more when compared to peak Net Sales of such Licensed Product in such country in [***], and such decrease is attributable to such Biosimilar Product Presence, then the
royalty rate (used with Net Sales to determine royalty payments) for such Licensed Product in such country during such calendar quarter and for the remainder of the Royalty Term will be reduced by [***] percent ([***]%) for purposes of determining
Arcus&#146;s obligation to make royalty payments under this Agreement. Notwithstanding any other provision of this Agreement, Arcus will at all times pay a minimum royalty of [***] percent ([***]%) of Net Sales under Section&nbsp;5.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.5.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Royalty Reduction for Payment</U><U> to Third Party Intellectual Property</U>. If, following the Effective
Date, it is necessary for Arcus (or its sublicensee) to obtain from one or more Third Parties&#146; rights to intellectual property in order to Develop, manufacture or Commercialize any Licensed Product in the Field in the Territory, Arcus will have
the sole right to negotiate and obtain a license under such intellectual property (each such Third Party license is referred to herein as a &#147;<B><I>Third Party License</I></B>&#148;). Intellectual property from a Third Party will be deemed
&#147;necessary&#148; under this Section if Arcus reasonably determines that such rights are necessary for avoiding or preventing one or more claims of infringement or misappropriation by a Third Party in connection with, or otherwise necessary for,
the Development, manufacture or Commercialization of the applicable Licensed Product using the rights licensed by WuXi hereunder in such country(ies). Except as set forth in this Section or to the extent of any Third Party claim for which WuXi
provides indemnification under Section&nbsp;8.1, or as the Parties may otherwise agree in writing, Arcus shall bear any payments associated with any payments owed to any Third Party for such a Third Party License (collectively, the &#147;<B><I>Third
Party</I></B> <B><I>Royalties</I></B>&#148;). Arcus may credit up to [***] of the amount of any Third Party Royalties paid by Arcus under a Third Party License pursuant to this Section against the running royalty amounts payable to WuXi at any time
under Section&nbsp;5.4. In no event shall the application of any credit reduce an amount owed under Section&nbsp;5.4 by more than [***]. If a credit may not be fully offset as a result of the foregoing limitation, then it may be carried forward and
offset against future amounts owed under Section&nbsp;5.4. Notwithstanding any other provision of this Agreement, Arcus will at all times pay a minimum royalty of [***] percent ([***]%) of Net Sales under Section&nbsp;5.4 even if it owes more to a
Third Party. For the purpose of clarity, any increase in royalty due to a Transfer Election in connection with manufacturing rights under Section&nbsp;3.2 [***]. Thus, in the event of a Transfer Election, the minimum royalty due to WuXi will be
either [***] percent ([***]%) or [***] percent ([***]%) depending on whether a Third Party, or Arcus or its Affiliate or sublicensee, respectively, will be manufacturing Licensed Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.5.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Royalty Reporting</U>. Royalties shall be calculated and reported for each calendar quarter within [***] days
after the end of each calendar quarter. With delivery of such report, Arcus shall also pay the corresponding amount of the royalty due to WuXi, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Each report of royalties shall include Net Sales by Arcus and its Affiliates in the Territory on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis for each Licensed Product during the applicable calendar quarter, which report shall include the gross amounts invoiced and Net Sales, the
royalties payable, how such royalties payable amounts were calculated (including an accounting of any reductions in applicable royalty rates and/or deductions in determining Net Sales), and the exchange rates used, in each case presented on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis for each Licensed Product, and only for the applicable calendar quarter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Sublicensing Income</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.6.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Sublicense Income Payments</U>. Arcus shall pay WuXi a percentage of option exercise fees, annual license
fees, license maintenance fees, technology access fees, and clinical, development or regulatory milestone payments, in each case, that it receives from its sublicensees in direct connection with the sublicensees&#146; grant of rights to the Licensed
IP, which payments, if applicable, may be prorated by Arcus, acting in good faith, to determine the proportion of such payments reasonably attributed to the Licensed IP (all such payments, collectively, &#147;<B><I>Sublicense
Income</I></B>&#148;).<B><I> </I></B>Notwithstanding the preceding sentence,<B> </B>Sublicense<B> </B>Income<B> </B>shall exclude (a)&nbsp;any payments received by Arcus from any sublicensee&#146;s Commercialization of Licensed Products, including
royalty payments and sales milestones and (b)&nbsp;any reimbursements, refunds or amounts paid to support Arcus and/or its Affiliates&#146; research, development and commercialization activities. The percentage of Sublicense Income owed by Arcus to
WuXi is determined by the date on which Arcus enters into the applicable sublicense agreement with the applicable sublicensee: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.6.2&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.6.3&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.6.4&nbsp;&nbsp;&nbsp;&nbsp;[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.6.5&nbsp;&nbsp;&nbsp;&nbsp;[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All
payments under Section&nbsp;5.6 shall be made within [***] days after the end of the calendar quarter in which Arcus received the corresponding Sublicense Income. When Sublicense Income is received in the form of monies other than United States
dollars, the exchange rate that will be used to convert such amounts to U.S. dollars for Sublicense Income payments will be the rate published by the <I>Wall Street Journal</I> for purchase of United States dollars on the last business day of the
applicable calendar quarter in which such Sublicense Income was received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment Terms</U>. All sums due
under this Agreement shall be payable in United States dollars by bank wire transfer in immediately available funds to such bank account(s) as the applicable payee shall designate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>. If Applicable Law requires Arcus to withhold any taxes from payments made to WuXi under this
Agreement, then such taxes shall be deducted by Arcus as required by and shall be paid by Arcus to the proper tax authorities. All official receipts or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
evidence of payment, as applicable, of any withholding tax shall be promptly sent to WuXi as evidence of such payment. Arcus will reasonably assist WuXi in obtaining any necessary documentation
to demonstrate such withholding upon reasonable request. Except for the foregoing provisions and as provided in the Net Sales definition, all payments by Arcus shall be made free and clear of, and without reduction for, any and all taxes owed by
Arcus or any of its Affiliates or sublicensees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">5.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial Audits</U>. Arcus shall use commercially
reasonable efforts to keep accurate and complete records of all financial information needed to calculate Net Sales and/or any other information necessary to determine whether other payments are due to WuXi under this Article 5. Arcus shall retain
such records relating to Net Sales and/or any payments made to it in connection with this Agreement during the [***] preceding calendar years. At WuXi&#146;s written request, such records shall be made available for inspection, review and audit,
during normal business hours, without undue business interruption and with reasonable advance notice to Arcus, by an independent certified public accountant appointed by WuXi and reasonably acceptable to Arcus for the sole purpose of verifying that
Arcus has complied with its payment obligations under this Article 5. In no event may WuXi conduct such audit more than once per calendar year, and prior to the start of any such audit, Arcus may require that such accountant enter into a reasonable
confidentiality agreement with it. A copy of any report provided to WuXi by the accountant shall be given concurrently to Arcus. WuXi shall be responsible for all costs and expenses incurred in performing any such audit unless the audit discloses,
and Arcus does not reasonably dispute such result, at least a [***] percent ([***]%)<B><I> </I></B>shortfall, in which case Arcus shall bear the reasonable cost of the entire audit. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONFIDENTIAL INFORMATION AND PROPRIETARY RIGHTS</B>.<B> </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Definition</U>. &#147;<B><I>Confidential Information</I></B>&#148; means confidential or proprietary information,
data or <FONT STYLE="white-space:nowrap">know-how,</FONT> whether provided in written, oral, visual or other form, provided by one Party (the &#147;<B><I>Disclosing Party</I></B>&#148;) to the other Party (the &#147;<B><I>Receiving
Party</I></B>&#148;) in connection with this Agreement, including, but not limited to, the terms of this Agreement and information relating to the Disclosing Party&#146;s existing or proposed research, development efforts, patent applications,
business or products, including without limitation pricing information, vendor and customer information, plans, proprietary technical information, processes, formulae, data, inventions, methods, knowledge, discoveries,
<FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, and the like. Confidential Information shall not include any such information that: (i)&nbsp;is already known to the Receiving Party or its Affiliates (other than under an obligation
of confidentiality) at the time of disclosure (as evidenced by written records of the Receiving Party); (ii) is or becomes generally available to the public other than through any act or omission of the Receiving Party or its Affiliates;
(iii)&nbsp;is disclosed to the Receiving Party or its Affiliates by a Third Party who had no separate nondisclosure obligation in respect of such information; or (iv)&nbsp;is independently discovered or developed by or on behalf of the Receiving
Party or its Affiliates without the use of the Confidential Information of the Disclosing Party (as evidenced by written records of the Receiving Party). The terms of this Agreement shall be deemed Confidential Information of each Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Confidentiality</U>. The Receiving Party shall keep in
confidence all Confidential Information of the Disclosing Party with the same degree of care it employs to maintain the confidentiality of its own Confidential Information, but no less than a reasonable degree of care. The Receiving Party shall not
use such Confidential Information for any purpose other than in performance of this Agreement, or in the case of Arcus as the Receiving Party, in accordance with the rights granted to Arcus under this Agreement, or disclose the same to any other
Person other than to such of its Affiliates, its own and its Affiliates&#146; employees, agents, sublicensees and subcontractors (&#147;<B><I>Permitted Representatives</I></B>&#148;) who have a need to know such Confidential Information to implement
the terms of this Agreement. A Receiving Party shall advise any Permitted Representative who receives Confidential Information of such obligations. The Receiving Party will be liable for breach of this Article 6 by any of its Permitted
Representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Permitted Disclosure and Use</U>. The Receiving Party shall have the right to disclose
Confidential Information if, (i)&nbsp;in the reasonable opinion of the Receiving Party&#146;s legal counsel, such disclosure is required by any Applicable Laws, provided that the Receiving Party gives adequate prior notice of such disclosure to the
Disclosing Party and the Receiving Party uses commercially reasonable efforts to seek confidential treatment of such Confidential Information and to limit the required disclosure to only that which is required; or (ii)&nbsp;a court, tribunal,
administrative agency or other Governmental Authority orders such disclosure, provided that the Receiving Party gives adequate prior notice of such disclosure to the Disclosing Party to permit the Disclosing Party to intervene and to request
protective orders or other confidential treatment and to limit the scope of any potential disclosure. The Receiving Party will cooperate reasonably with any such efforts by the Disclosing Party. Furthermore, notwithstanding any other provision of
this Agreement, each Party may disclose Confidential Information (a)&nbsp;as necessary in connection with any financing, merger, sublicensing or similar transaction, subject to confidentiality substantially similar to that required in this Article
6, or as necessary to obtain legal or financial advice from its attorneys, and financial advisors who have an obligation of confidentiality to the Party; and (b)&nbsp;in connection with prosecuting or defending litigation, Regulatory Approvals,
Pricing Approvals and other regulatory filings and communications, and filing, prosecuting and enforcing the Licensed Patents in connection with the Party&#146;s rights and obligations pursuant to this Agreement, where each Party will use reasonable
efforts to seek protective orders or other applicable confidentiality, and seek to limit the scope of disclosure, as to any such uses. The Parties shall also be permitted to make disclosures consistent with, and pursuant to, Sections 11.1 and 11.2.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, notwithstanding the foregoing, to the extent that either Party&#146;s legal counsel reasonably determines that it is
required to make a filing or any other public disclosure with respect to this Agreement or the terms or existence hereof to comply with the requirements, rules, laws or regulations of any applicable stock exchange, Nasdaq or any governmental or
regulatory authority or body, including without limitation the U.S. Securities and Exchange Commission (the &#147;<B><I>SEC</I></B>&#148;) (collectively, the &#147;<B><I>Disclosure Obligations</I></B>&#148;), such Party shall promptly inform the
other Party thereof and shall use reasonable efforts to (i)&nbsp;maintain the confidentiality of the other Party&#146;s confidential information in any such filing or disclosure and (ii)&nbsp;limit the scope of such required disclosure. To the
extent that either Party reasonably determines that it is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required to file a copy of this Agreement to comply with the Disclosure Obligations, such Party shall promptly inform the other Party thereof. Prior to making any such filing of a copy of this
Agreement, the Parties shall mutually agree on the provisions of this Agreement for which the Parties shall seek confidential treatment, it being understood that if one Party determines to seek confidential treatment for a provision for which the
other Party does not, then the Parties will use reasonable efforts in connection with such filing to seek the confidential treatment of any such provision. The Parties shall cooperate, each at its own expense, in such filing, including without
limitation such confidential treatment request, and shall execute all documents reasonably required in connection therewith. The Parties will reasonably cooperate in responding promptly to any comments received from the SEC with respect to such
filing in an effort to achieve confidential treatment of such redacted form; provided, however, that a Party shall be relieved of such obligation to seek confidential treatment for a provision requested by the other Party if such treatment is not
achieved after the first round of responses to comments from the SEC. Notwithstanding anything to the contrary in this Agreement, either Party may make reference to the existence of this Agreement and describe the relationship between the Parties in
connection with any required securities filings or other required public disclosure without seeking the other Party&#146;s prior consent. This paragraph shall apply with respect to the filing of a copy of this Agreement or any public disclosure
relating to this Agreement to comply with the Disclosure Obligations, notwithstanding the provisions of this Article 6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>. Money damages will not be an adequate remedy if this Article 6 is breached and, therefore, either
Party may, in addition to any other legal or equitable remedies, seek an injunction or other equitable relief against such breach or threatened breach in relation to Confidential Information that it disclosed to the other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Attorney-Client Privilege</U>. Neither Party is waiving, nor will be deemed to have waived or diminished, any of
its attorney work product protections, attorney-client privileges or similar protections and privileges recognized under Applicable Law of any jurisdiction as a result of disclosing information pursuant to this Agreement, or any of its Confidential
Information (including Confidential Information related to pending or threatened litigation) to the Receiving Party, regardless of whether the Disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections. The
Parties may become joint defendants in proceedings to which the information covered by such protections and privileges relates and may determine that they share a common legal interest in disclosure between them that is subject to such privileges
and protections, and in such event, may enter into a joint defense or other common interest agreement setting forth, among other things, the foregoing principles, but are not obligated to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">6.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. This Article 6 shall survive the expiration or termination of this Agreement for a period of [***]
years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;REPRESENTATIONS AND WARRANTIES</B>.<B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Mutual Representations and Warranties</U>. Arcus and WuXi each represents and warrants to the other as of the
Effective Date: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1.1&nbsp;&nbsp;&nbsp;&nbsp;Such Party (i)&nbsp;is a company duly organized, validly existing and in good standing
under the Applicable Laws of the jurisdiction of its organization; and (ii)&nbsp;has the requisite corporate power and authority and the legal right to enter into this Agreement and to carry out the provisions of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1.2&nbsp;&nbsp;&nbsp;&nbsp;The execution, delivery and performance of this Agreement by such Party, including, without limitation, in the
case of WuXi, the license grant under Section&nbsp;2.1 and the delivery by WuXi of any Licensed Technology to Arcus for use as contemplated under this Agreement, (i)&nbsp;do not conflict with any provision of the organizational documents of such
Party; (ii)&nbsp;will not, to such Party&#146;s knowledge, violate any Applicable Laws including any order or decree of any court or Governmental Authority; and (iii)&nbsp;will not violate or conflict with any terms of any indenture, mortgage, deed
of trust, lease, agreement or other instrument to which such Party is a party, or by which such Party is bound or becomes bound during the Term; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1.3&nbsp;&nbsp;&nbsp;&nbsp;This Agreement has been duly executed and delivered by such Party and constitutes a legal, valid and binding
obligation of such Party, enforceable against such Party in accordance with its terms. The execution, delivery and performance of this Agreement by it does not materially conflict with any agreement, instrument or understanding, oral or written, to
which it is a party or by which it is bound, nor violate any Applicable Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.1.4&nbsp;&nbsp;&nbsp;&nbsp;It has not granted, and shall
not grant during the Term, any right to any Third Party which would materially conflict with the rights granted to the other Party hereunder. It has, and covenants that it shall, maintain and keep in full force and effect all agreements necessary to
perform its obligations hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Party further covenants that it will at all times comply with all Applicable Laws relating to the import and
export of Licensed Products, or any materials or components related thereto, during the Term of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.2&nbsp;&nbsp;&nbsp;&nbsp;<U>WuXi</U><U> Representations and Warranties</U>. Except as set forth in a document separately submitted by WuXi
to Arcus on or before the Effective Date setting forth exceptions to the following representations and warranties: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2.1&nbsp;&nbsp;&nbsp;&nbsp;WuXi (i)&nbsp;represents and warrants to Arcus as of the Effective Date that it has the sole and exclusive right
to grant the licenses hereunder and (b)&nbsp;neither it nor any of its Affiliates has previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in the Licensed Patents, or any component of the Licensed <FONT
STYLE="white-space:nowrap">Know-How</FONT> (other than the transfer of such Licensed Patents and/or Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> to WuXi from its Affiliates), (ii) covenants that, with respect to any agreements or other
instruments pursuant to which WuXi acquires its rights to the Licensed Patents and Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> it will maintain in full force and effect and commit no act or omission that would give rise to any Third
Party or Affiliate right to terminate such licenses or other instruments that could materially impair Arcus&#146; ability to exercise its rights under this Agreement during the Term, and (iii)&nbsp;represents and warrants as of the Effective Date
that there are no Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> owned or controlled by WuXi or any of its Affiliates in the Territory, other than the Licensed Patents and Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> that
would prevent Arcus, its Affiliates or its or their sublicensees </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from Developing, manufacturing and/or Commercializing Licensed Products as set forth herein, and from exploiting the rights granted under Section&nbsp;2.1. WuXi represents and warrants to Arcus
as of the Effective Date that WuXi has provided Arcus with a true and complete (other than redacted financial terms) copy of the Third Party agreement(s) and any agreements with WuXi&#146;s Affiliates that are referenced in (ii)&nbsp;directly above,
including, without limitation, any and all amendments and side letters and other material documentation related thereto, and WuXi covenants that during the Term it shall not amend, waive any rights under, or allow to terminate or expire any such
agreements, amendments and/or side letters in any manner that would impair Arcus&#146; ability to exercise its rights under this Agreement, nor shall it permit its Affiliates to do any of the foregoing; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2.2&nbsp;&nbsp;&nbsp;&nbsp;WuXi represents and warrants to Arcus as of the Effective Date that there are no claims, judgments or
settlements against or pending with respect to any Licensed IP, and to WuXi&#146;s knowledge as of the Effective Date, no such claims, judgments or settlements are threatened. To the knowledge of WuXi as of the Effective Date, the proposed Licensed
Products covered by the Licensed IP will not violate, infringe, misappropriate or unlawfully use any intellectual property of any Person. WuXi represents and warrants to Arcus as of the Effective Date that, to the knowledge of WuXi, no Person has
violated, infringed, misappropriated or unlawfully used any of the Licensed IP. WuXi represents and warrants to Arcus as of the Effective Date that WuXi has not commenced or threatened any proceeding, or asserted any allegation or claim, against any
Person for infringement or misappropriation of any Licensed IP; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2.3&nbsp;&nbsp;&nbsp;&nbsp;WuXi represents and warrants as of the
Effective Date that it is not a party to any agreement, and covenants that during the Term it shall not be a party to any agreement, that prohibits or restricts the full exploitation of any Licensed IP as contemplated under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2.4&nbsp;&nbsp;&nbsp;&nbsp;WuXi represents and warrants that it has disclosed to Arcus on or prior to the Effective Date all material
agreements (other than redacted financial terms) and information relating to the Development of the Licensed Products that are in WuXi and its Affiliates&#146; possession as of the Effective Date, and WuXi covenants to provide to Arcus promptly all
material information, as requested by Arcus from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> during the Term, relating to the Development and/or manufacturing of the Licensed Products that are in the
possession of WuXi or its Affiliates to the extent such material information has not already been provided to Arcus, subject to Sections 2.5, 3.2, 3.4 and 4.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2.5&nbsp;&nbsp;&nbsp;&nbsp;WuXi represents and warrants as of the Effective Date that, to the best of its knowledge, each of the excluded
entities from the Affiliates does not Control any of the Licensed IP necessary to carry out this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.2.6&nbsp;&nbsp;&nbsp;&nbsp;WuXi represents and warrants that, as of the Effective Date and during the Term of this Agreement, neither
(i)&nbsp;WuXi, nor any of its Affiliates&#146; employees, officers, subcontractors, or consultants who developed the Antibody and/or the Licensed IP and who have rendered services relating to the Licensed Products under this Agreement, has ever been
debarred nor is subject to debarment or convicted of a crime for which an entity or person could be debarred (including by the FDA under 21 U.S.C. &#167; 335a (or subject to a similar sanction of any other Governmental Authority)). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Arcus Representations and Warranties</U>. Except as set forth
in a document separately submitted by Arcus to WuXi in writing on or before the Effective Date setting forth exceptions to the following representations and warranties: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.3.1&nbsp;&nbsp;&nbsp;&nbsp;Arcus covenants that it will not, and will not authorize any Affiliate, subcontractor, or sublicensee (or their
further sublicensee or subcontractor) to, assign, transfer, convey or otherwise encumber its right, title and interest in the Licensed Patents, or any component of the Licensed <FONT STYLE="white-space:nowrap">Know-How,</FONT> in the Territory
except as permitted under this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.3.2&nbsp;&nbsp;&nbsp;&nbsp;Arcus represents and warrants to WuXi, as of the Effective Date,
that there are no claims, judgments or settlements against or pending with respect to Arcus or its commercial activities in the Territory, and to Arcus&#146;s knowledge as of the Effective Date, no such claims, judgments or settlements are
threatened. Arcus represents and warrants to WuXi that to the knowledge of Arcus as of the Effective Date, Arcus&#146;s contemplated use or actual use of the Licensed IP in the Territory will not violate, infringe, misappropriate or unlawfully use
any intellectual property of any Person. Arcus represents and warrants to WuXi, as of the Effective Date, that Arcus has not commenced or threatened any proceeding, or asserted any allegation or claim, against any Person for infringement or
misappropriation of any Licensed IP in the Territory; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.3.3&nbsp;&nbsp;&nbsp;&nbsp;Arcus is not presently and will not become, and
will not authorize any Affiliate, subcontractor, or sublicensee (or their further sublicensee or subcontractor), to become, a party to any agreement (other than a sublicense agreement or subcontract agreement that is permitted under this Agreement
and entered into by Arcus and any of its sublicensees or subcontractors, as the case may be) that materially prohibits or restricts the exploitation of any Licensed IP in the Territory as contemplated under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">7.3.4&nbsp;&nbsp;&nbsp;&nbsp;Arcus covenants that, as of the Effective Date and during the Term of this Agreement, neither (i)&nbsp;Arcus,
nor any of its or its Affiliates&#146; employees, officers, subcontractors, consultants, or sublicensees (or their further sublicensees or subcontractors), who will render services relating to the Licensed Products in performing under this
Agreement, has ever been debarred nor is subject to debarment or convicted of a crime for which an entity or person could be debarred (including by the FDA under 21 U.S.C. &#167; 335a (or subject to a similar sanction of any other Governmental
Authority)); and (ii)&nbsp;Arcus will require language materially similar to that in Section&nbsp;7.3.4(i) in every sublicense and subcontract agreement under this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">7.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclaimer of Warranty</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">Except for the express warranties set forth in this Agreement, nothing in this Agreement shall be construed as a representation or warranty by
either Party (i)&nbsp;that any Licensed Product made, used, sold or otherwise disposed of under this Agreement is or will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
free from infringement of patents, copyrights, trademarks or other intellectual property rights of any Third Party; (ii)&nbsp;regarding the effectiveness, value, safety, or <FONT
STYLE="white-space:nowrap">non-toxicity</FONT> of any technology; or (iii)&nbsp;that any Licensed Product will obtain Regulatory Approval or achieve success or achieve any milestone events specified in Section&nbsp;5.3. EXCEPT AS OTHERWISE EXPRESSLY
SET FORTH IN THIS AGREEMENT, THE LICENSED IP IS PROVIDED &#147;AS IS&#148; AND: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;NEITHER PARTY MAKES, AND EACH
PARTY EXPRESSLY DISCLAIMS, WAIVES, RELEASES AND RENOUNCES, ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THE INTELLECTUAL
PROPERTY RIGHTS OF THIRD PARTIES, AND ALL WARRANTIES ARISING FROM ANY COURSE OF DEALING OR PERFORMANCE OR USAGE OF TRADE; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;EACH PARTY EXPRESSLY DISCLAIMS AND RENOUNCES ANY REQUIREMENT TO MANUFACTURE LICENSED PRODUCT OR PROVIDE CELL LINE
SERVICES UNDER THIS AGREEMENT, EXCEPT AS PROVIDED FOR UNDER THE BIOLOGICS MSA BETWEEN THE PARTIES AND THE MANUFACTURING AGREEMENT(S) TO BE MUTUALLY AGREED UPON BETWEEN THE PARTIES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS ARTICLE 7 OR OTHERWISE, (I)&nbsp;THE ARCUS IMPROVEMENTS LICENSED TO WUXI UNDER SECTION 2.5 AND (II)&nbsp;THE
IMPROVEMENTS OF WUXI&#146;S OTHER LICENSEES AND THEIR DIRECT AND INDIRECT SUBLICENSEES LICENSED TO ARCUS UNDER SECTION 2.5 ARE PROVIDED &#147;AS IS&#148;, WITHOUT ANY WARRANTY OF ANY KIND AND TO THE MAXIMUM EXTENT PERMITTED BY LAW, NEITHER PARTY
SHALL HAVE ANY LIABILITY TO THE OTHER PARTY AS A RESULT OF THE USE OF SUCH IMPROVEMENTS BY SUCH OTHER PARTY OR ITS AFFILIATES OR SUBLICENSEES.&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>INDEMNIFICATION</B><B>; INSURANCE; LIMITATION ON LIABILITY</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification by </U><U>WuXi</U>. Subject to Section&nbsp;8.3, WuXi shall defend, indemnify and hold harmless
Arcus and its Affiliates and each of their officers, directors, employees, independent contractors, successors and assigns (collectively, &#147;<B><I>Arcus</I></B><B><I> </I></B><B><I>Indemnitees</I></B>&#148;) from and against all Third Party
Claims, and pay all associated Losses, arising out of or relating to any material breaches by WuXi of any representations, warranties, or covenants under Section&nbsp;7.1 or 7.2 of this Agreement, except in each case, to the extent any such Third
Party Claims or Losses arise out of or relate to any breaches by any Arcus Indemnitees of this Agreement, including, without limitation, any representations, warranties or covenants thereof, or any gross negligence or willful misconduct of any Arcus
Indemnitee(s). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification by </U><U>Arcus</U>. Subject to Section&nbsp;8.3, Arcus shall defend,
indemnify and hold harmless WuXi and its Affiliates and each of their officers, directors, employees, independent contractors, successors and assigns (collectively, &#147;<B><I>WuXi</I></B><B><I> </I></B><B><I>Indemnitees</I></B>&#148;) from and
against all Third Party Claims, and pay all associated Losses, arising out of or relating to (i)&nbsp;any material breaches by Arcus or its Affiliates of any representations, warranties, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
covenants under Section&nbsp;7.1 or 7.3 of this Agreement; and (ii)&nbsp;the Development, manufacture, transfer, use, handling, storage, sale or other disposition of Licensed Products by or on
behalf of Arcus or any of its Affiliates, sublicensees, agents and contractors, including claims and threatened claims based on product liability, bodily injury, risk of bodily injury, death or property damage or the failure to comply with any
Applicable Law, except in each case, to the extent any such Third Party Claims or Losses arise out of or relate to any breaches by any WuXi Indemnitees of this Agreement, including, without limitation, any representations, warranties or covenants
thereof, or any gross negligence or willful misconduct of any WuXi Indemnitees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure for
Indemnification</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">8.3.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice</U>. The indemnified party will notify promptly the indemnifying Party in
writing if it becomes aware of a Claim (actual or potential) by any Third Party or any proceeding (including any investigation by a Governmental Authority) (&#147;<B><I>Third Party Claim</I></B>&#148;) for which indemnification may be sought, and
will give such related information as is necessary to defend or as the indemnifying Party shall reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">8.3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Defense of Claim</U>. The indemnifying Party shall defend or control the defense of Third Party Claims. The
indemnifying Party shall be responsible for satisfying and discharging any award made to or settlement reached with the Third Party pursuant to the terms of this Agreement. The indemnifying Party shall retain counsel to represent the indemnified
party and shall pay the reasonable fees and expenses of such counsel related to such proceeding. In any such proceeding, but without limiting the foregoing, the indemnified Party, at its sole expense, shall have the right to retain its own counsel.
The indemnified Party shall cooperate in all reasonable respects in the defense of such Third Party Claim, as requested by, and at the reasonable expense of, the indemnifying Party. The indemnifying Party shall not, without the written consent of
the indemnified Party (which consent shall not be unreasonably withheld, refused, conditioned or delayed), effect any settlement of any such Third Party Claim, unless such settlement includes a full and unconditional release of the indemnified Party
from all liability on such Claims. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation of Liability</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">8.4.1&nbsp;&nbsp;&nbsp;&nbsp;IN NO EVENT SHALL EITHER PARTY BE LIABLE HEREUNDER TO THE OTHER PARTY FOR ANY PUNITIVE, INDIRECT, SPECIAL,
INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING LOST REVENUE, LOST PROFITS, OR LOST SAVINGS) HOWEVER CAUSED AND UNDER ANY THEORY, EVEN IF IT HAS NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">8.4.2&nbsp;&nbsp;&nbsp;&nbsp;BEFORE THE FIRST COMMERCIAL SALE, WUXI&#146;S MAXIMUM LIABILITY IN RESPECT OF ANY AND ALL CLAIMS ARISING OUT OF
OR IN CONNECTION WITH THIS AGREEMENT, IN THE AGGREGATE, SHALL NOT EXCEED [***]. AFTER THE FIRST COMMERCIAL SALE, WUXI&#146;S MAXIMUM LIABILITY IN RESPECT OF ANY AND ALL CLAIMS ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, IN THE AGGREGATE,
SHALL NOT EXCEED [***].<B><I> </I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">8.4.3&nbsp;&nbsp;&nbsp;&nbsp;THE LIMITATIONS SET FORTH IN THIS SECTION 8.4 SHALL NOT APPLY
WITH RESPECT TO (A)&nbsp;ANY BREACH OF ARTICLE 6 (CONFIDENTIAL INFORMATION AND PROPRIETARY RIGHTS) OR (B)&nbsp;THE WILLFUL MISCONDUCT OR GROSS NEGLIGENCE OF A PARTY. NOTHING IN THIS SECTION 8.4 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION
RIGHTS OR OBLIGATIONS OF A PARTY UNDER SECTION 8.1 OR SECTION 8.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">8.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>. Arcus shall procure and
maintain insurance or self-insurance, including product liability insurance, adequate to enable it to cover its obligations hereunder and which are consistent with normal business practices of prudent companies similarly situated, at all times
during which any Licensed Product is being clinically tested in human subjects or commercially distributed or sold by or on its behalf (including by an Affiliate or sublicensee). At a minimum, beginning from Initiation of its first Clinical Trial
for a Licensed Product until the first Regulatory Approval in the Territory, Arcus shall obtain umbrella and/or general liability insurance with minimum amounts of [***] U.S. dollars (US$[***]) and product liability insurance with minimum amounts of
[***] U.S. dollars to enable Arcus to cover its obligations under this Agreement. After Regulatory Approval in a jurisdiction in the Territory and before (and after) the First Commercial Sale, Arcus shall obtain umbrella and/or general liability
insurance with minimum amounts of [***] U.S. dollars (US$[***]) and product liability insurance with minimum amounts of [***] U.S. dollars (US$[***]) to enable Arcus to cover its obligations under this Agreement, or if Arcus is not then insured,
Arcus shall require that its Affiliate, Sublicensee, or Third Party manufacturing on its behalf, carry such insurance. It is understood that such insurance or self-insurance shall not be construed to create a limit of Arcus&#146; liability with
respect to its indemnification obligations under this Article 8. Arcus shall provide WuXi with written evidence of such insurance or self-insurance, and any revised insurance policy, within [***] days of it being obtained or revised. Arcus shall
provide WuXi with written notice at least [***] days prior to the cancellation, <FONT STYLE="white-space:nowrap">non-renewal</FONT> or material change in such insurance or self-insurance which materially adversely affects the rights of the other
Party hereunder. [***]. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>PATENT</B><B>S</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Prosecution and Maintenance</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.1.1&nbsp;&nbsp;&nbsp;&nbsp;Arcus shall have the first right to file, prosecute and maintain all Licensed Patents in the Territory using its
own outside counsel reasonably acceptable to WuXi. All such prosecution and maintenance in the Territory will be at Arcus&#146; sole expense. Arcus shall keep WuXi reasonably informed of all decisions or actions concerning the prosecution and
maintenance of such Licensed Patents in the Territory, including, without limitation, by providing copies of office actions and other communications with patent offices, and providing a reasonable opportunity for WuXi to deliver comments to Arcus or
its selected counsel regarding such prosecution materials, such comments to be considered by Arcus in good faith and acting reasonably. WuXi shall reasonably cooperate with Arcus in its efforts to prepare, file, prosecute and maintain Licensed
Patents, including, without limitation, in disclosing new Improvements to Arcus within thirty (30)&nbsp;days, and in responding promptly to Arcus&#146; requests for data, affidavits, and other information and assistance to support filing,
prosecution and maintenance of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Licensed Patents in a timely manner. Arcus shall not take any action during prosecution and maintenance of the Licensed Patents that would materially adversely affect any Patent or Licensed <FONT
STYLE="white-space:nowrap">Know-How</FONT> to be covered by or within the Licensed Patents, without WuXi&#146;s prior written consent, such consent not to be unreasonably withheld or delayed, and Arcus shall file patent applications (based on
Licensed Patents) in countries in the Territory as determined by Arcus. WuXi shall have the exclusive right to file, prosecute, and maintain all Licensed Patents in the Excluded Territory, at its sole expense and in its sole discretion, jointly in
the names of WuXi and Arcus as applicable, and all other requirements of this Section&nbsp;9.1.1 shall apply <I>mutatis mutandis</I> so that WuXi may exercise its reserved rights in the Excluded Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.1.2&nbsp;&nbsp;&nbsp;&nbsp;The Parties will confer and must mutually agree before any Patent within the Licensed Patents may be abandoned,
<I>provided that </I>if this Agreement has been terminated with respect to a particular country, WuXi may act in its sole discretion regarding the prosecution, maintenance, or abandonment, regarding any such Patents in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.1.3&nbsp;&nbsp;&nbsp;&nbsp;Subject to Section&nbsp;9.1.2, in the event that Arcus decides not to continue the prosecution or maintenance of
a Patent within the Licensed Patents in any country in the Territory still in force under this Agreement, or decides not to file a patent application based on Licensed Patents in any countries in the Territory, Arcus shall provide WuXi with express
written notice of such decision at least [***] days prior to any pending lapse or abandonment thereof, or if a decision not to continue prosecution or maintenance is responsive to an official communication from governmental agency that is received
by Arcus less than [***] days prior to a deadline for taking action in response to such communication, then the deadline for giving such notice to WuXi shall be [***]% of the time remaining for response after such communication is received by Arcus.
In such event, provided that the Parties have not expressly agreed to abandon a Patent within the Licensed Patents under Section&nbsp;9.1.2, then Arcus shall provide WuXi with an opportunity to assume responsibility for prosecution and maintenance
of such Patent. In such case, WuXi shall provide Arcus timely updates of the filing, prosecution and maintenance status for each such Patent, including copies of any material official correspondence to or from patent offices, to permit Arcus to
better coordinate corresponding Patents in other countries in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.1.4&nbsp;&nbsp;&nbsp;&nbsp;Arcus shall have the first
right, but not the obligation, to prosecute and maintain Patents to Joint Improvements and to co-owned Improvements in the Territory, at its sole cost and expense; and WuXi shall have the same rights in the Excluded Territory. Each Party shall
consult with the other Party as to the prosecution and maintenance of such Patents reasonably prior to any deadline, submission to or action with any patent office, and shall furnish to the other Party copies of all relevant drafts and documents
reasonably in advance of such consultation. Each Party shall consider in good faith any reasonable comments provided by the other Party in connection with the prosecution and maintenance of such Patents, so long as such comments are provided in a
timely manner. In the event that either Party desires not to file (including any national phase filing), or desires to abandon or cease prosecution or maintenance of, any such Patent to a Joint Improvement or co-owned Improvement in any country, the
Party with the first right to control the prosecution shall provide written notice to the other Party of such intention reasonably in advance of the date any such filing is required to avoid a loss of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such rights or abandonment of such rights. In such case, at other Party&#146;s sole discretion, upon written notice to the Party having the first right of control, such other Party may elect to
continue prosecution or maintenance of any such Patent, in the name of both Arcus and WuXi, or even in the name of the other, at its sole cost and expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">9.1.5&nbsp;&nbsp;&nbsp;&nbsp;The Parties shall coordinate and discuss which of the Patents within the Licensed Patents should be selected for
term extensions, supplementary protection certificates, and equivalents thereof offering patent protection beyond the initial term with respect to any issued Patents (&#147;<B><I>Patent Term Extensions</I></B>&#148;) with respect to the Licensed
Products in the Territory. Arcus shall have the right to make the final decision regarding which Patents are selected for Patent Term Extension in the Territory, and shall have the right to seek and obtain such Patent Term Extensions with respect to
the Licensed Patents in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Infringement</U><U> of Licensed Patents</U>. Each Party will notify
the other Party, and will require its Affiliates and sublicensees to notify it, promptly in writing upon becoming aware of any alleged or threatened infringement or violation by a Third Party of any Licensed Patents or Licensed <FONT
STYLE="white-space:nowrap">Know-How.</FONT> Arcus shall have the first right to enforce any patent within the Licensed Patents or any rights in the Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> against any infringement or alleged
infringement or other violation thereof in the Territory. Arcus may, at its own expense, institute suit in the Territory against any infringer or alleged infringer (or violator) and control and defend such suit and recover any damages, awards or
settlements resulting therefrom. The amount of such damages, awards or settlements remaining after deduction of Arcus&#146;s expenses and reimbursement to WuXi for its reasonable and documented, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs may be retained by Arcus, [***]. WuXi shall reasonably cooperate in any such litigation, including, without limitation, joining any such suit in the Territory, at Arcus&#146;s request and
expense. Arcus shall not enter into any settlement of any claim described in this Section&nbsp;9.2 that would admit to the invalidity, narrowing of scope or unenforceability of the Licensed Patents, incurs any financial liability on the part of WuXi
or requires an admission of liability, wrongdoing or fault on the part of WuXi, without WuXi&#146;s prior written consent. If Arcus decides not to promptly pursue such litigation in the Territory, WuXi shall have the right in its sole discretion to
do so. In the event of enforcement by WuXi, Arcus will reasonably cooperate in any such litigation, including without limitation, joining any such suit if needed to provide standing. WuXi, after deducting its attorney&#146;s fees, costs, and any
other expenses (including reimbursement to Arcus of its reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs), will split the proceeds [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Infringement Claims by Third Parties</U>. If either (i)&nbsp;any Licensed Product Developed, made,
Commercialized or otherwise exploited by or under authority of Arcus becomes the subject of a Third Party&#146;s claim or assertion of infringement of a patent relating to the manufacture, use, sale, offer for sale or importation of such Licensed
Product in the Field in the Territory, or (ii)&nbsp;if a declaratory judgment action is brought naming either Party as a defendant and alleging invalidity of any of the Licensed Patents in the Territory, the Party first having notice of the claim or
assertion shall promptly notify the other Party, and the Parties shall promptly confer to consider the claim or assertion and the appropriate course of action. Unless the Parties otherwise agree in writing, each Party shall have the right to defend
itself against a suit that names it as a defendant (the &#147;<B><I>Defending Party</I></B>&#148;). If WuXi is named in such legal action </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
but not Arcus, then Arcus shall have the right to join, at its own expense, any such legal action and to be represented in such action by its own counsel. None of the Parties shall enter into any
settlement of any claim described in this Section in the Territory that admits to the invalidity, narrowing of scope or unenforceability of the Licensed Patents or this Agreement, incurs any financial liability on the part of the other Party or
requires an admission of liability, wrongdoing or fault on the part of the other Party without such other Party&#146;s prior written consent. In any event, the other Party shall reasonably assist the Defending Party and cooperate in any such
litigation at the Defending Party&#146;s cost and the Defending Party shall reimburse the other Party&#146;s reasonable, documented, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs associated
therewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">9.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Biosimilars</U>. Each Party shall promptly, but in any event no later than ten
(10)&nbsp;business days after receipt of notice of such application, notify the other Party if it becomes aware of any application for regulatory approval of any pharmaceutical product of a third party (excluding any Arcus Affiliate, sublicensee (or
their further sublicensees), related to this Agreement) that relies on such Licensed Product as a Reference Product under the Biologics Price Competition and Innovation Act, or any comparable regulatory regime in any other country in the Territory,
and (i) for which biosimilarity or interchangeability (as applicable) with such Licensed Product has been or is sought to be demonstrated and (ii) which seeks regulatory approval in such country relying in whole or in part on any data generated in
support of a Regulatory Approval for such Licensed Product. Arcus shall take the lead and be responsible for preparing and filing any responses with any Regulatory Authority in the Territory and WuXi shall take the lead and be responsible if in the
Excluded Territory, and each respective Party will be responsible for negotiating any patent resolution in connection with any such application as set forth in paragraphs 2 through 6 of Section&nbsp;351(l) of the United States Public Health Service
Act (42&nbsp;U.S.C. &#167; 262(l)(2)-(6)), or any foreign equivalent thereof. Each Party shall cooperate with the other Party&#146;s reasonable requests for assistance in connection therewith. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.&nbsp;&nbsp;&nbsp;&nbsp;TERM AND TERMINATION</B>.<B></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Term</U>. The term of this Agreement (the &#147;<B><I>Term</I></B>&#148;) shall commence on the Effective Date,
and unless terminated earlier as provided in this Article 10, shall continue in full force and effect, on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until expiry of the Royalty Term for such Licensed Products for the applicable country. Subject to the other terms and conditions of this Agreement
and provided that the Agreement is not terminated for cause by WuXi, solely upon natural expiration after the Term of this Agreement with respect to a particular Licensed Product in a particular country, the licenses granted to Arcus by WuXi under
this Agreement to make, have made, use, register, sell, offer to sell, have sold, import, export, exploit, research, improve, Develop, manufacture and Commercialize such Licensed Products in the Field in such country of the Territory shall be fully <FONT
STYLE="white-space:nowrap">paid-up,</FONT> royalty-free, perpetual, irrevocable and <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.2.1 <U>Convenience</U>. Arcus may terminate this Agreement, in its entirety or on a Licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, with or without cause at any time by giving WuXi at least [***]
days&#146; prior written notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Material Breach</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;In the event of WuXi&#146;s material breach of this Agreement, Arcus may deliver notice of such breach to WuXi,
such notice containing full details of said breach. In such notice, Arcus shall identify (acting reasonably and in good faith) examples of the actions or conduct that Arcus would consider to be an acceptable cure of such breach. WuXi shall have,
subject to Section&nbsp;10.2.2(c), [***] days to cure such breach. Subject to Section&nbsp;10.2.2(c), if WuXi fails to cure such breach within the Cure Period, Arcus may terminate this Agreement upon written notice to WuXi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event of Arcus&#146;: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:17%; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WuXi may deliver notice
of such breach to Arcus, such notice containing full details of said breach. In such notice, WuXi shall identify (acting reasonably and in good faith) examples of the actions or conduct that WuXi would consider to be an acceptable cure of such
breach. Arcus shall have, subject to Section&nbsp;10.2.2(c), [***] days to cure such breach. Subject to Section&nbsp;10.2.2(c), if Arcus fails to cure such breach within such [***] day period, then WuXi may terminate this Agreement, upon written
notice to Arcus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;If a Party gives notice of termination under Section&nbsp;10.2.2(a) or
Section&nbsp;10.2.2(b) and the other Party disputes in writing prior to the end of the applicable cure period whether such notice was proper, then the issues of whether a breach has occurred shall be resolved in accordance with Section&nbsp;11.4. If
as a result of such dispute resolution process it is determined that the notice of breach was proper, then such termination shall be deemed to have been effective if the breaching Party fails thereafter to cure such breach in accordance with the
determination made in the resolution process within the applicable cure period set forth in Section&nbsp;10.2.2(a) or Section&nbsp;10.2.2(b), as applicable, using its best efforts to do so following such determination. If as a result of such dispute
resolution process it is determined that the notice of breach was improper, then no termination shall have occurred and this Agreement shall have remained in effect. All of the terms and conditions of this Agreement shall remain in full force and
effect during the pendency of such dispute resolution process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.2.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Bankruptcy</U>. To the extent permitted
under Applicable Law, either Party may terminate this Agreement in its entirety immediately upon written notice, if the other Party makes an assignment for the benefit of creditors, or a receiver, trustee in bankruptcy or similar officer is
appointed to take charge of all of the other Party&#146;s property, or the other Party seeks protection under any bankruptcy, receivership, trust deed, creditors arrangement, composition or comparable proceeding or such a proceeding is instituted
against the other Party and is not dismissed within [***] calendar days, or the other Party, without a successor, dissolves or liquidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.2.4&nbsp;&nbsp;&nbsp;&nbsp;[***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Effects of Termination</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.3.1&nbsp;&nbsp;&nbsp;&nbsp;Upon termination pursuant to the terms of this Agreement, all rights and licenses granted to Arcus and its
Affiliates, as well as all sublicenses granted under this Agreement by Arcus and/or any of its Affiliates, shall immediately terminate. If this Agreement is properly terminated by Arcus under Section&nbsp;10.2.2 or 10.2.3, however, all such rights
and licenses shall remain in effect and shall automatically become perpetual and irrevocable, and shall remain exclusive, subject only to Arcus&#146; (i) Development, manufacturing and Commercialization of Licensed Products solely in and for the
Territory as permitted in Section&nbsp;2.1 and (ii)&nbsp;continued payment of amounts owed to WuXi pursuant to Sections 5.1, 5.2, 5.3, 5.4 and 5.6. If such termination is by Arcus under Section&nbsp;10.2.2, the royalty rates to be paid by Arcus
thereafter shall be equitably reduced based on the economic impact to Arcus (if any) of the breach giving rise to such termination right. If the parties are unable to agree on whether and to what extent an adjustment should be made pursuant to the
preceding sentence, royalty payments shall be put into an escrow account until the adjustment (if any) has been determined, either by agreement of the parties or pursuant to Section&nbsp;11.4. Upon termination of this Agreement for any reason, any
sublicensee of WuXi shall have the right to seek a license from Arcus to the Arcus Improvements, and Arcus agrees to negotiate such licenses in good faith under reasonable terms and conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">10.3.2&nbsp;&nbsp;&nbsp;&nbsp;In the event that this Agreement is terminated by WuXi pursuant to Section&nbsp;10.2.2, Section&nbsp;10.2.3, or
Section&nbsp;10.2.4(a): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Arcus shall return WuXi&#146;s <FONT STYLE="white-space:nowrap">Know-How</FONT> and
otherwise provide to WuXi the tangible embodiments of all <FONT STYLE="white-space:nowrap">Know-How</FONT> owned or Controlled by Arcus, to the extent necessary for the Development and Commercialization of Licensed Products in existence as of the
date of such termination, subject to WuXi&#146;s reimbursement of Arcus&#146;s reasonable, documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred in transferring such items, and WuXi
shall have an exclusive, sublicensable right and license under such <FONT STYLE="white-space:nowrap">Know-How</FONT> solely for researching, manufacturing, Developing and Commercializing Licensed Products. For clarity, WuXi&#146;s exclusive rights
in such <FONT STYLE="white-space:nowrap">Know-How</FONT> are limited to its application with respect to Licensed Products and Arcus shall be free to exploit such <FONT STYLE="white-space:nowrap">Know-How</FONT> for all purposes other than
researching, manufacturing, Developing and Commercializing Licensed Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Arcus shall provide to WuXi all
data generated during the Term of this Agreement that is necessary for the Development and/or Commercialization of Licensed Products, subject to WuXi&#146;s reimbursement of Arcus&#146;s reasonable, documented, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred in transferring such items, and preparing and making such items available in connection with such transfer to WuXi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Arcus, its Affiliates and any of its or their sublicenses shall be entitled to sell, for a period of [***] months
after the effective date of termination, any inventories of Licensed Products in the Field in the Territory that are on hand as of the effective date of termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Accrued Rights; Surviving Obligations</U>. Except as provided
elsewhere, termination or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration. Such termination or expiration shall not
relieve any Party from obligations which are expressly or by implication intended to survive termination or expiration of this Agreement, including, but not limited to, Articles 1, 6 (for the [***] period set forth in Section&nbsp;6.6), 8 (other
than Section&nbsp;8.5) and 11, and Sections 2.2 (the second sentence of the fourth paragraph only), 2.4 (other than the first sentence), 2.5 (the first and second sentences of the first paragraph, the first sentence of the second paragraph and the
third paragraph only) 2.6, 2.7, 5.7, 5.8, 5.9 (for the [***] year period set forth therein), 7.4, 10.1, 10.2.2(c), 10.3 and this Section&nbsp;10.4, and shall not affect or prejudice any provision of this Agreement which is expressly or by
implication provided to come into effect on, or continue in effect after, such termination or expiration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">10.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Additional Matters Relating to Change of Control of </U><U>Arcus</U>. In the event that Arcus undergoes
a Change of Control (as defined below), Arcus shall notify WuXi not more than [***] days after execution of the agreements for such Change of Control transaction, and shall thereafter provide written notice to WuXi promptly following consummation
(i.e., closing) of such Change of Control transaction. If the consummation of the Change of Control shall result in Arcus or its Affiliates (including any acquiring entity) to have possession of, or control over, any product being developed,
manufactured, or commercialized that includes any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody for application in the Field (except a Licensed Product), the terms and conditions (and rights and
obligations) of this Agreement shall continue in effect as provided in this Agreement (subject to the each Party&#146;s termination rights under Section&nbsp;10.2), except that the provisions of the following Sections 10.5(a) and 10.5(b) shall apply
upon (and only upon) the consummation of the Change of Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The definition of &#147;Commercially
Reasonable Efforts&#148; shall be amended in its entirety to read, as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Commercially Reasonable Efforts&#148; means those efforts
commensurate with those efforts commonly used in the biopharmaceutical industry by a company of comparable size in connection with the development, manufacturing or commercialization of products that are of similar status, including market
potential, profit potential and strategic value, as determined based on conditions then prevailing, including safety, efficacy, competitive considerations within the marketplace, projected market size, intellectual property protection and duration,
manufacturing costs, resource allocation, pricing, <FONT STYLE="white-space:nowrap">re-importation</FONT> concerns, regulatory requirements needed to achieve Regulatory Approval, and other relevant commercial and regulatory considerations, provided
that no other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody product being developed, manufactured, or commercialized by Arcus or its Affiliates (including any acquiring entity) will be taken into
consideration in connection with determining such efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Arcus shall pay WuXi [***] within [***] days after
the consummation of a Change of Control of Arcus unless Arcus gives WuXi written notice of termination of this Agreement prior to the end of such ninety (90)&nbsp;day period or this Agreement is otherwise terminated prior to the end of such ninety
(90)&nbsp;day period, in which case Arcus shall not be required to make such payment. Any payment required to be made by Arcus under this Section&nbsp;10.5(b) shall be creditable against any other amounts payable by Arcus to WuXi under this
Agreement at any time on or after the consummation of such Change of Control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;10.5, a &#147;<B><I>Change of Control</I></B>&#148; of Arcus means:
(i)&nbsp;the sale of all or substantially all of Arcus&#146; assets or business relating to this Agreement; (ii)&nbsp;a merger, reorganization or consolidation involving Arcus in which the voting securities of Arcus outstanding immediately prior
thereto cease to represent at least fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization or consolidation; or (iii)&nbsp;a person or entity, or group of persons or entities, acting in
concert (other than financial investment groups that do not have as a primary business the development and/or commercialization of pharmaceutical products or companion diagnostics) acquire more than fifty percent (50%) of the voting equity
securities or management control of Arcus. Notwithstanding the foregoing, a &#147;Change of Control&#148; of Arcus does not include an initial public offering of Arcus&#146; securities or an issuance of Arcus&#146; securities to where the primary
purpose of such issuance is to raise capital for Arcus, even if securities are issued to an entity whose primary business is the development and/or commercialization of pharmaceutical products, <I>provided that</I> such entity acquires less than
fifty percent (50%) of the voting equity securities or management control of Arcus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>MISCELLANEOUS</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Publications</U>. As between the Parties, Arcus shall have the sole and exclusive right, but not the obligation,
to make any publication and other scientific disclosures in respect of the Licensed Products in the Territory, including, without limitation, in respect of data and results arising out of Development of Licensed Products in the Territory, and WuXi
shall make no such publication or other scientific disclosure related to any Development of Licensed Products in the Territory without the prior written consent of Arcus. Notwithstanding anything to the contrary in this Agreement, including, without
limitation, Article 6 (Confidential Information and Proprietary Rights), Arcus may disclose, without the prior written consent of WuXi, any and all properties of the Licensed Products in connection with any publication and other scientific
disclosures in respect of the Licensed Products, provided that Arcus follows this procedure: Arcus will provide each proposed publication in writing to WuXi at least thirty (30)&nbsp;days in advance of any proposed publication date. WuXi may
request, and Arcus will grant, one or more of the following: (i)&nbsp;an extension of up to sixty (60)&nbsp;additional days to make any desired patent filing(s) in advance of any actual publication by Arcus or transfer of such proposed publication
to a third party for publication; and (ii)&nbsp;that Arcus redact any Confidential Information of WuXi from any such proposed publication. WuXi shall notify Arcus promptly of any publication and other scientific disclosures (and proposed
publications and other scientific disclosures) in respect of the Licensed Products that it becomes aware of outside the Territory, including, without limitation, in respect of data and results arising out of Development of Licensed Products outside
the Territory, and WuXi shall consider any comments that Arcus provides to WuXi in relation thereto in good faith and acting reasonably. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Public Announcements</U>. Except as may be expressly permitted under Article 6 or this Section&nbsp;11.2 or
mandated by Applicable Laws or the rules of any stock exchange, neither Party will make any public announcement of any information regarding this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed. Once any statement is approved for disclosure by the Parties,
either Party may make a subsequent public disclosure containing the same information disclosed in such prior public announcement without further approval of the other Party. Notwithstanding the foregoing, Arcus and its sublicensees shall have the
right to issue a press release and/or make a public announcement concerning the Development or Commercialization status of any Licensed Product, including, but not limited to, achievement of any Development milestones. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Relationship of the Parties</U>. Each Party shall bear its own costs incurred in the performance of its
obligations hereunder without charge or expense to the other except as expressly provided in this Agreement. Neither Party shall have any responsibility for the hiring, termination or compensation of the other Party&#146;s employees or for any
employee benefits of such employee. No employee or representative of a Party shall have any authority to bind or obligate the other Party to this Agreement in any manner whatsoever, or to create or impose any contractual or other liability on the
other Party, or to hold itself out to a third party as having any of the foregoing rights regarding the other Party, without said other Party&#146;s advance, written approval. For all purposes, the Parties&#146; legal relationship under this
Agreement to each other shall be that of independent contractor. This Agreement is not a partnership agreement and nothing in this Agreement shall be construed to establish a relationship of partners or joint venturers or any other relationship
between the Parties, except that of licensor and licensee as set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Dispute
Resolution</U>. Any dispute arising from or relating to the subject matter of this Agreement that cannot be resolved within a period of thirty (30)&nbsp;days after notice of a dispute has been given by one Party hereunder to the other, will be
escalated to the CEO or President of each Party for a period of discussion of up to fifteen (15)&nbsp;days following the initial 30 days (the last day of such fifteen (15)&nbsp;day period being herein referred to as the &#147;<B><I>Arbitration
Date</I></B>&#148;). If the heads of the Parties still cannot resolve the dispute after this 15 day period, such dispute shall be finally settled by arbitration in New York, New York, using the English language in accordance with the Arbitration
Rules and Procedures of JAMS then in effect, by one or more commercial arbitrator(s) with substantial experience in resolving complex commercial contract disputes, who may or may not be selected from the appropriate list of JAMS arbitrators. If the
Parties cannot agree upon the number and identity of the arbitrators within fifteen (15)&nbsp;days following the Arbitration Date, then a single arbitrator shall be selected on an expedited basis in accordance with the Arbitration Rules and
Procedures of JAMS. Any arbitrator so selected shall have substantial experience with pharmaceutical or biopharmaceutical industry licensing. The arbitrator(s) shall have the authority to grant specific performance and to allocate between the
Parties the costs of arbitration (including service fees, arbitrator fees and all other fees related to the arbitration) in such equitable manner as the arbitrator(s) may determine. Judgment upon the award so rendered may be entered in a court
having jurisdiction or application may be made to such court for judicial acceptance of any award and an order of enforcement, as the case may be. Notwithstanding the foregoing, each Party shall have the right to institute an action in a court of
proper jurisdiction for preliminary injunctive relief pending a final decision by the arbitrator(s), provided that a permanent injunction and damages shall only </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be awarded by the arbitrator(s). For all purposes of this Section, the parties consent to exclusive jurisdiction and venue in the United States federal courts located in the Southern District of
New York (i.e., New York City). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. This Agreement shall be construed, and the respective
rights of the Parties determined, according to the substantive law of New York, USA without regard to the provisions governing conflict of laws. The United Nations Convention on the International Sale of Goods shall not apply to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U>. This Agreement may not be assigned or transferred by either Party, in whole or in part, without
the prior written consent of the other Party; <I>provided</I> that, without consent of the other Party, either Party may assign this Agreement, in whole or in part, to any of its Affiliates if such Party guarantees the performance of this Agreement
by such Affiliate; and <I>provided</I> <I>further</I> that, without consent of the other Party, either Party may assign this Agreement to a successor to all or substantially all of the assets or business of such Party to which this Agreement
relates, whether by merger, sale of stock, sale of assets or other similar transaction or series of transactions if such successor agrees in writing to be bound by all obligations to the other Party under this Agreement. Any assignment in violation
of this provision is void and without effect. This Agreement shall be binding upon and inure to the benefit of the Parties hereto, their permitted successors, legal representatives and assigns. In the event WuXi assigns or transfers any of the
Licensed IP to a Third Party, WuXi shall impose on such assignee or transferee such obligations as are necessary so that Arcus retains and obtains all of the rights to which it is entitled with respect to such Licensed IP under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.7&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>. All demands, notices, consents, approvals, reports, requests and other communications hereunder
must be in writing, in English, and will be deemed to have been duly given only if delivered personally, by mail (first class, postage prepaid, return receipt requested), or by overnight delivery using a globally-recognized carrier, to the Parties
at the following addresses: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Arcus:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>WuXi:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Arcus Biosciences, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Wuxi Biologics (Cayman) Inc.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">3928 Point Eden Way</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">PO Box 309, Ugland House</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hayward, CA 94545</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1104</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn: Juan Jaen, Ph.D., President</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cayman Islands</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Chris Chen,
CEO</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>with a courtesy copy to:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>with a courtesy copy to:</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gunderson Dettmer Stough, Villeneuve,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Franklin
and Hachigian, LLP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Haynes and Boone, LLP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">201 South Main Street</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Suite 700</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1221 McKinney Street</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Suite
2100</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ann Arbor, MI 48104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Houston, TX 77010</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attn: Marcia Hatch, Esq.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Attn: Frank Wu, Esq.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the addressee shall have last furnished in writing in accord with this provision.
All notices shall be deemed effective upon receipt by the addressee. For clarity, the courtesy copy of any such notices will not be effective to provide notice to the Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.8&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. If any provision of this Agreement is held to be invalid, illegal or unenforceable in any
respect, that provision shall be limited or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.9&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>. The headings used in this Agreement have been inserted for convenience of reference only and do
not define or limit the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.10&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver</U>. No waiver of any term or condition of this
Agreement shall be effective unless set forth in a written instrument duly executed by or on behalf of the waiving Party. No waiver by any Party of any term or condition of this Agreement, in any one or more instances, shall be deemed to be or
construed as a waiver of the same or any other term or condition of this Agreement on any prior, concurrent or future occasion. Except as expressly set forth in this Agreement, all rights and remedies available to a Party, whether under this
Agreement or afforded by Applicable Law or otherwise, will be cumulative and not in the alternative to any other rights or remedies that may be available to such Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.11&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement</U>. This Agreement (including any exhibits and schedules hereto) constitutes the entire
agreement between the Parties hereto with respect to the subject matter hereof and supersedes all previous agreements and understandings between the Parties, whether written or oral, including, but not limited, to all proposals, negotiations,
conversations, letters of intent, term sheets, memoranda of understanding or discussions, between the Parties relating to the subject matter of this Agreement and all past dealing or industry custom. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.12&nbsp;&nbsp;&nbsp;&nbsp;<U>Modification</U>. This Agreement may be altered, amended or changed only by a writing making specific
reference to this Agreement and the clause to be modified, which amendment is signed by duly authorized representatives of Arcus and WuXi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.13&nbsp;&nbsp;&nbsp;&nbsp;<U>No Third Party Beneficiaries</U>. None of the provisions of this Agreement shall be for the benefit of or
enforceable by any Third Party, including, but not limited to, any creditor of either Party hereto, except the Indemnification provision in Article 8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.14&nbsp;&nbsp;&nbsp;&nbsp;<U>Ambiguities</U>. This Agreement shall be deemed to have been drafted jointly by both Parties; and ambiguities,
if any, shall not be construed against either Party, irrespective of which Party may have actually drafted the ambiguous provision. Each Party has had an opportunity to consult independent legal counsel in reaching this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">11.15&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be executed in counterparts, each of which, when executed, shall be
deemed to be an original and all of which together shall constitute one and the same document. Execution of a facsimile copy (including PDF) shall have the same force and effect as execution of an original, and a facsimile signature shall be deemed
an original and valid signature. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<B><I>Remainder of Page Intentionally Left Blank</I></B>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, Arcus and WuXi, by their duly authorized officers, have executed
this Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARCUS BIOSCIENCES, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>WUXI BIOLOGICS (CAYMAN) INC.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Juan C. Jaen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Chris Chen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Juan C. Jaen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Chris Chen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LICENSED PATENTS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>LICENSED TECHNOLOGY </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>DOSE ESCALATION BATCH SPECIFICATIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>INITIAL CLINICAL AND COMMERCIAL MANUFACTURING PRICES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.12 </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPTION AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> O<SMALL>PTION</SMALL> <SMALL>AND</SMALL> L<SMALL>ICENSE</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL>
(&#147;<B><I>Agreement</I></B>&#148;) is made and entered into effective as of September&nbsp;19, 2017 (the &#147;<B><I>Effective Date</I></B>&#148;), by and between <B>A<SMALL>RCUS</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>.</B>, a
company organized under the laws of State of Delaware, U.S.A., having a business address at 3928 Point Eden Way, Hayward, CA 94545, U.S.A. (&#147;<B><I>Arcus</I></B>&#148;), and <B>TAIHO P<SMALL>HARMACEUTICAL</SMALL> C<SMALL>O</SMALL>.,
L<SMALL>TD</SMALL>.</B>, a corporation organized under the laws of Japan, having a business address at <FONT STYLE="white-space:nowrap">1-27</FONT> <FONT STYLE="white-space:nowrap">Kandanishiki-cho,</FONT> Chiyoda-ku, Tokyo <FONT
STYLE="white-space:nowrap">101-8444,</FONT> Japan (&#147;<B><I>TAIHO</I></B>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ECITALS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL>,</B> Arcus owns or controls certain intellectual property assets, including patents, patent applications and <FONT
STYLE="white-space:nowrap">know-how,</FONT> relating to innovative cancer immunotherapies; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL>,</B> TAIHO is a
company that specializes in developing and commercializing pharmaceutical and therapeutic products in the Territory (defined below); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL>,</B> the parties desire to establish a strategic relationship, pursuant to which, among other things: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;TAIHO will provide research and development support to Arcus in the form of certain <FONT
STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable,</FONT> cash payments; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;Arcus would grant to TAIHO, with respect to each Option Product (defined below): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;during the Exercise Period (defined below) for such Option Product, an exclusive option to obtain an
exclusive license to Develop and Commercialize such Option Product in the Field in and for the Territory; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;upon TAIHO&#146;s exercise of the Option (defined below), an exclusive license to Develop and
Commercialize Licensed Products in the Field in and for the Territory during the Term (defined below); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in each case, on the terms and subject to the
conditions set forth herein. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>, T<SMALL>HEREFORE</SMALL>,</B> in consideration of the foregoing premises and the mutual covenants contained herein and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Arcus and TAIHO hereby agree as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>D<SMALL>EFINITIONS</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Accounting
Standards</B>&#148; shall mean International Financial Reporting Standards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Achievement</B>&#148; shall mean, with respect to
a Development and Regulatory Milestone or a Sales Achievement Milestone, the achievement of such milestone by TAIHO or any of TAIHO&#146;s Sublicensees. &#147;<B>Achieve</B>&#148; and &#147;<B>Achieved</B>&#148; shall have a correlative meaning.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Acquiring Party</B>&#148; shall have the meaning provided in Section&nbsp;13.4(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Act</B>&#148; shall mean, as applicable, the United States Federal Food, Drug and Cosmetic Act, 21
U.S.C. &#167;&#167;301 et seq., and/or the Public Health Service Act, 42 U.S.C. &#167;&#167;262 et seq., as such may be amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Affiliate</B>&#148; shall mean, with respect to a Person, any company or entity controlled by,
controlling, or under common control with such Person, for as long as such control exists. As used in this definition and Section&nbsp;13.4, &#147;control&#148; shall mean: (a)&nbsp;possession, directly or indirectly, of the power to direct the
management and policies of such company or entity, whether through ownership of voting securities or by contract relating to voting rights or corporate governance; or (b)&nbsp;direct or indirect beneficial ownership of more than 50% of the voting
share capital in such company or entity. Notwithstanding the foregoing, (i)&nbsp;the Affiliates of TAIHO shall exclude any Person that is controlled by Otsuka Holdings Co. Ltd., having offices at <FONT STYLE="white-space:nowrap">2-9</FONT>
Kanda-Tsukasamachi, Chiyoda-ku, Tokyo <FONT STYLE="white-space:nowrap">101-0048</FONT> Japan (other than TAIHO and any Person that is controlled by TAIHO) and (ii)&nbsp;the Affiliates of Arcus shall exclude PACT Pharma, Inc.
(&#147;<B>PACT</B>&#148;) and any Person that is controlled by PACT. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Amounts Owed</B>&#148;
shall have the meaning provided in Section&nbsp;5.9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Antibody</B>&#148; shall mean an antibody
that is Controlled by Arcus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Anti-Corruption Laws</B>&#148; means the U.S. Foreign Corrupt
Practices Act, as amended, the Organization for Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development (OECD) Convention on combating bribery of foreign public officials in international business transactions, and any other
applicable anti-corruption laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Applicable Laws</B>&#148; shall mean the applicable
provisions of any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidances, ordinances, judgments, decrees, directives, injunctions, orders, permits of or from any
court, arbitrator, regulatory authority or governmental agency or authority having jurisdiction over or related to the subject item, including the Act, Anti-Corruption Laws and Export Control Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Approved Indication</B>&#148; shall have the meaning provided in Section&nbsp;5.2(d)(iv). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Approved Licensed Product</B>&#148; shall have the meaning provided in Section&nbsp;5.2(d)(iv).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Approval Pathway</B>&#148; shall have the meaning provided in Section&nbsp;5.2(d)(iv). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Arcus Indemnitees</B>&#148; shall have the meaning provided in Section&nbsp;11.1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Arcus</B><B> Invention</B>&#148; shall mean any
Invention made solely by one or more employees, consultants or contractors of Arcus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Arcus</B><B> <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; shall mean all Information
Controlled by Arcus that is reasonably necessary for or actually used in the Development or Commercialization of Licensed Product or Companion Diagnostic in the Field, including any such Information relating to Arcus Inventions for such Licensed
Product or Companion Diagnostic, but excluding Arcus&#146;s interest in Joint Inventions and Arcus Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Arcus License</B>&#148; shall have the meaning provided in Section&nbsp;3.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Arcus</B><B> Patents</B>&#148; shall mean, subject to Section&nbsp;8.2, only those Patent Rights
Controlled by Arcus and only to the extent such Patent Rights cover the Development or Commercialization of Licensed Product or Companion Diagnostic in the Field in or for the Territory, excluding Arcus&#146;s interest in Joint Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Arcus Partner</B>&#148; shall have the meaning provided in Section&nbsp;3.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Arcus Partner Agreement</B>&#148; shall have the meaning set forth in Section&nbsp;3.4(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Arcus</B><B> Program</B>&#148;<B> </B>means [***], in each case that have been, at least in part,
[***], provided that [***] prior to or during the Option Period. For clarity, during the period prior to the end of the Option Period, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Arcus Technology</B>&#148; shall mean the Arcus Patents and the Arcus <FONT
STYLE="white-space:nowrap">Know-How</FONT> and the Arcus Inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Arcus
Trademarks</B>&#148; shall have the meaning provided in Section&nbsp;8.7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Asia</B>&#148;
shall mean [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Assigning Party</B>&#148; shall have the meaning provided in
Section&nbsp;13.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Auditor</B>&#148; shall have the meaning provided in Section&nbsp;6.4.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Biosimilar Application</B>&#148; shall mean an application submitted to the FDA under 42
U.S.C. &#167;262(k) or Section&nbsp;351(k) of the PHS Act, or any analogous application submitted to a Regulatory Authority in the United States or in another country in the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.27</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>BLA</B>&#148; shall mean a Biologics License Application or similar application or submission
filed with or submitted to a Regulatory Authority in a jurisdiction that is necessary to obtain Marketing Approval of a biologic product in such jurisdiction, including any such application filed with the FDA pursuant to 21 C.F.R. Part&nbsp;601.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.28</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;BPCI Act&#148; </B>means the Biologics Price Competition and Innovation Act of 2009 within
the Patient Protection and Affordable Care Act, as set forth in Section&nbsp;351(k) of the PHS Act (42 U.S.C. 262), which was signed into law in the United States in March 2010, and as may be subsequently amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.29</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Bridging Study</B>&#148; shall mean a
supplemental Clinical Trial of a Licensed Product conducted in Japan that is designed to (a)&nbsp;allow extrapolation of pivotal data obtained from a Registrational Clinical Trial within the Arcus <FONT STYLE="white-space:nowrap">Know-How</FONT>
that, in TAIHO&#146;s good faith opinion, did not include sufficient number of Japanese (or other acceptable Asian) patients to obtain Marketing Approval for such Licensed Product by Japanese Regulatory Authorities based solely on the Arcus <FONT
STYLE="white-space:nowrap">Know-How</FONT> and (b)&nbsp;generate all additional clinical data that, along with data within the Arcus <FONT STYLE="white-space:nowrap">Know-How,</FONT> will be sufficient to obtain Marketing Approval for such Licensed
Product in Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.30</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Bridging Study Pathway</B>&#148; shall have the meaning provided in
Section&nbsp;5.2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.31</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Bring-Down Disclosure Schedule</B>&#148; means a schedule of exceptions
to the representations and warranties of Arcus, as made in accordance with Section&nbsp;9.3 with respect to an applicable Arcus Program, as such document may be provided pursuant to Section&nbsp;2.1(c), which (a)&nbsp;shall have been prepared in
good faith in an attempt to accurately and specifically state, as of the applicable License Date, any exceptions to, or other information required to be disclosed pursuant to, the representations and warranties of Arcus set forth in Section&nbsp;9.2
of this Agreement, (b)&nbsp;shall not contain any general disclaimers (as opposed to specific exceptions to any representation or warranty of Arcus set forth in this Agreement) other than general disclaimers that are not material, and any attempt to
include such general disclaimers that are material shall be disregarded; and (c)&nbsp;shall not limit the scope of representations and warranties made by Arcus other than with respect to such applicable Arcus Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.32</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Broadened Indication</B>&#148; shall have the meaning provided in Section&nbsp;5.2(d)(iii)(2).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.33</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Business Day</B>&#148; means any day excluding Saturday, Sunday and any day which is a legal
holiday under the laws of Japan or the State of California, as applicable, or is a day on which banking institutions located in Japan or the State of California are authorized or required by law or other governmental action to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.34</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Challenging Party</B>&#148; shall have the meaning provided in Section&nbsp;10.2(d). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.35</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Claims</B>&#148; shall have the meaning provided in Section&nbsp;11.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.36</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Clinical Trial</B>&#148; shall mean a clinical trial in human patients (not including healthy
volunteers) that has been approved by, as applicable, a Regulatory Authority and an institutional review board or ethics committee, and is designed to measure the safety and/or efficacy of an Antibody, Compound or Therapeutic Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.37</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>CMO</B>&#148; shall have the meaning provided in Section&nbsp;4.8(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.38</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>CMO Supply Agreement</B>&#148; shall mean each agreement and all related material documents,
including exhibits, attachments and amendments thereto, entered into by Arcus or an Arcus Partner, with a Third Party pertaining to the manufacture, production or supply of Option Product or Licensed Product, including any agreement for the
manufacture of a component or intermediate of an Option Product or Licensed Product such as an Antibody or Compound. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.39</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Combination Product</B>&#148; shall mean
(a)&nbsp;a finished dosage form of a Therapeutic Product containing both a given Antibody or Compound and one or more pharmaceutically active ingredients other than such Antibody or Compound or (b)&nbsp;a Therapeutic Product sold as one of a bundle
of products without a separate price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.40</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercialization</B>&#148; shall mean engaging in any
and all activities directed or related to manufacturing, marketing, promoting, distributing, offering for sale, selling, importing, exporting or otherwise commercially exploiting a product (and any use for such purposes), including conducting
marketing and post-marketing studies. TAIHO may conduct marketing and post-marketing studies of Licensed Products only in or, subject to Section&nbsp;4.12 below, for use in the Territory. &#147;<B>Commercialize</B>&#148; shall have a correlative
meaning. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.41</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercialization Milestone Payments</B>&#148; shall have the meaning provided in
Section&nbsp;5.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.42</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Commercially Reasonable Efforts</B>&#148; shall mean, with respect to the
efforts to be expended by a party with respect to any objective, using those reasonable, good faith efforts at least consistent with the efforts such party would devote (and which shall in any case be at least consistent with the level of effort and
resources that would be reasonably expected of a company in the pharmaceutical industry of similar size and scope to such party) to a product of similar market potential, profit potential (determined without taking into account payments under this
Agreement), stage of development and strategic value resulting from its own research efforts, based on all relevant factors and conditions then prevailing. Without limiting the foregoing, Commercially Reasonable Efforts in all cases requires at
least that (i)&nbsp;each party promptly assigns responsibility for such obligations on an ongoing basis; (ii)&nbsp;each party sets and consistently seeks to achieve meaningful objectives for carrying out such obligations; and (iii)&nbsp;each party
consistently makes and implements decisions designed to advance progress with respect to such objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.43</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Companion Diagnostic</B>&#148; shall mean, subject to Section&nbsp;8.2, a product, test or
procedure Controlled by Arcus to identify patients who may or may not benefit from a Licensed Product, to monitor the progress or effect of therapy using or exposure levels of a Licensed Product, or to provide information used to measure, guide or
inform the diagnosis, treatment or prognosis of a patient with a Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.44</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Competitive Infringement</B>&#148; shall have the meaning provided in Section&nbsp;8.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.45</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Compound</B>&#148; shall mean a chemical compound or other composition (of any modality) that is
Controlled by Arcus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.46</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Confidential Information</B>&#148; shall have the meaning provided in
Section&nbsp;7.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.47</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Confidentiality Agreement</B>&#148; shall mean, collectively, any and all
confidentiality or <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements between the parties, and/or their Affiliates, entered into prior to the Effective Date relating to the subject matter of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.48</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Control</B>&#148; or &#147;<B>Controlled
by</B>&#148; shall mean, with respect to any Patent Rights, Information or other intellectual property rights, the possession by a Person of the ability (whether by ownership or license, other than pursuant to a license granted to such Person by a
party to this Agreement) to grant access to, or a license or sublicense of, such Patent Rights, Information or other intellectual property rights in accordance with this Agreement without violating the terms of any agreement or other arrangement
with any Third Party existing at the time such Person would be first required to grant such access, license, or sublicense. A Person shall be deemed to Control any subject matter so controlled by its Affiliates (subject in each case to
Section&nbsp;13.4(b) below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.49</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Credits</B>&#148; shall have the meaning provided in
Section&nbsp;5.9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.50</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Development</B>&#148; shall mean, engaging in research, or <FONT
STYLE="white-space:nowrap">pre-clinical,</FONT> <FONT STYLE="white-space:nowrap">non-clinical</FONT> or clinical drug development activities, including, but not limited to, test method development, stability testing, toxicology, manufacturing of
supplies for Development purposes, manufacturing <FONT STYLE="white-space:nowrap">scale-up,</FONT> analytical method validation, manufacturing process validation, cleaning validation, post-approval changes, quality assurance/quality control,
statistical analysis, report writing, clinical studies, regulatory filing submission and approval and regulatory affairs, but expressly excluding manufacturing of commercial supplies, provided that &#147;Development&#148;, as such term applies to
TAIHO, does not include engaging in any <FONT STYLE="white-space:nowrap">pre-clinical</FONT> drug development activities, including, without limitation, any discovery, formulation, process development or preclinical studies or modifying any Licensed
Products, except only to the extent reasonably necessary or useful in connection with efforts to obtain Marketing Approval or develop Licensed Products in accordance with the terms of this Agreement, and in such event, TAIHO shall keep Arcus
informed of such activities and, at Arcus&#146;s request, consult with Arcus, in good faith, with respect thereto and how best to proceed. For the avoidance of doubt, any such modified versions of Licensed Products shall be deemed to be Licensed
Products under this Agreement. In addition, TAIHO may only conduct clinical studies of the Licensed Products in the Territory, or (subject to Section&nbsp;4.12 below), outside the Territory for the purpose of Developing and Commercializing the
Licensed Products in the Territory. &#147;<B>Developing</B>&#148; and &#147;<B>Develop</B>&#148; shall have correlative meanings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.51</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Development and Regulatory Milestones</B>&#148; shall have the meaning provided in
Section&nbsp;5.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.52</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Development and Regulatory Milestone Payments</B>&#148; shall have the
meaning provided in Section&nbsp;5.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.53</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Disclosing Party</B>&#148; shall have the meaning
provided in Section&nbsp;7.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.54</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Dose Escalation Data Package</B>&#148; shall mean with respect
to an Arcus Program: (a)&nbsp;all <FONT STYLE="white-space:nowrap">Top-Line</FONT> Data from the first completed Dose Escalation Study for a first Therapeutic Product in such Arcus Program, including for each patient of the Dose Escalation Study, <FONT
STYLE="white-space:nowrap">follow-up</FONT> results directed to evaluating safety and tolerability of the Therapeutic Product for a period of at least [***] days after the last dosing of the last patient in such Dose Escalation Study, or if shorter,
the <FONT STYLE="white-space:nowrap">follow-up</FONT> period set forth in the trial protocol, (b)&nbsp;all Regulatory Filings and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantive Regulatory Documents with respect to such Arcus Program through the end of the period described in (a), and (c)&nbsp;if then available, the final trial report from such Dose
Escalation Study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.55</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Dose Escalation Study</B>&#148; shall mean, with respect to a Therapeutic
Product, a Phase I Clinical Trial for such Therapeutic Product that includes the dosing of the number of patients defined in the protocol to (a)&nbsp;establish the maximum tolerated dose of such Therapeutic Product or, if no maximum tolerated dose
is established, evaluates dosing levels sufficient to establish recommended therapeutic dose for the Therapeutic Product provided for in the protocol for such Phase I Clinical Trial and (b)&nbsp;establish the recommended dose of such Therapeutic
Product for use in a Phase Ib Clinical Trial or Phase II Clinical Trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.56</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>EMA</B>&#148; shall
mean the European Medicines Agency or any successor Regulatory Authority thereto in the European Union having substantially the same function. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.57</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Excess Withholding Tax</B>&#148; shall have the meaning provided in Section&nbsp;13.4.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.58</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Executives</B>&#148; shall mean the President or Chief Executive Officer of TAIHO and the
President or Chief Executive Officer of Arcus, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.59</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Exercise Period</B>&#148; shall
mean, with respect to a particular Arcus Program, the period commencing upon the Effective Date and ending on the later of (a) [***] days after TAIHO&#146;s receipt of [***] and (b)&nbsp;the expiration of the Option Period, provided the Exercise
Period with respect to a particular Arcus Program shall terminate if the Option Products in such Arcus Program have become Licensed Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.60</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Export Control Laws</B>&#148; shall mean: (a)&nbsp;all applicable U.S. export control laws,
including the Arms Export Controls Act (22 U.S.C. Ch. 39), the International Emergency Economic Powers Act (50 U.S.C. &#167;&#167; 1701 et seq.), the Trading With the Enemy Act (50 U.S.C. app. &#167;&#167; 1 et seq.), the Export Administration Act
of 1979 (50 U.S.C. app. &#167;&#167; 2401 et seq.), International Boycott Provisions of Section&nbsp;999 of the U.S. Internal Revenue Code of 1986, and all rules, regulations and executive orders relating to any of the foregoing, including but not
limited to the International Traffic in Arms Regulations (22 C.F.R. &#167;&#167; 120 et seq.), the Export Administration Regulations (15 C.F.R. &#167;&#167; 730 et. seq.), and the regulations administered by the Office of Foreign Assets Controls of
the United States Department of the Treasury; and (b)&nbsp;all export controls imposed on any Licensed Product by any country or organization or nations within whose jurisdiction either party operates or does business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.61</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>FDA</B>&#148; shall mean the U.S. Food and Drug Administration, or any successor Regulatory
Authority thereto in the U.S. having substantially the same function. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.62</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Field</B>&#148; shall
mean all human uses and indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.63</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>First Commercial Sale</B>&#148; shall mean, with respect
to a given Licensed Product in a given country, the first commercial transfer or disposition for value of such Licensed Product by TAIHO or its Sublicensee to a Third Party (other than a Sublicensee) for end use or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consumption of such Licensed Product in such country after receipt of Marketing Approval for such Licensed Product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.64</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Flow Down Provisions</B>&#148; shall have the meaning set forth in Section&nbsp;3.4(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.65</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>GCP</B>&#148; shall mean then-current good clinical practices, as set forth in 21 C.F.R.
Parts&nbsp;50, 54, 56, 312 and 314 and as interpreted by relevant ICH guidelines; in each case, as amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.66</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Generic Competition</B>&#148; shall have the meaning provided in Section&nbsp;5.6(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.67</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Generic Product</B>&#148; shall mean, with respect to a particular Licensed Product and a
particular country, any pharmaceutical product (other than the Licensed Product sold under authority from TAIHO) that: (a)&nbsp;contains the same active ingredient(s) and route of administration as such Licensed Product and has received Marketing
Approval in such country; or (b)&nbsp;contains a substantially similar active ingredient as such Licensed Product and (i)&nbsp;for which biosimilarity or interchangeability (as applicable) with such Licensed Product has been demonstrated and
(ii)&nbsp;which has received Marketing Approval in such country relying in whole or in part on any data generated in support of a Marketing Approval for such Licensed Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.68</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Generic Product Presence</B>&#148; shall have the meaning provided in Section&nbsp;5.6(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.69</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Global Study</B>&#148; shall mean a multi-country Phase II Clinical Trial or Phase III Clinical
Trial of a Licensed Product that is conducted by Arcus, its Affiliates or a Third Party under authority from Arcus, is joined by TAIHO or any of its Affiliates or Sublicensees with respect to any part of the Clinical Trial conducted in Japan and is
designed (a)&nbsp;to satisfy the requirements of the Regulatory Authorities in Japan (including sufficient numbers of Japanese (or other mutually agreed Asian) patients to satisfy such requirements) and (b)&nbsp;(i) if such Clinical Trial is a Phase
II Clinical Trial, to be sufficient without a further Clinical Trial, to form the basis for proceeding to a Phase III Clinical Trial (or filing a BLA or NDA in Japan and one or more Major Markets) or (ii)&nbsp;if such Clinical Trial is a Phase III
Clinical Trial, to provide an adequate basis to obtain Marketing Approval in Japan and one or more Major Markets. For such purposes, to &#147;join&#148; a Clinical Trial means that TAIHO or any of its Affiliates or Sublicensees (or a combination of
them)&nbsp;(A) is the sponsor of such Clinical Trial in Japan, or is primarily responsible for carrying out or overseeing the conduct of such Clinical Trial in Japan, (B)&nbsp;is responsible for no more than its proportionate share of the costs of
such Clinical Trial based on the number of patients in Japan (or other mutually agreed Asians) relative to all patients in the Clinical Trial and (C)&nbsp;has mutually agreed with Arcus in a writing specifically referencing this Agreement that it is
joining such Clinical Trial. If TAIHO (or its Affiliate or Sublicensee or any combination of them) is &#147;joining&#148; a Global Study, then the parties shall enter into an agreement specifying the parties&#146; respective roles and
responsibilities and describing how costs associated therewith shall be handled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.70</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Global Study
Pathway</B>&#148; shall have the meaning provided in Section&nbsp;5.2(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.71</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>GLP</B>&#148; shall mean then-current good
laboratory practices, as set forth in 21 C.F.R. Part&nbsp;58 and as interpreted by relevant ICH guidelines; in each case, as amended from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.72</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>GMP</B>&#148; shall mean the then-current good manufacturing practices and standards for the
production of drugs and finished pharmaceuticals, as set forth in (a) 21 C.F.R. Parts&nbsp;210, 211, 601 and 610, (b) and the ICH Q7 guidelines; and (c)&nbsp;the equivalent Applicable Law in any relevant country, in each case, as amended from time
to time, subject to any arrangements, additions or clarifications agreed in writing from time to time between the parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.73</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>ICH</B>&#148; means the International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.74</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IND</B>&#148; shall mean an investigational
new drug application, clinical study application, clinical trial exemption, or similar application or submission filed with or submitted to the FDA, TGA or EMA (including data collected under the IND Enabling Studies) that is necessary to commence
human clinical trials in the applicable jurisdiction, including any such application filed with the FDA pursuant to 21 C.F.R. Part&nbsp;312 or with the TGA or EMA pursuant to the equivalent thereto in the applicable jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.75</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IND Acceptance</B>&#148; shall mean, with respect to a Clinical Trial, written approval from the
FDA, TGA or EMA that approves the IND and the commencement of such Clinical Trial in the applicable jurisdiction, provided that such written approval will be deemed to have been granted if (a)&nbsp;thirty-five (35)&nbsp;days have elapsed following
confirmation by the FDA of its receipt of such IND (as confirmed either via a letter or fax) without (i)&nbsp;imposition of a clinical hold by the FDA or (ii)&nbsp;any other notification by the FDA that the applicable Clinical Trial cannot so
proceed as contemplated by such IND or (b)&nbsp;notification by FDA, TGA or EMA that the applicable Clinical Trial can so proceed as contemplated by such IND, in each case (a)&nbsp;and (b), as a consequence of such events, the Clinical Trial may
lawfully proceed as described in the applicable IND. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.76</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>IND Enabling Studies</B>&#148; means,
with respect to Antibodies, Compounds or Therapeutic Products, toxicity studies evaluating such Antibodies, Compounds or Therapeutic Products that are conducted in accordance with GLP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.77</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Indemnified Party</B>&#148; shall have the meaning provided in Section&nbsp;11.3.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.78</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Indemnifying Party</B>&#148; shall have the meaning provided in Section&nbsp;11.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.79</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Indication Category</B>&#148; shall have the meaning provided in Section&nbsp;5.2(d)(iii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.80</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Information</B>&#148; shall mean any and all tangible and intangible information, techniques,
technology, practices, trade secrets, inventions (whether patentable or not), methods, processes, knowledge, <FONT STYLE="white-space:nowrap">know-how,</FONT> skill, experience, data and results (including pharmacological, toxicological and clinical
test data and results), reports, analytical and quality control data, results or descriptions, software and algorithms, materials and cell lines, including Regulatory Filings and Regulatory Documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.81</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Infringement</B>&#148; shall have the meaning
provided in Section&nbsp;8.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.82</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Initial Disclosure Schedule</B>&#148; means the schedule of
exceptions referenced in Exhibit 1.82. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.83</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Initiation</B>&#148; of a human Clinical Trial shall
mean the first dosing, whether of the investigational product, placebo or comparator, of the first subject so dosed in such trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.84</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Intra-Portfolio Combination</B>&#148; shall have the meaning provided in Section&nbsp;5.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.85</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Invention</B>&#148; shall mean any invention, whether or not patentable, made in the course and as
a result of the conduct of activities conducted pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.86</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Japanese
Regulatory Authority(ies)</B>&#148; means, individually and together, the Ministry for Health, Labor and Welfare of Japan and any successor entity thereto and the Pharmaceutical and Medical Devices Agency (formerly known as IYAKUHIN IRYOKIKI SOGO
KIKO), or any successor entity thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.87</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Joint Development Committee</B>&#148; shall have the
meaning provided in Section&nbsp;4.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.88</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Joint Invention</B>&#148; shall mean any Invention made
jointly by one or more employees, consultants or contractors of TAIHO and one or more employees, consultants or contractors of Arcus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.89</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Joint Patents</B>&#148; shall mean Patent Rights claiming Joint Inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.90</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Joint Steering Committee</B>&#148; shall have the meaning provided in Section&nbsp;4.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.91</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Joint Technology</B>&#148; shall mean Joint Inventions and Joint Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.92</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>License</B>&#148; shall have the meaning provided in Section&nbsp;3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.93</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>License Date</B>&#148; shall have the meaning provided in Section&nbsp;3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.94</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Licensed Products</B>&#148; shall have the meaning provided in Section&nbsp;3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.95</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Losses</B>&#148; shall mean any and all damages (including, but not limited to, all loss of
profits, diminution in value, and incidental, indirect, consequential, special, reliance, exemplary, punitive, statutory and treble damages), awards, deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees,
liabilities, obligations, taxes, liens, losses and expenses (including, but not limited to, court costs, interest and reasonable fees of attorneys, accountants and other experts) incurred by or awarded to Third Parties and required to be paid to
Third Parties with respect to a Claim by reason of any judgment, order, decree, stipulation or injunction, or any settlement entered into in accordance with the provisions of this Agreement, together with all documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses incurred in contesting any Third Party Claim or complying with any judgments, orders, decrees, stipulations and injunctions that arise from or
relate to a Third Party Claim. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.96</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Major Cancer Indication</B>&#148; shall mean an
indication which meets the following conditions: (a)&nbsp;first line or second line treatment in [***] and (b)&nbsp;the number of target patients in Japan is greater than [***]. For clarity, the target patients for (i)&nbsp;a given Clinical Trial
will be the population of patients in Japan who would meet the inclusion criteria for such Clinical Trial, (ii)&nbsp;a given NDA/BLA will be the patient population in Japan for which approval for treatment with the Licensed Product is sought, as
defined in the requested labelling included in such NDA/BLA, and (iii)&nbsp;a given Marketing Approval will be the patient population in Japan approved for treatment with the Licensed Product, as defined in the approved label. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.97</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Major Market</B>&#148; shall mean any of the United States, France, Germany, Italy, Spain, the
United Kingdom, and the People&#146;s Republic of China. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.98</B>&nbsp;&nbsp;&nbsp;&nbsp; &#147;<B>Marketing Approval</B>&#148; shall
mean approval from the relevant Regulatory Authority in a given country necessary to market and sell a pharmaceutical product in such country, which for the sake of clarity, shall not include pricing and reimbursement approval, prior to any
commercial disposition of such product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.99</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Milestone Stage</B>&#148; shall have
the meaning provided in Section&nbsp;5.2(d)(iii). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.100</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Minor Cancer Indication</B>&#148; shall
mean any indication that is not a Major Cancer Indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.101</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Narrowed Indication</B>&#148;
shall have the meaning provided in Section&nbsp;5.2(d)(iii)(2). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.102</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>NDA</B>&#148; shall mean:
(a)&nbsp;in the United States, a New Drug Application (as more fully defined in 21&nbsp;CFR 314.5, <I>et seq.</I>) filed with the FDA, or any successor application thereto; or (b)&nbsp;in any other country or group of countries, the equivalent
application or submission for approval to market a pharmaceutical product filed with the governing Regulatory Authority in such country or group of countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.103</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Net Sales</B>&#148; shall mean the gross amounts invoiced for sales or other dispositions of
Licensed Products by a Selling Party to Third Parties (other than another Selling Party), less the following deductions actually allowed or taken on the sale of Licensed Products by the Selling Party, all in compliance with applicable Accounting
Standards, consistently applied by the Selling Party: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In no event shall any particular amount identified above be deducted more than once in calculating Net Sales (<I>i.e.</I>, no &#147;double
counting&#148; of deductions). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, if a Licensed Product under this Agreement is sold in the form of a Combination Product in a country, Net Sales for the purpose of determining
royalties due hereunder shall be calculated as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.104</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Option</B>&#148; shall have the meaning provided in Section&nbsp;2.1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.105</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Option Exercise Payments</B>&#148; shall have the meaning provided in Section&nbsp;5.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.106</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Option Period</B>&#148; shall mean, the five (5)&nbsp;year period from and after the Effective
Date, unless extended as provided in Section&nbsp;2.1(f), in which case, it shall mean the period determined under such Section&nbsp;2.1(f) from and after the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.107</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;</B><B>Option Product</B><B>&#148;</B> shall mean each of the Antibodies, Compounds, and/or
Therapeutic Products included in a particular Arcus Program. Without limiting the scope of Option Products, <B>Exhibit 1.107</B> includes a pipeline list (together with <FONT STYLE="white-space:nowrap">non-binding,</FONT> estimated development
timelines of such Option Products) as of the Effective Date<I>.</I> For the sake of clarity, an Option Product ceases to be an Option Product upon the earlier of (a)&nbsp;such Option Product becoming a Licensed Product and (b)&nbsp;the end of the
Exercise Period for the Arcus Program of which such Option Product is part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.108</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Other
Active</B>&#148; shall mean, with respect to a Combination Product, any active pharmaceutical ingredient other than a particular Antibody or Compound within such Combination Product. It is understood that an Other Active may be another Antibody or
Compound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.109</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Patent Certification</B>&#148; shall have the meaning provided in
Section&nbsp;8.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.110</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Patent Clearance</B>&#148; shall have the meaning provided in
Section&nbsp;8.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.111</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Patent Rights</B>&#148; shall mean (a)&nbsp;all applicable national,
regional and international patents and patent applications, including without limitation provisional patent applications, (b)&nbsp;all patent applications filed either from such patents and patent applications or from a patent application claiming
priority from any of these, including any continuation, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuation-in-part,</FONT></FONT> division, provisional, converted provisional and continued prosecution applications, or any
substitute applications, (c)&nbsp;any patent issued with respect to or in the future issued from any such patent applications including utility models, petty patents and design patents and certificates of invention, and (d)&nbsp;any and all
extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, reexaminations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or
patent applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.112</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Patent Term Extensions</B>&#148; shall have the meaning provided in
Section&nbsp;8.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.113</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Person</B>&#148; shall mean any individual, partnership, joint venture,
limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.114</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase</B><B></B><B>&nbsp;I Clinical Trial</B>&#148; shall mean a Clinical Trial of a Therapeutic
Product conducted in the United States, European Union or Australia that would satisfy the requirements for a Phase&nbsp;I study as defined in 21&nbsp;CFR &#167;&nbsp;312.21(a) or a Phase I study as defined in ICH E8 Guideline, in each case, as
amended (or its successor regulation). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.115</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase</B><B></B><B>&nbsp;Ib Clinical
Trial</B>&#148; shall mean the cohort expansion phase of a Phase I Clinical Trial of a Therapeutic Product after the Dose Escalation Study portion of such Phase I Clinical Trial that includes the dosing of one or more cohorts of patients at the
recommended dose determined in such Dose Escalation Study, the principal purpose of which cohort expansion phase is to evaluate safety, tolerability and indication of efficacy of such Therapeutic Product in patients, and which cohort expansion phase
would generally be considered a phase Ib Clinical Trial in the oncology field in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.116</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase Ib</B> <B>Data Package</B>&#148; shall mean, with respect to an Arcus Program: (a)&nbsp;all
<FONT STYLE="white-space:nowrap">Top-Line</FONT> Data from the first completed Phase Ib Clinical Trial for a first Therapeutic Product in such Arcus Program, including for each patient <FONT STYLE="white-space:nowrap">follow-up</FONT> results
directed to evaluating safety, tolerability and indication of efficacy of the Therapeutic Product through the period ending on [***] days after the last dosing of the last patient in such Phase Ib Clinical Trial, or if shorter, the <FONT
STYLE="white-space:nowrap">follow-up</FONT> period set forth in the trial protocol, as well as all <FONT STYLE="white-space:nowrap">follow-up</FONT> results from patients in the related Dose Escalation Study of such Therapeutic Product through the
end of such <FONT STYLE="white-space:nowrap">[***]-day</FONT> period, or if shorter, the <FONT STYLE="white-space:nowrap">follow-up</FONT> period set forth in the trial protocol, (b)&nbsp;all Regulatory Filings and substantive Regulatory Documents
then available with respect to such Arcus Program, and (c)&nbsp;if then available, the final clinical trial report from such Phase Ib Clinical Trial and the related Dose Escalation Study. The Phase Ib Data Package for a Therapeutic Product shall
also include the Dose Escalation Data Package for such Therapeutic Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.117</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase II
Clinical Trial</B>&#148; shall mean a Clinical Trial, the principal purpose of which is to make a preliminary determination as to whether a product is safe for its intended use and to obtain sufficient information about such product&#146;s efficacy,
in a manner that is generally consistent with and as defined in 21 CFR &#167; 312.21(b), as amended (or its successor regulation), to permit the design of further Clinical Trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.118</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Phase III Clinical Trial</B>&#148; shall mean a pivotal Clinical Trial with a defined dose or a
set of defined doses of a therapeutic product designed to ascertain efficacy and safety of such product, in a manner that is generally consistent with and as defined in 21 CFR &#167; 312.21(c) as amended (or its successor regulation), for the
purpose and design of establishing with statistical significance that the Therapeutic Product is safe and effective with respect to a given indication sufficient to obtain Marketing Approval for such Therapeutic Product. A Clinical Trial shall not
be deemed a Phase III trial unless it is described as such in the protocol for such trial filed with the applicable Regulatory Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.119</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>PHS Act</B>&#148; means the Public Health Services Act (Title 42, U.S.C., Chapter 6A). As used
herein the PHS Act shall refer, more specifically, to 42 USC &#167; 262, which governs the regulation of biological products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.120</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Post-Breach Continuation</B>&#148; shall have the meaning provided in Section&nbsp;10.2(e). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.121</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Product Materials</B>&#148; shall have the meaning provided in Section&nbsp;4.8(a). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.122</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>PV Agreement</B>&#148; shall have the meaning
provided in Section&nbsp;4.11. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.123</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Receiving Party</B>&#148; shall have the meaning provided in
Section&nbsp;7.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.124</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regional Study Pathway</B>&#148; shall have the meaning provided in
Section&nbsp;5.2(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.125</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>&#147;Registrational Clinical Trial&#148;</B> shall mean, with respect to a
Licensed Product, either (a)&nbsp;a Phase III Clinical Trial for such Licensed Product or (b)&nbsp;a pivotal Phase II Clinical Trial, in each case that, at the time of commencement, is expected to provide an adequate basis for the preparation and
submission of a BLA or NDA to obtain Marketing Approval of such Licensed Product in a Major Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.126</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Authority</B>&#148; shall mean any country, federal, supranational, state or local
regulatory agency, department, bureau or other governmental or regulatory authority having the administrative authority to regulate the development or marketing of pharmaceutical products in any country or other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.127</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Documents</B>&#148; shall mean all correspondence and materials submitted to or
received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority), and all reports and documentation submitted to or received from Regulatory Authorities in connection
with any Regulatory Filing, in each case, related to Option Products, Licensed Products or Companion Diagnostic, as applicable, in the Field, including, by way of example only, advertising and promotion documents, adverse event files and complaint
files. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.128</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Filing</B>&#148; means any approvals, licenses, registrations, submissions
and authorizations, and applications therefor, including IND, NDA, BLA, drug dossier or drug master file filed, or Marketing Approval obtained, with respect to an Option Product, Licensed Product or Companion Diagnostic, as applicable, in the Field,
including all amendments, supplements, annual reports and the like thereof or therefor filed with or otherwise provided to the applicable Regulatory Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.129</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Regulatory Pathway</B>&#148; shall have the meaning provided in Section&nbsp;5.2(d)(iii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.130</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Representatives</B>&#148; shall have the meaning provided in Section&nbsp;7.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.131</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Reverted Product</B>&#148; shall have the meaning provided in Section&nbsp;10.3(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.132</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Royalty Term</B>&#148; shall have the meaning provided in Section&nbsp;5.7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.133</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sales Achievement Milestones</B>&#148; shall have the meaning provided in Section&nbsp;5.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.134</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sale Transaction</B>&#148; shall have the meaning provided in Section&nbsp;13.4(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.135</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>SEC</B>&#148; shall have the meaning provided in Section&nbsp;7.3 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.136</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Securities Disclosure Obligations</B>&#148; shall have the meaning provided in Section&nbsp;7.3.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.137</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Selling Party</B>&#148; shall mean
(a)&nbsp;TAIHO and its Affiliates, [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.138</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Single-Agent Product</B>&#148; shall have the
meaning provided in Section&nbsp;1.103. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.139</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Stage 1 Period</B>&#148; shall mean, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.140</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Stage 2 Period</B>&#148; shall have the meaning provided in Section&nbsp;5.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.141</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Stage 3 Period</B>&#148; shall have the meaning provided in Section&nbsp;5.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.142</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Stanford License</B>&#148; shall have the meaning provided in Section&nbsp;3.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.143</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Subcontractor</B>&#148; shall have the meaning provided in Section&nbsp;3.3(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.144</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Sublicensee</B>&#148; shall mean Third Parties and/or Affiliates to the extent they receive
rights under any sublicense of proprietary Arcus Technology granted by TAIHO hereunder, provided, however, as used herein &#147;Sublicensee&#148; shall not include a wholesaler, reseller or distributor who does not market or promote the Licensed
Product in the applicable country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.145</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>TAIHO Indemnitees</B>&#148; shall have the meaning
provided in Section&nbsp;11.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.146</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>TAIHO Invention</B>&#148; shall mean any Invention made
solely by one or more employees, consultants or contractors of TAIHO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.147</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>TAIHO <FONT
STYLE="white-space:nowrap">Know-How</FONT></B>&#148; shall mean, with respect to a Licensed Product and/or any Companion Diagnostic therefor, all Information that is (a)&nbsp;Controlled by TAIHO prior to the expiration of the Royalty Term for such
Licensed Product and/or Companion Diagnostic, (b)&nbsp;was made by or under the authority of TAIHO or its Affiliate or its or their Sublicensees in connection with the Development and/or Commercialization of such Licensed Product or Companion
Diagnostic and (c)&nbsp;reasonably necessary for or actually used by TAIHO or its Affiliate, or by a Third Party under authority of TAIHO or its Affiliate, in the Development and/or Commercialization of such Licensed Product or Companion Diagnostic
in the Field, but excluding TAIHO&#146;s interest in Joint Inventions. For avoidance of doubt, any particular Information shall be included within TAIHO <FONT STYLE="white-space:nowrap">Know-How</FONT> only if such Information meets the requirements
of each of the foregoing subsections (a), (b) and (c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.148</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>TAIHO Patents</B>&#148; shall mean,
with respect to a Licensed Product and/or any Companion Diagnostic therefor, all Patent Rights that are (a)&nbsp;Controlled by TAIHO prior to the expiration of the Royalty Term for such Licensed Product and/or Companion Diagnostic, (b)&nbsp;claim
inventions made by TAIHO or its Affiliate, or by a Third Party under the authority of TAIHO or its Affiliate or its or their Sublicensees, in connection with the Development and/or Commercialization of such Licensed Product and/or Companion
Diagnostic, and (c)&nbsp;reasonably necessary for or actually used by TAIHO or its Affiliate, or by a Third Party under authority of TAIHO or its Affiliate, in the Development and/or Commercialization of such Licensed Product and/or Companion
Diagnostic in the Field, but excluding TAIHO&#146;s interest in Joint Inventions. For avoidance of doubt, any particular Patent Rights shall be included within TAIHO Patents only to the extent such Patent Rights meets the requirements of each of the
foregoing subsections (a), (b) and (c). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.149</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>TAIHO Regulatory Documentation</B>&#148; shall
have the meaning provided in Section&nbsp;10.3(b)(iv). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.150</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>TAIHO Technology</B>&#148; shall mean
the TAIHO Patents, TAIHO <FONT STYLE="white-space:nowrap">Know-How</FONT> and the TAIHO Inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.151</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>TAIHO Trademarks</B>&#148; shall have the meaning provided in Section&nbsp;10.3(b)(vii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.152</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Target</B>&#148; means a human protein, biomolecule or biological target to which an Antibody,
Compound or Therapeutic Product is directed, which target in each case shall be deemed to include functional fragments, isoforms, and variants thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.153</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Term</B>&#148; shall have the meaning provided in Section&nbsp;10.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.154</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Terminated Products</B>&#148; shall have the meaning provided in Section&nbsp;10.3(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.155</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Territory</B>&#148; shall mean Japan and Asia (excluding mainland China, Hong Kong, and Macao).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.156</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>TGA</B>&#148; shall mean the Therapeutic Goods Administration or any successor Regulatory
Authority thereto in Australia having substantially the same function. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.157</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Therapeutic
Product</B>&#148; shall mean any pharmaceutical formulations containing as active pharmaceutical ingredient an Antibody or a Compound, including a Combination Product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.158</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party</B>&#148; shall mean an entity other than TAIHO and its Affiliates, and Arcus and its
Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.159</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party Acquirer</B>&#148; shall have the meaning provided in
Section&nbsp;13.4(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.160</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party Agreement</B>&#148; shall mean any agreement between Arcus
and any Third Party pursuant to which Arcus Controls any Patent Rights, Information or other intellectual property rights that pertain to the Development or Commercialization of an Antibody or Compound or, unless such agreement is terminated in
accordance with Section&nbsp;9.2(f)(ii), Arcus otherwise first acquired rights to any such Patent Rights, Information or other intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.161</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party License</B>&#148; shall have the meaning provided in Section&nbsp;5.6(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.162</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party Royalties</B>&#148; shall have the meaning provided in Section&nbsp;5.6(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.163</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Third Party Technology</B>&#148; shall have the meaning provided in Section&nbsp;5.6(c)(iii).
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.164</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><FONT STYLE="white-space:nowrap">Top-Line</FONT>
Data</B>&#148; from a Clinical Trial shall mean the audited, quality-controlled tables, listings and figures in reasonable and customary form reflecting all results of the Clinical Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.165</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Valid Claim</B>&#148; shall mean with respect to a Patent Right in a country, any claim of a
(a)&nbsp;issued Patent Right that has not (i)&nbsp;expired, irretrievably lapsed or been abandoned, revoked, dedicated to the public or disclaimed or (ii)&nbsp;been found to be unpatentable, invalid or unenforceable by an unreversed and unappealable
decision of a court or other governmental agency of competent jurisdiction in such country or (b)&nbsp;application for a Patent Right that (i)&nbsp;is within [***] years from the earliest claimed priority date and is being prosecuted in good faith
and has not been abandoned or finally disallowed without the possibility of appeal or <FONT STYLE="white-space:nowrap">re-filing</FONT> and (ii)&nbsp;has not been admitted to be invalid or unenforceable through reissue, reexamination, or disclaimer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.166</B>&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B>Wind-Down Period</B>&#148; shall have the meaning provided in Section&nbsp;10.3(b)(ii). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>O<SMALL>PTION</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1&nbsp;&nbsp;&nbsp;&nbsp;Option. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Grant.</B> Subject to the terms and conditions of this Agreement, with respect to each Arcus Program, Arcus
hereby grants to TAIHO an exclusive option during the Exercise Period for such Arcus Program to obtain&nbsp;an exclusive, <FONT STYLE="white-space:nowrap">royalty-bearing</FONT> license, with the right to sublicense as expressly provided in
Section&nbsp;3.3, under the applicable Arcus Technology and Arcus&#146;s interest in the Joint Technology, but only for the Field in the Territory:&nbsp;to Develop, make, use, sell, have sold, offer for sale, import, and Commercialize the Option
Products in such Arcus Program, solely in the Field, for the Territory, all as described in Section&nbsp;3.1 below (the &#147;<B><I>Option</I></B>&#148;). For the avoidance of doubt, the Option is exercisable only on an Arcus <FONT
STYLE="white-space:nowrap">Program-by-Arcus</FONT> Program basis. TAIHO may not exercise the Option on an Option <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Option</FONT></FONT> Product basis. In other words, TAIHO
must exercise the Option in relation to all Option Products in an Arcus Program and not with respect to select Option Products in an Arcus Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>Diligence</B>. Arcus (directly or through its Affiliates or Arcus Partners) shall use Commercially Reasonable
Efforts to (i)&nbsp;initiate IND Enabling Studies for at least [***] Arcus Programs, each directed to a different Target(s), during the Option Period, and (ii)&nbsp;thereafter to further Develop such Arcus Programs during the applicable Exercise
Period. Subject to the foregoing, TAIHO acknowledges and agrees that [***] and so long as Arcus uses Commercially Reasonable Efforts to do so, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B>Information Sharing</B>. If reasonably requested by TAIHO, Arcus shall provide an update to TAIHO regarding the
Development by or under the authority of Arcus of Option Products during the applicable Exercise Period, including with respect to estimated timelines for initiation of IND Enabling Studies, filing of an IND and IND Acceptance with respect to each
then-lead Option Product within the applicable Arcus Program, and without limiting the foregoing, to notify TAIHO within [***] of each initiation of IND Enabling Studies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of an Option Product. In addition, following execution by Arcus of a Third Party Agreement or Arcus Partner Agreement during the applicable Exercise Period pursuant to which Arcus obtains or
grants rights pertaining to any Option Products, Arcus will, promptly after execution thereof and in conjunction with each item due from Arcus to TAIHO under subsections (i)&nbsp;through (iii) below, provide TAIHO with a copy of such Third Party
Agreement or Arcus Partner Agreement, as applicable. Arcus will provide to TAIHO each Third Party Agreement and Arcus Partner Agreement and related material documents, including all exhibits, attachments and amendments thereto, <I>provided that</I>
Arcus may redact any part of any such Third Party Agreement, and of any related material documents, that are not material to TAIHO&#146;s consideration of whether to exercise the Option with respect to a particular Arcus Program and Arcus may redact
any part of any such Arcus Partner Agreement, and of any related material documents, that are neither relevant to the determination that such agreement would be compliant with Section&nbsp;3.4 below nor material to TAIHO&#146;s consideration of
whether to exercise the Option with respect to a particular Arcus Program. Without limiting Arcus&#146;s obligations under Section&nbsp;9.2(f)(ii), if Arcus desires to amend, modify or terminate in any manner that would materially impair
TAIHO&#146;s rights hereunder any Third Party Agreement, Arcus will promptly notify TAIHO thereof and provide TAIHO an explanation of Arcus&#146;s reasons for desiring such amendment, modification or termination. [***] In addition: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Within [***] after filing the first IND with the FDA, TGA or EMA for an Option Product, Arcus shall provide TAIHO
with all Regulatory Filings (including the IND) and substantive Regulatory Documents relating to such Option Product and thereafter until [***] days after IND Acceptance of such IND, provide to TAIHO all further Regulatory Filings and substantive
Regulatory Documents relating to such Arcus Program within [***] after the submission or receipt of such items to or from the applicable Regulatory Authority; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Within [***] after the first Dose Escalation Data Package for an Option Product in the applicable Arcus Program
is complete, Arcus shall provide TAIHO with such Dose Escalation Data Package. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Within [***] after the first
Phase Ib Data Package for an Option Product in the applicable Arcus Program is complete, Arcus shall provide TAIHO with such Phase Ib Data Package. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp; To facilitate TAIHO&#146;s decision of whether to exercise the Option with respect to a particular Arcus Program
or to extend the Option Period, from time to time until the end of the applicable Exercise Period, Arcus shall, upon TAIHO&#146;s reasonable request, cooperate to permit TAIHO to conduct a reasonable and customary due diligence review of each Arcus
Program, and Arcus shall promptly provide such existing Arcus <FONT STYLE="white-space:nowrap">Know-How</FONT> and, within [***] of TAIHO&#146;s request, provide a Bring-Down Disclosure Schedule, in each case, pertaining to such Arcus Program as is
reasonably requested by TAIHO during such Exercise Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;The items to be provided or made available by
Arcus under this Section&nbsp;2.1(c) may at Arcus&#146;s election either (A)&nbsp;be delivered to TAIHO in tangible or reasonable electronic form or (B)&nbsp;alternatively, if such items are in electronic form, may be made available to TAIHO by
granting personnel designated by TAIHO access (including print access) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to a virtual data room containing such items or (C)&nbsp;a combination of the means described in clauses (A)&nbsp;and (B). If any of the items to be provided or made available by Arcus under this
Section&nbsp;2.1(c) were provided to TAIHO or made available to TAIHO by Arcus as specified in the foregoing clauses (A)&nbsp;through (C), such items shall be deemed to have been timely delivered pursuant to this Section&nbsp;2.1(c) and Arcus shall
not be required to provide them or make them available again after such initial delivery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;If Arcus
determines that after provision of a Bring-Down Disclosure Schedule with respect to an Arcus Program as provided in this Section&nbsp;2.1(c), but prior to TAIHO&#146;s exercise of the applicable Option, that an update to the Bring-Down Disclosure
Schedule is required, but only as a result of facts or circumstances occurring after the delivery the Bring-Down Disclosure Schedule is required pursuant to this Section&nbsp;2.1(c), then Arcus may deliver such updated Bring-Down Disclosure Schedule
to TAIHO. If any such updated Bring-Down Disclosure Schedule is provided less than [***] days before the end of the then-current Option stage (<I>i.e.</I>, less than [***] days before the end of each of Stage 1 Period, Stage 2 Period, or Stage 3
Period), the relevant Option stage shall be extended to the date that is [***] following the delivery by Arcus of any such updated Bring-Down Disclosure Schedule. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp; If and as reasonably requested by TAIHO, Arcus shall provide to TAIHO, to the extent that it has not yet
already been provided, all material data and other Information under Arcus Control regarding the efficacy and side effects of the Option Products and the <FONT STYLE="white-space:nowrap">non-clinical</FONT> use, clinical use, studies,
investigations, or tests of Option Products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<B>Exercise.</B> Subject to the terms and conditions of this
Agreement, TAIHO may, in its sole discretion, exercise the Option with respect to an Arcus Program at any time during the Exercise Period for such Arcus Program by delivering written notice of exercise to Arcus prior to expiration of the Exercise
Period for such Arcus Program, whereupon the License shall immediately and automatically become effective with respect to the Option Products in such Arcus Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<B>Effect of Failure to Exercise Option.</B> If the Exercise Period for the particular Arcus Program expires
without TAIHO having exercised the Option for such Arcus Program in accordance with Section&nbsp;2.1(d), then, effective upon either such expiration, the Option for such Arcus Program shall automatically terminate and be of no further force or
effect, and neither TAIHO nor Arcus shall have any further obligation to the other party with respect to such Arcus Program, and the same shall thereafter cease to be an Arcus Program for all purposes of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<B>Extension of Option Period. </B>In the event that Arcus has not initiated IND Enabling Studies for at least
[***] Arcus Programs prior to the expiration of the Option Period (as such Option Period may be extended according to this Section&nbsp;2.1(f)), TAIHO may, at its option upon written notice to Arcus, extend the Option Period for [***] from and after
the end of the then-current Option Period (<I>i.e.</I>, so that on the first such extension (if any), the Option Period, as extended, runs for [***] years from and after the Effective Date, and on [***] extension (if any), the Option Period, as
extended, runs for [***] years from and after the Effective Date), but in no event shall the Option Period exceed [***] years in total as a result of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any such extension(s). For the sake of clarity, in the event that Arcus has not initiated IND Enabling Studies for at least [***] Arcus Programs prior to the expiration of the original Option
Period, and as a result, TAIHO extends the Option Period for [***] pursuant to this Section, then if Arcus has initiated IND Enabling Studies for at least [***] Arcus Programs prior to the expiration of the first extension of the Option Period
(i.e., [***] years from the Effective Date), TAIHO may not extend the Option Period [***]. TAIHO&#146;s written notice of its desire to extend the Option Period pursuant to this Section must be given, if at all, prior to the expiration of the
then-current Option Period and must be accompanied by a <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> payment to Arcus of [***] dollars (US$[***]), payable <FONT
STYLE="white-space:nowrap">one-time</FONT> only with respect to each such extension. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>E<SMALL>XCLUSIVE</SMALL> D<SMALL>EVELOPMENT</SMALL> <SMALL>AND</SMALL> C<SMALL>OMMERCIALIZATION</SMALL> L<SMALL>ICENSES</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>License Grant </B><B>Upon</B><B> Option Exercise.</B> Subject to the terms and conditions of this
Agreement, and effective automatically as of the date upon which TAIHO exercises the Option in accordance with Section&nbsp;2.1(d) with respect to a particular Arcus Program (the &#147;<B><I>License Date</I></B>&#148;), Arcus shall grant and hereby
grants to TAIHO&nbsp;the following <FONT STYLE="white-space:nowrap">royalty-bearing</FONT> license, with the right to sublicense as expressly provided in Section&nbsp;3.3, under the Arcus Technology and Arcus&#146;s interest in the Joint Technology:
(a)&nbsp;an exclusive (even as to Arcus and its Affiliates), <FONT STYLE="white-space:nowrap">royalty-bearing</FONT> license to Develop and Commercialize the Option Products (and Licensed Products) in such Arcus Program, but only in the Field for
the Territory, (b)&nbsp;a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to Develop and Commercialize only in the Field for the Territory Companion Diagnostics applicable to such Arcus Program, and (c)&nbsp;subject to
Section&nbsp;4.12 below, a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to Develop and manufacture the Option Products (and Licensed Products) in such Arcus Program anywhere in the world only for applications in the Field for the
purpose of Development, obtaining Marketing Approval and Commercializing the Option Products (and Licensed Products) solely in and for the Territory (collectively, the &#147;<B><I>License</I></B>&#148;). Any and all Option Products in Arcus Programs
for which TAIHO has exercised the Option during the applicable Exercise Period and in connection with which it has obtained the License shall be referred to herein as &#147;<B><I>Licensed Products</I></B>&#148;. In the event a License to be granted
by Arcus to TAIHO under the Arcus Technology pursuant to this Section involves Arcus Technology under which Arcus was granted a license by a Third Party then (x)&nbsp;if such Third Party Agreement requires [***]; provided that such Third Party
Agreement, [***] was disclosed to TAIHO in a Bring-Down Disclosure Schedule and (y)&nbsp;Arcus agrees to [***]. Notwithstanding anything to the contrary in this Agreement, neither Arcus nor TAIHO have any obligations to Develop or Commercialize any
Companion Diagnostic, other than as expressly set forth in Section&nbsp;3.5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Arcus</B><B>
License.</B> Subject to the terms and conditions of this Agreement, effective automatically as of the License Date with respect to Licensed Products and their related Companion Diagnostics, TAIHO hereby grants and agrees to grant to Arcus an
exclusive (to the extent of TAIHO&#146;s rights and interests), <FONT STYLE="white-space:nowrap">royalty-free,</FONT> <FONT STYLE="white-space:nowrap">fully-paid</FONT> license, with the right to sublicense through multiple tiers of sublicenses,
under the TAIHO Technology and TAIHO&#146;s interest in the Joint Technology, solely to develop, use, sell, have sold, make, have made, offer for sale, import and otherwise exploit such Licensed Products and Companion Diagnostics in the Field
outside the Territory, and subject to Section&nbsp;4.12 below, a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to manufacture and Develop such Licensed Products and Companion Diagnostics within the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Territory solely for sale and use outside the Territory (collectively, the &#147;<B><I>Arcus</I></B><B><I> License</I></B>&#148;). Subject to the terms and conditions of this Agreement, effective
automatically as of the License Date with respect to a particular Arcus Program for which TAIHO exercises the Option, TAIHO hereby grants and agrees to grant to Arcus a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT
STYLE="white-space:nowrap">royalty-free,</FONT> and <FONT STYLE="white-space:nowrap">fully-paid</FONT> license, with the right to sublicense through multiple tiers of sublicenses, under the TAIHO Technology and TAIHO&#146;s interest in the Joint
Technology, solely to make and have made Licensed Products for the Field for the Territory as reasonably required for Arcus to meet its obligations under Section&nbsp;4.8. Arcus may subcontract any of its rights and obligations to any of its
Affiliates or Third Parties, subject to the other terms of this Agreement, and Arcus shall remain responsible for the performance of any such subcontractors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3&nbsp;&nbsp;&nbsp;&nbsp;Subcontracting and Sublicensing by TAIHO. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Subcontracting.</B> Subject to Section&nbsp;3.3(c), TAIHO may subcontract its Development and/or
Commercialization activities under this Agreement to its Affiliates or to its or its Affiliates&#146; Third Party contractors, sublicensees, manufacturers, contract sales organizations, distributors, wholesalers and resellers. Such Third Parties and
Affiliates, to the extent performing any such activities on behalf of TAIHO, are hereinafter referred to as &#147;<B><I>Subcontractors</I></B>&#148;. For the purposes of this Agreement, TAIHO shall remain responsible and liable for any performance
of any such activities by any such Subcontractors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>Sublicensing.</B> Subject to Sections 3.3(c) and
(d)&nbsp;below, TAIHO may sublicense its rights to Develop and/or Commercialize Licensed Products and Companion Diagnostics under Section&nbsp;3.1, in whole or in part, to any Affiliates or Third Parties engaged in the development, manufacture
and/or sale of pharmaceutical products; provided that any such sublicensing shall be subject to TAIHO providing prompt written notice of any such sublicense to Arcus and, to the extent consent for such sublicensing is required by any Third Party
Arcus licensor under the agreements pursuant to which Arcus first acquired rights to the particular subject matter, subject to such consent. To the extent reasonably requested by TAIHO, Arcus shall fully and reasonably cooperate to obtain such
consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B>Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT></B>. In the event TAIHO or its
Affiliates grant to a Sublicensee directly or indirectly rights to market or commercialize any Licensed Product in the Territory, TAIHO shall obtain the right to Control and include within the TAIHO <FONT STYLE="white-space:nowrap">Know-How</FONT>
and TAIHO Technology, all Information and Patent Rights that: [***]. For avoidance of doubt, (x)&nbsp;TAIHO shall have an obligation to Control and include within the TAIHO <FONT STYLE="white-space:nowrap">Know-How</FONT> and TAIHO Technology [***].
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<B>Conditions.</B> In subcontracting any of its obligations pursuant to Section&nbsp;3.3(a) to Subcontractors
or sublicensing any of its rights under Section&nbsp;3.3(b) to Sublicensees, (i)&nbsp;TAIHO shall not [***], as applicable and (ii)&nbsp;TAIHO shall ensure that [***]. TAIHO shall secure [***]. A copy of any agreement executed by TAIHO with any
Third Party Sublicensees shall be provided to Arcus within [***] days after the execution thereof; provided that [***]. TAIHO shall be responsible to Arcus for [***]. Any such agreement entered into by TAIHO shall also provide that the applicable
Subcontractor and/or Sublicensee shall have [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4&nbsp;&nbsp;&nbsp;&nbsp;Arcus Partners. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;It is understood that Arcus may enter into collaboration and/or partnerships arrangements with one or more Third
Parties for the purpose of Developing and/or Commercializing Option Products, Licensed Product or Companion Diagnostic, and in such case, the intent of the parties is that as a material aspect of this Agreement, TAIHO will have access to and the
right to utilize Information and Patent Rights Developed by such Third Parties as the basis, in whole or in substantial part, for obtaining Marketing Approval of the Licensed Products in the Territory (and for Developing and Commercializing Licensed
Products and Companion Diagnostics for such purpose). Accordingly, in the event Arcus or its Affiliate grants to a Third Party directly or indirectly rights to Develop or Commercialize any Option Product, Licensed Product or a related Companion
Diagnostic in a Major Market (such Third Party, an &#147;<B><I>Arcus</I></B><B><I> Partner</I></B>&#148;), Arcus shall obtain, in all material respects, the right to Control and include within the Arcus
<FONT STYLE="white-space:nowrap">Know-How</FONT> and Arcus Patents, all Information and Patent Rights that [***]. For avoidance of doubt, Arcus shall have an obligation to Control and include within the Arcus
<FONT STYLE="white-space:nowrap">Know-How</FONT> and Arcus Patents [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In addition, except with the written
consent of TAIHO, which consent shall not be unreasonably withheld, conditioned or delayed, Arcus shall obtain the written agreement of such Arcus Partner to be bound by the provisions substantially equivalent to those of Sections [***], and to
provide Information to Arcus sufficient for Arcus to comply with Arcus&#146;s obligations under Section&nbsp;2.1, and [***]. Arcus shall provide to TAIHO a copy of any agreement executed by Arcus with an Arcus Partner
(&#147;<B><I>Arcus</I></B><B><I> Partner Agreement</I></B>&#148;) on or after the applicable License Date for an Arcus Program within [***] days after the execution thereof; provided that the terms of any such agreement may be redacted to the extent
not relevant to the determination that such agreement complies with this Section&nbsp;3.4. Except to the extent TAIHO has consented to the release of obligations under the Flow Down Provisions pursuant to the first sentence of this
Section&nbsp;3.4(b), Arcus shall be responsible to TAIHO for any failure of any Arcus Partners to comply with the Flow Down Provisions and any breach thereof by an Arcus Partner shall be deemed a breach by Arcus of this Agreement. For clarity, TAIHO
shall not be required to pursue any right or remedy it may have against any Arcus Partner as a condition to enforcing its rights under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5&nbsp;&nbsp;&nbsp;&nbsp;Companion Diagnostics. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If either party (including, in the case of Arcus, an Arcus Partner) intends to, itself or with a Third Party,
develop, supply or commercialize a Companion Diagnostic, such party shall promptly notify the other party and, upon the request of the other party, the parties (including the Arcus Partner as required by Arcus if applicable) shall discuss a mutual
agreement and cooperate in good faith to make such Companion Diagnostic available on a global basis. Any such agreement would include provisions on how costs should be shared in connection with the development, supply and commercialization of a
Companion Diagnostic (to be determined taking into account factors such as market share and benefit). In no event shall a party (or an Arcus Partner as required by Arcus) restrict by contract any such Third Party from developing, manufacturing, or
commercializing such Companion Diagnostic for the other party (or an Arcus Partner) or for outside its respective territory, provided that the foregoing shall not limit either party&#146;s rights to enforce the terms of its agreement with any such
Third Party or terminate its agreement with any such Third Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The provisions of Sections 4.1, 4.4, 4.6, 4.10, 4.11, and 4.12 and
Articles 7 - 9 and 11 hereof shall apply with respect to Companion Diagnostics, to the same extent as they apply to Licensed Products, <I>mutatis mutandis</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6&nbsp;&nbsp;&nbsp;&nbsp;Reservation of Rights; License Exclusion. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>By Arcus.</B> Arcus hereby reserves the exclusive right to practice, and to grant licenses under, the Arcus
Technology and Arcus&#146;s interest in the Joint Technology for any and all purposes other than the purposes for which TAIHO has been granted the License. In addition, except as expressly provided in Sections 4.8 and 4.12 below, this Agreement
shall not be construed as limiting Arcus&#146;s (i)&nbsp;research, development, testing or manufacturing of any Licensed Products within the Field or within the Territory for Development or Commercialization of Licensed Products outside the Field or
outside the Territory; (ii)&nbsp;research, Development, testing, manufacturing, promotion, marketing, distribution, sales or other Commercialization activities with respect to any Licensed Products, or its appointment of other Licensed Product
dealers, distributors, licensees, representatives or agents, in each case outside the Field or outside the Territory; (iii)&nbsp;research, development, testing, manufacturing, promotion, marketing, distribution, sales or other commercialization
activities with respect to any product other than Licensed Products or Option Products (but with respect to a particular Option Product, only for so long as TAIHO has the right to exercise the Option with respect to such particular Option Product),
or its appointment of other dealers, distributors, licensees, representatives or agents for any product other than Licensed Products or Option Products (but with respect to a particular Option Product, only for so long as TAIHO has the right to
exercise the Option with respect to such particular Option Product), inside the Field inside the Territory; subject in each case to Section&nbsp;4.12 below; or (iv)&nbsp;rights to make and have made Licensed Products for the Field for the Territory
as reasonably required for Arcus to meet its obligations under Section&nbsp;4.8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>By TAIHO.</B> TAIHO hereby
reserves the exclusive right to practice, and to grant licenses under, the TAIHO Technology and TAIHO&#146;s interest in the Joint Technology for any and all purposes other than the purposes for which Arcus has been granted the Arcus License. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Implied Licenses.</B> No right or license under any Information, Patent Rights or other intellectual
property rights is granted or shall be granted by implication. All rights or licenses are or shall be granted only as expressly provided in the terms of this Agreement. For clarity, no right or license is granted by a party hereunder with respect to
Patent Rights covering the composition of matter of any active pharmaceutical ingredient other than an Antibody or a Compound that is a Licensed Product or Option Product (but with respect to a particular Option Product, only for so long as TAIHO
has the right to exercise the Option with respect to such particular Option Product). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>3.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>License
Registration</B>. Upon TAIHO&#146;s request, Arcus shall (and shall require its Arcus Partners to), at its own expense, promptly register or record the exclusive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
licenses granted to TAIHO under this Agreement with appropriate governmental authorities in Japan and South Korea and TAIHO shall cooperate and assist Arcus (or such Arcus Partners as
applicable), at TAIHO&#146;s own expense, in the preparation of any documents reasonable necessary for such purposes, including, without limitation, drafting and agreeing upon a short form version of this Agreement as necessary for such
registrations and recordings. Without limiting the foregoing, upon TAIHO&#146;s request, Arcus shall (and shall require its Arcus Partners to) promptly register the exclusive licenses granted to TAIHO under this Agreement (a)&nbsp;with respect to
Arcus Patents, as a &#147;Senyo-Jisshiken&#148; in accordance with Article 77 of the Japanese Patent Law, Article 18 of the Japanese Utility Model Act, Article 27 of the Japanese Design Act, and as a &#147;Kari-Senyo-Jisshiken&#148; in accordance
with Article <FONT STYLE="white-space:nowrap">34-2</FONT> of the Japanese Patent Law and (b)&nbsp;with respect to Arcus Trademarks, as &#147;Senyo-Shiyoken&#148; under Article&nbsp;30 of the Japanese Trademark Act, in each case with the applicable
registry maintained in the Japanese Patent Office. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>D<SMALL>EVELOPMENT</SMALL>, M<SMALL>ANUFACTURE</SMALL> <SMALL>AND</SMALL> C<SMALL>OMMERCIALIZATION</SMALL> <SMALL>OF</SMALL> P<SMALL>RODUCTS</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Governance</B>. The parties shall form a joint steering committee (&#147;<B><I>Joint Steering
Committee</I></B>&#148; or &#147;<B><I>JSC</I></B>&#148;) and joint development committee (&#147;<B><I>Joint Development Committee</I></B>&#148; or &#147;<B><I>JDC</I></B>&#148;) within thirty (30)&nbsp;days after the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint Steering Committee</B>. The Joint Steering Committee shall consist of two (2)&nbsp;members, with each
party designating one (1)&nbsp;member, who shall be any officer or employee of the party making such designation, provided that following the first exercise of an Option with respect to any Arcus Program, the Joint Steering Committee shall, unless
otherwise mutually agreed by the parties, consist of four (4)&nbsp;members, with each party designating two (2)&nbsp;members. The Joint Steering Committee shall monitor and discuss the overall plan and progress of the Development and
Commercialization of Antibodies and Compounds with respect to which Arcus intends or already has initiated IND Enabling Studies, for so long as such Antibodies and Compounds may become or are Option Products. Following the first exercise of an
Option with respect to any Arcus Program, the Joint Steering Committee shall additionally perform the following functions: (i)&nbsp;monitor and discuss the overall progress of the Development and Commercialization of the Licensed Products;
(ii)&nbsp;review the status of intellectual property protection for the Licensed Products and any threats or challenges thereto; and (iii)&nbsp;resolve any disputes arising at the Joint Development Committee. The number of members on the Joint
Steering Committee may be adjusted as mutually agreed by the parties. The Joint Steering Committee shall meet in person or by remote means (<I>e.g.</I>, by phone or videoconference) at least once per calendar quarter, and more frequently as mutually
agreed by the parties or as required to resolve any disputes at the Joint Development Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint
Development Committee</B>. Following the first exercise of an Option with respect to any Arcus Program, the Joint Development Committee shall be formed and consist of, unless otherwise agreed by the parties, four (4)&nbsp;members, with each party
designating two (2)&nbsp;members, each of whom shall be any officer or employee of the party making such designation who is not a member of the Joint Steering Committee. The Joint Development Committee shall perform the following functions:
(i)&nbsp;facilitate knowledge transfer for purposes of conducting activities and enabling rights granted hereunder; (ii)&nbsp;communicate and coordinate anticipated Development activities between the parties, and (iii)&nbsp;discuss the status
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and overall progress of the Development of Option Products and Licensed Products. The Joint Development Committee shall meet in person or by remote means (<I>e.g.</I>, by phone or
videoconference) at least once per calendar month, and more frequently as mutually agreed by the parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B>Representation</B>. Each party may (i)&nbsp;replace its representative(s) on the Joint Steering Committee and/or
Joint Development Committee at any time upon written notice to the other party, (ii)&nbsp;designate a substitute officer or employee to temporarily attend and perform the functions of such party&#146;s designee at any meeting of the Joint Steering
Committee and/or Joint Development Committee, as applicable and (iii)&nbsp;on advance written notice to the other party, invite <FONT STYLE="white-space:nowrap">non-member</FONT> employees of such party to attend meetings of the Joint Steering
Committee and/or Joint Development Committee, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<B>Information Sharing</B>. At each meeting of
the JDC, each party will report in reasonable detail on Development activities since the last JDC meeting relating to Licensed Products by or under authority of such party. In addition, each party shall keep the JSC or JDC, as applicable, reasonably
informed with respect to the Licensed Products, including the Development and Commercialization thereof (and, if applicable, Companion Diagnostics), by or under authority of such party, and provide to the JSC or JDC such information as may be
reasonably requested with respect to the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<B>Decisions</B>. All decisions, if any, before the Joint
Steering Committee and Joint Development Committee shall be decided by consensus of the members of the relevant committee or if such consensus cannot be reached at the Joint Development Committee within a reasonable period of time after the matter
is first raised at that committee, then the matter will be submitted to the Joint Steering Committee for resolution. If consensus at the Joint Steering Committee cannot be reached within a reasonable period of time after the matter is first raised
at that committee, then the matter will be escalated for resolution by a senior, top management level executive of each party (who is not a representative on either the Joint Steering Committee or Joint Development Committee).<I> </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>TAIHO Development and Commercialization Responsibilities.</B> From and after TAIHO&#146;s exercise of the
Option with respect to an Arcus Program, and subject to Section&nbsp;4.8, TAIHO shall be solely responsible for the Development and Commercialization of the applicable Licensed Product in the Field in the Territory. Without limiting the generality
of the foregoing, TAIHO (itself or with or through its Sublicensees) shall be solely responsible for preparing and submitting all required Regulatory Filings in connection with obtaining and maintaining Marketing Approvals with respect to such
Licensed Product in the Field in the Territory, at TAIHO&#146;s sole expense. Without limiting Arcus&#146;s rights and title in, and ownership of, its Regulatory Filings and Arcus <FONT STYLE="white-space:nowrap">Know-How,</FONT> all of such
Regulatory Filings submitted for such Licensed Product in the Field in the Territory shall be submitted in the name of, and owned by, TAIHO (or its Sublicensee). Before it begins Developing or Commercializing any Licensed Products within the Field
but outside of cancer in the Territory, TAIHO shall notify Arcus in writing. Without limiting any of TAIHO&#146;s other obligations under this Agreement, TAIHO shall also keep Arcus reasonably informed of its efforts outside of cancer with respect
to Licensed Products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Option Period Studies.</B> Prior to any exercise by
TAIHO of an Option with respect to a particular Arcus Program, if reasonably requested by TAIHO in writing, the parties shall enter into a Materials Transfer Agreement in the form attached hereto under <B>Exhibit 4.3</B> (with such changes as the
parties may agree) under which Arcus would provide to TAIHO quantities of the Option Products and the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right to conduct <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies in relation to
one or more such Option Products, including syngeneic models, solely as reasonably necessary for the purpose of data validation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4&nbsp;&nbsp;&nbsp;&nbsp;Knowledge Transfer. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Initial Technology Transfer.</B> Commencing promptly after each License Date for a particular Licensed Product,
and to the extent not already provided to TAIHO, Arcus shall provide to TAIHO all existing and available to Arcus (in recorded form) Arcus <FONT STYLE="white-space:nowrap">Know-How</FONT> that enabled the filing of the IND by or under authority of
Arcus outside of the Territory for the applicable Licensed Product, all Regulatory Filings and substantive Regulatory Documentation for the applicable Licensed Product and all other Arcus <FONT STYLE="white-space:nowrap">Know-How</FONT> which is
reasonably necessary or useful for the Development or manufacture of the Licensed Product in or for the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>Ongoing Knowledge Transfer. </B>Following the completion of initial technology transfer as described in the
Section above, on an ongoing basis (as appropriate) during the period in which the License with respect to such Licensed Product remains in effect, each party shall disclose to the other party any and all additional Arcus <FONT
STYLE="white-space:nowrap">Know-How,</FONT> TAIHO <FONT STYLE="white-space:nowrap">Know-How,</FONT> Regulatory Filings (for the Major Markets, including with the EMA, in the case of Arcus as the disclosing party) and substantive Regulatory
Documentation in relation thereto as applicable, that is available to such party and generated after the applicable License Date or not previously provided to the other party that is reasonably necessary for the Development and/or Commercialization
of such Licensed Product in the other party&#146;s territory. Without limiting the generality of the foregoing, each party shall provide to the other party, to the extent it has not already done so, existing and available (in recorded form) final
reports of any clinical trial of, and all CMC, pharmacology, toxicology and pharmacokinetic data with respect to, such Licensed Product in the Field, and shall promptly disclose to the other party in writing each Arcus Invention, TAIHO Invention and
Joint Invention, as applicable, for such Licensed Product. In addition, if and as reasonably requested by a party, the other party shall provide to the requesting party, to the extent that it has not yet already been provided, all material data and
other Information under the other party&#146;s Control regarding the efficacy and side effects of the Licensed Products and the <FONT STYLE="white-space:nowrap">non-clinical</FONT> use, clinical use, studies, investigations, or tests of the Licensed
Products. TAIHO agrees that Arcus may share information disclosed hereunder with its Affiliates and its Arcus Partners, subject to Arcus&#146; compliance with Article 7. Arcus agrees that TAIHO may share information disclosed hereunder with its
Affiliates and Sublicensees, subject to TAIHO&#146;s compliance with Article 7. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B>Electronic Transfer.</B> To
the extent available in electronic format, each party may satisfy the requirements to provide items under this Section&nbsp;4.4 by making such items available in such electronic format, provided the other party is able to reasonably access and use
such electronic format using the receiving party&#146;s existing IT systems. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<B>Compliance with Privacy Laws.</B> Upon request by a party, the
other party shall reasonably cooperate with the requesting party, at its own cost, in enabling the requesting party to transfer information required to be transferred under this Agreement, or to use information transferred to it under this Agreement
in accordance with rights granted to it under this Agreement, in each case, in compliance with applicable privacy laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Diligence. </B>TAIHO (directly or through its Sublicensees) shall use Commercially Reasonable Efforts to
Develop, obtain Marketing Approval for, and Commercialize at least one Licensed Product per Arcus Program for the Territory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Disclosure Regarding Development and Commercialization Efforts.</B> TAIHO shall notify Arcus within [***]
days after achieving each milestone event described in Sections 5.2 or 5.3, and each party shall answer any questions, and provide any information, reasonably requested by the other party promptly after any request by the other party. In addition,
(without limiting TAIHO&#146;s obligations under Section&nbsp;4.7 below), each party will, to the extent it is aware and has not already included such update through a JSC or JDC meeting, notify the other party at least [***] days in advance of the
Initiation of each Clinical Trial of a Licensed Product by, on behalf of, or under authority of such party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Development in the Territory.</B> The parties agree that, at least [***]&nbsp;days prior to the proposed
initiation by TAIHO or any of its Sublicensees of (a)&nbsp;any <FONT STYLE="white-space:nowrap">GLP-compliant</FONT> <I>in vivo</I> <FONT STYLE="white-space:nowrap">pre-clinical</FONT> study, the results of which would be required to be reported to
any Regulatory Authority in the Territory to which TAIHO has submitted or proposes to submit an IND or NDA for a Licensed Product, or (b)&nbsp;any Clinical Trial of Licensed Product in the Territory, TAIHO shall deliver to Arcus the draft protocol
for such study or trial for review. Arcus shall review such draft protocol and notify TAIHO within [***] days of Arcus&#146;s receipt thereof if Arcus in good faith believes that the conduct or design of the proposed study or trial poses an
unreasonable risk to the successful Development, registration or Commercialization of Licensed Products in the Field outside the Territory. If Arcus so notifies TAIHO, the parties&#146; Executives shall meet and attempt to resolve any dispute
regarding whether such risk exists and how to address such risk. If the Executives are unable to reach a mutually agreeable resolution within [***], TAIHO shall have the final decision making rights with respect to the conduct or design of the
proposed study or trial, provided, however that TAIHO shall consider Arcus&#146;s concerns in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Manufacture and Supply Arrangements</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Manufacture by CMO.</B> For each Licensed Product, until the first Marketing Approval is obtained for such
Licensed Product in the US or EU (via the EMA centralized procedure), all manufacturing of the Licensed Products for use in IND Enabling Studies or Clinical Trials (including for all purposes of this Section&nbsp;4.8, any components, intermediates,
or active pharmaceutical ingredients thereof, collectively &#147;<B><I>Product Materials</I></B>&#148;) by or on behalf of Arcus or an Arcus Partner shall be performed by one or more established, generally reliable Third Party contract manufacturers
of pharmaceutical products (each, a &#147;<B><I>CMO</I></B>&#148;).<B><I> </I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>Supply by </B><B>Arcus</B>. In the event that Arcus obtains
supply of any Product Materials, Arcus shall obtain such supply pursuant to a CMO Supply Agreement, and shall supply such Product Materials to TAIHO [***], as reasonably requested by TAIHO, under terms and conditions no less favorable as apply to
the supply of such Product Materials to Arcus under such CMO Supply Agreement (subject to Section&nbsp;4.8(b)(ii) below). Arcus shall obtain such supply for TAIHO from the CMO and shall cooperate reasonably to extend to TAIHO the benefits of such
CMO Supply Agreement with respect to such supply, including with respect to ordering, inspection rights, specifications and (subject to Section&nbsp;4.8(b)(ii) below) changes thereto, technology transfer and other provisions of such CMO Supply
Agreement. In addition, Arcus shall use reasonable efforts to pursue any rights and remedies Arcus may have under the CMO Supply Agreement for TAIHO&#146;s benefit with respect to such supply, as reasonably requested by TAIHO, provided that TAIHO
shall [***]. In connection with such supply: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;So long as Arcus exercises its rights under its CMO Supply
Agreements at the request and for the benefit of TAIHO in accordance with this Section&nbsp;4.8, if Arcus is in breach of its supply obligations under this Section&nbsp;4.8 due to the default of a CMO&#146;s obligations under the applicable CMO
Supply Agreement, Arcus&#146; liability for such breach shall [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing in this
Section: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;The prices charged by Arcus for the manufacture and supply of Product Materials shall not exceed
(a)&nbsp;for any such Product Material, to be used in Clinical Trials or otherwise not for commercial sale, the amounts paid by Arcus to the CMO for such Product Materials, and (b)&nbsp;for supply of such Product Materials to be sold commercially by
TAIHO, [***] percent ([***]%) of the transfer price paid to the CMO for such Product Materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;If TAIHO
requests that modifications be made to any Product Materials supplied by the CMO that do not apply to the Product Materials supplied for use by Arcus or an Arcus Partner (or the manufacture, storage or other aspects of such Product Materials or
supply), then [***] Arcus shall cooperate [***] to supply the modified Product Materials to TAIHO under a separate supply agreement and apply such modifications to and for the benefit of the Product Materials to be supplied to TAIHO in accordance
with this Section&nbsp;4.8(b), provided TAIHO shall [***]. For the avoidance of doubt and by way of example, in the event of a modification to the formulation for a Licensed Product and not any other aspect of the Licensed Product (<I>e.g.</I>, the
active pharmaceutical ingredient remains the same), Arcus&#146; obligation to supply the active pharmaceutical ingredient to TAIHO shall not be affected by this Section&nbsp;4.8(b)(ii)(2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in Sections 4.8(b)(ii)(1) and (2)&nbsp;above, [***], and as provided in Section&nbsp;11.1(a),
TAIHO shall not be obligated to bear or share other costs or payments provided for in the CMO Supply Agreement, and shall not be obligated to pay for any Product Materials that TAIHO has not ordered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(4)&nbsp;&nbsp;&nbsp;&nbsp;Arcus shall provide to TAIHO a complete and correct copy of each
of its CMO Supply Agreements within [***] days after the execution thereof, or exercise of the Option with respect to the applicable Licensed Product, whichever occurs later. Prior to entering into a CMO Supply Agreement Arcus shall provide a draft
copy to TAIHO and consider in good faith any timely comments or suggestions with respect to the provisions thereof that TAIHO may provide (it being understood that Arcus is not obligated to obtain TAIHO&#146;s approval of the CMO Supply Agreement or
the provisions thereof). Upon request, Arcus shall cooperate reasonably with TAIHO to enable and facilitate the negotiation and execution by TAIHO of a supply agreement directly between TAIHO and the CMO on reasonable and customary terms. In no
event shall Arcus nor an Arcus Partner restrict by contract any CMO from manufacturing Licensed Product for TAIHO, provided that the foregoing shall not limit Arcus&#146; or an Arcus Partner&#146;s right to enforce the terms of its CMO Supply
Agreement with any such CMO or terminate its agreement with any such CMO (which termination shall not relieve Arcus of its obligations under this Section&nbsp;4.8). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The intent of this Section&nbsp;4.8(b) is that TAIHO be able to obtain supply of Product Materials produced by
the CMO in sufficient quantities, on such timelines and otherwise as is reasonably necessary and customary for TAIHO to Develop and Commercialize the Licensed Products in accordance with and as contemplated by this Agreement. If for any reason TAIHO
or Arcus believes that the provisions of this Section&nbsp;4.8 are insufficient for purposes of such supply (e.g., in substance or clarity), the parties shall negotiate and enter into a supplemental agreement containing such provisions as are
appropriate and reasonable to fulfill such objective, and if the parties are unable to reach agreement on such provisions within [***] days of a request by either Party to enter into such supplemental agreement (which [***] day period may be
extended upon the mutual agreement of the Parties), upon request by either party, the same shall be determined pursuant to Section&nbsp;12.2 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;In the event Arcus obtains supply of Product Materials for a period of time, and then an Arcus Partner takes over
from Arcus responsibility for all supply of any such Product Materials, Arcus shall retain and maintain its CMO Supply Agreement in place between Arcus and the CMO for a reasonable period of time as reasonably requested by TAIHO, to facilitate the
continued supply to TAIHO of such Product Materials from such CMO, until such time as TAIHO, acting in good faith, is able to obtain an acceptable alternative supply arrangement for such Product Materials. If Arcus is retaining and maintaining any
CMO Supply Agreement solely for the benefit of TAIHO, then TAIHO shall [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B>Manufacture for an
</B><B>Arcus</B><B> Partner. </B>Similarly, if an Arcus Partner obtains supply of Product Materials other than from Arcus, Arcus: (i)&nbsp;shall require the Arcus Partner to obtain such supply from a CMO pursuant to a CMO Supply Agreement, and to
supply such Product Materials to TAIHO [***], as reasonably requested by TAIHO, under terms and conditions no less favorable as apply to the supply of such Product Materials to such Arcus Partner under such CMO Supply Agreement, and require the
provisions of this Section&nbsp;4.8 to apply to the Arcus Partner and such supply in the same manner as they apply to Arcus, <I>mutatis mutandis </I>(including Section&nbsp;4.8(b)(iii) above), or (ii)(A) if the Arcus Partner has at least equivalent
capabilities of an established CMO that has the capabilities and capacity to manufacture pharmaceutical products on a commercial scale, (B)&nbsp;Arcus has retained the right to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Commercialize the applicable Licensed Products in a Major Market and (C)&nbsp;such Arcus Partner is supplying Product Materials itself to Arcus for all of Arcus&#146;s requirements of applicable
Product Materials for such Major Market, shall require the Arcus Partner to supply such Product Materials to TAIHO, as reasonably requested by TAIHO, under terms and conditions no less favorable as apply to the supply of such Product Materials to
Arcus or any other Arcus Partner, or (iii)(A) if Arcus has not retained the right to Commercialize the applicable Licensed Products in a Major Market, (B)&nbsp;prior to the execution of the relevant Arcus Partner Agreement, Arcus used a CMO to
supply the applicable Licensed Product to Arcus for use in clinical trials under one or more CMO Supply Agreements (&#147;<B><I>Transitioned CMO Supply Agreements</I></B>&#148;), and (C)&nbsp;such Arcus Partner is not supplying Product Materials to
Arcus for a Major Market, shall require the Arcus Partner to supply such Product Materials to TAIHO in accordance with the terms of the foregoing subclause (i)&nbsp;utilizing such a CMO or, if the Arcus Partner has at least equivalent capabilities
of an established CMO that has the capabilities and capacity to manufacture pharmaceutical products on a commercial scale, shall require the Arcus Partner to supply directly to TAIHO such Product Materials, as reasonably requested by TAIHO, under
reasonable terms and conditions acceptable to TAIHO, provided that Arcus shall, or Arcus shall require such Arcus Partner to, retain and maintain, as applicable, such Transitioned CMO Supply Agreements or any other CMO Supply Agreements entered into
by such Arcus Partner with the same CMO as the CMO that was party to the Transitioned CMO Supply Agreements for the applicable Product Materials, in place for [***], or a shorter period as mutually agreed by the Parties, following the date on which
Arcus provides TAIHO with written notice of the Arcus Partner&#146;s intent to supply itself with any Product Materials rather than obtain supply of such Product Materials from a CMO pursuant to such CMO Supply Agreement; provided further that if
Arcus or the Arcus Partner is retaining and maintaining such Transitioned CMO Supply Agreements or other CMO Supply Agreements, as applicable, solely for the benefit of TAIHO, then TAIHO [***]. If TAIHO&#146;s ability to rely on or otherwise utilize
any Regulatory Filings or Regulatory Documentation, or otherwise on any Arcus <FONT STYLE="white-space:nowrap">Know-How,</FONT> in each case relating to the relevant Licensed Product, would be impaired by not having supply of Product Material
manufactured by such CMO or such Arcus Partner, then Arcus shall require such Arcus Partner to supply TAIHO with such Product Material manufactured by such CMO or such Arcus Partner in accordance with the foregoing subclauses (i), (ii) or (iii), as
the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<B>TAIHO Independent Supply</B>. For clarity, and without limiting any of the foregoing, it
is understood that TAIHO may manufacture, or obtain from another source supply of, some or all of its requirements of a Licensed Product (including, for clarity and subject to Section&nbsp;1.49, any modified formulation of or packaging for a
Licensed Product), or any Product Materials at any time and from time to time. In addition, it is understood the Product Materials supplied to TAIHO under this Section&nbsp;4.8 may be used for any Development or Commercialization activities
permitted to be conducted by TAIHO in accordance with this Agreement (<I>i.e.</I>, not just in IND Enabling Studies and Clinical Trials, but Commercialization and other permitted Development activities as well). If TAIHO wishes to manufacture
itself, or have manufactured, a Licensed Product and/or Product materials, without limiting Section&nbsp;4.4(b) above, Arcus shall, and shall require any applicable Arcus Partner or CMO to, provide technical assistance as reasonably requested by
TAIHO to promptly transfer to TAIHO or its designee the production process for the manufacture of such Licensed Product or Product Material, as applicable, including without limitation the manufacturing methods, test methods, specifications,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
materials, and other procedures, directions and controls associated with the manufacture and testing of such Licensed Product or Product Material, as the case may be, used by Arcus, its Arcus
Partners and/or a CMO, to the extent Arcus, such Arcus Partner and/or such CMO Controls such parts of such production process. Arcus shall, and Arcus shall require any such Arcus Partner to, provide such assistance without charge, provided that,
TAIHO shall [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Performance Standards.</B> TAIHO shall conduct, or have conducted, all Licensed
Product Development and Commercialization in accordance with the terms and conditions of this Agreement. In addition, each party (directly or through its Sublicensees) shall use Commercially Reasonable Efforts to perform all such activities in good
scientific manner and in compliance with all Applicable Laws and, as applicable, GLP, GCP and/or GMP. TAIHO shall use Commercially Reasonable Efforts to ensure that any and all Licensed Products manufactured by or on behalf of it meets any and all
specifications for such Licensed Products applicable in the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.10&nbsp;&nbsp;&nbsp;&nbsp;Rights of Access and Reference to
Regulatory Documents. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Effective as of the applicable License Date, TAIHO hereby grants to Arcus the right
to access and reference all Regulatory Filings submitted to, and Marketing Approvals obtained from, any Regulatory Authority in the Territory by TAIHO or any of its Sublicensees for the applicable Licensed Products; in each case, solely for the
purposes of (i)&nbsp;obtaining and maintaining Regulatory Approvals for such Licensed Products in the Field outside the Territory, and (ii)&nbsp;complying with applicable pharmacovigilance and other regulatory requirements with respect to such
Licensed Products outside the Territory. Arcus shall have the right to grant access and reference to such Regulatory Filings and Marketing Approvals to its Affiliates and to its sublicensees and their Affiliates solely for the purposes described in
the foregoing clauses (i)&nbsp;and (ii). TAIHO shall, promptly upon Arcus&#146;s request, file with the applicable Regulatory Authority(ies) such letters of access or reference as may be necessary to accomplish the intent of this
Section&nbsp;4.10(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Effective as of the applicable License Date, Arcus hereby grants to TAIHO the right to
access and reference all Regulatory Filings submitted to, and Marketing Approvals obtained from, any Regulatory Authority for a Major Market, including the EMA, by or under authority of Arcus for the applicable Licensed Product; in each case, solely
for the purposes of (i)&nbsp;obtaining and maintaining Regulatory Approvals for such Licensed Product in the Field in the Territory, and (ii)&nbsp;complying with applicable pharmacovigilance and other regulatory requirements with respect to such
Licensed Product in the Territory. TAIHO shall have the right to grant access and reference to such Regulatory Filings and Marketing Approvals to its Affiliates and to its Sublicensees and their Affiliates solely for the purposes described in the
foregoing clauses (i)&nbsp;and (ii). Arcus shall, promptly upon TAIHO&#146;s request, file with the applicable Regulatory Authority(ies) such letters of access or reference as may be necessary to accomplish the intent of this Section&nbsp;4.10(b).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.11</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Safety Data Exchange.</B> Each party shall be solely responsible, at its own expense, for complying
with all applicable regulatory requirements with respect to Licensed Products in such party&#146;s territory (i.e., the Territory in the case of TAIHO and outside the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Territory in the case of Arcus), including all safety reporting to Regulatory Authorities in such party&#146;s territory. The parties shall, promptly upon reasonable request by either party,
negotiate in good faith and enter into a pharmacovigilance/safety data exchange agreement for Licensed Product (each, a &#147;<B></B><B><I>PV Agreement</I></B><B></B>&#148;), which shall set forth standard operating procedures governing the
collection, investigation, reporting, and exchange of information concerning adverse drug reactions/experiences. The terms of each PV Agreement shall be no less stringent than those required by FDA, Japanese Regulatory Authorities and ICH guidelines
(unless such FDA, Japanese Regulatory Authorities and ICH guidelines conflict with guidelines promulgated by any Regulatory Authority having jurisdiction in the Territory, which guidelines shall control for the Territory) and shall be sufficient to
permit each party to comply with its regulatory and legal requirements for the management and reporting of safety data regarding the applicable Licensed Product by providing for the exchange of relevant information in appropriate format within
applicable timeframes. Each PV Agreement shall provide for Arcus to establish and manage the core database in relation to all such safety reporting activities. In the event the terms of a PV Agreement cannot be fully agreed, the same shall be
determined in accordance with Section 12.2 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.12</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Clinical Studies in Other
Party</B><B>&#146;</B><B>s Territory</B>. Each party shall be entitled to conduct Clinical Trials and other Development activities with respect to the Licensed Products in countries of the other party&#146;s territory solely for purposes of
obtaining Marketing Approvals in its own territory, provided that (a)&nbsp;TAIHO shall not conduct or authorize any Third Party to conduct any human clinical studies of a Licensed Product in a Major Market without Arcus&#146;s consent, and
(b)&nbsp;Arcus shall not conduct or authorize a Third Party to conduct any human clinical studies of a Licensed Product or Option Product in Japan, without TAIHO&#146;s consent; in each case, which consent shall not be unreasonably withheld. It is
understood that after Marketing Approval has been obtained in a Major Market or Japan with respect to a Licensed Product, this Section&nbsp;4.12 shall not prevent, and each party shall have the right, to conduct Clinical Trials of another product of
such party in which such Licensed Product is used as a comparator or combination agent in the indication being studied, provided that if a party wants to conduct any such Clinical Trials outside of its respective territory in which such Licensed
Product is used in combination with such other product of such party, then such party must first obtain the other party&#146;s prior written consent to do so, which consent shall not be unreasonably withheld. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>F<SMALL>INANCIAL</SMALL> T<SMALL>ERMS</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Option Fee.</B> As partial consideration of Arcus&#146;s grant of the Option to TAIHO hereunder, TAIHO
shall pay to Arcus <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> Option fees as follows: (a)&nbsp;a <FONT STYLE="white-space:nowrap">one-time</FONT> payment of [***] dollars (US$[***])
within [***] days after TAIHO&#146;s receipt of an invoice from Arcus following the Effective Date; (b) [***] payments of [***] dollars (US$[***]) each, the [***] payment due within [***] after TAIHO&#146;s receipt of an invoice from Arcus following
the Effective Date and the [***] payments due [***] days after TAIHO&#146;s receipt of an invoice following the [***] and [***] anniversaries of the Effective Date respectively; and (c)&nbsp;Option exercise payments (in the applicable amount set
forth in the table below) (&#147;<B><I>Option Exercise Payments</I></B>&#148;) within [***] days after TAIHO&#146;s receipt of an invoice from Arcus following any exercise by TAIHO of the Option for a particular Arcus Program, based on when the
Option is so exercised: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:94.95pt; font-size:8pt; font-family:Times New Roman"><B>Option Exercise Timeframe</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Option Exercise Payment Amount</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prior to the end of the Stage 1 Period for the applicable Arcus Program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***] (the &#147;<B><I>Stage 2 Period</I></B>&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***] (the &#147;<B><I>Stage 3 Period</I></B>&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Development and Regulatory Milestone Payments.</B> With
respect to each Arcus Program for which TAIHO exercised the Option and has been granted the License, TAIHO shall, subject to the terms of this Section&nbsp;5.2, pay to Arcus the corresponding (depending on regulatory pathway and indication) <FONT
STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> milestone payment within [***] days after TAIHO&#146;s receipt of an invoice from Arcus
following the first achievement, by TAIHO or any of TAIHO&#146;s Sublicensees, of each of the milestone events set forth in the applicable table below by a Licensed Product in such Arcus Program (&#147;<B><I>Development and Regulatory
Milestones;</I></B>&#148; and such payments &#147;<B><I>Development and Regulatory Milestone Payments</I></B>&#148;). For the sake of clarity and as an example only, if TAIHO exercises the Option with respect to six (6)&nbsp;Arcus Programs, then
TAIHO may owe to Arcus a particular milestone payment up to six (6)&nbsp;times. TAIHO shall notify Arcus in writing within [***] days after the Achievement of any Development and Regulatory Milestones. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Global Studies</B><I>.</I> The milestones in the table immediately below in this Section&nbsp;5.2(a) shall be
due upon Achievement (<I>i.e.</I>, by TAIHO or its Sublicensee) of such milestones so long as TAIHO or its Sublicensee would be able (in TAIHO&#146;s opinion, acting in good faith) and intends to obtain Marketing Approval based solely on Arcus <FONT
STYLE="white-space:nowrap">Know-How</FONT> and clinical data from Global Studies conducted by or under authority of Arcus or its Affiliates (&#147;<B><I>Global Study Pathway</I></B>&#148;). For avoidance of doubt, the milestones in the table
immediately below shall not be due if TAIHO determines (in its opinion, acting in good faith) not to pursue the Global Study Pathway for the particular Licensed Product, and TAIHO or its Sublicensee conducts a Clinical Trial for such Licensed
Product that is not a part of the Global Studies. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.25pt; font-size:8pt; font-family:Times New Roman"><B>Milestone</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>[***] Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>[***] Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>[***] Indication</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[***]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>Bridging Study in Territory</B><I>. </I>The milestones in the table immediately
below in this Section&nbsp;5.2(b) shall be due upon Achievement of such milestones so long as TAIHO or its Sublicensee is able (in TAIHO&#146;s opinion, acting in good faith) and intends to obtain Marketing Approval based solely on Arcus <FONT
STYLE="white-space:nowrap">Know-How</FONT> generated from Clinical Trials conducted by, or by a Third Party under authority of, Arcus or its Affiliates and a Bridging Study conducted by TAIHO or its Sublicensee in the Territory (&#147;<B><I>Bridging
Study Pathway</I></B>&#148;). For avoidance of doubt, the milestones in the table immediately below shall not be due if TAIHO determines (in its opinion) not to pursue the Bridging Study Pathway for the applicable Licensed Product and TAIHO or its
Sublicensee conducts a human clinical study of such Licensed Product that is not a Bridging Study (in which case Section&nbsp;5.2(a) above or 5.2(c) below shall apply). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.25pt; font-size:8pt; font-family:Times New Roman"><B>Milestone</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>[***] Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>[***] Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>[***] Indication</B></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B>Regional
Study</B>. The milestones in the table immediately below in this Section&nbsp;5.2(c) shall be due upon Achievement of such milestones where Section&nbsp;5.2(a) and 5.2(b) do not apply to such Achievement (&#147;<B><I>Regional Study
Pathway</I></B>&#148;). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.25pt; font-size:8pt; font-family:Times New Roman"><B>Milestone</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>[***] Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>[***] Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>[***] Indication</B></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Certain
Matters: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<B>Maximum Total Milestone Payments.</B> Each of the foregoing milestone payments shall be paid no
more than once for an Arcus Program for the first Achievement of the corresponding event by TAIHO or its Sublicensee with respect to a Licensed Product in such Arcus Program (regardless of the number of times such event is achieved by other Licensed
Products in such Arcus Program), and in no event shall the cumulative milestones payments for an Arcus Program exceed the amounts that would be paid if only the Global Study Pathway was followed. For clarity: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;In no event will the total milestone payments for a given Arcus Program exceed [***] for all Regulatory Pathways
and Indication Categories combined, and if all Marketing Approvals within the Development and Regulatory Milestones for an Arcus Program are obtained based on the Regional Study Pathway (<I>i.e.</I>, based on neither the Global Study Pathway nor the
Bridging Study Pathway) the total milestone payments for such Arcus Program will not exceed [***] for all Indication Categories combined; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;In no event will the total Development and Regulatory Milestone Payments for a given Arcus Program exceed [***]
for the [***] Indication, [***] for the [***] Indication or [***] for all [***] Indications combined, and if all Marketing Approvals within the Development and Regulatory Milestones for an Arcus Program are obtained based on the Regional Study
Pathway (<I>i.e.</I>, based on neither the Global Study Pathway nor the Bridging Study Pathway), the total Development and Regulatory Milestone Payments for such Arcus Program shall not exceed [***] for the [***] Indication, [***] for the [***]
Indication or [***] for [***] Indications combined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<B>Discontinued Licensed Product</B>. If Development of
a Licensed Product within an Arcus Program is terminated after TAIHO has made one or more milestone payments on Achievement of one or more Development and Regulatory Milestones by such Licensed Product but prior to First Commercial Sale of such
Licensed Product, then TAIHO shall have the right to credit and offset all such milestone payments actually made against other payments due to Arcus under this Article 5 with respect to any other Licensed Product within such Arcus Program, and all
such Development and Regulatory Milestones shall be deemed to not have been Achieved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<B>Skipped Milestones</B>. Except as otherwise provided below,
if a subsequent milestone within a given regulatory pathway (<I>i.e.</I>, the Global Study Pathway, Bridging Study Pathway or Regional Study Pathway, each a &#147;<B><I>Regulatory Pathway</I></B>&#148;) for an indication category (<I>i.e.</I>, [***]
Indication, [***] Indication, and [***] Indication, each an &#147;<B><I>Indication Category</I></B>&#148;) within an Arcus Program is Achieved prior to one or more particular milestone(s) of an earlier stage (determined by reference to the milestone
numbers 1, 2, 3, 4, each a &#147;<B><I>Milestone Stage</I></B>&#148;) within such given Regulatory Pathway for such Indication Category within such Arcus Program, then the prior, previously unpaid milestone(s) shall be deemed to have been met for
such given Regulatory Pathway and Indication Category within such Arcus Program, and the corresponding milestone payment(s) shall become due and payable to Arcus within [***] days after the later of TAIHO&#146;s receipt of an invoice from Arcus for
such amounts and [***]. For example, if the Global Study Pathway milestones apply and the parties conduct a Phase II Global Study for a [***] Indication, and then TAIHO or its Sublicensee files a first NDA or BLA in Japan for a [***] Indication
based on the results of such Clinical Trial without conducting a Phase III Global Study, milestone 2 of the Global Study Pathway for such [***] Indication will be due upon the filing of such NDA or BLA. Notwithstanding the foregoing: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;<B>Achievement of Milestone in One Regulatory Pathway Deemed Achievement of the Corresponding Milestone for All
Regulatory Pathways</B>. For a given Arcus Program, if the milestone for a particular Milestone Stage (<I>i.e.</I>, milestone 1, 2, 3 or 4 under Sections <FONT STYLE="white-space:nowrap">5.2(a)-5.2(c)</FONT> above) has been Achieved with respect to
a given Indication Category in one Regulatory Pathway, the milestone of such Milestone Stage and Indication Category shall be deemed to have been Achieved for the same Milestone Stage and Indication Category for all other Regulatory Pathways with
respect to such Arcus Program, provided that no milestone payment will be owed by TAIHO by reason of any such deemed Achievement. For example, if a Licensed Product of an Arcus Program Achieves milestone 2 under the Global Study Pathway (Initiation
of a Phase III Clinical Trial that is a Global Study) for a [***] Indication and then later Achieves milestone 2 under the Bridging Study Pathway (Initiation of a Bridging Study) for another [***] Indication, the milestone payment for such later
Achievement of such milestone 2 shall be paid as a milestone for the [***] Indication under the Bridging Study Pathway (<I>i.e.</I>, because milestone 2 for the [***] Indication under the Bridging Study Pathway shall be deemed to already have been
achieved). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;<B>No Deemed Achievement by Reason of Switched Indication Category</B>. Notwithstanding Sections
5.2(d)(iii) and 5.2(d)(iii)(1) above, for a given Licensed Product, if such Licensed Product [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;<B>Milestone Reconciliation </B><B>Upon</B><B> Marketing Approval</B>. Upon first receipt of Marketing Approval
in Japan for a Licensed Product (&#147;<B><I>Approved Licensed Product</I></B>&#148;) for a given indication, as determined by the approved label (&#147;<B><I>Approved Indication</I></B>&#148;) and under a given Regulatory Pathway, as determined at
the time of such Marketing Approval (&#147;<B><I>Approval Pathway</I></B>&#148;), the prior Achievement of milestones with respect to the Approved Licensed Product and other Licensed Products within the same Arcus Program shall be
re-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determined and reconciled as if such Approved Licensed Product had only Achieved milestones within such Approval Pathway and for the Approved Indication (taking into account all other milestones
that have been Achieved with respect to the applicable Arcus Program as of the date of such Marketing Approval). In such event: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman">a.&nbsp;&nbsp;&nbsp;&nbsp;If any additional milestone payments are owed as a result of such
<FONT STYLE="white-space:nowrap">re-determination</FONT> and reconciliation under this Section&nbsp;5.2(d)(iv), then such additional milestone payments shall be due [***] days after the later of TAIHO&#146;s receipt of an invoice from Arcus for such
amounts and [***]. Additionally, if an additional milestone payment is made under this paragraph, then the milestone for which such milestone payment is made shall be deemed to have been Achieved. For clarity, in no case shall payments made by
TAIHO, including after <FONT STYLE="white-space:nowrap">re-determination</FONT> and reconciliation under this Section&nbsp;5.2(d)(iv), exceed the milestone caps as set forth in Section&nbsp;5.2(d)(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:21%; font-size:10pt; font-family:Times New Roman">b.&nbsp;&nbsp;&nbsp;&nbsp;Conversely, if the payments previously made with respect to such Arcus Program (or with respect to a Licensed
Product, Regulatory Pathway or Indication Category within such Arcus Program) exceed the total milestones that would have been due pursuant to such <FONT STYLE="white-space:nowrap">re-determination</FONT> and reconciliation under this
Section&nbsp;5.2(d)(iv) or the applicable milestone caps set forth in Section&nbsp;5.2(d)(i), then [***].&nbsp;Additionally, if the amount previously paid with respect to a milestone is so [***], such milestone shall be deemed not to have been
Achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Commercialization Milestone Payments.</B> With respect to each Arcus Program for which
TAIHO has exercised the Option and been granted the applicable License, TAIHO shall pay to Arcus the corresponding <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT
STYLE="white-space:nowrap">non-creditable</FONT> milestone payment within [***] days after TAIHO&#146;s receipt of an invoice from Arcus following the first Achievement, whether by TAIHO or any of TAIHO&#146;s Sublicensees, alone or in combination,
of each of the milestone events set forth in the table below by the first Licensed Product in such Arcus Program for which Net Sales in the Territory Achieve such Sales Achievement Milestone. For the sake of clarity and as an example only, if TAIHO
exercises the Option with respect to six (6)&nbsp;Arcus Programs, then TAIHO may owe to Arcus each of the milestone payments listed in the table below once per Arcus Program, for a total of up to six (6)&nbsp;times across all six (6)&nbsp;Arcus
Programs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="37%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Milestone</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:169.65pt; font-size:8pt; font-family:Times New Roman"><B>(collectively, the &#147;Sales Achievement Milestones&#148;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Milestone Payment</B><br><B>(collectively,&nbsp;the&nbsp;&#147;Commercialization</B><br><B>Milestone Payments&#148;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the foregoing milestone payments will be paid only once for an Arcus Program, for the first
Achievement of the corresponding event by a Licensed Product in such Arcus Program. In determining cumulative Net Sales, Net Sales of Licensed Product for one indication will be added to Net Sales of the same Licensed Product for other indications.
If a subsequent milestone is achieved prior to one or more particular milestone(s) being met for a particular indication, then the prior, previously unpaid milestone(s) shall be deemed to have been met for such indication, and the corresponding
milestone payments shall become due and payable to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Arcus. Notwithstanding the foregoing, if more than one of the foregoing milestone payments for the Sales Achievement Milestones becomes due in the same TAIHO fiscal year, then the second and
subsequent of such payments will be due [***]. Net Sales of a Licensed Product that is a Combination Product that includes an Antibody or a Compound from more than one Arcus Program shall be allocated to the applicable Arcus Program in accordance
with the provisions in the definition of Net Sales with respect to Combination Products (<I>i.e.</I>, <I>mutatis mutandis</I>, treating the Antibody or Compound from such other Arcus Program as an Other Active). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Certain Deductions from Option Exercise Fees and Milestone Payments. </B>Notwithstanding Sections <FONT
STYLE="white-space:nowrap">5.1-5.3</FONT> above, in the event that TAIHO concurrently exercises an Option with respect to Licensed Products from two (2)&nbsp;or more Arcus Programs that are being Developed as a combination therapy (an
&#147;<B><I>Intra-Portfolio</I></B><I> </I><B><I>Combination</I></B>&#148;) then each Option Exercise Payment and Development and Regulatory Milestone Payment for such Licensed Products included in such Intra-Portfolio Combination will be reduced by
[***] percent ([***]%). If TAIHO or a Sublicensee obtains Marketing Approval of one (1)&nbsp;or more of the Licensed Products in an Intra-Portfolio Combination for use as a single agent prior to obtaining Marketing Approval for the Intra-Portfolio
Combination, then TAIHO will pay Arcus the portion of the Option Exercise Payments and Development and Regulatory Milestone Payments with respect to each such Licensed Product as a single agent that was discounted pursuant to the preceding sentence
(<I>i.e.</I>, TAIHO shall pay the remaining [***] percent ([***]%) of such Option Exercise Payments and Development and Regulatory Milestone Payments). Such amounts shall be paid by TAIHO to Arcus within [***] days after TAIHO or a Sublicensee
obtains Marketing Approval of such one (1)&nbsp;or more of the Licensed Products as a single agent. There will be no discounts to any Commercialization Milestone Payments or any royalty payments based on such Intra-Portfolio Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Royalties.</B> Subject to Sections&nbsp;5.6 and 5.7, TAIHO shall pay royalties to Arcus on annual Net
Sales of a Licensed Product in the Territory by TAIHO and its Sublicensees in each calendar year at the applicable rate(s) set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:99.25pt; font-size:8pt; font-family:Times New Roman"><B>Annual Net Sales Increments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty<BR>Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***]</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, if annual Net Sales of a Licensed Product in the Territory is $3,800,000,000, then the royalty
payable by TAIHO to Arcus would be calculated as [***]. In determining annual Net Sales, Net Sales of Licensed Product for one indication will be added to Net Sales of the same Licensed Product for other indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***]. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6&nbsp;&nbsp;&nbsp;&nbsp;Royalty Adjustments. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Generic Products</B>. If one or more Generic Products (other than a Generic Product sold by TAIHO or any of its
Affiliates or Sublicensees) with respect to a Licensed Product is sold commercially in a particular country in the Territory during a particular calendar </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
quarter (&#147;<B><I>Generic Product Presence</I></B>&#148;), and during such calendar quarter the Net Sales of such Licensed Product has decreased by [***] percent ([***]%) or more when compared
to peak Net Sales of such Licensed Product in such country in [***] prior to such Generic Product Presence, and such decrease is attributable to such Generic Product Presence (&#147;<B><I>Generic Competition</I></B>&#148;), then, only for so long as
such Generic Competition continues to exist, the royalty rate (used with Net Sales to determine royalty payments) for such Licensed Product in such country during such calendar quarter will be reduced by [***] percent ([***]%) for purposes of
determining TAIHO&#146;s obligation to make royalty payments under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>Payments on Third Party
Intellectual Property</B>. If, following the Effective Date, it is necessary for TAIHO (or its Sublicensee) to obtain from one or more Third Parties rights to intellectual property in order to Develop or Commercialize any Licensed Product in the
Field in the Territory, TAIHO will have the sole right to, and may, in its sole discretion, negotiate and obtain a license under such intellectual property (each such Third Party license is referred to herein as a &#147;<B><I>Third Party
License</I></B>&#148;). Intellectual property from a Third Party will be deemed &#147;necessary&#148; under this Section if such rights are reasonably necessary for avoiding or preventing infringement or misappropriation of Third Party intellectual
property rights in connection with, or otherwise actually required for, the Development or Commercialization of the applicable Licensed Product in the Field in the Territory. Except as set forth in this Section or to the extent of any Third Party
claim for which Arcus provides indemnification under Section&nbsp;11.2, or as the parties may otherwise agree in writing, TAIHO shall bear any payments associated with any payments owed to any Third Party for such a Third Party License
(collectively, the &#147;<B><I>Third Party Royalties</I></B>&#148;). TAIHO may credit up to [***]percent ([***]%) of the amount of any Third Party Royalties paid by TAIHO under a Third Party License pursuant to this Section against amounts payable
to Arcus under Article 5 in accordance with Section&nbsp;5.9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B>Arcus
<FONT STYLE="white-space:nowrap">In-License</FONT> Technology</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;In the event that Arcus intends to obtain
a right or license to intellectual property or other subject matter, Arcus will use good faith efforts to include all of the countries within the Territory in such right or license, provided that nothing herein shall require Arcus to obtain rights
and licenses to any of the countries in the Territory except on such terms and conditions that Arcus deems acceptable in its sole and reasonable discretion, provided further that if Arcus does not obtain any such rights and licenses in and for Japan
with respect to any Arcus Program, such Arcus Program shall not be considered an Arcus Program under Sections 2.1(b) or 2.1(f) for the purpose of determining whether Arcus has initiated IND Enabling Studies for at least [***] Arcus Programs. If
Arcus obtains a right or license to intellectual property or other subject matter, Arcus shall, for so long as TAIHO has an Option or License to such intellectual property or other subject matter, Control such intellectual property and other subject
matter, with the right to license or sublicense the same to TAIHO hereunder on terms no less favorable than apply to Arcus and any other Arcus Partners, and, to the extent TAIHO is responsible for any payments thereunder pursuant to
Section&nbsp;5.6(c)(iii), on a proportionate basis with respect to TAIHO&#146;s payment obligations, taking into account the relative size of the market in the Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;It is understood and agreed that Arcus shall be responsible for
any and all payments due to a Third Party, including an Arcus Partner, under a Third Party Agreement pursuant to which Arcus obtains a right or license to intellectual property or other subject matter included in the Arcus Technology, or relates to
any applicable Antibodies or Compounds directed to the Target(s) of an Arcus Program or the applicable Target(s) of an Arcus Program, and which is entered into by Arcus prior to TAIHO exercising its Option with respect to the applicable Arcus
Program pursuant to Section&nbsp;2.1(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;If, following the License Date with respect to an Arcus Program,
Arcus enters into a Third Party Agreement with a Third Party (other than an Arcus Partner) under which Arcus obtains a right or license to intellectual property or other subject matter included in the Arcus Technology to the extent directed to such
Arcus Program or that relates to any applicable Antibodies or Compounds directed to the Target(s) of such Arcus Program or the applicable Target(s) of such Arcus Program (such other intellectual property or other subject matter, &#147;<B><I>Third
Party Technology</I></B>&#148;) included in the Arcus Technology, and for which payments would become due to such Third Party as a result of TAIHO&#146;s Development or Commercialization of a Licensed Product hereunder in exercise of rights under
such Arcus Technology, then the following shall apply: Promptly upon entering into any such Third Party Agreement, Arcus shall provide TAIHO with a true, complete and correct written description of such Third Party Technology and such payment
obligations, and TAIHO&#146;s obligation to reimburse such amounts shall be limited to those payment obligations as so disclosed to it. The License granted to TAIHO under such Third Party Technology shall be subject to TAIHO&#146;s agreement to
reimburse Arcus for the payments owed to such Third Party to the extent such payments become due by reason of TAIHO&#146;s exercise of TAIHO&#146;s License hereunder with respect to such Third Party Technology in the Territory. If TAIHO elects not
to or does not agree to reimburse such payments, then to such extent, such Third Party Technology shall thereafter be deemed excluded from TAIHO&#146;s License with respect to such Licensed Product, and TAIHO will not be obligated to reimburse any
payments attributable to such Third Party Technology with respect to such Licensed Product. [***] percent ([***]%) of any payments that TAIHO reimburses pursuant to this paragraph may be offset against amounts due to Arcus in accordance with
Section&nbsp;5.9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;If Arcus fails to make any payment when due under any Third Party Agreement or is
otherwise in breach of such Third Party Agreement, TAIHO shall have the right to make such payment and/or cure such breach on behalf of Arcus. In such event, Arcus shall promptly reimburse TAIHO for TAIHO&#146;s reasonable costs incurred in making
such payment and/or curing such breach or, at TAIHO&#146;s election, TAIHO may offset such amounts paid by TAIHO against any future amounts payable to Arcus hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Royalty Term.</B> Royalties under Section&nbsp;5.5 shall be payable on a Licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis during the period of time commencing
on the First Commercial Sale of a Licensed Product in a country and ending upon the later of: (a)&nbsp;[***] years from the date of First Commercial Sale of such Licensed Product in such country; and (b)&nbsp;expiration of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> Valid Claim of the Arcus Patents covering the manufacture, use or sale or exploitation of such Licensed Product in such country (the &#147;<B><I>Royalty
Term</I></B>&#148;). Notwithstanding the foregoing, for the second or any subsequent Licensed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Product of the applicable Arcus Program to be sold in a country in the Territory, clause (a)&nbsp;of the Royalty Term shall only apply for such second or subsequent Licensed Product if [***].
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Controlled Antibodies and Compounds</B>. Notwithstanding anything to the contrary in this Agreement,
TAIHO&#146;s royalty or milestone payment obligations under this Agreement shall be owed on an Antibody or Compound only if and to the extent the chemical structure of such Antibody or Compound was first discovered by Arcus or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> to Arcus by a Third Party, and in any event shall not be owed on any compound or antibody first discovered by TAIHO or <FONT STYLE="white-space:nowrap">in-licensed</FONT> to TAIHO, directly or
indirectly, by a Third Party that first discovered such compound or antibody. The foregoing shall not be deemed to grant to TAIHO any implied right or license under any intellectual property right of Arcus other than as expressly set forth herein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Credits. </B>Under [***], TAIHO has rights to credit certain amounts (the
&#147;<B><I>Credits</I></B>&#148;) against certain amounts owed by TAIHO to Arcus pursuant to this Article 5 (&#147;<B><I>Amounts Owed</I></B>&#148;). In each case, TAIHO may only credit each Credit actually paid by TAIHO in a calendar quarter
against Amounts Owed in the same calendar quarter for the Arcus Program to which the applicable Credit relates. If the Credit relates to more than one Arcus Program, then such Credit will be divided and distributed equally across each Arcus Program
to which such Credit relates. In no event shall the application of any Credit reduce each Amount Owed by more than [***] percent ([***]%) in a given calendar quarter and TAIHO may not apply the particular amounts paid by TAIHO as Credits under more
than one of the applicable [***]. For example, a particular amount paid by TAIHO to a licensor shall not qualify as a Credit under both [***]. If a Credit may not be fully offset as a result of the foregoing limitation, then it may be carried
forward and offset against Amounts Owed in future calendar quarters; provided that in the event of any [***]. Arcus shall not be liable to TAIHO for any Credits which cannot be carried forward, credited, offset, or deducted by TAIHO. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>P<SMALL>AYMENTS</SMALL>; R<SMALL>ECORDS</SMALL>; A<SMALL>UDITS</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Payment; Reports.</B> Royalties shall be calculated and reported for each calendar quarter within [***]
days after the end of each calendar quarter. Upon delivery of such report, Arcus shall invoice TAIHO for the corresponding amount of the royalty due to Arcus, if any, and TAIHO shall pay such amount due, if any, within [***] days after receipt of an
invoice from Arcus therefor. Each report of royalties shall include the Net Sales of Licensed Products by TAIHO and its Sublicensees in the Territory on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis during the applicable calendar quarter, which report shall include the gross amounts invoiced and Net Sales of such Licensed Products, the
royalties payable, how such royalties payable amounts were calculated (including an accounting of any reductions in applicable royalty rates and/or deductions in determining Net Sales), and the exchange rates used, in each case presented on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis and only for the applicable calendar quarter. Each such report shall also include an accounting of any other amounts paid under Article 5 in the
applicable calendar quarter, including an accounting of any reductions made to such amounts (<I>e.g.</I>, under Section&nbsp;5.9), and a list of the unused Credit carry forwards to date with their respective remaining amounts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Exchange Rate; Manner and Place of Payment.</B> All
payments hereunder shall be payable in U.S. dollars. When conversion of payments from any foreign currency is required, such conversion shall be calculated using an exchange rate equal to the weighted average of the rates of exchange for the
currency of the country from which the royalties are payable as reported on Oanda.com, during the calendar quarter for which a payment is due. All payments owed under this Agreement shall be made by wire transfer in immediately available funds to
the bank and account designated in writing by Arcus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Income Tax Withholding.</B> All payments by
TAIHO hereunder shall be made to Arcus by TAIHO or an Affiliate of TAIHO that is either a resident of Japan or the United States for income tax purposes and unless specifically required by a governmental agency shall not be subject to any deduction
for withholding imposed upon the sale of Licensed Product outside the United States or otherwise and Arcus will then pay any and all taxes levied on account of any payments made to it under this Agreement. If any taxes are paid or required to be
withheld by TAIHO or an Affiliate for the benefit of Arcus on account of any royalties or other payments payable to Arcus under this Agreement, TAIHO will (a)&nbsp;be entitled to deduct and withhold such taxes from the amount of royalties or other
payments otherwise due to Arcus, (b)&nbsp;timely pay the taxes to the proper taxing authority, and (c)&nbsp;send proof of payment to Arcus and any receipt by the taxing authority received by TAIHO within thirty (30)&nbsp;days of payment or receipt
following such payment. TAIHO and Arcus shall reasonably cooperate to minimize any such withholding, including by Arcus providing a Certification of U.S. Tax Residency on Form 6166, an Application Form for Income Tax Convention (Form 3) and an
Attachment Form for Limitation on Benefits Article (US) (Form 17). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Audits.</B> TAIHO shall keep (and
shall require its Affiliates and Sublicensees to keep) complete and accurate records pertaining to the manufacture, Development, sale or other disposition of Licensed Products in sufficient detail to permit Arcus to confirm the accuracy of all
payments due hereunder for a period of [***] years from the end of the calendar year to which such records relate. Arcus shall have the right, once annually, to cause an independent, certified public accountant (the
&#147;<B><I>Auditor</I></B>&#148;) to audit such records solely to confirm the amounts payable by TAIHO to Arcus under this Agreement for a period covering not more than the preceding [***] years, including, without limitation, calculation of Net
Sales and payment of royalties, provided that with respect to such records of Sublicensees, TAIHO shall only be obligated to use Commercially Reasonable Efforts to obtain such rights for Arcus from its Sublicensees and, if TAIHO is unable to obtain
from any Sublicensee such right for Arcus to audit such records of such Sublicensee, TAIHO shall obtain the right to inspect and audit such Sublicensee&#146;s books and records for itself and shall exercise such audit rights on behalf and at the
reasonable expense of Arcus upon Arcus&#146;s written request and disclose the results of any such audit to Arcus in accordance with this Section. Such audits may be exercised during normal business hours upon reasonable prior written notice to
TAIHO. The Auditor will, prior to the conduct of any such audit, execute a reasonable written confidentiality agreement with TAIHO. The Auditor will send a copy of the report to TAIHO at the same time it is sent to Arcus that states whether the
royalties and other payments hereunder are correct or incorrect and, if they are incorrect, the amount of any underpayment or overpayment along with reasonable details for how such underpayment or overpayment was determined. The report sent to both
parties will include the methodology and calculations used to determine the results. Prompt </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjustments shall be made by the parties to reflect the results of such audit. Arcus shall bear the full cost of such audit unless such audit establishes an underpayment by TAIHO of more than
[***] percent ([***]%) of the amount due for the period covered by the audit, in which case, TAIHO shall bear the full cost of such audit and shall promptly remit to Arcus the amount of any underpayment, together with a late fee which shall be
calculated on such late payment in accordance with Section&nbsp;6.5 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Late Payments.</B> In the
event that any amount due under this Agreement is not paid when such amount is due, the amount shall accrue (and TAIHO shall pay) interest from the date due at a rate per annum equal to (a) [***] percent ([***]%) per month for payments owed prior to
[***] years after the Effective Date; and (b)&nbsp;the prime rate as reported by the Bank of Tokyo-Mitsubishi UFJ, Ltd., plus [***] percent ([***]%) per year for payments owed more than [***] years after the Effective Date; <I>provided, however,</I>
that in no event shall such rate exceed the maximum legal annual interest rate. The payment of such interest shall not limit Arcus from exercising any other rights it may have as a consequence of the lateness of any payment. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>C<SMALL>ONFIDENTIALITY</SMALL>. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Confidential
Information.</B> Except to the extent expressly authorized by this Agreement, each party agrees that, during the Term, and for [***] years thereafter, such party (the &#147;<B><I>Receiving Party</I></B>&#148;) shall keep confidential, and shall not
publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement, any information furnished to it by or on behalf of the other party (the &#147;<B><I>Disclosing Party</I></B>&#148;) pursuant to
this Agreement or any Confidentiality Agreement that is marked or otherwise identified as confidential or proprietary at the time of disclosure or is disclosed in such a manner or is of such a nature that a reasonable person would understand such
information to be confidential or proprietary (collectively, &#147;<B><I>Confidential Information</I></B>&#148;). The Receiving Party may use and disclose Confidential Information only to the extent required to accomplish the purposes of this
Agreement. The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but in no event less than reasonable care) to prevent unauthorized access, use and disclosure of
the Confidential Information and to ensure that its, and its Affiliates&#146;, employees, agents, consultants, other representatives and sublicensees (&#147;<B><I>Representatives</I></B>&#148;) do not disclose, except as otherwise expressly
permitted under this Agreement, or make any unauthorized use of, the Confidential Information. The Receiving Party shall promptly notify the Disclosing Party upon discovery of any unauthorized use or unauthorized disclosure of the Disclosing
Party&#146;s Confidential Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Exceptions.</B> Confidential Information of a Disclosing
Party shall not include any information to the extent that such information (which the Receiving Party can prove by competent evidence): (a)&nbsp;is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party in
violation of this Article&nbsp;7, generally known or available; (b)&nbsp;is lawfully known by the Receiving Party or any of its Affiliates (to the extent such Receiving Party or Affiliate has the right to use and disclose such information) at the
time of receiving such information from the Disclosing Party; (c)&nbsp;is hereafter furnished to the Receiving Party or any of its Affiliates by a Third Party, as a matter of right (to the extent such Receiving Party or Affiliate has the right to
use and disclose such information); or (d)&nbsp;is independently discovered or developed by the Receiving Party or any of its Affiliates, without the use of or reference to Confidential Information of the Disclosing Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Authorized Disclosure.</B> Notwithstanding the
provisions of Section&nbsp;7.1, the Receiving Party may disclose Confidential Information of the Disclosing Party as expressly permitted by this Agreement, or if and to the extent such disclosure is reasonably necessary in the following instances:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;filing or prosecuting Patent Rights as permitted by this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;exercising or enforcing such party&#146;s rights under this Agreement and in performing its obligations under this
Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;seeking, obtaining and maintaining Marketing Approvals (including complying with the requirements
of Regulatory Authorities with respect to filing for, obtaining and maintaining Marketing Approvals); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;prosecuting or defending litigation as permitted by this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;complying with applicable court orders, Applicable Laws, or the listing rules of any exchange on which the
Receiving Party&#146;s securities are traded (specifically including the recommendations and requests from the Tokyo Stock Exchange (TSE) or the SEC or otherwise submitting information to tax or other governmental authorities); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;disclosure in Regulatory Filings or Regulatory Documents that the Receiving Party has the right to make under this
Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;in the case of Arcus, disclosure to any licensors to the extent required to comply with the terms
and conditions of any agreement between Arcus and such licensors, provided that any such licensors agree to be bound by terms of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> at least as restrictive as those set forth in this
Article 7; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;disclosure to the Receiving Party&#146;s Affiliates, to actual or potential Sublicensees (or
licensees or sublicensees) or Subcontractors (or subcontractors, including those of Sublicensees) and to the Receiving Party&#146;s and its Affiliates&#146; Representatives who, in each case, have a need to know such information in order for the
Receiving Party to exercise its rights or fulfill its obligations under this Agreement or any agreement between the Receiving Party and any such persons, provided, in each case, that any such Affiliate, actual or potential Sublicensee (or licensee
or sublicensee) or Subcontractor (or subcontractor, including those of Sublicensees), or Representative agrees to be bound by terms of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> at least as restrictive as those set forth in
this Article&nbsp;7; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;disclosure to Third Parties in connection with due diligence or similar
investigations by such Third Parties, and disclosure to potential Third Party investors in confidential financing documents, provided, in each case, that any such Third Party agrees to be bound by obligations of confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> similar to those contained in this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party shall be responsible for any breaches of confidentiality by any of its Affiliates,
Sublicensees (or licensees or sublicensees), Subcontractors (or subcontractors, including those of Sublicensees), Representatives, advisors and Third Parties (to whom it discloses Confidential Information pursuant to Sections 7.3(h), 7.3(i) and
7.6). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the event the Receiving Party is required to make a disclosure of the Disclosing Party&#146;s
Confidential Information pursuant to Section&nbsp;7.3(d) or 7.3(e), it will, except where impracticable, (a)&nbsp;give reasonable advance notice to the Disclosing Party of such disclosure, (b)&nbsp;use efforts to secure confidential treatment of
such information at least as diligent as the Receiving Party would use to protect its own confidential information, but in no event less than reasonable efforts, and (c)&nbsp;cooperate with any efforts by the Disclosing Party, at the Disclosing
Party&#146;s request and expense, to secure confidential treatment of such Confidential Information. [***]. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, notwithstanding
the foregoing, to the extent that either party reasonably determines that it is required to make a filing or any other public disclosure with respect to this Agreement or the terms or existence hereof to comply with the requirements, rules, laws or
regulations of any applicable stock exchange, Nasdaq, Tokyo Stock Exchange, or any governmental or regulatory authority or body, including without limitation the U.S. Securities and Exchange Commission (the <B><I>&#147;SEC&#148;</I></B>)
(collectively, the <B><I>&#147;Securities Disclosure Obligations&#148;</I></B>), such party shall promptly inform the other party thereof and shall use reasonable efforts to maintain the confidentiality of the terms of this Agreement in any such
filing or disclosure. Prior to making any such initial filing of the terms of this Agreement, the parties shall mutually agree on the provisions of this Agreement for which the parties shall seek confidential treatment, it being understood that if
one party determines to seek confidential treatment for a provision for which the other party does not, then the parties will use reasonable efforts in connection with such filing to seek the confidential treatment of any such provision. The parties
shall cooperate, each at its own expense, in such filing, including without limitation such confidential treatment request. The parties will reasonably cooperate in responding promptly to any comments received from the SEC with respect to such
filing in an effort to achieve confidential treatment of such redacted form; provided, however, that a party shall be relieved of such obligation to seek confidential treatment for a provision requested by the other party if such treatment is not
achieved after the first round of responses to comments from the SEC. Notwithstanding anything to the contrary in this Agreement, either party may make reference to the existence of this Agreement and describe in general terms the relationship
between the parties in connection with any required securities filings without seeking the other party&#146;s prior consent. This paragraph shall apply with respect to the filing of the terms of this Agreement or any public disclosure relating to
this Agreement, in each case to comply with Securities Disclosure Obligations, notwithstanding the provisions of this Article 7 or the Confidentiality Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4&nbsp;&nbsp;&nbsp;&nbsp;Publications. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Clinical Trial Results.</B> TAIHO and its Affiliates may publish, and authorize Sublicensees to publish, the
results of any Clinical Trial of a Licensed Product conducted by or on behalf of TAIHO, its Affiliate or a Sublicensee without the prior written approval of Arcus; provided that they are in compliance with the terms and conditions of this
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section. TAIHO shall provide a copy of the proposed publication to Arcus for review at least [***] days in advance of any such publication. Arcus may request, and TAIHO shall remove, from the
proposed publication any information that is Arcus Confidential Information. Furthermore, TAIHO shall consider in good faith and acting reasonably any other changes requested by Arcus with respect to such proposed publication. Notwithstanding the
foregoing, once the results of a Clinical Trial have been published, no further notice shall be required with respect to a subsequent publication of such results. The parties shall reasonably cooperate with each other to coordinate their strategies
for publishing the results of any Clinical Trial of a Licensed Product.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5&nbsp;&nbsp;&nbsp;&nbsp;Public Announcements.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint Press Release.</B> If requested by a party, the parties shall issue a joint press release
announcing the execution of this Agreement in substantially the form(s) mutually agreed upon by the partie<B>s</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>Additional Press Releases.</B> It is understood that each party may desire or be required to issue subsequent
press releases relating to this Agreement or activities hereunder. Should a party wish to issue any subsequent press release with respect to this Agreement and/or the activities hereunder, such party agrees to consult with the other party reasonably
and in good faith with respect to the text and timing of such press release prior to the issuance thereof. After release of a press release in accordance with this Section&nbsp;7.5, each party may disclose to Third Parties the information contained
in such press release without the need for further notice to the other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Confidential
Terms</B>. Each party agrees not to disclose to any Third Party the terms of this Agreement without the prior written consent of the other party hereto, except each party may disclose the terms of this Agreement: (a)&nbsp;to advisors (including
financial advisors, attorneys and accountants), actual or potential acquisition partners or private investors, and others on a need to know basis, in each case under appropriate confidentiality provisions substantially equivalent to those in this
Agreement; or (b)&nbsp;to the extent necessary to comply with Applicable Laws and court orders, including securities laws, regulations or guidances; provided that in the case of paragraph (b)&nbsp;the Disclosing Party (A)&nbsp;complies with the
provisions set forth above with respect to Securities Disclosure Obligations, and (B)&nbsp;in the case of disclosures under paragraph (b)&nbsp;other than to comply with Securities Disclosure Obligations, promptly notifies the other party and allows
the other party a reasonable opportunity to oppose with the body initiating the process and, to the extent allowable by Applicable Law, to seek limitations on the portion of the Agreement that is required to be disclosed. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>I<SMALL>NTELLECTUAL</SMALL> P<SMALL>ROPERTY</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Ownership of Inventions.</B> Inventorship of Inventions shall be determined in accordance with the rules
of inventorship under U.S. patent laws. Arcus shall solely own all Arcus Inventions. TAIHO shall solely own all TAIHO Inventions. The parties shall jointly own all Joint Inventions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Prosecution and Maintenance.</B> For purposes of this
Section&nbsp;8.2, (a) the terms &#147;prosecution&#148; and &#147;maintenance&#148; (including variations such as &#147;prosecute&#148; and &#147;maintain&#148;) shall mean, with respect to a Patent Right, the preparation, filing, prosecution, and
maintenance of such Patent Right, in the applicable jurisdiction, as well as <FONT STYLE="white-space:nowrap">re-examinations</FONT> and reissues with respect to such Patent Right, together with the conduct of interferences, the defense of
oppositions and other similar proceedings with respect to a Patent Right, (b)&nbsp;the term &#147;Arcus Patents&#148; shall also include those Patent Rights Controlled by Arcus to the extent such Patent Rights cover the Development or
Commercialization of an Antibody, Compound, Therapeutic Product unless TAIHO has either not exercised its Option with respect thereto or terminated its License with respect thereto, and (c)&nbsp;the term &#147;Companion Diagnostic&#148; shall apply
to Antibodies, Compound, and Therapeutic Products, to the same extent as it applies to Licensed Products, <I>mutatis mutandis</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Arcus</B><B> Patents</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<B>Territory.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;Arcus shall have primary responsibility for the prosecution and maintenance of any Arcus Patents in the Territory
at its sole cost and expense. Arcus shall prosecute and maintain Arcus Patents in [***], and use commercially reasonable efforts to obtain issued Patent Rights therein that cover each of the Licensed Products. Arcus shall use commercially reasonable
efforts to prosecute and maintain Arcus Patents in [***], and use commercially reasonable efforts to obtain issued Patent Rights therein that cover each of the Licensed Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;Prior to TAIHO&#146;s exercise of the applicable Option, Arcus (a)&nbsp;shall notify TAIHO in the event Arcus
elects not to file (directly or through the national phase of the PCT procedure) an Arcus Patent in any of [***] (the &#147;<B><I>Patent Prosecution Countries</I></B>&#148;), (b) is not required to consult with or provide TAIHO with the opportunity
to review any draft patent applications prior to filing, and (c)&nbsp;shall use commercially reasonable efforts to consult with TAIHO as to the prosecution and maintenance of Arcus Patents related to the applicable Option Products in the Patent
Prosecution Countries once examination has begun in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;After TAIHO&#146;s exercise of the
applicable Option, Arcus shall consult with TAIHO as to the prosecution and maintenance of Arcus Patents related to the Licensed Product in the Territory, including providing to TAIHO for review all relevant drafts and documents reasonably prior to
any deadline or submission to or action with any patent office. Arcus shall consider in good faith any reasonable comments thereto provided by TAIHO in connection with the prosecution and maintenance of such Arcus Patents, so long as such comments
are provided to Arcus in a timely manner. If reasonably requested by TAIHO, Arcus shall provide TAIHO with an update on progress with regard to the prosecution and maintenance of Arcus Patents relevant to the Territory, and Arcus shall provide to
TAIHO copies of all patent office submissions and material correspondence directly related to the Arcus Patents in the Territory within a reasonable amount of time following submission or receipt thereof by Arcus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(4)&nbsp;&nbsp;&nbsp;&nbsp;Beginning on the grant of the applicable Option until the earlier
of exercise thereof or expiration of the Option Period (solely with respect to Arcus Patents in [***]) and after TAIHO&#146;s exercise of the applicable Option (with respect to all Arcus Patents in any country in the Territory), if Arcus plans not
to file (directly or through the national phase of the PCT procedure) such Arcus Patent or, if Arcus desires to abandon or cease prosecution or maintenance of any such Arcus Patent without filing a continuation, divisional or similar patent
application, Arcus shall provide written notice to TAIHO of such intention at least [***] days in advance of the date any such filing is required to avoid a loss of such rights or abandonment of such Arcus Patent, and TAIHO shall have the right, but
not the obligation, subject to the rights of Third Parties under any Third Party Agreements, to assume responsibility for prosecution and maintenance of such Arcus Patent in Arcus&#146; name at its sole cost and expense; provided that if TAIHO
elects to assume such responsibility, Arcus shall promptly (in any case reasonably in advance of any applicable deadline) furnish all communications received from any patent office with respect to such Arcus Patents to TAIHO and Arcus shall
cooperate reasonably to allow TAIHO to prosecute and maintain such Arcus Patents at TAIHO&#146;s request; provided further that TAIHO shall keep Arcus reasonably informed as to the prosecution of such Arcus Patents in the Territory and shall
consider in good faith any reasonable comments provided by Arcus in connection with the prosecution of such Arcus Patents, so long as such comments are provided by Arcus in a timely manner. To the extent Arcus obtained Control of any such Arcus
Patent under a Third Party Agreement, TAIHO&#146;s rights to assume responsibility for prosecution and maintenance of such Arcus Patents shall be subject to the rights of Third Parties under such Third Party Agreement, provided that Arcus shall, at
TAIHO&#146;s request, cooperate reasonably to allow TAIHO to exercise its right to assume such prosecution and maintenance. In the event that TAIHO elects to assume the prosecution and maintenance of an Arcus Patent as provided for in this
Section&nbsp;8.2(a)(i)(4), Arcus shall permit TAIHO to offset [***] percent ([***]%) of the expense incurred in prosecuting and maintaining such Patent Rights against the amounts otherwise payable to Arcus hereunder with respect to Licensed Products
covered by such Patent Rights in accordance with Section&nbsp;5.9. Such Patent Rights shall thereafter cease to be considered an Arcus Patent solely for purposes of determining the Royalty Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<B>Arcus Territory</B>. Arcus shall have the sole right, but not the obligation, to prosecute and maintain the
Arcus Patents outside the Territory, at its sole cost and expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>TAIHO Patents.</B> TAIHO shall have the
sole right, but not the obligation, to prosecute and maintain the TAIHO Patents throughout the world, at its sole cost and expense. TAIHO shall consult with Arcus as to the prosecution and maintenance of TAIHO Patents outside the Territory
(including PCT applications) reasonably prior to any deadline, submission to or action with any patent office, and shall furnish to Arcus copies of all relevant drafts and documents reasonably in advance of such consultation. TAIHO shall consider in
good faith any reasonable comments thereto provided by Arcus in connection with the prosecution and maintenance of such TAIHO Patents, so long as such comments are provided by Arcus in a timely manner. TAIHO shall keep Arcus reasonably informed of
progress with regard to the prosecution and maintenance of TAIHO Patents relevant to outside the Territory and shall provide to Arcus copies of all patent office submissions and material correspondence relevant to outside the Territory within a
reasonable amount of time following submission or receipt thereof </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by TAIHO. TAIHO shall consider the comments of Arcus in good faith, so long as such comments are provided by Arcus in a timely manner. If TAIHO plans not to file (directly or through the national
phase of the PCT procedure) a TAIHO Patent in any country outside of the Territory or, if TAIHO desires to abandon or cease prosecution or maintenance of any TAIHO Patent without filing a continuation, divisional or similar patent application in any
country outside of the Territory, TAIHO shall provide written notice to Arcus of such intention at least [***] days in advance of the date any such filing is required to avoid a loss of such rights or abandonment of such TAIHO Patent, and, Arcus
shall have the right, but not the obligation, subject to the rights of any applicable Third Party licensor, to assume responsibility for prosecution and maintenance of such TAIHO Patent in TAIHO&#146;s name at its sole cost and expense; provided
that if Arcus elects to assume such responsibility, TAIHO shall promptly (in any case reasonably in advance of any applicable deadline) furnish all communications received from any patent office with respect to such TAIHO Patents to Arcus and TAIHO
shall cooperate reasonably to allow Arcus to prosecute and maintain the TAIHO Patents at Arcus&#146; request; provided further that Arcus shall keep TAIHO reasonably informed as to the prosecution of such TAIHO Patent outside the Territory and shall
consider in good faith any reasonable comments provided by TAIHO in connection with the prosecution of such TAIHO Patents, so long as such comments are provided by TAIHO in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint Patents.</B> Arcus shall have the first right, but not the obligation, to prosecute and maintain Joint
Patents in the Territory and outside the Territory, at its sole cost and expense. Arcus shall consult with TAIHO as to the prosecution and maintenance of Joint Patents reasonably prior to any deadline, submission to or action with any patent office,
and shall furnish to TAIHO copies of all relevant drafts and documents reasonably in advance of such consultation. Arcus shall consider in good faith any reasonable comments thereto provided by TAIHO in connection with the prosecution and
maintenance of such Joint Patents, so long as such comments are provided to Arcus in a timely manner. If reasonably requested by TAIHO, Arcus shall provide TAIHO with an update on progress with regard to the prosecution and maintenance of Joint
Patents, and Arcus shall consult with, and consider in good faith the requests and suggestions of, TAIHO with respect to the prosecution and maintenance of Joint Patents, so long as such comments are provided by TAIHO in a timely manner. In the
event that Arcus desires not to file (including any national phase filing), or desires to abandon or cease prosecution or maintenance of, any Joint Patent in any country, without filing a continuation, divisional or similar patent application, Arcus
shall provide written notice to TAIHO of such intention at least [***] days in advance of the date any such filing is required to avoid a loss of such rights or abandonment of such Joint Patent. In such case, at TAIHO&#146;s sole discretion, upon
written notice to Arcus, TAIHO may elect to continue prosecution or maintenance of any such Joint Patent, in the name of both Arcus and TAIHO, at its sole cost and expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<B>Cooperation of the Parties.</B> Each party agrees to reasonably cooperate with the party responsible for
prosecution and maintenance of Patent Rights in the prosecution and maintenance of Patent Rights under Section&nbsp;8.2 and in the obtaining and maintaining of any Patent Term Extensions (in accordance with Section&nbsp;8.3), supplementary
protection certificates and the like with respect thereto respectively at its own costs, as requested by the responsible party. Such cooperation may include, but is not limited to executing all reasonable papers and instruments, or requiring its
employees or contractors, to execute such papers and instruments, so </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as to enable the other party to apply for and to prosecute patent applications in any country as permitted by Section&nbsp;8.2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Patent Term Extensions in the Territory</B>. The parties shall coordinate and discuss which of the Patent
Rights within the Arcus Patents, TAIHO Patents and Joint Patents should be selected for term extensions, supplementary protection certificates, and equivalents thereof offering patent protection beyond the initial term with respect to any issued
Patent Rights (&#147;<B><I>Patent Term Extensions</I></B>&#148;) with respect to the Licensed Products in the Territory. TAIHO shall have the right to make the final decision regarding which Patent Rights are selected for Patent Term Extension in
the Territory, and shall have the right to seek and obtain such Patent Term Extensions with respect to the Arcus Patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Enforcement and Defense of Patent Rights.</B> Each party shall notify the other party in writing within
[***] (except as expressly set forth below) of becoming aware of any alleged or threatened infringement by a Third Party of any of the Arcus Patents, TAIHO Patent or Joint Patents (&#147;<B><I>Infringement</I></B>&#148;), including (a)&nbsp;any such
alleged or threatened Infringement on account of a Third Party&#146;s manufacture, use or sale of a Licensed Product in the Field, (b)&nbsp;any certification filed in the United States under 21 U.S.C. &#167;355(b)(2) or 21 U.S.C. &#167;355(j)(2) or
similar provisions in other jurisdictions in connection with an ANDA (an Abbreviated New Drug Application) or a comparable application for Marketing Approval under Applicable Law in any country other than the United States or other NDA for a
Licensed Product in the Field (a &#147;<B><I>Patent Certification</I></B>&#148;), (c) patent clearance under the BPCI Act patent exchange and litigation process or similar provisions in other jurisdictions in connection with a Biosimilar Application
or other BLA for a Licensed Product in the Field (&#147;<B><I>Patent Clearance</I></B>&#148;) and (d)&nbsp;any declaratory judgment action filed by a Third Party that is developing, manufacturing or commercializing any product directed to the Target
of Licensed Product in the Field alleging the invalidity, unenforceability or <FONT STYLE="white-space:nowrap">non-infringement</FONT> of any of the Arcus Patents or Joint Patents ((a)-(d), collectively, &#147;<B><I>Competitive
Infringement</I></B>&#148;); <I>provided, however,</I> that each party shall notify the other party of any Patent Certification or Patent Clearance regarding any Arcus Patent or Joint Patent that it receives, and such party shall provide the other
party with a copy of such Patent Certification or Patent Clearance, within [***] after receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Arcus</B><B> Patents.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<B>Territory.</B> Arcus shall have the first right, but not the obligation, to bring (or defend) and control any
action or proceeding with respect to Competitive Infringement of any Arcus Patent in the Territory, at Arcus&#146;s own expense and by counsel of its own choice. If Arcus fails to bring any such action or proceeding with respect to Competitive
Infringement of any Arcus Patent in the Territory within [***] days following the notice of alleged Competitive Infringement, TAIHO shall have the right to bring (or defend) and control any such action or proceeding at its own expense and by counsel
of its own choice, <I>provided, however,</I> that (A)&nbsp;if the applicable Competitive Infringement is the result of a party&#146;s receipt of a Patent Certification or Patent Clearance with respect to a Arcus Patent, Arcus shall notify TAIHO of
Arcus&#146;s decision to bring (or defend) and control any action or proceeding [***]&nbsp;days of Arcus&#146;s receipt of such Patent Certification or Patent Clearance with respect to such Arcus Patent and (B)&nbsp;the [***] or [***] day period
shall be shortened to the extent necessary for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
TAIHO to initiate and maintain such action or proceeding, after which time TAIHO shall have the right to bring (or defend) and prosecute such action. If TAIHO brings any action or proceeding
against any Third Party with respect to Competitive Infringement of any Arcus Patent pursuant to this Section, (x)&nbsp;it will have sole control of any such action and Arcus shall, at TAIHO&#146;s expense, execute all necessary and proper documents
that are reasonable, take such actions and otherwise cooperate as reasonably requested to allow TAIHO to undertake any such action; and (y)&nbsp;TAIHO may offset [***] percent ([***]%) of its <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred in connection with such action or proceeding against amounts payable to Arcus under Article 5 in accordance with Section&nbsp;5.9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<B>Outside the Territory.</B> Arcus shall have the sole right, but not the obligation, to bring (or defend) and
control any action or proceeding with respect to Competitive Infringement of an Arcus Patent anywhere outside the Territory, at Arcus&#146;s own expense and by counsel of its own choice, and TAIHO shall have no rights in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>TAIHO Patents.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<B>Outside the Territory.</B> TAIHO shall have the first right, but not the obligation, to bring (or defend) and
control any action or proceeding with respect to Competitive Infringement of a TAIHO Patent outside the Territory, at TAIHO&#146;s own expense and by counsel of its own choice. If TAIHO fails to bring any such action or proceeding with respect to
Competitive Infringement of any TAIHO Patent outside the Territory within [***]&nbsp;days following the notice of alleged Competitive Infringement, Arcus shall have the right to bring (or defend) and control any such action or proceeding at its own
expense and by counsel of its own choice, provided, however, that if the applicable TAIHO Patents cover [***]; provided further, that if the applicable TAIHO Patents cover [***]. If Arcus brings any action or proceeding against any Third Party with
respect to Competitive Infringement of any TAIHO Patent pursuant to this Section, it will have sole control of any such action and TAIHO shall, at Arcus&#146;s expense, execute all necessary and proper documents that are reasonable, take such
actions and otherwise cooperate as reasonably requested to allow Arcus to undertake any such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<B>Territory.</B> TAIHO shall have the sole right, in its discretion, to bring (or defend) and control any action
or proceeding with respect to Competitive Infringement of an TAIHO Patent anywhere in the Territory, at TAIHO&#146;s own expense and by counsel of its own choice, and Arcus shall have no rights in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint Patents.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<B>Competitive Infringement</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;<B>Worldwide.</B> Arcus shall have the first right, but not the obligation, to bring (or defend) and control any
action or proceeding with respect to Competitive Infringement of any Joint Patent, at its own expense and by counsel of its own choice, and TAIHO shall have the right, at its own expense, to be represented in any such action by counsel of its own
choice. If Arcus fails to bring any such action or proceeding with respect to Competitive Infringement of any Joint Patent within [***] days following the notice of alleged </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
infringement, TAIHO shall have the right to bring (or defend) and control any such action at its own expense and by counsel of its own choice, and Arcus shall have the right, at its own expense,
to be represented in any such action by counsel of its own choice; <I>provided, however,</I> that (A)&nbsp;if the applicable Competitive Infringement is the result of a party&#146;s receipt of a Patent Certification or Patent Clearance with respect
to a Joint Patent, Arcus shall notify TAIHO of Arcus&#146;s decision to bring (or defend) and control any action or proceeding within [***] days of Arcus&#146;s receipt of such Patent Certification or Patent Clearance with respect to such Joint
Patent and (B)&nbsp;the [***] or [***] day period shall be shortened to the extent necessary for TAIHO to initiate and maintain such action or proceeding, after which time TAIHO shall have the right to bring (or defend) and prosecute such action,
and Arcus shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Infringement.</B> The parties shall mutually agree on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis (A)&nbsp;whether to bring (or defend) any action or proceeding with respect to Infringement of any Joint Patent anywhere in the world to the extent the Infringement is not Competitive
Infringement, (B)&nbsp;which party would bring (or defend) and control such action, and (C)&nbsp;how the expenses of, and any recovery from, any such action would be allocated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<B>Cooperation.</B> In the event a party brings (or defends) an infringement action in accordance with this
Section&nbsp;8.4, or in the event a party is entitled to bring (or defend) an infringement action in accordance with this Section&nbsp;8.4 but lacks standing to do so, the other party shall cooperate reasonably, including, if required to bring (or
defend) such action, the furnishing of a power of attorney or being named as a party (by joining). Neither party shall enter into any settlement or compromise of any action under this Section&nbsp;8.4 which [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<B>Recovery.</B> Except as otherwise agreed by the parties in connection with a cost-sharing arrangement, any
recovery realized by a party as a result of any action or proceeding in the Territory pursuant to this Section&nbsp;8.4, whether by way of settlement or otherwise, shall be applied first to reimburse the documented <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal expenses of the party that brought (or defended) and controlled such action or proceeding incurred in connection with such action or proceeding, and second to reimburse the documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal expenses of the other party incurred in connection with such action or proceeding, and any remaining amounts shall be [***]; <I>provided, however,</I>
that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;any recovery realized by Arcus as a result of any action brought (or defended) and controlled by Arcus
pursuant to Section&nbsp;8.4(a)(i)or Section&nbsp;8.4(c)(i)(1) (after reimbursement of the parties&#146; documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal expenses relating to the action
or proceeding) shall be allocated as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;any recovery realized by TAIHO as a result of any action brought and controlled by TAIHO pursuant to
Section&nbsp;8.4(c)(i)(1) (after reimbursement of the parties&#146; documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal expenses relating to the action or proceeding) shall be [***]; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp; any recovery realized by Arcus or TAIHO as a result of any other action brought and controlled by such
party pursuant to this Section&nbsp;8.4 (after reimbursement of the parties&#146; documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> legal expenses relating to the action or proceeding) shall
[***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.5&nbsp;&nbsp;&nbsp;&nbsp;Infringement of Third Party Rights. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Each party shall promptly notify the other in writing of any allegation by a Third Party that the activity of
either party pursuant to this Agreement infringes or may infringe the intellectual property rights of such Third Party. Neither party shall have the right to settle any infringement litigation under this Section&nbsp;8.5 in a manner that [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Except to the extent Arcus has provided indemnification under Section&nbsp;11.2, TAIHO shall have the right to
offset [***] percent ([***]%) of all damages and settlement costs paid to a Third Party (including any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred to defend such a claim), as a result
of any suit or action with such Third Party that claims that the production, use or sale of the Licensed Product infringes any issued patent of a Third Party against any and all payments to be made to Arcus under this Agreement with respect to such
Licensed Product in accordance with Section&nbsp;5.9. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Marking.</B> To the extent required by
Applicable Law and to the extent TAIHO ordinarily marks its own products, TAIHO shall, and shall require its Affiliates and Sublicensees to, mark all Licensed Products made, used or sold in the Field in the Territory, or their containers, with the
number of each issued Arcus Patent and Joint Patent that applies to such Licensed Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Trademarks</B>. Subject to the terms and conditions of this Agreement, and effective automatically as of
the applicable License Date, Arcus hereby grants to TAIHO a <FONT STYLE="white-space:nowrap">royalty-fee,</FONT> fully paid up exclusive license to use any Licensed Product-specific trademarks and trade dress Controlled by Arcus
(&#147;<B><I>Arcus</I></B><B><I> Trademarks</I></B>&#148;) in the Territory solely for the packaging, marketing, sale and/or promotion of Licensed Products. Such trademark license shall be sublicensable to an Affiliate, Sublicensee or Subcontractor
for use in connection with the Development and/or Commercialization of the Licensed Products for the Territory in accordance with this Agreement. As between the parties, ownership of all right, title and interest in and to, and all good will from
the use of, the Arcus Trademarks in the Territory shall vest in Arcus. TAIHO shall use the Arcus Trademarks in accordance with reasonable trademark guidelines that Arcus has provided to TAIHO from time to time. At least [***] days prior to
TAIHO&#146;s use of any Arcus Trademarks, TAIHO shall submit a sample of the proposed use for Arcus&#146; review and TAIHO shall make any reasonably requested changes to the use of the Arcus Trademark to the extent necessary for the use to comply
with such trademark guidelines. Arcus shall have the right at any time and from time to time to inspect samples of TAIHO&#146;s use of the Arcus Trademarks and TAIHO shall immediately remove and cease use of any instance of the Arcus Trademarks that
Arcus determines in its reasonable discretion to violate such trademark guidelines. Without limiting the foregoing, TAIHO shall have the right with respect to Licensed Products to brand such Licensed Products in the Territory using its own or a
Third Party&#146;s trademarks and trade names as it determines appropriate for such Licensed Product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL>; D<SMALL>ISCLAIMER</SMALL>; L<SMALL>IMITATION</SMALL> <SMALL>OF</SMALL> L<SMALL>IABILITY</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Mutual Representations and Warranties.</B> Each party represents and warrants to the other that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has
full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the
person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with,
nor constitute a breach of, any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound (including its organizational documents), nor violate any material law or regulation of any court, governmental
body or administrative or other agency having jurisdiction over it; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;neither this Agreement, nor any term
hereof, nor the performance of this Agreement by it or exercise of its rights hereunder (including without limitation, any right to terminate), is prohibited by, contrary to or in conflict with, or is ineffective or unenforceable, under any material
law or regulation of any organization, country, group of countries or political or governmental entity having jurisdiction over it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Arcus</B><B> Representations and Warranties.</B> Except as set forth in the Initial Disclosure Schedule
or pursuant to Section&nbsp;2.1(c) setting forth exceptions to the following representations and warranties, Arcus represents and warrants to TAIHO that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Arcus (i)&nbsp;has the right to grant the Option during the applicable Exercise Period and the License during the
applicable Exercise Period and for the remainder of the applicable Royalty Term (or such longer term during which TAIHO may have rights to Arcus <FONT STYLE="white-space:nowrap">Know-How</FONT> for the applicable Licensed Product); and (ii)&nbsp;has
not granted, and will not grant to any Third Party during the Exercise Period, and upon TAIHO&#146;s exercise of an Option in accordance with this Agreement with respect to an Arcus Program, for the remainder of the applicable Royalty Term (or such
longer term during which TAIHO may have rights to Arcus <FONT STYLE="white-space:nowrap">Know-How</FONT> for the applicable Licensed Product) any license or other right in the Territory in the Field with respect to a composition or intellectual
property that would be an Antibody, Compound, Therapeutic Product, or Arcus Technology, that conflicts with or is in derogation of the Option, licenses and rights granted to TAIHO herein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, <B>Exhibit 9.2(b)</B> lists all Third Party Agreements that pertain to any existing
Option or License; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, <B>Exhibit</B><B> 9.2(c)</B> lists all Arcus Partner Agreements;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, except for rights to Arcus Technology
obtained under Third Party Agreements listed in <B>Exhibit 9.2(b)</B>, Arcus Partner Agreements listed in <B>Exhibit 9.2(c)</B> and those agreements listed in<B> Exhibit 9.2(d)</B>, Arcus owns the entire right, title and interest in and to the Arcus
Technology; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, other than the Third Party Agreements listed in <B>Exhibit 9.2(b)</B>,
Arcus Partner Agreements listed in <B>Exhibit 9.2(c) </B>and those agreements listed in<B> Exhibit 9.2(e)</B>, there are no agreements between Arcus or its Affiliates on the one hand, and any Third Party on the other, that impose (or would be
reasonably foreseeable to impose with the passage of time) obligations or limitations with respect to the Information or Patent Rights being optioned and/or licensed to TAIHO hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp; (i) As of the Effective Date, the Third Party Agreements listed in <B>Exhibit 9.2(b) </B>are in full force and
effect, no written notice of default or termination has been received or given by Arcus under any such Third Party Agreement, and to the knowledge of Arcus, there is no act or omission by Arcus that would provide a right to terminate any such Third
Party Agreement and (ii)&nbsp;during the Exercise Period with respect to an Arcus Program, Arcus shall not amend, waive or otherwise modify or allow to terminate (or provide consent with respect to any amendment, waiver, modification or termination
of) the rights under any Third Party Agreement, in each case, in any manner that materially diminishes the options, licenses or rights granted to TAIHO hereunder, materially impairs TAIHO&#146;s ability to exercise its rights hereunder or otherwise
materially adversely affects TAIHO&#146;s rights with respect to Option Products, in all cases without the prior written consent of TAIHO, which shall not be unreasonably withheld or conditioned, (iii)&nbsp;upon TAIHO&#146;s exercise of an Option in
accordance with this Agreement with respect to an Arcus Program, for the remainder of the applicable Royalty Term (or such longer term during which TAIHO may have rights to Arcus <FONT STYLE="white-space:nowrap">Know-How</FONT> for the applicable
Licensed Product), Arcus shall not amend, waive or otherwise modify or allow to terminate (or provide consent with respect to any amendment, waiver, modification or termination of) the rights under any Third Party Agreement, in each case, in any
manner that diminishes the options, licenses or rights granted to TAIHO hereunder, impairs TAIHO&#146;s ability to exercise its rights hereunder or otherwise adversely affects TAIHO&#146;s rights with respect to a Licensed Product, in all cases
without the prior written consent of TAIHO, which shall not be unreasonably withheld or conditioned (it being understood that it will not be considered unreasonable for TAIHO to withhold or condition such consent to any such amendment, waiver,
modification or termination that diminishes the options, licenses or rights granted to TAIHO hereunder, impairs TAIHO&#146;s ability to exercise its rights hereunder or otherwise adversely affects TAIHO&#146;s rights with respect to a Licensed
Product, in each case, in any material way), and (iv)&nbsp;except as set forth in 5.6(c)(iii), Arcus shall be responsible for and pay all amounts owed by Arcus under Third Party Agreements; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, <B>Exhibit 9.2(g)</B> lists all Patent Rights with respect to which Arcus or its
Affiliates currently have any rights, or with respect to which they have at any time in the past had rights (other than Patent Rights that have been abandoned or lapsed in the normal course of prosecution), in each case that cover an Option Product;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, Arcus has complied with all Applicable
Laws in all material respects, including Applicable Laws relating to any disclosure requirements, in connection with the filing, prosecution and maintenance of the Arcus Patents and, to Arcus&#146;s knowledge, none of the issued Arcus Patents are
invalid or unenforceable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, the Arcus Technology is free and clear of all liens,
security interests or other encumbrances of any kind and during the Exercise Period, and upon TAIHO&#146;s exercise of an Option in accordance with this Agreement with respect to an Arcus Program, for the remainder of the applicable Royalty Term (or
such longer term during which TAIHO may have rights to Arcus <FONT STYLE="white-space:nowrap">Know-How</FONT> for the applicable Licensed Product), Arcus shall not permit the Arcus Technology to become encumbered by any liens, security interests or
other encumbrances, except (i)&nbsp;in a manner that does not materially adversely affect TAIHO&#146;s rights and licenses under this Agreement or (ii)&nbsp;with the prior written consent of TAIHO, which shall not be withheld unreasonably; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, to Arcus&#146; actual knowledge without any duty of investigation or search, the practice
of the Arcus Technology and the making, using, selling, offering for sale and importing of any Compound, Antibody or Therapeutic Product for which TAIHO has an Option or License does not infringe, violate, or misappropriate any intellectual property
rights of any Third Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, Arcus has not received written notice from any Third
Party claiming that the manufacture, use, sale, offer for sale or import of any Antibody, Compound or Therapeutic Product for which TAIHO has an Option or License or practice of the Arcus Technology infringes, misappropriates, or violates or would
infringe, misappropriate, or violate any intellectual property rights of any Third Party; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective
Date, there are no asserted claims, judgments or settlements against or owed by Arcus (or any of its Affiliates) with respect to the Arcus Technology, and Arcus is not a party to any legal action, suit or proceeding relating to the Arcus Technology,
nor has Arcus received any written communication from any Third Party, including, without limitation, any Regulatory Authority or other government agency, threatening such action, suit or proceeding; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, to Arcus&#146;s knowledge, there is no actual, pending, alleged or threatened
infringement by a Third Party of any of the Arcus Technology; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, neither Arcus nor any
of its Affiliates is debarred or disqualified under the Act or comparable Applicable Laws outside of the United States; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, neither Arcus nor any of its Affiliates has employed or otherwise used in any capacity,
in connection with the development or manufacture of any Option Products, the services of any person it knew to be debarred or disqualified under United States law, including 21 U.S.C. &#167;335a, or any foreign equivalent thereof; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;It shall comply, in all material respects, with all applicable
laws and regulations in each place where Licensed Product is advertised, marketed or sold by it or its Arcus Partners; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;To Arcus&#146;s knowledge, none of the material data or other Information provided by Arcus to TAIHO contain any
untrue statement of material fact or omit to state a fact where such omission makes the facts stated materially misleading. As of the Effective Date, there is no material matter within the knowledge of Arcus which Arcus has intentionally or
knowingly failed to disclose, which would have an adverse effect on the ability to Develop or Commercialize any Option Products or Licensed Products in any material manner; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;As of the Effective Date, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Arcus</B><B> Bring-Down</B>. For each Arcus Program that TAIHO exercises its Option, Arcus represents and
warrants that the representations and warranties of Arcus set forth in Section&nbsp;9.2 with respect to such Arcus Program are true and correct, and that any such representations and warranties that are stated to be made as of the Effective Date are
true and correct as of the applicable License Date (<I>i.e.</I>, substituting &#147;License Date&#148; for Effective Date), except as set forth in the last Bring-Down Disclosure Schedule provided by Arcus to TAIHO pursuant to Section&nbsp;2.1(c) for
such Arcus Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>TAIHO Representations and Warranties.</B> TAIHO represents and warrants to Arcus
that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;as of the Effective Date of this Agreement, neither TAIHO nor any of its Affiliates is debarred or
disqualified under the Act or comparable Applicable Laws outside the United States; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;it shall comply, in all
material respects, with all applicable laws and regulations in each place where Licensed Product is advertised, marketed or sold by it or its Sublicensees; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;TAIHO shall not [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.5</B>&nbsp;&nbsp;&nbsp;&nbsp; <B>Arcus</B><B> Covenants</B>. Arcus hereby covenants to TAIHO that Arcus will not: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;During the Term, assign any Arcus Patents for the Territory to a Third Party (including PACT) other than to a Third
Party Acquirer pursuant to a Sale Transaction conducted in accordance with Section&nbsp;13.4; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;During the
Exercise Period and, upon TAIHO&#146;s exercise of an Option in accordance with this Agreement with respect to an Arcus Program, for the remainder of the applicable Royalty Term (or such longer term during which TAIHO may have rights to Arcus <FONT
STYLE="white-space:nowrap">Know-How</FONT> for the applicable Licensed Product), grant any Third Party (including PACT) any license or other right with respect to, or assign to any Third Party (including PACT) rights to, Option Products, Licensed
Products or Arcus Technology, in each case, in derogation of the Option, licenses and rights granted to TAIHO hereunder; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;During the Exercise Period and, upon TAIHO&#146;s exercise of an
Option in accordance with this Agreement with respect to an Arcus Program, for the remainder of the applicable Royalty Term (or such longer term during which TAIHO may have rights to Arcus <FONT STYLE="white-space:nowrap">Know-How</FONT> for the
applicable Licensed Product), grant any Third Party (including PACT) any license or other right with respect to, or assign to any Third Party (including PACT) rights to Develop or Commercialize for the Territory (i)&nbsp;any composition that would
be an Option Product or Licensed Product (or Antibody or Compound thereof) or (ii)&nbsp;any intellectual property that would be Arcus Technology included under any potential or actual License, in each case of (i)&nbsp;and (ii) in derogation of the
Option, licenses and rights granted to TAIHO hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;During the Term, [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>TAIHO Covenants</B>. TAIHO hereby covenants to Arcus that during the Term, TAIHO will not: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Mutual Covenants.</B> In addition to any covenants made by it elsewhere in this Agreement, each party
hereby covenants to the other party as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;neither such party nor any of its Affiliates will knowingly
employ or use the services of any Person who is debarred or disqualified under United States law, including 21 U.S.C. &#167;335a, or any foreign equivalent thereof, in connection with activities relating to any Licensed Products; and in the event
that such party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any Person providing services to such party or any of its Affiliates with respect to any activities relating to any Licensed Products,
such party will promptly notify the other party in writing and such party will cease, or cause its Affiliate to cease (as applicable), employing, contracting with, or retaining any such Person to perform any services relating to the applicable
Licensed Product; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;neither such party nor any of its Affiliates will, in connection with the exercise of such
party&#146;s rights or performance of its obligations under this Agreement, directly or indirectly through Third Parties, pay, promise or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the
giving of anything of value to a public official or entity or other Person for purpose of obtaining or retaining business for or with, or directing business to, any Person, including such party and its Affiliates, nor will such party or any of its
Affiliates directly or indirectly promise, offer or provide any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift or hospitality or other illegal or unethical benefit to a public official or entity or any other Person in connection
with the exercise of such party&#146;s rights or performance of such party&#146;s obligations under this Agreement, in each case described above in this Section to the extent prohibited by Applicable Law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;neither such party nor any of its Affiliates (or any of their respective employees and contractors), in connection
with the exercise of such party&#146;s rights or performance of such party&#146;s obligations under this Agreement, shall cause the other party to be in violation of Anti-Corruption Laws or Export Control Laws; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;such party shall promptly notify the other party if such party has
any information or suspicion that there may be a violation of Anti-Corruption Laws or Export Control Laws in connection with the exercise of such party&#146;s rights or performance of such party&#146;s obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Disclaimer.</B> EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE, THE TECHNOLOGY AND INTELLECTUAL PROPERTY
RIGHTS AND OTHER MATERIALS AND INFORMATION PROVIDED BY EACH PARTY HEREUNDER ARE PROVIDED &#147;AS IS.&#148; EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE AND EXCEPT FOR ANY EXPRESSLY AGREED WARRANTIES PERTAINING TO THE SUPPLY OF LICENSED PRODUCT (IF
ANY), EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENTS, <FONT
STYLE="white-space:nowrap">NON-INFRINGEMENT</FONT> OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Limitation of Liability.</B> NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY, REGARDLESS
OF THE FORM OF ANY CLAIM OR ACTION (WHETHER IN CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE), FOR ANY SPECIAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER, EVEN IF SUCH PARTY HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES; <I>PROVIDED, HOWEVER,</I> THAT THIS SECTION&nbsp;9.9 SHALL NOT BE CONSTRUED TO LIMIT AMOUNTS OWED TO THIRD PARTIES IN CONNECTION WITH EITHER PARTY&#146;S INDEMNIFICATION OBLIGATIONS UNDER ARTICLE&nbsp;11,
EITHER PARTY&#146;S BREACH OF CONFIDENTIALITY UNDER SECTION 7, ANY VIOLATION OF THE OTHER PARTY&#146;S INTELLECTUAL PROPERTY RIGHTS, OR ANY LIABILITY FOR ITS GROSS NEGLIGENCE OR WILLFUL MISCONDUCT ([***]). THESE LIMITATIONS ARE INDEPENDENT FROM ALL
OTHER PROVISIONS OF THIS AGREEMENT AND SHALL APPLY NOTWITHSTANDING THE FAILURE OF ANY REMEDY PROVIDED HEREIN. NOTWITHSTANDING THE FOREGOING, NEITHER PARTY EXCLUDES OR LIMITS ITS LIABILITY IN THE CASE OF FRAUD OR TO THE EXTENT THAT ANY EXCLUSION OR
LIMITATION OF ITS LIABILITY IS VOID, PROHIBITED OR UNENFORCEABLE BY APPLICABLE LAW. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>T<SMALL>ERM</SMALL> <SMALL>AND</SMALL> T<SMALL>ERMINATION</SMALL>. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Term.</B> This Agreement shall commence on the Effective Date and shall remain in effect until
(a)&nbsp;expiration of the last Exercise Period if TAIHO has not exercised any of its Options prior to such expiration or (b)&nbsp;if TAIHO has exercised any of its Options prior to the expiration of the applicable Exercise Period, expiry of all
Royalty Terms for the Licensed Products, in each case unless earlier terminated in its entirety pursuant to Section&nbsp;10.2(a), (b), (c) or (d) (the &#147;<B><I>Term</I></B>&#148;). Upon the expiration of the Agreement under this
Section&nbsp;10.1, the licenses granted to TAIHO under this Agreement as of such expiration will become <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> fully-paid, royalty-free and perpetual, but shall otherwise remain subject to the terms
and conditions of this Agreement to the extent provided in Section&nbsp;10.3, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2&nbsp;&nbsp;&nbsp;&nbsp;Termination. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Breach</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Each party shall have the right to terminate this Agreement in its entirety upon written notice to the other party
if such other party is in material breach of this Agreement and has not cured such breach within [***] days (or [***] with respect to any undisputed payment breach) after notice from the terminating party requesting cure of the breach. Each party
shall have the right to terminate this Agreement with respect to an Arcus Program upon written notice to the other party if such other party is in material breach of this Agreement with respect to such Arcus Program and has not cured such breach
within [***]&nbsp;days (or [***] with respect to any undisputed payment breach) after notice from the terminating party requesting cure of the breach. Any such termination shall become effective at the end of such
<FONT STYLE="white-space:nowrap">[***]-day</FONT> (or [***] with respect to any undisputed payment breach) period unless the breaching party has cured such breach prior to the end of the applicable period, subject to Section&nbsp;12.2 below. If a
party would like to dispute a payment obligation, then such party shall notify the other party of such dispute, with reasonable details for the dispute, prior to the due date of the payment obligation. The disputing party shall cooperate and work
diligently with the other party to resolve any such dispute as soon as possible. All amounts owed and not disputed shall be paid by the applicable due date. Each party must act in good faith in disputing a payment obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding Section&nbsp;10.2(a)(i), if any material breach and failure to cure contemplated by
Section&nbsp;10.2(a)(i) by TAIHO applies only as to TAIHO&#146;s obligations under this Agreement with respect to a particular Arcus Program, Arcus shall not have the right to terminate this Agreement in its entirety, but shall instead have the
right to terminate this Agreement solely with respect to such Arcus Programs and any Licensed Products (including Companion Diagnostics therefor) within such Arcus Program, provided that if TAIHO materially breaches this Agreement and fails to cure
such breach as contemplated by Section&nbsp;10.2(a)(i) with respect to [***] or more Arcus Programs, then Arcus shall have the right to terminate this Agreement in its entirety under Section&nbsp;10.2(a)(i) if TAIHO again materially breaches this
Agreement and fails to cure such breach as contemplated by Section&nbsp;10.2(a)(i). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>Insolvency</B>. Either
party may terminate this Agreement immediately upon written notice to the other party in the event the other party shall have become insolvent or bankrupt, or shall have made an assignment of substantially all of its assets for the benefit of its
creditors, or there shall have been appointed a trustee or receiver of the other party for all or a substantial part of its property, or any case or proceeding shall have been commenced or other action taken by or against the other party in
bankruptcy or seeking reorganization, liquidation, dissolution, <FONT STYLE="white-space:nowrap">winding-up,</FONT> arrangement, composition or readjustment of its debts or any relief under any bankruptcy, insolvency, reorganization or other similar
act or law of any jurisdiction now or hereinafter in effect that has not been dismissed within [***] days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;[***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;[***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<B>Post-Breach Continuation</B>. In the event TAIHO has the right to terminate this Agreement under
Section&nbsp;10.2(a)(i) above because of Arcus&#146; uncured material breach of this Agreement, then subject to Section&nbsp;12.2 below, as an alternative to exercising its right to terminate this Agreement in its entirety or with respect to the
Arcus Program to which such uncured material breach relates, TAIHO may in its discretion elect to continue this Agreement (&#147;<B><I>Post-Breach Continuation</I></B>&#148;) by providing written notice of such election to Arcus. Following delivery
of such notice, with respect only to the Arcus Program to which such uncured material breach relates, unless Arcus has failed to cure material breaches with respect to [***] or more Arcus Programs, in which case with respect to this Agreement in its
entirety, unless an alternative arrangement is agreed in writing by the Parties within&nbsp;[***] days following Arcus&#146; request to TAIHO to discuss alternative arrangements to subsections (i)&nbsp;through (iv) below, which discussions will be
held by both Parties in good faith considering the type and scope of Arcus&#146; uncured material breach and which request by Arcus must be made within [***] following delivery of the Post-Breach Continuation notice from TAIHO: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as expressly set forth above, in
the case of a Post-Breach Continuation, the terms and conditions of this Agreement shall otherwise remain in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3&nbsp;&nbsp;&nbsp;&nbsp;Effect of Expiration or Termination. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<B>Any Termination.</B> Upon any termination of this Agreement, as a whole (<I>i.e.</I>, with respect to all
Licensed Products and Companion Diagnostics therefor) or with respect to a particular Licensed Product and Companion Diagnostics therefor, prior to its expiration, all licenses and rights granted by either party to the other party pursuant to this
Agreement with respect to the terminated Licensed Products and Companion Diagnostics therefor (the one or more particular Licensed Products and Companion Diagnostics therefor so terminated, or all Licensed Products and Companion Diagnostics therefor
so terminated, as the case may be, &#147;<B><I>Terminated Products</I></B>&#148;) shall automatically terminate and revert to the granting party, and all other rights and obligations of the parties under this Agreement with respect to the Terminated
Products shall terminate; in each case, except as expressly provided below in this Section&nbsp;10.3 or elsewhere in this Article&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<B>Exceptions.</B> Upon the termination, but not expiration, of this Agreement, as a whole or with respect to a
particular Terminated Product, the following provisions of this Section&nbsp;10.3(b) shall apply solely with respect to, and only to the extent applicable to, each Terminated Product for which Arcus (or an Arcus Partner) has Initiated Clinical
Trials prior to the date of notice of such termination (each such Terminated Product, a &#147;<B><I>Reverted Product</I></B>&#148;). For avoidance of doubt, the following provisions of this Section&nbsp;10.3(b) shall not apply to a Terminated
Product if Arcus or an Arcus Partner has not Initiated Clinical Trials on such Terminated Product prior to such notice of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<B>Partial Termination</B>. For avoidance of doubt, if this
Agreement is terminated only as to one or more Arcus Programs and not in its entirety, then from and after such termination, the terminated Arcus Program shall no longer be deemed an Arcus Program, and the Licensed Products and Companion Diagnostics
therefor within such Arcus Program shall be Terminated Products and shall no longer be deemed Licensed Products or Companion Diagnostics, for all purposes of this Agreement. In such event the provisions of this Section&nbsp;10.3 shall apply only
with respect to the Reverted Products comprising such Terminated Products, <I>mutatis mutandis</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Accrued Obligations; Survival.</B> Neither expiration nor any termination of this Agreement shall
relieve either party of any obligation or liability accruing prior to such expiration or termination, nor shall expiration or any termination of this Agreement preclude either party from pursuing all rights and remedies it may have under this
Agreement, at law or in equity, with respect to breach of this Agreement. In addition, the parties&#146; rights and obligations under Sections&nbsp;3.2 (with respect to the Arcus License only and not if this Agreement is terminated by TAIHO pursuant
to Section&nbsp;10.2(a) or 10.2(b); and in any event, such survival of the Arcus License shall apply only to the Taiho Technology generated prior to the effective date of termination or expiration, as the case may be and the foregoing survival of
the Arcus License shall not limit the terms of Section&nbsp;10.3(b)(v) above), 3.3(d) (to the extent necessary for Arcus to exercise its rights under the first sentence of this Section&nbsp;10.4), 3.4(b) (with respect to [***] corresponding to the
surviving rights and/or obligations under this Agreement), 3.6, 4.8 (with respect to any surviving rights and/or obligations under any CMO Supply Agreement or supplemental agreement entered into pursuant to Section&nbsp;4.8(b)(iii)), 4.11 (with
respect to any legally required continuing exchange of safety-related data under a PV Agreement), <FONT STYLE="white-space:nowrap">6.1-6.3</FONT> (with respect to payment obligations accruing prior to, but not yet paid as of, the effective date of
termination), 6.4 (for a period of [***] years from the end of the calendar year in which termination or expiration occurs), 6.5, 7.1, 7.2, 7.3, 7.6, 8.2 (but only with respect to the introductory language preceding Section&nbsp;8.2(a) and the
entirety of Section&nbsp;8.2(c) and Section&nbsp;8.2(d) to the extent necessary for the prosecution and maintenance of Joint Patents under Section&nbsp;8.2(c)), 8.4 (with respect to Joint Patents or Arcus Patents or TAIHO Patents, as the case may
be, to which the other party retains a license following the effective date of such expiration or termination, as applicable), 8.5 (with respect to infringement action initiated prior to the effective date of termination), 9.8, 9.9, 11.1, 11.2,
11.3, and Articles&nbsp;1 (to the extent required to interpret or enforce other surviving rights and/or obligations), 5 (with respect to payment obligations accruing prior to, but not yet paid as of, the effective date of termination), 10, 12, and
13 of this Agreement shall survive expiration or any termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Return of
Confidential Information.</B> Within [***]&nbsp;days following the termination of this Agreement, except to the extent that a party retains a license from the other party as provided in this Article&nbsp;10, each party shall promptly return to the
other party, or delete or destroy, all relevant records and materials in such party&#146;s possession or control containing Confidential Information of the other party; provided that such party may keep one copy of such materials for archival
purposes only subject to Article&nbsp;7. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Damages; Relief.</B> Termination of this Agreement
shall not preclude either party from claiming any other damages, compensation or relief that it may be entitled to hereunder as a result of the other party&#146;s breach of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination Absolute.</B> Each party understands that the rights of termination hereunder are absolute
and that it has no right to a continued relationship with the other after termination, except as expressly stated herein. Neither party shall incur any liability whatsoever for any damage, loss or expense of any kind suffered or incurred by the
other (or for any compensation to the other) arising from or incident to any termination of this Agreement for any reason which complies with the terms of the Agreement whether or not such party is aware of any such damage, loss or expense. [***].
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>I<SMALL>NDEMNIFICATION</SMALL>. </B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnification
by TAIHO.</B> TAIHO hereby agrees to save, defend, indemnify and hold harmless Arcus, its Affiliates and Arcus Partners (only for so long as the applicable Arcus Partner is [***]),<B><I> </I></B>and its and their respective officers, directors,
agents, employees, successors and assigns (the &#147;<B><I>Arcus</I></B><B><I> </I></B><B><I>Indemnitees</I></B>&#148;), from and against any and all Losses, to which any Arcus Indemnitee may become subject as a result of any claim, demand, action
or other proceeding by any Third Party (each, a &#147;<B><I>Claim</I></B>&#148;) to the extent such Losses arise out of or relate to: (a)&nbsp;the Development, manufacture, use, handling, storage, sale, offer for sale, import, Commercialization or
other disposition by or on behalf of TAIHO or any of its Sublicensees of Licensed Products, or any other exercise of the License by or on behalf of TAIHO or any of its Sublicensees, including without limitation, manufacture of products for TAIHO
pursuant to Section&nbsp;4.8 and any Claim that arises or relates to [***]; (b) TAIHO&#146;s use of materials provided by Arcus to TAIHO under Section&nbsp;4.3, (c)&nbsp;the gross negligence or willful misconduct of any TAIHO Indemnitee (defined
below); or (d)&nbsp;the breach by TAIHO of any warranty or representation made by TAIHO in this Agreement or any covenant under Sections 9.6 or 9.7; except, in each case, to the extent such Losses result from the gross negligence or willful
misconduct of any Arcus Indemnitee or for which Arcus is obligated to indemnify under Section&nbsp;11.2 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnification by </B><B>Arcus</B><B>.</B> Arcus hereby agrees to save, defend, indemnify and hold
harmless TAIHO, its Affiliates and Sublicensees and its and their respective officers, directors, employees, successors and assigns (the &#147;<B><I>TAIHO </I></B><B><I>Indemnitees</I></B>&#148;) from and against any and all Losses to which any
TAIHO Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party to the extent such Losses arise out of or relate to: (a)&nbsp;the Development, manufacture, use, handling, storage, sale, offer for
sale, import, Commercialization or other disposition of Licensed Products by or on behalf of Arcus, its Affiliates or any of its Arcus Partners, (b)&nbsp;the exercise of (i)&nbsp;the Arcus License by or on behalf of Arcus or any of its Affiliates,
Arcus Partners licensees or sublicensees, or (ii)&nbsp;if applicable, any license granted to Arcus pursuant to Section [***]; (c)&nbsp;the gross negligence or willful misconduct of any Arcus Indemnitee; or (d)&nbsp;the breach by Arcus of any
warranty or representation made by Arcus in this Agreement or any covenant under Sections 9.5 or 9.7; in each case except to the extent such Losses result from the gross negligence or willful misconduct of any TAIHO Indemnitee or for which TAIHO is
obligated to indemnify under Section&nbsp;11.1 above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Control of Defense.</B> In the event a party (the
&#147;<B><I>Indemnified Party</I></B>&#148;) seeks indemnification under Section&nbsp;11.1 or 11.2, it shall inform the other party (the &#147;<B><I>Indemnifying Party</I></B>&#148;) of a claim as soon as reasonably practicable after it receives
notice of the claim (it being understood and agreed, however, that the failure by an Indemnified Party to give notice of a claim as provided in this Section&nbsp;11.3 shall not relieve the Indemnifying Party of its indemnification obligation under
this Agreement except to the extent that such Indemnifying Party is actually damaged or prejudiced as a result of such failure to timely give notice), shall permit the Indemnifying Party to assume direction and control of the defense of the claim
(including the right to settle the claim), and shall cooperate as reasonably requested (at the expense of the Indemnifying Party) in the defense and/or settlement of the claim. If the Indemnifying Party does not assume control of such defense within
thirty (30)&nbsp;days after receiving notice of the claim from the Indemnified Party or if the Indemnifying Party fails to actively and diligently conduct such defense and does not cure such failure within thirty (30)&nbsp;days after receiving
written notice thereof from the Indemnified Party with reasonable details of such failure, the Indemnified Party shall control such defense and, without limiting the Indemnifying Party&#146;s indemnification obligations, the Indemnifying Party shall
reimburse the Indemnified Party for all reasonable costs, including reasonable attorney fees, incurred by the Indemnified Party in defending itself. The party not controlling such defense may participate therein at its own expense. The party
controlling such defense shall keep the other party reasonably advised of the status of such action, suit, proceeding or claim and the defense thereof and shall consider recommendations made by the other party with respect thereto. The controlling
party shall not agree to any settlement of such action, suit, proceeding or claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Indemnified Party from all liability with respect
thereto or that acknowledges fault by the Indemnified Party without the prior written consent of the Indemnified Party, which shall not be unreasonably withheld. If the parties cannot agree as to the application of Section&nbsp;11.1 or 11.2 to any
claim, pending resolution of the dispute pursuant to Article&nbsp;12, the parties may conduct separate defenses of such claims, with each party retaining the right to claim indemnification from the other party in accordance with Section&nbsp;11.1 or
11.2, as applicable, upon resolution of the underlying claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.4</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Insurance.</B> Each party shall
procure and maintain insurance, including comprehensive or commercial general liability insurance (including contractual liability and product liability), adequate to enable it to cover its obligations hereunder and which is consistent with normal
business practices of prudent companies similarly situated, provided however that either party may satisfy all or part of its obligation through an insurance captive or reasonable plan of self-insurance. It is understood that such insurance shall
not be construed to create a limit of either party&#146;s liability with respect to its indemnification obligations under this Article&nbsp;11 or otherwise. Each party shall provide the other party with written evidence of such insurance promptly
upon request. Each party shall provide the other party with written notice at least ten (10)&nbsp;days prior to cancellation or <FONT STYLE="white-space:nowrap">non-renewal</FONT> without substitute insurance that meets the obligations above or
material change in such insurance which materially adversely affects the rights of the other party hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>D<SMALL>ISPUTE</SMALL> R<SMALL>ESOLUTION</SMALL>. </B> </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Disputes.</B> If the parties are unable to resolve any dispute between them arising out of or in
connection with this Agreement, either party may, by written notice to the other, have such dispute referred to the Executives of the parties for attempted resolution by good faith negotiations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.2&nbsp;&nbsp;&nbsp;&nbsp;Arbitration. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Except that either party may seek equitable or similar relief from any court of competent jurisdiction, any dispute,
controversy or claim arising out of or in relation to this Agreement that cannot be settled amicably by agreement of the parties hereto shall be finally and exclusively settled in accordance with the arbitration rules of JAMS (f/k/a Judicial and
Mediation Services), then in force by one or more arbitrators appointed in accordance with said rules. The appointing authority shall be JAMS. The place of any arbitration shall be San Francisco, CA, USA. The proceedings shall be in English and the
governing law shall be as set forth in Section&nbsp;13.1. The monetary award and/or any other decision rendered shall be written in the English language only. The arbitrator may only award damages as permitted by Sections 9.8 and 9.9, and the
arbitrator has no right to materially modify Section&nbsp;9.9 of this Agreement. The monetary award and/or any other decision rendered shall be final and binding on the parties, and judgment on the award may be entered in any court of competent
jurisdiction. The costs of any arbitration, including administrative fees and fees of the arbitrator(s), shall be shared equally by the parties, unless otherwise specified by the arbitrator(s). Each party shall bear the cost of its own
attorneys&#146; and expert fees; provided that the arbitrator(s) may in their discretion award to the prevailing party the costs and expenses incurred by the prevailing party in connection with the arbitration proceeding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event a party disputes in good faith whether it is in breach of this Agreement and so notifies the other
party in writing prior to the expiration of the applicable cure period set forth in Section&nbsp;10.2(a) above, the cure period shall be tolled from the date of such notice. Promptly following the initiation of a proceeding under this
Section&nbsp;12.2 with respect to such dispute, the arbitrator shall make a determination as to whether there is a good faith dispute as to the existence of a material breach of this Agreement. If the arbitrator determines there is no good faith
dispute, then the cure period shall end as of the end of the remainder of the cure period set forth in Section&nbsp;10.2 (after giving effect to the tolling of such cure period up to the date of such determination), and the allegedly breaching party
shall have no further right to cure the disputed breach after the end of such cure period. If the arbitrator determines that there is a good faith dispute as to the existence of a material breach of this Agreement, the Agreement shall not terminate
by reason of the disputed breach unless and until it has been finally determined in accordance with this Section&nbsp;12.2 that a material breach actually occurred, and the breaching party fails to cure such breach within [***] days after such final
determination (or such longer period as the arbitrator may specify). In addition, in the event of a Post-Breach Continuation, if the parties are unable to agree on whether and to what extent an adjustment should be made under [***] above, payment of
any amounts due from the event giving rise to such Post-Breach Continuation shall be put into an escrow account until the adjustment (if any) has been determined (either by agreement of the parties or pursuant to this Section&nbsp;12.2). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>M<SMALL>ISCELLANEOUS</SMALL>. </B> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.1</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Governing Law.</B>
This Agreement shall be governed by and construed in accordance with the laws of the State of California, USA, excluding its conflicts of laws principles. The United Nations Convention on Contracts for the International Sale of Goods shall not apply
to this Agreement. In the event of any conflict between the laws and regulations of the United States and any other nation or jurisdiction, the laws and regulations of the United States shall govern. Except as specifically provided otherwise, each
right and remedy in this Agreement is in addition to any other right and remedy, at law or in equity, and the exercise of one right or remedy will not be deemed a waiver of any other right or remedy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.2</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Entire Agreement; Amendments.</B> This Agreement is both a final expression of the parties&#146;
agreement and a complete and exclusive statement with respect to all of its terms. This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written or otherwise, concerning any and all matters contained
herein, including any Confidentiality Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.3</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><FONT STYLE="white-space:nowrap">Non-Waiver.</FONT></B> The failure of a party to insist upon strict
performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any
other instance. Any waiver by a party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.4&nbsp;&nbsp;&nbsp;&nbsp;Assignment. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be
assigned or otherwise transferred by either party without the prior written consent of the other party (which consent shall not be unreasonably withheld, conditioned, or delayed); <I>provided, however,</I> that either party (the
&#147;<B><I>Assigning Party</I></B>&#148;) may assign this Agreement and its rights and obligations hereunder without the other party&#146;s consent: (i)&nbsp;to a successor to all or substantially all of the business of such party to which this
Agreement relates (&#147;<B><I>Third Party Acquirer</I></B>&#148;), whether by merger, sale of stock, sale of assets, change of control or otherwise (each, a &#147;<B><I>Sale Transaction</I></B>&#148;)<I> </I>or (ii)&nbsp;to an Affiliate, provided
that the Assigning Party shall remain liable and responsible to the <FONT STYLE="white-space:nowrap">non-assigning</FONT> party hereto for the performance and observance of all such duties and obligations by such Affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;[***]. Neither party shall enter into or become the subject of a change of control or party to a Sale Transaction,
unless (x) [***] (the &#147;<B><I>Acquiring Party</I></B>&#148;) agrees to [***], and (y)&nbsp;the ultimate parent company of the Acquiring Party [***]. In the event of any such change of control or Sales Transaction (whether this Agreement is
actually assigned or is assumed by the Third Party Acquirer or the surviving corporation resulting from such Sale Transaction by operation of law (<I>e.g.</I>, in the context of a reverse triangular merger)): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;intellectual property rights, antibodies, compounds, compositions and products Controlled by the Acquiring Party
prior to the Sale Transaction or change of control shall not be included in the technology licensed hereunder (<I>i.e.</I>, the Arcus Technology, in the case of a Sale Transaction or change of control involving Arcus, or the TAIHO Technology in the
case of a Sale Transaction or change of control involving TAIHO), and shall not be deemed to be Antibodies, Compounds or Therapeutic Products (or Licensed Products, Option Products, or Companion Diagnostics within an Arcus Program) for purposes of
this Agreement, provided that this Section&nbsp;13.4(b)(i) shall not limit the other party&#146;s rights to intellectual property rights, antibodies, compounds, compositions and products existing prior to such Sales Transaction or change of control
(<I>e.g.</I>, where the Acquiring Party is an Arcus Partner); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Patent Rights, Information, antibodies, compounds, compositions
and products that, following such change of control or Sale Transaction, are developed, made or otherwise acquired or Controlled by the Acquiring Party or its Affiliate without material use of the Arcus Technology or the TAIHO Technology shall not
for purposes of this Agreement be included within the Arcus Technology (in event of a change of control or Sales Transaction with respect to Arcus) or the TAIHO Technology (in event of a change of control or Sales Transaction with respect to TAIHO),
and shall not be deemed to be Antibodies, Compounds or Therapeutic Products (or Licensed Products, Option Products, or Companion Diagnostics within an Arcus Program) or included in Arcus Technology or TAIHO Technology for purposes of this Agreement.
However, notwithstanding the definition of &#147;Arcus Partner&#148; in Section&nbsp;3.4(a) above, if the Acquiring Party or its Affiliate was an Arcus Partner prior to the Sale Transaction, it shall continue to be deemed an Arcus Partner,
notwithstanding that, as a result, it became an Affiliate (and not a Third Party). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the foregoing
Sections 13.4(a) and 13.4(b), the rights and obligations of the parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the parties, and the name of a party appearing herein will be
deemed to include the name of such party&#146;s successors and permitted assigns to the extent necessary to carry out the intent of this section. Any assignment not in accordance with this Agreement shall be void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;If TAIHO assigns this Agreement pursuant to Section&nbsp;13.4(a) above and such assignment subjects any of the
amounts contemplated in this Agreement to any deduction of tax or withholding tax in excess of the amount of such deduction tax or withholding tax that would have been imposed had the payor been a resident of Japan or the United States for income
tax purposes (an &#147;<B><I>Excess Withholding Tax</I></B>&#148;), but not, for the avoidance of doubt, because of any assignment of this Agreement by Arcus, then any amounts subject to such Excess Withholding Tax shall be increased to the extent
necessary to ensure that Arcus receives a sum equal to the sum which it would have received had no such Excess Withholding Tax been applicable, net of any tax credit Arcus is entitled to claim for such Excess Withholding Tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.5</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Force Majeure.</B> Each party shall be excused from liability for the failure or delay in performance of
any obligation under this Agreement by reason of any event beyond such party&#146;s reasonable control, including but not limited to Acts of God, fire, flood, explosion, earthquake, or other natural forces, war, civil unrest, acts of terrorism, any
lack or failure of transportation facilities, any lack or failure of supply of raw materials, any strike or labor disturbance, or any other event similar to those enumerated above. Such excuse from liability
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the party has not caused such event(s) to occur. The affected
party shall notify the other party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake reasonable efforts necessary to cure such force majeure circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.6</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Severability.</B> If any one or more of the provisions contained in this Agreement is held invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely
affects the substantive rights of the parties. The parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical,
implement the purposes of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.7</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Notices.</B> Any notice to be given under this Agreement
must be in writing, in English and delivered either in person, by any method of mail (postage prepaid), or by internationally-recognized express courier, to the party to be notified at its address(es) given below, or at any address such party has
previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a)&nbsp;the date of actual receipt; (b)&nbsp;if mailed, seven (7)&nbsp;days after the date of postmark;
(c)&nbsp;if delivered by express courier, the next Business Day the express courier regularly makes deliveries; or (d)&nbsp;if delivered by email, upon the date upon which the receipt of such email is confirmed by return email or other written or
electronic confirmation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If to Arcus, to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Arcus Biosciences, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3928 Point Eden Way</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hayward, CA 94545</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">USA</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Juan Jaen, Ph.D., President</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: jjaen@arcusbio.com</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CC: Legal Affairs</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email: contracts@arcusbio.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">If to TAIHO, to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TAIHO PHARMACEUTICAL CO., LTD.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">1-27,</FONT> <FONT STYLE="white-space:nowrap">Kandanishiki-cho</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chiyoda-ku, Tokyo
<FONT STYLE="white-space:nowrap">101-8444</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Japan</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn:
Atsushi Azuma, Director, Business Development Department</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: azumaa@taiho.co.jp</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With a copy (which shall not constitute notice) to:</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilson Sonsini Goodrich&nbsp;&amp; Rosati PC</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">650 Page Mill Road</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, California 94304-1050</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">USA</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Kenneth A. Clark, Esq.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email: kclark@wsgr.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.8</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Interpretation.</B> The headings of clauses contained in this Agreement
preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. All
references in this Agreement to the singular shall include the plural where applicable. The term &#147;including&#148; or &#147;includes&#148; as used in this Agreement means including, without limiting the generality of any description preceding
such term, and the word &#147;or&#148; has the inclusive meaning represented by the phrase &#147;and/or.&#148; In context of the phrase &#147;not to be unreasonably withheld,&#148; &#147;shall not be unreasonably withheld&#148;, &#147;not withhold
unreasonably,&#148; and the like, the words &#147;withheld&#148; and &#147;withhold&#148; shall mean &#147;withheld, conditioned or delayed&#148; and &#147;withhold, condition or delay&#148;, respectively. Unless otherwise specified, references in
this Agreement to any section shall include all subsections and paragraphs in such Section and references in this Agreement to any subsection shall include all paragraphs in such subsection. All references to days in this Agreement shall mean
calendar days, unless otherwise specified. Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either party, irrespective of which party may be deemed to have caused the ambiguity or uncertainty to exist. This
Agreement has been prepared in the English language, and the English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between
the parties regarding this Agreement shall be in the English language. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.9</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Relationship between the
Parties.</B> The parties&#146; relationship, as established by this Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture or similar business relationship between the parties. Neither
party is a legal representative of the other party, and neither party may assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other party for any purpose whatsoever. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.10</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>No Third Party Rights.</B> The provisions of this Agreement are for the exclusive benefit of the
parties, and no other person or entity shall have any right or claim against any party by reason of these provisions or be entitled to enforce any of these provisions against any party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.11</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Counterparts.</B> This Agreement may be executed in counterparts, each of which shall be deemed an
original document, and all of which, together with this writing, shall be deemed one instrument. This Agreement may be executed by facsimile or PDF signatures, which signatures shall have the same force and effect as original signatures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page follows.</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL>,</B> the parties have duly
executed this Option and License Agreement as of the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>TAIHO P<SMALL>HARMACEUTICAL</SMALL> C<SMALL>O</SMALL>., L<SMALL>TD</SMALL>.</B>,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>A<SMALL>RCUS</SMALL> B<SMALL>IOSCIENCES</SMALL>, I<SMALL>NC</SMALL>.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Masayuki Kobayashi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Terry Rosen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Masayuki Kobayashi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Terry Rosen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">President&nbsp;&amp; Representative Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit 1.82 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Initial Disclosure Schedule </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit 1.107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Option Product Pipeline and Development Timeline as of the Effective Date </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit 4.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Form of MTA </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit 9.2(b) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Third Party Agreements </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit 9.2(c) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Arcus Partner Agreements </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit 9.2(d) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Arcus Technology </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit 9.2(e) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Other Agreements </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONFIDENTIAL TREATMENT REQUESTED </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit 9.2(g) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Arcus Patent Rights </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*** CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g317356g02z15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g02z15.jpg
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MD[*UN-+7&"(Q-G66F+.YU-49(R1!4]C9)78F)S(S-%'6_\0 & $! 0$! 0
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M\98B6A=*(QK8HD\5"#5&PK*.W7/\;CR'_I)Z]?U9*ZP3A&[UE.7"& P& P&
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MKOHZ;ZI.T&ZZ1FN[E'LEAA# 8# 8'GH_+8I+."FT6DT>DNH,JY!&N8^:&F>
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MFT(!1M%*4_+$CYA?R:M:+Z_Y<[ZX[..AM\L:H*PMUDQ'6;!H[-V([4NDU:2
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MB_DRKMX7I*/E%[S2>FS1Q\:> ODY'5NOP[X]M^-NA[/KZTM+/[O*?FA*&G[
M[*RN2OAUR=<8G4$91!N7K"2@;[8VF[?'4WXU!L#5C[:MX>HS;.1[@F_W,<DE
M]&ZHU%ERQ4V(:N&Q)B-$UX42/PA@5IO2M?JMV/O-U)^K]BX>N1S^$N;!AUF
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MQ?>(P9GHP="BA>N9PR=<6\H;?F9<W("9ND/;FXI2E:5B^.S73K];J8+'^&#
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M1K6;D.5!K29N@BW-(V<-T29$EG"0C?@8FV?B*7WS6EJEV-VNMVG1HVMMV&3
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MR(K.O#!C,_TDZLRHJ6.R.H QHV><;/#A<B7E+DD8>J :TBZSXH]4/<N7[YR
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M<Q6^E?EVKG7:9KKKIKKIIKQKIIKQKKKKQ\'&NNO'P:Z\<<?N<<<<<<<<<?\
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M-V[<86Z:4I7LS71?3AI;5.HTRM">"YA*IJ2Y/1$^,I>00B0[ I#%D2YB14=
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A:3+!7=?%# C8R;.Q.0.V8F(BOE?'R[#?ONV[89,!@?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g317356g08r74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g08r74.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!#0)' P$1  (1 0,1 ?_$ !\  0
M!P$! 0$            $!08'" D*"P,! O_$ &T0   % P$ !PT-$0T&!00#
M   " P0% 08'" D3%!98E]81$A47&!D:5%>3F-37(3<Y57>4E9:VTM/5V HX
M4U9D96ER>*2HM+>XT>3H(C$T-3919W1U=I*GYB-9A(BSM20S07&R)3)2D29A
M<__$ !D! 0$! 0$!               ! @0#!?_$ #H1  (  @4* P<% 0$!
M 0$    ! A$A,5&1T0,2$T%287&2H;$R@>$48J+!TN+P!"(S4W*R\4(C@O_:
M  P# 0 "$0,1 #\ [^                       '"!LS>K[5GB[9)-1=BX
MRU0ZB<=61"%Q)T%LZQ,V9*M&U8CHE@[&LM(]"[>M^YH^(C]WRK]])O=R,TMU
M2#UV]7VQRX64/ZPI9JH6O5O!J]ZO[7?PU]6_A(9CY9#4E8KD!U?VN_AKZM_"
M0S'RR"2L5R ZO[7?PU]6_A(9CY9!)6*Y =7]KOX:^K?PD,Q\L@DK%<@.K^UW
M\-?5OX2&8^6025BN0'5_:[^&OJW\)#,?+()*Q7(#J_M=_#7U;^$AF/ED$E8K
MD!U?VN_AKZM_"0S'RR"2L5R ZO[7?PU]6_A(9CY9!)6*Y =7]KOX:^K?PD,Q
M\L@DK%<@.K^UW\-?5OX2&8^6025BN0'5_:[^&OJW\)#,?+()*Q7(#J_M=_#7
MU;^$AF/ED$E8KD!U?VN_AKZM_"0S'RR"2L5R ZO[7?PU]6_A(9CY9!)6*Y =
M7]KOX:^K?PD,Q\L@DK%<@.K^UW\-?5OX2&8^6025BN0'5_:[^&OJW\)#,?+(
M)*Q7(#J_M=_#7U;^$AF/ED$E8KD!U?VN_AKZM_"0S'RR"2L5R ZO[7?PU]6_
MA(9CY9!)6*Y =7[KOX:^K?PD,Q\L@DK%<@?O5^Z\.&OJX\(_,?+()*Q7('YU
M?VN_AKZM_"0S'RR"2L5R ZO[7?PU]6_A(9CY9!)6*Y _NNOG7I1,JM=:>KJB
M1S'(16NHW,M$SG3H6IRE/6\N=,8E#DJ<M*UJ6ABUK2G/4YJ2L5R!_'5_:[^&
MOJW\)#,?+()*Q7(#J_M=_#7U;^$AF/ED$E8KD!U?NN_AKZM_"0S'RR"2L5R
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M:[#=?]:UK75;IBK6M:UK6K/4E6M:U\VM:UKI]YM:UK^_4,V+9=\/U#/AMZ/
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MKQ1>78%IAH                 78SMY\F3/[Y3GXZH,9/P0\ 6G&P
M         94:*?GF,;_:WC[@KH'GE?XXO+_I&H/$O/LS?@.,]@
M           -!VM7YYC)'_M9_N#M@=F2_CA\_P#IGC'XGY=D8L#T,@
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MDEOU3Z3]#$,>Q    NQG;SY,F?WRG/QU08R?@AX M.-@N#B:!C+IRCCFV9M
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M\T>RI2=ID@0!E1HI^>8QO]K>/N"N@>>5_CB\O^D:@\2\^S-^ XSV
M              T':U?GF,D?^UG^X.V!V9+^.'S_ .F>,?B?EV1BP/0R
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M+:N<VNBZU"<[MA^>LE8OR6"N0/CT2D:\Y6L@]YJ?,H3_ ,4O^XI1M1G2A/\
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MLJJ3F'4.:J0(0QC&-4QJU,8U:F,8U:U,8U:\VM:UKYM:UKYM:U\VM?-J /P
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M50I#&)0_-H4U:<RM?0%TK.\[3,7]2L;W6H#+\4/GV*JGP^:+4#1
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M/L55/A\T6H&B                 79O3SM,,_V9?'NT?C*\47EV!:8:
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MF$X&P                /2I^9KO0F\1>J;G#\H#\#@_5>-<,#?.!S
M           1TG_&#S^L*?\ RJ!76^+[D"!               "=6]_'#/\
MXC\57 W!7Y?-&@K.OGW9A]5&_O=5*CN@\$/^8>R,NM\7W*-L^X3VC=MK76FU
M*^4MBXX2X2,CJU0(\/"R;62*U.N5-4R)7!FU$C*T24JG0]3T3/6G.UK4TU:F
MKR*BDOV74L_>P$?;=PVLE*,4XN\H*7?L)M:'GY6'NAS9R\>FG*ECGI6<C;C:
MQX*%:R"C-\F^M]L6+=,J%H993ST=,T[*&IJ=*=$]<V]5-,RSU?CJP1\)O4K-
M32CY4]O-&VZV&0F!42R*KEJ0M\I6^W17<M7K1=*17AT+=:[<9[16DTNJLNZH
MASU4ZU9-+79TG59.>JH3(6V=0S^$AIUC(VZ24?SE9>KI)A*(V[8TG63@VT&W
MK<>-(V%K:L@I$)M2.F#J$0MA\JXK4\DZ?GI0]#R:;G.S>^9N=.^=% G^:KJN
M$I2(ASJ0E7*<@B:WBT0D$+B;G0Z-N3(E)/X>9XDYE4]QT*<K)%H6>3+6A:*.
M#[B_V12T=UFCJILG16U%.=>_>)_/JI=JB>S6J*LE1,C*PF<8@FWGT2H$F4#$
M)6X)['$\OSIVENQZJY&BV/$6K=>2/(2[A"3.I)RT@[:;H=-%KSNG'?OP2$]4
MKO+#_P!+8QF5619+)>^2U.CMM90E:34O"-)U6%?Q\@UGG<[%+QLY2.D"EJS.
M^>,ER.8I=-XU<J5YQNN5)5/3A?[9.3A4IRG7+5/<0KIAJ34BH!.!BK$B(=LQ
ME7JL0C&.FY6;.WY"YHJYG,&Y/)0LG/NU=T12:*4@A<3! U3I.GL4]<LV9T9H
MZ9MSXSG.34ZY:ZI%G1^53GQO;*85SBZ4O[&U][W6]%<=2+V01C>B2E4Y6KW(
M=T9 JDJYW'0S2B:US*1E#E1<5,FT(ZJ6AEJH)W-HB4_%NJ_:H;::$)U;JKYD
MXL[-UI6+(J.('&3JD=ODL.\T(]Y?3ARLE=-@O[@<Q[P[ZEMI55C7;6X7#9Q&
M4:I&*NV;NBO:DJLT4R\FW7%J:\.I^83E>G<32TM1CF-E[=*^BR,XV/Z5C%=U
MNAW*49,\>4G$%G:$:D>-4.M*(S[E6I6SYJNP62*LV6<K&I0'DZ'*O]UBGG2U
M[I>@F[I=*BA<W7A:UV3-HHV>=^M#6E8D7:1',@J\74<K,YB?E3'2<2*;=^X0
M22F46I5W3-@911NK5%BV:[0G3<":3GK<^B7R(66&@;^\9>=?BWU,,=^XV%'#
M'XXO]1=V5U^2[(K49(               4Y>/\C[N_NM<7_9WH%5:XKN>,D!
M]<                #-C 7SI&O?^ZNG7\O, !B+Q9/C%_RS"<#8
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MKMEQWY3WP";M=[&ZW7;+CORGO@$W:[V-UNNV7'?E/? )NUWL;K==LN._*>^
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M6M0/EMN;I=;UDVW6Z[9<=^4]\!)NUWL;K==LN._*>^ 3=KO8W6Z[9<=^4]\
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M#J                 ]GBW?Y.V]_8,-_P!L:@?(=;XON3@"
M   $ZM[^.&?_ !'XJN!N"OR^:-!6=?/NS#ZJ-_>ZJ5'=!X(?\P]D9=;XON6J
M&B   !7ME7\XL]O<$6O P5U6[=#9@A.6[<-)8C%TK$O*/XI\DZ@96$EV;Z/<
MU5VE5K))$4;NG39RDNBO4M,Q0YTJ6FIR:WE3E/>5DMG>XEHB4BZ6U9355XUN
M^+BI&.B'T6M:T#?:9$;E@;?CH^5;0)(]VW*HW;JRD1*23,CIXH@_HY7V\F=&
MJ*7)2HHI:UNC\Z"?#7UU?E.\G,EJ4O*46E7[J L_HW)+W/1O-ILYTKR'B;QG
MM\=Q0$:@:X#QIXU](F<T3<23&0F&C9\]0:RB6VI'0:-6N7[9JBEPJ2=4[-PG
M^63LU$+34=?U(NZ8Q-.-;[Y[DNZYZNF+JYX\T2\OAPW<7"T:,F5QH1,I'+U:
MD3:MKIC[@,S25=%25K5TJ:K1PT5T)+53FJ2U4:ZI";_-]=^\AW6>91Q+7%+$
ML7'S=2[6JQ;D:DCK@6:3$JXO&'OM:=>4=W*X<*NJW#!L5"1IG%;<38;?'%A=
MSN%J'*"4J70U*JI)PI5:IUUB==5.,_D?S?.H"[;]B)"#DHFW6,>_8M(VM&6^
M-RZ;M&-T2-VMTF[N;N.74*5.1DW#9)$_/MFL65M'L6[5%LCSE632:<W-4ZI3
ME*I+SXB>'698L;(     <A.SC>B6YG]3/2-^9S@(<#K?%]SZ>0_B@X?-FI40
M]0              #8=L2?HG>@G[JS"ONXB1'5YKNC&4\$7 ]8(4^4
M          !'-_X'(?:MO^O0"JI\/FB! @                '"'\UN_//:
M2ON>[C_*=/ =WZ7PQ>7>(Y*P.H                #V>+=_D[;W]@PW_;&H
M'R'6^+[DX @              !.K>_CAG_Q'XJN!N"OR^:-*F9L-9;E<P95D
MXW&=]/XZ1R/>SY@^9VM-.&CUD[N637:NVKA)F9)=NX04(JBLF8R:B9RG(:I:
MTJ.R&*'-A_=#X5K5A&G-T.MZBVO2+S1W*,A^U"=\1&L^#:AYEB23L=S'2+S1
MW*,A^U"=\1#/@VH>98B3L=S'2+S1W*,A^U"=\1#/@VH>98B3L=S'2+S1W*,A
M^U"=\1#/@VH>98B3L=S'2+S1W*,A^U"=\1#/@VH>98B3L=S'2+S1W*,A^U"=
M\1#/@VH>98B3L=S'2+S1W*,A^U"=\1#/@VH>98B3L=S'2+S1W*,A^U"=\1#/
M@VH>98B3L=S'2+S1W*,A^U"=\1#/@VH>98B3L=S'2+S1W*,A^U"=\1#/@VH>
M98B3L=S'2+S1W*,A^U"=\1#/@VH>98B3L=S'2+S1W*,A^U"=\1#/@VH>98B3
ML=S'2+S1W*,A^U"=\1#/@VH>98B3L=S.6+9C]".M?)>R$Y;O''>DK4=?5I2.
M/=+K)A<UI89R!<,"]>0&E'"5O3C5K+14 Z8KN(>>BI.&DDDES'92D>\8N"IN
M6RR9.)UOBSZ&2CAAR<*;2:5*\V:P>MJ[(=P'-67@_P"4>3 AZ:2#:0ZVKLAW
M <U9>#_E'DP TD&TAUM79#N YJR\'_*/)@!I(-I#K:NR'<!S5EX/^4>3 #20
M;2'6U=D.X#FK+P?\H\F &D@VD.MJ[(=P'-67@_Y1Y, -)!M(=;5V0[@.:LO!
M_P H\F &D@VD.MJ[(=P'-67@_P"4>3 #20;2'6U=D.X#FK+P?\H\F &D@VD.
MMJ[(=P'-67@_Y1Y, -)!M(SMV+_0%KEL+9%=$]ZWOH^U+VC9]K:E\13MRW1<
MF$\BPL! 0L;>,6YD):8EY&WF[&-CF3=,Z[IX[72;H)$,HJH4I:U$?S7=&8XX
M'!$E$IR/37Z&2/:+KO"GO13YLG8[F.ADCVBZ[PI[T!)V.YCH9(]HNN\*>] 2
M=CN8Z&2/:+KO"GO0$G8[F.ADCVBZ[PI[T!)V.YCH9(]HNN\*>] 2=CN8Z&2/
M:+KO"GO0$G8[F.ADCVBZ[PI[T!)V.YCH9(]HNN\*>] 2=CN8Z&2/:+KO"GO0
M$G8[F.ADCVBZ[PI[T!)V.YD8A'OBM7I:LW-#'*WYPM43\TW.K4,;G:<[YO,I
MYM?YJ 5)TT.JS>B#Z&2/:+KO"GO0))V.YCH9(]HNN\*>] 2=CN8Z&2/:+KO"
MGO0$G8[F.ADCVBZ[PI[T!)V.YCH9(]HNN\*>] 2=CN8Z&2/:+KO"GO0$G8[F
M.ADCVBZ[PI[T!)V.YCH9(]HNN\*>] 2=CN8Z&2/:+KO"GO0$G8[F.ADCVBZ[
MPI[T!)V.YCH9(]HNN\*>] 2=CN9QD?-/&C;5IJ+U$:8Y[ 6FC.F:82W<&ST-
M/R^+<6WG?4="RRV0YI^C&2CRVX>1;L7RK)9)VFU<J)K';J$6*2J9J&"<O_&^
MQV?IXE#"\YRJK\\4<Q_6KMDPX .L7P<\K\E1)K?<\#HTD&TAUJ[9,. #K%\'
M/*_)4)K?<\!I(-I#K5VR8< '6+X.>5^2H36^YX#20;2'6KMDPX .L7P<\K\E
M0FM]SP&D@VD.M7;)AP =8O@YY7Y*A-;[G@-)!M(=:NV3#@ ZQ?!SROR5":WW
M/ :2#:0ZU=LF' !UB^#GE?DJ$UON> TD&TAUJ[9,. #K%\'/*_)4)K?<\!I(
M-I#K5VR8< '6+X.>5^2H36^YX#20;2'6KMDPX .L7P<\K\E0FM]SP&D@VD.M
M7;)AP =8O@YY7Y*A-;[G@-)!M(]7Z'5190T.S>+MVCMI$1;9TU<KHH.&SE!@
MW270714.51)9%4ADU$SE*<ARU*:E*TK04^8TYNAUO43'=S#M]CZ\;?"@23L=
MS&[F';['UXV^% 2=CN8W<P[?8^O&WPH"3L=S&[F';['UXV^% 2=CN8W<P[?8
M^O&WPH"3L=S&[F';['UXV^% 2=CN8W<P[?8^O&WPH"3L=S&[F';['UXV^% 2
M=CN8W<P[?8^O&WPH"3L=S&[F';['UXV^% 2=CN9/+;=M%)ID1-VT4/7=',(F
MY04.;F-%ZUYA"*5-7F4I6M>92O,I2M:^92H&X$TZ4ZK&:$LZ^?=F'U4;^]U4
MJ.Z#P0_YA[(PZWQ?<M4-$                    .0G9QO1+<S^IGI&_,YP
M$.!UOB^Y]/(?Q0</FS4J(>H              !L.V)/T3O03]U9A7W<1(CJ\
MUW1C*>"+@>L$*?*                 CF_\#D/M6W_7H!54^'S1 @0
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M;U;+\]46-'H0Y"=G&]$MS/ZF>D;\SG 0X'6^+[GT\A_%!P^;-2HAZ@
M        &P[8D_1.]!/W5F%?=Q$B.KS7=&,IX(N!ZP0I\H
M  ".;_P.0^U;?]>@%53X?-$"!                 (UQ_!&'VCC\8,!I^&'
MS[D$!D                #R<ME?]$UU\_=;YY_*-/@?5R?@AX&OP#8
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M^:($"                 1KC^",/M''XP8#3\,/GW((#(
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M.[,#@                 C7'\$8?:./Q@P&GX8?/N00&0
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M49(               4Y>/\ (^[O[K7%_P!G>@55KBNYXR0'UP
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M]3#'?N-A1PQ^.+_47=E=?DNR*U&2               %.7C_ "/N[^ZUQ?\
M9WH%5:XKN>,D!]<                #K=^9'_GDM7GJ"6C^4F- YOU7@7'
M[LP.                 "-<?P1A]HX_&# :?AA\^Y! 9
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M4J(>H              !L.V)/T3O03]U9A7W<1(CJ\UW1C*>"+@>L$*?*
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MD[T'0VMY2(I    Y"=G&]$MS/ZF>D;\SG 0X'6^+[GT\A_%!P^;-2HAZ@
M           &P[8D_1.]!/W5F%?=Q$B.KS7=&,IX(N!ZP0I\H
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MYC&-6M= AP    <A.SC>B6YG]3/2-^9S@(<#K?%]SZ>0_B@X?-FI40]0
M          #8=L2?HG>@G[JS"ONXB1'5YKNC&4\$7 ]8(4^4
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MK2>:I-9)9PS:22#*23:2;=XT0XW6^+[GT,BXEDX)0-J5<X5K=K-7_4ZZ8/\
M>"X<XD=5OD7$/3.B_K?-#B.IUTP?[P7#G$CJM\BX#.B_K?-#B.IUTP?[P7#G
M$CJM\BX#.B_K?-#B.IUTP?[P7#G$CJM\BX#.B_K?-#B.IUTP?[P7#G$CJM\B
MX#.B_K?-#B.IUTP?[P7#G$CJM\BX#.B_K?-#B.IUTP?[P7#G$CJM\BX#.B_K
M?-#B.IUTP?[P7#G$CJM\BX#.B_K?-#B.IUTP?[P7#G$CJM\BX#.B_K?-#B.I
MUTP?[P7#G$CJM\BX#.B_K?-#B9V[%_@K3Q![(KHFF;>UNXKO:<C-3&(GL3:,
M7B+4G$2-R/V]XQ:C:&8REQXFBH!@Z?JE*W1=3$DQCD3GH=TZ01H90L?S7=&(
MXHLR+]C5%<X?DSTW-S-/3%'O#OX$4^=)6KK@-S-/3%'O#OX$!)6KK@-S-/3%
M'O#OX$!)6KK@-S-/3%'O#OX$!)6KK@-S-/3%'O#OX$!)6KK@-S-/3%'O#OX$
M!)6KK@-S-/3%'O#OX$!)6KK@-S-/3%'O#OX$!)6KK@-S-/3%'O#OX$!)6KK@
M-S-/3%'O#OX$!)6KK@-S-/3%'O#OX$!)6KK@8\:J-5>"]%.$[@SMG^[7UN8V
MB9BVH"0EH>V+AN=XA)7')E81*18B$8.Y%4CAU6B9UDD#)H4_=K&*3S0-P0.)
MN&%IMJA4JIS=+E8:HNR1-B3[NM]<1>6.3(&_9\K8N9#LD38D^[K?7$7ECDR
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M%V/-> ^B                !Z5/S-=Z$WB+U3<X?E ?@<'ZKQKA@;YP.8
M              #R<ME?]$UU\_=;YY_*-/@?5R?@AX&OP#8
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M'T0                /2I^9KO0F\1>J;G#\H#\#@_5>-<,#?.!S
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M                >E3\S7>A-XB]4W.'Y0'X'!^J\:X8&^<#F
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9AW0[_P )NO=[49CRN="X<V4Y4SG4T[#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g317356g20p40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g20p40.jpg
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MN)#$,9+$< < < < < < < < < < < < < < < < < < < < < < < < < <
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MC*5)5C&<*QG'AG&<9^[.,X^[.,_=G' /[P!P"FG;O^8>FG]9=!_M?N/@%R^
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MLTR[[*FSTX&'2Y<)Q.C/U(#S5WL=?A.U<-#KC!.E5XP$-V]+\B5%,S'_ !G
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M:=V &72X-/>>&!"B>$3-[.>_PEF2[K/O#LU;]J:K%[)LUW<*&+*'$'M<F=>
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MU6G5,3#!UX")BXSAF$-&0&F8T=KS*6Z[E*/4D2''I,A;LAYUQ?G-DSX X X
MX X X X X X X X X X!\9,:/,COPYC#,J)*9=C2HLEI#\>3'?0II]A]AU*F
MGF7FE*;=:<2I#B%*0M.4YSC@'VX X!33MW_,/33^LN@_VOW'P"Y? ' ' ' '
M ' ' ' ' ' ' ' *];*[0:DU/9EU*Y%"T0TB#$(J9A@YT]G$:;AS,=7N(Z,M
MY4K#2O,C&?%/W>/\>;I^G54I41Q,NI)Q<T85L%C[FE%4ZG?4%.ZU#%Q\;%N;
MS4@)8=L2U(;D.:\J6,YQ)@5AI*T,W WXH?EJ4X&CX:;1(Q-K7_CQAU9+&/\
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MW\%.K!\8[K3W?L<;J-UZD1[5<=ER$9%2FS>2LEMBI.HN)"1(8J0BRUD9"9@
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MTZ_IQOC$]-5GPL>=Q.BGM.N!W5U_KC7NIJF*H>K:+3];T@$S[<+3Z)6@U2K
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M-M?G5U?_ %>X$+5=_ ^T%V8_ 1MK\ZNK_P"KW A:KOX'V@NS'X"-M?G5U?\
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MG'0T/%;@-E;#F44A1\ 1CS,J0T1-9>?1\K@.L09K[<R=Z$=;,24XES*([JD
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MR0+33;5XAW7?XW16*A#B,#5@9(UTG2K:U9\FGY!1J6AMX8X'P-C*](@DGE4
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ME2D_XXTO$@DH:_%.?\*9$8=QCP5E'E4G.1#*< < < < < < < < < < < <
M< < < < < < < < < < < < < < < I7\1C_ $.]F?\ E>7_ /KP^"K%<5\G
M^OAU?Z(>M?\ RU'?_>3N"%TN . 4J[&_ZE^@7_./<7_\R;;X*L'P^Z-E]3/]
9.VK_ /Y//_\ SY;@A8K@#@#@#@#@#@'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g317356g31k47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g31k47.jpg
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M 0$! 0$!_\  $0@ NP$P P$1  (1 0,1 ?_$ !X  0 " @(# 0
M   ("08' P4"! H!_\0 /A   00" @ % 08$! 4#!0$ !0(#! 8!!P ("1$2
M$Q05%A@A69?8%R(Q-2,D>;<*05%A<24F,ADT0D-2@?_$ !@! 0$! 0$
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M#K>"LBU1F[OOKW8EH/&CA$-@<*@0A@^*C#46 /BL0H<9O']&V(L9MIAE&/\
MDAM"4X_Z<@LZ:XTJG[$K9*G7ZK5ZZU,QB+@M6;4''GP)+$&;&)0OG"2D>5!E
M?#(PXD^+EYA>8\R+'DM>AYEM:0.AUUJ+56H8) 7JK6]&UN.+RVYY6#1JL$JT
M4E-:9Q':ESF L*$W+D-,8PRVZ^E:VV_-",X3G.,IG$0E@H-B< ZLV)CG@Q<'
M+>G1HIH7/$R9 R;(&DF(Y&([#>>'D8JVY4"<TV\I<2;&<1(BOI;?96EQ"58
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MR,,PY#,J<W,BLR$YEQ6V(SK_ ,>;E3$>W4DG2LK3[D4TMM5/CF6<\YG0< <
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M2U[K;MS1:%6 %+I51\17N/7JK4:J(@ *U6P(K83,,8%!!!;$4:*%#XC34:%
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M'!SN+1>G_96OW+IP,VB:*[BNCNH*,L?LRS6?0V^*?>;N=I5'%6BS'J7KK8-
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MIA);4K6(WZ?732,4S>(W26+<DT< < < < < < < < < < < < < < < < <
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MP-I>2GK7^0^Y#VK_ #9.Y/Z7=&_VJ<#:7DIZU_D/N0]J_P V3N3^EW1O]JG
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MBL2ID2,_-D)B0V7Y#++LN4MB3)1&BMN+2M^0N-"F2$LM86XIB))=PG+;#JD
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M\8U[W;+XNIP8:[$ JW3A,H_UNK5@V'#1:YRX^]FY($;N-.#I"3>)V=;MF8K
M78Y4V])UV9 M;":E[1$JEA@M]7TPYN9^R1UMKKO>"3768PE/94;:7=G*=[.&
MI5B@6*CG*2BS;,<!IZTU.H[/H&Q1 ["'=9/$\ZEONL"+&IVI$4X,M&XTGA^
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M%OK2X^M"$I6\XEM#*7'5)QC+BTLM-M)4O.58;;0C&?2A., <G ' ' ' ' '
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2UXPI&,9QA2L>?\V?,#FX!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g317356g42x54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g42x54.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X5TY:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @
M('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+VEM9R\B"B @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B"B @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]T+W!G+R(*(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @("!X;6QN
M<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O
M;G0C(@H@(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+V<O(@H@(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @('AM;&YS.G-T
M179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R
M8V5%=F5N=",B"B @("!X;6QN<SI%>'1E;G-I<T9O;G1396YS93TB:'1T<#HO
M+W=W=RYE>'1E;G-I<RYC;VTO;65T82]&;VYT4V5N<V4O(@H@("!X;7 Z0W)E
M871E1&%T93TB,C Q-RTQ,BTQ,U0Q.#HR,#HT.2TP-SHP,"(*(" @>&UP.D-R
M96%T;W)4;V]L/2)!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I(@H@
M("!X;7 Z36]D:69Y1&%T93TB,C Q-RTQ,BTQ,U0Q.#HR,#HT.2TP-SHP,"(*
M(" @>&UP.DUE=&%D871A1&%T93TB,C Q-RTQ,BTQ,U0Q.#HR,#HT.2TP-SHP
M,"(*(" @<&1F.E!R;V1U8V5R/2)!9&]B92!01$8@;&EB<F%R>2 Q,"XP,2(*
M(" @9&,Z9F]R;6%T/2)A<'!L:6-A=&EO;B]P;W-T<V-R:7!T(@H@("!X;7!4
M4&<Z3E!A9V5S/2(Q(@H@("!X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC
M>3TB1F%L<V4B"B @('AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/2)4<G5E
M(@H@("!X;7!-33I$;V-U;65N=$E$/2)X;7 N9&ED.C(Y0S9&-C$Y-41%,$4W
M,3$X0C S0S-$.$(Q,3DS-3$U(@H@("!X;7!-33I);G-T86YC94E$/2)X;7 N
M:6ED.C(Y0S9&-C$Y-41%,$4W,3$X0C S0S-$.$(Q,3DS-3$U(@H@("!X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z-SDW0T8W1C@S141&13<Q
M,3E%0S=",D-&0C Y-SDW.#(B"B @('AM<$U-.E)E;F1I=&EO;D-L87-S/2)D
M969A=6QT(CX*(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @/')D9CI!;'0^"B @
M(" @/')D9CIL:0H@(" @("!X;7!'26UG.G=I9'1H/2(R-38B"B @(" @('AM
M<$=);6<Z:&5I9VAT/2(R,# B"B @(" @('AM<$=);6<Z9F]R;6%T/2)*4$5'
M(@H@(" @("!X;7!'26UG.FEM86=E/2(O.6HO-$%!45-K6DI29T%"06=%05-!
M0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!04)!
M05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!04%!
M04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#=V]+
M)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(>#AF
M2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&8O.$%!15%G07E!14%!=T52)B-X03M!04E205%-4D%F+T5!
M84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%04%G
M241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!0T%1
M341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC645537!'
M:$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51
M;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%
M)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58
M<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*
M,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B
M445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C133D-&
M5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ
M6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E75G!B
M6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A984AI
M26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q
M-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9<3=&6%EQ=VXX<68K
M)B-X03M/9C5J+W=$06PQ;B]!2VI8>%9M,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+)B-X03MU>%8R
M2W5X5C)+=7A6,DMU>%8R2W-*+TMN+VIN*UDO+T%!2F1:+S9J6'A60V%D-7(O
M34MF.'HW>GEV8U=U:W)P3FY%3#5R:4XW:S-*)B-X03MS-7!*231!058T9716
M0GI(,F9!;D98;T]+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+<V(X,2]M)B-X03M"-68X<E0R<T]R0S<U,W T,C5T<E-E
M-59N2F]%-5%O-#5N<W95-'%Y1T-:6C1)-6M"0U-Q2%5-0W)5659&5D\T4'1I
M<F-H8U)S63%$)B-X03M3045O<$Y!5%195GA6:$@U9BMC+T]8;4A69%=T=%@P
M3S$P,C P;6%3>6YN9W5Z8TUB>4Y96E!40T=/4#105&UR>7(Q1DU66GII<G-6
M)B-X03MD:7)S5F1I<G-69&ER0V9Y<"\T-2]M4"]!34-85V8X07%.9D953'!N
M+VLX.6,O-UE.:B\Q17I9<3E!>%8R2W5X5C)+=7A6,DMU>%8R)B-X03M+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C@W+T%*;2\X-4,K5U P.6(V3BMJ
M8C,Q+TQ7=G!,9'E5:3130W=K:VIK169X,2M))B-X03LO6G)41DY05B]W07-V
M>DXP;CAW9$IU=%0P>3%U3%-+,'50<7IP8SA/4F)G<C%(0FY&2U!I:$4O;4XK
M64=M*U)03'<Q>E5B86$V='I/)B-X03ML=C96=G<U.'!!>$(K37%+9D0T-'$X
M5SAH9CA!3U(O;&%Z,6Y73&0Y379M8GI&<EIU-U5G43!J5S1I9W0Q5U-R.5$P
M4DIP6&)&3E!P)B-X03M(1D1S5F1I<G-69&ER<U9D:7)!=GDR=G)+=S!4>E)E
M6#%X1F%7:TAM4%=N;75:,U=/3D8K=79U>G-1<6HU-'%X+U0O4'9K6E!Z;#%J
M)B-X03M51SAX85ET:$QO;&Y$1F1M.'1X0S!I6$5R36EY8RM*64%G:U9R:7(Q
M;3%U<F$W=&]R<3%L4S1T8FA&;&=N:5E01SAB:FMR;WDQ1$MW)B-X03M.45)I
M<7!I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER0B]W03)F
M>DPP=GE,;TM4,VXQ<$HY4SE7,G-B;3!H:75$)B-X03M$4#9:2WEV1DY,07)"
M5%$X95<O5$98;&XU5B\X-4A.96$S1G!0;5<Y=DY4=3E7=DEB2%1&:7-,5S)I
M:3E78C P:VQK5S1,9DAZ6&MO)B-X03M1.&5X8D9.4&]V1D0X+U!Z3B\X04IK
M*V)0*S)Z<4@O559*:7EF4F8O041I1"]W06]2<E O04<P>B]W0E$X94M#;6XO
M3U9V.$$U2S%0)B-X03LK,FIB+W=$14I-54(X;F56+W=$;$IT22\U:F)F+VLV
M=4Q)=C!6>%EU>%8R2W5X5DEF4%!M<&9+=FQQ-3%T;T)C:4(T67A%.&=G:G)0
M)B-X03M-:TEA4U5Q+T)&36Y*;31M9S=9<7=E8C@O3$-#4#9Z3&\X<3)8,4IB
M9W5::#9O=5<P,&%O3&8P*T9/4&]';G%C+W1B8V-66F1P6#5G)B-X03MA5$HU
M8697.61E2%$Q=')U-# K*U=E6E=I:G5B860T2%9::4EW-FQO+VA0159(8D98
M;6PQ95=T-RM2=C5H,VQP2W,Y<F,V<')-,790)B-X03M'47E02$IE;&MD4T]O
M6E1567$K4V-75#E"4'EY+W=$2F)E52\K,DYP+W=$,4-X-'-74S1Q-T9867$W
M1EA9<3=&6%EQ-T9867$W1E9#)B-X03LK=G)+=W1*8GDK=4ER4S!G6&Y.8WIU
M<V-A3#1S-T5+;RME2V]84G9-;FPS5S!L9E)D571.5%-!9U1.6GIX6$%1=%5Q
M1TUB3GAR5&%U)B-X03M+<&II<GEF.#%V2S)N86HU-CAM*W9.9'AJ5G)Q5WEV
M:V=U<#1&94=',FMM44)9,U5+968W43-W<3E9=TLK9G8K8W=V*U5:.'8O=T1-
M)B-X03MB3"]Y87A32'HW*U=8+VMY9DMF+T%',F10+S9I;SA5=C!$>%EV>C@O
M33,O>5I0;7HO=',V:"\Q1E-9<VXP6"]Z:40O>6A'<R\Y=$TO)B-X03LY43AE
M2T-M;B]/5G8O:W)5+W=#,FIB+SA1:WA12'ED-5@O-5-B4U K63(S+T%/5'$T
M<VDO4EA&:3=&56@Q3'HY-4DP>E4Q,'959&5S)B-X03M,5%5724@Q5V$T:E-1
M1G5G644O1%AT6$95*T)$045';T\T2395>%9!83-O5VQA-7 W-F9Q8TAR,G)S
M:VY%3SAB<3AB0C!D2DEY:VE/)B-X03MR2T-'5F=2:7%4<BM74&M.6#5$4C1G
M=C%4-F@V6$M4,"]Q+W!E:%0P*UA$;#98=V,V8S9B5GA633E/.'-A0G K:U(V
M4F)7568V3VI:)B-X03MN145T6C9U-T8R9#)L3',W<WI%;&U*2D]+=DDY4VEJ
M:2]*5#AX-&]K16-597)A,G%);T%65D8X=T%!2%%$0W(U1W=-;C9#9FQL+S5,
M)B-X03MB>6XO04YS8E0O.$%Q1FIX67-L>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+<DHT24HT;6AN:E=71GA2-#-!6E-006<W2$98;B]!3U%D)B-X03MT8E)F
M;&QP,&M54U)Y4WHS+W%U<6=-,T153&A6-45D841967$Y1'A6-2\X06U(+WEN
M4#5D+W=$8E1U=BMO2U1&6&]'2W9N-R]!2GI#)B-X03LO=T-56CAV+T%036),
M+WEA>%-(>C<K5U@O:WEF2V8X03(R9% O=T-O<5!&3#E!.%=,."]0>DXO.&U4
M-7,O=T,R>G%(+T%&1E-9<VXP)B-X03M8+WII1"]Y:$=S+SET32\Y43AE2T-M
M;B]!1&QB+W=#4W14+W1O,B\O04)#5$9!9DHS;&8O04I38E-0.$%M3G0O*U1Q
M-'-I+U)81FDW)B-X03M&6&HS;4ME5S<X,G(U575B+U-9-TDV>EHS='I9,E=J
M-FA*3S%,<$QU2T\V=5DR;'1"2DMV17E.24%0:35%04A&6'(P145&=D)(8C(X
M)B-X03MA=W=1<4DT;V]W1E)%55565E5B04%B041&5BM+=7A6,DMV1717+SA!
M2DUF;58O,C).8R\V:FUX5CAH-'-N-D-F;&PO-4QB>6XO=T)S)B-X03MB5"\K
M;U=01FEY6$9867$W1EA9<3=&570X>#9R9#96;W0Q<49P<#AU<5A&=49:8D="
M:U-2=UA!86I31E9(1E-73E0R>%9++WDK.#5Z)B-X03ME8CE!5%=J<%4K;#(P
M-4)S>$\X8FUA26=(,48Y36UG<E553RLR2W-M>%9I1W4O;6HU93!4>DQ"-6-U
M-V)52#%'-4DK<BMH85-Y>%-6)B-X03M#;&EK:6EJ0D$T-3 K>C-X5FPK2W9N
M6"]!2GDY,515-T0O0V8Q1S=M=&95+U-(<65H23AF3&HY5W!Y-&M6<%4T<$1Y
M-SAH3F$Q:"]Z)B-X03M6.'57:C,Q=S%Q,# S2S-A5GI'87=33G5H4$AR=FEP
M9F)E2TAY5C5S+W=#8VQ,,U5033)J6')A1$9'9DQD-U!-:4,U66EB;D4X1D-F
M)B-X03M4*T@W5F4K2V%F44@U4B]M2$XU*SAQ3G)S,6MU;G5,;5,R.4)*1$M+
M4G%P-6-I<61E9FAI:#5N+T%--6AF.&]Z-68X02M9,E@O:S%I)B-X03MK4&XS
M.'-V+T%#6E!L4#A!-V)/;B]W1%562&EL*V=E3$8K9FXU;2\K5$HX,F8Y=&Y5
M4#A!<4MK>%I0;W8O;D5(+VQ#3EHO-V%:+S9H)B-X03LT.%5&3E X06Y+,R]!
M36QA;B]B4G0O.$%I16U+02M4=DLO.$%Y:S)K9CAX='8O>6181FM8-DLT<UA9
M<3A3,6%Z=EDO>F=F54PY1%I7)B-X03LY>&8R6F=A43-S>7-K0WAX<5(K:C<Q
M26]X244U9C988C!&9FEQ=498='5"6%EQ-T9867$X4S%B+T%-:W@K6E@O04<R
M3F,O-FIM>%8X)B-X03MH-'-N-D-F;&PO-4QB>6XO04YS8E0O.$%Q1FIX67-L
M>%8R2W5X5C)+=7A61&%N+WAZ8G8O04EW>68X4D]+<U,O2E X03AL4C59+S5G
M)B-X03MK+S1K8U9:9F934$9:6$5S6F\V4D]Y;G)1:%-2,7A6.$U8;C4T9FUJ
M96%V<"MS6$]T8SE2,'!:,'-*+W%T;U!45S965FU(15%H1S5")B-X03M&*S!$
M5'1I>7 Y8B]!2DME6DYA.'DO;&QO,G1A,6-F5SE4=2]R4#%I-#12>#AV5'4U
M66LK0TI5455204YH:7A,>4PO;DUR+W!K4#A!)B-X03MT-"\Y:75+43AR+TE(
M+WEB+VQV+T%)>E,O=T154$II:W9U:D9I+T],5B\X06IR6'8O1V58+VE:>%I"
M.6,O=T1/2U@O:W)8+S=A3G@O)B-X03MX0U!&:55I+S5Z0R\U4FYY+W=$.'AS
M=B]!0V%X4TAZ-RM76"]!2DUN>6XO,C)D4"]!3V]Q4$9,.4$X5TPX+U!Z3B\X
M04IK*V)0*S)Z)B-X03MQ2"]55DII>6929B]!1&E$+W=!;U)R4"]!1S!Z+W="
M43AE2T-M;B]/5G8X035+,5 K,FIB+W=$14I-54(X;F56+W=$;$IT22\U:F)F
M)B-X03LO:S9U3$EV,%9X675X5C@T+VU:1#5C;2].93EJ,5=85$E.4&4W,#%D
M4FUV>%ET94I+65EH13!#>D983FM&2VTT<B]L659E+RM8.5!G)B-X03LP-U%.
M3C K0S1.,T):,G-&=D9D35%Z4W!&1W%,25=&86QG2S%W2VHX5F1I<G-694IA
M="\U2FHX>78K,GAR;B]58S)+=FM01FLO450X)B-X03MS=CA!>5<S;% O=&IA
M9CA!.5%S94Q&:W5+=7A6,DMU>%8R2V]B52\K3V)D+SA96E K26Y&5TIF:VXO
M-4MJ>7@O>D)*+WA)-'%Y,U4O)B-X03LK3V)D+W=$1T=4+VE*>%8K8BM,2CEV
M.$$O3T](+VMM4$PS+U(U+S%(5#1O3'I8+VY-<B]P:U X070T+SEI=4MH-5@K
M45 O:S,O3&8O)B-X03M!0FUL+W=#;V541DIF9$=,1BMC5W(O.$%(5W9F*TTX
M=B]%>FEY1#8U+W=#8U5V.$%Y5G(O05!B4G50.$%I165,17!&+WIM1B]Y:E!L
M)B-X03LO=T0U:EIF*U172U$K9F9Y>2\X04IK*U4O=T1T<S9F+T%.4E5E2U@V
M0C1S6#4K9FUB+S5-;GI:+S(R9%$O=T-O<51&:RMI+RMC468K)B-X03M523%N
M+W1P;B]Q2&IX454P+W=#8W)F.$%Y5G%F.71',R]W0TE366]$-4\X<B]W1$M4
M85(O>D<R+R]*,6-74F9O<FEX9&ER>B]!1FIY)B-X03MB-5!V4$Y%='90<C$U
M6C,Y,$1C>393='I';VQ$:VQM:DTP8GI!9&%I1U%"9F)B0W)/-U,R9W1B5T<R
M='AX9V=J5T]*4U,Q15%"5DA*)B-X03MI4V1H,4IW2W$T<3=&6%EQ.%,Q8B]W
M06MX*UI8+V)9,7HO<4]B1EAY2&EY9F]**U=8+VMT=DMF+T%'>'10+S9H63A7
M3$IC5F1I<G-6)B-X03MD:7)S5F9-;B]/5S)R87!:95E.05-Y=DHW6DI,4UEY
M3$1).%E9*V]"=49)<FEK35,O=T-C8618,6%B.#%.371*<C(T:W120F15=#-L
M)B-X03MD;SEO1TDK06YJ=&EP9E@K<"\X04A.=2\K34UN+T54:6@K8BM,2CEV
M+W=$3T](+VMM4$PS+U(U+S%(5#1O3'I8+VY-<B]P:U K,VHO)B-X03M!3FEU
M2V@U6"M14"]!2DXO>3,O>&UL+S9H-4U5;#DP67-8-7AA=CA!.&1A.2]W0TTX
M=CA!>$TT<V<K=68K8U5V+TI7=B]W0G1'-"\T)B-X03MH2&EX2U)F.#5H9CAO
M>C5F+W=#63)8+VLQ:6M0;C,X<W8O2FLK52\K,GIP+R]55DAI;"MG94Q&*V9N
M-6TO=T1K>69.;B]B6C%$+W%+)B-X03MK>%I0;W8X035X0B\U46I79BLR;68K
M;V501D)45"]N2S,O>59Q9CA!8E)T+RM)4UEO1#5/.'(O.'!.<$@O36)B+W=$
M2C%C5U)F;W)I)B-X03MX9&ER>DQ74$TS-6)8+S5H,C)L6&QX<'5Q4UA+>39F
M93(Q-4I$3CE8=DE:5FIG9VET-5%X1'I.3DMR.&8U440R>%8V4F%7;'):,G-.
M)B-X03MP85%P8C)T=6EX=U%2<49215555E958D%!67%Q-'$W1EA9<3A3,6(O
M04UK>"M:6"]!1S).8R\V:FUX5CAH-'-N-D-F;&PO-4QB>6XO)B-X03M!3G-B
M5"\X07%&:GA9<VQX5C)+=7A69V0W-70X*W@O;51"-5ET=$TP-3E-;6@K=FDX
M931L5UE756,P54TW8T%H6#%1,#-W<E=H.%)I)B-X03MR4$U69DQ0+T%$;48O
M=T%P2#5E+S5G-78K5&]X4T=*9C@T>"\K5&4P,R]J0F0O.$%*:'-63#=+,5 O
M:FTS9CA!>&AK+S1I8U50>F9X)B-X03M:4'0O+VY(1"]W06MX-64O-E!0*V\V
M9D9"96$O.#5L9CE-:"\R.&8K>%A&43AR+TE(+WEB+VQV+T%)>E,O=T154$II
M:W9U:D9I+T],)B-X03M6+SA!:G)8=B]'95@O:5IX6D(Y8R]W1$]+6"]K<E@O
M-V%.>"]X0U!&:55I+S5Z0R\U4FYY+W=$.'AS=B]!0V%X4TAZ-RM76"]!2DUN
M)B-X03MY;B\R,F10+T%/;W%01DPY03A73#@O4'I.+SA!2FLK8E K,GIQ2"]5
M5DII>6929B]!1&E$+W=!;U)R4"]!1S!Z+W="43AE2T-M;B]/)B-X03M6=CA!
M-4LQ4"LR:F(O=T1%2DU50CAN958O=T1L2G1)+S5J8F8O:S9U3$EV,%9X675X
M5C16;RMP84IF.$$U=$Y,965B2DED55<O=C19)B-X03M,0SAB5'!L:49L<4,R
M<V1L0C8P9G%W1S96<6])-D]Y9S=K-S1Q.3%X5FIN-6@V6#5H,6)Y<&5A8F]2
M:"MT,UE%57=N;&5!3F)N*RM2)B-X03M*63!L2W4V+T%$5'8Q2%A&6&M%6#56
M+VU9,7)%:3(V,E8K;6E2,E,S:3--6D-O;6II>49H>59U65 Q=&972D$T03E'
M4%A#<C!N>7 U)B-X03MA.#(R6&M986)A6$5F;#8O3C5D5#)C17-36#8R;&Y,
M8WE343)V1DI543A);59F:&-G9'%J07)"3&E+-VDO278X=UER>61B;3=J,5!7
M)B-X03M6=6)L13E*6DI"945/-&IQ+T%-,B](:V%E3T98>59G6E P12],3"]Y
M5S-L4"]T:F%F+S%#>#1S5U,T<3=&6%EQ=VTT+SAN6%EF*T$Q)B-X03ME9CA!
M569A-'%Z8D98>7HO04TU:&8X<$@U92\U9S5V*U1O>%-'2F8X-'@O*U1E,#,O
M:D)D+W=$2FAS5DPW2S%0+VIM,V8O1T=4+VE*)B-X03MX42].+T9K*S,O.$%N
M2$0O04UK>#5E+S904#A!<4]N>%%8;78O3UI8+U1)9CEV2"]!3$9C5D1Y=CAG
M9B]!0V(O04IB+T%/33!V+U50)B-X03M*:6MV=6I&:2]/3%8O=T1J<EAV+T%"
M;FPO=T-*;D9K2#%Z+WII;"\U2S$O*S)J8V8X46IX66Q)=BMC=W8K55HX=B\X
M04UB3"]!36US)B-X03M5:#@K+VQL+S5-;GEN+S(R9% X02MO<5!&3#E!.%=,
M."]0>DXO=T1*:RMB4"LR>G%(+U562FEY9E)F.$%Z:40O04UO4G)0.$$R,'HO
M)B-X03M!3E$X94M#;6XO3U9V+VMR52\W84YV.$$X46MX44AY9#58+S538E-0
M*UDR,R]W0U1Q-'-I+U)81FDW1E=(+SA!2W)F3'8K268P.3EA)B-X03LQ4#8U
M.6$K=2MN.69U9E$Y5#%0530K:GHT8T]8-T9+53(V67%Z1$9867$W1EA9<3A3
M,6(O04UK>"M:6"]!1S).8R\V:FUX5CAH-'-N)B-X03LV0V9L;"\U3&)Y;B]!
M3G-B5"\X07%&:GA9<79N=2\X04TR;F578GI59DQV,4PV-UI).7I+3E%75C1J
M1$9'>G5&14Q),TTX4E1E;4MR)B-X03MV23$O-6DQ2'EV639J-6<K<"]8-S)*
M3&=#=U=625)&2V]E355L6C(U04XX5SE-5E9V3V)V2#50,3$P66\V869D37)+
M845%44]145)I)B-X03MR."\O05!%9FU(,5),*VQ,=C%1<%53979,>31K,4ER
M>7)3;WA:52LU9GE:;FYU4'EU.'1Z5'E.3$Y*6G%8:V-L;5DQ3S5*,T],1C1:
M)B-X03LO=T$U:&8X04M2*UAV*UE/8B]K-DU5:&E8+T]-9B]K,W1.+S1W6&8O
M04-98D93*WET5"\T-70S+T%-65I0*TEN1D0X,SA75#=F+S5X)B-X03MW+SA!
M2DUE6'8K:GHO<4]N>%%8;78O3UI8+U1)9CEV2"]S5GA54$LO>4(O.&TO-6(O
M=T--,'8X03%$>5EP3#=O>%EV>FDQ9B]!238Q)B-X03LW+WAN;"\T;6-74698
M4#A!>FEL+S5+,2\K,FIC9CA1:GA9;$EV*V-W=BM56CAV.$$O36),+W=!;7-5
M:#@K+VQL+W=#5$HX<"\Y=&Y4)B-X03LO=T1Q2VIX4R]14$9I+U!Z.'IF+T%#
M6E!M>B]T<S9H+S%&4UES;C!8+W=!-&<O.$%+16%Z+W="=$TO.$%54$AI9W!P
M+WIL8B]!3U-T)B-X03M4+W1O,B\X07A#5$9!9DHS;&8X03538E-0*UDR,R\U
M3W)I>4PY1F-73'-69&ER<U9D:7)S5F1I<GA,5G8O2DUF;58O,C).8R\V:FUX
M)B-X03M6.&@T<VXV0V9L;"\U3&)Y;B\R>'10.$$K;U=01FDK678K8W-0+TIO
M4F8X06)-="\K5&MU2U$W+T%*>% O=T1*;U,O.7-Y-"\U3U)9)B-X03MQ6#%2
M-3(O-5%Z6"]!4'1N6&8X07E99D9$.#A-5U0W>B]*4"]!36Q2-5DO-6=K+S1K
M8U=,=R\X035Z0R\U4U!Y.2]Z0GIF.$%*,%EP)B-X03M$178K8UDO+T%#8C)M
M+SA!1T,W+T%/5$19<5@R5G%F+T%">F)V+VI$2B]X131O9FTO:7EF8B\X07IJ
M:"\U2FIY.2\P968Y4C K2T,X)B-X03LQ+S5Z2R\V6D0O=#0O=T19<FEO958O
M:T0O=T-49CAT+SA:<&8K;V541DIF9$=,1BMC5W(O05!(5W9F.$%J4$PO04U4
M3TQ)4')N+VY&)B-X03M,+WE6<B\X06)2=5 K25(T<U-K6"]/65@O2TTK6"\X
M06U.;"\U3EEP1#4Y+TQ,+WE:4&Q0+W1S-F8O,492-'!F;TAI>&9N-2M:=CA!
M)B-X03LU36YZ6B\R,F11+S9I<$U75#9,+T%/8U%F*U5),6XO='!N+W%(:GA1
M53 O-7ET+SAL86XO04<P8F8O:45M2T$K5'9++R]+5&%2+WI')B-X03LR+SA!
M>6181FM8-DLT<UA9<3=&6%EQ-T9867$W1EAI5W)F.$%K;5!Z2R\W8D=U9CE2
M>EEQ*U$X5U0Y0E!Y>2\X;'0U5"]W0S).<"\O)B-X03M!1D-X-'-8>D8O>FQH
M+S5.0TPO=&U7+R]!0V-L>%-(9C@T;B]!4&LP2F8X071M6$@O2GE,1E,K<5!/
M,R]!0VAM=B\X06)/=2\K5$0T)B-X03MO9FYH:7EF968U2B\K4V\X<V8X04U%
M;B]!0DDT<UAH+R]/65@O2U(K6'8X06U$;2\U3VI&25EL+WIJ2"]!3U1E,#,O
M:D)D+SAM1WA5)B-X03MV<W)5+W=$:FTS9B]!0FAK+W=#26Y&1#@S.%=4-V8X
M02MC8U O2DUE6'8X06\X+S9J<#A51C5R+T%--6QF.4UH+W="=D@O<U9X55!+
M)B-X03LO=T%G9B]*=BM7+RM-,'8O049$>5EP3#=O>%EV>FDQ9B]J<EAV+T=E
M6"]I6GA:0CEC+SA!3TM8+T%*2S$O=T1T;S-(+T%"0U!&:55I)B-X03LO=T-C
M=W8X06Q'9DPO=T1Z1WDO.&US56@X*R]L;"\U36YY;B]!3G1N5"\X07%+:GA3
M+U%01FDO4'HX>F8O2FLK8E X071S-F@O=T)2)B-X03M5;4Q*.48O.#1G+SAO
M4G)0+V)44"]54$AI9W!P+W=!-5<O.$%K<E4O-V%.=B]W05%K>%%(>60U6"]W
M0U5M,&HO04IJ8F8O:S9U3$EV)B-X03LP5GA9=7A6,DMU>%8R2W5X5C)+=D5T
M5R\X:W@K6E@O8EDQ>B]!2VIM>%8X:#1S;C9#9FQL+W=#4S(X<"\Y<V)4+W=$
M<49J>%EV;4PO)B-X03M!2GEW+W=$2F]29CES>3,O04]4:W5+43<O;D4O+W=!
M;6A,+S)Z3&HO04I/4EEQ6#%2-3(O-5%Z6"]W1'1N6&8O04-99D9$.#A-5U0W
M)B-X03MZ+TI0+W=!;%(U62\U9VLO-&MC5TQW+R]!2GI#+W=#56HX=F8X=V,S
M+THP67!$178K8UDO+TIV86(O>&=U+SA!:W<R2VPY;&%N+WAZ)B-X03MB=CA!
M-'=Y9CA23TM(-78T<VXR+R]W030T9CA!:VU03#,O4C4O=T)2,"M+0S@Q+S5Z
M2R\V6D0O=#0O.$%9<FEO958O:T0O-4XO=T%T)B-X03LO=T1'85@O<4AK>%-8
M,U)I>&9N1G$O.$%X,7(S+VI03"]W051/3$E0<FXO;D9,+WE6<B\Y=$<T+S1H
M2&EX2U)F.#5H9CAO>C5F+S5J)B-X03M:9CA!:S%I:U!N,SAS=CA!>5I0;% O
M=',V9CA!.5)594M8-D(T<U@U*V9M8B]W0U1*.#)F.71N55 K;W%41FLK:2\X
M06Y%2"]!2E%J)B-X03M79CA!='!N+T%+:#0X549.4"MC<F8O2E=P+S(P8F8X
M031H2FEG4&LW>78X03AP3G!(+TUB8B\X04HQ8U=29F]R:7AD:7)S5F1I<G-6
M)B-X03MD:7)S5F5*870O-4IJ.'EV*S)X<FXO56,R2W9K4$9K+U%4.'-V+TIB
M954O*S).<"\O54Q(:7AF35@O3U=(+VLP278X071M5R\O2GE8)B-X03M&260O
M>FEF+T%/5%%L+S=:;'@O>6-I>%5V<6IZ="]Y:&UV.$$O8D]U+W=$:W<K2T@U
M-%ES;C-N*U-F.$$U2VIY>"]Z0DHO>$DT<UAH)B-X03LO=T1Z;48O>6MF;#<O
M;41M+W=#5&]X4T=*9CA!3TUF+T%*3C=49CA!:D)D+SAM1WA5=G-R52\X06IM
M,V8O1T=4+VE*>%$O3B]&:RLS)B-X03LO=T1N2$0O>51(;#<O;S@O-FIP.%5&
M-7(O=T$U;&8X051)9CEV2"]S5GA54$LO>4(O=T1*=BM7+RM-,'8O55!*:6MV
M=6I&:2]/3%8O)B-X03LK3W1E+W=$1V58+VE:>%I".6,O.#1P9BM3=&8O04QA
M3G@O>$-01FE5:2\U>D,O-5)N>2\O04UX<W8O2G)&2690=C5:9BM42CAP+SA!
M)B-X03MB6C O+W%+:GA3+U%01FDO4'HX>F8O2FLK8E K,GIQ2"]55DII>692
M9B]/25 O2T5A>B\R,'HO,41X-&]+868X-5<O*U-T5"]!3&%.)B-X03MV+WA#
M5$9!9DHS;&8O;$IT22\U:F)F.$$U3W)I>4PY1F-73'-69&ER<U9D:7%",3-7
M<DA1.4=V9%EV,DM75VYW=F-81$M/5&-),4Q()B-X03MI3S4X3593;40X=V9,
M:F57+W=$148R.'5N,F%Z>5=L>$9C4G-:;V)M1U9O6DEP16@Y6#1L9$-0:$I(
M=FER>&4O.#EE5G)J.')F4&5K)B-X03MW6&I386IQ97%A=DY9,C9W>FMY2E!E
M33A:0C152$ID-D4T5F9.9C9.,4@Q9E,K<7IE<G@U96XV8F-U3F%6<%-T2S1'
M5#=0.$%)6#5Q)B-X03LK43E/.&IE6&10=F1434XU6C9:6E<Y>D-B935*4U=+
M,U)(53!I23)915ES6&=8+T]2;7$R9FU8>C9M<6%)6DPS5#!S25EN=49H;%91
M)B-X03LV4$E70C5Q<#)$1$9)9"]Z:FYQ=&XU83@K=G%M=&U3>3 Y-T-A2DQH
M;UI7574W>&Q13T-S9'=P>%5V;V)Z6"MB4#5F,VYL9E=,4S(Q)B-X03M1>5A.
M>%DS355-670W;7)/.$Q+<3=X9'EC55!I:CE'86PV9VHK<51E;U%70V5M,TQI
M1%%M;$]M*TQ*.6=F;%8K6G9K:E(O>38P1%1.)B-X03M3,44R,2]A5W%X,T5$
M5SEY4VI!;EEL67E-5TQY9B]N2G)Z0G!F;7)7.49U4$PW>5@X1G)B4W!/-E%Z
M2T9:<$%11'I293)+47AR.&=.)B-X03M1='1"+TUF5#E9,6(Q3%A416AU03$P
M67!(4W)X37$O659J=51I<&953B\X06Y"*UA5;&IC4G!Q,THS:6162#%E-C-*
M56=F-W%X42M')B-X03MM,#-55FM73G)765-06&=H:EE&=5!79W!V5$9K*W-V
M>5 O35AY9#5F+TLW4F1),6DK87HQ1S(K=&5V8G9B,T):9E5U-7!&<59J66)O
M)B-X03LT4%A&:5=#9C@U4"M:=$<X,B\T82]W04]Y>6%J.5,K=F97=E1G;5AH
M-G8Q9FA8;6DO83E.=6YH:6M03R]Y6'55,&HX>4Y#,6I55FMG)B-X03LP>3)L
M;&%E-CE+4C!51T=24#)&62]A3DYS5DPV-2\U6$HK5R\O5C,O04]N838O-G!9
M;V9$;7$R3C@R<#-$:3)M-'IZ>4='<V)G<T-X)B-X03MB645E1TQ*.4MF.$%/
M3R]N<GEV-5HO3#ET3C$R-V5X=FIF5'EI0C1,:&IW9%5#=%9),D<O131S4VQ0
M.$%Z:WHU=3!$>EAO3VI7+VPV)B-X03LT9E5*<F$V:VMN4T]#9%-Q=$A12#0P
M6'9I;V5++VPX:S%L-30X=F%J8W=Y<%DR5W$R8S$Q4#9B<W%*1&-),&A0144O
M0T9.8U=4-U O)B-X03M!3U9Y9FQV+T%.6&8O<#)U=BMQ5TQ&.%DO;4)(3F9E
M969-3V]7<TUS;&YF87)E5%=K,W!U;VM3831D-'EV24$O17!R5$9K.78O=T-C
M)B-X03MA9D]8;#-Y<C55,5-Z.'=83#9F8WHS-6UI:6MG;EET2#9-83AV9U)H
M,54T<U-M2"]!1&M2-38X<BM:=GDO6%1D0W4S=G(T6#!%<&=3)B-X03M#-%4X
M159W>E9E3E)T>4=+:#@U95A,4SAH,2]4-VE3,VU%3G1E471/-&IC.$%K:7,S
M2V=04F0X5U)F8FXO2S50>3,O-G4O.$$P-UA8)B-X03LO5DQ&:3<O;&-N-6(O
M=T16,R\V9')R+W%L:7).359D:7)S5E%/=39,638U;S$W;SDK<&5Y,4-&-V4T
M5E1X8FA)<%4X5#)0:&EQ:C5A)B-X03LX=3)F;"]3>' Y<DI,3T1,3F-4,TYW
M=V5A864T:V%75U=1<7%,>60S2BM&45!!67%M;4MP379L93!8>FLO;7(Q6E!R
M:VUN2G!:9RM()B-X03LP=E-39'!W+U1L>3505')3;4MP>FEQ1C%B5&]T5#!Q
M.3 V5FU32SEG;'0U2%=N24Q+:%%K5C)Q03)+=3!N5&]T33!Q>3 V2FUE2WEG
M)B-X03MI=#0S86Y)<D5G444P,G%1=4MO<D95<&9Y-6%V-7-H.'EM5B]R54YH
M3'!Q=S=E;5DU<&\U:7@R-6-G,$E(6$95,GA66F-1<E!"2D-X)B-X03M)5U9'
M46MD44=&3593>GEN-6-T9DQ8;'I4.4)T2EAM='1/:45-57-T3V)!16UR8U%"
M6&9W>%9.<U938E4O2SEP<4AM8E)0345K<VE8)B-X03M/:'!D>#(X4SAF5&-8
M<4EJ.#9I=G<K;4M53TMP>FER<U938GED-5AT4$LS;#8S,$]Z;&MN=#=:-35&
M;&TT.'EB:60U,G)X0VI:<%-")B-X03LW67%N3TMP3')F;&%Z,696.40Q4V5A
M4T]B47)I4S5T,%1J>&1P66UH265O2G!2-C=9<6Y72W5X5DIF2VYL87HX=#).
M,5HR<S!K>5A6)B-X03LU8S,W=$QX<4AU<$1)>6II0CA)2C)X5D]S5E-R6"],
M,71R6#9..656-"\P6F91-FI&=W X56M(3&ER5D(K13AT-EEQ;75+=7A62V1!
M)B-X03LX=5=U:7IA=DQ"2SAJ87AF=G%5-&5L16MK:6EI2W!11#1A46<W-'%M
M,DMU>%8R2W5X5C)+=7A6,DMS1R].8GE6-6PX,S9F66%D;RMO)B-X03M186)&
M8E1.97EZ>6E2;DYX0VXK:4MQ<'@K15-.>EII,W=L5BM&.7AI<50K679Y+S@O
M=T-S875B,F)566UT>&1A9F5X,E,S.3=$0T1A)B-X03MV8E!,8G)':UI604=H
M;5I*:%9Y6$913TE/2W958U932'HS;T8U<B]L83@P<3!A251Z=$%W4V-S<TUQ
M=WIP2SA-<%9825-:14UB9D-D)B-X03MM-DAP:7)8:U!13'IY+S56<SE+=7I&
M-CA$5'55='EZ47A,3E!*36M-4EI52E-&2D)'=G=J661":7)8;GIY+V5E65!,
M53)M5VYO=$LX)B-X03LQ=$TQ=F-L;'0U-#=E-&IM:W0U;5):1T5C>4E586EN
M<C!05$98;3)U9FLW-30Q4S(P-C)A.7-';# W5&),5&)B5DI*<F<S14IT0GEL
M)B-X03MM:E99;$E.,'IM2U%#4E0V87%E5$4P0E9M+S55*U1.5#AO*U<U=$TQ
M0C1':VMU;G5);S=:9S!C84Y(1W9$:W-.;VA*6D=B-%E61R]C)B-X03LQ66A5
M<W9V25AM5"]!2E=8+VEU>BMO>5%E=DA)6EIP<&]R<C9S8E%78W1M3T5-9SE)
M2&QC<CAE.&Q"469A>%9*3%0X;G9.1G(U<S!V)B-X03M5,'8W96)4=%!V2G!O
M-#=M4C=I84<S8E5:<F]C2&YH;&UE5U,S;%-.,D4X9$-V>$=69'-696AE93E!
M=DYF.')8;6Q7:E)#961O1T-4)B-X03ML;&AL5T=D2EAH;$MQ-4-426AJ8C14
M<S-1.4U665)B+T%*6F5A>G S;&UY;2]2,$DP1%4R=EDU25HW;'94='!,:$QN
M,%E6.4M)9G5X)B-X03MZ9U5F0V5!53AL579%>7).9DI(;'DV.'9A4%!P,7A.
M-C1..64S1G-X;&QN65<Y>&-Y4W=+.&LQ6D=D63)535-4=C-06$95:CAX95,O
M)B-X03M-;'HK649N-7$P>5<Q9&)+,E9);W)M4U-.=SAC5C)H9T)32U5#1S1E
M-VIE5G9T07A,44AB:7%W>GDO.$%K;#5X,#8K,"ME-'9.3VU.)B-X03MN<49T
M95!D:&Y%-RMH24AM;4EI9V=6,VY58U-R,6M(961K3$EX5C=C-FAL2VUT1T)"
M;U-$=C1%8FI!<GEV5E!Y,3@Q5"M43&)Y,'%7)B-X03M.-FQT9GI8:V1Z8S,Y
M-&MW4V4W=3544U0P2GHV>5%Z4D)*2D$O1BM41#1K4FEQ>40X=2]*5W$K5W(O
M>D10971A4U(V<F1T8W=3=TEN)B-X03LQ;"MC,#!R1S1M14U$=CA!,W=#2S=3
M1F0V4%%H5E96=GI1.'%A;#5N.'5X-EIP.$YR3DPY6E-343-C.'1U16I#3W)0
M13A55G@K*TA0)B-X03LT0SA:0VXT>#A3<FEQ0DAK>GI*3BM:5FHU<G5"<#8R
M,79B1WID1%,U;E-+3G)O4D="-6):6EDS:U<U47E-<WEJ-U-L6D)X6E97931Q
M)B-X03MW<C@P=DI7<2MA-T1424Y/83 Y4WAU+W),4F%G:5,R>E9H:VE"94=3
M1S536&HV=&5*5E0T3V@K3$97831Q;S-L<$1E5VLQ<DU8154V)B-X03M.2$E9
M<$AH9FEW;V5-:UI2,% X06Q+=TEX5C5:-4HO2VIZ3F]N;512=%0Q0S5S-VHV
M:$)%;'IE<$I-.3!W:C W-FTQ;V]E2E%B9C%V)B-X03LY235&>#A8-TAF1EAR
M3TMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A62U!.9FPK6%@Y16TP>4Q5
M-WI2,VQ:1T8O<#!P:'5%-$U')B-X03MO<FIO1W!1*S)+<T0O=T-62&%L+S5C
M6'I8+S-%5R]P:71U+S559'%8+VQX9DYF.$$S15<O<&ET=2]W0U9(86PO-6-8
M>E@O,T57+W!I)B-X03MT=2\U561Q6"]L>&9.9CA!,T57+W!I='4O=T-62&%L
M+S5C6'I8+S-%5R]P:71U+S559'%8+VQX9DYF.$$S15<O<&ET=2]W0U9(86PO
M)B-X03LU8UAZ6"\S15<O<&ET=2\U561Q6"]L>&9.9CA!,T57+W!I='4O=T-6
M2&%L+S5C6'I8+S-%5R]P:71U+S559'%8+VQX9DYF.$$S15<O)B-X03MP:71U
M+W=#5DAA;"\U8UAZ6"\S15<O<&ET=2\U561Q6"]L>&9.9CA!,T57+W!I='4O
M=T-62&%L+S5C6'I8+S-%5R]P:71U+S559'%8)B-X03LO;'AF3F8X03-%5R]P
M:71U+W=#5DAA;"\U8UAZ6"\S15<O<&ET=2\U561Q6"]L>&9.9CA!,T57+W!I
M='4O=T-62&%L+S5C6'I8+S-%)B-X03M7+W!I='4O-55D<5@O;'AF3F8X03-%
M5R]P:71U+W=#5DAA;"\U8UAZ6"\S15<O<&ET=E1R5T$R.7)$05I(;4U32VAL
M:TY89FE!3U1()B-X03MU5#%/2W%U2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%9*=D]0;5=$>7HU8G9T86QI*W-',5%E:F)"
M)B-X03MH1UIP<$=%8U5166<X96-J2W1A8EEQ.#4Q5"]N24Y,4F10;6<P1G)M
M,75D36@Q3SAC5'E";T1*8U17,#!.571P66%X4&)T.&-S<V%N)B-X03LR>%9&
M4V9N;GDQ3%5T3W0Y26A.>EE'9'HY63%#3S-72S-T6GIB>7I8,TM-;3%Q,T5X
M<E)Y-%I4:7%9959F>FAH,2]Z5&)A1"MI;G-:)B-X03M,;3-39FI034)D4G,Q
M<$AD;FYB8T)32VMV05-C.3)"2$59<7)T*V-M9W<S:5%81FQD0T-E-FUG=')U
M1E9K:CE+0SEJ,#5R:5AK,&)))B-X03MP=35E04-H='9I.6=Q>#50*V-H27!B
M:4LP9S!&-4QY5RLQ2W@Y2#9Y0E%A9D8V:V-V3#!V*U!H9U9!-V-7,TY-5F5Q
M-E9Q5G)Q;6PR)B-X03ME<#)J1G)3*V=J=6)D:G-42$UG9$0S+UIB1E56:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-663$U<"]-;GE2
M)B-X03LU5G4T8E!Z0G%S96XS33AF<E%X>4Q)>%I/4EAL.$-S3V]/2W!,+WEV
M=CAO9BMP:V<O=T-28R\X03%4>%8S+TLK+W=!;V8K<&MG+S5&)B-X03MZ+SA!
M5E!&6&8X<C<O2T@O04MM4T0O:UA0+S%4>%8S+T%#=G8X;V8K<&MG+S5&>B]!
M4%901EAF.'(W+TM(+W%:25 X06M84"]!3E4X)B-X03M69"]Y=G8X04M(+W%:
M25 K4F,O+T%&5'A6,R]+*R]Y:"]W0W!K9R\U1GHO.54X5F0O=T%R-R]+2"]Q
M6DE0*U)C+W=$,51X5DQD92].)B-X03MJ.&AV349P2%HV>G).<&978U5Y6$%T
M<%DW9WA.2DA8:C9I0D%S:3<O04=80E4K1TMS9&)6=BMC5U1-,&DS<T5+=7!2
M-V%'6%598EIO)B-X03MZ2SAX:F$S:DMW;5 Q2E=007!X,S95>%97,51Z2"]Z
M:DIQ:VLP;#EQ8V-J>GIR8W5Y>F%L1U)):$Q$,"]42RMM=DIU6$)+3'EO,4MG
M)B-X03M(1E5:<&YN<B]N2%143E9J,5=Z,6E)86A%2TI03$IF>D5.-E%G36Y'
M6&UP;&%)0D=K235K8D4T<6=R6'I6+WIJ>6I82#%V6&],=$=U)B-X03M*<')2
M4W0S2#9-5GAE4F%I,%!W04)G3'E!4T$P-F9$,')65E)U.60O-7AS84]E6%0Y
M6'1R2%4U4%5E0R]!=EI$1DY*.5E0<6A'259I)B-X03M$97EK03=B:G-Q,%9:
M6G!V-3$O:WAP=6Y7=6Y7;FU+0DQ7>6AJ=#=D3T4U<$A%;U)"+V0K07A612]W
M1$LK+WEH+W=#<&MG+S5&>B\Y)B-X03M5.%9D+W=!<C<O2T@O<5I)4"M28R]W
M1#%4>%8S+TLK+WEH+S9M4T0O04I&>B]W1%901EAF.'(W+T%#:"\V;5-$+VM8
M4"]W0E4X5F0O)B-X03MY=G8X;V8X07%:25 K4F,O+U901EAF.$%+*R]Y:"\V
M;5-$+VM84#A!.54X5EHS8C-%3GAB>%A%3&,T6FM74TYX5596:%5(9GA">%95
M)B-X03MX5C)+=7A6,DMU>%8R2W5X5C)+=7A606%J-68P2%5P5FPQ2%1B5SEL
M4F5#4UA%16-R0F$Q;T,V<U%+;D952B]G;GE:+S%93D\O=T-K)B-X03M31"]M
M:D989C1*.&UF.5=$5'8X07!%9R\U;WA6,RM#9DIN+U9G,#<O04M225 K84U6
M9"]G;GE:+S%93D\O=T-K4T0O;6I&6&8T2CAM)B-X03MF.5=$5'8X07!%9R\U
M;WA6,RM#9DIN+U9G,#<O04M225 K84U69"]G;GE:+S%93D\O=T-K4T0O;6I&
M6&8T2CAM9CE71%1V.$%P16<O)B-X03LU;WA6,RM#9DIN+U9G,#<O04M225 K
M84U69"]G;GE:+S%93D\O=T-K4T0O;6I&6&8T2CAM9CE71%1V.$%P16<O-6]X
M5C,K0V9*;B]6)B-X03MG,#<O04M225 K84U69"]G;GE:+S%93D\O=T-K4T0O
M;6I&6&8T2CAM9CE71%1V.$%P16<O-6]X5C,K0V9*;B]69S W+T%+4DE0*V%-
M)B-X03M69"]G;GE:+S%93D\O=T-K4T0O;6I&6&8T2CAM9CE71%1V.$%P16<O
M-6]X5C,K0V9*;B]69S W+T%+4DE0*V%-5F0O9VYY6B\Q64Y/)B-X03LO=T-K
M4T0O;6I&6&8T2CAM9CE71%1V.$%P16<O-6]X5C,K0V9*;B]69S W+T%+4DE0
M*V%-5E1M3TY),%=/3E%I24%Q26]O04)S04%-)B-X03M68GA6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5FDY-W%V;DM0>C59-F1B
M-EI(2C5C:W1*-4QI*TUR0VMI)B-X03MY5S15;CDP=U9W2&-,2'HK359A;S0T
M<3@Y,#=89GIE:C%F>EAQ2S94<5@Q9E8W4SAM.'1W6%E$=W=4,DQ&3&16:#5&
M-$1.16525U)6)B-X03LU=4YQ.6-64S=1.6(O3W50>DM)-%)Q3GIO,7IQ:5!(
M8S9P6GE1=DY!571K;%=335<W:3)124A:84Y#=E!K87-A<FA6368X4V9N1VXQ
M)B-X03MG6$,V9W1N3$E(;'5O3DY34S5T25)F6#!"1G1&-E)%-TY&0F)04FQ9
M.%@U9$--5E%'="M9=GIY;&EU8F5A>'9"-C)I:5)O3$<R9$)&)B-X03MD+U4Q
M9'5-,%-E;UI$4%9127 K45!W*VY18SA64DAM1'I**V5.=G%6-$Y0:G4U3E!M
M=7114D<K;T0O4F)A,G9X1&)00WE7,7DX:&QH)B-X03ME=GA24V-L2$I2<U=W
M2SED.')483%0-6(P>6)815=05C5,84IR.55"5F972VIN4E-!5C,W16)9<6UM
M2W5X5C)+=7A6,DMU>%8R2W5X)B-X03M6,DMV+SEK/2(O/@H@(" @/"]R9&8Z
M06QT/@H@(" \+WAM<#I4:'5M8FYA:6QS/@H@(" \9&,Z8W)E871O<CX*(" @
M(#QR9&8Z4V5Q/@H@(" @(#QR9&8Z;&D^<G(R-C<X.30\+W)D9CIL:3X*(" @
M(#PO<F1F.E-E<3X*(" @/"]D8SIC<F5A=&]R/@H@(" \9&,Z=&ET;&4^"B @
M(" \<F1F.D%L=#X*(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B
M/F<T,G@U-#PO<F1F.FQI/@H@(" @/"]R9&8Z06QT/@H@(" \+V1C.G1I=&QE
M/@H@(" \>&UP5%!G.DUA>%!A9V53:7IE"B @("!S=$1I;3IW/2(V,3(N,# P
M,# P(@H@(" @<W1$:6TZ:#TB-SDR+C P,# P,"(*(" @('-T1&EM.G5N:70]
M(E!O:6YT<R(O/@H@(" \>&UP5%!G.D9O;G1S/@H@(" @/')D9CI"86<^"B @
M(" @/')D9CIL:0H@(" @("!S=$9N=#IF;VYT3F%M93TB2&5L=F5T:6-A+4)O
M;&0B"B @(" @('-T1FYT.F9O;G1&86UI;'D](DAE;'9E=&EC82!";VQD(@H@
M(" @("!S=$9N=#IF;VYT1F%C93TB0F]L9"(*(" @(" @<W1&;G0Z9F]N=%1Y
M<&4](E1Y<&4@,2(*(" @(" @<W1&;G0Z=F5R<VEO;E-T<FEN9STB,# Q+C P
M,"(*(" @(" @<W1&;G0Z8V]M<&]S:71E/2)&86QS92(*(" @(" @<W1&;G0Z
M9F]N=$9I;&5.86UE/2)H96QV971I8V$M8F]L9"YP9F([($A%3%9%5$E#02U"
M3TQ$+E!&32(O/@H@(" @/"]R9&8Z0F%G/@H@(" \+WAM<%109SI&;VYT<SX*
M(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @/')D9CI397$^"B @(" @/')D
M9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @/"]R9&8Z4V5Q/@H@(" \+WAM<%10
M9SI0;&%T94YA;65S/@H@(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(#QR
M9&8Z4V5Q/@H@(" @(#QR9&8Z;&D*(" @(" @>&UP1SIG<F]U<$YA;64](D1E
M9F%U;'0@4W=A=&-H($=R;W5P(@H@(" @("!X;7!'.F=R;W5P5'EP93TB,"(O
M/@H@(" @/"]R9&8Z4V5Q/@H@(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @
M(#QX;7!-33I$97)I=F5D1G)O;0H@(" @<W12968Z:6YS=&%N8V5)1#TB>&UP
M+FEI9#HR.$,V1C8Q.35$13!%-S$Q.$(P,T,S1#A",3$Y,S4Q-2(*(" @('-T
M4F5F.F1O8W5M96YT240](GAM<"YD:60Z,CA#-D8V,3DU1$4P13<Q,3A",#-#
M,T0X0C$Q.3,U,34B"B @("!S=%)E9CIO<FEG:6YA;$1O8W5M96YT240](GAM
M<"YD:60Z-SDW0T8W1C@S141&13<Q,3E%0S=",D-&0C Y-SDW.#(B"B @("!S
M=%)E9CIR96YD:71I;VY#;&%S<STB9&5F875L="(O/@H@(" \>&UP34TZ2&ES
M=&]R>3X*(" @(#QR9&8Z4V5Q/@H@(" @(#QR9&8Z;&D*(" @(" @<W1%=G0Z
M86-T:6]N/2)S879E9"(*(" @(" @<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI
M9#HW.3=#1C=&.#-%1$9%-S$Q.45#-T(R0T9",#DW.3<X,B(*(" @(" @<W1%
M=G0Z=VAE;CTB,C Q-RTQ,BTQ,E0R,#HP-3HQ-"LP-3HS,"(*(" @(" @<W1%
M=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD
M;W=S*2(*(" @(" @<W1%=G0Z8VAA;F=E9#TB+R(O/@H@(" @(#QR9&8Z;&D*
M(" @(" @<W1%=G0Z86-T:6]N/2)S879E9"(*(" @(" @<W1%=G0Z:6YS=&%N
M8V5)1#TB>&UP+FEI9#HR.4,V1C8Q.35$13!%-S$Q.$(P,T,S1#A",3$Y,S4Q
M-2(*(" @(" @<W1%=G0Z=VAE;CTB,C Q-RTQ,BTQ,U0Q.#HR,#HT.2TP-SHP
M,"(*(" @(" @<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@26QL=7-T<F%T
M;W(@0U,V("A7:6YD;W=S*2(*(" @(" @<W1%=G0Z8VAA;F=E9#TB+R(O/@H@
M(" @/"]R9&8Z4V5Q/@H@(" \+WAM<$U-.DAI<W1O<GD^"B @(#Q%>'1E;G-I
M<T9O;G1396YS93IS;'5G/@H@(" @/')D9CI"86<^"B @(" @/')D9CIL:0H@
M(" @("!%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#TB4&]S=%-C<FEP="(*
M(" @(" @17AT96YS:7-&;VYT4V5N<V4Z1F%M:6QY/2)(96QV971I8V$B"B @
M(" @($5X=&5N<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ93TB,CDP-C(B
M"B @(" @($5X=&5N<VES1F]N=%-E;G-E.D9O=6YD<GD](DQI;F]T>7!E($%'
M(@H@(" @("!%>'1E;G-I<T9O;G1396YS93I697)S:6]N/2(P,#$N,# P(@H@
M(" @("!%>'1E;G-I<T9O;G1396YS93I+97)N:6YG0VAE8VMS=6T](C B"B @
M(" @($5X=&5N<VES1F]N=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T]
M(C$X.#<X,S<X,#(B"B @(" @($5X=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M
M/2(Q.#@W.#,W.# R(@H@(" @("!%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R
M:7!T3F%M93TB2&5L=F5T:6-A+4)O;&0B+SX*(" @(#PO<F1F.D)A9SX*(" @
M/"]%>'1E;G-I<T9O;G1396YS93IS;'5G/@H@(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$(
M ,X!!P,!$0 "$0$#$0'_Q  ?  $  @,! 0 # 0          "@L'" D%!@$#
M! +_Q !"$   !0," @0+!@0& P$    #! 4&!P "" $)"CD4=GBW$1(3%3<X
M=YBUMK@6&%ES==47(3:Q(B0T='FS&E33(__$ !@! 0$! 0$
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M=8HK;()E[;N$4+CR9J@K1,%5LU(=,OLT - T-B4FU.<JGBC=^A@H!0"@% *
M4!RPP]YCN[_U_P */I%:5#78L.K/QE]S)MH7K9G!]*RK6.U8]&:KL7#,ZH5I
MR* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 8EGF:F1CC#$GSS)(JH"P(C9:\_
M7@*BI^JJK!M]N$15!2O3DVT4"X\;M+@WZ@EM!@]1;_!;X]OA\- E-I*UU+B1
M/R?$0[<P&Y*X\HA%>9?X6*>#[*@,J/I%P^J]K("%/+^D,^$(C^>O&L2-&XXD
MV\)2Z1K:(<N&*Z Z:A:WW#V^''H)2KTF[59)+:2S(4EQH3]#T6SE'PBB*Q)@
MC]HR6S15<CJF*HC8>R$1<2'>I)VHHVI$]>FJ):XT4U&%U+C:WA:B7:V^-J/%
MJ3:=JJ? T+W ]V[$+;?7V(R\E5"1":U*;:7G U+64R!765O3T4Z E'M3Y@-2
M(Z$QM#9P'0(+6P3R@>MU_AT\7P:CJ&"**ZIRE.M:SE_L3[OF';ZAC"+;E05"
M1KLD4Z)CS2,DS;&%+,O17CYGNM_.*VQU:J5X=Q>QOMU2O)C]"TT-&] 2VEMF
MHOCVCJD@B3BB:J<3KFM;^9*"H>8H!0"@% * 4!RPP]YCN[_U_P */I%:5#78
ML.K/.R[5DJ_<BVBA;%-/O" =F;NHPEIPM<&#H)BPJV!ZBWZ":VA^/?\ X;/'
MUT\:[_#;X=?Y5CU8]&:KL7#,ZM &"YH/08L."8"UUUTT% %L&#UUMU\%VFEX
M=UUNNNFO\M=--?Y:_P M:TY/W4 H!0"@% * 4 H!0"@% * 4 H!0"@(Y&[%O
MS1UA0YG3"L#2/#9_)J*5I&+R?%4W1)D2M$3R<Z4)K.%#!9;PCH! 9UBD50G,
M"X5498<XI*\@#>EE+?/G@*7#T@HW%6TY.QII9SR-\]M+<^@7<(:"LAL*5FC)
M<TQ:WF^IS9K',9S+'<<IYITJ2Z50QV@%,J*GN TGF@D0P'> .?43I<R7&$,:
MA #E?&',4#A=:DG.4VF_HSZK=[Y7F>W9;EWY3/T$%^'>AS140T+BX#VL.6AM
M_P#8VQN[HVG0ACOQ;T6;(C/&'>GS"[V02=\YH5#VH._Z>IRGX;[G,8@?D9"?
M2[--#NFN<46F="04 H!0&+9KF-C8_1:\)AD@X?(LQDD2QU7%2DHZMJ@PB@I$
MD5*3TU+3PA3)P^JK*DG)9.SP!E[3!P,4X9*$[!S0()3-.4S=1P^4C+2#O=+S
M2T]QIH)U<<2M';J)MJ,#IYTR^QD9O2FM]!%)--><+R@27&V@E=;SQ52/,X0P
M$=T2UQL*"V.M%_O#[KY^3EL5CAE-%>4C9<CFC;5V)UK06$5'<J"_VDL,5T(]
M[H8C3D]HJ!M#700#.B2ZX]?33=:&H!ZB!"D5?H1OH:TG*Z6GC&FK?HT_+5YF
MF>(H@8NXAO#WA7V"6:O?"_P7AW6WVZ^#$%J::^"ZW7737P:Z:Z:^#7^6NFNE
M [%AU94PT+RSIX83E'Q/[49P[P5*A)37^")!]#R% * 4 H!0"@% * 4 H!0"
M@/.6" JHD*B8 I'T8=13CQ %82KBUJHE"G"PI<-23;CA8X4M/D;Q-#1.XT4-
M%M# 0>HY8<+Q@K@./VUBBS<=D#.!2EK+C(6?TV$<KY/Q78[7E<W& R"7:[*:
MT//9,?!NQEQFS5(:03!EW+".=.!*(#;O1A PP&R7/67'[QU$TTI0I55RGM:Z
M?Z=DJ')54<0SSC,T?UV(?IZB2A91=G#Q]S.T/!S^DS.[J+ WQ^4*'G3]SU="
M4YN]\KS/;LMR[\IGZ'C!?AWH<T5$-"XN ]K#EH;?_8VQN[HVG0ACOQ;T6;(C
M/&'>GS"[V02=\YH5#VH._P"GJ<I^&^YS&('Y&0GTNS30[IKG%%IG0D% ?$+4
MF1PVW*CLQQ2 R$%X.+Q-6^U%IUH*6Y5WR@EP(?F="/'P%13\H-9<%9T(J/XP
MEMUEOANTUTT ^WH# V3D!(&4,%OZ"G0NK+;1'X510C:PA@)!TT *WW*BNL@7
M.I+@3U5!<+=45!"*IKL:JXG'$9V-8XL-M5!N(*ICP G(YRHNRW!:8326Z;E.
M3C[!4 4@S*T?ED]@H3:D==:D@Y"R<PS*471FH5OBMLLAS9+/PH@L6/-4AMEV
MLA1^V["X99MG1UQ+]_=AUI>2GJ^27SJMQG.=6TT&X"QC%T3S)$TD+RSD2E3X
M&V$B4S4FI+9(EW,SF-$+$@QH,X=!9Z4@HH:61C^/46Q5'L+=,7'$?7UD<4N"
MH%$Q-&3=6J5DM5<S4';?A")<<\S-VJ(8-8+>C&,FP^\11F^RFJ4U(H:2*O8L
MH;A6;R9:X074.Y16U104C/\ CU\<T;&O_EXW@T&Q-O1FYU:\6565"XLZ>&$Y
M1\3^U&<.\%2H24U_@B0?0\A0"@% * 4 H!0"@% * X.[EV'V-4U;@&UVL2E$
MC<>2E*TLS/'$B&U,=8#O=;'C_%J;)&9K<4[2*F4#U(-][DRSC)>0L!'Z>#9Y
M<84#P@ZCN%M**3L2:QTH:SO%0X% <K]L3^I]S_\ Y4)_[H<=Z&NQ8=6=4*&%
M51Q#/.,S1_78A^GJ)*%E%V</'W,[0\'/Z3,[NHL#?'Y0H>=/W/5T)3F[WRO,
M]NRW+ORF?H>,%^'>AS140T+BX#VL.6AM_P#8VQN[HVG0ACOQ;T6;(C/&'>GS
M"[V02=\YH5#VH._Z>IRGX;[G,8@?D9"?2[--#NFN<46F="04!'[RX=N.ULL'
M8'2MNXN2FV9LF86*+\U39%&&:^U)48:QD:P4V9G:&IR3+3AEETM]Q1("_6VQ
MC(,=CKB***B)342VT82DOS2_S_?H=I.4YU)/;55^XG>]"1$UM(B,W$4O<41T
M!*3T1)*WF31R\LFI10$B0+W&SPQDZ:N!*@!!W&3A@P:'UMU%,#"BW7WW#@]6
M@% * Y48D<Q/>(Z[X7?2 U*&NQ8=65+U"\LZ>&$Y1\3^U&<.\%2H24U_@B0?
M0\A0"@% * 4!HRV-R/#=Y9+*.'[=D]Q'LATE?<+:4F$-"L[II8FIM<5PEU<4
M9[JD9$H]M1.D-1P%TMS:.O5M. PG7@("LIC#E;!QUHN6E5+%93GKV&\U#D^(
MD:38WAYH*DA2W(+(BU@H=Y -:?$C.Q!9#01[U51*I"78J.5S'TQ%3[U)6/$4
MLA:;.@ZG%$X5)%]!#)@$*\#QHGF^%I[;QUW07+T7S0U$Q9';BDYXG?[4D9O)
M[A*DD]2,H1U:9ZLL)I19+IRLEJ Z6.9#.@DE)/-" 6@'"X@@2E:90H"J)F+>
MXW0'E,C'?#DRA,J3IQVD-_+\-JNL10(5N9JNY&XY8T6S890C%A8@N:GF0X%A
M#U!<I59+ 6G-3Y4$%4 +'@<5BP18J."5EJ4ZWCMVD\+8!RTR#S2V_"$UY,R$
M))LG#3%)36%<XK99K3NN04#5!\TD/-+$;K80=-"G3#/@,VI>AL;RG^9,#>)9
MXNDU(E#&TJDI9(W8SVS_ (#VXH=;TXY%_;;[$.>2$:+$S[!MP!SK'VI76T[W
M61Z0GF%5'L"3?-3)6O+&]#-]P9GH@.@%V@^H@8R&%Q.2Q(Z^WCO]8$,J4LHV
M:L_QKU6,M=PMYRA$_0XY)#E-&S+#7AA@-71SCW.D+5&4?/[84_.90$-0L)DN
MCF;!S%PNH5@[=%&E.JI.=?FWD3!*'D55'$,\XS-']=B'Z>HDH6479P\?<SM#
MP<_I,SNZBP-\?E"AYT_<]70E.;O?*\SV[+<N_*9^AXP7X=Z'-%1#0N+@/:PY
M:&W_ -C;&[NC:="&._%O19LB,\8=Z?,+O9!)WSFA4/:@[_IZG*?AON<QB!^1
MD)]+LTT.Z:YQ1:9T)!0$=":5 J^]V\BILP_=<,6"QU9BNA"D\(6B[S2C$,I2
M0,]3H[3S-9:ID:XVBFD7&FG$:0,4;&Z6<2*<Z4SU]872[9<-#M77-RME>KFE
M8U57*N>PD7T.!0"@% <J,2.8GO$==\+OI :E#78L.K*EZA>6=/#"<H^)_:C.
M'>"I4)*:_P $2#Z'D* 4 H!0"@.6K&YSN1__ !RXJ?4-E-0[_P#-;[]J.I5#
M@C4[[>\>#M]NAG8U*^*K-R);<Z0XJNY0./)\6(:>BF@W*K-X@#JV34?O$@L7
MIIQ+*KI,V.:)B '@@?(V!"@!FJ'K1T>G-Z4I/9/JC1OA]-YT*37EC%MEHN*#
M,CU-1XG54Y<F5OONWSD[UZ*8N%-F'>MLHI'J2 977<&UBA91-G'2>.E@[@O'
M/*&A0*RX;24<IQSMBLEM>V?0F=4/$I,GY_7#SZUN+XN<K%8L%D7JQ8+(LC>%
M=Y5*7V@IB_NV*TDI>TBX>U&*.+FY;$-]MF->X[(VAU07WNO-$!_$SUJ<9^T#
M#7>,VZ%$=R+=BR9<[T(2JHXAGG&9H_KL0_3U$E"RB[.'C[F=H>#G])F=W46!
MOC\H4/.G[GJZ$IS=[Y7F>W9;EWY3/T/&"_#O0YHJ(:%Q<![6'+0V_P#L;8W=
MT;3H0QWXMZ+-D1GC#O3YA=[().^<T*A[4'?]/4Y3\-]SF,0/R,A/I=FFAW37
M.*+3.A(* C*[IJ6K2'G.R(B-RL]2J Z ,13"0$@3]EE&T<P(X IQ=-IL:2F[
M%D.OZ$$Y\9*EK2$;0R^'O),9K",Z4\BHAD!K$DF=7QW#4IRUNN2>KS=:6NIU
M.O8Y$4-HC^;,0Q4W)7<A1Y2DWXW8R))+O(67AD76_DIL)9!XN0D&(5)7V%%Q
MQ **H6LO)E+[035EMQ4#734*P<&2* 4 H#E1B1S$]XCKOA=](#4H:[%AU94O
M4+RSIX83E'Q/[49P[P5*A)37^")!]#R% * 4 H!0'+5C<YW(_P#XY<5/J&RF
MH=_^:WW[4=2J'!7Y<8!ZWN*O9N4^\YT4*:"R+%9&AG#+<WV!^HL[=T#MH=4U
MSBBT H2%)D_/ZX>?6MQ?%SE8K%@LB]6+!9%D;PKO*I2^T%,7]VQ6DE+VD7#V
MHQ1Q<W+8AOMLQKW'9&T.J"^]UYH@/XF>M3C/V@8:[QFW0HCN1;L63+G>A"55
M'$,\XS-']=B'Z>HDH6479P\?<SM#P<_I,SNZBP-\?E"AYT_<]70E.;O?*\SV
M[+<N_*9^AXP7X=Z'-%1#0N+@/:PY:&W_ -C;&[NC:="&._%O19LB,\8=Z?,+
MO9!)WSFA4/:@[_IZG*?AON<QB!^1D)]+LTT.Z:YQ1:9T)!0'$W++"+(J=9Q<
MSKMC-BNE+<US*34N2&EN%YD8D@I;<B]XK#YB>^2,?XD8CQ;K]>D6KJV956Z[
MTB1T@RLN,&U;)%HVU$+%TT=II?\ S#%7Y-V37ZSL%'K=4F@P6.TUE9&<:PUV
M>VFZJN$P;<)\PO*2(BDDT\LCGG<X7:ZS@RH:+"GA3;G=;F<)B\>X9:<*TI7F
M5(R.#["@% * Y48D<Q/>(Z[X7?2 U*&NQ8=65+U"\LZ>&$Y1\3^U&<.\%2H2
M4U_@B0?0\A0"@% * T=W*I\D#%O!#)[(.*AD@O(D41BH.MI#+R9:LHX:L6/I
MY<*Y02[Q@+3I?0,R+XP.HP>FMWBZ^-_*AL*G%"G8VE\V5W";Q$&XTE9".[)H
MHM0YI*#VB5DPJN#B1:6O0[V1'[K>KR;P15(\\:6EU.Q:?S@N.*&@]UQHM>4+
MZA6:%M+KQ7\*"4JY3G;KJ70LH\19*<TS8H8PS ];R(KRE?'F%I*=HB84T()H
MCF?4;-IT+UZ>1MO%M)$;U54-W%"F@@FA8#4,'2^_2SQM<5:3\B1VO%D'CC /
M6]Q5[-RGWG.BM**"R+%9&AG#+<WV!^HL[=T#MH=4USBBT H2%)D_/ZX>?6MQ
M?%SE8K%@LB]6+!9%D;PKO*I2^T%,7]VQ6DE+VD7#VHQ1Q<W+8AOMLQKW'9&T
M.J"^]UYH@/XF>M3C/V@8:[QFW0HCN1;L63+G>A"55'$,\XS-']=B'Z>HDH64
M79P\?<SM#P<_I,SNZBP-\?E"AYT_<]70E.;O?*\SV[+<N_*9^AXP7X=Z'-%1
M#0N+@/:PY:&W_P!C;&[NC:="&._%O19LB,\8=Z?,+O9!)WSFA4/:@[_IZG*?
MAON<QB!^1D)]+LTT.Z:YQ1:9T)!0&BTJM,91RM:!+^/K[A5Q2-%:T6C%.BHX
MIGU9XF(W,GC,EF7ZU9(;,F8\"I;8(/UAFV6JC,5)D.]2-+I3[0J*(!8E@C9^
M7[G]?J;BL]'66\UF^AN%VJS]74E))$%9Z+J>WDE9=!\L!:&96U-,:2.WVR0.
M* MMQ@<JA(B6E@WWZV%"0 6EMF@P^DH!0"@.5&)',3WB.N^%WT@-2AKL6'5E
M2]0O+.GAA.4?$_M1G#O!4J$E-?X(D'T/(4 H#4[*[-[&O"1!:[GR4>CB8S?>
M!\VEH:NBQ1+LFDM3Y,RBDKBRL-%;$>VC=O-GG"CD$G5P^:[%I0.V$4BX\;#'
M!"&I-V&>8UD5J2XPFG)C&,JAQH/=%)N%NFEMM.9FJXZ6?L\H6$4&L\DA =2"
M:NM_F(FKR*F*1?7_  F"@5W\J&6'.O>UY4.='L-6/BR/0Z@OP[T.:*E.A<7&
M>W=R_L%^QUC)W*,FL5BP61 [7B\R%OQ@'K>XJ]FY3[SG16E%!9%BLC0SAEN;
M[ _46=NZ!VT.J:YQ1: 4)"DR?G]<//K6XOBYRL5BP61>K%@LBR-X5WE4I?:"
MF+^[8K22E[2+A[48HXN;EL0WVV8U[CLC:'5!?>Z\T0'\3/6IQG[0,-=XS;H4
M1W(MV+)ESO0A*JCB&><9FC^NQ#]/424+*+LX>/N9VAX.?TF9W=18&^/RA0\Z
M?N>KH2G-WOE>9[=EN7?E,_0\8+\.]#FBHAH7%P'M8<M#;_[&V-W=&TZ$,=^+
M>BS9$9XP[T^87>R"3OG-"H>U!W_3U.4_#?<YC$#\C(3Z79IH=TUSBBTSH2"@
M(T^K7G29MS,RX$)O9?HT/1I/J\?3RL/[E*,N)$CEV1)I%HR,\)&AA_Y8I]L=
MX\--V!6I+F@:,,>!UI2#)@-\T[K+3VC!,CN<H9?QKVPJ=EB>C;7;/9B26*'!
M@_)&6%>$(0D&3F\S'%(+C;B63!;31;#8=CP4%5RN%836PWKCR"Q$9QO$=KIJ
MRM$59ZGVZ@+*HALTBO+I=,.ZINI<0/W]F1[&=O 91G&A%KQ%_AZZ%0G&L)J*
M[%IV*'6R7QD2Y9:>N8C0=[ECQ.67"G+[4;L5VXYM95T*);:=A8X64W5<KJNI
M8P@FB@[T57Y3KG9)+9.=;U<#I-A#FI*DJPED.^W^3)Y&J4*&8S4F^H8T,Y.(
MJ$F!R-C!"T]JT>M)MJ\A*#>4'HS'-):NT"OEGNF FDD%MV+EQ);L53AL8TJM
M4YVZI-KS>I<9F+MMN4#LRYD[M,B*,4RM"9M=?F(P8L;3:AH#<DE!T2<6D1'#
M$7T=L.AY(I4-7#(6K*1J4<1ZXPBGT\P8M*&11B8 QZJYU=7M*K6A>6=/#"<H
M^)_:C.'>"I4)*:_P1(/H>0H!0'+7>=Y>4H^US#GZT<?*QV<5FC5;P>3.I5:8
M<L][7E0YT>PU8^+(]#J"_#O0YHJ4Z%Q<9[=W+^P7['6,G<HR:Q6+!9$#M>+S
M(6_& >M[BKV;E/O.=%:44%D6*R-#.&6YOL#]19V[H';0ZIKG%%H!0D*3)^?U
MP\^M;B^+G*Q6+!9%ZL6"R+(WA7>52E]H*8O[MBM)*7M(N'M1BCBYN6Q#?;9C
M7N.R-H=4%][KS1 ?Q,]:G&?M PUWC-NA1'<BW8LF7.]"$JJ.(9YQF:/Z[$/T
M]1)0LHNSAX^YG:'@Y_29G=U%@;X_*%#SI^YZNA*<W>^5YGMV6Y=^4S]#Q@OP
M[T.:*B&A<7 >UART-O\ [&V-W=&TZ$,=^+>BS9$9XP[T^87>R"3OG-"H>U!W
M_3U.4_#?<YC$#\C(3Z79IH=TUSBBTSH2"@. A'!K+IF9TJTX1VWY!0(U6)T<
MJ\?4TW<#928B&XQD29B$HR*!?!AS;J7%:Q'<BH (O*4;VSUJIFK]-6^4E!,\
MOHN%QZ:4.C)JN7AURE;IX5Z/ []T/,4!\J&Q60"I(2T"SFJ$L-<JH$6TK!MY
M(L4FZ25_#YU*(1^TGH:22JGX=?.!<@*7".^'7I-@GAUH#^QN-9L,Y-\S-%N(
M+62.E&SWFIN)">B)O33X]QD\<Z"F%RI7I1TS?>8-F/)>5,CWW"C7WB7:W:@<
MQL2.8GO$==\+OI :E#78L.K*EZA>6=/#"<H^)_:C.'>"I4)*:_P1WU<B^0:K
M=7W0J6* B8VT557U$-)2U!;5!"".1'43EB:BI!8XJJZA<7+B6DTM,)FE ^8U
M#*$BPYD4,*X>1J%BGN!XWYHK3[0('/2BI'HU,&$]Y"OB"YCBM-2%HB?L35)M
M7*TDLEKIIEU)!L4.U8;!4T,NI(8@8R@0+A7VWZCJ*%PRGK\T\FS=>AR00]\/
M?6FQ#F/*+;K!A.+!X_84J0Z,1?XJD[='B>UC1Y15.Z=H;*6*.B+;HHK;=+HA
MWR)6W6Q*,#"@>(;TL$T?Y]*SW@HII1:5J=4MM5L^AVTV+]X:6MUP?)X&4(EC
MJ+]((!AH1$U81]RG=5O63+Y3M4M%7[0GCODM$[[ D=271/)^/TXWY?Q_%!\4
M<4E'H2KG.>J5DO-[3;S>UY4.='L-6/BR/0Y@OP[T.:*E.A<7&>W=R_L%^QUC
M)W*,FL5BP61 [7B\R%OQ@'K>XJ]FY3[SG16E%!9%BLC0SAEN;[ _46=NZ!VT
M.J:YQ1: 4)"DR?G]<//K6XOBYRL5BP61>K%@LBR-X5WE4I?:"F+^[8K22E[2
M+A[48HXN;EL0WVV8U[CLC:'5!?>Z\T0'\3/6IQG[0,-=XS;H41W(MV+)ESO0
MA*JCB&><9FC^NQ#]/424+*+LX>/N9VAX.?TF9W=18&^/RA0\Z?N>KH2G-WOE
M>9[=EN7?E,_0\8+\.]#FBHAH7%P'M8<M#;_[&V-W=&TZ$,=^+>BS9$9XP[T^
M87>R"3OG-"H>U!W_ $]3E/PWW.8Q _(R$^EV::'=-<XHM,Z$@H!0"@% * 4!
MRHQ(YB>\1UWPN^D!J4-=BPZLJ7J%Y9T\,)RCXG]J,X=X*E0DIK_!&5]]7<KF
M[; QNB>8X*:$5O)R/R;R,9JR?+20[EE#+(9EAO=TWG$XNSGJQSX2KH?;1$&P
M8RHFR>A,8U9J2N&O!'!'-'!IMIN54_JON15MN?B%LQ&UD4A0N1BO&D5LYCYW
M 2%)2@;:THWKJ LY)20T45[%6.8!ET!/3TQ(*B:B-8%>37&:)CZ:7*QQ:#\(
M>H]HZ)2G-_QA^<DRQAH3%3MOO\W'-[VGHW=XRZ%M'<AP) ?!M?ZW<2_VN)__
M &Y(4/*G[GJZ$CK>UY4.='L-6/BR/0\8+\.]#FBI3H7%QGMW<O[!?L=8R=RC
M)K%8L%D0.UXO,A;\8!ZWN*O9N4^\YT5I10618K(T,X9;F^P/U%G;N@=M#JFN
M<46@%"0I,GY_7#SZUN+XN<K%8L%D7JQ8+(LC>%=Y5*7V@IB_NV*TDI>TBX>U
M&*.+FY;$-]MF->X[(VAU07WNO-$!_$SUJ<9^T##7>,VZ%$=R+=BR9<[T(2JH
MXAGG&9H_KL0_3U$E"RB[.'C[F=H>#G])F=W46!OC\H4/.G[GJZ$IS=[Y7F>W
M9;EWY3/T/&"_#O0YHJ(:%Q<![6'+0V_^QMC=W1M.A#'?BWHLV1&>,.]/F%WL
M@D[YS0J'M0=_T]3E/PWW.8Q _(R$^EV::'=-<XHM,Z$@H!0"@% * 4!RHQ(Y
MB>\1UWPN^D!J4-=BPZLJ7J%Y9T\,)RCXG]J,X=X*E0DIK_!&HW%[^HICCVM$
MGN>EFAM!?>Z\T0@<"/7IPN[66.?? SJ%$=R+=BR9<C4(2IVWW^;CF][3T;N\
M9="VCN0X$@/@VO\ 6[B7^UQ/_P"W)"AY4_<]70D=;VO*ASH]AJQ\61Z'C!?A
MWH<T5*="XN,]N[E_8+]CK&3N49-8K%@LB!VO%YD+?C /6]Q5[-RGWG.BM**"
MR+%9&AG#+<WV!^HL[=T#MH=4USBBT H2%)D_/ZX>?6MQ?%SE8K%@LB]6+!9%
MD;PKO*I2^T%,7]VQ6DE+VD7#VHQ1Q<W+8AOMLQKW'9&T.J"^]UYH@/XF>M3C
M/V@8:[QFW0HCN1;L63+G>A"55'$,\XS-']=B'Z>HDH6479P\?<SM#P<_I,SN
MZBP-\?E"AYT_<]70E.;O?*\SV[+<N_*9^AXP7X=Z'-%1#0N+@/:PY:&W_P!C
M;&[NC:="&._%O19LB,\8=Z?,+O9!)WSFA4/:@[_IZG*?AON<QB!^1D)]+LTT
M.Z:YQ1:9T)!0"@% * 4 H#E1B1S$]XCKOA=](#4H:[%AU94O4+RSIX83E'Q/
M[49P[P5*A)37^"-1N+W]13''M:)/<]+-#:"^]UYHA X$>O3A=VLL<^^!G4*(
M[D6[%DRY&H0E3MOO\W'-[VGHW=XRZ%M'<AP) ?!M?ZW<2_VN)_\ VY(4/*G[
MGJZ$CK>UY4.='L-6/BR/0\8+\.]#FBI3H7%QGMW<O[!?L=8R=RC)K%8L%D0.
MUXO,A;\8!ZWN*O9N4^\YT5I10618K(T,X9;F^P/U%G;N@=M#JFN<46@%"0I,
MGY_7#SZUN+XN<K%8L%D7JQ8+(LC>%=Y5*7V@IB_NV*TDI>TBX>U&*.+FY;$-
M]MF->X[(VAU07WNO-$!_$SUJ<9^T##7>,VZ%$=R+=BR9<[T(2JHXAGG&9H_K
ML0_3U$E"RB[.'C[F=H>#G])F=W46!OC\H4/.G[GJZ$IS=[Y7F>W9;EWY3/T/
M&"_#O0YHJ(:%Q<![6'+0V_\ L;8W=T;3H0QWXMZ+-D1GC#O3YA=[().^<T*A
M[4'?]/4Y3\-]SF,0/R,A/I=FFAW37.*+3.A(* 4 H!0"@% <J,2.8GO$==\+
MOI :E#78L.K*EZA>6=/#"<H^)_:C.'>"I4)*:_P1J-Q>_J*8X]K1)[GI9H;0
M7WNO-$(' CUZ<+NUECGWP,ZA1'<BW8LF7(U"$J=M]_FXYO>T]&[O&70MH[D.
M!(#X-K_6[B7^UQ/_ .W)"AY4_<]70D=;VO*ASH]AJQ\61Z'C!?AWH<T5*="X
MN,]N[E_8+]CK&3N49-8K%@LB!VO%YD+?C /6]Q5[-RGWG.BM**"R+%9&AG#+
M<WV!^HL[=T#MH=4USBBT H2%)D_/ZX>?6MQ?%SE8K%@LB]6+!9%D;PKO*I2^
MT%,7]VQ6DE+VD7#VHQ1Q<W+8AOMLQKW'9&T.J"^]UYH@/XF>M3C/V@8:[QFW
M0HCN1;L63+G>A"55'$,\XS-']=B'Z>HDH6479P\?<SM#P<_I,SNZBP-\?E"A
MYT_<]70E.;O?*\SV[+<N_*9^AXP7X=Z'-%1#0N+@/:PY:&W_ -C;&[NC:="&
M._%O19LB,\8=Z?,+O9!)WSFA4/:@[_IZG*?AON<QB!^1D)]+LTT.Z:YQ1:9T
M)!0"@% * 4 H#E1B1S$]XCKOA=](#4H:[%AU94O4+RSIX83E'Q/[49P[P5*A
M)37^"-1N+W]13''M:)/<]+-#:"^]UYHA X$>O3A=VLL<^^!G4*([D6[%DRY&
MH0E3MOO\W'-[VGHW=XRZ%M'<AP) ?!M?ZW<2_P!KB?\ ]N2%#RI^YZNA(ZWM
M>5#G1[#5CXLCT/&"_#O0YHJ4Z%Q<9[=W+^P7['6,G<HR:Q6+!9$#M>+S(6_&
M >M[BKV;E/O.=%:44%D6*R-#.&6YOL#]19V[H';0ZIKG%%H!0D*3)^?UP\^M
M;B^+G*Q6+!9%ZL6"R+(WA7>52E]H*8O[MBM)*7M(N'M1BCBYN6Q#?;9C7N.R
M-H=4%][KS1 ?Q,]:G&?M PUWC-NA1'<BW8LF7.]"$JJ.(9YQF:/Z[$/T]1)0
MLHNSAX^YG:'@Y_29G=U%@;X_*%#SI^YZNA*<W>^5YGMV6Y=^4S]#Q@OP[T.:
M*B&A<7 >UART-O\ [&V-W=&TZ$,=^+>BS9$9XP[T^87>R"3OG-"H>U!W_3U.
M4_#?<YC$#\C(3Z79IH=TUSBBTSH2"@% * 4!CJ8"[[-Q+*)6+1PRTFF8Z>Q>
M.3(HA8((N^QFTIAM$<04Y_E PPG!<GB7B&O\M9;;K</_ /EI=0',G;_863IO
M'_(AL*3LG^%#+C4X^)08[\B05^4I78CJTQFAA*F9W!($VK3F4EALWY$%))54
M5'<9^]L+*M<XEIL%OL:MHAHX.G*:L>V52M=7R\_JF?&LW;/S<8,ES7+K8W7'
M>0?>0A]C*<JJ]^&N.)P)P'(Y99./VD( FG;3"8BZ)S6(%D\0-#)IP9Z\/4Z?
ML,GK[S-PW2A\"YHON1[Y5X4A 8\Y8M1HU<B9D>C'FQTRHB2C(Q"#R0Z7#*6R
M(C<S\:RRNFDYQG4@B ]':C)K&(WN%11RXZ@K@%TX8XIWER(P]53N3_BJO/S2
MXVG>#%3:2RRPJAQ'@/'/=+>;)BY!5EY;3$ YB'C\[!RZDYE$5661[EIV"+2T
M-::/#"#6@C'Q 2^EWDB]@06FEF@\W&HG-P)O%]#XW,W94R)S_8#9C#*?<\>\
M@LMGO %^("60Q0@ME"DW0 BK#>"/WJ#*.("B:#M2EY4+]"-&AB5UQBT>X#4<
M$$0,(:10N<,"3LM;S9Q_PNX84T;?+XE(_DO,,)/;&_+]YMV&E!=@-&%L>B!"
MSI05>-9G()SN6RA!80W6>"L426A<JLM91"("!%SRF5N'MH=Q4SE*2::KKVZB
M2!]T/<F_%X=/N/8L_MU#STH?ZUS1?<CZ;F/#AO)VD)>S'5,J9=R5R)>C\B35
MP-AKX[-E,.NBUWR/',7.1?*MR.E0>PD79+%4U!XG[4AOAD0B+8-G%.XH2T/J
M (](::2EHJ23E6_-HZ,83;"DO[>-\E"8G;E;[CJ^7+&A8_-5#%V&'QYWM8FK
MGN;&@6CX5'#HF= U>+@U$U3-"FISIEG3/+]%*^1',5)I2TH4Y3E6U;+9@;,S
MMMIYNY)Q _X)F#=<>#EC*3D 9LO-!+8:XX((ZHC&!@!Q2H2P@AIJPGW7"EPK
MND)YXL8MTMUTM%TTNNTU&**%--0*:K7\HM7$CUHW"D("AE@_8+.9$S(0BEKP
M/&TGH,V"0>2M0',^W@^9';3DC4H>%<0;<%56DAM%N.,Z5)K1E8!*NPF*?32A
M,8B8-#T^,]&<E.;4IZI*LD<QK@#GU$<=,&*6'NSNU(8T8LIJQZS$D7"S&=3%
M2VHRT(@VVZG"J2F6-J2@(22$TF6O/*!HR>-W!:CFS PX@@EP\M*'P+FB^YH'
MGEP^\G9UJ2?*N3&XA(4KOJ,X_66^RPTK&6)V9<(E@&%)QA(=J>PE5% /#GE@
MR+:&8&)&S_A,6@!7766AA:#J&ET9Z,*4_-O,UDVO>'@D2%F_CIFPP\Q)6QKR
M678D(+RRS'/C<REY0C-8D9F7$'BS%5LR6I7:].3"RL?1QK5YN%%,F-9J+J6)
MG ]/$&QTLYPN%-)[77*RSYU'<S[H>Y-^+PZ?<>Q9_;J'&E#_ %KFB^Y&;F[A
M6$MJSIC.SV]D9,C_ &U/TDR4BRY(:=!B>(FPZEH$4/614=TK@B0X#:.G%'6\
MT))9!.Y>.HB?<H. L6(#F%$0H0'9'JJ9R=24E57;6E+Y-O@=R<2=H'*?!V(P
MH,QKW1WHQHT <:T[ D([B- +O'M77#T3SL;\\.\9;6-;#'0BWBEKCVI8#Q-?
M(!!^/?X1YN-1.;@3;\XON>/F1LR9*9\Q@B0YE)N@/9_Q\W7TER2DHQ#$V!V6
M,6>",@N9LIZG<JLLT@JHX8*,[U\KJ0'."$!;CEA@4M>8*E100AI%"YPP).RU
MO-G&7$GA==%Q_2^[EK).8H=7<<\LEMF0VLK<#)5P,CM:.4J.WDSYC2RKH721
M!61%EQK2JFE[TX):;)L5L&BX:@<OM/%P!VZ9M2T56G.O;-9$DW[H>Y-^+PZ?
M<>Q9_;J'GI0_UKFB^YP"W1>'4?K_ $>><VU[*V7,G<EUP6/S9YH-7')JI!]]
M& 3[$C&W4@V8U4A="WV?9)>Q4,VH;<UMO!0C!T];;I>=.Z#N&EE*%0I*>UZV
M;^X4[ DJ[>JK("UBAN3OR.U&4$]O);U&4,88;>]JH2:QE6-H@003X57 $G:E
M!UM2ON$3K"HAG0?2TS<+:"#I8,BI%%+2@3E96U;@;:3-MR9T3_%$A0E*>[ [
MW!'$IM-99#V0R^&6-J*,JMM?)B$%4B$KHH)!73KS!46\.TVG'2IP#77QP!P[
M]-+M!BBA334"FJU_*+5Q([Q?A2$ 7+=6@<3(F9 HE(XYMZ7"DXZP>2T;YZ15
M63'.S5"* S]SCT;5RPEMI&3'>,4#6[URPDL ##)01"\N;&'I\9RG)3G*5=DK
M?W82*XEV\<\(/BV.H9C7=C=R%'D4LEL1VQT4?"_&I7&26FSD8F@-].%55@ \
MJJ0A-+(%2]YY2.&CQJX/48T8&&OO$N'DXH6VW FVVW_*+7Q-,\V>'ZD[<#7&
M8[<JMR%^R,O1J@K"$SQT_&.'V3H03%@X IJ!2\LQU9 +G[S)PH!?:,>!,CA:
M6^3!OLLNNMU'4-)HST84IRG6W9/;B:/;5_#NR'&;;QGSI;&6<MXOY0W,=2<(
M[(=6.#265&,5E\-9Q,=S-U5:TFJ-FHIK[-+ZH2U#<39 -E+SMAL$N7-@%A[!
MU'2SG"X4U/:ZY.IU'>_[H>Y-^+PZ?<>Q9_;J'GI0_P!:YHON/NA[DWXO#I]Q
M[%G]NH-*'^M<T7W.I]#@4 H!0"@,43M,+3Q[A65YT?0VH+0B*/7=(KA\04,(
M<PFM)#.K0Q E<+_@O45/H=J<F >"Z\RH&BQ<*P046RRX+:D<\F[NX0ZX8 (S
M&FQT^'4XBT*2/+C[948J#;D1NQX<C)8E!G*C8691(*":WE0BXY"AR06HS'D@
M)RBBJQ9' =*D$B-]52C1L=:+G+S^VK!IG45J+NKH:S:<VJ:=1M7$@(Z[JCJ=
MQ2]12=5=.+*'FU0O3S)PA<=(](Z*;N)'#92X<(34L9'!UL%N')[] :9X@9?D
M<L4]['B[".,3[.6,IPH01AP@N/S_ !Y)B(:7F&OJ-X*0CZ-UTFB2<H!N9EZ6
MK(3;-!%@P',N!&[1PAK4OW7K7 W,H8<R&=N0D7E&DJ/LG$!PHIM%U0*@QZWC
M3W!U*/E-R?E_^",+*[I7@6K?='1DR\[!S,AHY='? C';E@:F2.NPV-YK#'6C
M9@V^"F\:OF?KQ$W+VWEI-1V'TJ*%UE:%8S.O8%T*:\*J)QUQMAN8[KS^9Q$<
M-KIK<5[FX-D<VDP VW'8NN(+[/*RN_&7'2(YXM/R"#4E.<_^M;?+_ILQEIDF
M)C''R$["#'UD)P.MVCM%N-H9S!,U-'-IK#?4G+1E5<XB*X_-0!9FQPY[T[2U
M#/><W#JBHHMZ<64AU=/&)3\O^RZF()RS^;<)H+1=YB)WXY&8\<5I;RB2W 1.
M(!<04G%[?9+A#C<%NA'5)SBN]<*OE*\L<%2"S>2K! ="RFMG-3Y%,"6:5=5N
M.&LV2QRF@OD#$#>E )'#;II25GRV5UNACN4?5O.N.'\YXW=Z$/\ ;)EQT[@#
M:0Z&DKD#A)SL-HKZ>:+C$E9 3CQ<8O8#4F8=2<QDY3RR>&,=S#-EB+4T<Z);
M(5SD*:WJ#\9T4P3-B\A"-,9++6)S:_A_D&S;TIYBN@:TVYDMSH)]"2"Y)+6%
M@)53_=?V?[9C&(]P(_([SC1A+L"KS07'MDT_L9'(I%GVWU]LL9SM#%-5RT1C
MPI@TG-IU.<-YL@B&G(1Y#9U[#5;0C[S:DANR/5*-73)8V7GJG]9>9N//4MI$
M P=,<Z+Z8H+:'#47/V4E=&2;BX:HKIK!:RHZ3B6G"F[PR@)U0 2[RA8<X*$4
M!&&L%-"A@6"7VCE5U&BDB[ER7%T1,20W9$IPNX5R;9WAE^H2>X70X&A'FF-"
MO)"=+S[&?38BQ<4U!F$"<;G59!6UMAL](Z"JE33_ %2.$Y,<"BDCJ5<D]FQ6
MJ>M\#9C'+)DS.SNG-DJT?WL%<A=U-]+TLT= +I*NEJO)&'7&DZR9P-$0RUUJ
M@5*'2QT9M"O!C!JQ)01F_(;G5$-RE$,8U*3VGV4LS@)%DCXV,"]B+CA)Y$2F
MY(MT>1-60"*&P5-!AN39@)BK1 X>^T:R9<9&,E9*22R&C&$XMK8>/+JXD"@(
MR:X@2J==GUK2ZFF\V[BKFA]\S0S2V-ZX]2\2F6SH*YVN[5]YI:>GK!,=8/GI
M53X@BJ67%%QRUKDE![MUKED=\N]18Y4!S.Y C\@LH&JJ-2G*N6,E\IM?-R6)
MTF;"\2=+;;SG33!(XG.-#25X@;33-YU/-$E<@74"I@@<$+$Q#9(< P&*5,B$
MRMXX%U@MQ8"Z_4*T<FNBED<KIV63=QGLC,5135]@G'L*_P!*>:0J*;>+E 5(
M0-5=D>)Q V?:4?J2@GZL] >CI7T50=#]%'0VHT%U(17&Y4<;*J?[_P!Z'\&)
MN4EV3B3(9M089J,5Y@.XL@'62N7OD%W%4981"+B:RZXDM\1A&OF_5R(YX,^G
MW-45]-(R#:+:FO93,ECQ<F#4I>?[^SD_(VVH8:DI>4EYW+I?Q<46&:;I5/:9
MI>;#_6Q'R4!D142D)B.-QI3*#NC#^'*L7;"<_P!)L7/%E_1W%3@1K6QC#)1<
MTK%ALJI_OWU;.)MM0PP+DM-XF.L0."6K6(MR& WC[<*'D-"5D!%&*DU]PIJ
M*N'S[@/%++$I'N4@S1T)**K2X/;I8$GHIO6X6\ :J_K]%,Q;C?F 1R&D^9XY
M 89MIAQ@95C#>7!G""M:O)NH,_9$8V*RDI)820G:L]6#D;&A\'2:%<><(9MG
M++351%<JNF'&UVT#4I/;]D^J-S*&"@% * 4 H!0'@N5JMAZ(X[>>+<0G6@&3
M*8=,H;E2$]<1S!Q%5"2XC&QTU3+FB0IE)6DY/5TP<0&X4BJ$"9\K<$:*@BV
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MGE@290D6*@66%P0P[1NA'XESFSQ?B.]MTH "5*IV3A8L6!#+ERY?&=]@@%P
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.. 4 H!0"@% * 4 H#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g317356g45t81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g45t81.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( )$!$0,!$0 "$0$#$0'_Q  >  $
M @(" P$             " D&!P0% 0,* O_$ $@0  $$ P$  0($ @8$!A,
M  4#! 8'  $"" D1$A,4%187(2(C,3EWM0HD,E$8&3,T-G0U04-%5E=887%U
M@I68I;.TU=;7_\0 ' $!  (# 0$!              $"!08'! @#_\0 11$
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M?-'D2)#)0!!QK\ D@K 3Z)@.Y$;X:)*"ET"3M1VZ;#Q54QA<Y12<&"!@# &
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M^5N3KK;K3KEWOO:3?\':.N5-*RJYW4A$QLA,G()/&^=;_MUK?_IUK> >< 8
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M80HHY5AR"O!D4+>Q$3MW=G?V[_T[3=/[(]A_^.4G_P"X::__ )]@C*=R?/\
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ME:K)89X7NCEBD8N%;)'(US'M5,M<BHNZ'998_$8 P!@# & , 8 P!@# & ,
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M>&6"9G-KD15:YJHJ/CD8YT<L;FR1O?&]KES;/U,>, 8 P!@# & , 8 P!@#
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ML]'GIH\\%W9-H<4.,.M#:[0Z]B>>19J7.DVT:$Z)_N4E(!9,<*]_GGX<2?\
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MKW[\U?N^THKS6U:>3_37AJ0P"8'G=I29NX/R*1N$XA6S"S7L3<O6=:1@C&$
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M<L6/Y<1E53'BJ^:XS]$)28(-,W?1,(OT!$P<TZ+,EX#9D#M^#2&/N&+8[%;
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M]#)-+(!0\.B933[LH$TP)3!XS#-#<E=E>!.5QCL^N^=_B;OJ?SI$Z@L_T/;
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g317356g47j95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g47j95.jpg
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MLHDHK9PP",V646#8NZ .M=+W_AF_3_$(M:N+:>J3#.2S 8# 8# 8# 8# 8#
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MB<IZI8EX,SF!L/%.H6MUFL1:W!.UR :E X21F1+$XU<RD:S03TJE:6>2(8%
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M<9^?^/-;.N/5'T#VR7!:/<>5;\NKN>2;C=;Z=8^F%:4J7"66$Z*E)Z1$G9F
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MC'#CQW_/%+4 83  ,!OJ P(1@WTWKJ$6M"#OIO6MZZZWK?3>M;U_7K6\,?6
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M*=T]I%+J@(8?358"C$KCZP:>!O\ (J2SB1IU?F/+G -*$68+1@-["MX# 8#
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MP+N FQ_,&2%I1[CPBV74-(,-9TVT@C]%*5#B8K1F86RQOG?=I;\K?I"M.64
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:& P& P& P& P& P& P& P& P& P& P&!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g317356g50c90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g50c90.jpg
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M 0$! 0$! 0$! 0'_P  1" #/ .P# 1$  A$! Q$!_\0 'P !  (#  ,! 0$
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MR'OQD?:NXS:5<E2;@E:%594?+D7ZSJBJCQQ<H+-N2K=GJR5C@J. . . . .
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M,RD@9^^$WOV+YC:1;-U6=SQFZ;46JLW6LL$R;L3(X-4.H/H1'IYO(\/[OZA
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:B&YRW0M?^FU*Z:MU$OG!4< < < < < __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g317356g52w03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g52w03.jpg
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MM;?7)#%769:8,S1A=;36V#<X0D-14E.4T__$ !D! 0$! 0$!
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MNQ/DI8R6TCXG15G*3(DD +R5JIJTQNW/E01@N%)&4LZ$7PDJ2'.G*K-\Y15
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M_K5T.V3X3O\ -C] _P"R-0G^'$?X.=?]ZO\ 57NS8+P9' ' ' ' ' ' ' '
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MSB1=D?BLM!BI+&SHU7"X\R!.,4"0DHR6QC'FM7[!R@Z0W]&,[)*ZYSC&?3C
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M8P)(GY))9$39!0$?!"&BK\J9-&"2S8>+%#&*"[Q^0?.$&C-JBJX<*II)[;X
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MXU%-2@&)AWB#C9>;$:PRIIS^C0_^\U+@[J*+01U$WD<[=286(CF"L33L$38
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MV,?\T++_ " X'V'XEP8_7(@'^[V,?\T++_(#@?8?B7!C]<B ?[O8Q_S0LO\
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M#C_V)=U/N^H__P!0W ^Q7KIXOH8WN']U'^%)?55V%2UJ==>Z4FKBTHB<@\U
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M^] ZE_5=ZZ_<G6G_ )9X!'GM?4G63K]UUMJWHQU!ZO2:6PZ)NG,,CA^HH"*
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M8QFK%<>!*L'PXV)FM6R+-LW9MD\)-VJ"39NEK_%3103U223Q_P!FFFNNN/\
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MUH@W=^0:#R-SC.?FQJUCLR*N%=LYQKJ@DKMMGU<9Y5\/VMS([*=J]R;G(4<
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M L9#[.N[=**N5%6>Q'9INFOOE5OE#V;?&NR6=<1XZN1I8+]\S+G ' ' ' '
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M!J9/'WZS'*F'(_321,VJ#U)%VJV7412\LZWDHYA4+-SR+>*^'6_3>;Z1&]R
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ML4_*ZV*#9WP9' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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=^YR/_>?A?_?[7_Q>G!P^K@]_Q2>DKP>8< < _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g317356g57w17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g57w17.jpg
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M 0$! 0$! 0$! 0$!_\  $0@ OP%/ P$1  (1 0,1 ?_$ !X  0 " @,! 0$
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M:B,B9 FR(K[3JA,5-:\8T;\X0X#@. X#@. X#@. X#@. X#@. X#@. X#@.
MX#@. X#@. X#@. X#@. X#@. X#@<.8\?*7TY89RF5Y_$IRTC*9'J;2RKW\9
M3Y/>;*$-9]SU>;:4MY_"G&,!RXQC&,8QC&,8QC&,8QY8QC'W8QC&/NQC&/\
M+' K3\(/^']I_P#G?LM_5-NKA9U](^(66\(<!P' <!P' <!P' <!P' <!P'
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M)Y2-U=2?'!ZD=O\ L*GKM30NS*983RS#>N+%?!($?7M@.@X<LE*@Q<C; 3(
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M9RGS\LYQCSQ]V.$J(TB'8YQC.<9SC&<ISYISG&,Y3G.,XSG&?^,^6<X\\?\
M&<X_RSPK&)E1K[K=I>BU\"V3MPYR >FJ&L,NGT)@O0(K)Z7#0Q/(QF8[RXR4
MNR%.,QEN-QUM^>.+TX=Y;DK6HB^]4#]9])K[KNU030[=4D.,R2'RSD"J0B8E
M\Q#&RLS&1CZUE78[\1;OFTMJ>S+8]AUWW&7LJRE6YQQ/[>_9F,%?NZ?Y3)39
MKR.N=X^LM;%C=55ZMQ3 .WQB'QA@G+8B(EG8\H+'<>EM-PL)FI:PF$TI>(K"
MF')RIV6X>:BHK7<U<W-Z;W<TR[579U-&6P"[F=6K*U,8BX)PEQ52DLRY8N9$
MD09J,97YR(DIA3:DN-2&TY6WEUE:5*3%31$W%H%=A/"'\/OLE\=.N'7RL4^T
M3?<6JZ:BPO5]A3+=\\N$)3%6Q#K1V<O.<J7(L]>.96KR6M*E8QGB,4QM57RK
MPD>]_5+.9WAW>(C=!]='YRL7I;L$A1FGML-?B^&;D,B[92'94IK&(J7&=4UU
M2<I;RHK'3Z78U\43KA]LN@_G]IMXG?4?_"=\?#W*7FFCOPS]U=;I#I 4P.9_
MS,EXHN5?*IA^2C"EXC%3NM4X5G&,P(JDY9XK#.F*N$]_V(,A_&-ZF6KQ+Z7N
M./5.Q8C15BI8"GD?K)M*W"H=;W$8N@TI]K!368G8IFIO5.O",_54Q58<MT3(
MA-SK'%KQ":U'@S;X)B)TW^E;Q[%&G6GVFWV'&WF7FT.LO-+2XTZTXG"VW&W$
M9RA;:T9PI"TYRE2<X4G.<9QGF!R<!P' <!P' <!P' <!P' <!P' <!P' <!P
M' <!P' C7;.U.NZM825=B57>%]=!3I(ZR&=6:!W!LFK IT)U4<C <M%2IQ,&
M=+BI3;\(S7ZA-L=B"D([XXJ)ASD?#Y%=Z-W4ZXUR_P!;&6ZID,DP)=$C,22Y
M"(#)33\*9(&DAQ(26BP# 4R(*0Y@DV#,0(!@*6A3116##(0Y,9H,FX#@5I>$
M'_#^T_\ SOV6_JFW5PLZ^D?$++>$. X#@. X#@:\NNKJA?DU)!Z)*PW2;(/M
M(%H9->&,LDQOJS&P\U$RA#L;&5>:F\80XGR\FG6L+<PNQ-7QBDF(FN&[)U^,
M;+!6C8EE+DA]BU^S7XTRDTP$*_\ JMLD-'9?*1E2%,LIF2"LEIQJ RN=+2\[
M(C);0-2RXB2RRW[9G0SSG964.6M[2"$JK2[#:V'=<$+Q)P.$UBYOL"S:RRY+
M\:.-;CR,L./R)F&4282,-(>>CRHF5LM//I9XK6LZVP>**C9>D-G<BO,1N7PH
M>E>ZO%7MH:R)M837NP]"6+=ML'5&ZCPP"5V*-;<3325?B$71<Y\9-(PB,NYO
M4F&1:(9L*?BF66JYE\$YN)Q1'M67"9^.B7&^/=GCOA<>(9TE=<,>&SW7,6BA
MP7%R6>N/8A<6<#<B(5E:A@>;(A$J*Y/G_@:=G0J]JN4AM'GFQ)6EO*9<3^J/
M6%=U6?&VVIUX.CM?>)WTSV7UW./R$CVMKZ]$S++J\Y+3C/ORX$&9-F(?'1TM
MN.//TF];(D+S^%N WA"N/#?Z9B>&WOV%S>@>V/6[M(#^L'7_ '-1-GQ&XZ),
MV  ,-HLH9IS*<(S8:>13!ME<6O*DX2T="CG%95CTISYXYFJU$AN X#@. X#@
M. X#@. X#@. X#@. X#@. X#@.!YO>RVS->P.RVTQ>JNP_9^P6V-?IT+8U+W
MAVB[0]?>LU",1Y#>2U9UG8]8[BU;L*O"T^;OPAFCZ4[*T=AU.80YH>TE.&S=
M349<JB)G?<Y<:UAZ0N&#@.!6EX0?\/[3_P#._9;^J;=7"SKZ1\0LMX0X#@.
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MG TM3=\#\@0L4NA6$2HC5^:3FOP68SBL-J<NR:1.6OU8P,QZ?/,G#//EF+C
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M=4B6S,:SZFHJG\JSJ*GDD3E<Q7-K7L)U$ZA]O!4 =OG4>N]C23 OW:]89<9
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M2L>>?)6,X\\\,/O@.!6EX0?\/[3_ /._9;^J;=7"SKZ1\0LMX0X#@. X#@.
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M>O"E%CM[$N1V%,MNK]MEXH@@$-Q$</VW%3.7[MD[7HZX8. X%:7A!_P_M/\
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M55LK++CGO6;\(<!P*TO"#_A_:?\ YW[+?U3;JX6=?2/B%EO"' <!P' <!P'
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MNQ=&M!JZD[37Q,J6>N[- HMN@@UKCL5H&7A5ED<NT5Z_3WS4Q41/&8OV^/\
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MQII-R)$BQ7)\EIV4N/&CLJ=RVRVE(9YP' <!P--[,ZZ]?=TDA!G<>BM-[9,
M(CT $5V9K&DWLD$@R9")4B&(G6D(5E#8C\IMN2]'ANLLNR$(>6A3B4JP+F-)
MIE('5VLJK;+3?JOKJB5N]7GX?-VN@&HU\/;+AF)GSB9M-C'CXYBP?#9^^/\
M-IDOV<_[?IX&=\!P' <#7>S-0ZFW2"AU?<>K]=[9K0XNQ8!]=V92JU>P4$]%
MASQT4W#$VD85@1B\8>5)P6"3,=$QF&2GQ6WDL3)"'!$S&DUR=@"UQKRKBZ>#
MK5"I==":\PZF@!P57!B1=&2^-G!GL4\? @QXE9P\()DA3N K,+#@TA.@K\XL
MN0TX+9IP' <!P' <!P' <!P' <!P' <!P' AYL_5=[-=E FRZT!2X#&=1^Q&
MN46!DD%A2HNR+I?-%':2-98D3XY9,B;"I=BF,FFHWRL8L;AN>2A2)<%N2$"Q
M/5/N*:%P)ESM_8N$=EL64(8A .VESK N+7Q_2_6HNCMCAE+VX+##)R.UP.Q3
MWSP5F-9YY"05DV,M+UN;>:FFKC+*..7&?X]/5LGK!K7OF'[&0+/OJP75^MY5
M=Y5MF*.Q"6M#E6)U<,QKRIC S/96R 1MKK);$'YN3JG5C7,U\U6KG*G[,LP>
MU1I=T$U41'^];V7UW9;OW0NE&YC\?<MC);,.U$^-[*]@=]]>*$H5JB13XU^,
MHMT?3M^LMK@U6P[#4#;(V%FSDJLBRB93JF4A; /D '2E9)B_B(U]_P"ML;:M
M'N^Z8[USJQ*<UB"[95<!%&4!0S75Z[,1+W>RVVA]#V9!V7:#5W ]R-?607JZ
MSD2>K1-3B"-Z/A*M?ZU8;X0Z[6*KET.8%QPGTY<-==FC?\_KSNG_ *2._.N6
MM:6J7LS;^QMKWFG@I6T05I$WU^_C:V>CQJ&8M][CC*J,9)9(UKY?:8FK1K14
M9(E-B(H1^$4D"=E3I&M5METMZU?V)ON[BV^PNB-SZDUG85Z+HVWM,T[;FJ->
M]A=QU37(+M,1D6F%<-/[U9J@"'7=A;3T<N/B/O>N7>TTRF[" $8WR=JOUBXC
M+2XVYUEG6^.$[-WIJ%[3OB=1);#M8,[)Q="6B[S6P1R^;<A%*)K>RS-#[/%:
MLDF70>]\U^Y7FJ['F:[@[!S9.LNRR%KNC3NR0W89NJQ7ZK#'XWPO/*LKBZUF
M-^O"D@*/K3MJ/Z9]UZR9D;.8V-;]=;-A=?*]<ST@I>@=CFZ':##\AK$0[-]L
M3[+)/8V%/B4F=SSW(1YLH4%! 8,@,9>&5Q.L97NUY1LX-56WKWO,PSNG='4Q
M_8 .+N+8),[J2-2=TR*313&ABGA,5O56LCD773M[#4D.=A]GJS1!00\6KT'9
M5<D5@&:CSQFOX3A%8N,KW9ZW?BSSY>GJV)!U7O'378X1839#;]EZIU^IDW]H
MG]Q[PL][I8"C1]$V>9<"CV;!V)+RK2M>T,>92G7+K;:C$5!1!^J;\ Z\ C]5
M!QE,3OV1'.-G*]OI>:<G4(-<ZYU3ZV -B1RD.\A=%:I%VN"><<=/CSD&CA(T
M\;8'WE+=D'QSS:H1N2XXXN258EOJ<7ESU9).L\Y2*X0X#@. X#@. X#@. X#
M@. X#@. X#@. X#@. X#@?SSQ_YX_P#[P.DL5GK50$R#ULL(.K@XBF$2C-B+
M0 @F,N4^W&C(D$24B-#95(DNM1V$N/)RZ^XVTWA3BTIR'<H=;<0AQMQ#C;B4
MK0M"TJ0M"L84E:%)SE*DJ3G&4JQG.,XSC.,^7 P_8U[!ZOU[?-F6;$U=;UU3
M+1>K"D8PB614$J(2=8"J8$5QZ.W)FY@#Y&(D=R0PAY_VVU/-)5E:1&>2+]<[
MQZ^(W>I:VNFNMN:AO-[S59=2 [%&4%U)FN6\3>RHVW,G-?;$OM9C@XF-=GH1
MB/--QK&*F/AUR@"1Y1B=PLQ6V)Y=]=&U$=L.K+E95=6^RN@'*:FQ)J*K:C<>
MNU5E-L4*P=36%'DV/(O%A4#5@RD+F5\RR)S@CB-\'G#W!4[I]GT8[6]7*\<(
MUD_V2T&#L@<E\F+5\QN+7@PV++_,W0GRHB*FV)F?")?.67A/P,F.U*P3:=@9
M:^*0IK!&;@=P:DM5VL.M*QM+75CV/467Y-KH &[5HQ=JQ'C2HL&2_8:J/)R#
MH5F/-G0HC[I*!&0S*F18[BDNR&4+%;=C8W <#YPM&5J;PI.5I2E:D85CUI0O
M*TH4I/GYX2O+;F$JSCR5E"\8SG*5>0?7 C1O;LEG1)V@A).D=R[*1LFP#J=6
M3.M\ZA4)<NI:.>GP:G-QL#;E *Q"3PNN$2F9^1:ZXW&PPRX<20=S"06(N\ZK
MG_$-BO[JU2+ ,6*S[#HM.A*:/9GIM%XI@[Y+.J)&*#NX@K.:/R@S9*BV*8Q6
M[@W$*3(P(\X@;+E8>>8]TC& ?:CK#9XYF76^QVA[!$KM7(7>P2@FW]?%8X*F
M"2"!)6W&7H%A?;%U@85<;&$3TY3 J$06B%)EM25);R6IW3[.["=@M"V4E1PU
M<W=J(^8V;'*R];"@FR::5);!B <&<G)5(@P33\JUQPV*Y8<EG@+4]L=@$9^,
M4S\LF^P2IW-O<!P.E;LM=>L4RH,GPKML'AX%BGU=LK!78H-?*S"(X6=F!4OY
M)1@Y(@(+0(!-Z,B%,F"R,6.^X_"DH:#NN!%'>W;>J:%LLRME]<;6O.0.J;!N
MZZF-?#Z+,%435]6(Y'';.>;M=_J)HEB"IN1)^3TP/:S\F-%=S$%/R%1X[Q8B
M^YV^C,2_:SK#7EF&;)V)T?6)5<9KSUE@6C:E(K9.L)M@^25K"+.+.&X!&N/G
MQL*;.$1346#)GQH4QV.TXF)(RV*G=/MN<9'M1UYK\@BU<=S:IHD:/88E<#$K
MEM+6P.!<),RCZYO[<NJN/6U;TV+@'M2F9RS.8&E5_.!A-D:[7+!5CAX5.Z4@
M>$. X#@. X#@. X#@. X#@. X#@. X#@4:;D^C\=)=W[7V+N&VW;LI#L^SKE
M8+Q8(H?8E-6)CF+*2D%2+0O%AUG8##(Y$J2ZF%&FF9ZXD;#<5M[V&6D)U&.8
MBLAIFQ?1F^DDT3(CUC;'94 :6IC,4H4LVN;%!82A]M4A+XEG60%V3[T?#K32
MD%8V6'EMOJP^AM4=V^.>'?J.Z1]&EZ#)0C"]A=I5KPE.%K^O^M$^M6,8PI7I
MQIO.$^K/GGTXSG&//R\^/'/#K_8D-HCP2^LG6,/OMK2]^W4Q9=[Z"V)H.>7V
M%9 %L!U\/L$<F*\=9JM9K.OFC1$9+8ARF&297*<LMR8L1\<[-<FHDXIG6B,I
MB=R2MF\/G4Z:15JWIZ)4-(VD(5@%C6PJWK8":/VF0&U-M'6E?25;+S/;FQ:_
M.V@3MHD6?>L(&/)03&*#N-V(C-3DYY]Y^Z-<KPM;]*%VIY?9.%]<K._7%1;6
MY6^Q,HM4FPFM3>N9*ZY;)G<61M#+1!!.$5ET\GL.9JDJ/B3ZA8M<FPA >X =
M]]_+7BX?&=SMRK3AKFVZ=\.9D[2[K5).WL.SKGI_Q"-6R;++UN.7/1.[XV^A
MV=^XRH@^T"X4F=K6/1TB'QD) F/=VB.'(\FD1(#0UX7PVX9]HIFNH>E]QUUV
M<D]A;'O!R[0F!_9H,$I:Z]>Q[<09V,W!0]L8QEDGN6R:SK\ND-T$7552=:ZC
MU^[L'W95OO3A.T2%24$F;BN72*[W)?;+UM7]K5KZJV608C#<%!I;W 9)8N;\
M2+?]^.G,A+;N%,J5G.'$*;RI*O0^PMF4RQ(:L36<,S%Y2^9VM*\0V0!VD_(-
M)L==KTVLP(S11U 1P?.=D.O.2QOHSB1+PJ4]Z7LO)0ORCK?:>=A0G(ZYJ8V2
M5%Q.V&IQG60&.L.VR?UPM3P3<<,K%LM=Q(0TF,X2ENRT3!Q7.79B)0]4L@S$
M^(3(CYB3Y$9]AYKTIQ?%E&6<;4C#KGE/>MLYF:1I\X;JL4],LJ8VH" HE5U-
M''D/2GP\=F/%2=<]K/S!I2&$>ZEM,16$Y=C,+8A/OQG)>NF9X8RX:/C;NI/M
M4GZ=F_6#Y#]DVY*]MOVOE7S3Y_\ (:Y;J_\ 5_U_,AWRKXOZU?%_-?02]CX#
MX?Y:]\5[T>-;^/\ <3_"$=T\/2UW>PF&26\:VQK7ZX;TN=7J:-.3)-FAD.P.
MY:+NNXQ+5;I&U_E%D'BCU3*AJXP-I%76V$L+:3+I>8'Q((FO%NURV[HF/Y=Q
M=_#T^M,Z,:&[7AA38C:FX=R G96MTE1GUPV%V?Z^]HJI%L@]J[BY!ZMU:R=?
M =5M0Z,1"D+Y7#D[, Q1ID.*XHD3OS]>$Q_+:F@.I$[4&WKWO&S7\1<;QLP3
M86+3% T-RF5R"7L=\D6^4_4X<NXVX@'"_ M!!LX5-)%9AD\/(W">8^)-9%#Q
M,W$1NX\OZ9%W2Z:ZI[WZ.(=?]RE]B@Z41L0"SO3M7W%^DV5)*MOO/P&E$40R
M4.<-<5(=Q*%E1A""ZYB/-;8:(P1\V*(F<,W&L<+4X_\ 9=/#N_\ 4KN9_P"^
MH3_XWX=/O8^'LUZ*^BF]'(FQ[9:B>]NUY&G%0=?'5:I1KY6AEBKA"%F4JQ3"
MM_34I<BT##"OEKH@+]7PF*\\R36^0/((06PKOOOG9][%PO;-:MA?]ET\.[_U
M*[F?^^H3_P"-^#[V/A[)M;6\+&J6\;J2KU,WILO3M1=9?^F2O0NU/7N9VJM0
MT*Q-@R!U^JURF[EU?*J^P(C$%IK)C XLCWVXK\)D?'A,0<&/%K.V9O*H_BFP
M2?0FV1ZZ@-4.PAJ!/?W>WN [8CP:[M6>U>WURJW7YN+8[MJK<&HMC/6;SJL6
MZ$;,%NP =9E2I=1L=5(!WL2D$B=^>[NI:SHOA7,4W7]GHTC=K1O-BZF;.ZNH
M+/:N1&4/QLCJIT3ZQ.7E,)>P)OOJ&,]*E7!VM)F1L$T;.76<GX2*?DY:RSBN
M;K;?69W<5M45G,:+&CY7EW,=AEG+F<>G+F6FTHRO*?4KRROT^KR]2O+S\O5G
/_/AES\!P' <!P' <#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g317356g61c05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g61c05.jpg
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M 0$! 0$! 0$! 0$!_\  $0@!#0'G P$1  (1 0,1 ?_$ !X   $$ P$! 0
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M%T)48J&BH^'B\"0S9-0E-#5#1'*"@Y6RXT5E<X2DLU9T=;3#\0C$)H7"_]H
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M<_/N^/HZ*[-T@=8%@ZI[AL!3E)&4FA#]/].FU]>L9/#K';B K>+VXIB)-NF
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M,9'QR+$4G#[]SQ0A':DH:F1O"+\!)0XUWZN\[[*JU/=N?DY_CSQ2CMS\G/\
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MXFNKC$+B\N'DFF>1VFN'WZ H4(H%5]E2R52#@MPV9+'5=PG?D!N MPHW  9
M;J]62.Z"=,<MLFS*Z+J;)9-LZYC&6GX% =;+1].D,%M1QR3;E*4F<SJTKC!+
M734K#K=)GXQ,K21DC'A.>2."F, H1C\P,9NBA#70*&^71>E,I^Y-XG<71&1N
M%[F76-U7_"M9_ DW1_I<7XOO?\Q^+T=715$.]9?1)9Y%4E6/N?.J#DBBF3=B
MICQ6JZNG.54]9;-)NMC, %2*&YD41/W.9+MYJ7#\"\4M4AZQ3EOF%JF9Z(^#
MN/Q"81<)[V,7$<<4X26\7;1Q1"WBCERNAK2.!5@C5LPD($2@(--4_"Q8;O\
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M5NYB!HE:%WV*[8A)L$:9'HJ\V+*$6*DT^@E68<>U4JRI %E@*.%0/N%:R&O
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MS)&0T<91%9))D=/U7.?$*^ISXK7]<4RXI1Q2HMWXXOZ[/%*3XI3.7_4_X?\
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M;0;ERU.,NYRW.%';-LHB\840B*+);DW,$4%RY/%K54XL(WFMQL(0MS*SQH
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M6/TJ/5?4_IHKOOV-^$\;"?P,OT;^:G&K;\H@^EC]*L9N%1QZ;37,?5-C,?\
MJN-A/X&7Z-_-4<:M1SW-N/\ ?1^E6/5E4/IJK?OX,^%<;"?P,OT;^:G&[7\I
MM_IH_2H]650^FJM^_@OX5QL)_ R_1OYJ<;M?RFW^FC]*L>K.G_396O?T7\*X
MV$_@9?HW\U.-VOY3;_31^E1ZLZ?]-E:]_1?PKC83^!E^C?S4XW:_E-O]-'Z5
M:^K:FX\V;;6,9_M\*^%\GB]QX";Z)_1J..6?Y5;?3Q>E1ZMJ9]-U8]_Q7POC
MB]QX";Z)_1IQRS_*[;Z>+TJ/5M3/INK'O^*^%\<7N/ 3?1/Z-..6?Y7;?3Q>
ME1ZMJ9]-U8]_Q7POCB]QX";Z)_1IQRS_ "NV^GB]*CU;4SZ;JQ[_ (KX7QQ>
MX\!-]$_HTXY9_E=M]/%Z56?F-=-? S=G^[!M3_K!N/\ E^?SZ9A_^(67_P K
M!_[2U\!QS_*^+?\ U"^_^XDJ#%:HM1W6UFV=!\G>I^LS$PYD5Z2\@S,PET4U
M.F#(28JVI4$2HV+R4D*E,^+)EMYPASL7WO1)?017<-DVO:S+J4A1LUW.55VS
M[EGV;Z!D=6D\U<\6$W<^&76*)L^+VK:'4LVV??$'>- A#1Q;>+:L672''/D<
MIG'3]9)0. 2C6JBNE"-&<V-"J/E(XU9GZPS!F$'WTH?KK03$AJ-!EK5'4<QW
MV6%I;6O.4=_@<4B$C(8+D(ER+1I]$1A$Q94 W3&7(LR[]ETYY5LO!ZY:!)5N
M[ RS8><2CM-K.+DVH1I2V1MA!J"1N2NW_%.1.ZJZ]HFXJ:J339&IJ/V^768H
MZH*L#,>TQTW)IJ0 ES1\MF.QXM(BO19<O$&9.E"8LR(\7C04R$=NG*,'NYTS
M"*W68O/LB83L#IE"LI)S# JNI5$C*1&6(K'D&\RM )+0W%X]JL=GQA5NE%X-
M5N[QN%72ZE78(\CQ*Z-,D885F5T[VYJ;E;EBHR*TBNN65Z]+.3$5!B"S9<TY
M;+TI8E)5$[U38\D(C8#Y\*]VO-+7#0Y)1*XK!H V5SMMKL1;"-=N6,7& 0->
MST[$[0G:;AN(U$ Z'@_=!]]S8"VXN;EKXSN+-8Q<FSTLYA$HDXR-B%$)S/=
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MW%"TRR/O;=I:WF&39,='<@ZESQ8;SXS3.C;KUEL@L6!TVS>5"(>.W.=0^&L
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M$IM^(8AMT".\/%KC:JDAT([1Z-2J[L%5B &8A023E0%TYMRRDJ7 'TBX,M[
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M_*(% MKA\0.&F"\2[@DBN>*3WGNO]&9(P(H'&AGVY8J1"8]4BT6'H?<$F;9
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MF:<PW"W2ML6#.Z;6..5M!S4+( PEC?4S4Y%*. 1@,X#G.P=K5\'!'AZBL/)
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M>8C%<6:6Z+)J M@P</H5K>)HVF4FZE3:W+,991';P$-+)KDF/=M!.[+YND]
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MJYA$Z>=X2SHN_P!C$:FF;%HUO%6.C/QMF6MNEXK$ D8CNZM$U&%I(/!UC6W
M-@E%%V6'C8MK*6X)7'[,^>'C1F _4<0LA&T$;72V\T+1S V\1FVA52+EI6O'
M:XD#H$V9,$2PO((Q&S,69]'1EOW;\]V_//?O'-N !.73GT$'TW6H</U>ZJP5
MF#9JS"ZA9UE*11SI6+#LF^2!RS*BUR*3A-),UFHV2QSF8,0X@:DB(AQ<OP([
MLI^(SS/B$3-<]Q(T<C6(C0MI)CLE2/.0JQT22QQJ6*:LG)R;( F<]QW<^0Y\
MMR_&.;/]'6>ESTH]/]GT8Q:$G_(L".8KFL*[#!B+_>=IX3+UX#*@YEES;]BA
M@MA$03\"6%@"]9CF)%/HS%=7) 2G)5F-=C%+Z*],6SUL4DN9&=X(;;=.ZNL>
MR@=T=HV#EKAB)9C)DX C6H)SR\>_(#G^(;O'SG/?S"OT7\^<U]/KRS9>C[4-
MK/G;(5]5/E&PE2!DAXL::9C^.$Y3LR3X!K(]S+37AGE^#1E:\H3V)RI79VY]
MJ''KZ"**)!!IB1(TU1L3I0!5S.L9G(;]U?E+K@=A%W<3W,IN]I<323R!)E"Z
MY7+MI!B) U$Y#,Y#=G5<7T+:.7CLSFY>GM\U@8_->?D\V]LN)?V?Z(^G7,>
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M3UJ@YLKIIZ9>JRIVZBTN\./42O73JRUUHZZTNR)NFQB@LPR6AVB*==/1VPR
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MX65M2D(,P%SS&^OT-[P:P>*\2T:.2T)QO#K& '$[>ZEQ&UN9]G=-Q:-!-9M
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ML(C'L"&&\,6.G2.>N'VKKLVOCBML,'%B+U<2XO='4&O6P];<V:QFX$_&U9&
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M%!\*N#Q#DF0P6DD8,#.4%O!Q=[JZ:70)UMTC@T:V<HTCNSOFJK&H7(:29&<
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M  [9L21F%&X;NG+?7#=WMQ=&W>9U8VL,-M!I1$"0PZC&F2*H.DL=Y!)SR)R
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MZ9K$<MY?BC8]!<!KJS7BI_\ 5MF7@9F=Y2RIYR2XEQQM=N1K'0%TS:Q.;CC
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M&=F8*"S$*J@LS,0 H S)).X #>2=P%8HCR.L<:L[NRHB(I9W=B%55502S,2
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M.!GI<!V/+*%'I>:8J\2P(MS"%MI(98@3$=+V\MQ-$3GO;3)=SDALPP8 @A5
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MOG6%[99"<R3I!.8KY]CLNO@]P9V^GCDDN.7>04*5LKF\BXOW(][&]U%?O"H
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M=9_D_P!$LK\EQ[9,3[^'Z$>>GM%X/^!N?K4E)*Z#>GU?9VC;1YO1^N:5[?\
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MO533]@F;$C=2NO[_ *-U8/FW?2\X#:ZON(3 K6PQK%0BD)]VE2;=7*39( >
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M<>;...2[?OYNTGJZ<O7G@[;L2^NI)[J'NK:<92+J^>W/9YX1;Y'[1O'*MAD
M&8>;G[Y/5TY>O/!VW8E]=3;V1MW^A=5]PE_SYRG)T'?2]I/0IR]>>#MNQ+ZZ
MCV1MW^A=5]PE_P ^<<G0=]+VD]"G+UYX.V[$OKJ1]DC=LJ4G RIYRC/8K&(1
M?.4Y[,9QA6,'?-G*<XSV9[/-G&?1GFHPNWR!US;QG[Y/5TY>N_!VW8E]=6?9
M(7CZ%53W"7_/O')=OW\W:3U=.7KSP=MV)?74BYU*WC#>5H%U)7G[.WQ(NI/F
M5WN<=N#WIQG&<9\_FSC.,\<EV_?S=I/5U!Q^\ )$=MV)>O+PU-5=3E[3C*E"
MJ@E*<94I2H)C&$XQCMSG.<G^S&,8\^<Y\V,<<EV_?S=I/5UG[8KWP5KV)?7U
MGV35\^A-1]P&?S_QR7;]_-VD]73VPWO@K7L2^OH]DU?/H34?<!G\_P#')=OW
M\W:3U=/;#>^"M>Q+Z^CV35\^A-1]P&?S_P <EV_?S=I/5T]L-[X*U[$OKZ/9
M-7SZ$U'W 9_/_')=OW\W:3U=/;#>^"M>Q+Z^O<W/!K]E7PNZF?\ =QV;_;O/
M^38?/I&#_P"3[/\ \,?\QKX7PG_RYB?_ (W_ .)*Z51M(#3FAI\B57H\J[6\
M-;+C5C2IT1HD*C4V2,\D XHEV6W-F8N#(^W=DEB(^TVVU#4XIK"D/)Y+K$GC
MQ15$Q6V@D@MYH]+%)&N ^TD+@%5XN7@W$@DDY9\U=]C@<=Q@$K/;*][=PW=Y
M:3F15DA2R:+8PI"7#OQP1WO=*C* L9.6XBA1M'Z_4T,<G6&Z/RH^EX>Y[/!%
M"1#B\C)S(N-&!UYQZ7EU^>DD07*FRYL1,.&'8[?YO(RXIK=L2NLWTQ6X!Q%L
M/A9WD UJSDR2@+D%T( JJVII#S!<L^*/ L.*1&2XO6=<%3&KI(HH2=G(L2K!
M;EFS:3:R%W9UT)"O.6S(LF.G&K97$J;),@J+8+WI" @T3"18MJ'0MA4ZP')L
M=*,276(/B[C3*)(UQ$KOGV6O"2N^C]KF8Q68!I]"ZH[;$6,:2,T+-:3Q1@YZ
M06U G2^[($Y+OW=8X.VN:6@DDTW%_@<6WEA5+J-,0LKBXD7+45CTD -$=7=*
M,W.G?SB+H&A&&JW9X!ZXJI,ZJ7@R9>(-U$'.'3:7:!=74[**$R[846(+RC$5
MZ-C/E<FRZG ]J*0<D>,1^PXK=1&:%XK?C FMHXPAGD5UN(9)L@B(9'D01L&]
MXF7=%E R;@7 </F%K=)/>FRDL[V:8R"S@DC>RNHK7-I99A!%%,\RE?ZZ16RC
M"R%M2RF>DNIY,;"K6;@<(6 /9YP"HB(C5=$DC#"*<.M<67%9LA$6/MD_#I1
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MR/\ C?[7WU$O_P!)_"^]S>N.3H\?W5#O?U7^']_DCG'SC[:Y7]\?%]@J(?\
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MO[NY-R)I+8ZK9DCMY9E5&M(MC;R:FD:1YHX]7NSNTA9W.8#950!^Q]@5Q4/
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MN[NQ9G9CFS,QS)8DDDDYDU_6$6'Q011P0:(8842****)4CBC10J1QHI"HB*
MJJH 4  #*GJZQWZ,I\>[.WV_%NW_ /;QC'*F72"=.?CZ]W5\=:<4^4_4_BIK
MZD/W1_\ "?Z3S/;_ )GZW[J<4^4_4_BH]2'[H_\ A/\ 2>-O^9^M^ZG%/E/U
M/XJ:OTOOUXSY2[/T.,?SGV^WG^RL?)Y<760RV?ZW\-.*?*?J?Q4CZB?W3_\
M!?Z7R>-_)_K_ ,-.*?*?J?Q4>HG]T_\ P7^E\&ZS!&SY_P [^&H-IN/NG0?Q
M/B_UJ;^HG]T__!?Z7QQOY/\ 7_AJG$?E?U/XZ/43^Z?_ (+_ $OCC?R?Z_\
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M<0^5_4_CI'UK_P!W/\&?ZPXXW\G^O_#3B/ROZG\='K7_ +N?X,_UAQQOY/\
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M^O\ P5!PS,9;?]G_ -2F?K-?OD_P/_K3CCWR7Z_\%4Y)_M'[+_J4>LU^^3_
M_P#K3CCWR7Z_\%.2?[1^R_ZE'K-?OD_P/_K3CCWR7Z_\%.2?[1^R_P"I1ZS7
M[Y/\#_ZTXX]\E^O_  4Y)_M'[+_J4>LU^^3_  /_ *TXX]\E^O\ P4Y)_M'[
%+_J5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g317356g75x91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g75x91.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X5_H:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I-;V1I9GE$871E/C(P,3<M,3(M,354,3$Z,# Z,#4M,#<Z,# \+WAM<#I-
M;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q-RTQ,BTQ
M-50Q,3HP,#HP-2TP-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX
M;7 Z365T861A=&%$871E/C(P,3<M,3(M,354,3$Z,# Z,#4M,#<Z,# \+WAM
M<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O
M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^,30T/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G06M!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'%K1W%2-G)A95E5,6E-
M,V0Q)B-X03MP5G1P9#9*.4]G2TU'=49K=#5)9E1H*T9N;61%;%934U%/;G<X
M=#%7039N;U U;'EY-C$K-3%35T=E-FQE=U,Q,457>DLW<&-I0U)')B-X03LK
M=6HY>$=Z=SAK+V1G,$@W;&E'6FER3%!*5VYE6G)853E:;#%/3S=33UAI26UV
M3'8V>D9.34HW:&I,8DE*<"]1:4U4>$1H>%1P.6YB)B-X03MC2VY8;&I73')6
M9$]L;74T23=E-G0W;31T2C!I8WE2.#=A5F]I>4UY;S%$>')U35949D9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&)B-X03M867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E=/95)V.31D52\W82MP
M9CE28VU+<VIX5C)+)B-X03MU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8U+W%8;E1Z0W9M
M.4Y))B-X03LP.3=A5W-H:2]2+S%79&Y65EE,-FLQ>3!K5%)H:#A12U<W<48S
M<7<S=W%Y2%9%,6$P.'=X-G=H=7)R4S=B4S<P6$=N449'5G)H6DQE)B-X03M3
M2# T9F=A4U8P4U962DY","M(;'5&64AQ;6=F;4DU,6A5:3%3-5-E.&YL<W!9
M3#@R56]-:5A(,6-Q=C93;&I&=D$W>&=Q;VE,0VY+)B-X03M*>4U66E8U2S O
M>DYA-FYR375P>%AA>'DX9E-.-60O5TEP<&A08TU:8EI"3% Y6&E-5'A$:'=4
M<#EJ8F1612]L,C$R*VHS-UAK8V-.)B-X03LP9%8Q17IX47E.3$=R+U=N<45K
M6DEM64$Y0U58-5EQ>6I&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9)B-X03MQ-T9867$P-%EO=U5H5TE01FE+9TAX<'1I<D9F
M23$O-7%V2G181W0S9')C<%DS8E=5271O1VA02TY66FY02U-463AX464R2W-R
M>%8R)B-X03M+=7A6,DMU>%9G569L5SDP-WI*9C,Q<&]-1C5C,W,U=4ED5FUU
M;$-1<UAD9U=4,"]81$0Q0T-!5W%T1D1+=G=Q5EHV2S S-C1&9&ER)B-X03MS
M5EDU-4<O,V@Q5"]!3&$K<&8X05582FER23A69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&EQ)B-X03MJ9E@Q;EE78S$U
M951*8C)T=6AK;6UK4$965F1Y4U1I<GEB.&YF3VUT-C,U:C%L4F)+,FHS;'A.
M971+:6M#2U)G9U5C>C$U2TM5-CDO)B-X03M(0W%E82\U.2]-,G<Q;3=S.4TO
M3'E85F)#1BM.=G%+-FQ"0TIL;U!I16)2358K4D]"57!0-7DK9')$5V1%<V9-
M9FM'6%)R5%<Y46<P)B-X03LR1SEB55EP*TUT=W=52# P:4).3W9567$Y6GA6
M,DMU>%8U3#5K:&YM+T]Z4W!)<&=S9'1(0VQW<G1+6E S:F,Q15!P>%-):2]U
M-DUR)B-X03MS2VAM-D)Q-%9:,W%M;S9L<#-M1DQQ-&U+*U=O9$QV8FTY0W=-
M,W!Z5SAL=7EU.'$X,DI-5%-C63%!<E)V=&1G<D)T8CAX96-F6#%C)B-X03MA
M6&0V.'1V1D]Y5VY,4BM5=G),1&--:5)(-FIW93!L;$5A8WIY9&%66C%$06Q6
M:R]K<E5F33%Z<65S<G%B,VMS55A(,&]R>3%&<D9&)B-X03M0-CEW<E)7,&=H
M:#EA3#!K:%!0;$HQ*S%V5$955"M8:C--;6M8-S-54W=81&%R<4IL:%(O559'
M3C Y5D0P5&Q4>&]-5EI2:7)S5F1I)B-X03MR<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<4(Q>EA.2S!05$IT5#%7-%<Q<V]"5C5(
M.%0P5E%.,EDY9TU6)B-X03ME6C)U;38Q*UHY,&UR*UE%:S!V>4IB2#%D4#!L
M:G=L=D])<4HU,D9+2C1E,U0K66Q74F9L:G$R9UA2,2LR,&DU=#59;W13:VMI
M:'1Y)B-X03MP5EE':FI337%Q-T)$=TE(>7A+<S1W2SAS+U!(+VIP9FPQ+S1&
M96YF.%-/2V@V;FER<U9D:7)Y9EA9=%9U=GI9,"LU<SE(,5%7>511)B-X03M2
M,U=O1TAH6C!H9&=X3#$U1F50,E1X23,W8C!+=E=-0W5X5C)+<V,X:F8W=S9P
M+S(Q.5,O-FDU359:2&ER<U9D:7)S5F1I<G-69&ER)B-X03MS5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U938GI:-74P5'ET<$PV;G$P,W!X1&%'1F%'5UHK
M>5))4T]42#A/<#)X5F<K:"M5.6,X)B-X03LX86Y"-6\X-WA'1%1)5#9M:657
M5%AG:3%.2DQP4U!I66EM>#8Y-D0T8TMV54])0V-&*T5!549.<40R=TMK,VQY
M>%,R92]+>5!*>&Y-)B-X03M)-3AF<V]!4C!!,RM,0W%D649E5V9N:B]!361,
M.'5V+T%!2SE/+S1K8U9#94XK8D]I<G%X,'HY2&%I6FAQ9S!C>4-!8U!72S$Y
M4W9,)B-X03LK-B]Y=D1F1E=B-'$W1EAK9#9D4G9V>F%T6FM%5W R.79C0TM3
M-3 K1V%387A%3$Y33U=D-E%123%E37ER27I/82]!=498<FU"6&ME)B-X03MR
M834K6G-.>')-87HV9TQ72S1K6%0W<7DP.7 R36]J=5=I9T55=6YQ9E%,3$-(
M:TAQ3%4W5&ET1DMS<CAL86HU;75D5#%L9%1A.&QI)B-X03MI-"ML1F0R;W19
M-' O6'5&84LQ:T5-4')296MK2C4X<$]V,G0V64924#5D>51Y-E)F>5A%4#%E
M9#E6,45Y=V-G+T)J9%!695$R3E!()B-X03M&5U59<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%X<GIX-3@P:GEL<#9Z6%A+-'8W
M:RMN<"MN4F)Z5'E()B-X03M90E%+:TQ7;%=P.34R>%9J=FQ4>4IQ,G)A<VYM
M+W=!.3!N,6(W5VUA4#%T-T9+9W)286M'5&(V3W!Q96A6-D]304-384%D5&=6
M1'I8)B-X03MN17E2=TE:-VU.0DE)4CA)25EK1#0R*TAT-#1Q:UAL=3(Q;&18
M,4]7-&Y6<E0Q;E5O3VI38D=Q<BMZ4F5V.&-+<VQW2SAS+U!(+VIP)B-X03MF
M;#$O-$9E;F8X4T]+:#9N:7)S5F1I<D-.5#@S-C-9*V9)=$AJ:6AM,&5:<EI*
M-3)"5G)E4V5O0V)%1GI)9G,P56=D>4U+<S-W2S=&)B-X03M867%X>GE.+W9$
M<6XO8E@Q3"]Q3&MX5FME2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+<48W9E=6:F)09%AT>$AA)B-X03LR,&4W>E1/<V%,.#)99UEQ.%$O
M3T0X=U!+6&U45$DY4#!E1F18;'-R:4M382]-56YO=TM:5E5Q<B]#0UI0<VYT
M5'!V,$MS="]+,SAV)B-X03LT8F%',S@P83!(=4YC;6E%9&MK>3A6<W)60G=I
M:6AJ-DPK-T$S<#!.4$=Q<C!&3#%*5$@Y6%5Z4GE&,4UY,#1),&5X-59.96]P
M<TU#)B-X03MR571:6E96<GAW>D=)>'IW2B]C3GDV;FDQ5SEU=4MQ>%@P8F9J
M0D=$-F%5:6E"-&<X4CA+,5!41E='9FQX-6XX=S8Q9&$S2'%M9V9O)B-X03MD
M3%,W6DAF-C5&9%9N-')Z:7!'<2]:6&EE6%$Q>%9M*TMV3%!Z>"\T-E@U9&8K
M0EAP,R]%:FEO97 T<3=&6%EQ.&TX>$,Q8C@V=$YM)B-X03MU5D)N9U<R:G-:
M1V%F:W%Y8R]55E)&2D=L1TQB:#%B-W1G55!78T-8:U=O95DO>DE#-G5J1%9B
M5U-'-VU7>FQS-T9B<$YK=5!Q,$M))B-X03LR;C$Y2C)J:3E345!+=30O97!5
M:D-R3%!*5V\K6G)N53E:6%9'=EI9665*:6EU-U9B5T]/8C$W:%=I=%I04F<Y
M94PP56A)8W,O6#=7)B-X03LK0E54*UAK<S R:U@X<S!$5S!Z-G)Q3%-7-VQ7
M6D=.,#E63$E753 Y:FER2TU69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<50R)B-X03LS;D1Y,61A>2MI45@X8VUQ4G,V4&%G3GE$4C$U:7!&4&AO92M+
M<&0U;2]-,WE6-6-*:3%$555E.$)O3$,R+V8S0F(K56]L94HO=T)C)B-X03MJ
M1E=/9C1Q+TY8>E(X4&QV4D4X=F%C+U163EDO=FEP-DY(8F=';3-3<7-09D-Q
M<&(O:R]P36MG,5!Z='$Y>C5J=30O:4IU<$1$85(O)B-X03LV:U-N6590.#%0
M8D95,3@Q-DA!3D97>3!Q,2MP5VQJ3D8O;S!+:4='475Y1TYK4E)X6FMK0VM(
M<V-1:&M/;#9D8TI95W%A;$MB;39G)B-X03M+=4A9,4MS1C0O849/6&9C*T]"
M2UI9<6Q(;51Z9#5:.'179C%Z6'139S K03$T;5IW1V5N54EG<3=N,E5(1E="
M="M:,VYB>E964$E()B-X03ML,6\Y3V%T9DUU=6-R5S!#,"LS1D%0,W-O,W%$
M.31X5FIV-4%7,VU5*V-03F5P,UAM4%,Y8G0W,F1H<4UD;% V:FTT46=X6$U3
M2W9%)B-X03M1<W)/9S-&868U3TMS>#%R.')F375O871D,S!(;C-79%!H=5I7
M:VIS;T=54E)+>'%%4W K>4U6445F-4@S,#)R-E)Q1W-E8SE7,6E0)B-X03M2
M-S)(56)A,'5I:E)M83-C3W97=$LP;V%D<U9E<#1Q-T9867$X,7-*1#5H.#)J
M54QZ4F161%=';S-&<$1D=W1::E0K3FIC>5)X>71Y)B-X03MK5S8O67%W0S=N
M8F1C2W93<T-U>%8R2W-C.&IF-W<V<"]W0G1F578K;W541E=2-'$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&5D<W=F)/)B-X03MY=#-U8GEE3S)T;WA74V%:,6I2
M4C1L;4E!>%9G1B\X06Y*63-6,"MN951.375F32MO:C13.$-M3S%J2C)":VU9
M9%!E;% X<D-R071")B-X03LP6'I(-6HX-UAU;&599%AV.5!M;55R9D,R955'
M6#!M6FIB<DEO35%J5W)5+UHO;'A1.6,X=651=DI0;&)G3DPP*T=+.$E9<F-3
M9G9B)B-X03MP*TDK3&DW,69V=48R=TI4=U,S3G=G34MM1TM717-K>FHY-&MH
M-D%X34]W3F5U2W%I5VM96FYE<VMK:4MK<&%V1G5&9"M(,E(Q-T1&)B-X03M7
M3RMF+TU8;#-23D]T-71D,4=F5')75U5"2DE,95<T-4]P1$M'1555>%@T9TM6
M<'9I<5<V>BMC9FM,4DQ3,&IB55@Q5%5R;4M.<EA4)B-X03M,3TIP<C98;6=:
M955!0VU*;4<O1U1J:7%41S@O3W9Z:U-,3S-H.&@V22]3-75G3')66%$Y,6@R
M:FER-$Y2:#0T<6Y(;'8X;69*;6M8)B-X03MN-E5V635D9C$Q<4Y*<2MR=CEB
M;4Q#=39H+V=3;&1Q3%@S>%9N6D%)24EQ1'-18U91;&IP1VQ70F,R3FQ"84=3
M;G%'0TI)*U9/;DQI)B-X03M"6$956&ER<U9D:7)S5F1I<D5D66<X+TYR<TQW
M5$PK:#%U<EEX4E=1:5)V4T5Y978Y8TYW4WI,-EA0:C9"0G)3;W!81E=867$X
M<3AX)B-X03MA.34V:79D6FHP*S0Q9C9L1DXO=5!N:#!Z,7!05SE#9&QG0W99
M2E<S37EX<5A#>4%#:$TT-5565FMN:W)59DTQ>G%E<W)Q:EAS<TU0)B-X03M%
M>%)89'%T<DA(3C8Y=W)25W-N;W=E=D8V2U%K3U=F<CER9D955"M8:W,P,FM8
M.',P1%<P>C9R<4Q35S=L5UI'3C Y5DQ)5U4P.6II)B-X03MR2TU69&ER<U9D
M:7)S5F1I<G-68U-&0DI.04YY5#!P:7%4*UE03TAL;GDY86DV,6I566)73FAY
M:E9M-5-/4#A!26I7<G0P-T1&5T9()B-X03LX>%!/+VUG*VXU1S!";V)*=&AR
M=7)!>%$P<E1L2$5.,SEQ12LV-%9D8B]L5&%8,7A&9CA!;GI82B]-9#1:06E7
M<%EW,E5C<$)00DEO)B-X03MY3B\K0CEX:7)03E!I<TQ#,FIT3DQS0F(R<V-P
M:$U-36%W;VQ/<CAF9T)88G%/=4)73F%.1F-T-3!U;6Q-351O>G-Y<2]):T5%
M551F)B-X03MC;717,C(Y=6U&1$IB>3@P4%)B5F)J57)Y1WIG:35C8G$Y;59+
M0FIY665P2U(K=D%L:%8Y*V9F:T),:')44FYV4$UT*T(O=DIO,7),)B-X03MD
M3C1$-'%,1V$K>EEQ;TAZ6"MD;7561V@K53=4>2]B='-T-W)T>5I(;V5P*W)7
M+WAQ4B]L5GA6:E!N,SAN+WIL.# V4W1R9"MC-$PQ)B-X03M:,T)U.4Y+3EE7
M86]H1$E"-DUC-U1%3TLO1T)48D98;V8U6B]L,W!8:S=Y-UI7;W-B3U!7:$%Q
M86QF,G%-5VUL<#A2.5=4.31W<C0P)B-X03M(9W$Y359::&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER2%!),RLX3W%F.71F578X07%,:WA6:V5+
M=7A6<#-21DQ/=U96)B-X03M&4WA.04)I<5)A:#4Y.&QA95-,>EA,1TIX,6HY
M94YN+T%/055L=G=X5FHY>"MD+VM*2D)&6GDS5W!Y<W!D57,W5UII5E4P2D)D
M67=1)B-X03M016)9,'%&8C@R4$U.,D0K:&9*3W!82S%O1W4R4S!!2DY!1S)L
M;U0T12]H=FAP5FHV=CA!;G!F9VDR,&I3.4I8;'A95'9*4$MT96Q#)B-X03MJ
M96UW1F1Y05)I<44Q8GEF*UID-UE8379M5'I*2%!P,$$Y4V948F5'3S-I:VI1
M8WEF5T)6=4MK5BM-9'-65V579DIV-60V5%EW82]Q)B-X03LQ>' X3GAC1DQQ
M,75R,F%*,$9Q44A89TIM.4EC9V%H=TMG2')I<5IA;"MD4#51,DQM3V)Z0VPY
M2UIH3$1$86EA-DEC9EI737=+>3A2)B-X03M4<%=M0E9&4'II838U1'DS-4@Q
M-U5V55EU6C)T0EHR-T]2,3E75G5P-R]$:7$T95DO=T$K3E,S<V9+5VQA1W)5
M-$YQ="MB:S!09&QT)B-X03M!1#<P>%8U<#5B+TPS.#<Y5B]-4S9U9DUD-W%E
M9U=&,EIN;'9D3W5534MS=W)X:E)P<%!45G1W3TE.1#=B:%8V<'!V-40O;'IB
M6$%U)B-X03LY4G1*.69V-E5A.#%I95,X9'4O>$MX15)R+W%9<7IQ># W5#E0
M=#%T<D,R:71,9&9S=W=)<V%$-4MG07A615EQ-T9867$W1EA9<3=&)B-X03M8
M67$W1EA9<3=&6%EQ-T9867$W1EA9<7<O=T%M86HU:W5.5C%P9%1E.6UG:' V
M558Q87)A<$A..5EU5F%+,6LY2T0Q-"]24T5H>3<Y)B-X03MF=#<W2W9)9DIV
M-3=E86)J>D)R5VAE6'9,63%T<$QU-79B3DDU4D-Y<DI+5VU:;6M01FQ%:C!8
M64=H*SAQ>4\W.#)F.#5.6%E$5VYK)B-X03MU,7,T4T=P>'4W5#%A;79'=G)4
M34)4+U4S=TMX>3EH+S5Y<'931&-A6E X05I:5U=(56)',E5L<6=-4'$X<U1$
M:41T=C(S>%9),B],)B-X03LW."MB;31J8E502W-6-G%+5DUT-691,U5P<E=P
M870Y17)-959+,$)!-F1-3G)363)N;$PX,7)#-71B6F9,9'995'IQ-E<U:'-T
M3G5I)B-X03MI4B]'-$5K*W!044Y89FUD-FMB-'%Y2S,P2#@X,55P.6,Q2WEG
M8V=V8E=/:RM7;W@X4%%H>G%824=O=TMI9CA!1% U<5,Q*W0V<#5W)B-X03MB
M:V9I*W(O-&9T.79B:F9T42LK2W1(>40U:FU.8C(T+TU3975Z4G!Q*VI24G-V
M.$%+55<X-SDY.%5P9#5I+TM:<C=2-VU#3%103TUD)B-X03MY-C<S9#-Q1VU8
M9T59,V1$1"MK;W<T2S%'+VII:%4O3'HX<E!,5VHV2D,Y-RM8*V\K66)I8R]7
M2711=D4P;$=-56EH:U9O2F14:U55)B-X03M(*U-08U9X4SE+,#=52DY-5&AP
M=C5E86A9;T)13&)F;T])53A+2F9R:6A'+S1S,3<O<51.6B\U2&%0.$$Y-41&
M6&8T<S$W+W%43EHO)B-X03LU2&%0+W="-41&5D)04$]R4&5Y,E,K5&1A*W-1
M4E)Z4TM8,&M+16UA4E5)8S,O06US3%9!3E(S<%565E8O=T1&;79F.5-:<E O
M23=2)B-X03LO=T1V25EQ-R]&;79F.5-:<E X07E/,&8O=DE9<3<O1FUV9CE3
M6G)0+TDW4B]W1'9)67%O,VYN:E9R3T%Z,TAK,U=L:41):$MV<$QN)B-X03ML
M23129FA3+UDO85ED='5P,GA65R]W05=A.2\Q2FUS+SAJ=$@O=T,X:&ER=CA7
M83DO=T)36G)0+T%#3S!F+W9)67$W+T%"6G(S+U5M)B-X03MA>B]Y3S!F+T%,
M>4=+=2]X6G(S+T%&2FUS+SA!23=2+RLX:&EQ:&$K94Y7=797.4AY8G)2.4-2
M;UI/5#93;$A4<4)Y=GA58CE2=&EQ)B-X03MV+VEZ6'8X07%43EHO=T-2,FHO
M.35$1EAF-',Q-R]Q5$Y:+S5(85 O04XU1$989C1S,3<O04MK>E=F.$%K9&\O
M+V51>%95<W9.9#=.)B-X03MQ9')96'9L>E4Y32MU1C%H=7)L<D-32&Q':&M)
M8C9R9%A,<E963D-6<%A&5U$T<3=&6%EQ-T963S5A6F)E5F]2>6U#35EL4&1G
M4&A()B-X03LS-'%X:CAU<C=88GI3<G%45C5B,F1L;E%7.#)O,F]S<'E$8E%T
M2W9P0T<Q*T)*,FM65S1B*TQD8U9:6&ER<U9D:7)&=DU/<&%L1#5S)B-X03LP
M3WIS-3E2:FEM8FQE2D9:1V94,F@K255M=49T-5AJ;$Q5-"]V:U5$9'5W6E9L
M3TMU>%8R2V]$6#=R5F)84C=Q9E-B339H<4M*+V\Q)B-X03MO<E)O5V-K0W1:
M6&E4-&$X:4,T<E-L8U91=FLR-S%I-SAR-F1C83%$3D)Q<GA$-C-(8TI(2$QZ
M0DE*6DEI>4QY<%=G>%9/8U9D:7)S)B-X03M666IO*W K84I0>D$Q97AV;V)G
M85!(14=S2$-5=%%!<U9$>DYQ;DM2,F0O<S-4,&]A>')S4W%Y-T9867$W1E=*
M+VU8<4AM87@X=GAY)B-X03LK6%)..61A-%983G9#,#=H4%1K65968F4Y64M:
M1E%%*VEE=$MO1#9I<7-P9V0S9VID,4M/>6=S:D-H0DEQ45%#,5!V3TMR.%9D
M:7%()B-X03LQ0F)X<D=C5V-I>%A802MJ27EE<49A;EAG1U1L.2M+<TDX=6%T
M-7EN.'@V9$1Q3#,T:F4Q:6$X='!,2EDW34MB1THR;$YX-D,P;BMT)B-X03MS
M-D=,,61H*W@S>%9N*TMU>%8R2W-*.#%A;#5K<UHY8V(Q.5)&:71T65!P4#9)
M<U9U2C%M:VQU5FY4-#1B=U-B4GAM43A0:%5I9T).)B-X03M75EI8<$5L>DIP
M3FQ*9% V;'DX1514>4=.-&55:%%&;3E+44LX9%0K>7="2%$T<6DX5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D)B-X03MI<G-6671,*UEM;#(Y,V-X,W1J
M93)L;&)V8WA,<6)2>'EW4WE786QP:VI3,VMM=4MH55EJ;$5+,$Y-5F%(-7!E
M4D<P<4Q65C%0;%EZ)B-X03MX<$Q$27-&=WI-:VYQ0E=%66HY5&1O2%@W4#)H
M>#8P1TMQ9FUJ.'IV3"]L,C,P<31U67 U-&19:6MN=$=1,CEU9E1J16)'<3-S
M,7%X)B-X03MD:$UV1TY16$\O=S1Q<3-8-6YE4W)74F\W:2MK4GA/3%92.59U
M>GIL3$]P159):C9G5F]85C)3<7%625EJ1E=P9GI!='AO839Z8392)B-X03MQ
M1C=B;3EK,#DT-&QG:6M74T\U3F]R15AC,7-#<GDP04MK,')V4VAO<7-L+TY8
M>5!B6#%P<#$Y9DY:86IE6$1754YP4$)-0V)L0T9E)B-X03M)4TMJ4DYW9&=H
M6EA+8W1G>'A60U$O;DXU1&YN5DQA-G5,:44K<VIZ4E=D,GA794=70T@P4%-%
M6')'4FUU:S1G2FEQ2F(X,U!Y.%)B)B-X03M&<$Y85TPY2EA(,4]X16M.>$=:
M2F5%8V=O1VI"0T9,:4YL:U!W14U#1%$T<7$V2BM:9FQF6&13<V)(4UAU3&LS
M.%4P.%4W5W1Z0D=%)B-X03MH4T=3<F5T2$=A4TIC2WE.5&EF2&-65EI6:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F%,)B-X03M+2U9)1E115C=N1E<X5F1I<DA,;CAV9DMD,5!D>C-&=$Y).39:
M1VQ6<G4W36%T35%:2&=J.5AH03=%9F)I0W0W-'%H-%!Y>3AR=VQK)B-X03M5
M6$IT1%IZ5T-7<'5*4&=I=5IZ8UA$0S1R.6),>7E(-&UA63=B0VQ45E9/8DAY
M-6]T:"MJ+W%L=#98-DQT-4Q3>"M.>C9C37!1=79X)B-X03M-95A)=W!U,51T
M,3-/2W!692]L<C5.=E)D3&,R57)P97EE<F-2:39U,5%N;3!P5E5754MI3DI)
M>G9';T-S>'%W2GA63EEV3&5J4E=-)B-X03ML9VM"1FY*8VTY845Y4T5#9' O
M<E):87164C8S>&-6;W9T5$953DPU3#AU>5A+6%!O4WAZ2DI.2U=H=6)I3&UB
M;"]5;5=54GE+2D5D)B-X03LY+U1E<2LR2V],5'9Y>3AL-F1,1$QA,E5O:W0U
M4DY%.&PS9'I%3U!1-"\S<W(Q0R]5-%%&3W=#,$$V-'%I25!)9FQE,V4Q:W1R
M85<R)B-X03MK<WEH9V5#-G5O;6]K34YU16-P2W!K5# W4TE&2'%P-#%)2C-X
M5E8P>GE8-6$P=65Z;G-,47=3,D5)=')6:$Q-94U+=WAW0D-'8VAX)B-X03LV
M8T-$-'$W<40Y<F9&53=X5C)+<$QQ;FY0>3%P5W%W-E9Q1C9,93EN5DAJ4FMK
M2T):0S14;DM&36%C=E)K241-3FM:=6ES47%X=68X)B-X03LV9DMI-G)D861A
M>%1A9S%S2W!.6GDR37EZ5F=7-%5X24QK5&-'5G="2SAA>#AV:#4Q27%Q;D50
M-6AA1UE,;UAI5&%F<6QM6E9M,$]F)B-X03LP6'9Y66\P;6(P-&]*2FQL6#!P
M56)L1WA502]%4E$P5E9.8C@Y85!O*VQX-FIC<$LP56QM,2]W6#!L6EE636$O
M1S!S:V-A:W9/:6ER)B-X03M5<C-O0U%Q9W)0.$%.8GE:8WEW=TYC>7<S57!H
M57@K:DI01VI4<$4V03-6<4HW4FAX=5EI>DI->7)Y1E1V:7%L9F9M+S5)=$Q,
M-CAB)B-X03MI95<R5U=+2UHQ='!K36%41TU*4'AM5TIN:2]F>&M.1T<U0FAX
M<FEQ66XX=U!,6#933VY*3$TY,FI)<W%M,VUJ5D)*3$A$57E3;VE.)B-X03MW
M;'5),&-+4WEK+T5"43!64CER-7 X=#-E=5A/:%=U<#(P,G,R84-3-G-%:U5Z
M27!.2VQ183=F=&9Y,49A5D9653!X5C)+=7A63'1A)B-X03MS=&%U;UDQ,')5
M;# R4E-42DDQ=71X>4)'=V]Z2E-M2W-#+TQV>50K84=J>3-R83$U:D5K371W
M:G)%-&$Y36EQ5'I94$M535A-54<Q)B-X03MC2V\S>DHU0CAY6'@Q6F1,,4E7
M355H375K3D)/.7902$ID>7A36'<Y6EEP=E),*VDO0U)68VHQ5RM(>$-P4D@K
M5FYN2T\R;CE(5U=3)B-X03LW=5-S:VIZ,W1X9$%446UX344U0FEH:F%:4'%S
M.5I"16AB:W1D=G-L5CEX*UA8;G5B54Y/=31.46LP>4=$,$)E5W1R<E8U2DQ+
M64I:)B-X03M8-5-8;'IA5'E4<%-8*S5D0417;DE"4E5+>C)043E36'I03')"
M,74W97=K:%=*9$1+=V9655IA,6--22]6<65V,C8Q-SAA2T970W(K)B-X03M8
M6&UY,C!T<F)4-'10<W)O96MT,V0R9#EE,F1X<69P<DEV<C-6>D)%<G=Y8S-7
M46A225=)-&PK3S)+;U174'ET+TU'-G1#.%AM0G!T)B-X03M41'IZ4E13,SDY
M1VE4=$)C45<X<U-O<FE(,'AC0FU61F]A54YE=495-S S>4PU<G1V36M6>E!Q
M0FXP;3%U:$Y!='AF6&PS2DI%=G%#)B-X03M+<U4V<VM,=WAU27E58RMR=3=N
M;&EQ1SAO*U=V4$=M9653=#1S;SAV,CA5>DID<F9-,7)+6FQJ-%%*63AQ2UDS
M16IM5FM"2F%N44$T)B-X03MQ>E17=$\Q=39T*T9L9FE&=E4U530X5'=Q0T)Z
M1E0X4#0T1E%V;692+TU6+S5F;',W0RLO,#5P26U$0U=3>#5X<$E'95 V>&)I
M4U=,)B-X03MK=3-*1E!H,$IX5FEL.2M697,V.7 R:3)V;5A72'5Z84%M+U(Q
M<S=X1FM%1%)'4S).,5ET>4UZ;C%(.55(:#!J24$S5E9D2R],5%5R)B-X03M0
M5S-N=&9Q,FM):W1W-C8Y67E,3'%T>$9+3TUC3G=T>&%T0U9154Y8851C0V=(
M6$-Q9%0K5DY1=#E(.#%7.6Q)6DIT6G5$9%<S2U)M)B-X03MK8T<P=#1:23-E
M4V=1>4Y!-$9$>%932U4V04MX9'9Y>#@Q<DYQ<C9D97!P4UAT>&-8:U1W6%AP
M6$1Z4U)80F<K<U,R9'!:<S!C8S@P)B-X03M:155J5$)656IK5BM%<7%$*U10
M>D@O>$UM;D-E-FPX=FM84W9Q:RMP>E-20WIN965.3%)R6C-A4U=:25IK8C%N
M5W9*479+9S595E5:)B-X03MV26XU:V%78D=Y<TIP<C8Q;C%'5V5783(Q2V$R
M:G,T6EIO2#5015=I.59%:E-60D-I.%<U.&U(2F542W949DLQ:F0R3V=79')D
M3#9C)B-X03MS86UK2$E0-E-&:3!C4$E60CE*0T4R,C(R=TMW+W=$37)24'ID
M=6)'5654.6%I16LX-D9,9&]O-$=G:5$X.7)G<S5C.&Q#,#0W9VY&)B-X03M7
M5656<DQZ6D)B0UAZ1'%C9#=03D9'5&)2,C91:4-3;%I&-6\W97!U859O3VU+
M<$IR,3<K5S R='DV=&93>E,V=F]5.$9T3#E33BLP)B-X03MI>DEK:SA+;4-Z
M<C8O0DI*:EAG=U9424118WAI<6IF*V)0>7AE,#%7,6YK=6YG,5-1>E@S;U<R
M<&MZ=7-14FYG:VAJ-4XV8V1R.%IG)B-X03M0=V-F:6]A-'%I<DA84$E';#94
M<61R879D>3)55',R<'I'3%5B,E)Z2T=I95IR:#%M;&U29E)+3DM(6E4T.%-Y
M,'!I<7!(9"M3.58K)B-X03MS;3-U-VTS:3!',&QT<G%34#8Q6D%78FUH6DQG
M<D4W;W(R6C1Y=WED5E!X8FUQ<5939CA!2W%T25<V5U<R=DEP2356:W5%;'0Y
M5VMN)B-X03MK:VQJ4G960W-J>7I!<'!A<SAI.&@K-UES86QQ<7%&;#52+TM4
M44E*3DXQ8E=O<G5A-SE/-$,V=G%%87I#079$-D5C84%W0EE&84-*)B-X03M5
M54Q464PP,GA684Y'+TQ(4TYB,416;CAX>7I01DQ$1&,V8CEA4S9I=$=G65A(
M<"ML1VIY>&U2<DU025AB:S548SEA;%=9<C5T.&M#)B-X03LT95=(5F)#4S=M
M9VEM8W=44E-44&)%+W5P0TEY>FU)96]31RMY05-A,')G5E!C5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S)B-X03M69&EQ5RM9-$YF;C!3-V@X=C-C
M1FQQ-WAS3%,U=6]J3D5J:V)%<4=8-D0X44A5<3,R4W%K;FU/3#AX;&ES53!A
M-'0U<F@T2FQV-7A')B-X03MK34M4>'%*65A32U8U;C1Y<W!H6F5B535C<6EL
M8U995F)A3BMD,&QP97I83W!8,#$Q3'!Y,GE24TQP=&YZ;5ID47$S0S)N=45I
M:VI:)B-X03LW8FI*1DEN254U5C0W2V]Z5TQ8.#5:62]6,#)E+W0W,69R56,X
M:DQP33!3:#=I,DU2<W)F,5E%:TAP2DIX3C!W8T1L=4-25E8V8G!O)B-X03MV
M0G Q<4PQ+U5V4D1'3&PK0W@X<&5)-6YG:E-+=%=R<TA91'A06$955&ER<U9D
M:7)S5F1I<D-:=GEM.'9M-%,X<W)U-S S575$:38Q)B-X03M',"MR0V4V;&LU
M8W W:WEW4W!*3'AL:UAL>#9/9'1L-'%R2E!Y:S!S:%9G,6I5-UI94DET:W-B
M5VA&=6LV>4Q/:V9Q5WHQ179R3GDY)B-X03M4;%$O6C0T<79B.'!T0T5E<7A1
M6&PQ0D9R1&\Q,FEX,DQG<D<W3W%(,6)A4792;2M&<$]4<%%"1U5#;4MO,C,O
M04,K<TE,3%=,55@Y)B-X03LQ3TY69V$Q47IM1G9Q,%)E5U)6:#E/3TEK3$IC
M33,W=W-E9W)41E50<4@U83(R;UAD,V9Z-GAE=S9H94UR4UA&<6QL1G@T=U-7
M-5)6)B-X03M.=2].9E-N6E%:=E5D4E-J8EEQ:4Y8+TQJ>2]Q:GI.3S V0V%"
M8EER1S!D1FI7,'5B26-E4T]F-W4K:T\O=T,P0C=G<7!*869K.6)0)B-X03MD
M-GI*<D]Q>39H86%K<&=T3$M/1T]#3S%T:DQ,2TDV;C%J2S%B;5%C,S=-9'5L
M1S%B5#AP2D4Q4S9L1W53=G!%,6TQ;D1P,&M#3DEN)B-X03MR45%7<SAR6$%9
M33=08C)Y;W9W9TPY<F,Q-4MV+SEK/3PO>&UP1TEM9SII;6%G93X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @
M(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @
M(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(^"B @(" @(" @(#QX;7!-33I$;V-U;65N
M=$E$/GAM<"YD:60Z1D)#.#0Q,D)"1D4Q13<Q,4%#-S9!1$)"-T1$0T%%-#D\
M+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$
M/GAM<"YI:60Z1D)#.#0Q,D)"1D4Q13<Q,4%#-S9!1$)"-T1$0T%%-#D\+WAM
M<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^=75I9#HV.#DP96-A92UC-CAC+31C8C(M.64T,"TV9C)D-S,W868T
M,34\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S
M/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N
M:6ED.D9!0S@T,3)"0D9%,44W,3%!0S<V041"0C=$1$-!130Y/"]S=%)E9CII
M;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N
M9&ED.D9!0S@T,3)"0D9%,44W,3%!0S<V041"0C=$1$-!130Y/"]S=%)E9CID
M;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/G5U:60Z-C@Y,&5C864M8S8X8RTT8V(R+3EE-# M-F8R9#<S-V%F-#$U
M/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E
M9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S
M<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM
M<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.C1%1C4T,$4R-#%%,44W,3%!,3DT049%-3(U,D-!,3=$/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$W+3$R
M+3$T5#(P.C,T.C0X+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I&0D,X-#$R0D)&13%%
M-S$Q04,W-D%$0D(W1$1#044T.3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C Q-RTQ,BTQ-50Q,3HP,#HP-2TP
M-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-
M33I(:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @
M(" @/&1C.F9O<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M
M870^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^
M9S<U>#DQ/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @
M(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/E1R:7!P+"!4
M:&]M87,@6T-#0RU/5%]/4%T\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R
M87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIP9&9X/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9G@O
M,2XS+R(^"B @(" @(" @(#QP9&9X.D-O;7!A;GD^0VET:3PO<&1F>#I#;VUP
M86YY/@H@(" @(" @(" \<&1F>#I00E]$:7-C;&%I;65R1$(^665S/"]P9&9X
M.E!"7T1I<V-L86EM97)$0CX*(" @(" @(" @/'!D9G@Z24-'5&]O;&MI=$ES
M1&ES8VQA:6UE<CY997,\+W!D9G@Z24-'5&]O;&MI=$ES1&ES8VQA:6UE<CX*
M(" @(" @(" @/'!D9G@Z5$]#3W!T/C$\+W!D9G@Z5$]#3W!T/@H@(" @(" @
M(" \<&1F>#I03E-/<'0^,7,\+W!D9G@Z4$Y33W!T/@H@(" @(" @(" \<&1F
M>#I0:71C:&)O;VOBAH(P,#(P0V]M<&%T:6)L93Y997,\+W!D9G@Z4&ET8VAB
M;V]KXH:",# R,$-O;7!A=&EB;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @
M(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI.4&%G
M97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I
M8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS
M<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \
M>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @/'-T1&EM.G<^-S(P+C P,# P,#PO<W1$:6TZ=SX*(" @
M(" @(" @(" @/'-T1&EM.F@^-30P+C P,# P,#PO<W1$:6TZ:#X*(" @(" @
M(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @
M(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT
M<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L($U4/"]S
M=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# S
M/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86QM="YP9F([($%2
M24%,350N4$9-/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.
M86UE/D-A;&EB<FD\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$9A;6EL>3Y#86QI8G)I/"]S=$9N=#IF;VYT1F%M:6QY
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F5G=6QA<CPO
M<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#4N-S(\+W-T1FYT
M.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP
M;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1&:6QE3F%M93YC86QI8G)I+G1T9CPO<W1&;G0Z9F]N
M=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y3>6UB;VQ-5#PO<W1&;G0Z
M9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY
M/E-Y;6)O;#PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N
M=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3
M=')I;F<^5F5R<VEO;B U+C P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC
M;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA
M;64^<WEM8F]L+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @
M(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A
M=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U
M<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R
M;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!4
M4&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z17AT96YS:7-&;VYT4V5N<V4](FAT=' Z+R]W=W<N97AT96YS:7,N
M8V]M+VUE=&$O1F]N=%-E;G-E+R(^"B @(" @(" @(#Q%>'1E;G-I<T9O;G13
M96YS93IS;'5G/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#Y/<&5N5'EP
M92 M(%14/"]%>'1E;G-I<T9O;G1396YS93I&;VYT2VEN9#X*(" @(" @(" @
M(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9A;6EL>3Y#86QI8G)I/"]%
M>'1E;G-I<T9O;G1396YS93I&86UI;'D^"B @(" @(" @(" @(" @(" @(#Q%
M>'1E;G-I<T9O;G1396YS93I/=71L:6YE1FEL95-I>F4^,#PO17AT96YS:7-&
M;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/@H@(" @(" @(" @(" @(" @(" \
M17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3Y-:6-R;W-O9G0\+T5X=&5N<VES
M1F]N=%-E;G-E.D9O=6YD<GD^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I
M<T9O;G1396YS93I697)S:6]N/C4N-S(\+T5X=&5N<VES1F]N=%-E;G-E.E9E
M<G-I;VX^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I+
M97)N:6YG0VAE8VMS=6T^,#PO17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H
M96-K<W5M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z
M1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3XR-3,V.34S-3<\+T5X=&5N<VES1F]N
M=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^"B @(" @(" @(" @(" @
M(" @(#Q%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3XR-3,V.34S-3<\+T5X
M=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M/@H@(" @(" @(" @(" @(" @(" \
M17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64^0V%L:6)R:3PO17AT
M96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N
M=%-E;G-E.D9O;G1+:6YD/D]P96Y4>7!E("T@5%0\+T5X=&5N<VES1F]N=%-E
M;G-E.D9O;G1+:6YD/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT
M4V5N<V4Z1F%M:6QY/E-Y;6)O;#PO17AT96YS:7-&;VYT4V5N<V4Z1F%M:6QY
M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN
M949I;&53:7IE/C \+T5X=&5N<VES1F]N=%-E;G-E.D]U=&QI;F5&:6QE4VEZ
M93X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9O=6YD
M<GD^36]N;W1Y<&4@5'EP;V=R87!H>3PO17AT96YS:7-&;VYT4V5N<V4Z1F]U
M;F1R>3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.E9E
M<G-I;VX^-2XP,#PO17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CX*(" @(" @
M(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U
M;3XP/"]%>'1E;G-I<T9O;G1396YS93I+97)N:6YG0VAE8VMS=6T^"B @(" @
M(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR
M7T-H96-K<W5M/C<Q-C<S-3<Q.#PO17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E
M;G-E7S$N,E]#:&5C:W-U;3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES
M1F]N=%-E;G-E.D-H96-K<W5M/C<Q-C<S-3<Q.#PO17AT96YS:7-&;VYT4V5N
M<V4Z0VAE8VMS=6T^"B @(" @(" @(" @(" @(" @(#Q%>'1E;G-I<T9O;G13
M96YS93I0;W-T4V-R:7!T3F%M93Y3>6UB;VQ-5#PO17AT96YS:7-&;VYT4V5N
M<V4Z4&]S=%-C<FEP=$YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D9O;G1+
M:6YD/D]P96Y4>7!E("T@5%0\+T5X=&5N<VES1F]N=%-E;G-E.D9O;G1+:6YD
M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F%M:6QY
M/D%R:6%L/"]%>'1E;G-I<T9O;G1396YS93I&86UI;'D^"B @(" @(" @(" @
M(" @(" @(#Q%>'1E;G-I<T9O;G1396YS93I/=71L:6YE1FEL95-I>F4^,#PO
M17AT96YS:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/@H@(" @(" @(" @
M(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3Y-;VYO='EP92!4
M>7!O9W)A<&AY/"]%>'1E;G-I<T9O;G1396YS93I&;W5N9')Y/@H@(" @(" @
M(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CXU+C$P/"]%
M>'1E;G-I<T9O;G1396YS93I697)S:6]N/@H@(" @(" @(" @(" @(" @(" \
M17AT96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/C \+T5X=&5N<VES
M1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U;3X*(" @(" @(" @(" @(" @(" @
M/$5X=&5N<VES1F]N=%-E;G-E.D9O;G1396YS95\Q+C)?0VAE8VMS=6T^,C4Y
M,#DT-3@U,#PO17AT96YS:7-&;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C
M:W-U;3X*(" @(" @(" @(" @(" @(" @/$5X=&5N<VES1F]N=%-E;G-E.D-H
M96-K<W5M/C(U.3 Y-#4X-3 \+T5X=&5N<VES1F]N=%-E;G-E.D-H96-K<W5M
M/@H@(" @(" @(" @(" @(" @(" \17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C
M<FEP=$YA;64^07)I86Q-5#PO17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP
M=$YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI"86<^"B @(" @(" @(#PO17AT96YS:7-&;VYT4V5N<V4Z<VQU9SX*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM
M<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB
M=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_  !$( +@!1@,!$0 "$0$#$0'_Q  =  $  @(# 0$
M    " D&!P0%"@,!_\0 0!   00" @$" P4%!@0%!0  !0(#! 8!!P ("1(3
M$105%ADA5]<*%QAVF2(C)#DZN!I!E[8Q,U%9UC(T1%*1_\0 %P$! 0$!
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M,CY><R.#"&#!$D0E,AA^8HQPN]],2:?BNE6*]6V)C8(>(9AP!P!P"M+JC_F
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MEQR*)*!0@9R)D<VEQVQ,NYEMY8PT_P CHDF[O96L3R13O][]YA?_ &$]O_\
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M<!H4AU+3Y-0TS:Y$YN$E?PP^]&CNID.,(SE[V,.O)0IMEY3=_;.]^2,S^O\
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M65-<K]7,7*VZCJXW7]7K@2Q;(8"[8LIB/L2<1&ZIO\H)-B4.TX#O*/2<):1
M97A>$7*-[]/8UL?OVJ8:B)<SBU$96+KN0R. >9KR(?Z@_P ,7\D;T_[:O_!U
MI_I=IQI\T>F7@Y#@#@#@%,W?F5.+=A6:-7[Q8]5.G.OP%O8I>DT?LAMF?MN@
ME+QL<5&US=JQUV%3R&O 5:=^TDRKWPD4JMML3M_NXG7!YG%5NRHXTI\':8W:
MO'NL7#!8\>&&$Q(;$>+$BC($>+%BQ78,6-'8BM-,,1H3^,/PX[+24MLQ7L8=
MCMI2RYC"T9X,F@NT/8@;ULH(&U2!$.P';GL&J:RI8,D6*@AA.TVER;(::(%
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M:<2_55+3A&1NGLZFIM33_<W"(A_8GSZ>3;^\OMNJWB&ZPF_Q^R5'<E7#M:>
MR/[;;9$U%EBSE;(9;R]$DO).Z6(Q/4RN922[>%I<&O\ 3I_ZC\*5[^7 GQTX
M\'/C]Z=$H]Y':Q?WQO#,OZN1WKV,EQ]H7I\^XY\R^;#P2<-JGU4GF:M]]@P
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MV&<Y$W?':^;>(V3$6;M*=4OX;.I3MY7LZ7L&9/9[;.XW;_$?'E*V$XX0AWY
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M97-&CXXJ-6AWJ2XTEI Y+B'FI.78S;<64ZU(=[X8R3:5L7)UU^+[:L-$W"-
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M\[+P%AD(P".:).*+EX0N+,*?XQQW@YU/:J;PG(G%P9' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' *TNJ/^8#Y6/YWZ>_[6:QP5X+AZLLMX(. . . . ?)]]B*R
M[)DO-1X[#:G7GWW$,LLM(QE2W'77,I0VVA.,Y4M:L)3C&<YSC' (M[$[S=,]
M3^^C8?:;0=7F1O5[HB;M.G/6#^Q\?7[=<@EI1U_*<X^"L,#G,X5G"<X]2L8S
M8;P3!!J]>>3QMU',Y@!M6X[7GCHTF9,'ZQU5?"66HT1'KD2,%+,'JE?=C-(^
M"W)C)AR&TG.%.R$8^.<79J>77F".$WSY2[O$1/ZT>//M;N8;*CS9<(V:@L4\
M'F /5Z)QB<3J(;;$$>%'YS[A I-EQX$)E#KDR7&0R\MML;UIZ"5?=B8;+[^^
M:S:SU:C:LZ2:/TZ+V#/D"Z6;V59)EKDEI$=S"9*A1*->JZ+RW#9RN8X1)5?(
MR3$8?<A9D*1Z.792F[MCEY]<D25;?@1MV%UH[<[=V)-F]GKW9D]ISST< .SK
M?ZE%K040EET,L518<1('U!2P_P"96]*".CX&9*Y9"1*(N.E)<W:B+8=3/J<G
M\SQQMKNCT+9NI'B+ZS]4+91K14]25.ZDFJRN?;-@[OD?O$VR+O*\-2(JJFE,
M&-KRN-0'UN,Y*UJO"R[K?S:7R<W"HCG.;JF9UM%ET^1UO*TB^YE@A/7JDT%8
MW:^VC<N.)M_VR7<V)H_7RX<*&15-&A"$IEQR'](BI5[4E3SK2G<Y0N.J$J-#
M^7DPY2RB]R;+:AMXY6?KU!%/9_D7\6VB;/8[=L#MYUA#78L-CA[,R)VC7+M;
MI(T<G"(\*=4*:1LIQM*4-H:]/T1MV6EAIE>7\1VD-S<;5#;E4N^</#R[R!%N
M_:8O%K4Y+%5T_-WMV%)M(^4$5K0^A;&TY)RSCT(BBX6RG-7X4PA7P0E41A;/
MHSA;&'491ZAOX5:QBE;VHY203[Y>>/M)8^I6[IE \67;_2>K;33"-,1V<W._
M-U8W2)-T1]G@EB! I^K;$'L!!DA/C+CLP;8XTTM*U*DLI;5+CC5/94[2555+
MO\JO,7AZ89E5_A/+^6?O49WG5.OGD:KVCF0 FH,[,E7ZL_O!V@BKDIA7 LQK
MN#/U^0$1H^9Z)D,K.B[ J1]$EJ WC/RJV9&$MXW[S5=/9]G'Z-<'"?'.WKF>
MANN?LWVD-AF8-R[\]O.WW?6Y17</O,;'V<;J- 4M7_FH'U^"7L=W"1\XSEEB
M,(V=$C18N?EV&$82A21S^(U\M--/!*>]EN?7KQY]'NJ28;G7SJSI?6I:"E"(
M]L%TH63OV4MXQA&).Q+"V8O4WT?BI/SMBD?!:EN8_MN+4H8=53Q;?%DR."#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'PDR8\*-(F2WVHT2(P[)E27W$M
M,1X[#:G7GWG5YPAMIIM"G''%YPE"$Y4K.,8SG@$?]$]EJ/V R4:JX2[5F9"J
M&O=E#1UZ#0 T^R:IVVW9G-7;-#1QQ@UEBN7?-+MK, 585 KP&E5\A#MU0KDO
MY9F0*U'6:Q7-;BNK1W9+1&K?*#Y%-7;$VE4Z=>-L%^MMIU\(.SU08]D!4'K]
M3J;;IS!QQK[/PLA;9-8KCT0H4@S7S/O#X<:3)BRFV77IYAX)Y?+_ )2W'&":
M=_\ (;T<UC(GP+?VITDP6%0I!(H!!7H/<[(.'Q8^)<B9.K5,?L!Z)&:BJ3(4
M]('-H]E2',9RE:<Y0].NFO$A _8?[0?XU*1 $DPNR;3LR$>+.A!,BG5N"!8D
M$&'FX[WS+NVC^LT"Q[;SGI49+?)!U(;D.M3G&HTA;=V7NXRA?1^#]B%&Q_VG
M?20N3L@;KC6%!(2:".7-CS]@]E:4*CVUSXX4U"I,;6U=V@,MA%;/Q=5#CVL:
MRTK'RSQ!J9_ALV%G4KX1<JIK<115?_BU'&2(=B_:/]KV_P"P\@7NOIII>L'H
M;\^\N0:=LS8.P=?X;7ZV!,9J::)@[:5G1,X]EP?4V8$&<EYH@[AE,94M%&;;
MX+SQ&QVEXH>Z;21QLWEV1L.#8(6U?-U;@<@F4]56(=<NM^WZPFL5MEY3BH]F
M!P=$:4F&+*1B+:C(: [-6+"SFI#^+/88J6%RK-&2;X]>AI=EVKC],+.6IX&H
MYG:[Q+WPRT7V?V%\B_:FQC(38Y@0]03][K%FE(9S'D6VPB-C[0'6AHV3PZ_+
M8#";8/#A2"(+K3Q-EE]E]MQ$4JVEKX6_(^%VEY:3R;:\.[ D!KWL3XD0"(,'
M6?B*\F&]A412YK,*\:0"EW"9]:6V$EW[  V&<L#T+$1'R[-:RZFKX<6H@H#D
MDK,CD=3:B>M!\*\_$HLH^;#EYDSZ?Y IX6/$QI_]G,[PG"3)2,81=['JPYK^
MRFI4%[#@UD_>A6G)\LR+@--Q8; <F1GB$PH4%AZ$]B*SG$=3F<\.[F/@TQ#[
M2EI;Y\HWV)",>3;RMV$N:.:^_9][X!-66+$@&#=[WP%%33,."Q\K!8,(+ZEI
M;BV(\?.&,1Y$UQ"6$-M9<]MIO")+U+\/L_\ <4Y_I;];X>6X[F+W"_:,C,9B
M+2O$7UQH MEI#$)-T[%Z\F1H3*,82RS@8'W;6)[;3*,8QAMH<RG"<>E&$_#T
MX#9[)?O?=2UUH4A]H/)AY]F.Z=)P>T6*TU==%LVW4[C6H=#;BV%H=].V$5?-
M@MEO(9D[9;V ]4TCP\D69JBB,40H43;KX<HHJ78-#:I[+9^:[OC2JK9+2>9=
MY]V!YJMW_P![V6\V-AUU&>_^ZKO5/4<2FX2TO\%0QUQJTK1Y2'AM.<I:(2PA
M.6O"<9>2IQ67,#.W0L.S[ZG/+TP.>+_9F>GEHGQC_9[L5W7[:6)#F'I;VV]X
MYR'D/?C[CC#(L W;(N7O4K#JEW:4[E.?@AQ&?4I0?%JR5-/!=>1.K5'A%\4>
MFOEE5+H_I<P]%]*D2=H#C.ZGE.I^&?><_? 8O#67,K_MX]+2$-J^'LH;2E*4
MC+[2M_N?<X\BQFBZQUKJ\9@+K37M'UV'PE",":+4P%2&82W^"$X@ !X^+A*,
M?@C'M?!/_+&.#$SB9F^PS)9=CR66I$=]M;+[#[:'67F7$Y0XTZTYA2'&W$9R
ME:%IRE:<Y2K&<9SC@'!'! PC+N1(@8,R_A&'\CH$6%E[#?JRWAW,9IK+F&\K
M7Z,+^/I]:O3\/5GX@=GP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M#K3(F"?#E01-M3PTT-G"2#*5J;4[!(Q78<MM+B,X4A2V'G$X6G.%)SGU8S\<
M8X!%7K)UHLVC2! U==DB=CFF]-:,Z_5N6$HLBB1X>M>OZ]CR*G./Q)5RNGUB
M^V"?M"PR[<;%OURN/MPP<0+40^(<M\B*W/GX^AY6>SG[.GV4[?=^=I;E-=G>
MN9C5SFWX,@WK&)L/8KVVJMHZ;95E1]0-RX^NRK86\V&HN$23Q0L].9(VTH2/
M/S3&'Y$Z0Z]N1UI[2FFC95-[N;?,\^LBTH'^R^^)02E*9^L]M6=6,?#+AS=M
MUCK7G_\ 96*W(KR/CG_GZ$)3_P"F,<&?B]I_=R7L9+_PS7B _("Z_P#7?<O_
M ,SX'Q>T_NY4^P_X9KQ ?D!=?^N^Y?\ YGP/B]I_=RI]CE1/V:?Q&#WTR8&B
M[_"DHS\42(F_]UQGT9Q^.,I=9NR'$YQG_P!%8X'Q:]>5/L9';?!7T-INNKNN
MC7/L)H<FFHV!@+LMOMSV%:$:\,2!4J,'N4X7.VT'"$XM:(NQ2S@HK.ACB28G
MR,N2RQ(6XD3XE4K!_P"-/AAF;KH7BEZ]L4JIH9[#]X[7C[.A<NVP#Y!.WHP/
M:I&1T;YBRCAX7=[XB'#./>LG'BC9#\&.U)0S%?=80A:A-IZ4_11]IEOW5>@?
MSH[]?U$NZ'ZU<#:>E/T4?:/NJ] _G1WZ_J)=T/UJX&T]*?HH^T?=5Z!_.COU
M_42[H?K5P-IZ4_11]H^ZKT#^='?K^HEW0_6K@;3TI^BC[36]B\3FJ\[(UL9A
M]MN]E:I,<?>P5AUC*[W=MIDG:%H,0@96GD!MLF[W8- 96OQ58N\]X$#A3D6>
M <ES2N8K%68<6&VXPIX[-/VY^ALC[JO0/YT=^OZB7=#]:N!M/2GZ*/M'W5>@
M?SH[]?U$NZ'ZU<#:>E/T4?:/NJ] _G1WZ_J)=T/UJX&T]*?HH^T?=5Z!_.CO
MU_42[H?K5P-IZ4_11]H^ZKT#^='?K^HEW0_6K@;3TI^BC[34VH?%GI5\7<DE
M^Y?=K=$EK:.Q5Q"U?[]]K K5' SK--)5C4Q*/6=^$X\TQK2NS1E6G'2CD4_8
MEP4FS0^%-G.,I%=3TI5E^RGQ^7/$VS]U7H'\Z._7]1+NA^M7!-IZ4_11]H^Z
MKT#^='?K^HEW0_6K@;3TI^BC[1]U7H'\Z._7]1+NA^M7 VGI3]%'VC[JO0/Y
MT=^OZB7=#]:N!M/2GZ*/M-2[H\6FE(M-B.".Y?=K1<S%TH#KMWLO?SM8;'3!
M$.Y!2%CHR(5JWX*%MSMBUN&7I$(JW*44 /G$GA$682&QHSH;;TI>/[*?;+$V
MU]U7H'\Z._7]1+NA^M7 VGI3]%'VC[JO0/YT=^OZB7=#]:N!M/2GZ*/M'W5>
M@?SH[]?U$NZ'ZU<#:>E/T4?:/NJ] _G1WZ_J)=T/UJX&T]*?HH^T?=5Z!_.C
MOU_42[H?K5P-IZ4_11]IIW[L#1(+81:XV+NMW1QJ^TP*KKND:YG>0/M.(;$[
M5"V*ZQK9-A7U>_DE;0=MGO!JS]@W(J<UR?1IKD'#\XL48BB[;B(IF]]BGVBQ
MN+[JO0/YT=^OZB7=#]:N";3TI^BC[1]U7H'\Z._7]1+NA^M7 VGI3]%'VC[J
MO0/YT=^OZB7=#]:N!M/2GZ*/M'W5>@?SH[]?U$NZ'ZU<#:>E/T4?:=2=\6?7
M^.*EX_B"[WU^1,2V*&EYOD1[C+9B&2[K8L+E$>9N]F/-E.EI<-B$.6YA1*8Z
MQ!;PIR0A.0VGI3]%/L39T/$;I6NJ/I8[N:/NS:&GM>T*G;*N<^:-;N]G/BJU
M &R+Q=*Y%+F9M>*7>3"DV!R-.ER?6],>]F;-2C,A8CUB$V_X[C=?!!P!P!P!
MP!P"K[J_I79%.[  BQ_6)2H,Z^K/>$+L79$U550.W*>[ =K=>;;U*="R@QH@
M;LR44VLV^Q&7[$/&OT0E:DU=G"IQ0Y'BC3B'_CR34896OTK0>#(X X X!&3M
MT^?BZ6(RJEH7^)"W0[512%3UO(4(^CL64;;!1$-?+"P:+!H\\-K6=%:O3HN)
M)R6*S ,(<'^4)28Q2 *L=#F=2:*WKC0%(J_TJW!9V)MYL9^!> =<JQ[[6WC8
M=KN]RFHJ=0.6:L5&O%+78C)2G5$(>*#ZK3Y@*OL2EX'9PD'CUAD2/X(. . .
M 5G[UTGV9MO>'JEN<8#UY;=/ZFVX_D3[EZL@(]K2F6;K/V!INTK69J7V,F!K
M">M=JM]5"!R4:SS9$5L'1P$$-5!=BV=;GQJ5#U?NO3=K<LPX,C@#@#@&$[+"
MV*R:XO\ 7:@6P!MI^DVH+5SF77F,!;$4!3X(0ME^.E;[.!Q-^-,RZPA3S?L^
MMM*EX3C($"/';J79NJ!UL&W.D6*HUYK5W7:JCU7VIZ,J]W5L*CUZZ"-E5L:Y
MH@<."GM/U&,_1X>LS-F47L;Y6;L!,>P&:LFN2,"OJ[CGF\^[.2RW@@X X X!
M6_Y$M,WC<@G4<&N +^3K@&?MURR%=3 M57#8H<E<=,7#7%9B0JANYQW7,^JV
M+%P-B+09?&3+*!><!?2B%6!D;7:PPU2X?O*SG%7RZ<3-;3 JS M/:G"742*
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'@K<]/U/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g317356g77v65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g77v65.jpg
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M04)1D;/3U=8E5K2U_\0 & $! 0$! 0                $"! /_Q  V$0$
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M5# 8# 8# 8# 8# 8# 8# 8$;WCD_TN^7^LA[/?\ IP3#57^/VPDAPR8# 8#
M8# 8# 8&@,R\=]?S672>8N^R'?P"[E4@,2)R$AO>SLQ$XB(<&7[@BL-C$6"V
M"U#1N/LE'&S<0"$M6PP2P308,&Z+5!)+4UTIV4_C3/?,3+0_H?TO9WS19Z=6
M-VU\B9&1,.Q_;ZMVSAAWZ[0"D-8K3_:BX*J@[79JRL1-'=RQAT/!LWCW;7U@
MB[06?NMMW+E7?8U55,3A%/5IGJ4ZZ8F=6V4W5=0=E6L'C,#''II)V,6%H"6L
M@L28'[ FY9)#G;G5Y)II*'I&0R,HI\OGTY,N^<O%N.->%%=N->/B/-[3 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# C=ZE_CR^5KZ9NK7U,J;R1G/'RA9RCAYRD
MBRH8# 8# 8# 8# 8# 8# 8# C>\<G^EWR_UD/9[_ -."8:J_Q^V$D.&3 8#
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M;-]R1TX1(&3#[9/ET3+/GA%ZJN\=+K;CHTSG33LRAW7W\/=3\K[M%^W^V/\
M[;@Z%'TT_C'HM-_$%*)--?&1THE<RD1V6RD]1,5(')+)BY \?,OUN77I7Q4P
M5<.R)%XK\GCTCEXY66W^+CY6_/Q<8<=76J^Z?%(_ADP& P& P& P& P& P&
MP& P& P& P(W>I?X\OE:^F;JU]3*F\D9SQ\H6<HX><I(LJ& P& P& P& P&
MP& P*M?X25[Y+MA^C>OWU;*BP[-%\NGG^TH+\/0P&!:@_!S/<S]-/S%^?6BN
MS)&7.?&7%I.O5Q3;Y6# 8# 8# 8%2[YP?>R=Y?IH=?PY'\.W1]2G@BIPV8#
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M'9HOET\_VE!?AZ& P+4'X.9[F?II^8OSZT5V9(RYSXRXM)UZN*;?*P8# 8#
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M_AR/X=NCZE/!%3ALP&!;>>%SW5/1+]7V(_O>8<-?7J^ZKQE)YADP& P& P&
MP& P& P& P& P& P& P(W>I?X\OE:^F;JU]3*F\D9SQ\H6<HX><I(LJ& P&
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M73[;:26+))7)E455^>=TFBQA1HU^/G1H@@GSSKR9F9F;SFROA# 8# 8# 8#
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ML^Q>=D]WJ6H^N?P_V/OSO,__ &*T-_Q**)^S[%YV3W>I:CZY_#_8^_.\S_\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g317356g84s24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g84s24.jpg
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MH:YL""9GQH(4GLC#L=9<.5912KS(3;DU-K#-UPD=D,G&0Q9QZ\X[_H)_<?\
M8O14?W_Q2[F*?78J"$,S8;W<:/95LGJ!9*QS75.XR<[E(M5TOU0N)^CMU<O4
M0^H068%L!>;,/J-0-CVV:-?IE8+&/]GKZXP/M^[/J*9Z['WZ5R?=:X[U:0&Z
M[=NG4D.9GZH(9^OO<GNO0:A:3ULJA>\0KL& ,L<_58-RE5QV5!8M=0K):' O
MI?\ )-DF/6/M\2Y!/U.[-MYNF<QY/;.J%*RY>9IQ0<W50#*J_P ZL4.C6)P$
MNRDQZ"UHF]#9N5+K5=D+%#B!#G=IF&;/7![U<D'B8]?E]?\ L_AYX\BGVQ&8
M;L<LGQRZ1A8Z!WT_7BK%JYJW L%5\T=0C<OZP;GRK%;:U%JJQ$F=#M$&$8?^
MDE5_OST>7^*CW12R8_=T\>HRO=T?U0)L_0H?-;5S+HO*++.XQ+[@W!OKE%V0
MB58,CGS5ECE0=3NEG/"Y@4UT-BKLR)(W0L[8:=T&*#GSH=>ASC),=,^O"\M)
M]\>>9%1NEDJI:W60G4ZF]98%5)<ZZ#S4E<);WYNV*[6*T4ZQ5Z/7)!VTD^P<
MB'B69!B.PVWTVFER#T,(6:(X3'V^+O[EVO+_ &SQ?JDB#'#?EK$V>@TPC49#
ME NI8;;&KMQ^J=J@#!!RN@"]?7;H-/LTF63HJBWY91H-7LQ_83=<%OE4%C&,
M^KHOY'O858 ^B'?//Y*$#!]@F(#NJ!V2JSK5I\USPET:.;9YJHDQ<9=)BCQJ
M@I*WQ(K\&!894:)(83#3*GQ2SCIG[>7?Y_;O.%R ?M/CLD+4K%<WRG+15ZHH
M*\5=5[9C1IDY!0O9A!6O/1@TDRW&/U1P!"?/,:DO0FVK('U#FRW/OB8Q,'KX
MXZ=%76%A1SW7TQ:.0WAVGQ:56IL.?6^<3:]9C5OF#(*#/0^[\]XDXY:8K-=D
M:!URKNWYBR2Y\:>2DEF(+L!+(A2DR]ECYOM_L^W58X\T^ZG^]NEII'FCU>$1
MN0HZK$%ULB8O5ZCH&@:*5- R-3&UF).DSCKUX;7S5@*B<1N(L2]+8'-2IS$%
MGTCB,LL<371M,DC(VOED9%$TO<&ATDLA;'%&"<ODD<UC&Y<XAH)6-P )P3@$
MD 9)P ?1:.ISX #)/3&4\&7>!T>X>\[J+"W.NP#GL:$Y'#=!I=EYY<(6H?D7
MRB.6DU3K@-$6,*X\[#7(B-DQT9<L>]$(1].0Y<=YRU<557TZ_"M9\M:9\7#C
MLR5+,-RN[=Q#K[QR[%=\D,F X-<6/=M>',.'-($:H\/=:< YH-GN>US'#%>N
M.K7 .'=TR.HP>XJSS/5^75R[UKF5AZ30072+G%D3:?S\S<*\,NUKA1/MOO<N
MMU2:18.G(L;[M)^\/C($IIG[N_\ :+3]BY]--,L37MB=)&V1X)9&7M#W =Y:
MPG<X#Q(!PMWVZL4\562S7CLS@NAKOFC9/,T9R8H7.$D@&#DL:0,'/<5[[/12
M$PB81:D?BP>1_:WK"L<.&^-_0J>&S*/=C)>_Q%WF[<\19(Y%D&W63VCU%'$R
M<UZBR(!A]JORF6XD_1]<YMW[^*A,N\G5:EVVR!M.SV<LD+I/3>S<#MVG=&"3
ML()VGH=W?D!4_B[1]<U>&@W1=2[ ZO8>^P.?/6$H<&"*3F0-<]QKEKR(R-KN
M9NSN8T':E6(!<56J\+/F-V(Z-!B8!NP*BM0=G2\.!'CDC&X+.]LP]DYC;TW<
M5K>VH^W_ +%O>THUO.HT$-:''<X- +L8W$#J<>&3UPK9$U[(HV2/YDC8V-?)
M@-YCVM <_:.@W$%V!T&<+O,V7HF$3")A$PB81,(F$3")A%TUBKE>MX(O5[8"
M#6>LGQ\D4=KMA&0C0(T+FM*8F#2PDDQ)@$8$ME:FI,.9'>COM*4VZVI.]ZS#
MFM>TM<T.:X$.:X M(/>"#D$'Q!6DD4<T;XIHV2Q2-+)(Y&-?&]CAAS7L<"US
M2.A:X$$=X7 I='I?-ZP(I//*C6*'30#"XH*I4T"*K%:#1G'W9+D<4""Q80L>
MRY)?>D.-Q(K2%OO.O*UMQQ:E88QD;0R-C6,;T:QC0UK1WX#6@ =?(+6"""M$
MR"M#%7@C&(X88V11,&2<,C8&M:,DG  ZDGO*Z_H7-J/U:N+J70J]$M%;=G02
M+P><[+;AR)8U[4B(J2F'(C*DLH<U_JQ'UN1)+>U,RF'F5*1O9>JPN'\;>?:V
M2"%ZK6KA3B0 >-$P9=*[+VJF.R18FK<ZI< <=_)?H8E-HA-5KD] '.1K*DLS
M*V!W.EH?(ECDLD3/A]O'^)7]0?COSS7XC$&#2C$J- :!Q0R;!TCJ-K<K(ZMR
MIDX*%J$BT70Q(IU>AS)KLG=<JSH@%)?9'N3!\A0L9N(6<G[?;[=?-?:/XV\P
M(<K\LCQBH6HO63!,Z.LM^9G=%N$DB7KM@J<[=@N5[FV*U6R"JMV@P&BB;28,
MB1\)R"V/A1=A@RAY87M^?^?>+\IFC9_-N=5VDO"$]+0,9KD=X9 A)[#< 5]Z
M/]@*COI&)W9;36*[.<5N)M0V*%&!@VQP2&R.03[?1T"\*:\B\6M#QO=H$'2<
M(P;Z 1_#!MSNE.@J"=7G"[#TNB'VJ38:[J]4&[76&4N)VG7O5CKTHI8B\78W
M0M[4+1,_;[?N7.'>3."#)%CDMT\M._*EZTNDHI[H72[*+A,WGH,/J=X%U</8
MK@4%4D!=;Z-&'[A7*;" @+0H6+''1L\0-@P(Y,_;YL+V#/">8,WRP=*T$*/6
MRS"#P,D],N5VG@HX^U1ZQ%L^@%.FV*13JI,L;5-K6SA.K@0Y,J\,U*FRWI4N
M>]*)GIA>3?\ )?G>7)&29W,1)+\(D1942&4)6$H)==A"N2AH2280@8DAS3$.
M'PKDCD6*9@SXL<G1Q)MEE!E<Z?+)]OM]*ZD)XYX%5)Y K2:U8J00G'3=I855
MNC=$'B@5GL++\$K8ZK57+1)IU5.N IDZI0B@"O#Y@:DSYU*"NCJK*=$*+))/
M?]OXK/HFI5X&;M5C%#DQ#5VFC"-HG:D2W5%9H8+"KPU];+\AV-%W%#CH4+2(
M3,9MQ+&GGD.2%N/++"P>0\F\0-2QVC]/B'J]7JL)JM1JA5Z9+%55B"8LQDI/
M&/O2EE'9]C?L,9@LN=.E-;CUX,B*W'4B4N06<GS_ '*D\+"ZLD#"F6I,<N'%
ME6)L)T9,9)#XDYJ6.?6EQX?);E,NH?A/.(0MV([I;#BTI4MO:DZWHB0@84;,
MF$!X<7 GD68,<A.A#XD69/8%LJC#&9DEAE#TID='6IB"V^M:(C*E-1TMHWM.
MR+5?RK?K77H/W_\ F&;\ZKJ/^+"O_B6^NO=+;L?Y1?X0O*WWK4'5-8=&?@OX
M;^%?=]OJU.^_?B'VFOL/NV=GB'M_8^%=@I\KVO/Y.\S<S9[8->W<S V[N;S-
MNWIR]F?2W+A/]FNTW.PC2^1SVX[6;?.W]FK[O@1LV]VWQ[\K37Z\\Z>JNB>_
MG?<EC%\)<5X>Z'YFI_2VJ[=>B#@).V/S*?T"DD0==+C';3.#5:)T^DSKI%@$
M@Z;0UN:'J<,B;08<?YT/ =W4[.BZ@[4J$%[4ZEZ[I]/E7'Q2QZ5-<C L66L+
M:[YYZ5EC&M;(UK6-DL.@9('&%/\ [F^M:SK6AZ_+J.CP7Y8)+=.DUNI.@F&D
MSVC%SIQ$[D&6>M,TM87-V,#I3"'[W?H:^KXD7_8^(?\ O/>/_"9RO[1\J7TS
M_P %-_RF\M"^G4/X+5U[?^*SZ[\*=KXAQ'HG.O-EM-]G8@D6C--;[$\*K(8C
M:VZE&ER$$7H<LW/^_(GR7@XEI<IJ+%C[VI3I*(TKEWM5MT9Z\$D=9[I\>DSG
M88"\,!.<%QSGHT9P/,A537N+M8T"]0HV:VF3/O .WP"Z61,=*(0XAQ#I';MQ
M+&#< !WEP"VB_5\2+_L?$/\ WGO'_A,ZG]H^5+Z9_P""M?\ E-Y:%].H?P3Z
MOB1?]CXA_P"\]X_\)C^T?*E],_\ !/\ *;RT+Z=0_@GU?$B_['Q#_P!Y[Q_X
M3']H^5+Z9_X)_E-Y:%].H?P7QJ3\2-OYIV%\02M?/YZ>U9^\C_GK>M?Y=Q_R
M2)?+:=_/_/J5OZM?+?T(W^K&=1_NTC_KSC_N%,\3#_>]"=Z^=J#/JY#_ /[O
MF3\6^)&Q_P#=_P"("?T[U\O^>#O(+[;6_E\]?+\QUB^[;;^>_DKYRM._3K_*
MS]I_ILZA_P '2/\ ULX__"['UIOXF'_DVA._^-U!F?\ L$F/KSZE*WL?W/[D
M\0\*L?=^G>3_ #O=JF!)!PTV1RSTSU$N0$/V&9^%BS1<%8?+-<82!9(KBL3W
MMV:&I#Q"#$:=4\]I>1+MZ]1KNL25*\C&X!Y5F4D;C@.+756^B#[X[NF1\:Y.
MM:]KNA:?+J%K2--GAB<QCC5U6T]S#([8Q[XY-)C'+#BT./-'5P .2O:>;???
MI?O_  SG'>XOP\^E2*AT,(LV/;I';N*S3ZX44C.%/D8];ZJ=XW,7!(NCGB=?
M_P"*6HL$EC)\9QQN:VK?I6OV;$$<_L?)MD;N 9/"78Z@G;*Z'H2,M\VX/CA>
M^F<0:GJ.GUM0'#EHPV8S(T07J)DP'.87".Y)1.UQ:7Q^EZ<;FN&=P6;%?$"Y
M!6?U=OH/H7S2C6])=+]NXC<1]%BJ^KZ7/Q#K="CW_CHQMGYZ4Y))= B1?LU:
M<0^M'S5KW[?$WX:.Q6]<T+PSYY8^9"/C,@'T%3CQ#3B_S^OJ.F?Z=ZC,VN/\
M5RN+%)F.\E]AHQUSA5_2[S2NCUP=<>>V^L7NI&&OMQ-HIQX59J\39_ZW(!D+
M*FCI:-;W\MJ8DN:UO]6_EO\ 5DIDC)6A\;VR,=W.8X.:?B()!79@G@LQ-FK3
M16(7C+)89&2QO'FU["YKOF*]3FZ]4PB81,(O*W>\TSFM4-WKH5I 4JFUN)]^
M/6BT%884&)B;=;CH=G$B#S$5C3TEYB+'0MS3DF6^Q%CH<D/--KD5:EJ]8BJ4
MZ\UJU.[9#7KQNEED=@N(9&P%QPT%SB!AK07'#02/:O7GM31UZT,EB>5VV.&%
MCI)'NP3AK&@DX )/3 :"3@ E=?SCIW.^OU2#>N6W6M7^GD7I<:)8JH7AF1;D
ML?(7$(05R83KJ6" ^4VY%GP)'V4R#)0MB4PTZG:-;WJ%W3;#ZFH59Z=E@:YT
M-B-T4@:\;F/#7 ;F/:0YCVY:]I!:2.JVM5+-*9U>W!+6G8 713,<QX#AN:[#
M@,M<""UPRUP.02%["=.A#(4PD2F11XX?%D3I\^=(:B0H,*(TM^5,F2GUML1H
ML9AMQZ1(><0TRTA;CBTH3O>HBCKH4W>EKLJ:8BWU=5P7!T315$GQ*K*L:IK[
M=)!(+4O914';/^MJ7J+N/MK_ %-.?1^O"+FQ;-6YVQZ85@"2U%HLN<*3%*P)
M&R<(>M#<^6/TU(7N;%A..-HER(WVC49:T)>6A2DZV1<E@T'E#XA:,6&R!1!4
M-, FQ/BNCYJB$AJ) 3$FMNJC253I3[,:'IEQ>Y,AYIEGZW'$)V1?V@D(!1C<
MH;.AD8J9,V&J3!DLRV-3!LV0-(Q-O1UN-ZDCR,25 FL;5]K%FQI$5]+;[+C:
M2+F81<?4N+N4J#J3'W-3'3+5#T\W]Z3%6XME$E4?ZOM=1UNMN-)>VC[-3B%H
MTK:DJUHBX#]@ QF&9,DV(CQI!"2(CR'R4)IA\M"<FM3!C+KCR6W2$1T:1:DP
MD*5)8<@34.M(5%?TV1<UN;#>DR(;4N*[+B?1J5%;?:7)C;<;;>1J0PE>W6?K
M:>9=1]HE/U-NMKU\TN)WLB^ZI49$EJ$N0PF9(8D2F(BG6TR7HT1R*U+D-,;5
MIUQB*[-A-R'4(4VRY+BH<4E4AK2R+^^$3")A$PB811+Y._;!\0W^,H/_ $:^
M1LLNO?>_A'\7)/VDXA4:#X2W\I'ZM67-]#>10/5;;6>NT /Q:N=QK1VME-W;
MJG++-U (<AU%!&168QBJ5CJ_)XI [6C$J(4JEM/2K%/J:H:VP4.*^^S+A[:+
MQ)-I]:?3;DNJ3Z3/%/'V33]0@H2Q.L[&V'1V+&G:BYD,\37QV*T3866-^97$
M M=9=,UJ2G#+2LOO2T)8Y6<BG;BJ21NFVB4LFEIW'-CE8"R:&,1-FW9D+@"U
MW%V3^(A64Z=E5'Q[V!EE7S>8"7'L/""DMK7ZMZ@QC-5[P,;D_P#VD-33;3"O
MG]"IC?R^T5MR^"Y^C;/$NF$]QEK:;J\;3_INBL:1(6^ML1/CM/<MMG#,O1LV
MMTB<=9(*6HL:?'<YDVG/(_PQD^H]R\%;>S#W3-2L?JWX?O3!Y/GQ)1RG=-"<
M^Y]ZQ!4(AM3.Y!^K$.8OVGL%5E-KBQWGR47EP62EB.Q)6[I,=7V&CN%]/O.8
M[3.(-"U"5AS%!J!ET:XU_>-CM5ABH!QP .7J+B7>CW[<QY>&]-OOAEKZCHM^
M:!^^LR^SL%N&0]=T+]1B95C><#THKN2[ R3A5GR3T#Q3N\&=.Y#TVH7S\)<^
M[G1H0LRJQ5J5\_IW!M56E?=K)5B"5?J6.L(H9.1OY:7'3O>LY>HZ/JFD/8S4
MJ%FGS!F%\L9Y,[?[]>PW=!89Y/@DD8?!RCW=-OZ<YK;M2:OO&8W2,/*E;_>A
MF;F*9ODZ)[VGS68<YJ@IA%K%^*OUWW1QK@%9L?@OFDGH_1YW1Q JX($TQSHU
MAK]*=&%I"B >E-:=613,.1Q(PH2U"):##I3S^X;&GOQ@3S-5FO0UVNH1<V4R
MM:_#.8YK,..0SQRX-!/7:#G'B*MQ;<U^EIT4O#]4VK+K+&3;(>TR1P%KSN9
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MER[#PCHSG)X_0F0[ME*!=43DI?BTFZS0T<\H4=@WE 91.$Y6UEC/[O >7?\
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MC74ZCIRZ2J9GR!YIV)G5K#VLC,[1LC;MD\R*(*\Y\)07Z0'[$9C\CY["-]5
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MG:I2]&6H)8'.'OF<QA:'M\GQN(>PC!#F@@@A8V\?=8/=A\_4@]=TMQ^IU?\
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MB[!:TYVNQ[TXRGGJI:81,(F$3")A%JA!!O(]&]WU8%Q_R@,<[+=;IVRY]<[
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MMB,Y:ZK8=W]*UV.M8<<$[(W@=ZIRH6NOWRIUB\5,G'-5:Y5X+:JT8B[VJ*5
M6$=&+!R,=6]:WMB:/EQY+6]ZUOZ'$_/6M_JS@V:\U2Q/4L,,5BK-+7GB=[Z.
M:%[HY6.];'M<T^L+DS0R5YI:\S2R:"22&5A[V21.+'M/K:YI!]87HL\5YIA$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$7D;S>:]SFM2[9:%EDB8<D7"4V!
MK=CMYJ5--%(887#&5JHBC=B+2I9&?%82R-%REM(6N5(TS#CR)#3O3N7A>5>A
M>1]MDFH_+[/)M30 =7"Q$HS5[<-K^X%M#1+  ='V4R"' #*YH>;&F.1A!*=*
M@Z6MDBS$DLOLMYP?M]"P"#\WS?I6"_):TKZ]\0Q2%)6G?LH/\E)WI2=_+QKY
M'UOY;UO>M_+>MZ_5_P!>637QC3^$<]/\G)/VDXA4>#X2W\I'ZM65N96E)3")
MA$PB81,(F$3")A$PB81-ZUO6];U\];_5O6_UZWK?^^MZPBAGR>O7'+QV#QT1
MWN- YF45U3@C;N_DB?YTZH7)$1P$;M6]J=;X]T5%PYHJ(E;JQ-1C<X<D*;2:
MB)W;.(A[)U-,XE9Z3[T8T_6".I9K>GQLC?-(!W'4Z79KV[ $EEUX-SRG*P:Q
M]W5Z6MMZNML[)J)'X.ITV,8Z1_D;M;D6MV!OG-K&2QV+FRIJOIA$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$6->O<P$]EYZ?YL?-V@ $LJ8+!:;4"4848D
M089&(1?$KD31Y2)(#F4Q/PNPBID"3 . I9$*18?'$)3#I8(SXD?$L:TORIRR
MGE[J7>9)7#\OZ+&YO8A5N8K$D#*I_P!UW',AG0X6M H<^'95J<?+1#*"<*(V
MZZ(K<8!75?@VO2*62&2.:%[HI89&RQ2QN+)(Y&.#F/8\$%KF. <US2"T@$=5
M@M!!!ZAP((/4$'.01Z\G/\%@CP=SRB<IN/O2@<SIU;H%'KWL:$T!J-0#0*_7
M S<_R)Y1*S6Q@<8Q&@PD2R<Z;/D)CL-Z=ERI#Z];<=6K=JXIN6K]?A6W=LS6
M[4W#KC+8L2OFFD+.(=?C:7R2%SW;6,:P9)PUH Z *-58R-UIC&M8T6>C6@!H
MS7KDX Z#J2?C6PO*BI:81,(F$3")A$PB81,(F$3")A%KR^(@;D<*YU7O;U9@
MMS[IY0(NE2(/<B3 3T?D'19H:G].YA-)1(1-R T14]6;R"(O#"$87<J!6Y<I
MC0[9':KIP7$-6NS<*3N+:O$3!&R7:UYHZE29+9H7V,<Z,/+,3U)HQ(QTE6Y.
MUIYG+5EX9C&H6I=!E<6P:PP,;)@.[-=K-DGJ6VL+F;MF)8)&A[2^"S*UIW[5
MDKRIZ<-][D7:N6^L4<':*=7.57V(8Y7T&?T[F=QYYVP$9/\ /[!7K.8IG/SC
M!%;%=,QC8$O58;\-#(LO%E3!IZ$IJ!Q!H46D-JSUK%N6O9GU"FZ+4*;*%^K=
MTJ:*&Y!/7BM78BP&:)T4T=AP<3)$YK9(7YBZQI4>G"O+!+8DAGEN5RRY6;4M
MP6:$D<=F*6)D]F-S098RR1DQ#LO8YK7QNS8>5I<1,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB811+Y._;!\0W^,H/_1KY&RRZ]][^$?Q<D_:3B%1H/A+
M?RD?JU96UE:4E,(F$3")A$PB81,(F$3")A$PBZ6QUNOW  :JEL"";+6+&+FA
M+!7CH^*5"FPY*.Y$("RHV:T]#GP)L5UR/*BR67&7V5J;<0I*MZSU@GFK316*
M\LD%B"1DL,T+W1RQ2QN#F21R,(<Q[' .:YI!! (*WBEDAD9-#(^*6)[9(Y(W
M%CXWL(<U['M(<US2 0X$$$9"UU\$HE'\&=M->?@M5!U#A'I6V3KQP>SP!T>&
MD+U= 5M5RX!:S*$)>F*?#!?RNX=(,ONR'J[&M7.X3^VZ97(LVZZQ<M\7Z7%K
M,MB6SJ^AUF5-7KO>7&73N:>RZQ7B[F@2R]FU5L0 ;,:]UXS:G<RSZC9L<0T(
M]1DFDFU'2H6U]1B<\N,E/F'D:E#&>@P^00:@(P )3#:</=Y7-V791554PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%$OD[]L'Q#?XR@_P#1KY&RRZ]]
M[^$?Q<D_:3B%1H/A+?RD?JU96UE:4E,(F$3")A$PB81,(F$3")A$PB818Q[#
MR*E=SYZ>YK?H4J0"-IB2&)PN:\*L-;/")C!6MV^IG(N]3 %MJAR'!/5LY"4F
M2-+08TA/UH2MIR?INI6M)NPWJ;VMFBW-+9&"2&>&1ICGK6(G>A-7L1.?#/$_
MT9(WN;TZ$2Z5V?3[,=JLX"2/<"U[0^*6-[2R6":,^C+#-&YT<L;NCV.(]:C"
M-V+O5;J/2/*M[+BAGKY7+.B-^7.Q$8D(5SWTF1'54IJFVL=]NA08%T^LD]B'
M^N<QDI5J"MI^XUF.5HA#_DFSNTW2)[-+B"I'(_AOV0I'7],C<^2[H<<EB/M5
M=^#S9:$[.:--OM/IY;5L.CML]U[CJ.G2S5=8KL>_1>UU?9>DQSGV=*:^9O/A
M=_ODE25@>*5L>^R()7,L-]/K_$@+JPSH5PE/ _4]6X^YRZDQ#@GUM>Y][MY3
MT(R7+N6\Y09!JWW0F/K&P"XC-E=#3A'.3)MX6_00C4>"7?7OQ5+I\E*LT2\/
MV-2%^VZ*3ARHRI6CT8QQ]FBN-BK58WS\[<8!*R6]%$)!<E+GQA;:])3?6A D
MTB:[VNP8W:-7;7@9II:P01V.7# Q\O,!,(>U]J.(.%F0ES -EN4959,(F$3"
M)A$PB81,(F$3")A%,?;O4(/C-F$TB#S#KO9+K/J)KHA6K<> UHP4JO.J_.BC
M"5R/N6VW4L=N(Z1E?AX4"%GF+A9)L6>R KA'[A+4SWM*T";4X)+;K^FZ9599
MBI1V-3FGBCL79FN>RK"*U:T_<&-WRS2LBJP-<PS3LWMSUJ&DR7HGV'6Z5&!L
M\=5DUZ25C)K,K2YL$8@@L.R&C=))(V.")I:9)6[FYSG1[I6ND4JH=#IA-LW3
M[Y5P%RJIEEMYIHM7+.*B&@A)MJ0VU(:1.&38TE+3[33[>G=(=;0XE2=<FW5G
MHVK-*U&8K-2Q-5L1$@F.>"1T4L9()!+)&.:2"0<9!(7/L02U9YJT[#'/7ED@
MF82"62Q/,<C202#M<TC()!QD$A>IR.O%,(F$3"*)?)W[8/B&_P 90?\ HU\C
M99=>^]_"/XN2?M)Q"HT'PEOY2/U:LK:RM*2F$3")A$PB81,(F$3")A$PB81,
M(F$6,>N\<YUW2FR:)TRO-G@;DR$7'O,RYH@]6K$+<V^&M=0LHB1"/5*V Y._
MO(:R5\@/+CGMKW'EH0Z\AR?INIW=)M-MT)C#*&NC>"UDD,\,@Q+7LP2-?#9K
MRM]&6"9CXGC&YI(!$NE>M:?.+%24QR!I8X$-?'+&[H^&:)X='-#(.CXI6N8X
M=[>@4J1KAZ7\KIT+Z>$MGK'AL!&FA78.? HL_P!%4D6Q_E::Z[RT3]S1UF/#
MC[0AR^\@@?E?/U'4\7Y7(DN2CC]@=6T+B#,E":OP[JSSF33;LKF:+:D=WG3=
M0DW'3BX]13U-W9F;L1:B&AL+>P8-*U?TZDD.CZ@X^G1LR.;IEAY[S2N/W&F7
M.ZBM=/(;G#+@ $8I[DO>>-]W$RC7(>CU6^11SWW4S%"$VU'*W.TI25#+76I6
MHUBJ9=M2%)>$604+)L*3O3T1&_U9P=1TC4](D;%J5&Q4<\;HG2QGE3LZ'F5Y
MV[H+$9!!$D$DD9\'%<F[IU[3WB.[5FKEPRQSV^YRM_OPRMS%,P^#XGO8? K+
M><Y0DPB81,(I*_QG<F_.M^:_\(Z3]R_.1OC'YVOR'G_F:_/'ICZ]\Q_+7[;Z
M_P I/OFM@?O?X3^2_P"5?_FC^4/Y3?\ )66+VL:C[']OYM'=V'V4]CNUL]D_
M8S..W=EQ\#M]VV<SM'9_NGD<CW1=GV"N=C[7OJ[NR]O[%VAO;NPYQVOD8QRM
MONFW?SN3[ORN5Z:K7*ZN,F$3")A$PBFWMOERA]R-A[26LO3J#:Q5;-T>3:.2
MWPI03E@H%DDPYIRC6*4/2\@D ESH$:?$<TRP< SM2)E;,AI$V<Y)[FE:_<TF
M*2O'!0N5Y)XK;:^HTX[D,-R!KF16X6R8V3-8]S'#)BF9M;/%*UC WJ4-6L:?
M&^)D52S"^6.P(;M=MB..S$'-CL1-<1MD:UQ:X9,<C<-E9(&M SE4JK7J)5:S
M2*B)B@:G3J^&JM8!P=+3"#5ZO#HPD**B)<6XYJ*/&Q(T1C2W%KTTRGZEJ5\U
M;Y-BQ-;L3V[,CIK%F:6Q/*_&Z6:9[I)9'8 &Y[W.<< #)/1<^::6Q-+8F>9)
MIY'S2R.]\^65Q?(]V,#+G.+CT[RO09XKS3")A$PBB7R=^V#XAO\ &4'_ *-?
M(V677OO?PC^+DG[2<0J-!\);^4C]6K*VLK2DIA$PB81,(F$3")A$PB81,(F$
M3")A$PB813SUCREY_P"UEXUHOW-Q;UY@,;CB^F5:<9Y_U00S]*4H:%=.H1*M
MWN"PUM#:VXK%@3$TMM&U1U?+Y;[6G<0ZSI4;J].](*CSNDHV&17=/D/B9*%R
M.>F\GJ"XPEV#WKI4]8U&@PQ5[3A7<<OJS-CLTWGS?4LLEKN)!(R8]V#WJ6Z3
M4S)>QVRF^6OB9S[@;H$G<2W\TZ:KCOJ=5)FI><B:B6*0+=H_:X"4R6'(3[=E
MZ9+D_?&)3&Y#<U#R6^];LQ1P5[.O\",K17&[JUZB-3X?[6S =N@$@MZ6_P!$
MA[704&MVN:=I9A=>>9C(H9]7X4;#'9&Z"U4[=H_/;@.+H@\6*+L@AP,50-VD
M$-+<+*FG/B*5[6D[A^,>LH:^7U.I)=LX))EIU_OO4;8OT3&BO*U^OZ=RW6?K
MW\OJ;3^O4#'!4WX7$^G9\-FE:P&_&[F:(7 ?X0<>94/'#,OX6N4\]PVT-1 /
M^+?IA('^'/J*^WYY_:([?TF?$M;*[3K_ #N<]]44\XRM6O\ ?<?\O>><M>4C
M>O\ H[?:CJ^K?R4E.O\ /F#I?"[_ (+BJ=F>X7>'[,)'J=V2[J S_A+A^A.P
MZ$[X/7I6>7:=(FC^GLUFW]6?W+[;],=_@_/\8^'UZ24G7SU]I6>C>0K A6_U
M_+:6Y7I(%+VG?TJW\U14*UK;?S1I:]H2]@M'=\%QEH?Q3TN)83\Y;H4S?_J/
M7/>!DO8K37>\XDTOXI:NM1?3C2Y!]?FH\T(@-=3UT2=Y+^)5!K6NJ[[JKAR7
MO,Q;C".SJ^<I/1_PD!V4M<W"BSN_RM_ &KNY26[DK\IWJLV5TJ2FR<QYT_L3
M.(N!WS^Q_L3[*XUZ/5#I?O>P\V?2XJO+$/W-S34%LU?<!8,?HKM[WFGV9NL\
M+&7LGL?V_&JLO]A[NR[Y*+(-G+]PYAK]HY'N(F+,!6(GV(7^7^KXZ]HL+U\_
MJ;5RZD/[3_ZM_:PNI2HZ_GKY*U]D\OY?/Z5?2O2DZK7M:C\.)>&"//M]L?4[
M3VD?.!]'5<3V$9X:WH1]?:[ ^HU ?I"^W^,O_P#"G[/_ /V+W_\ ZC,>UK_V
M@X9_^:__ ,ZQ["?^M]#_ "__ /2G^-& GYI?\Q>SV'-?[M_X=;'*^6M_KUO3
MX^=,BJ^>MZW\D2%;3_T5Z2O6TZS[6'GJ->X8(\_9J%OU/8UWU?$L^P3CW:MH
M1'_O.)OU.:T_2%&_<OBOVOG-MLT*C>/>TV*F<AI /I'=C'005LYO9:M4ST\X
MU'> 5Y%-LT!6F@M9/G635V/4ZO%7AKH& 0W*1.FC[/I/^YY7O5J[K?$NEP6M
M3MRT=(BIRU[T%BQ"R(D33]J@>,RSPPF*K#:FC$@F>S;L8_MT.#H;,,3K&MT(
MY[L\E73V5I(;44TT;69$DO/B=GF2Q1F.".>5@>)'-VEH=8C/M<.^TT^UYI]G
M+:>;0ZVO7FVX_)3;B=+0K7^I_LI.];_]^5D\+2 D'7.&,@D'^W*W>/F7%.@O
M!(.JZ$".A'LI#WCYE[GG?IR!T6WBJ>QP[TU3G2J9ZDV+HG$[)3ZA ^X#99+>
MBMA(+W$@*EIB;A0-.ZW][)2(D-'^I(1D2[H3Z5:2R=5T*R(]GN-+5(+-E^][
M6>YPL&Y^W=N?CWK&N<>@4:UI+JL+YSJ&E3AFWW*K?BGF=N<&^A$T9=MSN=CN
M:"[P5-9PERDPB81,(F$42^3OVP?$-_C*#_T:^1LLNO?>_A'\7)/VDXA4:#X2
MW\I'ZM65M96E)3")A$PB81,(F$3")A$PB81,(F$3")A$PBXLZ*F="EPENR&$
M3(LB*M^(\J/*93(:6RIV,^G_ #,2&]+VMEY/^9MS25Z_6G-FNV.:X!IVN#L.
M&YIP<X<#T+3C!'B.BRT[7!V =I!P1D'!S@CQ!\1Y+77YE\:]'X_=.-3KQ:N4
M3:GYGXS:^'<I>YI2"U6N?00%JF4M3UD[).(%9H[1.-#H@Z=) UQN2-,78P;N
M4DC&=W$%-737>)J6I5=394KZBVQKNJ5]6U 7K<=BK3FKMM8@TQC(V/V.=;>Q
MLTY:^*K%%5:QPW2&SZKKE6[7O-KPW&S:K>AU"X+5ADT%:2%L^(J+6L:[876'
M-;)+AT==D< 80"\['LI*JZEJB>Q>)=&Z3'YC6YUQ_$#)*Y!:5;"_/KB$YKTP
MYSIR:U?0W->ADP\:K7(C55#"SDYD20=3-B!C1$&X5'!B<N)W[?#6JTJ+K\[*
MVR*.K+:KQW:LMZC%=##3EO4HY76*K+',B##(P;'2Q,E$<DL;7=>QHE^K5-J5
ML&UC())X668)+56.UM[/):K,>98&S;V!I>T%IDC;(&.D8TU+G 7(3")A%J)[
MEZT[)2O1]TI0CI%:K)NI=/X=3N0^59W-E&;3ZBY_T")0G[[T@+=-RDFHK0"=
M9[R%C$ZFWNM<]?Y?+(](CS(152&/H^D\.Z9:T.M:DHSV(K&GZM:U+B!EX15^
M'[E-UQM.C+5VF)QF97J3.CLD3W6Z@UE%S71@FYZ?HU&?2X)WU99635-0GNZN
MVT(X=)LUG6!6JO@VECC*V&!Y9,>;:%MK:I869.W;/G"IBPGT?S=P3K]JK%WZ
MAR*@WRVTW3#=</V:N#RA$?'B$4&8<%;TAI7W\;",-H,0AA'4L?#+)_$HL9J=
MO;^^K1US6-,KV*NGZE<IU[63/#!.^-CW.88G/ !]"1\1Y3Y(]KW1^YN<6=%/
MJZIJ-*&:"I=L5X9\\V.*5S&N+F&-SL ^BYT9V.<W:YS/0<2WHLV9RE 3")A$
MPB81,(I+JWJ>*:ZQU_GY>F2A5?Y@'NIJ+9 \TQ<+&;B\U?K$.Y(F\^!U-98?
M+>E6J&ND# !"XE[G!BRWHXX?.5$&2?2*-TTL<+-N^61D;-\D<3-SW!K=\LKF
M11MR1NDD>R-@RY[FM!(U+@ 2<X ). 7' \F@$G('0 $GN *C3SS[#Y%2.D>R
MSUGK?I08*ZIZ9&W^ARO\&/L&;^.U*/YF\YT!TKM@?PR7)&?1;:+:17W PR/)
M*_#/OZ8>QLT=,EWW5^'M0LTN'(H)M&DDHZ(^I:;[8^'F\JP=;UFV(\OU1H?]
MSVX)-T9>ST]F[>U[6P(;,;7V2YM@!\X>W[DM'+>1 S.!"2/28X8.#TSW8*J7
M](/YQ_<O2G\D7M3^W_.%[4]8\]'_ #EX;_JR]^V0^5C\CM_R%U.OB2^55'%U
MC4WOV[*V):/.5[7C/V3LXV#?F/#V3*Q.N"_?T"7I\=^"T15'U#<F,/1D/;>;
M6A/I[3M=Y0GV:7R3(8A-[8N'>490T/,8D]E=G,#"'%F=P:0[&""L=NK[MON^
M[&[;V2WNVYQG')SC/3/=GHNV_2#^<?W+TI_)%[4_M_SS]J>L>>C_ )R\-_U9
M9[9#Y6/R.W_(3](/YQ_<O2G\D7M3^W_'M3UCST?\Y>&_ZLG;(?*Q^1V_Y"?I
M!_./[EZ4_DB]J?V_X]J>L>>C_G+PW_5D[9#Y6/R.W_(74F_B2^5:R,?-62;W
MZOAHJXK<HL;\9^R1(R,Y.EL0(3;\^?P6/%97,GRHT**EQU*I$N0Q&:TMYYM"
MO2+@[79GB.%FERR.#BV.+B+AV1Y#6E[B&MU4N(:QKG.P.C07'H"5AUZNT9=S
MV@8ZNJ6P.IP.IAQU) 'F3A=M^D'\X_N7I3^2+VI_;_GG[4]8\]'_ #EX;_JR
MSVR'RL?D=O\ D)^D'\X_N7I3^2+VI_;_ (]J>L>>C_G+PW_5D[9#Y6/R.W_(
M3](/YQ_<O2G\D7M3^W_'M3UCST?\Y>&_ZLG;(?*Q^1V_Y"?I!_./[EZ4_DB]
MJ?V_X]J>L>>C_G+PW_5D[9#Y6/R.W_(74BOB2^53VR>@<WOQG84M+ &="O&?
ML@CL2='I95/"D]0^"O?<"T),AA4L=*^RF1DO,[>91IQ'U>DG!VNQ;.:S2X^;
M&V6/F<1<.LYD3\[9&;M5&^-V#M>W+3@X)P5@7J[L[>><$M.*ELX<.\'$/0CQ
M!ZA=M^D'\X_N7I3^2+VI_;_GG[4]8\]'_.7AO^K+/;(?*Q^1V_Y"?I!_./[E
MZ4_DB]J?V_X]J>L>>C_G+PW_ %9.V0^5C\CM_P A/T@_G']R]*?R1>U/[?\
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G?_\ E<6PL>!^,?H*H["PF$3")A$PB81,(F$3")A$PB81,(F$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g317356g85h82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g85h82.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!! 'F P$1  (1 0,1 ?_$ !\  0 " P$! 0$! 0         '" 4&"00#
M"@(!"__$ %$0   %!   !PL(!@@%! ,!  (#! 4&  $'" D1$AA66)<3%!46
M&9:8U-;7V!<X455XD96W-C=VM;C5(2(C5W5WE+8Q-#5QDT%T>;0D);-A_\0
M& $! 0$! 0                $" P3_Q  W$0 "  (( @D$ @(# 0$
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MN\QQZB3OEL;9X!DZ-R7DB<5LL[V<&AQ4-:EM.L:=8XW*3DK4JN4U6E.[ARX
MSI.!]WWR/-LJ.V=>T$9>_!\R@Y\HR-F%.LE"YV9\*;#Q]:V@;8\]M_AY9)<I
MPA6:[B=1,[9E*(OQJF1@M&6E]7JKE-5.2J5L_)Z7@SX=2MM7:/O4'?-H'M0L
M*!'<5 @JEZS(DARMH);LA-S"T'R2:L47BJN&-3E%9)&$+O'0R*&JFE:Z'QU\
M<FHMU3635U[X3X8[6 ISFS2#(^*<3SO(3Y,L>KV^.L:ISNQ(0Y&;)8XL R,-
M)E#X4QRW'<9,9RD2_/N/4*AGE1T?DQ@E+DO1,:MG1D.2Q2FFI.Q\K'Q[F56K
MFO,B#87YQ^S'VF=B_P ZYU5@ZJ[_ #9")*T!0"@% * N%KYGN!XPPYG[',I:
MGTQZRJ=#3&)\96MP< I$$>C.561Y8EYK5E3&*A&F?54Z9% C',F?1NX&4T;O
M!'HXIN[CEJ<K*IV]V#!.*S:C4-S(-CRK6?O"&.LT/D#PVLC5&T;DD;$4T>#X
MX5&UQKJ<-J=",<7C,9>SN6).^N3:X+'6SAX4<%3A)17ZRX5U2\I/O!YG+8W2
ME6\#LBUJ$WM1B*R@IWM$XR>XH)H. GQX,I\5O'$EF<X^WS949/ 8P/>D<6=K
MITT>6*$K>$@Q&E%?KZRFN>@,&GV2UAC^3->9Q \'+8@AQL[RMPR$E3-Q"A>_
ME.S2C;FDM*I#.4Q\A D= .LG366KHF[QZ[T.+-4C5MS2RN:&R<G-SG9/A\Y5
MRF"2T&\F$!M+M"IEBYPG,0?94^O;HX+8>QDOJLEX<(H\MQZN\FR!/92[!CSW
M$8^M''9#DYZ1RE!&&>//+R0SGC)01PNIV-56\,K;>5P-51[-:<-RQQ CUM"7
M&9 G5H7J,VBT?,4$("]@(!DOO9NEKE,G607*DN/8J\0?^J8@<<= =@(&!VDS
M>8N6'V3X/-X-7<->-X(EEV9]:72?X><6'"HT<'ADQ8Y-E,E,RLD;?\KDL[7#
M2'5 0@2OK\S0EGF#NR2IT.B[8J7-,2#+QHFX]Z2,S<2"R<G?S]N%7/"L$RRC
M;35R1/[I.T.!UK-,9B3.C9D%YBV/IJ&TEG6$'6 *I<UO-CHDUC WS]Q-FQ4+
M18_C+ 8J5GNZ!4S.:)N2%R3ONKLL^6SN[QZFW</5YKR2MG:/7962)^G,B?Y5
M=:2R/_AQA-VBQQE2)MRAE>7(YJ4'-^'XS)XA($Z\U8D?IDYM3P8:64F$X)Y1
M?%W/ODU\=O?6"H>PTGP_(5F-B\01YL9RD6+XB;D9:VMR]M(=\KKVQ.*9#1I7
M!.D&B:T9B=$2!J1D&L[<^CD86!S>6(YM=%6E/C\^>4JD"N]4"@% * 4! FQ/
MZ$M?[4HOW2]UB.SO]&;@M[O5'_4;T6^9'IS]E?7O\I(C7(R[7S?F6HH04 H!
M0&J3S]!YG^RDB_="R@/Q(<,Q_P!*X,[[!,)_^M$:Z='Q[O4O!<WY(XHUT(*
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * DR-&&$XBRZ<28,HT
MK)6MQA1I8A ,+, P;/" 86,-[" , K6$$0;V$$5K7M>U[5E]:'O\C2ZL7=YD
M<C4J#"24YAYPTZ?E]P(&:,1)/=!"&/N)0A7 7RQB$,?("'E"$(5^.][WK1D^
MRAP7JSSE*I<L4J5!825"A0I..//*  LL!1QI@Q&&E@ 44 (!B$$("RPVM:P
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M36-Q1V$I#G^2&4Y/Y7Y;6EDYRQD:7/\ "TJQ^S)Y(X&MZ^/JW-(TD+T)]QF
M6K$"I>G*6IK!%W@,\+<ZA3D*#@JS2V\:SO8")2B/46&-156.O1R$I?,)_.3(
M@K9!0"@/#?\ 3#"/VH-3?XF<3USZ7_'%W?V1OH^LN47]61_A/]3.(_\ +&!?
M[5::U!U(?QA\D9=KYOS+X135J32^-1B3MTHC9"*3M"M<5X0/N@):'%*VSYV"
MV/RY880C:B5"&#"4DO2HX#6(EQ.'<[C8W<)&7TB3DTZGI-*:SLM"4_G-^G(T
M9'@N8/4EE$:CUT:Y5&9@WP._A4SQ:4NTI<S78I(V-[>\W(5%&G!87E4&SE9
M(M&B#WX!(O4IV\;^1))M.M3JKDN>PEP]O/YWFZAU5G8T:>X':-B=5+H0WDH.
M_P#_ /$&2I8W&1D+0.=K7 *YK2WW&6V62^&!KE!31WA9UY2.Q](E7)RUR]Y<
M;"?/DBM[FW+&=R<&EQ)$F<&M<K;ER<=KV&0L1'F)E)([7M:]A%'%# *U[6O:
MX;VO:NBKK!%.,FHQ]RA9D*- 0:\JG5J+/,"(19)CADUZ2 -&$/\ 6$ L1UAB
M"'^M<-KVM_37F@<NDZ1W*-Y1(ZQ5P0+!>I?B2:@Y%9PCNTKFB1"+)FZT8"+G
MM_*;(B<8>@5DF+ ]Q$;+(V"TJ8DIQB>YK6847<T2LTDDSJND5C4NKBDW.UX-
M2F<Y78]\I>CF::'6[(0S3 !5Q#N93PX,@U'C,C[C9:TBC:5QO;B!<ZZ=(\2^
M-,!JCN7<_"SNF"&XD(3UQ5IJY_)XX/(ADD^KN13&Q6O5*(XA4%($"E*VFO!
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ME& O_2$PL81!O_3:]KT!F6J72MB3 1,DGD+.C*<0.Y:1J>G)O3%NQ9/>Y;H
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MEP4.*HM*488<86G >I,"0 9IHP%6"$1@Q6N*^DI)*Y)9 P54$1X;_19#^Q>
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M2=S)(=/!["H.2EDJ FZZW5BS3'*5<"DTF<EPPUJ>02%@O)U+C;3I$<RMS)>
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M6KFO<S#PKY$V "G#_7&68:9;^J4*LQ1)J2G:=.B5&)MM2E+C>L#]2E8** 4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M?QF9\H5V]R\D6[H04 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M.\HF+P_RA_=WV3OSP]NCJ^/+BX+%[@H..4BN*UK"&^\=OIM]]J <=OIM]]J
M<=OIM]]J <=OIM]]J <=OIM]]J <=OIM]]J <=OIM]]J <=OIM]]J <=OIM]
M]J <=OIM]]J <=OIM]]J <=OIM]]J <=OIM]]J <=OIM]]J <=OIM]]J <=O
MIM]]J <=OIM]]J <=OIM]]J <=OIM]]J <=OIM]]J <=OIM]]J <=OIM]]J
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MUFAX_:)=0)\]">,_R2GU_=J)J]9H>/VB74"?/0GC/\DI]?W:B:O6:'C]HEU
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M@..W#;_-4Q_]H.*?EQE>MP6]WJ@7AT6^9'IS]E?7O\I(C6"NU\WYEJ*$% *
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MG!(H&B7I4RU*(RY"H@D\L988'54[4;?0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0'';AM_FJ8_P#M!Q3\N,KUN"WN]4"X>H#
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MFGV4M=_RAA]><]4?7B_*+S9:VAD4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MH?VV!X7Q\M31V-0"2-[NS\V#6V1ISU!<TCCX:E6)EJ@\L(T)A #2#+!- ,0
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MSD8G /SSIG]F&+?FM)JY1V]WJSMT?4?Y+R9TFK!H4 H!0"@% * 4 H!0"@%
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MC?\ MA3^$#6>J[%R]6#H+4 H!0"@-?EDJC<$BTEF\R>FZ-1"&Q]YE4JD;NI
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M6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X
M\ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6I
MVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8
MZ; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB
M^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ
MX \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >
M6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E
M!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \U
MLB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVF
MZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z;
M >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]
M6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X
M\ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6I
MVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8
MZ; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB
M^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; >6IVFZ
MX \ULB^]6E!8Z; >6IVFZ X \ULB^]6E!8Z; _@?#5;3\00V@> 0W&,!?*M%
M<AW$'N@K N(/*RF(/*#Q\8>4$0>.UN4$5N.UXX$DW79\X [\Z_1).*-MV7GU
MU>);DC*45C+C(I3(34 U*)INE&Z-4+C2!I;FEGCL-8%+HN&WM;:W%*5ZM2H>
,9*X/TA5JW=1S!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g317356g87a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g87a01.jpg
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M 0$! 0$!          H+!P@)!@0% @,!_\0 3Q    4$  $&" H(! 0%!0
M P0%!@<  0(("0H1$A,Y>!05(79WM;:W%A<9-UATF+/5UC$U-EEYE9>X(C0X
M5QBQQM<C05%AD1HD,W'4_\0 &0$!  ,! 0                (#! $%_\0
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MDWTLPC[;%J%5CG[,K'J&LZE\$OM7M%_3FC>JU>A7:_+EV^Y%M;0QB@% * 4
MH!0"@% ?(?/D4HB;4U0Z434U/+#'#Z@?,@DR)(H6#R%,&C9LQF& 6+ !89"C
M#C"8!!!XY9YY8XVO>P'@2DS0^?-@)Y&5HV.GS0X!4L2*/IKF39@R:$L$5+@%
M@53,84<R+EB& $'AD(,)>V >.65[6H#)- 0=^62_K#AV_4]L/OM;Z&BP_?\
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M ]DG)OI9A'VV+4*K'/V96/4-9U+X)?:O:+^G-&]5J]"NU^7+M]R+:VAC% *
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MW9&^H6D^?D>G^G/<CTUQ_P"PIRAEM\ZZ5JS!'+)?UAP[?J>V'WVM]"5A^_\
MY_TA'T-!*UY(=V@D_P#<X=GOL@RN;UR>J*+?"/-Z'>OE6O9;$N\U$?J"0ZZ5
MV.?LRM?H:SL-P!>U^TG\^'Q[G9&H5VORY=ON18D\8SLM-\N[5)/J?.AEAGCU
M1U1484-QE:"/GPAKTK1W[7H]#CP?)Z%U%0P%(>;_ ,T9^L#?>94/0/GH"X=X
M9_9Q</\ [DVJON*8E##//+JEJS=NA$4 H!0''/3;1.>H,V0;[MD(]&OQ4P8U
M]Y&G%KA:;K<"N_9;+[I;<-_9D-3D-L*+)04MDB1JEM\%J'"1%UO6SF<1K->)
MFDTB7\',"3E54X[/_F+7]U\J8'N@>%@G%I*79@*[X<0LM)#E9;;CM:=8,OQ)
MBI'F0SUYV.9L-H7+*!<@O%J*NOIV*)+"P=A<1ULY?,7/'+&V(;7E'?NXTKO\
MD8,V9X#.O&Y6#+#V@VDWIFC".\G#FR<7A+<7C6;F3KLB8N+)/\ @\CT;JUFX
MAV-=;UO/XM+]#H<V?2'5:.."BNQSK<')1M,@I]C%-;JKL:8U[-QI+9N4W <E
MJ.\7:ER@27HI#AY,0P;QJ ,(AJ[?.2V8<(@:(HX!&TIOV$4$RX@8*D)_&E1X
M5JJ7;KZ_X;SZX\G>U)U$>ZI)&M>PV[</OE;:QUDJKE:<M1H$HGFHHJR*N'D,
M;(["9T*Y(RKMQ#/B8XA8B=>FE[V$MC;/'(1=I*5SHUR,S[ <&6--J8^$BG8;
M<O?N5X[%64QPB--T2[%0J7FM(W7^*U&^)."B@WA!+PHQU-^NZ-NMRZ6.7DYA
MQ3:=4HI\CE?,G)1M-")J';0HJ[&+)0]-33(33DY):CL(1&@X9'<^;N6VWUL:
MI76N8HM!-8%/"#Q51<BQH]?%(,VQR%+B:MI7UIA==O-L(DY,GH; \C-67(@E
M_<E@R2QSXBHTW@ARO'."LA* Q(TG"FB69F&# &(N9(Z:+7N(");JQ\_)S\U[
M"+M9M4=*<C=J1N%D1EQA.^+Y)WSXAKO8#^;RJTWBUE:8(ER3' W%LH(15D@_
MB! H(V14\4&%+CV#%#SN'G>V.>-_+0CM4OI&Z_#@<=MBN2C:9I<'R8H:V*NQ
MKCG<HV#8T7(;SEJ.P&LINK$0&Q,JN##1HA!!D,P[C7$RS6$_&U[8_P#W&/Z+
MBQ6TJJK5*WW;MYG5/Y*-PT$E0(JB<^-MRB@FG"R@0-!2K']A2QPF-@8*F ^E
M#N6/6 CAX"8<]KVZ6-N>U[>2AQVLW<Z4?D=2/D]G1^\6XCO]8H@_[ 4(;7\8
M^ARN.\E X9QL0V;$>>V@YTSF8,B""2K'_.,:&RS%RS$O\3V-N<07*^67Z+>6
M_P"BA/XT_+T,,:\<E%TO4X+B51V05MCF[/AU@MHS+Z$SI:CL=J),@BIH&3G(
M-X8&-%T(1)+*ES 9+,-94\,@,<+XG3%O_$N.NVE5TI2MU5NW'8J/^%R6BQBL
MZ,X]WVXA[48<?MA#9C,;"7,$28IK>:[:32R.A(I#$:!!A<2:8F%"Q,MB**()
M8$'"V>>67/E<5[5;Z1OOPXFC,J<F+T'F^0W9+$L2WN.^9&?2KFMNYW+4KQUF
MJKRL($$!F>/9EX9 !R&R! !#O<,$/'HAX_X:$E:S2HJ4Y&J\,<E&TR/X2I\=
MRML:BYDYH?Q")K-F6H[%LJP@6'(6CU:7^JC16ZMS* &2ADKA"731<,@P>FDD
MKWMCF).VGNIZ>IU4@/@VQUJY'9.)=?MS]_(KC@@IJBR3:+8EZ*0DHNJ+8]C2
MJ=#P.02;&ZX\8M84:]QKXWRM_AQQMY*$'-MU:BWR,&[%<G7U#VU?9*3=D-@M
MV9=?J<VB#.(NAURS&@JD6;"6H*RJGHP>1*$R8/@95075<V%:X5Q+"GQ[WSOC
M?&V(ZK24;E1;\/S@:.-;DHVF8TZS G.Q5V-*P$19,.&(97B$M1WDZUA]'C4G
MVFDBXP<8U,BA):,4*17FV\Q$9+P%S4UWJSBK<,3%/$OC2HL*U=;MUU/].C>L
M_ AU^TW*O CK#M1O5#!1_F$0V\@&A+<7@X. PW U0%#%/^'0<>OEDFA+2I@7
MZJX=K6.C=.V7/CT1!VCEBHOL?ULOP)( W')-%.V>VIWKF8BPC2P=9Y9WRY%X
MP: ;< 2< LCD? 8.(WQS4 4E.#,=9<2U\2@71MC>V7."M''!178YQ.ODHVF8
M,Z0XGM%5V--P(>9LQ#S2NJ$M1WBZD9ZD1HTM"Q)M@Y1H6%%35D$W*&3DS#1E
M7$+),1.L-I76864!/XTZ/"MV[G7_  WBUVY.MJ%J6^SDG:X; [LQ$_C[;4&@
M<=#4EF- E(PVE4\E*:@CB9'83. ^"&SZ(E&A;6"MG<0B#S9VM;*V0B[24KG1
M[\/SB9UGK@X1YM#'1^)-@-T=_93C=344I6/M!S2]%(J2:4D0UB>238N!."2@
M]Q2)O'$<"]AK8VSM;I8Y6\E#BFTZI13Y'*F:.2C:9$ HNO"*ML:M#&YHCTA*
MUG-+4=A8I<(F3IO&1EI"ZV-$GK',GD<2F:.$'=1%S%S$M@DGN:^&(FK:6^F#
MI=OW&T\6<F*T&A*0VG+$42UN.QY&8JL$NM%VHLKQU@JH*N &($$?(YF(9'!Q
M'P#&%PM<0$3'FSOSXWH1=K)JCHUR.BOR>SH_>+<1W^L40?\ 8"A':_C'T'R>
MSH_>+<1W^L40?]@*#:_C'T/\3'#N<)LN.4,\1'B-C%S((I<<+.88@Z(H(V&0
M8H>7- %K]'/#++&_->U^:]_+0;7\8^AR9</).N&\$WUP1MNK:HPX@T=3S02Y
MR5H_Q)CK6!(?)+!-97B,"UBPIZP& ][C@VL%EE>XH=O\=A-6T]]*<CP\(<E"
MT94(7B$_.RWLLAS>=B]@&YD16M+,>#-E'E4RU$D:0TMNBA1>L!"H2>[LU<HD
M"!JRIAFG@E\L%$[C>QD4==M*KI2E72[=N.P30X9(C!:;78K.W_XB3?:+*;J(
MTFJ@D)@B/$BB-QN)I9'0T@GB+ 8@EBJ:F$RI,O8003.P(.%L\\LN?*XKVOXQ
M]#0&1N2]\/J7'Z[Y0DF4]PW>_P!_.%5=CQ=*M*\=YJ;@<:V;$/*JL?R!AH$'
M(T>-C"CC7""#POGG?HX8VYK4)*UFE14IR-8X/Y*-IFH(K\$G=5V-0UPO-$Q$
M&  UI:CL8J?A C("V6A9:5KA1HL6P<RS'8:$H.0+(8D($KCFL!$E*SM<B").
MVENI@MV^E_\ >'D=8(-X/K'UIC1"AV"-U^(!&48MD=8,H+,;<O10&D)@Z^L'
ME]9%+8&X(-#VR4%E2/* _3'SM<<R)?&V.-[8V$'-MMM1;?EV-==@.3CZ;;4R
M")*VPT];JRO(@J,F-X1V.B68V%5,D5&\(\6)U\B<*% ?!R7A1CJ;6!Z5NMSZ
M667DYAU6LHJBHER-)F3R4;34Q,TXD7TJ[&$833R\77@=:2Y:CO-RKADXWE86
M5L72%C&IL4'!+<>"070>M24?K"8QC(/)1M:XX0E\:=V%>7Y^4WU.E.M? Q@K
M3Q$<S<UDVPWNAM#>2H36W0FM&7(N!+K2JGE,B)(\<L>@T[E<8N3SR #N'EAC
MT,K\^-[^6A!S<KVHM\C\G9G@)ZY[E9LL3:#:'>>:,XZQ<.#(R>$MQ@-=N8NR
MZ'DX\4_P"#R/1LKW;:%<UUO6\_BPMT.AS9](=5I*."BJXW'.U6Y*-IIAL,QD
MQ(5=C!=<#$028>?KB,2U'=GB1F4H[XN B]'2@+QJ$-FW%-FG)6.+@N"$<##4
M4M!QS5$_(0,JHB7QI4>%:JEVZ^O^&]VM_)Y-3M0GDL2#K3L3NY#ST<#9,LU9
M<+2EJ,PCZ@US:JDK9E%,9'H2.A7)C*J$D'L[8A8B=<0 O;.V-LL<A%VDI8J+
M[&7MA."_%^UK QBW8K<C?F68^P74YSX-5TR[%0J7BOI )TNFJEL24%$QO"28
M*B=#"OUW0MB9$Z6&5^:]AQ3<75**?(Y:R_R4;3,DJPGA#2KL:L))^:$4A.8K
MBEJ.PC")" C-?0ZXM-BPD:)=Q7, ]2[")E0@@U<6Z:>5<K)(V.&9LF)_&E?6
MF%UV^JQ[5-LH?Y,QHC $DM:8(;F+<J/I,9)LV>:CQ098CD-70S9Y-.HYL<EF
M9A@R!CF.F*)XEGU@(EK@F1+6M;*]LK"+M9-4=&N7"\W1DSA5I<QL!W19)^]_
M$+><>OU#/-IX-18F")<TM?05(*X)Y,/8@0* -D6,A7O@)8,8/.]OT9VH14J7
MI1JO(X^;$<E&TR3(7?Y_6]5V-<4WEDDOG'B*\I:CL!LJ"O=4(8& E<4:-4(+
M OBE9* N-\U8E;KPPK6$RO>P>8L5M*M[5.1GA(Y*9PU4%53%Q'?>W!!61E D
MK)9X"58^L.244XR$<)&P;Y0[EC84L9!"&#OECEC;/"W/:]O)0Y\:?EZ'43Y/
M9T?O%N([_6*(/^P%"&U_&/H<H5+DG7#2\"/BD'=M>,I>"FA"6(\JQ_8(4]U0
MF1;$:_Q0AVL'F8Z%A+]/"W1O?_%C^FPG\:?EZ&+(!Y*)I,I0=$2AL,L;(M^>
M#L<,XU,:&T99CP9K)$ECH)$1Z)K=&!C);"%12;@R/ETT0-85,,B@866)\U:]
MALQUVTJNE*5NNW;CL.Q>%^'&;)9T<,/?GB(-AC1^UF^R68VDV8(CQ3F\U&HD
ME$)NH9#$6 Q1<222D$"9 KB**()8 OA;,3/+GRN*]KRCZ'JOD]G1^\6XCO\
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MHY"254_)57G>E_5[.LU"(H#A]L=O!M?"TA<0UKYF(E#)0XP]##NO0R:VEI4
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MZ"\&_P G5OQB@VY^*7U/W'R)7"A^@O!O\G5OQB@VY^*7U/W'R)7"A^@O!O\
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M\;F0D4NMKRXL@)88N)$)56550# Q-J)P882>6/?4W+H1% .:UOT6YN?RW_\
MW_ZT H!0'_+VM>U[7M:]KVYKVOY;7M?]-KV_\[7H#_F...&..&&...&.-L<<
B<;6QQQQQMS8XXXVYK6QM:UK6M:W-:WDM0']4 H!0"@/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g317356g89w98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g89w98.jpg
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M   #  ,! 0$             "0H'" L&!0'_Q  \$  !! ,  0(% @,#"@<
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M:=0SS*RDVNB(0I\MUXEM?RZCCX7PUS+KCRD>=S4ME;O/DJUY$U=7K)' ;0U
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MHD:J L<:@+&H"K8 XV:ZMO6W-%\S[.V#SEJ?^-.X:D'$R:-JYJ(4F+MQ"79
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MJ\#<K&UN@$BW##X[O( @8RS=?(CYU_(B->U%RSQ?:N6:Q:V\BSVU%@+?72D
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MH6Q,VBEP04/$LVT:<-,S ,R;.4Z*9&MPGX6(TZ7)<DL1,T'4_+[L&*1=*]&
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LNIT>@V:ECA N57#L]I-C(ORQ:;4/#@9Y>$V6=A#'@"]R";GG]7/7_I@Q_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g317356g91y73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g91y73.jpg
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MHNC&!OLD,.)^RVG$*Q]L]<621O%(\4BE)(W:.1&%F1T)5E([BK @CQ&)4""
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MJMDU25+(;/'1Q$J'TFZO.Q$4;74=;(CQA%55J4_9 URVOIOLM^1<]WB%YD>
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M+9=$^@\I5M_66[+?X:AZD8V$W7,>)!B=&#%2N??\"?-7^Z5R._D[<NGKAO\
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M >'VN=ZJ<A!-AM-/TS<]:@\.,!UG:-<2RU.,B@$%GE1\180WXVX5T4@XYYB
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M_+@P)Z#\1!QWL]4/O=:XB<]+#1XMPMJ3N4'IVCRU4CG8]IM\]L^Q ;5(B!'
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M %5W(?\ ]ZTI_._7O6R>\/C^0X,9N[/?]6;P]_X5I_Q)/]8/,^I_+@P$+O\
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M17I=XB0 :!)";62^I9B2O:&PQ@&V^#&6NP1,VQ7%>[4:<NEDM=9UGL >KZ^
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H(QV$KPL,%@4S$;*3T>.PHUV%'18YTYN(Q,GYDV\MML-AS_7ZL&/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g317356g92e49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g92e49.jpg
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M,!@,!@,"B0RX/1M@W5-(1"EJY@\?B3J7;%#9[4$HE'$Y'0:3,(P3[:VB"O\
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M=QB9R@U&5,L_MI7[?>G8[#)@,!@4A\%?WLKJ_KO>\?\ .ZN#"SGTCVA=["&
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M(]H7>PA@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#2"$T2_5%0<99)RTT(D$;%3
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M*NF_INMFZBX9,!@,"D/@K^]E=7]=[WC_ )W5P86<^D>T+O80P& P& P& P&
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MPPK\<W7!O21B3R(E'#DB.AB!DVYVLU4DFGB+@>L@-T.8D!@]D][8B6I%H[_
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MZZY;&+=I$Z93YEF;6'?Y]NKS,_1%6/U O#<]SKDW(3T<X77_ !VJ US'M/\
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M2<_T9QSVJ]Z\4?55\(/XW3:VH@>O7T33-@51'Y"Y/*Q"">G;(\^SK3ANQ(I
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M& P& P&!K4?AD/B;@Z[BL4C49=2@LL?DSF/@A89Q(CKG_7!HZL.:ME"Y9?\
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M0*C0(=#D0BZ;H,E%F0QJVC_ ETDJNDY&<B4VFF+A-=;A=KI)7E937>N^@V;
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MEKI3E^5CW<[Q;OUM4V\._LRNO8M [WK6I2:^>]ZUK_4).=_W?Y?W-1W>]_\
M)K>_][6/ROQ/I[X?DV\._M*);9]<V#"O2;2CX-43BQ!Z<.\YS BY&"+8>'%Q
MUZVU:-=&77!.+UC*:^AS2N@-;.9P[<6;+8:Q.M.WX[1$,B/<ET>;<16*USK[
M5[M4:?%(\\%XH1F<9CUG3$(.C!&P^U8>TKF1]*56+AQV?N['4[&V6LT%L4XC
M&#Q9> 'G0FZF/3)J,)U>Q,'XR/-%V;TK'\UB*=^7%L0_W]&E+ DL:.5%:,<C
M$4:U<*E<D?)P=X[K^P;+O*W*#%Q.<C0\W)HJMBDVKZ-M8T9KI_839PG,=D9+
MS%PH0@3X)2WFZ)^_DL8;^(Q TJY>3P%6-GHI+ G"H%>8,XF&!K3AQ2S[T9&*
M[/+ Y?)I"$/2BBV["S6KW4;>1\2*.B(Q(S(:R%7<'9BEZ=^M*\;MT'^YH3HA
M&!1F!V%\I(#:2+4H -X<7B8L44M 9405P<1U-DIO'>3$U+)!PW<@APQ*1K")
M:XBZIIC$I Y'BGGITUWO%(/B 5J)E#Z) ZQNN>$QTDE\.<K1,+7Z+#4HA9OT
M&()ADG$OLF*=+++M_+]Q'FCM-+H8D&!#-%'PPO)0 D@*?;O3YC[5:O*?B/5D
MB9;16M8?*K,ECXO67 <('*UZ@ZDT?G%G4S7)MV,9+3G]9BAF.+7=$W;9A;PJ
MLAA[7;IX+-+QX<4.L12?.$3/V;];'KM]%:3B5S5I7;.9HRCN2-.(A-IKJ!2M
M:61EL:;]U#%P$=C5FR"=W.>EH(G#043AX4P&5=BCQM63_I YAT;)#U5GZS>S
M2;'P<DKM&*1;H1Z//P0VREO<BD1@9Y6N9G2%J<3&,[C0<=$2#N2%PI>%M1$J
MF21@&\>Z+.0!(5VR=%I]N\5AI8?XBU6%.-*.JMO*/Z>NX\!C?)L#7O*DNG4U
M U'*H!781(79I11M*9Q&KSK(N(<23D!$Q7[@6$S&3QB0!#H@<*>7MG6MM*,!
M,_B-P6(/*Z*DH?( $,D%AR2I9NG*]CV<YC=EL7OI.*1^&!!(,B?C!XP5L;S%
M+(JLX_=C:.ICI3$9;Q(>8ZN\?)"(SX17I;[358N"^I(1.YL;A;>,3R/\"1UN
M%&4MD8Z.HQ22M*)L1C5%J] EQ$H,F^%(I/GO8-1,Z""=%DF:IL%^IQYV(+$A
M3SG>/56EG\26O^I1742>!Q&C,G\_2"^)F);S4-J1PI?^' BWH553"-*\[)2R
M=%Z^*Z+'NF_Z4Q$)JQUXQX*M92ER*%)YWI;WZZ-YH'U]+[HLJR*E)5F&B,EA
M@>QM@S>Y!,G<9E,AJJS"%12Q)@1,UM&0,C!(RMHR>O2%42NU.X*T+L8O:G,$
MG[@?&R0F*=N\5>6#>R#@J%3*;^@(O&(R/!2+TV%"MJN)GI@X>M/)IZS!5F%"
MFY&(BG#/98?7NRL28M=N^W';_H>279]H\.%2[.[A7KD]Y'X@M3!CAMD;@MNA
MXG'90_C!BSGP2%Z@[+]+O$OYO?'NT6T^<3?L$A<PG]HZ43A?95=)^TDS82M$
M4"IX82D^<HGVGRU=T@?L:%V!/8K6 ^NK:#SV4L29_J.2 1#&KB.0D>"@$B0G
MLC>,9V2&-XV6865&41S88^*RG@KLF$*1L:7%NF7 IQCGZ_')$,?]Q2!0O:Q&
M2UB8[A5?6])*:",XA#K6=R68RI'T8+\V09L$F\SA,)\_$WTKF)L0X?BA=N.G
M<8:.GW1?:24<D2XX3&5]*]J^;WYU\4'S7MB1=M]R%RLG*QD0CC+9^FAW$S($
MV-HE>%1ATS;0R(Q;;813D]*+A;1D5?2Q5JQ#\CXZ]=2R*-C0I/E;99^L>L+4
M4C=P>ZD9RN(:J(-XC)(\Q8NU$GK71V-3FKZ_N"&'N1Q)LS)BEUXK8PL67&$6
MZ+MG(@YI/2>FOXN^A,4IYK,?9..$,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@8MB$##'A4B.$C6! XX1=FGK-DV;.RSENWX:H."+A%/A5
MZLBV3X124<=J=)IZ^GC>M;W\U>V7 93 J'8/H"JJ@N><?J]<3A8N+K&EBEQW
M(!%1EY%(16TAG%Q!:NZFG3B7LYLN%!R1G:14F]C$(D(^(B2CZ021\.$;<NF9
M=/7[51[I+X<L7#3-@O)J%9 Q^S56RUL5L%@\91X9(X],HV3KA'DI(7/,6A36
M,QJR!C.'!?TR&Q,9&K#Y%#0R0"5],Q?CY3^.SU*[\#&;/6?GR%/"+95-3!5^
M#,V"":%BZ];6!;!)X=D<<'2YR$+-@<SAUJSR.=R=HN_BIF.28\DRCLJAQQ(
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M$S$UTR[13AGV2E\/^O@A*XO5]TQ8_P 2.H MMV-2_FULJ,=C'$3"$Y\2N;U
MFV:D-ID&K(UZ?F<E@[)LY8#&_P"U*1A*@-EW'.A!4J2=-^<_;AEUK,UG2-#.
M_#TO$])K9;M)Q7L.KV8DK0,L 8R46;,P\A.V7Z1@-[*2%K K"'G4O.Q!NA%3
M*<^#TW8!.#V_/#VIL3B,0Z8L1K,M8F/2](TB;6I73.\>]*F\3*>C[IL/P;7!
MRNUG-+L?BDMI/)C J6,+&AW?KCFR0D9>3SE</^SGPQ:4VXQ=;>UG-[&-ST(Q
M'2R=@JADXYS"G):TBN_9_P"-/,K:5B[J=*O$TA+^@XI;@61Q(-&HW(*/+:CB
M(]\@Z_$J?SWZ\I9TT:\M6W+%+;MUZ)BKL7KY\IH!HJ3:J_;4V.2[,UM3S./A
M"<2^'K<59K^>)K%9A6,JF_G"O/&L>#1*4+R@#!Y\>\Z^=_3WGJ:<FY .CTC+
MQA@48^C^IK 3C2*R=\)D4.8)%0/2+OI=O(BT<%K%^,SWF)^S%6?X'],3@B$<
MM971K%J@T\TR9R(A1.RJ,@@.;47>Y*]9/%^:TK8(Z&VI%9T6(JC8[*[9D1G=
M;/71B6#:O-'3A'M6E8C*NL7I-IBG2>4<*MQG_P .>52^F3-7CII"PI U&OBB
M@US7(DETCRY]^RRPY%&'ZB**"*[G<0XF W]W\]J)]DW8KKH<HOSINIR-K_\
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=47[NR*@G?([6^]J+15&..EN45EU&Z))TY?>7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g317356g92p14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g92p14.jpg
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M ' ' ' ' ' ' .,)!A)E,)!8=$(H'$H1F$W,81(:C%1KGO#B#;3F%-_+@/\
MIE0G\IRN)+:8EQ\MR6&76P/O6RRZA33K3;C:_+"VUH2M"O+/GCU(5C*5>6<8
MSCSQGRSCS_/P![367</9;;]Y+:FDN^A/NX:4I*U-X<\O5AM2D(4I&,^G*DIS
MG'FG&< 5J^*-^BOJ]^TB\.O^+36/!JG%_;7_  J++N#(X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
MX X X X X X X X!6CXHWZ*^KW[2+PZ_XM-8\&J<7]M?\*BR[@R. . . . .
M . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M . . . . . . . . . . . 5H^*-^BOJ]^TB\.O^+36/!JG%_;7_  J++N#(
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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MJM$IIX61E(4V30095B1AZ.EI3<=372O]KY>J.='[N"_H[7W.)U' ' ' ' '
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M#(X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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MM65HY1HM7H6S<ID< < K1\4;]%?5[]I%X=?\6FL>#5.+^VO^%19=P9' ' '
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MO3\ASU"2WBY-R< < < K1\4;]%?5[]I%X=?\6FL>#5.+^VO^%19=P9' ' '
M' .N1X]O2GO]NK2M\V'TD[ [:(5\A2"-<WOTTBDX\^O;1HZAZXI8KJ^$_!>G
MMVOZ8E;9Z@,3,,7.*C,NJIBVYMP1<1T^G52G^I+&ST?P?S5QM<L!FP0:D(!&
M"MJ*&(U>&5H<,FS; 0/S)B!T0'!#1F'2,LO*(.-P8XUB,Y,?F+1&;94\K",C
MV2HF;:Y']1'P4>G?>W0FD:Q<^^79#9MNMTRC@:QKCK)+.0'*)H>BC!T&$$@6
M/Z7$:^X=A,B84,>J%B=* TZ$ER A1@XXL@,'CKJI;BE))9YO?P_.Y7G<',<
M< < < < < < < < Q&^7RH:QJ)R^7T]"K%0K<5$TX>(^]\,=%<D,Q&W7_8:>
M>SA<F0PPA+;3BU..H3A.?/@$88_B&=*I+N&D]BM?QU*'R2;:B$@F+9=AQ([\
MIQ;+Y(;$8>=<;CNIAQ6G%RY\CVXD%B3+>99<ULU:>AG:IU\\R(#;K\7_ .K*
M=K?4+6!6_3)LZ0%&[.O(8Y J<PFRAM;S-2J$%IJS6J6RQ(COY:)/UMV$MV,J
M6*E1Y#7NZ5&KZ>Y'7I?S+7S4H-O+6U#-PV20OLS$2_V2[&SEB<(1)5?E#[.8
M/32=L;G VXC:@;C)67,PL4S#2J*O#L3XS?LH:1T6[ YO&=;OKYJ=V?6%6'PM
M;ZCC$XP,R5J%#JD(<:89CD6HTIJK#Q<V?7R3\=,AJ.080M"94?$=<N"XE+J?
M0O+?.#Q>]OU.^GG0Y2\[,I>NHL63:SH\<J83KPUB([/'L3LXL=B'5J.2S%ER
MXKGT@?+)(F&2"?4T.%Q)\USU)BK1DDW@B-I8LC[=>^'5JC+>C3=H03I!G.<?
M3ZB,+V5;F<?E\D$!T)P(GS_)Z<O%&L*QG&4YRG\O*J:GE''R2.JE9SP\@E!5
MK&-N-9KUL#?*R(LP48?%YG1'X$S(\O"9GP\RH4E")$5_,=]O+K#J,+;7YISY
M^7GG+M8TKW,9UX4V25CVO.R:N$JDB'<CH^I(!&L&DEZ5'S'^A'IR\ISB&1G>
MN3[\-:6UHPRA;L.)E?L\KBT:7XD4WG6W HU)RM:[S[:!1FSQ.^+@"DD:OKJ-
M@FG7=?DR3[=RGP%RK.JBUJJPTTM,<HJ1E8N+$M/]O-<R7]"8S6.L.FG!+%YQ
M$93GV.4IU+&]LEGN6GY+E(MAU5I[7]A;U94HY@10S$<"8I6HA0\H:B&WI<.!
M*8F"X+S+CA2+\A,@J^0>5.RAB0N0XZ^TXG'.&VIM.#JE*.+_  =)25L%IYW9
M5CV\<*3NR.,,6NDQ\9?&,CWV6X0E-17EF(J2W>TK8?>=)Q\.(E3)TOZG\^!E
MB+#;QF/]&A^CZ?\ MX5/=K?_ ([O'OYU7?\ 41QX<_8MNJVJP\<#K'[SE+V'
M;M<0EN![N=6])*?5",=MLD18=4\I:T2$H9;CXF+EO)8B07'7GIK&)6?/M.\6
M3Q2PM@=4E"SC,QS=.D2.X5#6,;-M=.#P<0W7P82./?@$"0THV6&E9&)2/=Q,
MA2V(RF,I7EM.8[2L)QGU>I34J?\ BF];VLT_4E2G.#:M+ $JO610(O9BMQ(C
MT2$2;(<3'04)Y>F2)+:Y28J$,8S&:>;AM>A/GEB.UE>5.94K,;EMQ&Y9&E9:
MF4<@*H?&*V\K7W4>QTD;6=B&;5M)V/%KARE0S38FG?91NO6XV?MMA"3(<@+$
MC!8<MT;'5\EHM)8?1.C9#0R[[&Z%>=#%;M&OL5-^!/M+;)3LUL&IS)ECM]+-
M:JF$+,1-%#)1FL3@9P9]N2VGYLM^)'<)O$B(S,3+?R9B7<R6%8:&2L*U7AZ&
M:,>).WMQXT5VZM]B-D:&%>&GW7WL/U_*K\:/M?5=&+%J#;L':B M+CU>(1JS
M/9DM"G3C@*?E$M[VRHN<TK*%-Y;1R/330FD]NE;F[D</\HAV/_T/'B,?X:G?
M_1O!?]-?]RCJODAJ+[*;U\2/QG_#.W1 Z$=MNO%&Z^Q]L#+J=W#K2T#P,>(<
MIUJG-&)=C<K@T('A-OXC#&TDI;3DTG.A0H>'94EAAT:M116MJFJ8B&ITP.Y=
MP<!P!P!P!P!P!P!P"M'Q1OT5]7OVD7AU_P 6FL>#5.+^VO\ A467<&1P!P!P
M!P!P"!E?\,SI/5^XI_O>$T=6878ZPB?ARK.AO.0D$](7*29V&'JN<?0Q6RK+
M!D(%V"ZQ(K9B?#9>6EUB>:LLXV-;56SLS;3SL3SX,C@#@#@#@#@&+3+O4Q]O
M"T&:?'QKE8PY@^$KSKV<$2(@ ] CEIL=OTY1[<1TE%QZ%K0\^C$IV,V\U GK
MC(<3D)4QF>Z5<*E!,0J]-M-<AGR3OL#@<HV,CF)[_H4Y[,(8]*1-E.^VA;GM
ML,.+]"5+\O2G.<(SR$Y9E</=CQ(1W4W88G5@^A0K:?+TL;<LV C;(HL&'3*L
M982Z$(#FHCLYTBY!!RY<?*9T7T?+BOK8>89=2[NFF;SG[&:JH\]>1K&G^-7U
MN,5A4VSTW9(J^*-3AD36E/%8O9>?#8:C+@E89UQ%6KSS91;K[;$-N<J6UB*I
MUU'M/L*6V'EU\D;:>$O<E<]L?NWWLVR^XK1?2XH&#3'7,AR^TQ5C%X?@+7G$
M:6[-L!#7%>1(RSE*WVXQ,G$CO^ME$F:AOW'&S2E>KI^&2:W,+K^8,!WSI;Q7
M.P&IKA6;I8]* *86&06B^K*JR&S<[BU'*09[H]1\I"G5X*EAQA$M,J)>ARG$
M0?85[OOJ;>J=">?%^>V(>VUE>S7]^=2"_1_IPUN/L15%W>FTB_ZIU@6L,+9@
MZ'?Z'8X,&4U4K&S58Y$95[?++$Q;MP8$YC.Q(\ZOD\PID>2Y+@LD&TZJ<+>\
M/,N']&:5?"5R\9VE P.M5,0,!5X0#K0$6VW #!P\" '$CFE9]MF$,'PFH\.(
MA2E90W'BM-X4I64I1G.?+G$ZE;.X^^70C7.[C>L=@!!9JT BL,;LB]Q-8"[+
M7*0=FI3B/$MI[XKI>5(BH;RV7E!AYQ@"ZU\,O(ARV),>-M*J+/E,&&Z9NIU<
M$K-E;HL<BJTM?7D0+V'9-F*]RFGYL8A-UJ.'P5P)9&7;B@B5$GBDRA+LQ 9.
M,84X0C.)DI;1&=;7%3CM.(WW?#4KJPV;S@56>()L,F-V<#A[>D:]H,MH6414
M(F+ &3--T]DW+:'V"23FS&9[R9TM,Y#8IZ+#0*6R\YB/[T]]6>_TME)PWOEQ
M?-)>_I%^=4S=1\<?.Y.7IIK8.3I6L-N@96M"58.4"7'E*#ZYJ;)XO:8EE(1&
M+"[>H7S"A'X ^$D-E>)Z6)RHF9[L)F7*=RSSK:FI*9VL9M$=Y=_?75*P=HX7
MGS>26:I>X$T@&&E[C8S<(%N9,&;@U2P[;9BKMD93[E9^C>ZF'"R[#<C,Y(M9
M]]/QO9SZT.N/*Q-,_M<1AM8/68[?@U%48WU2,@4'LV;3=36-G(;K9.K1X(.M
MI$"%-THK&8>3*L_U-Q]3I#U.9S*S%GM-Q?/*FGEK9CL>F2H2BZ<S.*T_LK6-
M[1TWG7 TIW3TTWVMJ4HEO,Y(<-;2@ R5S5 ,#H]B:GV%D6Q)L10BIL)"JQ):
MHSIB3**RAHP-[K[#CS<9ES'IJ:=$*F'%EDN%I[*YR3_5CGC\^Y>%-[E]#]:/
M&WT=A^O >89)OF;"FKWBH%B!(P_A*9,\K&JLLC-DD7L)Q[KLEI<EQ7FI7FI2
MLY\\5.)EQ93-NN!TFE9KE_11EV+\:@H W;L$/J/477#:>N!YAABJ[ /U.UOF
M;-!2,@*>FS7WRP9QQQJ<J7#;7],CMY9C-Y9]]GT2'MJEV_4UN\9AU*_Z4]_B
M.RIJ39->W%K"@[3JBI*JY?ZH%M0?$R&^/E(AEX+,M#3\.2E+K+C.7%,JQ_7:
M7Z/<CO/QUM/.<CHKI,ZRWBQ=\^S%3[(-T75A/>?7JL4D00KV7I+\VK#MID(E
M@))>OM9;9;]@M5Y$7$.('+-S)*I+32\O,0'<+C\ZT)1>'T9SJJ<VE1;^S?G4
M%KQ6^X77VBE(O9:JZ;U)*S8A;6S98*3:=Y7MF'9S$><4>?G1W?-L;/3+!#9X
MRS4J1F$(ALXQ+RB1-?CV4W:7:V"\ZE6TTKPM<_.A:-U.Z+ >L-GM&QR6Y]S;
MOVI=P+5>M-PV?:Y!*')A-$(Y/'TX$M<IR.]\N,VIN47,GY\1I<F-!F18\V:U
M(RZIM$+0TJ8O,O4DONJCW38^MK#3=?;/(:=M1GZ:B!L 76PUMF!V(I:%,)1T
M #ZD"YS1D;'EA9'R%IRPQ/<D-9RZTE*L]RNZQC>1=Z1]++#TYAV\(]O&1M"K
MV9S$^& <U=4*'@2=D%B98J:?+ I4\N=D3W":XS$<I+7&%0F688YMF&S&C1ZW
M.*7?Y)33LS>2>W(:' ' ' ' ' ' ' ' ' ' *T?%&_17U>_:1>'7_%IK'@U3
MB_MK_A467<&1P!P!P!P"I6-XTW2V5.BPTR-I--RSZ:VV0?I,-H>DEE;*%>Z[
MFQ9>:BMI?;=<DJC^VEO.?+S6E2,;V*MW4SMTDVK+W ZNU(A*$&=\:SR8@M>_
M-#![/ LIF$UG#6<*EB:VX6(QO5AYE2$OQD*6EUM24Y2M.<YV:M'T@KJ2S]RI
M?N+XF>UQ&R #/4FTTDEJN/3<R+::M50FL$E6]!([ER.,39VA3V!Z!30)Q3KT
M)J/ZG9?I?RYC/L[IH_R7?X,55Z=?R<'UE\9BV3Z?'#[PTW?-D;#D6R5#^[M.
MUT$O6D0%(CB_I[$TM"/DTI*0GW9KI/VX^4,1WH:5J]S#BL'1>V&\*O"5?=\$
MTIWBB4B/(&086@]^DY9IMY4.1%JC#H0:XTGT8;M!*+*ER@WO3$NM,KB"C'G%
M2W/6E#3V$(?Z;M=7WX%V[8/SRUKD?MT>)[M212KQ'H&C;WK/*Q9%@)M(R"L1
MI^K>?]G'LDFN$]<Y *=CX_MDP"<R7!]2VTN.OIQYK*A3BG&/DD==6D+)M>(J
MAZ_]Y.W%$W;3G=9;&W)VGGVT3.?)ZDL+QFS#=A^LE:</3(KY9XP2II ,^PEQ
MM^K@8*U#J_%&/2E!GG8[>G33&2WV1E553:^[$N'!=D/%:NA5VT .G06K0'QS
M(5C6=[L0*$/A24O8E.WMZU$R].-OR'$J^E9K#;F6FXR/EHCKE9R]S,49U<U_
M4FYK;PMH_EP==.YF;2]M;<4Z]WZ!5+3'W"9R;&1@]AD8$FRAJYR3=;5$)(0O
M/S)T9.(#D,V9S&CC<LQIZ\R6GIG11EAZG-MMW)_#O#)[A6H21(A0A0$44"2<
M SB-DJ(*--ES(KLH8VW(C2B!9N0^XE&)+7RXDN'AU.9:F%.(PK.U3KYY_1=F
MK3SKZ>I&O97AS=I.N(VC[*VI0Q%U#65Z<DFY2CADN2I$V1%DH8$VR'@= 0F:
M?2YGV)D+)B"TOU,2)[$M/LYJ:;<9>6W$::B?/$7S^&/H3<^E>JUMB3-;5#6-
M\N)DG<]<LV60X6+P8)Z##CPA5RD1$2"D:'$;%1"$2&MU;S#I:2B2-;S'4V_B
MITMJ6VLTM-W',Z4[4/+2>_D&\SNB.[A@Q-*Q>W(D%'(O+F)""]>P<#0N7\)<
MR*&J?0[)DP("E+B19DQW$V4PRU*F)^4^\E&9I_Q[B*_\ETGI)%[?W2GQ#;[2
MKF&#]V/N$"5K!)J?K!RN(K?WW*RB5(>KBKK&?9GUJ#8D>P%<0S(:%,LK7B4A
M$)^4G%3IG]OOV#IJC]TYK+OZ<N44O"^Z?]C]<]D:Y>;KIJQZ=JM(IMD"V\R?
M,S8*K4DN+,"A]"%BL27,V2#&.2AMR4=:5*!QW <;VYN2*AV%6IIK&?.Q*4T\
M(\[EUUYZCZNO.IP6FW9]VKM3KML^\AK]=L>$G$ELY,Y<0\1-P3:'8;F3LU7L
M9BX6VZF.^TZA]M3CF=IS.;272/A&ME1&6/G4JRVMX/>R+)L27'UWO8& TV;F
MB79JK*$D%-E@1^$K39!\;,8=BO6MXFYGWX1"9*K&8J'/B2HDS#3LJ;I5VNK[
ML#+HO9VWXF[G? ]Z-+].6(.V(3N,8_MXNQ7<.Y5C'EE?^<")"$J5G^MG"$)1
MC.?)*4I\L8FV]W?Y+L+?V^"./B">$%L+=!S3YWKC:0:QVO=45734NL[/LYK!
M%@+3911P$>A6/Z89R26_'+OLFH,EJ#EAZ*U*&)DXFNPX2FI*9UFWH2JEY7XN
M_<V+J?P,-"A]=U49MK8>V3U_8'Y<M;]&NC "CY+29+\IZ-7!,ZL22#8V&EY$
M1$N8^W*)N,.%'H@Y<S(^*VWN\YEV%FW)L3'@==(E9\Y7X8Y^?^67L5"LYS_R
MYRR 9_\ YY<;;W><QL+?YR-]:'\,'JEUSL5AM6N MU:-V:DV'7Y*49O!4BW]
MN6AN.T899B(Q%B?)>;C-)9D/LR,QE)P\PA#Z4.ICJ;C=<JI2W\2CK6/@?]B0
MV\Z5+V*&UO:M'#ME"'+= _"*1A&36MF+ U]33_O0'@3VR4FOI<<S&@2QS[LG
M/Q69H_+F)3&W6LIGE\F%0[3&\OYK?AP]%ZK[?TOJ_JF5[?EZ?N0&NY>?E^;W
M/N^2<]W_ .ON^OS_ +_/F-JK4WLTZ$<MF^"]TKV=L AL!X7?*.HI,Q,FTW6Y
MJM52A9],.-#1$@5YJG2E!(*$QL/IC 9HQ.9+S[B\J2O"$W;>XFPMY:B$"BZV
M%$5T'"CC0H$6/"B!T5M+,6 +%Q&H(^%&:1A*&H\6(PTPRVA.$H;;2E.,8QC'
M,&S1VX^J'73L$8$G]SZDJFPS((:L.((GV):Y,$8Y*<FKA,KBRXW]AF6\Z_A*
M\+]+CCF4YQZU>=3:P9&D\4;/UUKBC:DI@37FMJR-I])KC<QH'7 [:VAPUL@1
MF%IN(Z'7'7,?*)3YLUY2W%J7(DNKSGS5R-S=E2BR,VX X X X X X X X X
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MM7"Z^) K[+K.N]:P*F,M+KIITP*%;F^?DSJWK8LYX(. . . . . . . . .
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M'B@F[I90Y_:%JJUUI-!'4*H:KWMLFQ;0J-F,U-0;8==%O:),B7F@9!A3PDI
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M\,N136S.S[Q3@Q6JU3SMSFI@"U,[ +BAK44$;='4^>S%OQ2)4% TT_%G'G7
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M=(LU=&:UJ&\:E=-7ZR W[7^V* =U[$B:W;9D-02--W%;80Z;<S)V^"1<4 ,
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MD-=MCSZZ<L'8S;]XB!]#2_#;-BRC[=;F6^\$5&'^[R6K,Q.%5$_L88=:B7
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M6JOMS6FS;+MZU[>,!*M5-0FZ-V(L5)EW+:+G9HV[>]ZJJ<78(%^Z#]OZXL%
M2]I2IA;TWUZBU>W4-BG4?1]A%7PN"C&T8NVY*(YXO'%W1;KU@ADDSNRYU+3\
M6C6SM#?2VLX3R%L(9""*EKVDWZ;#BK2E3,&R[XJ>W[?$D)3[)IJPXL45Q^*8
M8D/"/+A?SA!*?@@X X X X X X X X X X X X!J3=.WQ6D::FZ&*K>+?$47
M@AOI=!!-GS+;LYJ6\B9(C/3A[$8:UB(II^8]*0E,E^)&0E;TIM.:E-K<R-PI
M]#X-';O#[WK9.S!:?L"FQQ9A89R%L&OM )\IY$2-,S*'IC$"<:7"]$I+2G4R
M4NMR&W&W64)]M;AJ-.03G)\STD-W0H&\0^D\TVZOR2M6(V+-N9KQ5=:8<AR0
MC349$Y,)463 PT56DH<1+3!#%$0 \GUS"6,146F5PGS^Q-XOYYB<UN7;0S2U
M+=NY>L72VPVB4 9D30PB#QO#D_+N$2G(KTT?'8@,^UE,B6_*;0AQQAA&''I#
M3:B4N W"GT(MW_NW#:ZN;BW72=?[*!VRL)AT?7-7O%#*/E+;MR^S!=1U:)$5
MRHKM!NSPB5[L]=@$H%>A$3R8JY>8HF2YB.A\U&C?FX4O:PMO??H0MC=ONR>R
M4:'UM29?8 ILT&CMG2MYC]3ZLZ_ZTV[:+9H8GHS&L;\>H'=J/0:[KVM[2UGM
MBL;;GU*$T"L3"-FUN(&9^A#I$IF&X5\,HF6KY33IAR>9[-?]V^R5I=T/:R!Q
ME]S9Z^LM/BA:UJYJ7H HC;&BAQW:NQK3=IZ8M[J5WH>Z9=@<$ZN?N5?(OZ=J
M@VP?9QX59BNQ:@$*^43QME_<.\Y')G.P_;9P!71NI[Y?-VA-D['>':LV-7Z)
MH2F[0VR"IV@=DW#9-BU##V(-JVD?P%M;<&ZPA4VU7QA-MN&O9>PI='L-ZB/Z
M[V :><1&-DK;[-OF\.4XWL2_MW;FYU/JGUNWY6-5F][DMTM=5_J3VL$UP%6X
M\;?-PU-6YYJ! VI>-?V&'',1]@RU4"!+9E28ICZ0Q?55P.DL7BB)7:=HGLMT
MF8;TV+L69:^L.JJI8#6AGNP!>W9LUTD":$?OE2Q3-<3+TG6578/LW[5[>S#[
M[4E]XA.&;$ 1ZK1[^L*.)OK'6,2"S>,<;_UTR(MC.^EXU5:!.FK\$%;H-FNU
M%IZI:]V_'M=5UTU<[$+3I\S!-WT!%#+#AA];%[.LNOK_ '2DP7!$K>6M8>MP
M>OPMIVW1ZJP+'I/KSWK=?!2;I[*[GW7!NVU=;Z4(B0MBHFGNNY<9DK.H G)V
MW=J>Q-FU(!G#3&REL5A@UKZO:?N[U<K<YR6U?K3>@0%D.;+Q1 >>(O.5_?$\
M:UV<N-7ZOQ[P\ LFT=KA.PE>ZS' FS;'0Z0^_LFV=F0'7YR03N6IZ)/IF:=6
M"-MB&(AFKT!\N1JPIN,5KT2[K+C(H1?ORB<_GG!JZO\ B);'*$:A5RG76H"+
MIM$X:J&KH+.^RA"KSK;1=W'-&[(9O]H<T8/E4FN0#E>G&Z&:#5R]E;R*D"AY
M*LTJRD4A&HK^:?V6%.+PEVW3J:GV=XD&Q@P"J;A@TPL(J&N[+/J^Z]5ZXBPM
MU&KH:D[EWIK2*(HUD9K029)D"H766RG,RX\$!%:![4!ES>4#A+95FA).>V"O
M;''7X)+!>Z-RN5_IM#A:ZI8VIWC; KKK-VG4=WQK.6K^TS_4.3VRQ8J'5"VG
MXX#8.MX59='!J[;2)X,5LD][-B<ULFFH9G$0C/2\1EM1>Y*3K5LPQN#1.L]A
MV./"BV@[74,6QL8VXR(7;@,R77+7)!M.NR'D 9EB$$I8+#S[SWTA^%EYUQS*
ME9$>/F=S>7!!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!
MP!P!P!P!P!P!P!P#U989R\F3EEK,A#3C"'\MHR\AEU;;CK*7?+UI:<6RRMQO
M"L(6MIM2L9RA.< >W@'"F:W7;$H0JP 0IU5?-0[(!49%P2:@EB'MR&8!X1F:
MP_D::@M2Y;4,I"]F=&;E2$,OH2\YA0&I=@]7NL^VBKAW:O7?1>S#;TKYSQC8
M.I*!<RKLWZ6-"?+<(6.ODI:Y7T4,'$?(4]EWZ6*&P/7\2#%::%EK!M<S[I/7
M+KY,+0SLS1>GY1D=2\ZX@%)&M::].A:^R#(5C-&BR7 RG8]1^VBY:N8KK2DB
M$@"I,,F)@:0F1GA#$H/33J"+K$RE"NJ_7(33B)0<<GU45I+6HRNS30D>2$"R
MTL+!K4<=()#Q!HR)AS7HZY,<48*C6G$PB,UA\67J^I(F#!A#(4,:-AQ1PX=%
MCP1X^#':B0H,*(TB/%APXL=#;$:+&8;;9CQV6T-,M(0VVA*$I3@0Q2_ZVUYM
M>N/4_:%%J&Q:I(E0Y[U;O%;#VD&N>.>Q)'3\BS<.;"Q/'24IDP)J6<2H4A*7
MXKK3J4KP!C$3K_H> $'5J%I34D2NB*T[3!0&-KBG,AAM/?/P;6_58 QL,F%$
MK;]I&#;*\$89;&.V ?",N1E$8K$EL)/&WZ+UK?K7.M-QKH^RH.Z]DZPN%5/#
M0YNF7NJ8L<*U (]RKY@9/9,OTPR@Y(J*U.LL"OO*VY=C2W24=V"$F1"=6:R!
M5$)K\+KNCB:)6B@DW7:8.J@*'501L#98]T!F1 !B @4.+A[C$BVT83B16IT&
MSQF#\9]HLTB6D#5^V.K&GMLT:=19-7K]/BS7UO?5ZM0=5$)K34R^1-F'ASP7
M8- O5&-![7>(B;/:!%EJ!L<8L:_N=^,FT1H!N(+-Y^?8^K3'5[2NBM>5G6],
MI(!\363GW>P3+UVK+,3[TIZ;)>O4K @"&"C[-E\E/Q!=K@8$-KT&3]$JXP&!
MCPQ<<3$U)_0#T5%W;6]Z5YB33;%18RV]<@J?2M) @6NYB=5&M.P)%2*Q]2YV
M#'#AZE8C<D5KHG>2FI8UG(NV=6OW3#<>2R+M.(UQQO>=8[$K=?46MZOHM.UQ
M3H2Q]4HE9"5*NPW9#TR0P' #HXR!B7-DJ7*GS5QXR')I"6X[+GRUO2Y3KLAY
JQQ0AF' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g317356g94e89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g317356g94e89.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X4U.:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*
M(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*
M(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]G+VEM9R\B"B @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+VUM+R(*(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @>&UL;G,Z
M<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(*(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N
M861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B"B @("!X;6QN<SIX;7!44&<]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @('AM;&YS
M.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM
M96YS:6]N<R,B"B @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @>&UL;G,Z>&UP1STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(@H@(" @>&UL;G,Z<&1F/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @>&UL;G,Z17AT96YS:7-&
M;VYT4V5N<V4](FAT=' Z+R]W=W<N97AT96YS:7,N8V]M+VUE=&$O1F]N=%-E
M;G-E+R(*(" @9&,Z9F]R;6%T/2)A<'!L:6-A=&EO;B]P;W-T<V-R:7!T(@H@
M("!X;7 Z365T861A=&%$871E/2(R,#$W+3$R+3$U5#$P.C,S.C4U+3 W.C P
M(@H@("!X;7 Z36]D:69Y1&%T93TB,C Q-RTQ,BTQ-50Q,#HS,SHU-2TP-SHP
M,"(*(" @>&UP.D-R96%T941A=&4](C(P,3<M,3(M,354,3 Z,S,Z-34M,#<Z
M,# B"B @('AM<#I#<F5A=&]R5&]O;#TB061O8F4@26QL=7-T<F%T;W(@0U,V
M("A7:6YD;W=S*2(*(" @>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#HR-C Y
M0T-%0T)"13%%-S$Q.$9$-T5$-4,S149",44R-2(*(" @>&UP34TZ1&]C=6UE
M;G1)1#TB>&UP+F1I9#HR-C Y0T-%0T)"13%%-S$Q.$9$-T5$-4,S149",44R
M-2(*(" @>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/2)U=6ED.C5$,C X.3(T
M.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X(@H@("!X;7!-33I296YD:71I;VY#
M;&%S<STB9&5F875L="(*(" @:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4]
M(E!R:6YT(@H@("!X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#TB5')U92(*
M(" @>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD](D9A;'-E(@H@("!X
M;7!44&<Z3E!A9V5S/2(Q(@H@("!P9&8Z4')O9'5C97(](D%D;V)E(%!$1B!L
M:6)R87)Y(#$P+C Q(CX*(" @/&1C.G1I=&QE/@H@(" @/')D9CI!;'0^"B @
M(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CXQ,#@\+W)D9CIL:3X*
M(" @(#PO<F1F.D%L=#X*(" @/"]D8SIT:71L93X*(" @/'AM<#I4:'5M8FYA
M:6QS/@H@(" @/')D9CI!;'0^"B @(" @/')D9CIL:0H@(" @("!X;7!'26UG
M.G=I9'1H/2(R-38B"B @(" @('AM<$=);6<Z:&5I9VAT/2(Q-#@B"B @(" @
M('AM<$=);6<Z9F]R;6%T/2)*4$5'(@H@(" @("!X;7!'26UG.FEM86=E/2(O
M.6HO-$%!45-K6DI29T%"06=%05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$
M375-04$T46ML3D$K,$%!04%!04)!05-!04%!045!)B-X03M!44))04%!04%1
M04(O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"9U5&0F=K
M1T)164I#=V='0F=G3$1!;TM#=V]+)B-X03M$0D%-1$%W341!=U%$031014$X
M3T1"351&0E%417AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%9
M1VA54D92;V9(>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G06Q!14%!
M=T52)B-X03M!04E205%-4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!
M05%&07=)1T%104A#06M+0W=%04%G241!445"05%%04%!04%!04%!)B-X03M!
M44%#07=11D)G8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!
M049)4DEX459%1T4R16EC645537!':$)X5WA1:5!")B-X03M5=$AH37A::3A#
M4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG
M6FA*4D92<5,P5G1.5DM"<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:
M,FAP86UT<V)7-799,U(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO
M*T-K-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]2
M04%)0T%1241"455%0E%914-!341B445!06A%1$)#15--545&55).:$EG6GAG
M6D5Y)B-X03MO8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-"
M,U!33F5*16=X9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP
M*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q
M9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:
M;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X
M03E5-'$W1EA9<3=&6%EQ-T9867$W)B-X03M&6%EQ-T9867$W1EA9<6QT+W=#
M671-<V)V-FY..5EK=5)'<WI2,C%R8S-25DA:;%)M.4-/44QY36)5<C1(1E50
M+VDW4W8Y.&%J+S-#)B-X03LY4B\W2CA64T1Y:W9L+WDQ2&9*8GDV-65#*W5'
M=5=.-5DV;DU9*U@W169+1%I186YX>%90;3@T85%I;&UH,496559::G!M;V=!
M1'%3)B-X03MF<2M+<'9B,T5.>&)X6$5,8S1::U=33GA55E9H54AF>$)X5E5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6:E@U)B-X03MG
M5U=U6&UH2D)O83-",44S34IJ:W1P:D%9,55K<SAJ0S1T87!X,G K.$932WAU
M359E9%=(;&HX-# T;31N=C)J1G9%<W-B86=R3WER)B-X03MY1C=%<D-B864T
M:TEE0U=O16%F1%9/;498;U=M6&9M8E1,8GER<"MP0TM:-W5+3S Q2V534FYU
M0F12,F-S>FUO<6IF1D)1='DS<6-#)B-X03MS;WA6,DMU>%8R2W5X5C)+=7A6
M,DMU>%9*8E0O04I44%90.$%T;F%D+W=!;C<W1E4V>%8R2W!6<E=S-F):<$IA
M,VE89D=726PU3&5Z)B-X03MU<FA!:E95,6MH:6Q1154V13%X5E0X=6%T<$YX
M85<Q;'!W=3)H9W0P.4=A-'1,;4)(:5)65E-*6EEO;S)*0D(K13<Y855X5D]C
M5F1I)B-X03MR<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U91=6]A
M<G!E;7AX>39J95%756,P:7=1=F-32D5R>78Y:4Y3-5=R3E1:4G5C)B-X03M6
M46-F;2]Y;$MH:VHQ=7=D0D4Y=U=7-FA)14U2<$I*54XY:$0Y<'5G>%91,6EE
M1V4O=T1+.#A%:7EW>3,W=D9+:$1+>71P=#)66E=')B-X03MX0DA1-'%N=4MU
M>%8R2W5X5C)+=7A6,DMU>%8R2W!,868X<&YQ;B]B3S W+T%*4#,R2W Q:7)S
M5E$R<"\X8S(W+W=#34UN+T54:7%()B-X03LX=&8X;S5P6"]-2&(O=T1*<&-6
M5$A&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T95;#@R-DIQ
M3W1A5W5N,F0Y2%I2)B-X03MY5%)T92MR03%W2G)D1S500E)*8F-Q2DM"5V)L
M.6UO<'952W-+:2]*85I0<2],5W=6<V]O23=#15<X:&IH3FLX<E=K82MR8U-Y
M=$)')B-X03MS-T)O;FM*8F(T;$%P:%90+W=$1#0P96)Y5EIP9'I3>#9F24Q)
M4FUG:68P=$UU,3E5<%%S1TY0-7%91EIH:7)S5F1I<G-69&ER<U9D)B-X03MI
M<G-69&EQ4S)N+TM:-G O,GIT3R]W0U0Y.6EQ9%EQ.#DO-7E"6FPO2B]Z1WEK
M<6949S-'>#-U;W-69D1N<GIF-SAB-WII>60V.#,K)B-X03LO1RLX-'$K,R]W
M1&Y(:&UB.&Y03')-4W@T,T\U,T\Q-4YI>&5J67$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$X=3!38GIP)B-X03MD*V5:3&$U,&TW5T-Z=75'<#8U
M8F$X,#ER0S-O3&1,8B]O*V$S=%DS5FQL:E%S:T911RLS54A&5V8K661D:C!4
M5&IQ13%R3F17-D]Q)B-X03MZ+U9Z1GEJ4FI4,4-*6DEU44)O3TMC;DI0=W%C
M5EEJ8F9N6#57=4=6171,.%-/:TQ2>'1(0T,P;#!#.7!!4#-T4%5U23$U;T1S
M0CES)B-X03MQ9'-65&EF5V)(5G!02C$O87933RMU9G)5350P16=J;#!Y-UEC
M;$)04W1$-S1Q>6I&6%EQ-T9867$W1EA9<3=&6%EQ-T96;VEI17)3)B-X03MH
M1D5R<7%024%/4E934V]*-C!"63 K6GA69&ER>G8X035Y12\X:S<U:B\T>'=F
M.$%55D9I<C1A>%I/>%8Y>&8X-#=F*U-B.'4O=T-R)B-X03MD9CA!55I.:7A,
M,&9&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6&DX34]I84(K87,R
M<38Q<F8Q-C1A-E<S;'5P9$E%4FAU)B-X03M7<T573T4S-C)->6UT=E-2:$AD
M47%O<5-T3U%+<C%F6%!,*VPV-4)"0G%+>79(8E1X,V-):&YN='E*;U1Y:EET
M03AB3GAB8T%M;&%()B-X03MQ0FEQ5%$O;&0U1FA7:V5M8V8S6&]!*W9C8V=L
M4U9)8C%+:#0K4D5B:C1K1WEK1&)&5EA59$DP>7@Q2'EL2&$R,&-1=$QO,FQU
M=U=R)B-X03MP0DAP=#)&:D1M<F-25'AX5FMU2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMV3R\K8VA0+TI/*UDO.$%J2$(O,49267$K1W-75'-6)B-X03MF
M8U@O041J="]W0U-B.'4O-G0Q+S%'5%ES4SE(>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8T4G(Y-UIZ+T%*;UA-<C).)B-X03LW<3A-;#AS3#9$
M1%!A2DA*13%G3&,S67-*-W$S=5)C:68Y,%HR:D5F;T1R:%8V.35R,5<O,'93
M;W)Y>5=)>4<X<V]*5FU6;4AP6$XQ)B-X03M(0DIX-$UL1T-Y,4)R5#)/0EAM
M5G(K8W9M95))1F505#)L3G)'.38V4G,P5G9+.&MQ5'II4T\U;6IM=&)0,&Q%
M:F\O>&-H=6A&34MS)B-X03MZ:#$V9E4O.$14,U9T2D1D,WI*97I&63(Y0E=L
M,'4V3$E(3F%'<#)5;71-0W-Z>%8R2W5X5C)+=7A6,DMU>%8R2W%.-V)Y,T9S
M.$U6)B-X03MZ2EIY3E1J8U%I37E,46<W0U9*53,V8G%C5EDS65=/=5A'<6%P
M85 U:79X2%I34DI%5FDP+VM22D-S:#56=$0S8G1I<DMS5F5D+SA!)B-X03M/
M46XO04I*,WI(+WAJ9R\V:6]S5F9$5TQ*,DMV=4PO;DAB+WE49FPS+U9U=BMO
M>6)&:5AO*TMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X)B-X03M6,DMU>%8R2W-B
M,5A69D]-9FUD8DA33DYT-W)417,Q=4QM839E4S)(<74X:6E/1V1&;D10.$%,
M23!A,$<O3&5G5EI(1UA-86U247)K)B-X03M$;6]024$Y=T115BLW1E<X5E-8
M6"]W1&IQ*U<O*S)J2B]W0C V-WA63W-69&ER<U9D:7)S5F1I<G-69&ER-6@X
M-R\X04]4+VXW469/)B-X03M/=&%,6C9F<%0R=6TS<SER03@P3GDP:%-+46]P
M8W)C271A1&5G1TMA63%B9C@U5F9M1F(S;#5D<' K:T=3.5I(;$11,U!%1TY"
M1T].)B-X03M,9V1L-S1R5#%0.$%);C@X9DYN;B]W07DS*VPV>F%71G9B,G1K
M8G%.-T]/6DA,:5=.2T5Y5%-I;$A08D93>7HO04IY12]W1$I/*UDO)B-X03LK
M36-(+U561FEH.$Y9<VY9<2LT=BMC9'8O2DXK6&8X059U=BMO>6)&:5AO*TMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMV)B-X03M#4'EO,&YY479N
M3S(Q0S Q,WDW9C9V3D%S.%5&=' X1FQC<71X1DMF<3ES;'1F4$-K:TMQ9E8O
M8TTO2%IM,W)I<C$W>EI:86YD-EA%)B-X03MM;5!+;#-(95=5=C=M57=K>%(S
M56)4:&U$3%940TAQ=&9I-F(Y359E6%=(;&HX-# T;31N=C)J1G9%<W-B86=R
M3WER>48W17)#8F%E)B-X03LT:TEE0U=O16%F1%9/;4978G=W*UER9B]!04YB
M-F]9-4I9;5),*UIN6C5Z9')P9#!*2VM65F@T='DS3T)76C1Q-T9867$W1EA9
M<3=&)B-X03M867$W1EAW1BMB2"]!2DTW>E8O,C%B=B]!2E!.:7E$13A693=F
M.#1H9CAP-7$O.$$R>6XO04]O:4A&0F4S+SA!3U%N+T%*2C-Z2"]X)B-X03MJ
M9R\V:6]S55!H<D9K-T98,T8O>FIT+S5*=GDW+W$S6"]56DYI>$PP9D9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T95:C W)B-X03MY8G!';C-S9#5"
M8V%M.'-694LS3W$V;&122&MP53AO8FDT;&EB63=C;$Y$=C%X5E!-5E-L=DXO
M;$Y79%<Q=7=$4DY-:V].,4165W11)B-X03M$8T)V:3)-45!X+WDY.%953EEN
M:&YV.$%Y=E!"27-S370K-WA3;U%Y<W)A8F1L5U9H<U%2,$]+<#=I<G-69&ER
M<U9D:7)S5F1I<G-6)B-X03MF05@U<V8X06MZ=DY8+V)6=2\X06LX,DQ)351X
M5C=T+WII1B]Y;FUR+W=$8DMF.$$V:4EC548W9B]W035#9CA!:VYF368O1T]$
M+W%+)B-X03MI>%$K1W-75'-69F-8+T]/,R]K;2],=BMR9&8Y4FLR3$5V4CA6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9E6EA()B-X03LU
M37I46%-803%O4G)$8V97-V$S*W)Y>5)24$@V:G=)=G$S36HK;4IB:5(U5C4O
M2%AI3T-G1$1A<#<O:#AA4$XU2W,P=35P63E0:T9K)B-X03M)>E%24#97;5AA
M*W%5;U=$1VXX,4U#<W=X5C)+=7A6,DMU>%9!4RM93D)I:V5+6%5R5T]736Q8
M4G T=WES1%%G9W1S4FEQ2G1,-GEV)B-X03M)>DQ:,T5D>D5$>$QW=7)Q1T%"
M<%939#DX5E9S5F9!6#5S9BM43S@Q9CET5S<O-5!.:7E$13A693=F.$%/25@O
M04-N;7(O.$%B2V8O)B-X03M!2VE)8U5&-V8O>FM*+S5*,WI(+T%-6310*V]Q
M3$9$-&%X6D]X5CEX9C@T-V8K4V(X=2\V=#$O,4=467-3.4AX5C)+=7A6,DMU
M>%8R)B-X03M+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9#87AQ;')P3VLS=7%8
M9DPV=%EW4UA-,T%667!%:&1G;S)Q841967%X,C0X>&%B<55N;&$K)B-X03M6
M=G%W:S%'8U!"8TUI>7AT1EI8<TUI3T9:;'%K:4944FE+.41I<2\X>&18=%DO
M>2LX>GE7,39I6$-A5&9.0SAC;T1H>&)/5DML5%AL)B-X03M8<%1&6'=F9&$Y
M<FPS>"MT86IC,TA#=D0Q6G!(<%AR5&M44W1-5U9+9'1Q,G%7<V=K=')Y94-2
M9&QE3U(P24(X0W!'2W9R9B]!2GAF)B-X03LQ,E,U+TQM-&963E%-,7=.4VY6
M5W5::7IH4%-H24%,:VUL4V-72EEX+W=!-6-A,4Y&1#57+U(Q*WEC;79V5BMR
M>6M6;TQF:GDT2#4P)B-X03MR:6M0;D)T6C%H:E9R-C1*<E=P;&,W*U!81DY)
M;7@Q-U<Q=31!3E)U5DAQ251385%$-U$Y.%9F;U@K:SE.+S5A-&8X06M9=CEC
M5TPT)B-X03M*+TY:,&8X04UV>E,V34=2=%5U>7)!,4)";6)O8U=167)I<C-,
M+VY%:31G:#@Y87,P,&EX2V1,64%U=U56*W-1*T]+0SES+U K+W-:)B-X03M0
M>6<X>$I(8U)/-U)W559856LO-E9&,D)X42M)8U=4<U9F8F8O3U!6+UEX9FLY
M-6534S1I4G=T>E979%%2+W!K>#9%-'-3.4MH=7)A)B-X03ME=F]3<$QX<'DT
M34=P6'!7;4MQ;4MU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%92
M=G)+,79R2S1S8G5-4S)T,4<X3GA%)B-X03M344=J:U5Q-C%&1'5P>%9,-&9+
M9FQQ2S)T<F8Y1S(X<V1O=D<S861"4$EO2EEK*W!,>F-K;#)*2DY34V$Y8U96
M1SAS95<R57$R:S):)B-X03M5:6A"=#1I0T0O<V-665A:*V)0>61U=$]T-SA7
M1G1(2&-V2$1(1S)M;&XY5U%)5FHO9'A/<$Y::U5L5TMH;4,Q<5%-2W%&:#5L
M+TI7)B-X03LP,"MY:49R0T),1C9K8V-U;5-Y>DQ'3&%/.$Q48UE(-'%)2C%F
M;3-W.60O:&%G5DYV,'(K6'AT,&)39$9H,5-A83EB5#1R4S!T24EP)B-X03M(
M=45G835E:'5F<3!F1#!53&AY+T9H5&E4559654<X>F9L3$I+:TQ7545K-U9#
M>')P8W-P035X>#AQ<$%Y.$=K;5)6:W)W8S=+>&]C)B-X03M+<%I.-7$O2F$W
M,&$Q,6XV;$5)0C8Q,6)21%1M:652<E-*5$MH-7A):$%--G!5='=-:$,X=5<R
M2W-U,&Y3=DEM<C)Z,TYJ<$YL3$1()B-X03M.3&)U>E=A2BLY9V-X>7%/841L
M>&13=DIA:F)9-$943"]$6&QZ+W$Q5V8X03!J>&8X,#1Q=VYZ6#5O+TQ(>3%Q
M5C-96"MH47E83G)B)B-X03M1,W-J4C)T;7-B3%!C<&)C4DQ-,$M",&%61V9M
M=T%69V$Y<U975V5O95)'170Y8F556DIF<F0V=&DX8E<Q9W!79C9V1DI!1FIL
M;5%H)B-X03M:,&Q7;$)T=5I/04)/1E=4-D)P=FQ$5G1,9S%/,3!/,70P=4%W
M.4]3,G0O555O-5)L2FDY4D0X4SE667%E;TI'0E5W8GEX-6%D4W)A)B-X03M4
M6DUP-F<R.%)(+T5C5EE"+VI,.'),=2]84TE03'=L=7)M9E5R3TY%=$Q.0S!M
M;7A,2R]$;39K:6%/4E=H661145<T:D955&)A=C5")B-X03MT,#!Q,UAY;U1A
M6'1V65-7;#0Y=G W07<S>GA14E!)4%<Y86]K;E)'2$1K>')W1$%%-'%Z6F9,
M2&QP5C1R<$YK<6IO0F)X068X4GA6)B-X03M&5V5M-F1:8R]Q5G)$8F5P5#%0
M4FI74&QX<E-V14-T2VY&551I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D)B-X03MI<D9O4'EV.&I13D-Y86-3,$5K37-2931U6DM'
M,C0K:79X>4Y614UA:U)N-&%Q1%-O1TMP5$XK5&YL,F9556UK62]O*TY)3%9B
M1D=N)B-X03M6;7-R87IN=%5T-5HO5SE74W!U,TQ%;6I)1E%Q44ML5E!B6#AV
M9DM&;EE'=W-R13)L=6)X.5)8-G108U%Y2F132U5E4T]73U):22M3)B-X03M/
M>6M)=TA%:U5O5&EQ,C$O3')Y9&%T>6AS0T=&3TQ.4&-/5E9:;W)H555V23-&
M1FQT-#)60CA)<'-+13%6568K5E<K4E P6EHV661-)B-X03MR63)#5'A7<U)N
M=4123&]H<&Q::DIY8TUY<3-X:S!906EH07A64&1+,&)4=$MI;6ES63)J4S1M
M935M3'E34W,P<VXR;4Q333=D9T%+)B-X03LP03)&0FEQ35IL5E-Z1VEQ2VLK
M=WA6-'1.<4AK=GIB<#-M1'I.3#584G)Q,&=G,5=/-&MV<FTR=4QH9#1&:F%7
M,E)P25=",#AE;D-N)B-X03M*6&)I=RM*:6-+<G903W9E4G9,.75Z-F@U9#%&
M3&Y4-VTS9V8V;&5Z=U<T=3<R,'0T6EDT,W1P;&QD-#=&=FA*:$%016=&4S(T
M5FU()B-X03LU5RMB9$<Q:E0U9$PP;7EL<W)$4U963E Y5V0W:U,R8E-Y>#(X
M:7E3:WEF1DA#2#1K;FER2T%4:7%F.$%M<GI082M83DU&.6-24U0X)B-X03MN
M2U)W>%5,<U5J95HV5B]L:6ED=F]X5C4S;V5H*U5H3C58=CE0.'$R.71D,U8S
M8V%B2DA&<49Y0D5B2&UR,TA&62]4=3ER3W!L;31S)B-X03M7-&)L:4U+<V$Q
M9GHW*U<K:WE*<D9V-64Q34Y:,FM%,6ES;6\S54EA5WIG:4YH0TE96C=I24EB
M5S5K9FMW<4%(3$EE4D]+=F1.13%7)B-X03M,5G1-:'9O-#)H.5%U:VM,,#5*
M2D4W4GE)86)F0S9%6492,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+)B-X03MU>%8R2W5X5C)+=7A6,DMU>%8R2W!,62M3=DM.
M9VMA,G5J,FE'2DDT,&MA1DAK-'=M37A!>4]'9'5"9VI+,4\S0F8U4FEQ3G5T
M1#!3)B-X03LW671D869B6$1'5F)G=$Q$1S5->4M%5U0T9V9J5D%&1&1A8EEQ
M<S S>3EO;6PS3GAC-F1:4E=C,3!K561W659#2WEW8W932$9A2T]0)B-X03MQ
M3C!'2W$Y+W!T;&9X>'@S8U%L5T=62C1X56EK:UIQ<'%P2'E)-D560C)*>%9,
M2C=0>68U5C V9E9V<59L<%9P65)Y4U-4>%)1=T)&)B-X03M:559W1T%4-V9O
M>')3=2]&4C)'2W1796=E4CE4<S1,-C P>E1B=3!U23%-1GA(0F)Y23AF<$=&
M94Q+<$)8,&U-93,W3S-41E4P,#-4)B-X03MR4%1B1T=X<V\O4W1B9&5%4U9:
M:4(Q,UII>DU39'E386LY8U923TMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X)B-X03M6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMV2W)8.#=B1%=D4EA2-V)327)Q2S9U3E-S;6%3-411<W1T1D<Y<7HX
M65I%)B-X03M#6&=U15=J:V-395!X='1I<4EM+T]Y>7-O<DYR+U1K<U8Q0CE-
M:C V3V$T84UY>#9H1D1.3$]H949):D1B3$TV;&MD:5A4:5%L46-6)B-X03ME
M;31Q-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<7AF)B-X03MZ,35O,4A1-TIX
M<'-55#-H<W(K.5(W9TTP449J0TI/2E9#:%IN6C$R-41B;#19<3@X,4AZ6$A:
M-G1,2D(U8S!95#928S(Y:' X:'-X)B-X03LV.$52:75W;'%J:&=6:VY7>FE%
M2$AI<7)+;TMN87!6,VU$.'@W8E)D6&YG<W9+3F=%4V8V=$M9,58U-VU/,&UN
M<V)%0E)(0T5+6'1T)B-X03M#14),:%9/,T=G3TMV479Y,C@R6#-M:GEP839P
M<45%9'9F36M8,6Q)95AP1C5)234O9T1&;49"349)2DY#0TLT1EI4:7)S5F1I
M<G-6)B-X03MD:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U95-4QA,VQK:6QL:5(U24=,)B-X03MW
M3WEG<VI&4VA:0V9S:W%X6&)S8U96359D:7%N0F)7,75J2F)X2D-J=3AR<D=O
M548U1TQU-4%P.%1->%IJ,T]+<6U+<%4S;4\Q2&UH)B-X03MF3&XQ938K=$Y:
M;2M&,DE73F]%16YP*VU:=6=K<G9X.$U64TQ4=GI7.'18:D9F479O;D-8379!
M5WI83#A,3U=+1U5S;&UB;#!:6&Y7)B-X03MQ3T$V+W1+=3%65450>GHO04,K
M3%A91GAD371R1$QC0U)B5UHQ;6IG93174F]U2VUQ<CE58VQZ4E X<79)2W%M
M9'(K85!L1S1S8FDY)B-X03LY4S9I:71&;6MU,4YP8W4X355&>$QB3DQ-<U5C
M;G!+>C(X:$AQ56%I;6](1G%+<5=J9FUX-5 Q4SAU8DY:6G)A-70Y46TP<%DU
M-&EF)B-X03M6=4E*;TE(.4EX1U5C9E5U-"]T54Y+=%1I<D5+=%<S-75E4G)J
M55!Q358U2U=C,C1H;"MR5#A*1&-Z>5=Y8V%*>C1I5TAI,&I+239S)B-X03MV
M>&(T<6QE=F9N>C5&,&UZ<W)Q3F(O530W.4HU245S-U9H249T56IL;$QX,T)T
M,E%#1UE3.&U&3T%,5C965E0V-R]->GEB85<X5GIC)B-X03M88WE7,7A*-DYR
M4#E4=D1(4$E85D%S1&E%<DQY6GAX-$4X='E+9T=I<5=.*V1N-69R9G)A=&1Z
M<D4Q=DQD:2M.=$XY5TU55G)$94=J)B-X03LX86QM9W552W%"5W9W+V%:07EQ
M9%@O;B]!37$V9G%X,'4Y=3)G=6A+24-Z4E-M2EA)9RLS2W%T2$=+,W-+.&Y)
M2$IW06$T<6]R*UDS)B-X03ML<518<DA2-V534V53+W(V3C)I571H*S=M:VI0
M<4]6-4Q+='!.=V1!>4AG9FDV67%L5VIF;DXU53%E-&MI=&]B<$)"8C(Y-613
M4VDS)B-X03M8,&],<S%H:UI"35I31VI+>4AG:#1+=S4X5'1I<E!-5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S)B-X03M6
M9&ER<U9E538U+WEO+S9V9B]P<C9Z,&XO4VXQ<CE,+T%&:FI7=SE8-GIZ+T%(
M,T0O94QJ>C)P5&IT>7A62S=8+V]7,SE(3#903#E&)B-X03ME:DA4;"ML=G%N
M;R\V5'<U8W8S5D]8,6IR*S-Z+V%R:7%0,4@O;%)(-D0Q1#8U.6$O4EAO="MM
M2V9P:6Y$.4E49C<R8U!J-698=E<T)B-X03ME<CA6969(875+<6QJ+WER8B]'
M;6MF;TPP4%0O044W<6XQ-G9R97(K;G9Q;GAF-S!B8U!3.51L=RM(;C9F2$95
M:C%R+T%*5E@O:4MW)B-X03LO46YR+W!B.4Q72#9B-2]P3#8W5#8O.$%">BMS
M+W-F5TLK<C9N=SAF.'8P<TMP;DXO=T)#-RML6BMR=SE0-G)D9E90*T]H+W9.
M*V@W)B-X03MF-G@P+W=#,5HV4%AF=RM/=4)6.34O>6],.4YA1#ED.5@Y2697
M:"]H=C%V,'(V9G$K=79(-G)Y+V,K:C9V2&IX+V1E1S%C5E,W5W8K)B-X03M6
M33AT12]26$0P+U@P,S$V+UA+9E5E5FHV6' K="LU-3$K;V5R6#DU-E!80W%A
M-C4O9S,O04I7=$8K;&9R2#%4.2\X05=053E8-FPK)B-X03MK=65K9E9U6'!F
M1'<O=78W-SDS-G8K6%1!<6)29CAQ;"]43VHO5D]F,3<Q=CEW9C%,-B\V5F%T
M5#!042]C*VAX.5=L4#-F1#%A9D(V)B-X03MU2W!14"M632]O-C(O4G8Q=C9R
M=U Q8C!F<C-O*VI5979X*W,O=T-J,2MQ+V%P*S@K<C T9D)W=W$O+UHB+SX*
M(" @(#PO<F1F.D%L=#X*(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @/'AM<$U-
M.D1E<FEV961&<F]M"B @("!S=%)E9CII;G-T86YC94E$/2)U=6ED.F4U96(R
M,S1E+3,X838M-&$P8RUA-SDY+6-E834W8C)C,CEF-R(*(" @('-T4F5F.F1O
M8W5M96YT240](GAM<"YD:60Z,C,P.4-#14-"0D4Q13<Q,3A&1#=%1#5#,T5&
M0C%%,C4B"B @("!S=%)E9CIO<FEG:6YA;$1O8W5M96YT240](G5U:60Z-40R
M,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@B"B @("!S=%)E9CIR96YD
M:71I;VY#;&%S<STB9&5F875L="(O/@H@(" \>&UP34TZ2&ES=&]R>3X*(" @
M(#QR9&8Z4V5Q/@H@(" @(#QR9&8Z;&D*(" @(" @<W1%=G0Z86-T:6]N/2)S
M879E9"(*(" @(" @<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HR,S Y0T-%
M0T)"13%%-S$Q.$9$-T5$-4,S149",44R-2(*(" @(" @<W1%=G0Z=VAE;CTB
M,C Q-RTQ,BTQ-50Q,#HR-CHQ,"TP-SHP,"(*(" @(" @<W1%=G0Z<V]F='=A
M<F5!9V5N=#TB061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*2(*(" @
M(" @<W1%=G0Z8VAA;F=E9#TB+R(O/@H@(" @(#QR9&8Z;&D*(" @(" @<W1%
M=G0Z86-T:6]N/2)S879E9"(*(" @(" @<W1%=G0Z:6YS=&%N8V5)1#TB>&UP
M+FEI9#HR-C Y0T-%0T)"13%%-S$Q.$9$-T5$-4,S149",44R-2(*(" @(" @
M<W1%=G0Z=VAE;CTB,C Q-RTQ,BTQ-50Q,#HS,SHU-2TP-SHP,"(*(" @(" @
M<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@26QL=7-T<F%T;W(@0U,V("A7
M:6YD;W=S*2(*(" @(" @<W1%=G0Z8VAA;F=E9#TB+R(O/@H@(" @/"]R9&8Z
M4V5Q/@H@(" \+WAM<$U-.DAI<W1O<GD^"B @(#QX;7!44&<Z36%X4&%G95-I
M>F4*(" @('-T1&EM.G<](C8Q,BXP,# P,# B"B @("!S=$1I;3IH/2(W.3(N
M,# P,# P(@H@(" @<W1$:6TZ=6YI=#TB4&]I;G1S(B\^"B @(#QX;7!44&<Z
M1F]N=',^"B @(" \<F1F.D)A9SX*(" @(" \<F1F.FQI"B @(" @('-T1FYT
M.F9O;G1.86UE/2)->7)I860M4F]M86XB"B @(" @('-T1FYT.F9O;G1&86UI
M;'D](DUY<FEA9"(*(" @(" @<W1&;G0Z9F]N=$9A8V4](E)O;6%N(@H@(" @
M("!S=$9N=#IF;VYT5'EP93TB5'EP92 Q(@H@(" @("!S=$9N=#IV97)S:6]N
M4W1R:6YG/2(P,#$N,# Q(@H@(" @("!S=$9N=#IC;VUP;W-I=&4](D9A;'-E
M(@H@(" @("!S=$9N=#IF;VYT1FEL94YA;64](G=M<E]?7U]?+G!F8CL@=VUR
M7U]?7U\N<&9M(B\^"B @(" @/')D9CIL:0H@(" @("!S=$9N=#IF;VYT3F%M
M93TB4WEM8F]L350B"B @(" @('-T1FYT.F9O;G1&86UI;'D](E-Y;6)O;"(*
M(" @(" @<W1&;G0Z9F]N=$9A8V4](E)E9W5L87(B"B @(" @('-T1FYT.F9O
M;G14>7!E/2)/<&5N(%1Y<&4B"B @(" @('-T1FYT.G9E<G-I;VY3=')I;F<]
M(E9E<G-I;VX@-2XP,"(*(" @(" @<W1&;G0Z8V]M<&]S:71E/2)&86QS92(*
M(" @(" @<W1&;G0Z9F]N=$9I;&5.86UE/2)S>6UB;VPN='1F(B\^"B @(" \
M+W)D9CI"86<^"B @(#PO>&UP5%!G.D9O;G1S/@H@(" \>&UP5%!G.E!L871E
M3F%M97,^"B @(" \<F1F.E-E<3X*(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z
M;&D^"B @(" \+W)D9CI397$^"B @(#PO>&UP5%!G.E!L871E3F%M97,^"B @
M(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @/')D9CI397$^"B @(" @/')D
M9CIL:0H@(" @("!X;7!'.F=R;W5P3F%M93TB1&5F875L="!3=V%T8V@@1W)O
M=7 B"B @(" @('AM<$<Z9W)O=7!4>7!E/2(P(B\^"B @(" \+W)D9CI397$^
M"B @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @/$5X=&5N<VES1F]N=%-E
M;G-E.G-L=6<^"B @(" \<F1F.D)A9SX*(" @(" \<F1F.FQI"B @(" @($5X
M=&5N<VES1F]N=%-E;G-E.D9O;G1+:6YD/2)0;W-T4V-R:7!T(@H@(" @("!%
M>'1E;G-I<T9O;G1396YS93I&86UI;'D](DUY<FEA9"(*(" @(" @17AT96YS
M:7-&;VYT4V5N<V4Z3W5T;&EN949I;&53:7IE/2(S,#,P,R(*(" @(" @17AT
M96YS:7-&;VYT4V5N<V4Z1F]U;F1R>3TB061O8F4@4WES=&5M<R(*(" @(" @
M17AT96YS:7-&;VYT4V5N<V4Z5F5R<VEO;CTB,# Q+C P,"(*(" @(" @17AT
M96YS:7-&;VYT4V5N<V4Z2V5R;FEN9T-H96-K<W5M/2(P(@H@(" @("!%>'1E
M;G-I<T9O;G1396YS93I&;VYT4V5N<V5?,2XR7T-H96-K<W5M/2(R-S(R,#DP
M.#4R(@H@(" @("!%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3TB,C<R,C Y
M,#@U,B(*(" @(" @17AT96YS:7-&;VYT4V5N<V4Z4&]S=%-C<FEP=$YA;64]
M(DUY<FEA9"U2;VUA;B(O/@H@(" @(#QR9&8Z;&D*(" @(" @17AT96YS:7-&
M;VYT4V5N<V4Z1F]N=$MI;F0](D]P96Y4>7!E("T@5%0B"B @(" @($5X=&5N
M<VES1F]N=%-E;G-E.D9A;6EL>3TB4WEM8F]L(@H@(" @("!%>'1E;G-I<T9O
M;G1396YS93I/=71L:6YE1FEL95-I>F4](C B"B @(" @($5X=&5N<VES1F]N
M=%-E;G-E.D9O=6YD<GD](DUO;F]T>7!E(%1Y<&]G<F%P:'DB"B @(" @($5X
M=&5N<VES1F]N=%-E;G-E.E9E<G-I;VX](C4N,# B"B @(" @($5X=&5N<VES
M1F]N=%-E;G-E.DME<FYI;F=#:&5C:W-U;3TB,"(*(" @(" @17AT96YS:7-&
M;VYT4V5N<V4Z1F]N=%-E;G-E7S$N,E]#:&5C:W-U;3TB-S$V-S,U-S$X(@H@
M(" @("!%>'1E;G-I<T9O;G1396YS93I#:&5C:W-U;3TB-S$V-S,U-S$X(@H@
M(" @("!%>'1E;G-I<T9O;G1396YS93I0;W-T4V-R:7!T3F%M93TB4WEM8F]L
M350B+SX*(" @(#PO<F1F.D)A9SX*(" @/"]%>'1E;G-I<T9O;G1396YS93IS
M;'5G/@H@(#PO<F1F.D1E<V-R:7!T:6]N/@H@/"]R9&8Z4D1&/@H\+W@Z>&UP
M;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @( H\/WAP86-K
M970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_\  $0@!&P'K P$1  (1 0,1 ?_$ !\  0 " @,
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M%$U4:9<>&E7.FT:Y9S*[P&
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M+ZDAZ?=.N*C1#9J9L[%_!^>F'XUWV3ZE&CNX:F8Q3,Q%UW:XQ&MSNN+!@
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M]%B#Q^:73]G+?X8T$5;^!U]$UPU[&B?M/(@:Q^/%\6+WE:R#(
M          J3\:#]$^M/WWN%?]T-; UAUGX<?]&);8#(     ASU Y]_('6)
M:\90_D63LAC>Z;3HWI:>W!#G1(ZZJ4N&8N*D5C 9FE7(#4F5NSD:['H5!*C5
M+HE*.+W-WT-1W?\ EWN51$^\PK4L/KCQEJTZ"YRYN?J4\-55.NGF^Z'& .;5
M<'3:B+-9%%1J.RF7ZRU>KJ="ZMYJ]NDR J/:M#*^Z+%A2LMQW:B2RCSS5=G4
MS>/*N$<?5-BE7KQ:%5GQ0CHBN_#W9:9,4K\3=SINUNB)#925)AH<-FO:+,\S
MJ:.QE:H,?M6HE=HZO*$LII,7GD;FJRDZ<TS/<K*<5\XBOE*QD&0
M                                  ''/'YI=/V<M_AC0%6_@=?1-<->
MQHG[3R(&L?CQ?%B]Y6L@R                     *D_&@_1/K3]][A7_=#
M6P-8=9^''_1B6V R      "I7K7Z5_P@O\J^(U_1NHP:CPXO3W6U R
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M?M/(@:Q^/%\6+WE:R#(                     J3\:#]$^M/WWN%?]T-;
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MM0)M=F;77)ZQ:H)3DXVVUUR89KC.V,?.!_#Q_IE9T#
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MG[.6_P ,: JW\#KZ)KAKV-$_:>1 UC\>+XL7O*UD&0
M  !6MXJ=36/<O.$"BE70]XFTB;>M>0)LO:&0DL]8EBD&Z$@<GESZ;H885KA
MP,#:N=7 S&V=BTB4W?73?./>Y-89J<_TXHZX9B/G*RD&0   &L4]T]?2XVW[
M,*/_ *>-0.OL?!ZR\^0/4  &=>7?TF>=?;K4?V_CX).D^4^S=!@X
M                           5.=AWB[L]QJJ^>K'[^@<":(ZQ+-&OBWA2
MU;-,DKHYE'JUA\DZ-1TE=[$:C)*V2)T\4K1' I"P+$JK,CD[SHX%M+::PQRP
MS\6*(^4S'SN#D:8229V=J@J^\?$ 6Q)B18>)S!.]N0IU#HN],1J@MNVUK*W)
MK2M%RYMGI*Q6E6ZH%\PLMF-:$:W'Q$29,.?T(F*UC#_XXHGK4SEZ1,[K8P9
M   <<\?FET_9RW^&- 5;^!U]$UPU[&B?M/(@:Q^/%\6+WE:R#(
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MELPTIMMMU7I+&$IB*XS,>47]81C\#KZ)KAKV-$_:>1 N/QXOBQ>\K609
M                        :Q3W3U]+C;?LPH_^GC4#K['P>LO/D#U  !G7
MEW])GG7VZU']OX^"3I/E/LW08.
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MI<;;]F%'_P!/&H'7V/@]9>?('J  #.O+OZ3/.OMUJ/[?Q\$G2?*?9N@P<
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M7GR!Z@  SKR[^DSSK[=:C^W\?!)TGRGV;H,'
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M *>-0.OL?!ZR\^0/4  &=>7?TF>=?;K4?V_CX).D^4^S=!@X
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M84?_ $\:@=?8^#UEY\@>H  ,Z\N_I,\Z^W6H_M_'P2=)\I]FZ#!P
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M$Q&L1/G?TF/JC)X'7T37#7L:)^T\B!<?CQ?%B]Y6L@R
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MU Z^Q\'K+SY ]0  9UY=_29YU]NM1_;^/@DZ3Y3[-T&#@
M                           !QSQ^:73]G+?X8T!5OX'7T37#7L:)^T\B
M!K'X\7Q8O>5K(,@                  UJONJWZ4[/[M]0_S&< ZNP\$_%/
MM#S8@]@  =PKS^_\'_SA&?YTB!)TGRGV;L@'  -8I[IZ^EQMOV84?_3QJ!U]
MCX/67GR!Z@  SKR[^DSSK[=:C^W\?!)TGRGV;H,'
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M:]C1/VGD0+C\>+XL7O*UD&0                  :U7W5;]*=G]V^H?YC.
M=78>"?BGVAYL0>P  .X5Y_?^#_YPC/\ .D0).D^4^S=D X !K%/=/7TN-M^S
M"C_Z>-0.OL?!ZR\^0/4  &=>7?TF>=?;K4?V_CX).D^4^S=!@X
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MZ^EQMOV84?\ T\:@=?8^#UEY\@>H  ,Z\N_I,\Z^W6H_M_'P2=)\I]FZ#!P
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MBRU"-<C/)4IC]-#23--]<9P.YAG*>],?%B^Z:7_J'_&/]<]X_P!&N=/_ .0
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M4ZI.=DO!9Q>VQ*K5W@                                      1<Z
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MRPN;\<B1-IKVX-$0:6=O6.YK>W-Z QR4)S%FZ- C3;'9)2D::6JT2[U97
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M1NFD=ROTPJ-(.7')249"8S.?Y/UMF4
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M,>L<M></0*#
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M(
M                  *_Y':G4Z3M2%5ZV5I7YM;.%.W ^:I#KT>$F7IK8K5I
M-E;[!<&;6D%>&^5,[+(5I"*(%/2]"HUD#F09*R?,23U9>$[W'M/%8 "
M
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MB-R0<:5[PS8FC((
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M4Q,Y9Y8?EAB$_@9
M                            '!2B2L4+C,BF,H<D[-&8FQ.\ED3PKSMJ
ME:F)B;U#H[N2G.FN^^$Z%O2J%1V===ML%E;9UUSGR8R$<&OK*-G3+FJOI!7%
MK1:4].Q!7*XOERC*;:,PY0D@C]8N\-G,KPZ%-A,Y+CD9>O/H]%?C48SKDA.'
M@] V.S Z.XK7DQ*;XE- MNK^\2=CM*(UZGB=PS&N[4>HTPJH5>C91$A1Q6QD
MM0I(Y+'^=.3TG>W!$3$&:80N%K[.0*,/U9%2^/EGNA1:YQ>66=Q>]Q7S9YJ+
MIB(V@GM0A^B\SI"54BM;R;6@US;P9J?(8TO,42S9AEC@]0B<3VOU<0>HRI.7
MIW]IFKBD0*&E_9WST2]Q]X;40F*XQ/E_>G0KF[OYXJFCKBO2.3)DOMJHYRBC
M#.H=04M@MB3A#)YK+6.%QR*&M:24ID+7)')Y?D>J5I?W-H4*"BS\DXWWTQIL
M(B;K2>;\\^[BK&*VAS]3T28Y-:<SZ:KJ>V/5AL.W8BXT<UQ:M7^SHBED3X].
M[=LRFVXSQ25)*[4E('%(M51:1'.IC6B;#%&XJ:GEKOK7NDU65B1BW:X@5JPE
M4>MA]DPZ-3J+JE2;=&K.896SHWQJV6HC<_#(5V$2XG5:A/\ (>B5:G)3\:FE
M;ZX).63O
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MK6%XQHK:6E^6N#:U*=-=-3V]*F-QIIC?WF#,ZRD2
M
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M=6=X:5B9Q:W9K<4Y:QO<FUP1F')%S>N2'$JD:Q*<:G5)S2SR#-R]]=LAR
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M>65K%F6.H6UHAV$VOF>8FA9<HMC$F2#-C,_2/:%@H(
M                                  ^,XQGR9SC&<XSY<>7'Y,^3./+C
M]6?)G./+C_#.<?DR 9UQGR^7&,^7'O<^7&/GQ\_S9_7CY\_-^3Y\_K ,XQGR
M>7&,^3/EQY?\,_D\N/U9\F<X_P#L \F/+Y?)CR^3R>7_ !\GZO+^H!\XQC'Y
M,>3\N?F_7G/ESG_[SG.<_KS\X#XQKKCR>3&,>3.<X\F,?-G/E\N<?JSGRY\N
M?RY\N?UY =8G"E0BA4O6)#S4RM)%Y I2J2-]BCTZ@AI5FDGDF:9QN6:49IJ8
M7OKG&VF^N-M<XSC&0&+.7X%%:XH*KX_$&TYO;UT81S%T-6NKP_N[Y+Y_G>;S
M>52&0R%>ZR"0R25RY_>I$_OCVYKW1S=7)4J5JC##/+@N+6?.NF4=(9ZQC&/R
M8QCY\Y^;YOGS\^<__.<_/G]8(JZX9CZ667#?%ER]SEDSG-8/DBIBO9!,YQ,Y
M<?#ZUD3\AD<CC;$FDC^YH$/QB>8;$%<@>2TGI]\UBT=2.CJK1,K<G3%G2/+Z
MRM&! !\>]Q^K'Y???DQ^7\OE_P#GR_/Y?R@/D!\>3'E\ODQY<XQC.?\ '.,>
M7R8\OZL>7/D_5Y<_K 1<XYA<=BE%Q]X9DBOTW9K@Z6C8+\ZO#U(I!,)]*C2]
M7B1O[](7!T=W!5E$WM3(UISENR"/QEE88K'TC9&V)H:D0??(Z@K9)T%4U@(X
MF@12[9SMV2G.Z$U<CRLD$EKZ$PM]>'!"E5%-KBXN,7B,;9SE2]&I-U3M"7<K
M8M1\(<86YJN'][2=!#R8^;/D^?'Y,_J\OZ@'QY,?-\V/FSY<?-^3/Z\?^_SY
M^?\ ]P'QMIKMC;&<9Q[[7WF=M<YTW][\_P V-],Z[ZYQY<YUSKMC.N<^77.,
M_. X&*12-P6,L$,A[*WQR*Q9H0,,>86HC5*W-+.UIBTB! C(T^8LE.G*T+U\
/N=M]O)G<S;??;;;(?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
